

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 March 2001 (22.03.2001)

PCT

(10) International Publication Number
WO 01/19988 A1

(51) International Patent Classification⁷: C12N 15/12,
C07K 14/47, C12N 1/21, 5/10, C12Q 1/68, A61K 38/17

(74) Agents: CARROLL, Alice, O. et al.; Hamilton, Brook,
Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA
02421 (US).

(21) International Application Number: PCT/US00/25135

(22) International Filing Date:
14 September 2000 (14.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/398,829 17 September 1999 (17.09.1999) US

(71) Applicant: GENETICS INSTITUTE, INC. [US/US]; 87
CambridgePark Drive, Cambridge, MA 02149 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors: JACOBS, Kenneth; 151 Beaumont Avenue,
Newton, MA 02160 (US). MCCOY, John, M.; 56
Howard Street, Reading, MA 01867 (US). LAVALLIE,
Edward, R.; 113 Ann Lee Road, Harvard, MA 01451
(US). COLLINS-RACIE, Lisa, A.; 124 School Street,
Acton, MA 01720 (US). EVANS, Cheryl; 18801 Bent
Willow Circle, Germantown, MD 20874 (US). MER-
BERG, David; 2 Orchard Drive, Acton, MA 01720 (US).
TREACY, Maurice; 12 Foxrock Court, Dublin 18 (IE).
BOWMAN, Michael, R.; 63 Gloucester Road, Westwood,
MA 02090 (US). SPAULDING, Vikki; 11 Meadowbank
Road, Billerica, MA 01821 (US). AGOSTINO, Michael,
J.; 26 Wolcott Avenue, Andover, MA 01810 (US).

Published:

- With international search report.
- Before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments.
- With (an) indication(s) in relation to deposited biological
material furnished under Rule 13bis separately from the
description.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

(57) Abstract: Novel polynucleotides and the proteins encoded thereby are disclosed.

WO 01/19988 A1

5 **SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM****BACKGROUND OF THE INVENTION**

Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The
10 now routine hybridization cloning and expression cloning techniques clone novel polynucleotides
"directly" in the sense that they rely on information directly related to the discovered protein (i.e.,
partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of
the protein in the case of expression cloning). More recent "indirect" cloning techniques such as
15 signal sequence cloning, which isolates DNA sequences based on the presence of a now well-
recognized secretory leader sequence motif, as well as various PCR-based or low stringency
hybridization cloning techniques, have advanced the state of the art by making available large
numbers of DNA/amino acid sequences for proteins that are known to have biological activity by
virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or
tissue source in the case of PCR-based techniques. It is to these proteins and the polynucleotides
20 encoding them that the present invention is directed.

SUMMARY OF THE INVENTION

In one embodiment, the present invention provides a composition comprising an isolated
polynucleotide selected from the group consisting of:

- 25 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1
 from nucleotide 282 to nucleotide 565;
 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1
 from nucleotide 342 to nucleotide 565;
30 (d) a polynucleotide comprising the nucleotide sequence of the full-length
 protein coding sequence of clone AX65_22 deposited with the ATCC under accession
 number 98196;
 (e) a polynucleotide encoding the full-length protein encoded by the cDNA
 insert of clone AX65_22 deposited with the ATCC under accession number 98196;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone AX65_22 deposited with the ATCC under accession number 98196;

5 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone AX65_22 deposited with the ATCC under accession number 98196;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;

10 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:2;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

15 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:1.

20 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:1 from nucleotide 282 to nucleotide 565; the nucleotide sequence of SEQ ID NO:1 from nucleotide 342 to nucleotide 565; the nucleotide sequence of the full-length protein coding sequence of clone AX65_22 deposited with the ATCC under accession number 98196; or the nucleotide sequence of a mature protein coding sequence of clone AX65_22 deposited with the ATCC under accession
25 number 98196. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone AX65_22 deposited with the ATCC under accession number 98196. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably
30 twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 42 to amino acid 51 of SEQ ID NO:2.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID
35 NO:1 and SEQ ID NO:3.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

5 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:1;

(ab) SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3; and

10 (ac) the nucleotide sequence of the cDNA insert of clone AX65_22 deposited with the ATCC under accession number 98196;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

15 and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

20 (ba) SEQ ID NO:1;

(bb) SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3; and

(bc) the nucleotide sequence of the cDNA insert of clone AX65_22 deposited with the ATCC under accession number 98196;

25 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide
30 sequence corresponding to the cDNA sequences of SEQ ID NO:1 and SEQ ID NO:3, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:1 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
35 NO:1, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ

ID NO:1 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:1. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 282 to nucleotide 565, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence
5 of SEQ ID NO:1 from nucleotide 282 to nucleotide 565, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:1 from nucleotide 282 to nucleotide 565. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 342 to nucleotide 565, and extending contiguously from a nucleotide sequence corresponding to the 5'
10 end of said sequence of SEQ ID NO:1 from nucleotide 342 to nucleotide 565, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:1 from nucleotide 342 to nucleotide 565.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 15 (a) the amino acid sequence of SEQ ID NO:2;
(b) a fragment of the amino acid sequence of SEQ ID NO:2, the fragment comprising eight contiguous amino acids of SEQ ID NO:2; and
(c) the amino acid sequence encoded by the cDNA insert of clone AX65_22 deposited with the ATCC under accession number 98196;
- 20 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:2. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a protein comprising
25 a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 42 to amino acid 51 of SEQ ID NO:2.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:4;
30 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:4 from nucleotide 192 to nucleotide 2318;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:4 from nucleotide 653 to nucleotide 825;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BD335_14 deposited with the ATCC under accession number 98196;

5 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BD335_14 deposited with the ATCC under accession number 98196;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BD335_14 deposited with the ATCC under accession number 98196;

10 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BD335_14 deposited with the ATCC under accession number 98196;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:5;

15 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:5 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:5;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

20 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:4.

25 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:4 from nucleotide 192 to nucleotide 2318; the nucleotide sequence of SEQ ID NO:4 from nucleotide 653 to nucleotide 825; the nucleotide sequence of the full-length protein coding sequence of clone BD335_14 deposited with the ATCC under accession number 98196; or the nucleotide sequence of a mature protein coding sequence of clone BD335_14 deposited with the ATCC under
30 accession number 98196. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BD335_14 deposited with the ATCC under accession number 98196. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:5 from amino acid 148 to amino acid 240. In further preferred embodiments, the present
35 invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid

sequence of SEQ ID NO:5 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:5, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:5 having biological activity, the fragment comprising the amino acid sequence from amino acid 349 to amino acid 358 of SEQ ID NO:5.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:4.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 10 (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - 15 (aa) SEQ ID NO:4, but excluding the poly(A) tail at the 3' end of SEQ ID NO:4; and
 - (ab) the nucleotide sequence of the cDNA insert of clone BD335_14 deposited with the ATCC under accession number 98196;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - 20 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - 25 (ba) SEQ ID NO:4, but excluding the poly(A) tail at the 3' end of SEQ ID NO:4; and
 - (bb) the nucleotide sequence of the cDNA insert of clone BD335_14 deposited with the ATCC under accession number 98196;
 - 30 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
 - (iii) amplifying human DNA sequences; and
 - (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:4, and extending contiguously from

a nucleotide sequence corresponding to the 5' end of SEQ ID NO:4 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:4, but excluding the poly(A) tail at the 3' end of SEQ ID NO:4. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:4 from nucleotide 192
5 to nucleotide 2318, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:4 from nucleotide 192 to nucleotide 2318, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:4 from nucleotide 192 to nucleotide 2318. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:4 from
10 nucleotide 653 to nucleotide 825, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:4 from nucleotide 653 to nucleotide 825, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:4 from nucleotide 653 to nucleotide 825.

In other embodiments, the present invention provides a composition comprising a protein,
15 wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:5;
- (b) the amino acid sequence of SEQ ID NO:5 from amino acid 148 to amino acid 240;
- (c) a fragment of the amino acid sequence of SEQ ID NO:5, the fragment
20 comprising eight contiguous amino acids of SEQ ID NO:5; and
- (d) the amino acid sequence encoded by the cDNA insert of clone BD335_14 deposited with the ATCC under accession number 98196;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:5 or the amino acid sequence of SEQ ID NO:5
25 from amino acid 148 to amino acid 240. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:5 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:5, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:5 having biological activity, the fragment comprising
30 the amino acid sequence from amino acid 349 to amino acid 358 of SEQ ID NO:5.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7
35 from nucleotide 206 to nucleotide 391;

- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BG241_1 deposited with the ATCC under accession number 98196;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BG241_1 deposited with the ATCC under accession number 98196;
- (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BG241_1 deposited with the ATCC under accession number 98196;
- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BG241_1 deposited with the ATCC under accession number 98196;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:8;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:7.
- Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:7 from nucleotide 206 to nucleotide 391; the nucleotide sequence of the full-length protein coding sequence of clone BG241_1 deposited with the ATCC under accession number 98196; or the nucleotide sequence of a mature protein coding sequence of clone BG241_1 deposited with the ATCC under accession number 98196. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BG241_1 deposited with the ATCC under accession number 98196. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:8, or a polynucleotide encoding a protein comprising a fragment of the amino acid

sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 26 to amino acid 35 of SEQ ID NO:8.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:7, SEQ ID NO:6, and SEQ ID NO:9 .

5 Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X
10 SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:6;

(ab) SEQ ID NO:7;

(ac) SEQ ID NO:9, but excluding the poly(A) tail at the 3'
end of SEQ ID NO:9; and

15 (ad) the nucleotide sequence of the cDNA insert of clone BG241_1 deposited with the ATCC under accession number 98196;

(ii) hybridizing said probe(s) to human genomic DNA in conditions
at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

20 and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in
6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:

25 (ba) SEQ ID NO:6;

(bb) SEQ ID NO:7;

(bc) SEQ ID NO:9, but excluding the poly(A) tail at the 3'
end of SEQ ID NO:9; and

30 (bd) the nucleotide sequence of the cDNA insert of clone BG241_1 deposited with the ATCC under accession number 98196;

(ii) hybridizing said primer(s) to human genomic DNA in conditions
at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:9, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:6 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:7 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:7. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 206 to nucleotide 391, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 206 to nucleotide 391, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 206 to nucleotide 391.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:8;
- (b) a fragment of the amino acid sequence of SEQ ID NO:8, the fragment comprising eight contiguous amino acids of SEQ ID NO:8; and
- (c) the amino acid sequence encoded by the cDNA insert of clone BG241_1 deposited with the ATCC under accession number 98196;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:8. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:8, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 26 to amino acid 35 of SEQ ID NO:8.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:10;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:10 from nucleotide 302 to nucleotide 1762;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:10 from nucleotide 389 to nucleotide 1762;

- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:10 from nucleotide 1723 to nucleotide 2050;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BL187_4 deposited with the ATCC under accession number 98196;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BL187_4 deposited with the ATCC under accession number 98196;
- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BL187_4 deposited with the ATCC under accession number 98196;
- (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BL187_4 deposited with the ATCC under accession number 98196;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:11;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:11 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:11;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and
- (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:10.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:10 from nucleotide 302 to nucleotide 1762; the nucleotide sequence of SEQ ID NO:10 from nucleotide 389 to nucleotide 1762; the nucleotide sequence of SEQ ID NO:10 from nucleotide 1723 to nucleotide 2050; the nucleotide sequence of the full-length protein coding sequence of clone BL187_4 deposited with the ATCC under accession number 98196; or the nucleotide sequence of a mature protein coding sequence of clone BL187_4 deposited with the ATCC under accession number 98196. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BL187_4 deposited with the ATCC under accession number 98196. In further preferred embodiments, the present invention

provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:11 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:11, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:11 having biological activity, the fragment comprising the amino acid sequence from amino acid 238 to amino acid 247 of SEQ ID NO:11.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:10.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:10, but excluding the poly(A) tail at the 3' end of SEQ ID NO:10; and

(ab) the nucleotide sequence of the cDNA insert of clone BL187_4 deposited with the ATCC under accession number 98196;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:10, but excluding the poly(A) tail at the 3' end of SEQ ID NO:10; and

(bb) the nucleotide sequence of the cDNA insert of clone BL187_4 deposited with the ATCC under accession number 98196;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:10, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:10 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:10, but excluding the poly(A) tail at the 3' end of SEQ ID NO:10. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:10 from nucleotide 302 to nucleotide 1762, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:10 from nucleotide 302 to nucleotide 1762, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:10 from nucleotide 302 to nucleotide 1762. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:10 from nucleotide 389 to nucleotide 1762, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:10 from nucleotide 389 to nucleotide 1762, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:10 from nucleotide 389 to nucleotide 1762. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:10 from nucleotide 1723 to nucleotide 2050, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:10 from nucleotide 1723 to nucleotide 2050, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:10 from nucleotide 1723 to nucleotide 2050.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:11;
- (b) a fragment of the amino acid sequence of SEQ ID NO:11, the fragment comprising eight contiguous amino acids of SEQ ID NO:11; and
- (c) the amino acid sequence encoded by the cDNA insert of clone BL187_4 deposited with the ATCC under accession number 98196;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:11. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:11 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:11, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:11 having biological activity, the fragment comprising the amino acid sequence from amino acid 238 to amino acid 247 of SEQ ID NO:11.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:12;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:12
5 from nucleotide 2 to nucleotide 2290;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:12
from nucleotide 134 to nucleotide 2290;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:12
from nucleotide 1 to nucleotide 309;
- 10 (e) a polynucleotide comprising the nucleotide sequence of the full-length
protein coding sequence of clone BL249_18 deposited with the ATCC under accession
number 98196;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA
insert of clone BL249_18 deposited with the ATCC under accession number 98196;
- 15 (g) a polynucleotide comprising the nucleotide sequence of a mature protein
coding sequence of clone BL249_18 deposited with the ATCC under accession number
98196;
- (h) a polynucleotide encoding a mature protein encoded by the cDNA insert
of clone BL249_18 deposited with the ATCC under accession number 98196;
- 20 (i) a polynucleotide encoding a protein comprising the amino acid sequence
of SEQ ID NO:13;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino
acid sequence of SEQ ID NO:13 having biological activity, the fragment comprising eight
contiguous amino acids of SEQ ID NO:13;
- 25 (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h)
above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i)
or (j) above ;
- (m) a polynucleotide that hybridizes under stringent conditions to any one of
30 the polynucleotides specified in (a)-(j); and
- (n) a polynucleotide that hybridizes under stringent conditions to any one of
the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the
length of SEQ ID NO:12.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:12
35 from nucleotide 2 to nucleotide 2290; the nucleotide sequence of SEQ ID NO:12 from nucleotide

134 to nucleotide 2290; the nucleotide sequence of SEQ ID NO:12 from nucleotide 1 to nucleotide 309; the nucleotide sequence of the full-length protein coding sequence of clone BL249_18 deposited with the ATCC under accession number 98196; or the nucleotide sequence of a mature protein coding sequence of clone BL249_18 deposited with the ATCC under
5 accession number 98196. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BL249_18 deposited with the ATCC under accession number 98196. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:13 from amino acid 3 to amino acid 102. In further preferred embodiments, the present
10 invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:13 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:13, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:13 having biological activity, the fragment comprising the amino acid sequence from amino
15 acid 376 to amino acid 385 of SEQ ID NO:13.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:12.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 20 (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:12, but excluding the poly(A) tail at the 3'
25 end of SEQ ID NO:12; and
 - (ab) the nucleotide sequence of the cDNA insert of clone BL249_18 deposited with the ATCC under accession number 98196;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - 30 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
35 consisting of:

- (ba) SEQ ID NO:12, but excluding the poly(A) tail at the 3' end of SEQ ID NO:12; and
- (bb) the nucleotide sequence of the cDNA insert of clone BL249_18 deposited with the ATCC under accession number 98196;
- 5 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide
10 sequence corresponding to the cDNA sequence of SEQ ID NO:12, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:12 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:12, but excluding the poly(A) tail at the 3' end of SEQ ID NO:12. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:12 from nucleotide
15 2 to nucleotide 2290, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:12 from nucleotide 2 to nucleotide 2290, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:12 from nucleotide 2 to nucleotide 2290. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
20 NO:12 from nucleotide 134 to nucleotide 2290, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:12 from nucleotide 134 to nucleotide 2290, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:12 from nucleotide 134 to nucleotide 2290. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA
25 sequence of SEQ ID NO:12 from nucleotide 1 to nucleotide 309, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:12 from nucleotide 1 to nucleotide 309, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:12 from nucleotide 1 to nucleotide 309.

In other embodiments, the present invention provides a composition comprising a protein,
30 wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:13;
- (b) the amino acid sequence of SEQ ID NO:13 from amino acid 3 to amino acid 102;
- (c) a fragment of the amino acid sequence of SEQ ID NO:13, the fragment
35 comprising eight contiguous amino acids of SEQ ID NO:13; and

(d) the amino acid sequence encoded by the cDNA insert of clone BL249_18 deposited with the ATCC under accession number 98196; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:13 or the amino acid sequence of SEQ ID NO:13 from amino acid 3 to amino acid 102. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:13 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:13, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:13 having biological activity, the fragment comprising the amino acid sequence from amino acid 376 to amino acid 385 of SEQ ID NO:13.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 459 to nucleotide 539;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BO71_1 deposited with the ATCC under accession number 98196;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BO71_1 deposited with the ATCC under accession number 98196;
- (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BO71_1 deposited with the ATCC under accession number 98196;
- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BO71_1 deposited with the ATCC under accession number 98196;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:16;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;

(k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:15.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:15 from nucleotide 459 to nucleotide 539; the nucleotide sequence of the full-length protein coding sequence of clone BO71_1 deposited with the ATCC under accession number 98196; or the nucleotide sequence of a mature protein coding sequence of clone BO71_1 deposited with the ATCC under accession number 98196. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BO71_1 deposited with the ATCC under accession number 98196. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:16, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 8 to amino acid 17 of SEQ ID NO:16.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:15, SEQ ID NO:14, and SEQ ID NO:17.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:14;
(ab) SEQ ID NO:15;
(ac) SEQ ID NO:17, but excluding the poly(A) tail at the 3' end of SEQ ID NO:17; and

(ad) the nucleotide sequence of the cDNA insert of clone BO71_1 deposited with the ATCC under accession number 98196;
(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:14;

(bb) SEQ ID NO:15;

(bc) SEQ ID NO:17, but excluding the poly(A) tail at the 3' end of SEQ ID NO:17; and

(bd) the nucleotide sequence of the cDNA insert of clone BO71_1 deposited with the ATCC under accession number 98196;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:14, SEQ ID NO:15, and SEQ ID NO:17, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:14 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:17, but excluding the poly(A) tail at the 3' end of SEQ ID NO:17. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:15 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:15. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15 from nucleotide 459 to nucleotide 539, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:15 from nucleotide 459 to nucleotide 539, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:15 from nucleotide 459 to nucleotide 539.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:16;

(b) a fragment of the amino acid sequence of SEQ ID NO:16, the fragment comprising eight contiguous amino acids of SEQ ID NO:16; and

- (c) the amino acid sequence encoded by the cDNA insert of clone BO71_1 deposited with the ATCC under accession number 98196;
- the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:16. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:16, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 8 to amino acid 17 of SEQ ID NO:16.
- 10 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:18;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:18 from nucleotide 1237 to nucleotide 1944;
 - 15 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:18 from nucleotide 737 to nucleotide 1072;
 - (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BO365_2 deposited with the ATCC under accession number 98196;
 - 20 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BO365_2 deposited with the ATCC under accession number 98196;
 - (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BO365_2 deposited with the ATCC under accession number 98196;
 - 25 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BO365_2 deposited with the ATCC under accession number 98196;
 - (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:19;
 - (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:19 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:19;
 - 30 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
 - (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
 - 35

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:18.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:18 from nucleotide 1237 to nucleotide 1944; the nucleotide sequence of SEQ ID NO:18 from nucleotide 737 to nucleotide 1072; the nucleotide sequence of the full-length protein coding sequence of clone BO365_2 deposited with the ATCC under accession number 98196; or the nucleotide sequence of a mature protein coding sequence of clone BO365_2 deposited with the ATCC under accession number 98196. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BO365_2 deposited with the ATCC under accession number 98196. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:19 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:19, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:19 having biological activity, the fragment comprising the amino acid sequence from amino acid 113 to amino acid 122 of SEQ ID NO:19.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:18.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
- (aa) SEQ ID NO:18, but excluding the poly(A) tail at the 3' end of SEQ ID NO:18; and
- (ab) the nucleotide sequence of the cDNA insert of clone BO365_2 deposited with the ATCC under accession number 98196;
- (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
- (iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

5 (ba) SEQ ID NO:18, but excluding the poly(A) tail at the 3' end of SEQ ID NO:18; and

(bb) the nucleotide sequence of the cDNA insert of clone BO365_2 deposited with the ATCC under accession number 98196;

10 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:18, and extending contiguously
15 from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:18 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:18, but excluding the poly(A) tail at the 3' end of SEQ ID NO:18. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:18 from nucleotide 1237 to nucleotide 1944, and extending contiguously from a nucleotide sequence corresponding
20 to the 5' end of said sequence of SEQ ID NO:18 from nucleotide 1237 to nucleotide 1944, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:18 from nucleotide 1237 to nucleotide 1944. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:18 from nucleotide 737 to nucleotide 1072, and extending contiguously from a nucleotide
25 sequence corresponding to the 5' end of said sequence of SEQ ID NO:18 from nucleotide 737 to nucleotide 1072, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:18 from nucleotide 737 to nucleotide 1072.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

30 (a) the amino acid sequence of SEQ ID NO:19;

(b) a fragment of the amino acid sequence of SEQ ID NO:19, the fragment comprising eight contiguous amino acids of SEQ ID NO:19; and

(c) the amino acid sequence encoded by the cDNA insert of clone BO365_2 deposited with the ATCC under accession number 98196;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:19. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:19 having biological activity, the fragment preferably comprising eight (more preferably
5 twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:19, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:19 having biological activity, the fragment comprising the amino acid sequence from amino acid 113 to amino acid 122 of SEQ ID NO:19.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 10 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:20 from nucleotide 68 to nucleotide 328;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BV51_1 deposited with the ATCC under accession
15 number 98196;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BV51_1 deposited with the ATCC under accession number 98196;
- (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BV51_1 deposited with the ATCC under accession number
20 98196;
- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BV51_1 deposited with the ATCC under accession number 98196;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:21;
- 25 (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:21 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:21;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- 30 (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:20.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:20
5 from nucleotide 68 to nucleotide 328; the nucleotide sequence of the full-length protein coding sequence of clone BV51_1 deposited with the ATCC under accession number 98196; or the nucleotide sequence of a mature protein coding sequence of clone BV51_1 deposited with the ATCC under accession number 98196. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BV51_1
10 deposited with the ATCC under accession number 98196. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:21 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:21, or a polynucleotide encoding a protein comprising a fragment of the amino acid
15 sequence of SEQ ID NO:21 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:21.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:20 and SEQ ID NO:22.

Further embodiments of the invention provide isolated polynucleotides produced
20 according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

25 (aa) SEQ ID NO:20;

(ab) SEQ ID NO:22, but excluding the poly(A) tail at the 3' end of SEQ ID NO:22; and

(ac) the nucleotide sequence of the cDNA insert of clone BV51_1 deposited with the ATCC under accession number 98196;

30 (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:20;

5 (bb) SEQ ID NO:22, but excluding the poly(A) tail at the 3' end of SEQ ID NO:22; and

(bc) the nucleotide sequence of the cDNA insert of clone BV51_1 deposited with the ATCC under accession number 98196;

10 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:20 and SEQ ID NO:22, and
15 extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:20 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:22, but excluding the poly(A) tail at the 3' end of SEQ ID NO:22. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:20, and extending contiguously from a nucleotide sequence corresponding to the 5' end of
20 SEQ ID NO:20 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:20. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:20 from nucleotide 68 to nucleotide 328, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:20 from nucleotide 68 to nucleotide 328, to a nucleotide
25 sequence corresponding to the 3' end of said sequence of SEQ ID NO:20 from nucleotide 68 to nucleotide 328.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:21;

30 (b) a fragment of the amino acid sequence of SEQ ID NO:21, the fragment comprising eight contiguous amino acids of SEQ ID NO:21; and

(c) the amino acid sequence encoded by the cDNA insert of clone BV51_1 deposited with the ATCC under accession number 98196;

the protein being substantially free from other mammalian proteins. Preferably such protein
35 comprises the amino acid sequence of SEQ ID NO:21. In further preferred embodiments, the

present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:21 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:21, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:21 having biological activity, the fragment
5 comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:21.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:24;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:24
10 from nucleotide 57 to nucleotide 396;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BV140_3 deposited with the ATCC under accession number 98196;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA
15 insert of clone BV140_3 deposited with the ATCC under accession number 98196;
- (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BV140_3 deposited with the ATCC under accession number 98196;
- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert
20 of clone BV140_3 deposited with the ATCC under accession number 98196;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:25;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:25 having biological activity, the fragment comprising eight
25 contiguous amino acids of SEQ ID NO:25;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
- (k) a polynucleotide that hybridizes under stringent conditions to any one of
30 the polynucleotides specified in (a)-(h); and
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:24.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:24 from nucleotide 57 to nucleotide 396; the nucleotide sequence of the full-length protein coding sequence of clone BV140_3 deposited with the ATCC under accession number 98196; or the nucleotide sequence of a mature protein coding sequence of clone BV140_3 deposited with the ATCC under accession number 98196. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BV140_3 deposited with the ATCC under accession number 98196. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:25 from amino acid 29 to amino acid 57. In further preferred
 5
 10
 15
 embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:25 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:25, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:25 having biological activity, the fragment comprising the amino acid sequence from amino acid 51 to amino acid 60 of SEQ ID NO:25.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:24, SEQ ID NO:23, and SEQ ID NO:26 .

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 20 (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:23;
 - 25 (ab) SEQ ID NO:24;
 - (ac) SEQ ID NO:26, but excluding the poly(A) tail at the 3' end of SEQ ID NO:26; and
 - (ad) the nucleotide sequence of the cDNA insert of clone BV140_3 deposited with the ATCC under accession number 98196;
 - 30 (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:23;

5

(bb) SEQ ID NO:24;

(bc) SEQ ID NO:26, but excluding the poly(A) tail at the 3' end of SEQ ID NO:26; and

(bd) the nucleotide sequence of the cDNA insert of clone BV140_3 deposited with the ATCC under accession number 98196;

10

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide
15 sequence corresponding to the cDNA sequences of SEQ ID NO:23, SEQ ID NO:24, and SEQ ID NO:26, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:23 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:26, but excluding the poly(A) tail at the 3' end of SEQ ID NO:26. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the
20 cDNA sequence of SEQ ID NO:24, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:24 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:24. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:24 from nucleotide 57 to nucleotide 396, and extending contiguously from a nucleotide sequence
25 corresponding to the 5' end of said sequence of SEQ ID NO:24 from nucleotide 57 to nucleotide 396, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:24 from nucleotide 57 to nucleotide 396.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

30

(a) the amino acid sequence of SEQ ID NO:25;

(b) the amino acid sequence of SEQ ID NO:25 from amino acid 29 to amino acid 57;

(c) a fragment of the amino acid sequence of SEQ ID NO:25, the fragment comprising eight contiguous amino acids of SEQ ID NO:25; and

(d) the amino acid sequence encoded by the cDNA insert of clone BV140_3 deposited with the ATCC under accession number 98196; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:25 or the amino acid sequence of SEQ ID NO:25 from amino acid 29 to amino acid 57. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:25 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:25, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:25 having biological activity, the fragment comprising the amino acid sequence from amino acid 51 to amino acid 60 of SEQ ID NO:25.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27 from nucleotide 101 to nucleotide 328;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27 from nucleotide 1 to nucleotide 197;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BV141_2 deposited with the ATCC under accession number 98196;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BV141_2 deposited with the ATCC under accession number 98196;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BV141_2 deposited with the ATCC under accession number 98196;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BV141_2 deposited with the ATCC under accession number 98196;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:28;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:28;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

5 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:27.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:27 from nucleotide 101 to nucleotide 328; the nucleotide sequence of SEQ ID NO:27 from
10 nucleotide 1 to nucleotide 197; the nucleotide sequence of the full-length protein coding sequence of clone BV141_2 deposited with the ATCC under accession number 98196; or the nucleotide sequence of a mature protein coding sequence of clone BV141_2 deposited with the ATCC under accession number 98196. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BV141_2 deposited with the
15 ATCC under accession number 98196. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:28 from amino acid 1 to amino acid 37. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment preferably comprising eight
20 (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:28, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising the amino acid sequence from amino acid 33 to amino acid 42 of SEQ ID NO:28.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID
25 NO:27.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X
30 SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:27, but excluding the poly(A) tail at the 3' end of SEQ ID NO:27; and

(ab) the nucleotide sequence of the cDNA insert of clone
35 BV141_2 deposited with the ATCC under accession number 98196;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

5

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

10

(ba) SEQ ID NO:27, but excluding the poly(A) tail at the 3' end of SEQ ID NO:27; and

(bb) the nucleotide sequence of the cDNA insert of clone BV141_2 deposited with the ATCC under accession number 98196;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

15

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:27 to a nucleotide sequence
20 corresponding to the 3' end of SEQ ID NO:27, but excluding the poly(A) tail at the 3' end of SEQ ID NO:27. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27 from nucleotide 101 to nucleotide 328, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:27 from nucleotide 101 to nucleotide 328, to a
25 nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:27 from nucleotide 101 to nucleotide 328. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27 from nucleotide 1 to nucleotide 197, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:27 from nucleotide 1 to
30 nucleotide 197, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:27 from nucleotide 1 to nucleotide 197.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:28;

(b) the amino acid sequence of SEQ ID NO:28 from amino acid 1 to amino acid 37;

(c) a fragment of the amino acid sequence of SEQ ID NO:28, the fragment comprising eight contiguous amino acids of SEQ ID NO:28; and

5 (d) the amino acid sequence encoded by the cDNA insert of clone BV141_2 deposited with the ATCC under accession number 98196;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:28 or the amino acid sequence of SEQ ID NO:28 from amino acid 1 to amino acid 37. In further preferred embodiments, the present
10 invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:28, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising the amino acid sequence from amino acid 33 to amino acid 42 of SEQ ID NO:28.

15 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29 from nucleotide 28 to nucleotide 351;

20 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29 from nucleotide 328 to nucleotide 351;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CC194_4 deposited with the ATCC under accession number 98196;

25 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CC194_4 deposited with the ATCC under accession number 98196;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CC194_4 deposited with the ATCC under accession number 98196;

30 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CC194_4 deposited with the ATCC under accession number 98196;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:30;

- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:30;
- 5 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- 10 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:29.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:29 from nucleotide 28 to nucleotide 351; the nucleotide sequence of SEQ ID NO:29 from nucleotide 328 to nucleotide 351; the nucleotide sequence of the full-length protein coding sequence of clone CC194_4 deposited with the ATCC under accession number 98196; or the nucleotide sequence of a mature protein coding sequence of clone CC194_4 deposited with the ATCC under accession number 98196. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CC194_4 deposited with the ATCC under accession number 98196. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:30 from amino acid 56 to amino acid 108. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:30, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising the amino acid sequence from amino acid 49 to amino acid 58 of SEQ ID NO:30.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:29 and SEQ ID NO:31.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:29;

5 (ab) SEQ ID NO:31, but excluding the poly(A) tail at the 3' end of SEQ ID NO:31; and

(ac) the nucleotide sequence of the cDNA insert of clone CC194_4 deposited with the ATCC under accession number 98196;

10 (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

15 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:29;

(bb) SEQ ID NO:31, but excluding the poly(A) tail at the 3' end of SEQ ID NO:31; and

20 (bc) the nucleotide sequence of the cDNA insert of clone CC194_4 deposited with the ATCC under accession number 98196;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

25 (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:29 and SEQ ID NO:31, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:29 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:31, but excluding the poly(A) tail at the 3' end of SEQ ID NO:31. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:29, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:29 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:29. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:29 from nucleotide 28 to

30

35

nucleotide 351, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:29 from nucleotide 28 to nucleotide 351, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:29 from nucleotide 28 to nucleotide 351. Also preferably the polynucleotide isolated according to the above process
5 comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:29 from nucleotide 328 to nucleotide 351, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:29 from nucleotide 328 to nucleotide 351, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:29 from nucleotide 328 to nucleotide 351.

10 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:30;
- (b) the amino acid sequence of SEQ ID NO:30 from amino acid 56 to amino acid 108;
- 15 (c) a fragment of the amino acid sequence of SEQ ID NO:30, the fragment comprising eight contiguous amino acids of SEQ ID NO:30; and
- (d) the amino acid sequence encoded by the cDNA insert of clone CC194_4 deposited with the ATCC under accession number 98196;

the protein being substantially free from other mammalian proteins. Preferably such protein
20 comprises the amino acid sequence of SEQ ID NO:30 or the amino acid sequence of SEQ ID NO:30 from amino acid 56 to amino acid 108. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:30, or a protein comprising a
25 fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising the amino acid sequence from amino acid 49 to amino acid 58 of SEQ ID NO:30.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32;
- 30 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32 from nucleotide 338 to nucleotide 1198;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:32 from nucleotide 467 to nucleotide 1058;

- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone DA136_11 deposited with the ATCC under accession number 98196;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone DA136_11 deposited with the ATCC under accession number 98196;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone DA136_11 deposited with the ATCC under accession number 98196;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone DA136_11 deposited with the ATCC under accession number 98196;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:33;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:33 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:33;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:32.
- Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:32 from nucleotide 338 to nucleotide 1198; the nucleotide sequence of SEQ ID NO:32 from nucleotide 467 to nucleotide 1058; the nucleotide sequence of the full-length protein coding sequence of clone DA136_11 deposited with the ATCC under accession number 98196; or the nucleotide sequence of a mature protein coding sequence of clone DA136_11 deposited with the ATCC under accession number 98196. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone DA136_11 deposited with the ATCC under accession number 98196. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:33 from amino acid 124 to amino acid 182. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a

fragment of the amino acid sequence of SEQ ID NO:33 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:33, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:33 having biological activity, the fragment comprising the amino acid sequence from amino acid 138 to amino acid 147 of SEQ ID NO:33.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:32.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 10 (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - 15 (aa) SEQ ID NO:32, but excluding the poly(A) tail at the 3' end of SEQ ID NO:32; and
 - (ab) the nucleotide sequence of the cDNA insert of clone DA136_11 deposited with the ATCC under accession number 98196;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - 20 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - 25 (ba) SEQ ID NO:32, but excluding the poly(A) tail at the 3' end of SEQ ID NO:32; and
 - (bb) the nucleotide sequence of the cDNA insert of clone DA136_11 deposited with the ATCC under accession number 98196;
 - 30 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
 - (iii) amplifying human DNA sequences; and
 - (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:32, and extending contiguously

from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:32 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:32, but excluding the poly(A) tail at the 3' end of SEQ ID NO:32. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:32 from nucleotide
5 338 to nucleotide 1198, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:32 from nucleotide 338 to nucleotide 1198, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:32 from nucleotide 338 to nucleotide 1198. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
10 NO:32 from nucleotide 467 to nucleotide 1058, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:32 from nucleotide 467 to nucleotide 1058, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:32 from nucleotide 467 to nucleotide 1058.

In other embodiments, the present invention provides a composition comprising a protein,
15 wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:33;
- (b) the amino acid sequence of SEQ ID NO:33 from amino acid 124 to amino acid 182;
- (c) a fragment of the amino acid sequence of SEQ ID NO:33, the fragment
20 comprising eight contiguous amino acids of SEQ ID NO:33; and
- (d) the amino acid sequence encoded by the cDNA insert of clone DA136_11 deposited with the ATCC under accession number 98196;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:33 or the amino acid sequence of SEQ ID
25 NO:33 from amino acid 124 to amino acid 182. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:33 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:33, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:33 having biological activity, the fragment
30 comprising the amino acid sequence from amino acid 138 to amino acid 147 of SEQ ID NO:33.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:34;

- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:34 from nucleotide 437 to nucleotide 1159;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:34 from nucleotide 515 to nucleotide 1159;
- 5 (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:34 from nucleotide 539 to nucleotide 1099;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AR415_4 deposited with the ATCC under accession number 98232;
- 10 (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AR415_4 deposited with the ATCC under accession number 98232;
- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone AR415_4 deposited with the ATCC under accession number 98232;
- 15 (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone AR415_4 deposited with the ATCC under accession number 98232;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:35;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:35 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:35;
- 20 (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;
- 25 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and
- (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:34.
- 30

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:34 from nucleotide 437 to nucleotide 1159; the nucleotide sequence of SEQ ID NO:34 from nucleotide 515 to nucleotide 1159; the nucleotide sequence of SEQ ID NO:34 from nucleotide 539 to nucleotide 1099; the nucleotide sequence of the full-length protein coding sequence of clone AR415_4 deposited with the ATCC under accession number 98232; or the nucleotide

35

sequence of a mature protein coding sequence of clone AR415_4 deposited with the ATCC under accession number 98232. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone AR415_4 deposited with the ATCC under accession number 98232. In yet other preferred embodiments, the present invention
5 provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:35 from amino acid 51 to amino acid 221. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:35 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:35, or a
10 polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:35 having biological activity, the fragment comprising the amino acid sequence from amino acid 115 to amino acid 124 of SEQ ID NO:35.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:34.

15 Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting
20 of:

(aa) SEQ ID NO:34, but excluding the poly(A) tail at the 3' end of SEQ ID NO:34; and

(ab) the nucleotide sequence of the cDNA insert of clone AR415_4 deposited with the ATCC under accession number 98232;

25 (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

30 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:34, but excluding the poly(A) tail at the 3' end of SEQ ID NO:34; and

- (bb) the nucleotide sequence of the cDNA insert of clone AR415_4 deposited with the ATCC under accession number 98232;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- 5 (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:34, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:34 to a nucleotide sequence

10 corresponding to the 3' end of SEQ ID NO:34, but excluding the poly(A) tail at the 3' end of SEQ ID NO:34. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:34 from nucleotide 437 to nucleotide 1159, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:34 from nucleotide 437 to nucleotide 1159, to a

15 nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:34 from nucleotide 437 to nucleotide 1159. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:34 from nucleotide 515 to nucleotide 1159, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:34 from nucleotide 515 to

20 nucleotide 1159, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:34 from nucleotide 515 to nucleotide 1159. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:34 from nucleotide 539 to nucleotide 1099, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:34 from

25 nucleotide 539 to nucleotide 1099, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:34 from nucleotide 539 to nucleotide 1099.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:35;
- 30 (b) the amino acid sequence of SEQ ID NO:35 from amino acid 51 to amino acid 221;
- (c) a fragment of the amino acid sequence of SEQ ID NO:35, the fragment comprising eight contiguous amino acids of SEQ ID NO:35; and
- (d) the amino acid sequence encoded by the cDNA insert of clone AR415_4
- 35 deposited with the ATCC under accession number 98232;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:35 or the amino acid sequence of SEQ ID NO:35 from amino acid 51 to amino acid 221. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:35
5 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:35, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:35 having biological activity, the fragment comprising the amino acid sequence from amino acid 115 to amino acid 124 of SEQ ID NO:35.

In one embodiment, the present invention provides a composition comprising an isolated
10 polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:36;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:36 from nucleotide 59 to nucleotide 376;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:36
15 from nucleotide 179 to nucleotide 376;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AS63_29 deposited with the ATCC under accession number 98232;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA
20 insert of clone AS63_29 deposited with the ATCC under accession number 98232;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone AS63_29 deposited with the ATCC under accession number 98232;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert
25 of clone AS63_29 deposited with the ATCC under accession number 98232;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:37;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:37 having biological activity, the fragment comprising eight
30 contiguous amino acids of SEQ ID NO:37;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:36.

5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:36 from nucleotide 59 to nucleotide 376; the nucleotide sequence of SEQ ID NO:36 from nucleotide 179 to nucleotide 376; the nucleotide sequence of the full-length protein coding sequence of clone AS63_29 deposited with the ATCC under accession number 98232; or the nucleotide sequence of a mature protein coding sequence of clone AS63_29 deposited with the ATCC under accession number 98232. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone AS63_29 deposited with the ATCC under accession number 98232. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:37 from amino acid 1 to amino acid 91. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:37 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:37, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:37 having biological activity, the fragment comprising the amino acid sequence from amino acid 48 to amino acid 57 of SEQ ID NO:37.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:36 and SEQ ID NO:38.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

30 (aa) SEQ ID NO:36;
(ab) SEQ ID NO:38, but excluding the poly(A) tail at the 3' end of SEQ ID NO:38; and
(ac) the nucleotide sequence of the cDNA insert of clone AS63_29 deposited with the ATCC under accession number 98232;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

5 (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:36;

10 (bb) SEQ ID NO:38, but excluding the poly(A) tail at the 3' end of SEQ ID NO:38; and

(bc) the nucleotide sequence of the cDNA insert of clone AS63_29 deposited with the ATCC under accession number 98232;

15 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:36 and SEQ ID NO:38, and
20 extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:36 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:38, but excluding the poly(A) tail at the 3' end of SEQ ID NO:38. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:36, and extending contiguously from a nucleotide sequence corresponding to the 5' end of
25 SEQ ID NO:36 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:36. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:36 from nucleotide 59 to nucleotide 376, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:36 from nucleotide 59 to nucleotide 376, to a nucleotide
30 sequence corresponding to the 3' end of said sequence of SEQ ID NO:36 from nucleotide 59 to nucleotide 376. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:36 from nucleotide 179 to nucleotide 376, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:36 from nucleotide 179 to nucleotide

376, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:36 from nucleotide 179 to nucleotide 376.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 5 (a) the amino acid sequence of SEQ ID NO:37;
- (b) the amino acid sequence of SEQ ID NO:37 from amino acid 1 to amino acid 91;
- (c) a fragment of the amino acid sequence of SEQ ID NO:37, the fragment comprising eight contiguous amino acids of SEQ ID NO:37; and
- 10 (d) the amino acid sequence encoded by the cDNA insert of clone AS63_29 deposited with the ATCC under accession number 98232;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:37 or the amino acid sequence of SEQ ID NO:37 from amino acid 1 to amino acid 91. In further preferred embodiments, the present
15 invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:37 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:37, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:37 having biological activity, the fragment comprising the amino acid sequence from amino acid 48 to amino acid 57 of SEQ ID NO:37.

20 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:39;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:39 from nucleotide 198 to nucleotide 2039;
- 25 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:39 from nucleotide 490 to nucleotide 809;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AY304_14 deposited with the ATCC under accession number 98561;
- 30 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AY304_14 deposited with the ATCC under accession number 98561;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone AY304_14 deposited with the ATCC under accession number 98561;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone AY304_14 deposited with the ATCC under accession number 98561;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:40;

5 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:40;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

10 (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

15 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:39.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:39 from nucleotide 198 to nucleotide 2039; the nucleotide sequence of SEQ ID NO:39 from nucleotide 490 to nucleotide 809; the nucleotide sequence of the full-length protein coding
20 sequence of clone AY304_14 deposited with the ATCC under accession number 98561; or the nucleotide sequence of a mature protein coding sequence of clone AY304_14 deposited with the ATCC under accession number 98561. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone AY304_14 deposited with the ATCC under accession number 98561. In yet other preferred embodiments,
25 the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:40 from amino acid 106 to amino acid 204. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino
30 acids of SEQ ID NO:40, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising the amino acid sequence from amino acid 302 to amino acid 311 of SEQ ID NO:40.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:39.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

5 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:39, but excluding the poly(A) tail at the 3' end of SEQ ID NO:39; and

10 (ab) the nucleotide sequence of the cDNA insert of clone AY304_14 deposited with the ATCC under accession number 98561;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

15 (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

20 (ba) SEQ ID NO:39, but excluding the poly(A) tail at the 3' end of SEQ ID NO:39; and

(bb) the nucleotide sequence of the cDNA insert of clone AY304_14 deposited with the ATCC under accession number 98561;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

25 (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:39, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:39 to a nucleotide sequence
30 corresponding to the 3' end of SEQ ID NO:39, but excluding the poly(A) tail at the 3' end of SEQ ID NO:39. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:39 from nucleotide 198 to nucleotide 2039, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:39 from nucleotide 198 to nucleotide 2039, to a
35 nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:39 from

nucleotide 198 to nucleotide 2039. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:39 from nucleotide 490 to nucleotide 809, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:39 from nucleotide 490 to
5 nucleotide 809, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:39 from nucleotide 490 to nucleotide 809.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:40;
- 10 (b) the amino acid sequence of SEQ ID NO:40 from amino acid 106 to amino acid 204;
- (c) a fragment of the amino acid sequence of SEQ ID NO:40, the fragment comprising eight contiguous amino acids of SEQ ID NO:40; and
- (d) the amino acid sequence encoded by the cDNA insert of clone AY304_14
15 deposited with the ATCC under accession number 98561;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:40 or the amino acid sequence of SEQ ID NO:40 from amino acid 106 to amino acid 204. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40
20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:40, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising the amino acid sequence from amino acid 302 to amino acid 311 of SEQ ID NO:40.

25 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41
from nucleotide 102 to nucleotide 2027;
- 30 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41
from nucleotide 1902 to nucleotide 2027;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41
from nucleotide 1 to nucleotide 431;

- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BG160_1 deposited with the ATCC under accession number 98232;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BG160_1 deposited with the ATCC under accession number 98232;
- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BG160_1 deposited with the ATCC under accession number 98232;
- (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BG160_1 deposited with the ATCC under accession number 98232;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:42;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:42;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and
- (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:41.
- Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:41 from nucleotide 102 to nucleotide 2027; the nucleotide sequence of SEQ ID NO:41 from nucleotide 1902 to nucleotide 2027; the nucleotide sequence of SEQ ID NO:41 from nucleotide 1 to nucleotide 431; the nucleotide sequence of the full-length protein coding sequence of clone BG160_1 deposited with the ATCC under accession number 98232; or the nucleotide sequence of a mature protein coding sequence of clone BG160_1 deposited with the ATCC under accession number 98232. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BG160_1 deposited with the ATCC under accession number 98232. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:42 from amino acid 1 to amino acid 110. In further preferred embodiments, the present invention provides

a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:42, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having
5 biological activity, the fragment comprising the amino acid sequence from amino acid 316 to amino acid 325 of SEQ ID NO:42.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:41.

Further embodiments of the invention provide isolated polynucleotides produced
10 according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

15 (aa) SEQ ID NO:41, but excluding the poly(A) tail at the 3' end of SEQ ID NO:41; and

(ab) the nucleotide sequence of the cDNA insert of clone BG160_1 deposited with the ATCC under accession number 98232;

(ii) hybridizing said probe(s) to human genomic DNA in conditions
20 at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in
25 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:41, but excluding the poly(A) tail at the 3' end of SEQ ID NO:41; and

(bb) the nucleotide sequence of the cDNA insert of clone BG160_1 deposited with the ATCC under accession number 98232;

(ii) hybridizing said primer(s) to human genomic DNA in conditions
30 at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:41 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:41, but excluding the poly(A) tail at the 3' end of SEQ ID NO:41. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41 from nucleotide 102 to nucleotide 2027, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:41 from nucleotide 102 to nucleotide 2027, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:41 from nucleotide 102 to nucleotide 2027. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41 from nucleotide 1902 to nucleotide 2027, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:41 from nucleotide 1902 to nucleotide 2027, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:41 from nucleotide 1902 to nucleotide 2027. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41 from nucleotide 1 to nucleotide 431, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:41 from nucleotide 1 to nucleotide 431, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:41 from nucleotide 1 to nucleotide 431.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:42;
- (b) the amino acid sequence of SEQ ID NO:42 from amino acid 1 to amino acid 110;
- (c) a fragment of the amino acid sequence of SEQ ID NO:42, the fragment comprising eight contiguous amino acids of SEQ ID NO:42; and
- (d) the amino acid sequence encoded by the cDNA insert of clone BG160_1 deposited with the ATCC under accession number 98232;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:42 or the amino acid sequence of SEQ ID NO:42 from amino acid 1 to amino acid 110. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:42, or a protein comprising a

fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising the amino acid sequence from amino acid 316 to amino acid 325 of SEQ ID NO:42.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:44;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:44 from nucleotide 566 to nucleotide 631;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BO432_4 deposited with the ATCC under accession
10 number 98232;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BO432_4 deposited with the ATCC under accession number 98232;
- (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BO432_4 deposited with the ATCC under accession number
15 98232;
- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BO432_4 deposited with the ATCC under accession number 98232;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:45;
- 20 (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:45 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:45;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- 25 (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
- (l) a polynucleotide that hybridizes under stringent conditions to any one of
30 the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:44.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:44 from nucleotide 566 to nucleotide 631; the nucleotide sequence of the full-length protein coding sequence of clone BO432_4 deposited with the ATCC under accession number 98232; or the
35 nucleotide sequence of a mature protein coding sequence of clone BO432_4 deposited with the

ATCC under accession number 98232. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BO432_4 deposited with the ATCC under accession number 98232. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:45 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:45, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:45 having biological activity, the fragment comprising the amino acid sequence from amino acid 6 to amino acid 15 of SEQ ID NO:45.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:44, SEQ ID NO:43, and SEQ ID NO:46.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:43;
 - (ab) SEQ ID NO:44;
 - (ac) SEQ ID NO:46, but excluding the poly(A) tail at the 3' end of SEQ ID NO:46; and
 - (ad) the nucleotide sequence of the cDNA insert of clone BO432_4 deposited with the ATCC under accession number 98232;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (ba) SEQ ID NO:43;
 - (bb) SEQ ID NO:44;
 - (bc) SEQ ID NO:46, but excluding the poly(A) tail at the 3' end of SEQ ID NO:46; and

- (bd) the nucleotide sequence of the cDNA insert of clone BO432_4 deposited with the ATCC under accession number 98232;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- 5 (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:43, SEQ ID NO:44, and SEQ ID NO:46, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:43 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:46, but excluding the poly(A) tail at the 3' end of SEQ ID NO:46. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:44, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:44 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:44. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:44 from nucleotide 566 to nucleotide 631, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:44 from nucleotide 566 to nucleotide 631, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:44 from nucleotide 566 to nucleotide 631.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:45;
- (b) a fragment of the amino acid sequence of SEQ ID NO:45, the fragment comprising eight contiguous amino acids of SEQ ID NO:45; and
- 25 (c) the amino acid sequence encoded by the cDNA insert of clone BO432_4 deposited with the ATCC under accession number 98232;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:45. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:45 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:45, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:45 having biological activity, the fragment comprising the amino acid sequence from amino acid 6 to amino acid 15 of SEQ ID NO:45.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:47;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:47
5 from nucleotide 45 to nucleotide 428;
 - (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BO538_2 deposited with the ATCC under accession number 98232;
 - (d) a polynucleotide encoding the full-length protein encoded by the cDNA
10 insert of clone BO538_2 deposited with the ATCC under accession number 98232;
 - (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BO538_2 deposited with the ATCC under accession number 98232;
 - (f) a polynucleotide encoding a mature protein encoded by the cDNA insert
15 of clone BO538_2 deposited with the ATCC under accession number 98232;
 - (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:48;
 - (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising eight
20 contiguous amino acids of SEQ ID NO:48;
 - (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
 - (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
 - (k) a polynucleotide that hybridizes under stringent conditions to any one of
25 the polynucleotides specified in (a)-(h); and
 - (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:47.
- 30 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:47 from nucleotide 45 to nucleotide 428; the nucleotide sequence of the full-length protein coding sequence of clone BO538_2 deposited with the ATCC under accession number 98232; or the nucleotide sequence of a mature protein coding sequence of clone BO538_2 deposited with the ATCC under accession number 98232. In other preferred embodiments, the polynucleotide
35 encodes the full-length or a mature protein encoded by the cDNA insert of clone BO538_2

deposited with the ATCC under accession number 98232. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:48 from amino acid 52 to amino acid 128. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a
5 fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:48, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising the amino acid sequence from amino acid 59 to amino acid 68 of SEQ ID NO:48.

10 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:47 and SEQ ID NO:49.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
- 15 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
- (aa) SEQ ID NO:47;
- (ab) SEQ ID NO:49, but excluding the poly(A) tail at the 3'
- 20 end of SEQ ID NO:49; and
- (ac) the nucleotide sequence of the cDNA insert of clone BO538_2 deposited with the ATCC under accession number 98232;
- (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
- 25 (iii) isolating the DNA polynucleotides detected with the probe(s);

and

- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
30 consisting of:
- (ba) SEQ ID NO:47;
- (bb) SEQ ID NO:49, but excluding the poly(A) tail at the 3' end of SEQ ID NO:49; and
- (bc) the nucleotide sequence of the cDNA insert of clone BO538_2 deposited with the ATCC under accession number 98232;
- 35

- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
 - (iii) amplifying human DNA sequences; and
 - (iv) isolating the polynucleotide products of step (b)(iii).
- 5 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:47 and SEQ ID NO:49, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:47 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:49, but excluding the poly(A) tail at the 3' end of SEQ ID NO:49. Also preferably the polynucleotide isolated according to the
- 10 above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:47, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:47 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:47. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:47 from nucleotide 45 to
- 15 nucleotide 428, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:47 from nucleotide 45 to nucleotide 428, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:47 from nucleotide 45 to nucleotide 428.

- In other embodiments, the present invention provides a composition comprising a protein,
- 20 wherein said protein comprises an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence of SEQ ID NO:48;
 - (b) the amino acid sequence of SEQ ID NO:48 from amino acid 52 to amino acid 128;
 - (c) a fragment of the amino acid sequence of SEQ ID NO:48, the fragment
 - 25 comprising eight contiguous amino acids of SEQ ID NO:48; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone BO538_2 deposited with the ATCC under accession number 98232;

- the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:48 or the amino acid sequence of SEQ ID
- 30 NO:48 from amino acid 52 to amino acid 128. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:48, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment
- 35 comprising the amino acid sequence from amino acid 59 to amino acid 68 of SEQ ID NO:48.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:50;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:50
5 from nucleotide 144 to nucleotide 566;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BR595_4 deposited with the ATCC under accession number 98232;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA
10 insert of clone BR595_4 deposited with the ATCC under accession number 98232;
- (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BR595_4 deposited with the ATCC under accession number 98232;
- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert
15 of clone BR595_4 deposited with the ATCC under accession number 98232;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:51;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:51 having biological activity, the fragment comprising eight
20 contiguous amino acids of SEQ ID NO:51;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
- (k) a polynucleotide that hybridizes under stringent conditions to any one of
25 the polynucleotides specified in (a)-(h); and
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:50.

30 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:50 from nucleotide 144 to nucleotide 566; the nucleotide sequence of the full-length protein coding sequence of clone BR595_4 deposited with the ATCC under accession number 98232; or the nucleotide sequence of a mature protein coding sequence of clone BR595_4 deposited with the ATCC under accession number 98232. In other preferred embodiments, the polynucleotide
35 encodes the full-length or a mature protein encoded by the cDNA insert of clone BR595_4

deposited with the ATCC under accession number 98232. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:51 from amino acid 39 to amino acid 141. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a
5 fragment of the amino acid sequence of SEQ ID NO:51 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:51, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:51 having biological activity, the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO:51.

10 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:50 and SEQ ID NO:52.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
- 15 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
- (aa) SEQ ID NO:50;
- (ab) SEQ ID NO:52, but excluding the poly(A) tail at the 3'
- 20 end of SEQ ID NO:52; and
- (ac) the nucleotide sequence of the cDNA insert of clone BR595_4 deposited with the ATCC under accession number 98232;
- (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
- 25 (iii) isolating the DNA polynucleotides detected with the probe(s);

and

- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
- 30 consisting of:
- (ba) SEQ ID NO:50;
- (bb) SEQ ID NO:52, but excluding the poly(A) tail at the 3' end of SEQ ID NO:52; and
- (bc) the nucleotide sequence of the cDNA insert of clone BR595_4 deposited with the ATCC under accession number 98232;
- 35

- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
 - (iii) amplifying human DNA sequences; and
 - (iv) isolating the polynucleotide products of step (b)(iii).
- 5 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:50 and SEQ ID NO:52, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:50 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:52, but excluding the poly(A) tail at the 3' end of SEQ ID NO:52. Also preferably the polynucleotide isolated according to the
- 10 above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:50, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:50 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:50. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:50 from nucleotide 144 to
- 15 nucleotide 566, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:50 from nucleotide 144 to nucleotide 566, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:50 from nucleotide 144 to nucleotide 566.

In other embodiments, the present invention provides a composition comprising a protein,

20 wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:51;
- (b) the amino acid sequence of SEQ ID NO:51 from amino acid 39 to amino acid 141;
- (c) a fragment of the amino acid sequence of SEQ ID NO:51, the fragment
- 25 comprising eight contiguous amino acids of SEQ ID NO:51; and
- (d) the amino acid sequence encoded by the cDNA insert of clone BR595_4 deposited with the ATCC under accession number 98232;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:51 or the amino acid sequence of SEQ ID

30 NO:51 from amino acid 39 to amino acid 141. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:51 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:51, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:51 having biological activity, the fragment

35 comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO:51.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:53;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:53
5 from nucleotide 232 to nucleotide 1041;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:53
from nucleotide 460 to nucleotide 1041;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:53
from nucleotide 590 to nucleotide 1163;
- 10 (e) a polynucleotide comprising the nucleotide sequence of the full-length
protein coding sequence of clone CI490_2 deposited with the ATCC under accession
number 98232;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA
insert of clone CI490_2 deposited with the ATCC under accession number 98232;
- 15 (g) a polynucleotide comprising the nucleotide sequence of a mature protein
coding sequence of clone CI490_2 deposited with the ATCC under accession number
98232;
- (h) a polynucleotide encoding a mature protein encoded by the cDNA insert
of clone CI490_2 deposited with the ATCC under accession number 98232;
- 20 (i) a polynucleotide encoding a protein comprising the amino acid sequence
of SEQ ID NO:54;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino
acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising eight
contiguous amino acids of SEQ ID NO:54;
- 25 (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h)
above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i)
or (j) above ;
- (m) a polynucleotide that hybridizes under stringent conditions to any one of
30 the polynucleotides specified in (a)-(j); and
- (n) a polynucleotide that hybridizes under stringent conditions to any one of
the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the
length of SEQ ID NO:53.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:53
35 from nucleotide 232 to nucleotide 1041; the nucleotide sequence of SEQ ID NO:53 from

nucleotide 460 to nucleotide 1041; the nucleotide sequence of SEQ ID NO:53 from nucleotide 590 to nucleotide 1163; the nucleotide sequence of the full-length protein coding sequence of clone CI490_2 deposited with the ATCC under accession number 98232; or the nucleotide sequence of a mature protein coding sequence of clone CI490_2 deposited with the ATCC under
5 accession number 98232. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CI490_2 deposited with the ATCC under accession number 98232. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:54 from amino acid 133 to amino acid 270. In further preferred embodiments, the present
10 invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:54, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising the amino acid sequence from amino
15 acid 130 to amino acid 139 of SEQ ID NO:54.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:53.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 20 (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:53, but excluding the poly(A) tail at the 3'
25 end of SEQ ID NO:53; and
 - (ab) the nucleotide sequence of the cDNA insert of clone CI490_2 deposited with the ATCC under accession number 98232;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - 30 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
35 consisting of:

- (ba) SEQ ID NO:53, but excluding the poly(A) tail at the 3' end of SEQ ID NO:53; and
- (bb) the nucleotide sequence of the cDNA insert of clone CI490_2 deposited with the ATCC under accession number 98232;
- 5 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide

10 sequence corresponding to the cDNA sequence of SEQ ID NO:53, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:53 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:53, but excluding the poly(A) tail at the 3' end of SEQ ID NO:53. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53 from nucleotide

15 232 to nucleotide 1041, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:53 from nucleotide 232 to nucleotide 1041, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:53 from nucleotide 232 to nucleotide 1041. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID

20 NO:53 from nucleotide 460 to nucleotide 1041, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:53 from nucleotide 460 to nucleotide 1041, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:53 from nucleotide 460 to nucleotide 1041. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA

25 sequence of SEQ ID NO:53 from nucleotide 590 to nucleotide 1163, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:53 from nucleotide 590 to nucleotide 1163, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:53 from nucleotide 590 to nucleotide 1163.

In other embodiments, the present invention provides a composition comprising a protein,

30 wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:54;

(b) the amino acid sequence of SEQ ID NO:54 from amino acid 133 to amino acid 270;

(c) a fragment of the amino acid sequence of SEQ ID NO:54, the fragment

35 comprising eight contiguous amino acids of SEQ ID NO:54; and

(d) the amino acid sequence encoded by the cDNA insert of clone CI490_2 deposited with the ATCC under accession number 98232; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:54 or the amino acid sequence of SEQ ID NO:54 from amino acid 133 to amino acid 270. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:54, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising the amino acid sequence from amino acid 130 to amino acid 139 of SEQ ID NO:54.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:55;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:55 from nucleotide 268 to nucleotide 624;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide 624;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CI522_1 deposited with the ATCC under accession number 98232;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CI522_1 deposited with the ATCC under accession number 98232;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CI522_1 deposited with the ATCC under accession number 98232;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CI522_1 deposited with the ATCC under accession number 98232;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:56;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:56;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

5 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:55.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:55 from nucleotide 268 to nucleotide 624; the nucleotide sequence of SEQ ID NO:55 from nucleotide
10 325 to nucleotide 624; the nucleotide sequence of the full-length protein coding sequence of clone CI522_1 deposited with the ATCC under accession number 98232; or the nucleotide sequence of a mature protein coding sequence of clone CI522_1 deposited with the ATCC under accession number 98232. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CI522_1 deposited with the ATCC under
15 accession number 98232. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:56, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having
20 biological activity, the fragment comprising the amino acid sequence from amino acid 54 to amino acid 63 of SEQ ID NO:56.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:55 and SEQ ID NO:57.

Further embodiments of the invention provide isolated polynucleotides produced
25 according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

30 (aa) SEQ ID NO:55;

(ab) SEQ ID NO:57, but excluding the poly(A) tail at the 3' end of SEQ ID NO:57; and

(ac) the nucleotide sequence of the cDNA insert of clone CI522_1 deposited with the ATCC under accession number 98232;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

5 (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:55;

10 (bb) SEQ ID NO:57, but excluding the poly(A) tail at the 3' end of SEQ ID NO:57; and

(bc) the nucleotide sequence of the cDNA insert of clone CI522_1 deposited with the ATCC under accession number 98232;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:55 and SEQ ID NO:57, and
20 extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:55 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:57, but excluding the poly(A) tail at the 3' end of SEQ ID NO:57. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55, and extending contiguously from a nucleotide sequence corresponding to the 5' end of
25 SEQ ID NO:55 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:55. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55 from nucleotide 268 to nucleotide 624, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:55 from nucleotide 268 to nucleotide 624, to a nucleotide
30 sequence corresponding to the 3' end of said sequence of SEQ ID NO:55 from nucleotide 268 to nucleotide 624. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide 624, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide

624, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide 624.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 5 (a) the amino acid sequence of SEQ ID NO:56;
- (b) a fragment of the amino acid sequence of SEQ ID NO:56, the fragment comprising eight contiguous amino acids of SEQ ID NO:56; and
- (c) the amino acid sequence encoded by the cDNA insert of clone CI522_1 deposited with the ATCC under accession number 98232;
- 10 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:56. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:56, or a protein comprising
- 15 a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising the amino acid sequence from amino acid 54 to amino acid 63 of SEQ ID NO:56.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:58;
- 20 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:58 from nucleotide 288 to nucleotide 710;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:58 from nucleotide 868 to nucleotide 1887;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length
- 25 protein coding sequence of clone CN238_1 deposited with the ATCC under accession number 98232;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CN238_1 deposited with the ATCC under accession number 98232;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein
- 30 coding sequence of clone CN238_1 deposited with the ATCC under accession number 98232;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CN238_1 deposited with the ATCC under accession number 98232;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence
- 35 of SEQ ID NO:59;

- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:59 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:59;
- 5 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- 10 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:58.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:58 from nucleotide 288 to nucleotide 710; the nucleotide sequence of SEQ ID NO:58 from
15 nucleotide 868 to nucleotide 1887; the nucleotide sequence of the full-length protein coding sequence of clone CN238_1 deposited with the ATCC under accession number 98232; or the nucleotide sequence of a mature protein coding sequence of clone CN238_1 deposited with the ATCC under accession number 98232. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CN238_1
20 deposited with the ATCC under accession number 98232. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:59 from amino acid 1 to amino acid 109. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:59 having biological activity, the fragment
25 preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:59, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:59 having biological activity, the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO:59.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID
30 NO:58.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

5

(aa) SEQ ID NO:58, but excluding the poly(A) tail at the 3' end of SEQ ID NO:58; and

(ab) the nucleotide sequence of the cDNA insert of clone CN238_1 deposited with the ATCC under accession number 98232;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

10

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

15

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:58, but excluding the poly(A) tail at the 3' end of SEQ ID NO:58; and

(bb) the nucleotide sequence of the cDNA insert of clone CN238_1 deposited with the ATCC under accession number 98232;

20

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide
25 sequence corresponding to the cDNA sequence of SEQ ID NO:58, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:58 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:58, but excluding the poly(A) tail at the 3' end of SEQ ID NO:58. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:58 from nucleotide
30 288 to nucleotide 710, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:58 from nucleotide 288 to nucleotide 710, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:58 from nucleotide 288 to nucleotide 710. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
35 NO:58 from nucleotide 868 to nucleotide 1887, and extending contiguously from a nucleotide

sequence corresponding to the 5' end of said sequence of SEQ ID NO:58 from nucleotide 868 to nucleotide 1887, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:58 from nucleotide 868 to nucleotide 1887.

In other embodiments, the present invention provides a composition comprising a protein,
5 wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:59;
- (b) the amino acid sequence of SEQ ID NO:59 from amino acid 1 to amino acid 109;
- (c) a fragment of the amino acid sequence of SEQ ID NO:59, the fragment
10 comprising eight contiguous amino acids of SEQ ID NO:59; and
- (d) the amino acid sequence encoded by the cDNA insert of clone CN238_1 deposited with the ATCC under accession number 98232;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:59 or the amino acid sequence of SEQ ID
15 NO:59 from amino acid 1 to amino acid 109. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:59 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:59, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:59 having biological activity, the fragment
20 comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO:59.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:60;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:60
25 from nucleotide 87 to nucleotide 1871;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:60 from nucleotide 628 to nucleotide 1882;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CO390_1 deposited with the ATCC under accession
30 number 98232;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CO390_1 deposited with the ATCC under accession number 98232;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CO390_1 deposited with the ATCC under accession number
35 98232;

- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CO390_1 deposited with the ATCC under accession number 98232;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:61;
- 5 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:61 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:61;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- 10 (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:60.
- 15

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:60 from nucleotide 87 to nucleotide 1871; the nucleotide sequence of SEQ ID NO:60 from nucleotide 628 to nucleotide 1882; the nucleotide sequence of the full-length protein coding sequence of clone CO390_1 deposited with the ATCC under accession number 98232; or the nucleotide sequence of a mature protein coding sequence of clone CO390_1 deposited with the ATCC under accession number 98232. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CO390_1 deposited with the ATCC under accession number 98232. In yet other preferred embodiments,

20 the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:61 from amino acid 182 to amino acid 248. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:61 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:61, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:61 having biological activity, the fragment comprising the amino acid sequence from amino acid 292 to amino acid 301 of SEQ ID NO:61.

25 30

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:60.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

5 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:60, but excluding the poly(A) tail at the 3' end of SEQ ID NO:60; and

10 (ab) the nucleotide sequence of the cDNA insert of clone CO390_1 deposited with the ATCC under accession number 98232;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

15 (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

20 (ba) SEQ ID NO:60, but excluding the poly(A) tail at the 3' end of SEQ ID NO:60; and

(bb) the nucleotide sequence of the cDNA insert of clone CO390_1 deposited with the ATCC under accession number 98232;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

25 (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:60, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:60 to a nucleotide sequence
30 corresponding to the 3' end of SEQ ID NO:60, but excluding the poly(A) tail at the 3' end of SEQ ID NO:60. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:60 from nucleotide 87 to nucleotide 1871, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:60 from nucleotide 87 to nucleotide 1871, to a
35 nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:60 from

nucleotide 87 to nucleotide 1871. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:60 from nucleotide 628 to nucleotide 1882, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:60 from nucleotide 628 to
5 nucleotide 1882, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:60 from nucleotide 628 to nucleotide 1882.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:61;
- 10 (b) the amino acid sequence of SEQ ID NO:61 from amino acid 182 to amino acid 248;
- (c) a fragment of the amino acid sequence of SEQ ID NO:61, the fragment comprising eight contiguous amino acids of SEQ ID NO:61; and
- (d) the amino acid sequence encoded by the cDNA insert of clone CO390_1
15 deposited with the ATCC under accession number 98232;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:61 or the amino acid sequence of SEQ ID NO:61 from amino acid 182 to amino acid 248. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:61
20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:61, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:61 having biological activity, the fragment comprising the amino acid sequence from amino acid 292 to amino acid 301 of SEQ ID NO:61.

25 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:62;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:62
from nucleotide 68 to nucleotide 430;
- 30 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:62 from nucleotide 128 to nucleotide 430;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AJ20_2 deposited with the ATCC under accession number 98261;

- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AJ20_2 deposited with the ATCC under accession number 98261;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone AJ20_2 deposited with the ATCC under accession number 98261;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone AJ20_2 deposited with the ATCC under accession number 98261;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:63;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:63 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:63;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:62.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:62 from nucleotide 68 to nucleotide 430; the nucleotide sequence of SEQ ID NO:62 from nucleotide 128 to nucleotide 430; the nucleotide sequence of the full-length protein coding sequence of clone AJ20_2 deposited with the ATCC under accession number 98261; or the nucleotide sequence of a mature protein coding sequence of clone AJ20_2 deposited with the ATCC under accession number 98261. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone AJ20_2 deposited with the ATCC under accession number 98261. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:63 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:63, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:63 having biological activity, the fragment comprising the amino acid sequence from amino acid 55 to amino acid 64 of SEQ ID NO:63.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:62 and SEQ ID NO:64.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 5 (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
- 10 (aa) SEQ ID NO:62;
- (ab) SEQ ID NO:64, but excluding the poly(A) tail at the 3' end of SEQ ID NO:64; and
- (ac) the nucleotide sequence of the cDNA insert of clone AJ20_2 deposited with the ATCC under accession number 98261;
- 15 (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
- (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that hybridize in
- 20 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
- (ba) SEQ ID NO:62;
- (bb) SEQ ID NO:64, but excluding the poly(A) tail at the 3' end of SEQ ID NO:64; and
- 25 (bc) the nucleotide sequence of the cDNA insert of clone AJ20_2 deposited with the ATCC under accession number 98261;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- (iii) amplifying human DNA sequences; and
- 30 (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:62 and SEQ ID NO:64, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:62 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:64, but excluding the poly(A) tail at the 3' end of SEQ ID NO:64. Also preferably the polynucleotide isolated according to the

35

above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:62, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:62 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:62. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:62 from nucleotide 68 to nucleotide 430, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:62 from nucleotide 68 to nucleotide 430, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:62 from nucleotide 68 to nucleotide 430. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:62 from nucleotide 128 to nucleotide 430; and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:62 from nucleotide 128 to nucleotide 430, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:62 from nucleotide 128 to nucleotide 430.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:63;
- (b) a fragment of the amino acid sequence of SEQ ID NO:63, the fragment comprising eight contiguous amino acids of SEQ ID NO:63; and
- (c) the amino acid sequence encoded by the cDNA insert of clone AJ20_2 deposited with the ATCC under accession number 98261;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:63. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:63 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:63, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:63 having biological activity, the fragment comprising the amino acid sequence from amino acid 55 to amino acid 64 of SEQ ID NO:63.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:66;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:66 from nucleotide 289 to nucleotide 780;

- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AR440_1 deposited with the ATCC under accession number 98261;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AR440_1 deposited with the ATCC under accession number 98261;
- (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone AR440_1 deposited with the ATCC under accession number 98261;
- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone AR440_1 deposited with the ATCC under accession number 98261;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:67;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:67 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:67;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:66.
- Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:66 from nucleotide 289 to nucleotide 780; the nucleotide sequence of the full-length protein coding sequence of clone AR440_1 deposited with the ATCC under accession number 98261; or the nucleotide sequence of a mature protein coding sequence of clone AR440_1 deposited with the ATCC under accession number 98261. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone AR440_1 deposited with the ATCC under accession number 98261. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:67 from amino acid 1 to amino acid 160. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:67 having biological activity, the fragment

preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:67, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:67 having biological activity, the fragment comprising the amino acid sequence from amino acid 77 to amino acid 86 of SEQ ID NO:67.

5 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:66 and SEQ ID NO:65.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

10 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:65;

15 (ab) SEQ ID NO:66, but excluding the poly(A) tail at the 3' end of SEQ ID NO:66; and

(ac) the nucleotide sequence of the cDNA insert of clone AR440_1 deposited with the ATCC under accession number 98261;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

20 (iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

25 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:65;

(bb) SEQ ID NO:66, but excluding the poly(A) tail at the 3' end of SEQ ID NO:66; and

30 (bc) the nucleotide sequence of the cDNA insert of clone AR440_1 deposited with the ATCC under accession number 98261;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:65 and SEQ ID NO:66, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:65 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:66, but excluding the poly(A) tail at the 3' end of SEQ ID NO:66. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:66, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:66 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:66, but excluding the poly(A) tail at the 3' end of SEQ ID NO:66. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:66 from nucleotide 289 to nucleotide 780, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:66 from nucleotide 289 to nucleotide 780, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:66 from nucleotide 289 to nucleotide 780.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:67;
- (b) the amino acid sequence of SEQ ID NO:67 from amino acid 1 to amino acid 160;
- (c) a fragment of the amino acid sequence of SEQ ID NO:67, the fragment comprising eight contiguous amino acids of SEQ ID NO:67; and
- (d) the amino acid sequence encoded by the cDNA insert of clone AR440_1 deposited with the ATCC under accession number 98261;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:67 or the amino acid sequence of SEQ ID NO:67 from amino acid 1 to amino acid 160. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:67 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:67, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:67 having biological activity, the fragment comprising the amino acid sequence from amino acid 77 to amino acid 86 of SEQ ID NO:67.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:68;

- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:68 from nucleotide 76 to nucleotide 1050;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:68 from nucleotide 331 to nucleotide 567;
- 5 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AS164_1 deposited with the ATCC under accession number 98261;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AS164_1 deposited with the ATCC under accession number 98261;
- 10 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone AS164_1 deposited with the ATCC under accession number 98261;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone AS164_1 deposited with the ATCC under accession number 98261;
- 15 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:69;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:69 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:69;
- 20 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of
- 25 the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:68.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:68

30 from nucleotide 76 to nucleotide 1050; the nucleotide sequence of SEQ ID NO:68 from nucleotide 331 to nucleotide 567; the nucleotide sequence of the full-length protein coding sequence of clone AS164_1 deposited with the ATCC under accession number 98261; or the nucleotide sequence of a mature protein coding sequence of clone AS164_1 deposited with the ATCC under accession number 98261. In other preferred embodiments, the polynucleotide

35 encodes the full-length or a mature protein encoded by the cDNA insert of clone AS164_1

deposited with the ATCC under accession number 98261. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:69 from amino acid 87 to amino acid 164. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a
5 fragment of the amino acid sequence of SEQ ID NO:69 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:69, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:69 having biological activity, the fragment comprising the amino acid sequence from amino acid 157 to amino acid 166 of SEQ ID NO:69.

10 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:68.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:
15 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:68, but excluding the poly(A) tail at the 3' end of SEQ ID NO:68; and
20 (ab) the nucleotide sequence of the cDNA insert of clone AS164_1 deposited with the ATCC under accession number 98261;
(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the probe(s);

25 and

(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

30 (ba) SEQ ID NO:68, but excluding the poly(A) tail at the 3' end of SEQ ID NO:68; and

(bb) the nucleotide sequence of the cDNA insert of clone AS164_1 deposited with the ATCC under accession number 98261;

(ii) hybridizing said primer(s) to human genomic DNA in conditions
35 at least as stringent as 4X SSC at 50 degrees C;

- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:68, and extending contiguously
5 from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:68 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:68, but excluding the poly(A) tail at the 3' end of SEQ ID NO:68. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:68 from nucleotide 76 to nucleotide 1050, and extending contiguously from a nucleotide sequence corresponding to
10 the 5' end of said sequence of SEQ ID NO:68 from nucleotide 76 to nucleotide 1050, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:68 from nucleotide 76 to nucleotide 1050. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:68 from nucleotide 331 to nucleotide 567, and extending contiguously from a nucleotide
15 sequence corresponding to the 5' end of said sequence of SEQ ID NO:68 from nucleotide 331 to nucleotide 567, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:68 from nucleotide 331 to nucleotide 567.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 20 (a) the amino acid sequence of SEQ ID NO:69;
- (b) the amino acid sequence of SEQ ID NO:69 from amino acid 87 to amino acid 164;
- (c) a fragment of the amino acid sequence of SEQ ID NO:69, the fragment comprising eight contiguous amino acids of SEQ ID NO:69; and
- 25 (d) the amino acid sequence encoded by the cDNA insert of clone AS164_1 deposited with the ATCC under accession number 98261;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:69 or the amino acid sequence of SEQ ID NO:69 from amino acid 87 to amino acid 164. In further preferred embodiments, the present
30 invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:69 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:69, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:69 having biological activity, the fragment comprising the amino acid sequence from amino acid 157 to amino acid 166 of SEQ ID NO:69.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:70;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:70
5 from nucleotide 242 to nucleotide 1060;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:70
from nucleotide 596 to nucleotide 1060;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:70
from nucleotide 10 to nucleotide 373;
- 10 (e) a polynucleotide comprising the nucleotide sequence of the full-length
protein coding sequence of clone AX8_1 deposited with the ATCC under accession
number 98261;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA
insert of clone AX8_1 deposited with the ATCC under accession number 98261;
- 15 (g) a polynucleotide comprising the nucleotide sequence of a mature protein
coding sequence of clone AX8_1 deposited with the ATCC under accession number
98261;
- (h) a polynucleotide encoding a mature protein encoded by the cDNA insert
of clone AX8_1 deposited with the ATCC under accession number 98261;
- 20 (i) a polynucleotide encoding a protein comprising the amino acid sequence
of SEQ ID NO:71;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino
acid sequence of SEQ ID NO:71 having biological activity, the fragment comprising eight
contiguous amino acids of SEQ ID NO:71;
- 25 (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h)
above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i)
or (j) above ;
- (m) a polynucleotide that hybridizes under stringent conditions to any one of
30 the polynucleotides specified in (a)-(j); and
- (n) a polynucleotide that hybridizes under stringent conditions to any one of
the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the
length of SEQ ID NO:70.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:70
35 from nucleotide 242 to nucleotide 1060; the nucleotide sequence of SEQ ID NO:70 from

nucleotide 596 to nucleotide 1060; the nucleotide sequence of SEQ ID NO:70 from nucleotide 10 to nucleotide 373; the nucleotide sequence of the full-length protein coding sequence of clone AX8_1 deposited with the ATCC under accession number 98261; or the nucleotide sequence of a mature protein coding sequence of clone AX8_1 deposited with the ATCC under accession
5 number 98261. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone AX8_1 deposited with the ATCC under accession number 98261. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:71 from amino acid 1 to amino acid 44. In further preferred embodiments, the present invention provides
10 a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:71 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:71, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:71 having biological activity, the fragment comprising the amino acid sequence from amino acid 131 to
15 amino acid 140 of SEQ ID NO:71.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:70.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 20 (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:70, but excluding the poly(A) tail at the 3'
25 end of SEQ ID NO:70; and
 - (ab) the nucleotide sequence of the cDNA insert of clone AX8_1 deposited with the ATCC under accession number 98261;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - 30 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
35 consisting of:

- (ba) SEQ ID NO:70, but excluding the poly(A) tail at the 3' end of SEQ ID NO:70; and
- (bb) the nucleotide sequence of the cDNA insert of clone AX8_1 deposited with the ATCC under accession number 98261;
- 5 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide

10 sequence corresponding to the cDNA sequence of SEQ ID NO:70, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:70 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:70, but excluding the poly(A) tail at the 3' end of SEQ ID NO:70. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:70 from nucleotide

15 242 to nucleotide 1060, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:70 from nucleotide 242 to nucleotide 1060, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:70 from nucleotide 242 to nucleotide 1060. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID

20 NO:70 from nucleotide 596 to nucleotide 1060, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:70 from nucleotide 596 to nucleotide 1060, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:70 from nucleotide 596 to nucleotide 1060. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA

25 sequence of SEQ ID NO:70 from nucleotide 10 to nucleotide 373, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:70 from nucleotide 10 to nucleotide 373, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:70 from nucleotide 10 to nucleotide 373.

In other embodiments, the present invention provides a composition comprising a protein,

30 wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:71;
- (b) the amino acid sequence of SEQ ID NO:71 from amino acid 1 to amino acid 44;
- (c) a fragment of the amino acid sequence of SEQ ID NO:71, the fragment
- 35 comprising eight contiguous amino acids of SEQ ID NO:71; and

- (d) the amino acid sequence encoded by the cDNA insert of clone AX8_1 deposited with the ATCC under accession number 98261;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:71 or the amino acid sequence of SEQ ID NO:71 from amino acid 1 to amino acid 44. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:71 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:71, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:71 having biological activity, the fragment comprising the amino acid sequence from amino acid 131 to amino acid 140 of SEQ ID NO:71.
- In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:72;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:72 from nucleotide 773 to nucleotide 928;
 - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:72 from nucleotide 815 to nucleotide 928;
 - (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BD176_3 deposited with the ATCC under accession number 98261;
 - (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BD176_3 deposited with the ATCC under accession number 98261;
 - (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BD176_3 deposited with the ATCC under accession number 98261;
 - (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BD176_3 deposited with the ATCC under accession number 98261;
 - (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:73;
 - (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:73 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:73;
 - (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

5 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:72.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:72 from nucleotide 773 to nucleotide 928; the nucleotide sequence of SEQ ID NO:72 from nucleotide
10 815 to nucleotide 928; the nucleotide sequence of the full-length protein coding sequence of clone BD176_3 deposited with the ATCC under accession number 98261; or the nucleotide sequence of a mature protein coding sequence of clone BD176_3 deposited with the ATCC under accession number 98261. In other preferred embodiments, the polynucleotide encodes the full-length or a
15 mature protein encoded by the cDNA insert of clone BD176_3 deposited with the ATCC under accession number 98261. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:73 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:73, or a polynucleotide
20 encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:73 having biological activity, the fragment comprising the amino acid sequence from amino acid 21 to amino acid 30 of SEQ ID NO:73.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:72 and SEQ ID NO:74.

Further embodiments of the invention provide isolated polynucleotides produced
25 according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

30 (aa) SEQ ID NO:72;
(ab) SEQ ID NO:74, but excluding the poly(A) tail at the 3' end of SEQ ID NO:74; and
(ac) the nucleotide sequence of the cDNA insert of clone BD176_3 deposited with the ATCC under accession number 98261;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

5 (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:72;

10 (bb) SEQ ID NO:74, but excluding the poly(A) tail at the 3' end of SEQ ID NO:74; and

(bc) the nucleotide sequence of the cDNA insert of clone BD176_3 deposited with the ATCC under accession number 98261;

15 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:72 and SEQ ID NO:74, and
20 extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:72 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:74, but excluding the poly(A) tail at the 3' end of SEQ ID NO:74. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:72, and extending contiguously from a nucleotide sequence corresponding to the 5' end of
25 SEQ ID NO:72 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:72. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:72 from nucleotide 773 to nucleotide 928, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:72 from nucleotide 773 to nucleotide 928, to a nucleotide
30 sequence corresponding to the 3' end of said sequence of SEQ ID NO:72 from nucleotide 773 to nucleotide 928. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:72 from nucleotide 815 to nucleotide 928, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:72 from nucleotide 815 to nucleotide

928, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:72 from nucleotide 815 to nucleotide 928.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 5 (a) the amino acid sequence of SEQ ID NO:73;
 - (b) a fragment of the amino acid sequence of SEQ ID NO:73, the fragment comprising eight contiguous amino acids of SEQ ID NO:73; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone BD176_3 deposited with the ATCC under accession number 98261;
- 10 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:73. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:73 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:73, or a protein comprising
- 15 a fragment of the amino acid sequence of SEQ ID NO:73 having biological activity, the fragment comprising the amino acid sequence from amino acid 21 to amino acid 30 of SEQ ID NO:73.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:75;
- 20 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:75 from nucleotide 174 to nucleotide 440;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:75 from nucleotide 1 to nucleotide 313;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length
- 25 protein coding sequence of clone BD339_1 deposited with the ATCC under accession number 98261;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BD339_1 deposited with the ATCC under accession number 98261;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein
- 30 coding sequence of clone BD339_1 deposited with the ATCC under accession number 98261;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BD339_1 deposited with the ATCC under accession number 98261;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence
- 35 of SEQ ID NO:76;

- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:76;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:75.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:75 from nucleotide 174 to nucleotide 440; the nucleotide sequence of SEQ ID NO:75 from nucleotide 1 to nucleotide 313; the nucleotide sequence of the full-length protein coding sequence of clone BD339_1 deposited with the ATCC under accession number 98261; or the nucleotide sequence of a mature protein coding sequence of clone BD339_1 deposited with the ATCC under accession number 98261. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BD339_1 deposited with the ATCC under accession number 98261. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:76 from amino acid 1 to amino acid 46. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:76, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment comprising the amino acid sequence from amino acid 39 to amino acid 48 of SEQ ID NO:76.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:75.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

5 (aa) SEQ ID NO:75, but excluding the poly(A) tail at the 3' end of SEQ ID NO:75; and

(ab) the nucleotide sequence of the cDNA insert of clone BD339_1 deposited with the ATCC under accession number 98261;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

10 (iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

15 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:75, but excluding the poly(A) tail at the 3' end of SEQ ID NO:75; and

(bb) the nucleotide sequence of the cDNA insert of clone BD339_1 deposited with the ATCC under accession number 98261;

20 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide
25 sequence corresponding to the cDNA sequence of SEQ ID NO:75, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:75 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:75, but excluding the poly(A) tail at the 3' end of SEQ ID NO:75. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:75 from nucleotide
30 174 to nucleotide 440, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:75 from nucleotide 174 to nucleotide 440, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:75 from nucleotide 174 to nucleotide 440. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
35 NO:75 from nucleotide 1 to nucleotide 313, and extending contiguously from a nucleotide

sequence corresponding to the 5' end of said sequence of SEQ ID NO:75 from nucleotide 1 to nucleotide 313, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:75 from nucleotide 1 to nucleotide 313.

In other embodiments, the present invention provides a composition comprising a protein,
5 wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:76;
- (b) the amino acid sequence of SEQ ID NO:76 from amino acid 1 to amino acid 46;
- (c) a fragment of the amino acid sequence of SEQ ID NO:76, the fragment
10 comprising eight contiguous amino acids of SEQ ID NO:76; and
- (d) the amino acid sequence encoded by the cDNA insert of clone BD339_1 deposited with the ATCC under accession number 98261;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:76 or the amino acid sequence of SEQ ID
15 NO:76 from amino acid 1 to amino acid 46. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:76, or a protein comprising a
20 fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment comprising the amino acid sequence from amino acid 39 to amino acid 48 of SEQ ID NO:76.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:77;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:77
25 from nucleotide 509 to nucleotide 619;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:77 from nucleotide 1 to nucleotide 580;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BD427_1 deposited with the ATCC under accession
30 number 98261;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BD427_1 deposited with the ATCC under accession number 98261;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BD427_1 deposited with the ATCC under accession number
35 98261;

- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BD427_1 deposited with the ATCC under accession number 98261;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:78;
- 5 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:78;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- 10 (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of
- 15 the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:77.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:77 from nucleotide 509 to nucleotide 619; the nucleotide sequence of SEQ ID NO:77 from nucleotide 1 to nucleotide 580; the nucleotide sequence of the full-length protein coding sequence

20 of clone BD427_1 deposited with the ATCC under accession number 98261; or the nucleotide sequence of a mature protein coding sequence of clone BD427_1 deposited with the ATCC under accession number 98261. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BD427_1 deposited with the ATCC under accession number 98261. In yet other preferred embodiments, the present invention

25 provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:78 from amino acid 1 to amino acid 24. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:78, or a

30 polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment comprising the amino acid sequence from amino acid 13 to amino acid 22 of SEQ ID NO:78.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:77.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

5 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:77, but excluding the poly(A) tail at the 3' end of SEQ ID NO:77; and

10 (ab) the nucleotide sequence of the cDNA insert of clone BD427_1 deposited with the ATCC under accession number 98261;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

15 (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

20 (ba) SEQ ID NO:77, but excluding the poly(A) tail at the 3' end of SEQ ID NO:77; and

(bb) the nucleotide sequence of the cDNA insert of clone BD427_1 deposited with the ATCC under accession number 98261;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

25 (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:77, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:77 to a nucleotide sequence
30 corresponding to the 3' end of SEQ ID NO:77, but excluding the poly(A) tail at the 3' end of SEQ ID NO:77. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:77 from nucleotide 509 to nucleotide 619, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:77 from nucleotide 509 to nucleotide 619, to a
35 nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:77 from

nucleotide 509 to nucleotide 619. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:77 from nucleotide 1 to nucleotide 580, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:77 from nucleotide 1 to nucleotide 580, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:77 from nucleotide 1 to nucleotide 580.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:78;
- 10 (b) the amino acid sequence of SEQ ID NO:78 from amino acid 1 to amino acid 24;
- (c) a fragment of the amino acid sequence of SEQ ID NO:78, the fragment comprising eight contiguous amino acids of SEQ ID NO:78; and
- (d) the amino acid sequence encoded by the cDNA insert of clone BD427_1
- 15 deposited with the ATCC under accession number 98261;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:78 or the amino acid sequence of SEQ ID NO:78 from amino acid 1 to amino acid 24. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:78, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment comprising the amino acid sequence from amino acid 13 to amino acid 22 of SEQ ID NO:78.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:79;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:79 from nucleotide 300 to nucleotide 360;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BL229_22 deposited with the ATCC under accession number 98261;
- 30 (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BL229_22 deposited with the ATCC under accession number 98261;

- (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BL229_22 deposited with the ATCC under accession number 98261;
- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BL229_22 deposited with the ATCC under accession number 98261;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:80;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:80;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:79.
- Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:79 from nucleotide 300 to nucleotide 360; the nucleotide sequence of the full-length protein coding sequence of clone BL229_22 deposited with the ATCC under accession number 98261; or the nucleotide sequence of a mature protein coding sequence of clone BL229_22 deposited with the ATCC under accession number 98261. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BL229_22 deposited with the ATCC under accession number 98261. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:80, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment comprising the amino acid sequence from amino acid 5 to amino acid 14 of SEQ ID NO:80.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:79 and SEQ ID NO:81.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

5 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:79;

(ab) SEQ ID NO:81, but excluding the poly(A) tail at the 3' end of SEQ ID NO:81; and

10 (ac) the nucleotide sequence of the cDNA insert of clone BL229_22 deposited with the ATCC under accession number 98261;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

15 and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

20 (ba) SEQ ID NO:79;

(bb) SEQ ID NO:81, but excluding the poly(A) tail at the 3' end of SEQ ID NO:81; and

(bc) the nucleotide sequence of the cDNA insert of clone BL229_22 deposited with the ATCC under accession number 98261;

25 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide
30 sequence corresponding to the cDNA sequences of SEQ ID NO:79 and SEQ ID NO:81, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:79 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:81, but excluding the poly(A) tail at the 3' end of SEQ ID NO:81. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
35 NO:79, and extending contiguously from a nucleotide sequence corresponding to the 5' end of

SEQ ID NO:79 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:79. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:79 from nucleotide 300 to nucleotide 360, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:79 from nucleotide 300 to nucleotide 360, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:79 from nucleotide 300 to nucleotide 360.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 10 (a) the amino acid sequence of SEQ ID NO:80;
 - (b) a fragment of the amino acid sequence of SEQ ID NO:80, the fragment comprising eight contiguous amino acids of SEQ ID NO:80; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone BL229_22 deposited with the ATCC under accession number 98261;
- 15 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:80. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:80, or a protein comprising
- 20 a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment comprising the amino acid sequence from amino acid 5 to amino acid 14 of SEQ ID NO:80.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:82;
- 25 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:82 from nucleotide 604 to nucleotide 771;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:82 from nucleotide 1 to nucleotide 684;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length
- 30 protein coding sequence of clone BV123_16 deposited with the ATCC under accession number 98261;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BV123_16 deposited with the ATCC under accession number 98261;

- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BV123_16 deposited with the ATCC under accession number 98261;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert
5 of clone BV123_16 deposited with the ATCC under accession number 98261;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:83;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:83 having biological activity, the fragment comprising eight
10 contiguous amino acids of SEQ ID NO:83;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of
15 the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:82.
- 20 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:82 from nucleotide 604 to nucleotide 771; the nucleotide sequence of SEQ ID NO:82 from nucleotide 1 to nucleotide 684; the nucleotide sequence of the full-length protein coding sequence of clone BV123_16 deposited with the ATCC under accession number 98261; or the nucleotide sequence of a mature protein coding sequence of clone BV123_16 deposited with the ATCC under
25 accession number 98261. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BV123_16 deposited with the ATCC under accession number 98261. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:83 from amino acid 1 to amino acid 27. In further preferred embodiments, the present
30 invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:83 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:83, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:83 having biological activity, the fragment comprising the amino acid sequence from amino
35 acid 23 to amino acid 32 of SEQ ID NO:83.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:82.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 5 (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
- 10 (aa) SEQ ID NO:82, but excluding the poly(A) tail at the 3' end of SEQ ID NO:82; and
- (ab) the nucleotide sequence of the cDNA insert of clone BV123_16 deposited with the ATCC under accession number 98261;
- (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
- 15 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
- 20 consisting of:
- (ba) SEQ ID NO:82, but excluding the poly(A) tail at the 3' end of SEQ ID NO:82; and
- (bb) the nucleotide sequence of the cDNA insert of clone BV123_16 deposited with the ATCC under accession number 98261;
- 25 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide

30 sequence corresponding to the cDNA sequence of SEQ ID NO:82, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:82 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:82, but excluding the poly(A) tail at the 3' end of SEQ ID NO:82. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:82 from nucleotide

35 604 to nucleotide 771, and extending contiguously from a nucleotide sequence corresponding to

the 5' end of said sequence f SEQ ID NO:82 from nucleotide 604 to nucleotide 771, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:82 from nucleotide 604 to nucleotide 771. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
5 NO:82 from nucleotide 1 to nucleotide 684, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:82 from nucleotide 1 to nucleotide 684, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:82 from nucleotide 1 to nucleotide 684.

In other embodiments, the present invention provides a composition comprising a protein,
10 wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:83;
- (b) the amino acid sequence of SEQ ID NO:83 from amino acid 1 to amino acid 27;
- (c) a fragment of the amino acid sequence of SEQ ID NO:83, the fragment
15 comprising eight contiguous amino acids of SEQ ID NO:83; and
- (d) the amino acid sequence encoded by the cDNA insert of clone BV123_16 deposited with the ATCC under accession number 98261;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:83 or the amino acid sequence of SEQ ID
20 NO:83 from amino acid 1 to amino acid 27. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:83 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:83, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:83 having biological activity, the fragment
25 comprising the amino acid sequence from amino acid 23 to amino acid 32 of SEQ ID NO:83.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:84;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:84
30 from nucleotide 43 to nucleotide 297;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:84 from nucleotide 94 to nucleotide 297;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:84 from nucleotide 1 to nucleotide 379;

- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CH377_1 deposited with the ATCC under accession number 98261;
- 5 (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CH377_1 deposited with the ATCC under accession number 98261;
- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CH377_1 deposited with the ATCC under accession number 98261;
- 10 (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CH377_1 deposited with the ATCC under accession number 98261;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:85;
- 15 (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:85 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:85;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;
- 20 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and
- (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:84.
- 25 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:84 from nucleotide 43 to nucleotide 297; the nucleotide sequence of SEQ ID NO:84 from nucleotide 94 to nucleotide 297; the nucleotide sequence of SEQ ID NO:84 from nucleotide 1 to nucleotide 379; the nucleotide sequence of the full-length protein coding sequence of clone CH377_1 deposited with the ATCC under accession number 98261; or the nucleotide sequence of a mature
- 30 protein coding sequence of clone CH377_1 deposited with the ATCC under accession number 98261. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CH377_1 deposited with the ATCC under accession number 98261. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
- 35 NO:85 having biological activity, the fragment preferably comprising eight (more preferably

twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:85, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:85 having biological activity, the fragment comprising the amino acid sequence from amino acid 37 to amino acid 46 of SEQ ID NO:85.

5 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:84.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - 10 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:84, but excluding the poly(A) tail at the 3' end of SEQ ID NO:84; and
 - 15 (ab) the nucleotide sequence of the cDNA insert of clone CH377_1 deposited with the ATCC under accession number 98261;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);
 - 20 and
 - (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - 25 (ba) SEQ ID NO:84, but excluding the poly(A) tail at the 3' end of SEQ ID NO:84; and
 - (bb) the nucleotide sequence of the cDNA insert of clone CH377_1 deposited with the ATCC under accession number 98261;
 - (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
 - 30 (iii) amplifying human DNA sequences; and
 - (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:84, and extending contiguously

35 from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:84 to a nucleotide sequence

corresponding to the 3' end of SEQ ID NO:84, but excluding the poly(A) tail at the 3' end of SEQ ID NO:84. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:84 from nucleotide 43 to nucleotide 297, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:84 from nucleotide 43 to nucleotide 297, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:84 from nucleotide 43 to nucleotide 297. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:84 from nucleotide 94 to nucleotide 297, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:84 from nucleotide 94 to nucleotide 297, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:84 from nucleotide 94 to nucleotide 297. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:84 from nucleotide 1 to nucleotide 379, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:84 from nucleotide 1 to nucleotide 379, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:84 from nucleotide 1 to nucleotide 379.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:85;
 - (b) a fragment of the amino acid sequence of SEQ ID NO:85, the fragment comprising eight contiguous amino acids of SEQ ID NO:85; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone CH377_1 deposited with the ATCC under accession number 98261;
- the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:85. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:85 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:85, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:85 having biological activity, the fragment comprising the amino acid sequence from amino acid 37 to amino acid 46 of SEQ ID NO:85.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:87;

- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:87 from nucleotide 390 to nucleotide 563;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BD441_1 deposited with the ATCC under accession number 98264;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BD441_1 deposited with the ATCC under accession number 98264;
- (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BD441_1 deposited with the ATCC under accession number 98264;
- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BD441_1 deposited with the ATCC under accession number 98264;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:88;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:88 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:88;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:87.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:87 from nucleotide 390 to nucleotide 563; the nucleotide sequence of the full-length protein coding sequence of clone BD441_1 deposited with the ATCC under accession number 98264; or the nucleotide sequence of a mature protein coding sequence of clone BD441_1 deposited with the ATCC under accession number 98264. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BD441_1 deposited with the ATCC under accession number 98264. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:88 having biological activity, the fragment preferably

comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:88, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:88 having biological activity, the fragment comprising the amino acid sequence from amino acid 24 to amino acid 33 of SEQ ID NO:88.

5 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:87, SEQ ID NO:86, and SEQ ID NO:89.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - 10 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:86;
 - (ab) SEQ ID NO:87;
 - 15 (ac) SEQ ID NO:89, but excluding the poly(A) tail at the 3' end of SEQ ID NO:89; and
 - (ad) the nucleotide sequence of the cDNA insert of clone BD441_1 deposited with the ATCC under accession number 98264;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions
 - 20 at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in
 - 25 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (ba) SEQ ID NO:86;
 - (bb) SEQ ID NO:87;
 - (bc) SEQ ID NO:89, but excluding the poly(A) tail at the 3'
 - 30 end of SEQ ID NO:89; and
 - (bd) the nucleotide sequence of the cDNA insert of clone BD441_1 deposited with the ATCC under accession number 98264;
 - (ii) hybridizing said primer(s) to human genomic DNA in conditions
 - at least as stringent as 4X SSC at 50 degrees C;
 - 35 (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:86, SEQ ID NO:87, and SEQ ID NO:89, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:86 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:89, but excluding the poly(A) tail at the 3' end of SEQ ID NO:89. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:87, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:87 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:87. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:87 from nucleotide 390 to nucleotide 563, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:87 from nucleotide 390 to nucleotide 563, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:87 from nucleotide 390 to nucleotide 563.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:88;
- (b) a fragment of the amino acid sequence of SEQ ID NO:88, the fragment comprising eight contiguous amino acids of SEQ ID NO:88; and
- (c) the amino acid sequence encoded by the cDNA insert of clone BD441_1 deposited with the ATCC under accession number 98264;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:88. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:88 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:88, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:88 having biological activity, the fragment comprising the amino acid sequence from amino acid 24 to amino acid 33 of SEQ ID NO:88.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:90;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:90 from nucleotide 583 to nucleotide 756;

- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BD441_2 deposited with the ATCC under accession number 98264;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BD441_2 deposited with the ATCC under accession number 98264;
- (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BD441_2 deposited with the ATCC under accession number 98264;
- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BD441_2 deposited with the ATCC under accession number 98264;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:91;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:91 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:91;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:90.
- Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:90 from nucleotide 583 to nucleotide 756; the nucleotide sequence of the full-length protein coding sequence of clone BD441_2 deposited with the ATCC under accession number 98264; or the nucleotide sequence of a mature protein coding sequence of clone BD441_2 deposited with the ATCC under accession number 98264. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BD441_2 deposited with the ATCC under accession number 98264. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:91 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:91, or a polynucleotide encoding a protein comprising a fragment of the amino acid

sequence of SEQ ID NO:91 having biological activity, the fragment comprising the amino acid sequence from amino acid 24 to amino acid 33 of SEQ ID NO:91.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:90 and SEQ ID NO:92.

5 Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

10 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:90;

(ab) SEQ ID NO:92, but excluding the poly(A) tail at the 3' end of SEQ ID NO:92; and

15 (ac) the nucleotide sequence of the cDNA insert of clone BD441_2 deposited with the ATCC under accession number 98264;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

20 (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:90;

25 (bb) SEQ ID NO:92, but excluding the poly(A) tail at the 3' end of SEQ ID NO:92; and

(bc) the nucleotide sequence of the cDNA insert of clone BD441_2 deposited with the ATCC under accession number 98264;

30 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:90 and SEQ ID NO:92, and
35 extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:90

to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:92, but excluding the poly(A) tail at the 3' end of SEQ ID NO:92. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:90, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:90 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:90. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:90 from nucleotide 583 to nucleotide 756, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:90 from nucleotide 583 to nucleotide 756, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:90 from nucleotide 583 to nucleotide 756.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:91;
- (b) a fragment of the amino acid sequence of SEQ ID NO:91, the fragment comprising eight contiguous amino acids of SEQ ID NO:91; and
- (c) the amino acid sequence encoded by the cDNA insert of clone BD441_2 deposited with the ATCC under accession number 98264;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:91. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:91 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:91, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:91 having biological activity, the fragment comprising the amino acid sequence from amino acid 24 to amino acid 33 of SEQ ID NO:91.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:93;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:93 from nucleotide 426 to nucleotide 581;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:93 from nucleotide 495 to nucleotide 581;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:93 from nucleotide 354 to nucleotide 503;

(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BG102_3 deposited with the ATCC under accession number 98264;

5 (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BG102_3 deposited with the ATCC under accession number 98264;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BG102_3 deposited with the ATCC under accession number 98264;

10 (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BG102_3 deposited with the ATCC under accession number 98264;

(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:94;

15 (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:94 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:94;

(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;

(l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;

20 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and

(n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:93.

25 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:93 from nucleotide 426 to nucleotide 581; the nucleotide sequence of SEQ ID NO:93 from nucleotide 495 to nucleotide 581; the nucleotide sequence of SEQ ID NO:93 from nucleotide 354 to nucleotide 503; the nucleotide sequence of the full-length protein coding sequence of clone BG102_3 deposited with the ATCC under accession number 98264; or the nucleotide sequence
30 of a mature protein coding sequence of clone BG102_3 deposited with the ATCC under accession number 98264. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BG102_3 deposited with the ATCC under accession number 98264. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:94 from
35 amino acid 1 to amino acid 26. In further preferred embodiments, the present invention provides

a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:94 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:94, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:94 having
5 biological activity, the fragment comprising the amino acid sequence from amino acid 21 to amino acid 30 of SEQ ID NO:94.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:93.

Further embodiments of the invention provide isolated polynucleotides produced
10 according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

15 (aa) SEQ ID NO:93, but excluding the poly(A) tail at the 3' end of SEQ ID NO:93; and

(ab) the nucleotide sequence of the cDNA insert of clone BG102_3 deposited with the ATCC under accession number 98264;

(ii) hybridizing said probe(s) to human genomic DNA in conditions
20 at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in
25 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:93, but excluding the poly(A) tail at the 3' end of SEQ ID NO:93; and

(bb) the nucleotide sequence of the cDNA insert of clone BG102_3 deposited with the ATCC under accession number 98264;

(ii) hybridizing said primer(s) to human genomic DNA in conditions
30 at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:93, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:93 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:93, but excluding the poly(A) tail at the 3' end of SEQ ID NO:93. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:93 from nucleotide 426 to nucleotide 581, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:93 from nucleotide 426 to nucleotide 581, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:93 from nucleotide 426 to nucleotide 581. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:93 from nucleotide 495 to nucleotide 581, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:93 from nucleotide 495 to nucleotide 581, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:93 from nucleotide 495 to nucleotide 581. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:93 from nucleotide 354 to nucleotide 503, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:93 from nucleotide 354 to nucleotide 503, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:93 from nucleotide 354 to nucleotide 503.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:94;
- (b) the amino acid sequence of SEQ ID NO:94 from amino acid 1 to amino acid 26;
- (c) a fragment of the amino acid sequence of SEQ ID NO:94, the fragment comprising eight contiguous amino acids of SEQ ID NO:94; and
- (d) the amino acid sequence encoded by the cDNA insert of clone BG102_3 deposited with the ATCC under accession number 98264;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:94 or the amino acid sequence of SEQ ID NO:94 from amino acid 1 to amino acid 26. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:94 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:94, or a protein comprising a

fragment of the amino acid sequence of SEQ ID NO:94 having biological activity, the fragment comprising the amino acid sequence from amino acid 21 to amino acid 30 of SEQ ID NO:94.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:95;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:95
 from nucleotide 112 to nucleotide 978;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:95
 from nucleotide 436 to nucleotide 1048;
- 10 (d) a polynucleotide comprising the nucleotide sequence of the full-length
 protein coding sequence of clone BK158_1 deposited with the ATCC under accession
 number 98264;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA
 insert of clone BK158_1 deposited with the ATCC under accession number 98264;
- 15 (f) a polynucleotide comprising the nucleotide sequence of a mature protein
 coding sequence of clone BK158_1 deposited with the ATCC under accession number
 98264;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert
 of clone BK158_1 deposited with the ATCC under accession number 98264;
- 20 (h) a polynucleotide encoding a protein comprising the amino acid sequence
 of SEQ ID NO:96;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino
 acid sequence of SEQ ID NO:96 having biological activity, the fragment comprising eight
 contiguous amino acids of SEQ ID NO:96;
- 25 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g)
 above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h)
 or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of
30 the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of
 the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the
 length of SEQ ID NO:95.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:95
35 from nucleotide 112 to nucleotide 978; the nucleotide sequence of SEQ ID NO:95 from

nucleotide 436 to nucleotide 1048; the nucleotide sequence of the full-length protein coding sequence of clone BK158_1 deposited with the ATCC under accession number 98264; or the nucleotide sequence of a mature protein coding sequence of clone BK158_1 deposited with the ATCC under accession number 98264. In other preferred embodiments, the polynucleotide
5 encodes the full-length or a mature protein encoded by the cDNA insert of clone BK158_1 deposited with the ATCC under accession number 98264. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:96 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ
10 ID NO:96, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:96 having biological activity, the fragment comprising the amino acid sequence from amino acid 139 to amino acid 148 of SEQ ID NO:96.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:95.

15 Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X
SSC at 65 degrees C to a nucleotide sequence selected from the group consisting
20 of:

(aa) SEQ ID NO:95, but excluding the poly(A) tail at the 3'
end of SEQ ID NO:95; and

(ab) the nucleotide sequence of the cDNA insert of clone
BK158_1 deposited with the ATCC under accession number 98264;

25 (ii) hybridizing said probe(s) to human genomic DNA in conditions
at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

30 (i) preparing one or more polynucleotide primers that hybridize in
6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:

(ba) SEQ ID NO:95, but excluding the poly(A) tail at the 3'
end of SEQ ID NO:95; and

(bb) the nucleotide sequence of the cDNA insert of clone BK158_1 deposited with the ATCC under accession number 98264;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

5 (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:95, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:95 to a nucleotide sequence
10 corresponding to the 3' end of SEQ ID NO:95, but excluding the poly(A) tail at the 3' end of SEQ ID NO:95. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:95 from nucleotide 112 to nucleotide 978, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:95 from nucleotide 112 to nucleotide 978, to a
15 nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:95 from nucleotide 112 to nucleotide 978. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:95 from nucleotide 436 to nucleotide 1048, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:95 from nucleotide 436 to
20 nucleotide 1048, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:95 from nucleotide 436 to nucleotide 1048.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:96;
- 25 (b) a fragment of the amino acid sequence of SEQ ID NO:96, the fragment comprising eight contiguous amino acids of SEQ ID NO:96; and
- (c) the amino acid sequence encoded by the cDNA insert of clone BK158_1 deposited with the ATCC under accession number 98264;

the protein being substantially free from other mammalian proteins. Preferably such protein
30 comprises the amino acid sequence of SEQ ID NO:96. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:96 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:96, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:96 having biological activity, the fragment
35 comprising the amino acid sequence from amino acid 139 to amino acid 148 of SEQ ID NO:96.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:97;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:97
5 from nucleotide 16 to nucleotide 492;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BP163_1 deposited with the ATCC under accession number 98264;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA
10 insert of clone BP163_1 deposited with the ATCC under accession number 98264;
- (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BP163_1 deposited with the ATCC under accession number 98264;
- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert
15 of clone BP163_1 deposited with the ATCC under accession number 98264;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:98;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment comprising eight
20 contiguous amino acids of SEQ ID NO:98;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
- (k) a polynucleotide that hybridizes under stringent conditions to any one of
25 the polynucleotides specified in (a)-(h); and
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:97.

30 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:97 from nucleotide 16 to nucleotide 492; the nucleotide sequence of the full-length protein coding sequence of clone BP163_1 deposited with the ATCC under accession number 98264; or the nucleotide sequence of a mature protein coding sequence of clone BP163_1 deposited with the ATCC under accession number 98264. In other preferred embodiments, the polynucleotide
35 encodes the full-length or a mature protein encoded by the cDNA insert of clone BP163_1

deposited with the ATCC under accession number 98264. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:98, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment comprising the amino acid sequence from amino acid 74 to amino acid 83 of SEQ ID NO:98.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:97 and SEQ ID NO:99.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:97;

(ab) SEQ ID NO:99, but excluding the poly(A) tail at the 3' end of SEQ ID NO:99; and

(ac) the nucleotide sequence of the cDNA insert of clone BP163_1 deposited with the ATCC under accession number 98264;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:97;

(bb) SEQ ID NO:99, but excluding the poly(A) tail at the 3' end of SEQ ID NO:99; and

(bc) the nucleotide sequence of the cDNA insert of clone BP163_1 deposited with the ATCC under accession number 98264;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:97 and SEQ ID NO:99, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:97 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:99, but excluding the poly(A) tail at the 3' end of SEQ ID NO:99. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:97, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:97 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:97. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:97 from nucleotide 16 to nucleotide 492, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:97 from nucleotide 16 to nucleotide 492, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:97 from nucleotide 16 to nucleotide 492.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:98;
- (b) a fragment of the amino acid sequence of SEQ ID NO:98, the fragment comprising eight contiguous amino acids of SEQ ID NO:98; and
- (c) the amino acid sequence encoded by the cDNA insert of clone BP163_1 deposited with the ATCC under accession number 98264;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:98. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:98, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:98 having biological activity, the fragment comprising the amino acid sequence from amino acid 74 to amino acid 83 of SEQ ID NO:98.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:101;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:101 from nucleotide 72 to nucleotide 569;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BZ16_3 deposited with the ATCC under accession number 98264;

5 (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BZ16_3 deposited with the ATCC under accession number 98264;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BZ16_3 deposited with the ATCC under accession number 98264;

10 (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BZ16_3 deposited with the ATCC under accession number 98264;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:102;

15 (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:102 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:102;

(i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;

(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;

20 (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:101.

25 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:101 from nucleotide 72 to nucleotide 569; the nucleotide sequence of the full-length protein coding sequence of clone BZ16_3 deposited with the ATCC under accession number 98264; or the nucleotide sequence of a mature protein coding sequence of clone BZ16_3 deposited with the ATCC under accession number 98264. In other preferred embodiments, the polynucleotide
30 encodes the full-length or a mature protein encoded by the cDNA insert of clone BZ16_3 deposited with the ATCC under accession number 98264. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:102 from amino acid 1 to amino acid 124. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a
35 fragment of the amino acid sequence of SEQ ID NO:102 having biological activity, the fragment

preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:102, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:102 having biological activity, the fragment comprising the amino acid sequence from amino acid 78 to amino acid 87 of SEQ ID NO:102.

5 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:101 and SEQ ID NO:100.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - 10 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:100;
 - (ab) SEQ ID NO:101, but excluding the poly(A) tail at the 3'
 - 15 end of SEQ ID NO:101; and
 - (ac) the nucleotide sequence of the cDNA insert of clone BZ16_3 deposited with the ATCC under accession number 98264;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - 20 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
 - 25 consisting of:
 - (ba) SEQ ID NO:100;
 - (bb) SEQ ID NO:101, but excluding the poly(A) tail at the 3'
 - end of SEQ ID NO:101; and
 - (bc) the nucleotide sequence of the cDNA insert of clone BZ16_3 deposited with the ATCC under accession number 98264;
 - 30 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
 - (iii) amplifying human DNA sequences; and
 - (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:100 and SEQ ID NO:101, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:100 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:101, but excluding the poly(A) tail at the 3' end of SEQ ID NO:101. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:101, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:101 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:101, but excluding the poly(A) tail at the 3' end of SEQ ID NO:101. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:101 from nucleotide 72 to nucleotide 569, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:101 from nucleotide 72 to nucleotide 569, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:101 from nucleotide 72 to nucleotide 569.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:102;
 - (b) the amino acid sequence of SEQ ID NO:102 from amino acid 1 to amino acid 124;
 - (c) a fragment of the amino acid sequence of SEQ ID NO:102, the fragment comprising eight contiguous amino acids of SEQ ID NO:102; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone BZ16_3 deposited with the ATCC under accession number 98264;
- the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:102 or the amino acid sequence of SEQ ID NO:102 from amino acid 1 to amino acid 124. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:102 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:102, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:102 having biological activity, the fragment comprising the amino acid sequence from amino acid 78 to amino acid 87 of SEQ ID NO:102.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:103;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:103 from nucleotide 405 to nucleotide 662;
- 5 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:103 from nucleotide 519 to nucleotide 662;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:103 from nucleotide 1 to nucleotide 584;
- 10 (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CC182_1 deposited with the ATCC under accession number 98264;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CC182_1 deposited with the ATCC under accession number 98264;
- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CC182_1 deposited with the ATCC under accession number 15 98264;
- (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CC182_1 deposited with the ATCC under accession number 98264;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:104;
- 20 (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:104 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:104;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- 25 (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and
- (n) a polynucleotide that hybridizes under stringent conditions to any one of 30 the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:103.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:103 from nucleotide 405 to nucleotide 662; the nucleotide sequence of SEQ ID NO:103 from nucleotide 519 to nucleotide 662; the nucleotide sequence of SEQ ID NO:103 from nucleotide 1 to nucleotide 584; the nucleotide sequence of the full-length protein coding sequence of clone 35

CC182_1 deposited with the ATCC under accession number 98264; or the nucleotide sequence of a mature protein coding sequence of clone CC182_1 deposited with the ATCC under accession number 98264. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CC182_1 deposited with the ATCC under
5 accession number 98264. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:104 from amino acid 1 to amino acid 60. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:104 having biological activity, the fragment preferably comprising eight (more preferably
10 twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:104, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:104 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:104.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID
15 NO:103.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X
20 SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:103, but excluding the poly(A) tail at the 3' end of SEQ ID NO:103; and
 - (ab) the nucleotide sequence of the cDNA insert of clone
25 CC182_1 deposited with the ATCC under accession number 98264;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- 30 (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (ba) SEQ ID NO:103, but excluding the poly(A) tail at the 3'
35 end of SEQ ID NO:103; and

- (bb) the nucleotide sequence of the cDNA insert of clone CC182_1 deposited with the ATCC under accession number 98264;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- 5 (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:103, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:103 to a nucleotide

10 sequence corresponding to the 3' end of SEQ ID NO:103, but excluding the poly(A) tail at the 3' end of SEQ ID NO:103. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:103 from nucleotide 405 to nucleotide 662, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:103 from nucleotide 405 to nucleotide

15 662, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:103 from nucleotide 405 to nucleotide 662. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:103 from nucleotide 519 to nucleotide 662, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:103 from nucleotide 519

20 to nucleotide 662, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:103 from nucleotide 519 to nucleotide 662. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:103 from nucleotide 1 to nucleotide 584, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:103 from

25 nucleotide 1 to nucleotide 584, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:103 from nucleotide 1 to nucleotide 584.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:104;
- 30 (b) the amino acid sequence of SEQ ID NO:104 from amino acid 1 to amino acid 60;
- (c) a fragment of the amino acid sequence of SEQ ID NO:104, the fragment comprising eight contiguous amino acids of SEQ ID NO:104; and
- (d) the amino acid sequence encoded by the cDNA insert of clone CC182_1
- 35 deposited with the ATCC under accession number 98264;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:104 or the amino acid sequence of SEQ ID NO:104 from amino acid 1 to amino acid 60. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:104 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:104, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:104 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:104.

10 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:105;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:105 from nucleotide 311 to nucleotide 409;
- 15 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:105 from nucleotide 24 to nucleotide 414;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CG109_1 deposited with the ATCC under accession number 98264;
- 20 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CG109_1 deposited with the ATCC under accession number 98264;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CG109_1 deposited with the ATCC under accession number 98264;
- 25 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CG109_1 deposited with the ATCC under accession number 98264;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:106;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:106 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:106;
- 30 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- 35

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:105.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:105 from nucleotide 311 to nucleotide 409; the nucleotide sequence of SEQ ID NO:105 from nucleotide 24 to nucleotide 414; the nucleotide sequence of the full-length protein coding sequence of clone CG109_1 deposited with the ATCC under accession number 98264; or the nucleotide sequence of a mature protein coding sequence of clone CG109_1 deposited with the ATCC under accession number 98264. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CG109_1 deposited with the ATCC under accession number 98264. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:106 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:106, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:106 having biological activity, the fragment comprising the amino acid sequence from amino acid 11 to amino acid 20 of SEQ ID NO:106.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:105.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
- (aa) SEQ ID NO:105, but excluding the poly(A) tail at the 3' end of SEQ ID NO:105; and
- (ab) the nucleotide sequence of the cDNA insert of clone CG109_1 deposited with the ATCC under accession number 98264;
- (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
- (iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

5 (ba) SEQ ID NO:105, but excluding the poly(A) tail at the 3' end of SEQ ID NO:105; and

(bb) the nucleotide sequence of the cDNA insert of clone CG109_1 deposited with the ATCC under accession number 98264;

10 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:105, and extending contiguously
15 from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:105 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:105, but excluding the poly(A) tail at the 3' end of SEQ ID NO:105. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:105 from nucleotide 311 to nucleotide 409, and extending contiguously from a nucleotide sequence
20 corresponding to the 5' end of said sequence of SEQ ID NO:105 from nucleotide 311 to nucleotide 409, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:105 from nucleotide 311 to nucleotide 409. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:105 from nucleotide 24 to nucleotide 414, and extending contiguously from a nucleotide
25 sequence corresponding to the 5' end of said sequence of SEQ ID NO:105 from nucleotide 24 to nucleotide 414, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:105 from nucleotide 24 to nucleotide 414.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

30 (a) the amino acid sequence of SEQ ID NO:106;

(b) a fragment of the amino acid sequence of SEQ ID NO:106, the fragment comprising eight contiguous amino acids of SEQ ID NO:106; and

(c) the amino acid sequence encoded by the cDNA insert of clone CG109_1 deposited with the ATCC under accession number 98264;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:106. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:106 having biological activity, the fragment preferably comprising eight (more preferably
5 twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:106, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:106 having biological activity, the fragment comprising the amino acid sequence from amino acid 11 to amino acid 20 of SEQ ID NO:106.

In one embodiment, the present invention provides a composition comprising an isolated
10 polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:108;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:108 from nucleotide 471 to nucleotide 611;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length
15 protein coding sequence of clone CJ397_1 deposited with the ATCC under accession number 98264;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CJ397_1 deposited with the ATCC under accession number 98264;
- (e) a polynucleotide comprising the nucleotide sequence of a mature protein
20 coding sequence of clone CJ397_1 deposited with the ATCC under accession number 98264;
- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CJ397_1 deposited with the ATCC under accession number 98264;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence
25 of SEQ ID NO:109;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:109 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:109;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f)
30 above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:108.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:108
5 from nucleotide 471 to nucleotide 611; the nucleotide sequence of the full-length protein coding sequence of clone CJ397_1 deposited with the ATCC under accession number 98264; or the nucleotide sequence of a mature protein coding sequence of clone CJ397_1 deposited with the ATCC under accession number 98264. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CJ397_1
10 deposited with the ATCC under accession number 98264. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:109 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:109, or a polynucleotide encoding a protein comprising a fragment of the amino acid
15 sequence of SEQ ID NO:109 having biological activity, the fragment comprising the amino acid sequence from amino acid 18 to amino acid 27 of SEQ ID NO:109.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:108, SEQ ID NO:107, and SEQ ID NO:110.

Further embodiments of the invention provide isolated polynucleotides produced
20 according to a process selected from the group consisting of:

(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X
SSC at 65 degrees C to a nucleotide sequence selected from the group consisting
of:

25 (aa) SEQ ID NO:107;
(ab) SEQ ID NO:108;
(ac) SEQ ID NO:110, but excluding the poly(A) tail at the 3'
end of SEQ ID NO:110; and
(ad) the nucleotide sequence of the cDNA insert of clone
30 CJ397_1 deposited with the ATCC under accession number 98264;
(ii) hybridizing said probe(s) to human genomic DNA in conditions
at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the probe(s);

and

35 (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:107;

(bb) SEQ ID NO:108;

(bc) SEQ ID NO:110, but excluding the poly(A) tail at the 3' end of SEQ ID NO:110; and

(bd) the nucleotide sequence of the cDNA insert of clone CJ397_1 deposited with the ATCC under accession number 98264;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:107, SEQ ID NO:108, and SEQ ID NO:110, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:107 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:110, but excluding the poly(A) tail at the 3' end of SEQ ID NO:110. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:108, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:108 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:108. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:108 from nucleotide 471 to nucleotide 611, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:108 from nucleotide 471 to nucleotide 611, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:108 from nucleotide 471 to nucleotide 611.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:109;

(b) a fragment of the amino acid sequence of SEQ ID NO:109, the fragment comprising eight contiguous amino acids of SEQ ID NO:109; and

(c) the amino acid sequence encoded by the cDNA insert of clone CJ397_1 deposited with the ATCC under accession number 98264;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:109. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:109 having biological activity, the fragment preferably comprising eight (more preferably
5 twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:109, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:109 having biological activity, the fragment comprising the amino acid sequence from amino acid 18 to amino acid 27 of SEQ ID NO:109.

In one embodiment, the present invention provides a composition comprising an isolated
10 polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:111;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:111 from nucleotide 141 to nucleotide 1532;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:111
15 from nucleotide 204 to nucleotide 1532;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:111 from nucleotide 78 to nucleotide 476;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AM795_4 deposited with the ATCC under accession
20 number 98271;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AM795_4 deposited with the ATCC under accession number 98271;
- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone AM795_4 deposited with the ATCC under accession number
25 98271;
- (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone AM795_4 deposited with the ATCC under accession number 98271;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:112;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino
30 acid sequence of SEQ ID NO:112 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:112;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;

(l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and

5 (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:111.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:111 from nucleotide 141 to nucleotide 1532; the nucleotide sequence of SEQ ID NO:111 from
10 nucleotide 204 to nucleotide 1532; the nucleotide sequence of SEQ ID NO:111 from nucleotide 78 to nucleotide 476; the nucleotide sequence of the full-length protein coding sequence of clone AM795_4 deposited with the ATCC under accession number 98271; or the nucleotide sequence of a mature protein coding sequence of clone AM795_4 deposited with the ATCC under accession number 98271. In other preferred embodiments, the polynucleotide encodes the full-length or a
15 mature protein encoded by the cDNA insert of clone AM795_4 deposited with the ATCC under accession number 98271. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:112 from amino acid 1 to amino acid 112. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ
20 ID NO:112 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:112, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:112 having biological activity, the fragment comprising the amino acid sequence from amino acid 227 to amino acid 236 of SEQ ID NO:112.

25 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:111.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
- 30 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
- (aa) SEQ ID NO:111, but excluding the poly(A) tail at the 3' end of SEQ ID NO:111; and

- (ab) the nucleotide sequence of the cDNA insert of clone AM795_4 deposited with the ATCC under accession number 98271;
- (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
- 5 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
- 10 consisting of:
- (ba) SEQ ID NO:111, but excluding the poly(A) tail at the 3' end of SEQ ID NO:111; and
- (bb) the nucleotide sequence of the cDNA insert of clone AM795_4 deposited with the ATCC under accession number 98271;
- 15 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide

20 sequence corresponding to the cDNA sequence of SEQ ID NO:111, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:111 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:111, but excluding the poly(A) tail at the 3' end of SEQ ID NO:111. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:111

25 from nucleotide 141 to nucleotide 1532, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:111 from nucleotide 141 to nucleotide 1532, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:111 from nucleotide 141 to nucleotide 1532. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of

30 SEQ ID NO:111 from nucleotide 204 to nucleotide 1532, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:111 from nucleotide 204 to nucleotide 1532, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:111 from nucleotide 204 to nucleotide 1532. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence

35 corresponding to the cDNA sequence of SEQ ID NO:111 from nucleotide 78 to nucleotide 476,

and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:111 from nucleotide 78 to nucleotide 476, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:111 from nucleotide 78 to nucleotide 476.

5 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:112;
- (b) the amino acid sequence of SEQ ID NO:112 from amino acid 1 to amino acid 112;
- 10 (c) a fragment of the amino acid sequence of SEQ ID NO:112, the fragment comprising eight contiguous amino acids of SEQ ID NO:112; and
- (d) the amino acid sequence encoded by the cDNA insert of clone AM795_4 deposited with the ATCC under accession number 98271;

the protein being substantially free from other mammalian proteins. Preferably such protein
15 comprises the amino acid sequence of SEQ ID NO:112 or the amino acid sequence of SEQ ID NO:112 from amino acid 1 to amino acid 112. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:112 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:112, or a protein
20 comprising a fragment of the amino acid sequence of SEQ ID NO:112 having biological activity, the fragment comprising the amino acid sequence from amino acid 227 to amino acid 236 of SEQ ID NO:112.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 25 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:114;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:114 from nucleotide 19 to nucleotide 262;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:114 from nucleotide 91 to nucleotide 262;
- 30 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AT340_1 deposited with the ATCC under accession number 98271;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AT340_1 deposited with the ATCC under accession number 98271;

- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone AT340_1 deposited with the ATCC under accession number 98271;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert
5 of clone AT340_1 deposited with the ATCC under accession number 98271;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:115;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:115 having biological activity, the fragment comprising
10 eight contiguous amino acids of SEQ ID NO:115;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of
15 the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:114.
- 20 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:114 from nucleotide 19 to nucleotide 262; the nucleotide sequence of SEQ ID NO:114 from nucleotide 91 to nucleotide 262; the nucleotide sequence of the full-length protein coding sequence of clone AT340_1 deposited with the ATCC under accession number 98271; or the nucleotide sequence of a mature protein coding sequence of clone AT340_1 deposited with the ATCC under accession
25 number 98271. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone AT340_1 deposited with the ATCC under accession number 98271. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:115 from amino acid 1 to amino acid 66. In further preferred embodiments, the present invention provides
30 a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:115 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:115, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:115 having biological activity, the fragment comprising the amino acid sequence from amino acid 35 to amino
35 acid 44 of SEQ ID NO:115.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:114 and SEQ ID NO:113.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 5 (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
- (aa) SEQ ID NO:113;
- 10 (ab) SEQ ID NO:114, but excluding the poly(A) tail at the 3' end of SEQ ID NO:114; and
- (ac) the nucleotide sequence of the cDNA insert of clone AT340_1 deposited with the ATCC under accession number 98271;
- (ii) hybridizing said probe(s) to human genomic DNA in conditions
- 15 at least as stringent as 4X SSC at 50 degrees C; and
- (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that hybridize in
- 20 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
- (ba) SEQ ID NO:113;
- (bb) SEQ ID NO:114, but excluding the poly(A) tail at the 3' end of SEQ ID NO:114; and
- 25 (bc) the nucleotide sequence of the cDNA insert of clone AT340_1 deposited with the ATCC under accession number 98271;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- (iii) amplifying human DNA sequences; and
- 30 (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:113 and SEQ ID NO:114, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:113 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:114, but excluding

35 the poly(A) tail at the 3' end of SEQ ID NO:114. Also preferably the polynucleotide isolated

according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:114, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:114 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:114, but excluding the poly(A) tail at the 3' end of SEQ ID NO:114. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:114 from nucleotide 19 to nucleotide 262, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:114 from nucleotide 19 to nucleotide 262, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:114 from nucleotide 19 to nucleotide 262. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:114 from nucleotide 91 to nucleotide 262, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:114 from nucleotide 91 to nucleotide 262, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:114 from nucleotide 91 to nucleotide 262.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:115;
 - (b) the amino acid sequence of SEQ ID NO:115 from amino acid 1 to amino acid 66;
 - (c) a fragment of the amino acid sequence of SEQ ID NO:115, the fragment comprising eight contiguous amino acids of SEQ ID NO:115; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone AT340_1 deposited with the ATCC under accession number 98271;
- the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:115 or the amino acid sequence of SEQ ID NO:115 from amino acid 1 to amino acid 66. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:115 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:115, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:115 having biological activity, the fragment comprising the amino acid sequence from amino acid 35 to amino acid 44 of SEQ ID NO:115.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:116;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:116 from nucleotide 2 to nucleotide 601;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:116 from nucleotide 401 to nucleotide 601;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BG132_1 deposited with the ATCC under accession number 98271;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BG132_1 deposited with the ATCC under accession number 98271;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BG132_1 deposited with the ATCC under accession number 98271;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BG132_1 deposited with the ATCC under accession number 98271;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:117;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:117 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:117;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:116.
- Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:116 from nucleotide 2 to nucleotide 601; the nucleotide sequence of SEQ ID NO:116 from nucleotide 401 to nucleotide 601; the nucleotide sequence of the full-length protein coding sequence of clone BG132_1 deposited with the ATCC under accession number 98271; or the nucleotide sequence of a mature protein coding sequence of clone BG132_1 deposited with the ATCC under accession number 98271. In other preferred embodiments, the polynucleotide encodes the full-length or a

mature protein encoded by the cDNA insert of clone BG132_1 deposited with the ATCC under accession number 98271. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:117 from amino acid 119 to amino acid 200. In further preferred embodiments, the present invention
5 provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:117 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:117, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:117 having biological activity, the fragment comprising the amino acid sequence from amino
10 acid 95 to amino acid 104 of SEQ ID NO:117.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:116 and SEQ ID NO:118.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 15 (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:116;
 - 20 (ab) SEQ ID NO:118, but excluding the poly(A) tail at the 3' end of SEQ ID NO:118; and
 - (ac) the nucleotide sequence of the cDNA insert of clone BG132_1 deposited with the ATCC under accession number 98271;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions
25 at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that hybridize in
30 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (ba) SEQ ID NO:116;
 - (bb) SEQ ID NO:118, but excluding the poly(A) tail at the 3' end of SEQ ID NO:118; and

- (bc) the nucleotide sequence of the cDNA insert of clone BG132_1 deposited with the ATCC under accession number 98271;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- 5 (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:116 and SEQ ID NO:118, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID

10 NO:116 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:118, but excluding the poly(A) tail at the 3' end of SEQ ID NO:118. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:116, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:116 to a nucleotide sequence corresponding to the 3'

15 end of SEQ ID NO:116. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:116 from nucleotide 2 to nucleotide 601, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:116 from nucleotide 2 to nucleotide 601, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:116

20 from nucleotide 2 to nucleotide 601. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:116 from nucleotide 401 to nucleotide 601, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:116 from nucleotide 401 to nucleotide 601, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ

25 ID NO:116 from nucleotide 401 to nucleotide 601.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:117;
- (b) the amino acid sequence of SEQ ID NO:117 from amino acid 119 to
- 30 amino acid 200;
- (c) a fragment of the amino acid sequence of SEQ ID NO:117, the fragment comprising eight contiguous amino acids of SEQ ID NO:117; and
- (d) the amino acid sequence encoded by the cDNA insert of clone BG132_1 deposited with the ATCC under accession number 98271;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:117 or the amino acid sequence of SEQ ID NO:117 from amino acid 119 to amino acid 200. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID
5 NO:117 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:117, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:117 having biological activity, the fragment comprising the amino acid sequence from amino acid 95 to amino acid 104 of SEQ ID NO:117.

10 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:119;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:119 from nucleotide 225 to nucleotide 701;
- 15 (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BG219_2 deposited with the ATCC under accession number 98271;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BG219_2 deposited with the ATCC under accession number 98271;
- 20 (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BG219_2 deposited with the ATCC under accession number 98271;
- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BG219_2 deposited with the ATCC under accession number 98271;
- 25 (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:120;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:120 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:120;
- 30 (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
- (k) a polynucleotide that hybridizes under stringent conditions to any one of
35 the polynucleotides specified in (a)-(h); and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:119.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:119
5 from nucleotide 225 to nucleotide 701; the nucleotide sequence of the full-length protein coding sequence of clone BG219_2 deposited with the ATCC under accession number 98271; or the nucleotide sequence of a mature protein coding sequence of clone BG219_2 deposited with the ATCC under accession number 98271. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BG219_2
10 deposited with the ATCC under accession number 98271. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:120 from amino acid 1 to amino acid 97. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:120 having biological activity, the fragment
15 preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:120, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:120 having biological activity, the fragment comprising the amino acid sequence from amino acid 74 to amino acid 83 of SEQ ID NO:120.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID
20 NO:119.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X
25 SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:119, but excluding the poly(A) tail at the 3' end of SEQ ID NO:119; and
 - (ab) the nucleotide sequence of the cDNA insert of clone
30 BG219_2 deposited with the ATCC under accession number 98271;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- 35 (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

5 (ba) SEQ ID NO:119, but excluding the poly(A) tail at the 3' end of SEQ ID NO:119; and

(bb) the nucleotide sequence of the cDNA insert of clone BG219_2 deposited with the ATCC under accession number 98271;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

10 (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:119, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:119 to a nucleotide
15 sequence corresponding to the 3' end of SEQ ID NO:119, but excluding the poly(A) tail at the 3' end of SEQ ID NO:119. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:119 from nucleotide 225 to nucleotide 701, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:119 from nucleotide 225 to nucleotide
20 701, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:119 from nucleotide 225 to nucleotide 701.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:120;
25 (b) the amino acid sequence of SEQ ID NO:120 from amino acid 1 to amino acid 97;

(c) a fragment of the amino acid sequence of SEQ ID NO:120, the fragment comprising eight contiguous amino acids of SEQ ID NO:120; and

(d) the amino acid sequence encoded by the cDNA insert of clone BG219_2
30 deposited with the ATCC under accession number 98271;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:120 or the amino acid sequence of SEQ ID NO:120 from amino acid 1 to amino acid 97. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID
35 NO:120 having biological activity, the fragment preferably comprising eight (more preferably

twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:120, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:120 having biological activity, the fragment comprising the amino acid sequence from amino acid 74 to amino acid 83 of SEQ ID NO:120.

5 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:121;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:121 from nucleotide 2115 to nucleotide 2510;
- 10 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:121 from nucleotide 1 to nucleotide 324;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BG366_2 deposited with the ATCC under accession number 98271;
- 15 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BG366_2 deposited with the ATCC under accession number 98271;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BG366_2 deposited with the ATCC under accession number 98271;
- 20 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BG366_2 deposited with the ATCC under accession number 98271;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:122;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:122 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:122;
- 25 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- 30 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:121.
- 35

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:121 from nucleotide 2115 to nucleotide 2510; the nucleotide sequence of SEQ ID NO:121 from nucleotide 1 to nucleotide 324; the nucleotide sequence of the full-length protein coding sequence of clone BG366_2 deposited with the ATCC under accession number 98271; or the nucleotide
5 sequence of a mature protein coding sequence of clone BG366_2 deposited with the ATCC under accession number 98271. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BG366_2 deposited with the ATCC under accession number 98271. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence
10 of SEQ ID NO:122 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:122, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:122 having biological activity, the fragment comprising the amino acid sequence from amino acid 61 to amino acid 70 of SEQ ID NO:122.

15 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:121.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
20 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:121, but excluding the poly(A) tail at the 3' end of SEQ ID NO:121; and
 - 25 (ab) the nucleotide sequence of the cDNA insert of clone BG366_2 deposited with the ATCC under accession number 98271;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);
- 30 and
- (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:121, but excluding the poly(A) tail at the 3' end of SEQ ID NO:121; and

(bb) the nucleotide sequence of the cDNA insert of clone BG366_2 deposited with the ATCC under accession number 98271;

5 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide
10 sequence corresponding to the cDNA sequence of SEQ ID NO:121, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:121 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:121, but excluding the poly(A) tail at the 3' end of SEQ ID NO:121. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:121
15 from nucleotide 2115 to nucleotide 2510, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:121 from nucleotide 2115 to nucleotide 2510, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:121 from nucleotide 2115 to nucleotide 2510. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA
20 sequence of SEQ ID NO:121 from nucleotide 1 to nucleotide 324, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:121 from nucleotide 1 to nucleotide 324, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:121 from nucleotide 1 to nucleotide 324.

In other embodiments, the present invention provides a composition comprising a protein,
25 wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:122;

(b) a fragment of the amino acid sequence of SEQ ID NO:122, the fragment comprising eight contiguous amino acids of SEQ ID NO:122; and

(c) the amino acid sequence encoded by the cDNA insert of clone BG366_2
30 deposited with the ATCC under accession number 98271;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:122. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:122 having biological activity, the fragment preferably comprising eight (more preferably
35 twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:122, or a protein

comprising a fragment of the amino acid sequence of SEQ ID NO:122 having biological activity, the fragment comprising the amino acid sequence from amino acid 61 to amino acid 70 of SEQ ID NO:122.

In one embodiment, the present invention provides a composition comprising an isolated
5 polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:123;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:123 from nucleotide 27 to nucleotide 215;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:123
10 from nucleotide 27 to nucleotide 181;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BV172_2 deposited with the ATCC under accession number 98271;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA
15 insert of clone BV172_2 deposited with the ATCC under accession number 98271;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BV172_2 deposited with the ATCC under accession number 98271;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert
20 of clone BV172_2 deposited with the ATCC under accession number 98271;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:124;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:124 having biological activity, the fragment comprising
25 eight contiguous amino acids of SEQ ID NO:124;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of
30 the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:123.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:123 from nucleotide 27 to nucleotide 215; the nucleotide sequence of SEQ ID NO:123 from nucleotide 27 to nucleotide 181; the nucleotide sequence of the full-length protein coding sequence of clone BV172_2 deposited with the ATCC under accession number 98271; or the
5 nucleotide sequence of a mature protein coding sequence of clone BV172_2 deposited with the ATCC under accession number 98271. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BV172_2 deposited with the ATCC under accession number 98271. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid
10 sequence of SEQ ID NO:124 from amino acid 1 to amino acid 51. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:124 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:124, or a polynucleotide encoding a protein comprising a fragment of the
15 amino acid sequence of SEQ ID NO:124 having biological activity, the fragment comprising the amino acid sequence from amino acid 26 to amino acid 35 of SEQ ID NO:124.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:123.

Further embodiments of the invention provide isolated polynucleotides produced
20 according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - 25 (aa) SEQ ID NO:123, but excluding the poly(A) tail at the 3' end of SEQ ID NO:123; and
 - (ab) the nucleotide sequence of the cDNA insert of clone BV172_2 deposited with the ATCC under accession number 98271;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions
30 at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);

and

- (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

5 (ba) SEQ ID NO:123, but excluding the poly(A) tail at the 3' end of SEQ ID NO:123; and

(bb) the nucleotide sequence of the cDNA insert of clone BV172_2 deposited with the ATCC under accession number 98271;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

10 (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:123, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:123 to a nucleotide
15 sequence corresponding to the 3' end of SEQ ID NO:123, but excluding the poly(A) tail at the 3' end of SEQ ID NO:123. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:123 from nucleotide 27 to nucleotide 215, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:123 from nucleotide 27 to nucleotide
20 215, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:123 from nucleotide 27 to nucleotide 215. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:123 from nucleotide 27 to nucleotide 181, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:123 from nucleotide 27 to
25 nucleotide 181, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:123 from nucleotide 27 to nucleotide 181.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:124;
30 (b) the amino acid sequence of SEQ ID NO:124 from amino acid 1 to amino acid 51;

(c) a fragment of the amino acid sequence of SEQ ID NO:124, the fragment comprising eight contiguous amino acids of SEQ ID NO:124; and

(d) the amino acid sequence encoded by the cDNA insert of clone BV172_2
35 deposited with the ATCC under accession number 98271;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:124 or the amino acid sequence of SEQ ID NO:124 from amino acid 1 to amino acid 51. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:124 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:124, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:124 having biological activity, the fragment comprising the amino acid sequence from amino acid 26 to amino acid 35 of SEQ ID NO:124.

10 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:125;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:125 from nucleotide 338 to nucleotide 409;
- 15 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:125 from nucleotide 362 to nucleotide 409;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:125 from nucleotide 270 to nucleotide 419;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CC247_10 deposited with the ATCC under accession number 98271;
- 20 (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CC247_10 deposited with the ATCC under accession number 98271;
- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CC247_10 deposited with the ATCC under accession number 98271;
- 25 (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CC247_10 deposited with the ATCC under accession number 98271;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:126;
- 30 (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:126 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:126;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h)
- 35 above;

(l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and

5 (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:125.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:125 from nucleotide 338 to nucleotide 409; the nucleotide sequence of SEQ ID NO:125 from
10 nucleotide 362 to nucleotide 409; the nucleotide sequence of SEQ ID NO:125 from nucleotide 270 to nucleotide 419; the nucleotide sequence of the full-length protein coding sequence of clone CC247_10 deposited with the ATCC under accession number 98271; or the nucleotide sequence of a mature protein coding sequence of clone CC247_10 deposited with the ATCC under accession number 98271. In other preferred embodiments, the polynucleotide encodes the full-
15 length or a mature protein encoded by the cDNA insert of clone CC247_10 deposited with the ATCC under accession number 98271. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:126 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:126, or a
20 polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:126 having biological activity, the fragment comprising the amino acid sequence from amino acid 7 to amino acid 16 of SEQ ID NO:126.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:125.

25 Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X
SSC at 65 degrees C to a nucleotide sequence selected from the group consisting
30 of:

(aa) SEQ ID NO:125, but excluding the poly(A) tail at the 3' end of SEQ ID NO:125; and

(ab) the nucleotide sequence of the cDNA insert of clone CC247_10 deposited with the ATCC under accession number 98271;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

5

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

10

(ba) SEQ ID NO:125, but excluding the poly(A) tail at the 3' end of SEQ ID NO:125; and

(bb) the nucleotide sequence of the cDNA insert of clone CC247_10 deposited with the ATCC under accession number 98271;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

15

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:125, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:125 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:125, but excluding the poly(A) tail at the 3' end of SEQ ID NO:125. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:125 from nucleotide 338 to nucleotide 409, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:125 from nucleotide 338 to nucleotide 20 409, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:125 from nucleotide 338 to nucleotide 409. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:125 from nucleotide 362 to nucleotide 409, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:125 from nucleotide 362 25 to nucleotide 409, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:125 from nucleotide 362 to nucleotide 409. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:125 from nucleotide 270 to nucleotide 419, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:125 from 30

nucleotide 270 to nucleotide 419, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:125 from nucleotide 270 to nucleotide 419.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 5 (a) the amino acid sequence of SEQ ID NO:126;
- (b) a fragment of the amino acid sequence of SEQ ID NO:126, the fragment comprising eight contiguous amino acids of SEQ ID NO:126; and
- (c) the amino acid sequence encoded by the cDNA insert of clone CC247_10 deposited with the ATCC under accession number 98271;
- 10 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:126. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:126 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:126, or a protein
- 15 comprising a fragment of the amino acid sequence of SEQ ID NO:126 having biological activity, the fragment comprising the amino acid sequence from amino acid 7 to amino acid 16 of SEQ ID NO:126.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 20 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:127;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:127 from nucleotide 128 to nucleotide 1600;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:127 from nucleotide 281 to nucleotide 1600;
- 25 (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:127 from nucleotide 62 to nucleotide 373;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CI480_9 deposited with the ATCC under accession number 98271;
- 30 (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CI480_9 deposited with the ATCC under accession number 98271;
- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CI480_9 deposited with the ATCC under accession number 98271;

- (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CI480_9 deposited with the ATCC under accession number 98271;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:128;
- 5 (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:128 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:128;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- 10 (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and
- (n) a polynucleotide that hybridizes under stringent conditions to any one of
- 15 the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:127.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:127 from nucleotide 128 to nucleotide 1600; the nucleotide sequence of SEQ ID NO:127 from nucleotide 281 to nucleotide 1600; the nucleotide sequence of SEQ ID NO:127 from nucleotide

20 62 to nucleotide 373; the nucleotide sequence of the full-length protein coding sequence of clone CI480_9 deposited with the ATCC under accession number 98271; or the nucleotide sequence of a mature protein coding sequence of clone CI480_9 deposited with the ATCC under accession number 98271. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CI480_9 deposited with the ATCC under

25 accession number 98271. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:128 from amino acid 1 to amino acid 82. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:128 having biological activity, the fragment preferably comprising eight (more preferably

30 twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:128, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:128 having biological activity, the fragment comprising the amino acid sequence from amino acid 240 to amino acid 249 of SEQ ID NO:128.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID

35 NO:127.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

5 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:127, but excluding the poly(A) tail at the 3' end of SEQ ID NO:127; and

10 (ab) the nucleotide sequence of the cDNA insert of clone CI480_9 deposited with the ATCC under accession number 98271;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

15 (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

20 (ba) SEQ ID NO:127, but excluding the poly(A) tail at the 3' end of SEQ ID NO:127; and

(bb) the nucleotide sequence of the cDNA insert of clone CI480_9 deposited with the ATCC under accession number 98271;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

25 (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:127, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:127 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:127, but excluding the poly(A) tail at the 3' end of SEQ ID NO:127. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:127 from nucleotide 128 to nucleotide 1600, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:127 from nucleotide 128 to nucleotide 35 1600, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:127

from nucleotide 128 to nucleotide 1600. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:127 from nucleotide 281 to nucleotide 1600, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:127 from nucleotide 281 to nucleotide 1600, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:127 from nucleotide 281 to nucleotide 1600. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:127 from nucleotide 62 to nucleotide 373, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:127 from nucleotide 62 to nucleotide 373, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:127 from nucleotide 62 to nucleotide 373.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:128;
- (b) the amino acid sequence of SEQ ID NO:128 from amino acid 1 to amino acid 82;
- (c) a fragment of the amino acid sequence of SEQ ID NO:128, the fragment comprising eight contiguous amino acids of SEQ ID NO:128; and
- (d) the amino acid sequence encoded by the cDNA insert of clone CI480_9 deposited with the ATCC under accession number 98271;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:128 or the amino acid sequence of SEQ ID NO:128 from amino acid 1 to amino acid 82. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:128 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:128, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:128 having biological activity, the fragment comprising the amino acid sequence from amino acid 240 to amino acid 249 of SEQ ID NO:128.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:129;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:129 from nucleotide 383 to nucleotide 3958;

- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:129 from nucleotide 470 to nucleotide 3958;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:129 from nucleotide 271 to nucleotide 488;
- 5 (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CO722_1 deposited with the ATCC under accession number 98271;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CO722_1 deposited with the ATCC under accession number 98271;
- 10 (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CO722_1 deposited with the ATCC under accession number 98271;
- (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CO722_1 deposited with the ATCC under accession number 98271;
- 15 (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:130;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:130 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:130;
- 20 (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and
- 25 (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:129.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:129 from nucleotide 383 to nucleotide 3958; the nucleotide sequence of SEQ ID NO:129 from nucleotide 470 to nucleotide 3958; the nucleotide sequence of SEQ ID NO:129 from nucleotide 271 to nucleotide 488; the nucleotide sequence of the full-length protein coding sequence of clone CO722_1 deposited with the ATCC under accession number 98271; or the nucleotide sequence of a mature protein coding sequence of clone CO722_1 deposited with the ATCC under accession number 98271. In other preferred embodiments, the polynucleotide encodes the full-length or a

30

35

mature protein encoded by the cDNA insert of clone CO722_1 deposited with the ATCC under accession number 98271. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:130 from amino acid 1 to amino acid 34. In further preferred embodiments, the present invention provides
5 a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:130 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:130, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:130 having biological activity, the fragment comprising the amino acid sequence from amino acid 591 to
10 amino acid 600 of SEQ ID NO:130.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:129.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 15 (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:129, but excluding the poly(A) tail at the 3'
20 end of SEQ ID NO:129; and
 - (ab) the nucleotide sequence of the cDNA insert of clone CO722_1 deposited with the ATCC under accession number 98271;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - 25 (iii) isolating the DNA polynucleotides detected with the probe(s);

and

- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
30 consisting of:
 - (ba) SEQ ID NO:129, but excluding the poly(A) tail at the 3' end of SEQ ID NO:129; and
 - (bb) the nucleotide sequence of the cDNA insert of clone CO722_1 deposited with the ATCC under accession number 98271;

- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

5 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:129, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:129 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:129, but excluding the poly(A) tail at the 3' end of SEQ ID NO:129. Also preferably the polynucleotide isolated according to the above
10 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:129 from nucleotide 383 to nucleotide 3958, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:129 from nucleotide 383 to nucleotide 3958, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:129 from nucleotide 383 to nucleotide 3958. Also preferably the polynucleotide isolated according
15 to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:129 from nucleotide 470 to nucleotide 3958, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:129 from nucleotide 470 to nucleotide 3958, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:129 from nucleotide 470 to nucleotide 3958. Also preferably the
20 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:129 from nucleotide 271 to nucleotide 488, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:129 from nucleotide 271 to nucleotide 488, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:129 from nucleotide 271 to nucleotide
25 488.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:130;
- (b) the amino acid sequence of SEQ ID NO:130 from amino acid 1 to amino
30 acid 34;
- (c) a fragment of the amino acid sequence of SEQ ID NO:130, the fragment comprising eight contiguous amino acids of SEQ ID NO:130; and
- (d) the amino acid sequence encoded by the cDNA insert of clone CO722_1 deposited with the ATCC under accession number 98271;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:130 or the amino acid sequence of SEQ ID NO:130 from amino acid 1 to amino acid 34. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:130 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:130, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:130 having biological activity, the fragment comprising the amino acid sequence from amino acid 591 to amino acid 600 of SEQ ID NO:130.

10 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:131;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:131 from nucleotide 914 to nucleotide 2353;
- 15 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:131 from nucleotide 1793 to nucleotide 2353;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:131 from nucleotide 1037 to nucleotide 1260;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CT748_2 deposited with the ATCC under accession number 98271;
- 20 (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CT748_2 deposited with the ATCC under accession number 98271;
- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CT748_2 deposited with the ATCC under accession number 98271;
- 25 (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CT748_2 deposited with the ATCC under accession number 98271;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:132;
- 30 (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:132 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:132;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h)
- 35 above;

(l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and

5 (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:131.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:131 from nucleotide 914 to nucleotide 2353; the nucleotide sequence of SEQ ID NO:131 from
10 nucleotide 1793 to nucleotide 2353; the nucleotide sequence of SEQ ID NO:131 from nucleotide 1037 to nucleotide 1260; the nucleotide sequence of the full-length protein coding sequence of clone CT748_2 deposited with the ATCC under accession number 98271; or the nucleotide sequence of a mature protein coding sequence of clone CT748_2 deposited with the ATCC under accession number 98271. In other preferred embodiments, the polynucleotide encodes the full-
15 length or a mature protein encoded by the cDNA insert of clone CT748_2 deposited with the ATCC under accession number 98271. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:132 from amino acid 22 to amino acid 116. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid
20 sequence of SEQ ID NO:132 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:132, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:132 having biological activity, the fragment comprising the amino acid sequence from amino acid 234 to amino acid 243 of SEQ ID NO:132.

25 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:131.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

30 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:131, but excluding the poly(A) tail at the 3' end of SEQ ID NO:131; and

- (ab) the nucleotide sequence of the cDNA insert of clone CT748_2 deposited with the ATCC under accession number 98271;
- (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
- 5 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
- 10 consisting of:
- (ba) SEQ ID NO:131, but excluding the poly(A) tail at the 3' end of SEQ ID NO:131; and
- (bb) the nucleotide sequence of the cDNA insert of clone CT748_2 deposited with the ATCC under accession number 98271;
- 15 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).
- Preferably the polynucleotide isolated according to the above process comprises a nucleotide
- 20 sequence corresponding to the cDNA sequence of SEQ ID NO:131, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:131 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:131, but excluding the poly(A) tail at the 3' end of SEQ ID NO:131. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:131
- 25 from nucleotide 914 to nucleotide 2353, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:131 from nucleotide 914 to nucleotide 2353, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:131 from nucleotide 914 to nucleotide 2353. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of
- 30 SEQ ID NO:131 from nucleotide 1793 to nucleotide 2353, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:131 from nucleotide 1793 to nucleotide 2353, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:131 from nucleotide 1793 to nucleotide 2353. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence
- 35 corresponding to the cDNA sequence of SEQ ID NO:131 from nucleotide 1037 to nucleotide

1260, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:131 from nucleotide 1037 to nucleotide 1260, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:131 from nucleotide 1037 to nucleotide 1260.

5 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:132;
- (b) the amino acid sequence of SEQ ID NO:132 from amino acid 22 to amino acid 116;
- 10 (c) a fragment of the amino acid sequence of SEQ ID NO:132, the fragment comprising eight contiguous amino acids of SEQ ID NO:132; and
- (d) the amino acid sequence encoded by the cDNA insert of clone CT748_2 deposited with the ATCC under accession number 98271;

the protein being substantially free from other mammalian proteins. Preferably such protein
15 comprises the amino acid sequence of SEQ ID NO:132 or the amino acid sequence of SEQ ID NO:132 from amino acid 22 to amino acid 116. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:132 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:132, or a protein
20 comprising a fragment of the amino acid sequence of SEQ ID NO:132 having biological activity, the fragment comprising the amino acid sequence from amino acid 234 to amino acid 243 of SEQ ID NO:132.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 25 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:133;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:133 from nucleotide 22 to nucleotide 462;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AJ1_1 deposited with the ATCC under accession
30 number 98278;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AJ1_1 deposited with the ATCC under accession number 98278;
- (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone AJ1_1 deposited with the ATCC under accession number
35 98278;

- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone AJ1_1 deposited with the ATCC under accession number 98278;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:134;
- 5 (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:134 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:134;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- 10 (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
- (l) a polynucleotide that hybridizes under stringent conditions to any one of
15 the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:133.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:133 from nucleotide 22 to nucleotide 462; the nucleotide sequence of the full-length protein coding sequence of clone AJ1_1 deposited with the ATCC under accession number 98278; or the
20 nucleotide sequence of a mature protein coding sequence of clone AJ1_1 deposited with the ATCC under accession number 98278. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone AJ1_1 deposited with the ATCC under accession number 98278. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of
25 SEQ ID NO:134 from amino acid 52 to amino acid 147. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:134 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:134, or a polynucleotide encoding a protein comprising a fragment of the amino acid
30 sequence of SEQ ID NO:134 having biological activity, the fragment comprising the amino acid sequence from amino acid 68 to amino acid 77 of SEQ ID NO:134.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:133 and SEQ ID NO:135.

Further embodiments of the invention provide isolated polynucleotides produced
35 according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

5

(aa) SEQ ID NO:133;

(ab) SEQ ID NO:135, but excluding the poly(A) tail at the 3' end of SEQ ID NO:135; and

(ac) the nucleotide sequence of the cDNA insert of clone AJ1_1 deposited with the ATCC under accession number 98278;

10

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

15

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:133;

(bb) SEQ ID NO:135, but excluding the poly(A) tail at the 3' end of SEQ ID NO:135; and

20

(bc) the nucleotide sequence of the cDNA insert of clone AJ1_1 deposited with the ATCC under accession number 98278;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

25

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:133 and SEQ ID NO:135, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:133 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:135, but excluding the poly(A) tail at the 3' end of SEQ ID NO:135. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:133, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:133 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:133. Also preferably the polynucleotide isolated according to the above

30

35

process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:133 from nucleotide 22 to nucleotide 462, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:133 from nucleotide 22 to nucleotide 462, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:133 from nucleotide 22 to nucleotide 462.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:134;
 - (b) the amino acid sequence of SEQ ID NO:134 from amino acid 52 to amino acid 147;
 - (c) a fragment of the amino acid sequence of SEQ ID NO:134, the fragment comprising eight contiguous amino acids of SEQ ID NO:134; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone AJ1_1 deposited with the ATCC under accession number 98278;
- the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:134 or the amino acid sequence of SEQ ID NO:134 from amino acid 52 to amino acid 147. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:134 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:134, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:134 having biological activity, the fragment comprising the amino acid sequence from amino acid 68 to amino acid 77 of SEQ ID NO:134.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:136;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:136 from nucleotide 7 to nucleotide 1647;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:136 from nucleotide 1 to nucleotide 305;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AQ73_3 deposited with the ATCC under accession number 98278;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AQ73_3 deposited with the ATCC under accession number 98278;

- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone AQ73_3 deposited with the ATCC under accession number 98278;
- 5 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone AQ73_3 deposited with the ATCC under accession number 98278;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:137;
- 10 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:137 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:137;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- 15 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:136.
- 20 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:136 from nucleotide 7 to nucleotide 1647; the nucleotide sequence of SEQ ID NO:136 from nucleotide 1 to nucleotide 305; the nucleotide sequence of the full-length protein coding sequence of clone AQ73_3 deposited with the ATCC under accession number 98278; or the nucleotide sequence of a mature protein coding sequence of clone AQ73_3 deposited with the ATCC under
- 25 accession number 98278. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone AQ73_3 deposited with the ATCC under accession number 98278. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:137 from amino acid 1 to amino acid 68. In further preferred embodiments, the present
- 30 invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:137 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:137, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:137 having biological activity, the fragment comprising the amino acid sequence from
- 35 amino acid 268 to amino acid 277 of SEQ ID NO:137.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:136.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 5 (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

10 (aa) SEQ ID NO:136, but excluding the poly(A) tail at the 3' end of SEQ ID NO:136; and

(ab) the nucleotide sequence of the cDNA insert of clone AQ73_3 deposited with the ATCC under accession number 98278;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

15 (iii) isolating the DNA polynucleotides detected with the probe(s);

and

- (b) a process comprising the steps of:

20 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:136, but excluding the poly(A) tail at the 3' end of SEQ ID NO:136; and

(bb) the nucleotide sequence of the cDNA insert of clone AQ73_3 deposited with the ATCC under accession number 98278;

25 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

30 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:136, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:136 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:136, but excluding the poly(A) tail at the 3' end of SEQ ID NO:136. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:136

35 from nucleotide 7 to nucleotide 1647, and extending contiguously from a nucleotide sequence

corresponding to the 5' end of said sequence of SEQ ID NO:136 from nucleotide 7 to nucleotide 1647, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:136 from nucleotide 7 to nucleotide 1647. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:136 from nucleotide 1 to nucleotide 305, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:136 from nucleotide 1 to nucleotide 305, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:136 from nucleotide 1 to nucleotide 305.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:137;
- (b) the amino acid sequence of SEQ ID NO:137 from amino acid 1 to amino acid 68;
- (c) a fragment of the amino acid sequence of SEQ ID NO:137, the fragment comprising eight contiguous amino acids of SEQ ID NO:137; and
- (d) the amino acid sequence encoded by the cDNA insert of clone AQ73_3 deposited with the ATCC under accession number 98278;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:137 or the amino acid sequence of SEQ ID NO:137 from amino acid 1 to amino acid 68. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:137 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:137, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:137 having biological activity, the fragment comprising the amino acid sequence from amino acid 268 to amino acid 277 of SEQ ID NO:137.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:138;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:138 from nucleotide 62 to nucleotide 757;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:138 from nucleotide 357 to nucleotide 703;

- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BG142_1 deposited with the ATCC under accession number 98278;
- 5 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BG142_1 deposited with the ATCC under accession number 98278;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BG142_1 deposited with the ATCC under accession number 98278;
- 10 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BG142_1 deposited with the ATCC under accession number 98278;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:139;
- 15 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:139 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:139;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- 20 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:138.
- 25 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:138 from nucleotide 62 to nucleotide 757; the nucleotide sequence of SEQ ID NO:138 from nucleotide 357 to nucleotide 703; the nucleotide sequence of the full-length protein coding sequence of clone BG142_1 deposited with the ATCC under accession number 98278; or the nucleotide sequence of a mature protein coding sequence of clone BG142_1 deposited with the
- 30 ATCC under accession number 98278. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BG142_1 deposited with the ATCC under accession number 98278. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:139 from amino acid 184 to amino acid 214. In further preferred
- 35 embodiments, the present invention provides a polynucleotide encoding a protein comprising a

fragment of the amino acid sequence of SEQ ID NO:139 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:139, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:139 having biological activity, the fragment comprising the amino acid sequence from amino acid 111 to amino acid 120 of SEQ ID NO:139.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:138.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 10 (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - 15 (aa) SEQ ID NO:138, but excluding the poly(A) tail at the 3' end of SEQ ID NO:138; and
 - (ab) the nucleotide sequence of the cDNA insert of clone BG142_1 deposited with the ATCC under accession number 98278;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - 20 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - 25 (ba) SEQ ID NO:138, but excluding the poly(A) tail at the 3' end of SEQ ID NO:138; and
 - (bb) the nucleotide sequence of the cDNA insert of clone BG142_1 deposited with the ATCC under accession number 98278;
 - 30 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
 - (iii) amplifying human DNA sequences; and
 - (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:138, and extending contiguously

from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:138 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:138, but excluding the poly(A) tail at the 3' end of SEQ ID NO:138. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:138
5 from nucleotide 62 to nucleotide 757, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:138 from nucleotide 62 to nucleotide 757, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:138 from nucleotide 62 to nucleotide 757. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ
10 ID NO:138 from nucleotide 357 to nucleotide 703, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:138 from nucleotide 357 to nucleotide 703, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:138 from nucleotide 357 to nucleotide 703.

In other embodiments, the present invention provides a composition comprising a protein,
15 wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:139;
- (b) the amino acid sequence of SEQ ID NO:139 from amino acid 184 to amino acid 214;
- (c) a fragment of the amino acid sequence of SEQ ID NO:139, the fragment
20 comprising eight contiguous amino acids of SEQ ID NO:139; and
- (d) the amino acid sequence encoded by the cDNA insert of clone BG142_1 deposited with the ATCC under accession number 98278;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:139 or the amino acid sequence of SEQ ID
25 NO:139 from amino acid 184 to amino acid 214. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:139 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:139, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:139 having biological activity,
30 the fragment comprising the amino acid sequence from amino acid 111 to amino acid 120 of SEQ ID NO:139.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:140;

- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:140 from nucleotide 404 to nucleotide 535;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:140 from nucleotide 1 to nucleotide 666;
- 5 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BV66_1 deposited with the ATCC under accession number 98278;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BV66_1 deposited with the ATCC under accession number 98278;
- 10 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BV66_1 deposited with the ATCC under accession number 98278;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BV66_1 deposited with the ATCC under accession number 98278;
- 15 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:141;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:141 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:141;
- 20 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of
- 25 the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:140.
- Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:140
- 30 from nucleotide 404 to nucleotide 535; the nucleotide sequence of SEQ ID NO:140 from nucleotide 1 to nucleotide 666; the nucleotide sequence of the full-length protein coding sequence of clone BV66_1 deposited with the ATCC under accession number 98278; or the nucleotide sequence of a mature protein coding sequence of clone BV66_1 deposited with the ATCC under accession number 98278. In other preferred embodiments, the polynucleotide encodes the full-
- 35 length or a mature protein encoded by the cDNA insert of clone BV66_1 deposited with the

ATCC under accession number 98278. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:141 from amino acid 1 to amino acid 38. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid
5 sequence of SEQ ID NO:141 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:141, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:141 having biological activity, the fragment comprising the amino acid sequence from amino acid 17 to amino acid 26 of SEQ ID NO:141.

10 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:140.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - 15 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:140, but excluding the poly(A) tail at the 3' end of SEQ ID NO:140; and
 - 20 (ab) the nucleotide sequence of the cDNA insert of clone BV66_1 deposited with the ATCC under accession number 98278;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);
 - 25 and
- (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - 30 (ba) SEQ ID NO:140, but excluding the poly(A) tail at the 3' end of SEQ ID NO:140; and
 - (bb) the nucleotide sequence of the cDNA insert of clone BV66_1 deposited with the ATCC under accession number 98278;
 - (ii) hybridizing said primer(s) to human genomic DNA in conditions
 - 35 at least as stringent as 4X SSC at 50 degrees C;

- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:140, and extending contiguously
5 from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:140 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:140, but excluding the poly(A) tail at the 3' end of SEQ ID NO:140. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:140 from nucleotide 404 to nucleotide 535, and extending contiguously from a nucleotide sequence
10 corresponding to the 5' end of said sequence of SEQ ID NO:140 from nucleotide 404 to nucleotide 535, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:140 from nucleotide 404 to nucleotide 535. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:140 from nucleotide 1 to nucleotide 666, and extending contiguously from a nucleotide
15 sequence corresponding to the 5' end of said sequence of SEQ ID NO:140 from nucleotide 1 to nucleotide 666, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:140 from nucleotide 1 to nucleotide 666.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 20 (a) the amino acid sequence of SEQ ID NO:141;
- (b) the amino acid sequence of SEQ ID NO:141 from amino acid 1 to amino acid 38;
- (c) a fragment of the amino acid sequence of SEQ ID NO:141, the fragment comprising eight contiguous amino acids of SEQ ID NO:141; and
- 25 (d) the amino acid sequence encoded by the cDNA insert of clone BV66_1 deposited with the ATCC under accession number 98278;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:141 or the amino acid sequence of SEQ ID NO:141 from amino acid 1 to amino acid 38. In further preferred embodiments, the present
30 invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:141 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:141, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:141 having biological activity, the fragment comprising the amino acid sequence from amino acid 17 to amino acid 26 of SEQ
35 ID NO:141.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:142;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:142
5 from nucleotide 1204 to nucleotide 1389;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:142
from nucleotide 881 to nucleotide 1380;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length
protein coding sequence of clone BV291_3 deposited with the ATCC under accession
10 number 98278;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA
insert of clone BV291_3 deposited with the ATCC under accession number 98278;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein
coding sequence of clone BV291_3 deposited with the ATCC under accession number
15 98278;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert
of clone BV291_3 deposited with the ATCC under accession number 98278;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence
of SEQ ID NO:143;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino
20 acid sequence of SEQ ID NO:143 having biological activity, the fragment comprising
eight contiguous amino acids of SEQ ID NO:143;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g)
above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h)
25 or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of
the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of
30 the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the
length of SEQ ID NO:142.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:142
from nucleotide 1204 to nucleotide 1389; the nucleotide sequence of SEQ ID NO:142 from
nucleotide 881 to nucleotide 1380; the nucleotide sequence of the full-length protein coding
35 sequence of clone BV291_3 deposited with the ATCC under accession number 98278; or the

nucleotide sequence of a mature protein coding sequence of clone BV291_3 deposited with the ATCC under accession number 98278. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BV291_3 deposited with the ATCC under accession number 98278. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:143 from amino acid 1 to amino acid 59. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:143 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:143, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:143 having biological activity, the fragment comprising the amino acid sequence from amino acid 26 to amino acid 35 of SEQ ID NO:143.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:142.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:142, but excluding the poly(A) tail at the 3' end of SEQ ID NO:142; and

(ab) the nucleotide sequence of the cDNA insert of clone BV291_3 deposited with the ATCC under accession number 98278;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:142, but excluding the poly(A) tail at the 3' end of SEQ ID NO:142; and

- (bb) the nucleotide sequence of the cDNA insert of clone BV291_3 deposited with the ATCC under accession number 98278;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- 5 (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:142, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:142 to a nucleotide
10 sequence corresponding to the 3' end of SEQ ID NO:142, but excluding the poly(A) tail at the 3' end of SEQ ID NO:142. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:142 from nucleotide 1204 to nucleotide 1389, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:142 from nucleotide 1204 to
15 nucleotide 1389, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:142 from nucleotide 1204 to nucleotide 1389. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:142 from nucleotide 881 to nucleotide 1380, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:142 from
20 nucleotide 881 to nucleotide 1380, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:142 from nucleotide 881 to nucleotide 1380.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:143;
- 25 (b) the amino acid sequence of SEQ ID NO:143 from amino acid 1 to amino acid 59;
- (c) a fragment of the amino acid sequence of SEQ ID NO:143, the fragment comprising eight contiguous amino acids of SEQ ID NO:143; and
- (d) the amino acid sequence encoded by the cDNA insert of clone BV291_3
30 deposited with the ATCC under accession number 98278;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:143 or the amino acid sequence of SEQ ID NO:143 from amino acid 1 to amino acid 59. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID
35 NO:143 having biological activity, the fragment preferably comprising eight (more preferably

twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:143, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:143 having biological activity, the fragment comprising the amino acid sequence from amino acid 26 to amino acid 35 of SEQ ID NO:143.

5 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:144;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:144 from nucleotide 189 to nucleotide 1115;
- 10 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:144 from nucleotide 1 to nucleotide 451;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CK201_1 deposited with the ATCC under accession number 98278;
- 15 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CK201_1 deposited with the ATCC under accession number 98278;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CK201_1 deposited with the ATCC under accession number 98278;
- 20 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CK201_1 deposited with the ATCC under accession number 98278;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:145;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:145 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:145;
- 25 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- 30 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:144.
- 35

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:144 from nucleotide 189 to nucleotide 1115; the nucleotide sequence of SEQ ID NO:144 from nucleotide 1 to nucleotide 451; the nucleotide sequence of the full-length protein coding sequence of clone CK201_1 deposited with the ATCC under accession number 98278; or the nucleotide
5 sequence of a mature protein coding sequence of clone CK201_1 deposited with the ATCC under accession number 98278. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CK201_1 deposited with the ATCC under accession number 98278. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID
10 NO:145 from amino acid 1 to amino acid 88. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:145 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:145, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ
15 ID NO:145 having biological activity, the fragment comprising the amino acid sequence from amino acid 149 to amino acid 158 of SEQ ID NO:145.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:144.

Further embodiments of the invention provide isolated polynucleotides produced
20 according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - 25 (aa) SEQ ID NO:144, but excluding the poly(A) tail at the 3' end of SEQ ID NO:144; and
 - (ab) the nucleotide sequence of the cDNA insert of clone CK201_1 deposited with the ATCC under accession number 98278;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions
30 at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

5 (ba) SEQ ID NO:144, but excluding the poly(A) tail at the 3' end of SEQ ID NO:144; and

(bb) the nucleotide sequence of the cDNA insert of clone CK201_1 deposited with the ATCC under accession number 98278;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

10 (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:144, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:144 to a nucleotide
15 sequence corresponding to the 3' end of SEQ ID NO:144, but excluding the poly(A) tail at the 3' end of SEQ ID NO:144. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:144 from nucleotide 189 to nucleotide 1115, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:144 from nucleotide 189 to nucleotide
20 1115, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:144 from nucleotide 189 to nucleotide 1115. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:144 from nucleotide 1 to nucleotide 451, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:144 from
25 nucleotide 1 to nucleotide 451, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:144 from nucleotide 1 to nucleotide 451.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:145;
30 (b) the amino acid sequence of SEQ ID NO:145 from amino acid 1 to amino acid 88;

(c) a fragment of the amino acid sequence of SEQ ID NO:145, the fragment comprising eight contiguous amino acids of SEQ ID NO:145; and

(d) the amino acid sequence encoded by the cDNA insert of clone CK201_1
35 deposited with the ATCC under accession number 98278;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:145 or the amino acid sequence of SEQ ID NO:145 from amino acid 1 to amino acid 88. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:145 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:145, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:145 having biological activity, the fragment comprising the amino acid sequence from amino acid 149 to amino acid 158 of SEQ ID NO:145.

10 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:146;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:146 from nucleotide 117 to nucleotide 923;
- 15 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:146 from nucleotide 174 to nucleotide 923;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:146 from nucleotide 1 to nucleotide 316;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CQ331_2 deposited with the ATCC under accession number 98278;
- 20 (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CQ331_2 deposited with the ATCC under accession number 98278;
- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CQ331_2 deposited with the ATCC under accession number 98278;
- 25 (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CQ331_2 deposited with the ATCC under accession number 98278;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:147;
- 30 (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:147 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:147;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h)
- 35 above;

(l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and

5 (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:146.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:146 from nucleotide 117 to nucleotide 923; the nucleotide sequence of SEQ ID NO:146 from
10 nucleotide 174 to nucleotide 923; the nucleotide sequence of SEQ ID NO:146 from nucleotide 1 to nucleotide 316; the nucleotide sequence of the full-length protein coding sequence of clone CQ331_2 deposited with the ATCC under accession number 98278; or the nucleotide sequence of a mature protein coding sequence of clone CQ331_2 deposited with the ATCC under accession number 98278. In other preferred embodiments, the polynucleotide encodes the full-length or a
15 mature protein encoded by the cDNA insert of clone CQ331_2 deposited with the ATCC under accession number 98278. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:147 from amino acid 1 to amino acid 57. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ
20 ID NO:147 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:147, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:147 having biological activity, the fragment comprising the amino acid sequence from amino acid 129 to amino acid 138 of SEQ ID NO:147.

25 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:146.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

30 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:146, but excluding the poly(A) tail at the 3' end of SEQ ID NO:146; and

- (ab) the nucleotide sequence of the cDNA insert of clone CQ331_2 deposited with the ATCC under accession number 98278;
- (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
- 5 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
- 10 consisting of:
- (ba) SEQ ID NO:146, but excluding the poly(A) tail at the 3' end of SEQ ID NO:146; and
- (bb) the nucleotide sequence of the cDNA insert of clone CQ331_2 deposited with the ATCC under accession number 98278;
- 15 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).
- Preferably the polynucleotide isolated according to the above process comprises a nucleotide
- 20 sequence corresponding to the cDNA sequence of SEQ ID NO:146, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:146 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:146, but excluding the poly(A) tail at the 3' end of SEQ ID NO:146. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:146
- 25 from nucleotide 117 to nucleotide 923, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:146 from nucleotide 117 to nucleotide 923, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:146 from nucleotide 117 to nucleotide 923. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ
- 30 ID NO:146 from nucleotide 174 to nucleotide 923, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:146 from nucleotide 174 to nucleotide 923, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:146 from nucleotide 174 to nucleotide 923. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA
- 35 sequence of SEQ ID NO:146 from nucleotide 1 to nucleotide 316, and extending contiguously

from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:146 from nucleotide 1 to nucleotide 316, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:146 from nucleotide 1 to nucleotide 316.

In other embodiments, the present invention provides a composition comprising a protein,
5 wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:147;
- (b) the amino acid sequence of SEQ ID NO:147 from amino acid 1 to amino acid 57;
- (c) a fragment of the amino acid sequence of SEQ ID NO:147, the fragment
10 comprising eight contiguous amino acids of SEQ ID NO:147; and
- (d) the amino acid sequence encoded by the cDNA insert of clone CQ331_2 deposited with the ATCC under accession number 98278;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:147 or the amino acid sequence of SEQ ID
15 NO:147 from amino acid 1 to amino acid 57. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:147 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:147, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:147 having biological activity,
20 the fragment comprising the amino acid sequence from amino acid 129 to amino acid 138 of SEQ ID NO:147.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:148;
- 25 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:148 from nucleotide 223 to nucleotide 483;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:148 from nucleotide 22 to nucleotide 397;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length
30 protein coding sequence of clone CT550_1 deposited with the ATCC under accession number 98278;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CT550_1 deposited with the ATCC under accession number 98278;

- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CT550_1 deposited with the ATCC under accession number 98278;
- 5 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CT550_1 deposited with the ATCC under accession number 98278;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:149;
- 10 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:149 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:149;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- 15 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:148.
- 20 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:148 from nucleotide 223 to nucleotide 483; the nucleotide sequence of SEQ ID NO:148 from nucleotide 22 to nucleotide 397; the nucleotide sequence of the full-length protein coding sequence of clone CT550_1 deposited with the ATCC under accession number 98278; or the nucleotide sequence of a mature protein coding sequence of clone CT550_1 deposited with the
- 25 ATCC under accession number 98278. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CT550_1 deposited with the ATCC under accession number 98278. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:149 from amino acid 1 to amino acid 58. In further preferred
- 30 embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:149 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:149, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:149 having biological activity, the fragment comprising the
- 35 amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:149.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:148.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 5 (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

10 (aa) SEQ ID NO:148, but excluding the poly(A) tail at the 3' end of SEQ ID NO:148; and

(ab) the nucleotide sequence of the cDNA insert of clone CT550_1 deposited with the ATCC under accession number 98278;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

15 (iii) isolating the DNA polynucleotides detected with the probe(s);

and

- (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:148, but excluding the poly(A) tail at the 3' end of SEQ ID NO:148; and

(bb) the nucleotide sequence of the cDNA insert of clone CT550_1 deposited with the ATCC under accession number 98278;

25 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:148, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:148 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:148, but excluding the poly(A) tail at the 3' end of SEQ ID NO:148. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:148 from nucleotide 223 to nucleotide 483, and extending contiguously from a nucleotide sequence

30

35

corresponding to the 5' end of said sequence of SEQ ID NO:148 from nucleotide 223 to nucleotide 483, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:148 from nucleotide 223 to nucleotide 483. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:148 from nucleotide 22 to nucleotide 397, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:148 from nucleotide 22 to nucleotide 397, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:148 from nucleotide 22 to nucleotide 397.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:149;
- (b) the amino acid sequence of SEQ ID NO:149 from amino acid 1 to amino acid 58;
- (c) a fragment of the amino acid sequence of SEQ ID NO:149, the fragment comprising eight contiguous amino acids of SEQ ID NO:149; and
- (d) the amino acid sequence encoded by the cDNA insert of clone CT550_1 deposited with the ATCC under accession number 98278;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:149 or the amino acid sequence of SEQ ID NO:149 from amino acid 1 to amino acid 58. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:149 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:149, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:149 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:149.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:150;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:150 from nucleotide 112 to nucleotide 969;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:150 from nucleotide 154 to nucleotide 969;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:150 from nucleotide 1 to nucleotide 423;

- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CT585_1 deposited with the ATCC under accession number 98278;
- 5 (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CT585_1 deposited with the ATCC under accession number 98278;
- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CT585_1 deposited with the ATCC under accession number 98278;
- 10 (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CT585_1 deposited with the ATCC under accession number 98278;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:151;
- 15 (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:151 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:151;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;
- 20 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and
- (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:150.
- 25 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:150 from nucleotide 112 to nucleotide 969; the nucleotide sequence of SEQ ID NO:150 from nucleotide 154 to nucleotide 969; the nucleotide sequence of SEQ ID NO:150 from nucleotide 1 to nucleotide 423; the nucleotide sequence of the full-length protein coding sequence of clone CT585_1 deposited with the ATCC under accession number 98278; or the nucleotide sequence
- 30 of a mature protein coding sequence of clone CT585_1 deposited with the ATCC under accession number 98278. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CT585_1 deposited with the ATCC under accession number 98278. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:151 from
- 35 amino acid 1 to amino acid 104. In further preferred embodiments, the present invention provides

a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:151 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:151, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:151 having
5 biological activity, the fragment comprising the amino acid sequence from amino acid 138 to amino acid 147 of SEQ ID NO:151.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:150.

Further embodiments of the invention provide isolated polynucleotides produced
10 according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

15 (aa) SEQ ID NO:150, but excluding the poly(A) tail at the 3' end of SEQ ID NO:150; and

(ab) the nucleotide sequence of the cDNA insert of clone CT585_1 deposited with the ATCC under accession number 98278;

20 (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

- (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in
25 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:150, but excluding the poly(A) tail at the 3' end of SEQ ID NO:150; and

30 (bb) the nucleotide sequence of the cDNA insert of clone CT585_1 deposited with the ATCC under accession number 98278;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:150, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:150 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:150, but excluding the poly(A) tail at the 3' end of SEQ ID NO:150. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:150 from nucleotide 112 to nucleotide 969, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:150 from nucleotide 112 to nucleotide 969, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:150 from nucleotide 112 to nucleotide 969. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:150 from nucleotide 154 to nucleotide 969, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:150 from nucleotide 154 to nucleotide 969, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:150 from nucleotide 154 to nucleotide 969. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:150 from nucleotide 1 to nucleotide 423, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:150 from nucleotide 1 to nucleotide 423, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:150 from nucleotide 1 to nucleotide 423.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:151;
- (b) the amino acid sequence of SEQ ID NO:151 from amino acid 1 to amino acid 104;
- (c) a fragment of the amino acid sequence of SEQ ID NO:151, the fragment comprising eight contiguous amino acids of SEQ ID NO:151; and
- (d) the amino acid sequence encoded by the cDNA insert of clone CT585_1 deposited with the ATCC under accession number 98278;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:151 or the amino acid sequence of SEQ ID NO:151 from amino acid 1 to amino acid 104. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:151 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:151, or a protein

comprising a fragment of the amino acid sequence of SEQ ID NO:151 having biological activity, the fragment comprising the amino acid sequence from amino acid 138 to amino acid 147 of SEQ ID NO:151.

In one embodiment, the present invention provides a composition comprising an isolated
5 polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:152;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:152 from nucleotide 37 to nucleotide 2766;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:152
10 from nucleotide 243 to nucleotide 789;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CT797_3 deposited with the ATCC under accession number 98278;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA
15 insert of clone CT797_3 deposited with the ATCC under accession number 98278;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CT797_3 deposited with the ATCC under accession number 98278;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert
20 of clone CT797_3 deposited with the ATCC under accession number 98278;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:153;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:153 having biological activity, the fragment comprising
25 eight contiguous amino acids of SEQ ID NO:153;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of
30 the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:152.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:152 from nucleotide 37 to nucleotide 2766; the nucleotide sequence of SEQ ID NO:152 from nucleotide 243 to nucleotide 789; the nucleotide sequence of the full-length protein coding sequence of clone CT797_3 deposited with the ATCC under accession number 98278; or the
5 nucleotide sequence of a mature protein coding sequence of clone CT797_3 deposited with the ATCC under accession number 98278. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CT797_3 deposited with the ATCC under accession number 98278. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid
10 sequence of SEQ ID NO:153 from amino acid 75 to amino acid 251. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:153 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:153, or a polynucleotide encoding a protein comprising a fragment of the
15 amino acid sequence of SEQ ID NO:153 having biological activity, the fragment comprising the amino acid sequence from amino acid 450 to amino acid 459 of SEQ ID NO:153.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:152.

Further embodiments of the invention provide isolated polynucleotides produced
20 according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - 25 (aa) SEQ ID NO:152, but excluding the poly(A) tail at the 3' end of SEQ ID NO:152; and
 - (ab) the nucleotide sequence of the cDNA insert of clone CT797_3 deposited with the ATCC under accession number 98278;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions
30 at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:152, but excluding the poly(A) tail at the 3' end of SEQ ID NO:152; and

(bb) the nucleotide sequence of the cDNA insert of clone CT797_3 deposited with the ATCC under accession number 98278;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:152, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:152 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:152, but excluding the poly(A) tail at the 3' end of SEQ ID NO:152. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:152 from nucleotide 37 to nucleotide 2766, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:152 from nucleotide 37 to nucleotide 2766, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:152 from nucleotide 37 to nucleotide 2766. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:152 from nucleotide 243 to nucleotide 789, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:152 from nucleotide 243 to nucleotide 789, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:152 from nucleotide 243 to nucleotide 789.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:153;

(b) the amino acid sequence of SEQ ID NO:153 from amino acid 75 to amino acid 251;

(c) a fragment of the amino acid sequence of SEQ ID NO:153, the fragment comprising eight contiguous amino acids of SEQ ID NO:153; and

(d) the amino acid sequence encoded by the cDNA insert of clone CT797_3 deposited with the ATCC under accession number 98278;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:153 or the amino acid sequence of SEQ ID NO:153 from amino acid 75 to amino acid 251. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:153 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:153, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:153 having biological activity, the fragment comprising the amino acid sequence from amino acid 450 to amino acid 459 of SEQ ID NO:153.

10 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:155;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:155 from nucleotide 41 to nucleotide 760;
- 15 (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CB107_1 deposited with the ATCC under accession number 98279;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CB107_1 deposited with the ATCC under accession number 98279;
- 20 (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CB107_1 deposited with the ATCC under accession number 98279;
- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CB107_1 deposited with the ATCC under accession number 98279;
- 25 (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:156;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:156 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:156;
- 30 (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
- (k) a polynucleotide that hybridizes under stringent conditions to any one of
- 35 the polynucleotides specified in (a)-(h); and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:155.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:155
5 from nucleotide 41 to nucleotide 760; the nucleotide sequence of the full-length protein coding sequence of clone CB107_1 deposited with the ATCC under accession number 98279; or the nucleotide sequence of a mature protein coding sequence of clone CB107_1 deposited with the ATCC under accession number 98279. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CB107_1
10 deposited with the ATCC under accession number 98279. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:156 from amino acid 127 to amino acid 240. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:156 having biological activity, the fragment
15 preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:156, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:156 having biological activity, the fragment comprising the amino acid sequence from amino acid 115 to amino acid 124 of SEQ ID NO:156.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID
20 NO:155, SEQ ID NO:154, and SEQ ID NO:157.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X
25 SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:154;
 - (ab) SEQ ID NO:155;
 - (ac) SEQ ID NO:157, but excluding the poly(A) tail at the 3'
30 end of SEQ ID NO:157; and
 - (ad) the nucleotide sequence of the cDNA insert of clone CB107_1 deposited with the ATCC under accession number 98279;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);
35

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:154;

(bb) SEQ ID NO:155;

(bc) SEQ ID NO:157, but excluding the poly(A) tail at the 3' end of SEQ ID NO:157; and

(bd) the nucleotide sequence of the cDNA insert of clone CB107_1 deposited with the ATCC under accession number 98279;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:154, SEQ ID NO:155, and SEQ ID NO:157, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:154 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:157, but excluding the poly(A) tail at the 3' end of SEQ ID NO:157. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:155, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:155 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:155. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:155 from nucleotide 41 to nucleotide 760, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:155 from nucleotide 41 to nucleotide 760, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:155 from nucleotide 41 to nucleotide 760.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:156;

(b) the amino acid sequence of SEQ ID NO:156 from amino acid 127 to amino acid 240;

- (c) a fragment of the amino acid sequence of SEQ ID NO:156, the fragment comprising eight contiguous amino acids of SEQ ID NO:156; and
- (d) the amino acid sequence encoded by the cDNA insert of clone CB107_1 deposited with the ATCC under accession number 98279;
- 5 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:156 or the amino acid sequence of SEQ ID NO:156 from amino acid 127 to amino acid 240. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:156 having biological activity, the fragment preferably comprising eight (more preferably
- 10 twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:156, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:156 having biological activity, the fragment comprising the amino acid sequence from amino acid 115 to amino acid 124 of SEQ ID NO:156.

In one embodiment, the present invention provides a composition comprising an isolated

15 polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:158;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:158 from nucleotide 374 to nucleotide 1108;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:158
- 20 from nucleotide 500 to nucleotide 1108;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:158 from nucleotide 1 to nucleotide 387;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CG300_3 deposited with the ATCC under accession
- 25 number 98279;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CG300_3 deposited with the ATCC under accession number 98279;
- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CG300_3 deposited with the ATCC under accession number
- 30 98279;
- (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CG300_3 deposited with the ATCC under accession number 98279;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:159;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:159 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:159;

5 (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;

(l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and

10 (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:158.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:158 from nucleotide 374 to nucleotide 1108; the nucleotide sequence of SEQ ID NO:158 from
15 nucleotide 500 to nucleotide 1108; the nucleotide sequence of SEQ ID NO:158 from nucleotide 1 to nucleotide 387; the nucleotide sequence of the full-length protein coding sequence of clone CG300_3 deposited with the ATCC under accession number 98279; or the nucleotide sequence of a mature protein coding sequence of clone CG300_3 deposited with the ATCC under accession number 98279. In other preferred embodiments, the polynucleotide encodes the full-length or a
20 mature protein encoded by the cDNA insert of clone CG300_3 deposited with the ATCC under accession number 98279. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:159 from amino acid 23 to amino acid 57. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ
25 ID NO:159 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:159, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:159 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:159.

30 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:158.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

-201-

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:158, but excluding the poly(A) tail at the 3' end of SEQ ID NO:158; and

(ab) the nucleotide sequence of the cDNA insert of clone CG300_3 deposited with the ATCC under accession number 98279;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:158, but excluding the poly(A) tail at the 3' end of SEQ ID NO:158; and

(bb) the nucleotide sequence of the cDNA insert of clone CG300_3 deposited with the ATCC under accession number 98279;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:158, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:158 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:158, but excluding the poly(A) tail at the 3' end of SEQ ID NO:158. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:158 from nucleotide 374 to nucleotide 1108, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:158 from nucleotide 374 to nucleotide 1108, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:158 from nucleotide 374 to nucleotide 1108. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:158 from nucleotide 500 to nucleotide 1108, and extending contiguously from a

nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:158 from nucleotide 500 to nucleotide 1108, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:158 from nucleotide 500 to nucleotide 1108. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence
5 corresponding to the cDNA sequence of SEQ ID NO:158 from nucleotide 1 to nucleotide 387, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:158 from nucleotide 1 to nucleotide 387, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:158 from nucleotide 1 to nucleotide 387.

In other embodiments, the present invention provides a composition comprising a protein,
10 wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:159;
- (b) the amino acid sequence of SEQ ID NO:159 from amino acid 23 to amino acid 57;
- (c) a fragment of the amino acid sequence of SEQ ID NO:159, the fragment
15 comprising eight contiguous amino acids of SEQ ID NO:159; and
- (d) the amino acid sequence encoded by the cDNA insert of clone CG300_3 deposited with the ATCC under accession number 98279;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:159 or the amino acid sequence of SEQ ID
20 NO:159 from amino acid 23 to amino acid 57. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:159 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:159, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:159 having biological activity,
25 the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:159.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:160;
- 30 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:160 from nucleotide 126 to nucleotide 3053;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:160 from nucleotide 180 to nucleotide 3053;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:160
35 from nucleotide 49 to nucleotide 382;

- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CJ145_1 deposited with the ATCC under accession number 98279;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CJ145_1 deposited with the ATCC under accession number 98279;
- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CJ145_1 deposited with the ATCC under accession number 98279;
- (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CJ145_1 deposited with the ATCC under accession number 98279;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:161;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:161 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:161;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and
- (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:160.
- Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:160 from nucleotide 126 to nucleotide 3053; the nucleotide sequence of SEQ ID NO:160 from nucleotide 180 to nucleotide 3053; the nucleotide sequence of SEQ ID NO:160 from nucleotide 49 to nucleotide 382; the nucleotide sequence of the full-length protein coding sequence of clone CJ145_1 deposited with the ATCC under accession number 98279; or the nucleotide sequence of a mature protein coding sequence of clone CJ145_1 deposited with the ATCC under accession number 98279. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CJ145_1 deposited with the ATCC under accession number 98279. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:161 from amino acid 1 to amino acid 87. In further preferred embodiments, the present invention provides

a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:161 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:161, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:161 having biological activity, the fragment comprising the amino acid sequence from amino acid 482 to amino acid 491 of SEQ ID NO:161.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:160.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

- (aa) SEQ ID NO:160, but excluding the poly(A) tail at the 3' end of SEQ ID NO:160; and

- (ab) the nucleotide sequence of the cDNA insert of clone CJ145_1 deposited with the ATCC under accession number 98279;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

- (iii) isolating the DNA polynucleotides detected with the probe(s);

and

- (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

- (ba) SEQ ID NO:160, but excluding the poly(A) tail at the 3' end of SEQ ID NO:160; and

- (bb) the nucleotide sequence of the cDNA insert of clone CJ145_1 deposited with the ATCC under accession number 98279;

- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

- (iii) amplifying human DNA sequences; and

- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:160, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:160 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:160, but excluding the poly(A) tail at the 3' end of SEQ ID NO:160. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:160 from nucleotide 126 to nucleotide 3053, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:160 from nucleotide 126 to nucleotide 3053, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:160 from nucleotide 126 to nucleotide 3053. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:160 from nucleotide 180 to nucleotide 3053, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:160 from nucleotide 180 to nucleotide 3053, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:160 from nucleotide 180 to nucleotide 3053. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:160 from nucleotide 49 to nucleotide 382, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:160 from nucleotide 49 to nucleotide 382, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:160 from nucleotide 49 to nucleotide 382.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:161;
- (b) the amino acid sequence of SEQ ID NO:161 from amino acid 1 to amino acid 87;
- (c) a fragment of the amino acid sequence of SEQ ID NO:161, the fragment comprising eight contiguous amino acids of SEQ ID NO:161; and
- (d) the amino acid sequence encoded by the cDNA insert of clone CJ145_1 deposited with the ATCC under accession number 98279;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:161 or the amino acid sequence of SEQ ID NO:161 from amino acid 1 to amino acid 87. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:161 having biological activity, the fragment preferably comprising eight (more preferably

twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:161, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:161 having biological activity, the fragment comprising the amino acid sequence from amino acid 482 to amino acid 491 of SEQ ID NO:161.

5 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:162;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:162 from nucleotide 40 to nucleotide 342;
- 10 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:162 from nucleotide 127 to nucleotide 342;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:162 from nucleotide 11 to nucleotide 181;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length
15 protein coding sequence of clone CJ160_11 deposited with the ATCC under accession number 98279;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CJ160_11 deposited with the ATCC under accession number 98279;
- (g) a polynucleotide comprising the nucleotide sequence of a mature protein
20 coding sequence of clone CJ160_11 deposited with the ATCC under accession number 98279;
- (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CJ160_11 deposited with the ATCC under accession number 98279;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence
25 of SEQ ID NO:163;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:163 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:163;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h)
30 above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and

(n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:162.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:162 from nucleotide 40 to nucleotide 342; the nucleotide sequence of SEQ ID NO:162 from nucleotide 127 to nucleotide 342; the nucleotide sequence of SEQ ID NO:162 from nucleotide 11 to nucleotide 181; the nucleotide sequence of the full-length protein coding sequence of clone CJ160_11 deposited with the ATCC under accession number 98279; or the nucleotide sequence of a mature protein coding sequence of clone CJ160_11 deposited with the ATCC under accession number 98279. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CJ160_11 deposited with the ATCC under accession number 98279. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:163 from amino acid 7 to amino acid 48. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:163 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:163, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:163 having biological activity, the fragment comprising the amino acid sequence from amino acid 45 to amino acid 54 of SEQ ID NO:163.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:162.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 25 (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - 30 (aa) SEQ ID NO:162, but excluding the poly(A) tail at the 3' end of SEQ ID NO:162; and
 - (ab) the nucleotide sequence of the cDNA insert of clone CJ160_11 deposited with the ATCC under accession number 98279;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - 35 (iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:162, but excluding the poly(A) tail at the 3' end of SEQ ID NO:162; and

(bb) the nucleotide sequence of the cDNA insert of clone CJ160_11 deposited with the ATCC under accession number 98279;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:162, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:162 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:162, but excluding the poly(A) tail at the 3' end of SEQ ID NO:162. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:162 from nucleotide 40 to nucleotide 342, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:162 from nucleotide 40 to nucleotide 342, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:162 from nucleotide 40 to nucleotide 342. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:162 from nucleotide 127 to nucleotide 342, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:162 from nucleotide 127 to nucleotide 342, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:162 from nucleotide 127 to nucleotide 342. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:162 from nucleotide 11 to nucleotide 181, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:162 from nucleotide 11 to nucleotide 181, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:162 from nucleotide 11 to nucleotide 181.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:163;
- (b) the amino acid sequence of SEQ ID NO:163 from amino acid 7 to amino acid 48;
- (c) a fragment of the amino acid sequence of SEQ ID NO:163, the fragment comprising eight contiguous amino acids of SEQ ID NO:163; and
- (d) the amino acid sequence encoded by the cDNA insert of clone CJ160_11 deposited with the ATCC under accession number 98279;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:163 or the amino acid sequence of SEQ ID NO:163 from amino acid 7 to amino acid 48. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:163 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:163, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:163 having biological activity, the fragment comprising the amino acid sequence from amino acid 45 to amino acid 54 of SEQ ID NO:163.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:164;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:164 from nucleotide 180 to nucleotide 467;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:164 from nucleotide 267 to nucleotide 467;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CO20_1 deposited with the ATCC under accession number 98279;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CO20_1 deposited with the ATCC under accession number 98279;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CO20_1 deposited with the ATCC under accession number 98279;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CO20_1 deposited with the ATCC under accession number 98279;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:165;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:165 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:165;

5 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

10 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:164.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:164 from nucleotide 180 to nucleotide 467; the nucleotide sequence of SEQ ID NO:164 from
15 nucleotide 267 to nucleotide 467; the nucleotide sequence of the full-length protein coding sequence of clone CO20_1 deposited with the ATCC under accession number 98279; or the nucleotide sequence of a mature protein coding sequence of clone CO20_1 deposited with the ATCC under accession number 98279. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CO20_1
20 deposited with the ATCC under accession number 98279. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:165 from amino acid 1 to amino acid 37. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:165 having biological activity, the fragment
25 preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:165, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:165 having biological activity, the fragment comprising the amino acid sequence from amino acid 43 to amino acid 52 of SEQ ID NO:165.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID
30 NO:164 and SEQ ID NO:166.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

-211-

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:164;

(ab) SEQ ID NO:166, but excluding the poly(A) tail at the 3' end of SEQ ID NO:166; and

(ac) the nucleotide sequence of the cDNA insert of clone CO20_1 deposited with the ATCC under accession number 98279;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:164;

(bb) SEQ ID NO:166, but excluding the poly(A) tail at the 3' end of SEQ ID NO:166; and

(bc) the nucleotide sequence of the cDNA insert of clone CO20_1 deposited with the ATCC under accession number 98279;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:164 and SEQ ID NO:166, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:164 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:166, but excluding the poly(A) tail at the 3' end of SEQ ID NO:166. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:164, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:164 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:164. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:164

from nucleotide 180 to nucleotide 467, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:164 from nucleotide 180 to nucleotide 467, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:164 from nucleotide 180 to nucleotide 467. Also preferably the polynucleotide isolated according to
5 the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:164 from nucleotide 267 to nucleotide 467, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:164 from nucleotide 267 to nucleotide 467, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:164 from nucleotide 267 to nucleotide 467.

10 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:165;
- (b) the amino acid sequence of SEQ ID NO:165 from amino acid 1 to amino acid 37;
- 15 (c) a fragment of the amino acid sequence of SEQ ID NO:165, the fragment comprising eight contiguous amino acids of SEQ ID NO:165; and
- (d) the amino acid sequence encoded by the cDNA insert of clone CO20_1 deposited with the ATCC under accession number 98279;

the protein being substantially free from other mammalian proteins. Preferably such protein
20 comprises the amino acid sequence of SEQ ID NO:165 or the amino acid sequence of SEQ ID NO:165 from amino acid 1 to amino acid 37. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:165 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:165, or a protein
25 comprising a fragment of the amino acid sequence of SEQ ID NO:165 having biological activity, the fragment comprising the amino acid sequence from amino acid 43 to amino acid 52 of SEQ ID NO:165.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 30 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:167;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:167 from nucleotide 176 to nucleotide 520;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:167 from nucleotide 317 to nucleotide 520;

- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:167 from nucleotide 118 to nucleotide 413;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CO223_3 deposited with the ATCC under accession number 98291;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CO223_3 deposited with the ATCC under accession number 98291;
- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CO223_3 deposited with the ATCC under accession number 98291;
- (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CO223_3 deposited with the ATCC under accession number 98291;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:168;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:168 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:168;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and
- (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:167.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:167 from nucleotide 176 to nucleotide 520; the nucleotide sequence of SEQ ID NO:167 from nucleotide 317 to nucleotide 520; the nucleotide sequence of SEQ ID NO:167 from nucleotide 118 to nucleotide 413; the nucleotide sequence of the full-length protein coding sequence of clone CO223_3 deposited with the ATCC under accession number 98291; or the nucleotide sequence of a mature protein coding sequence of clone CO223_3 deposited with the ATCC under accession number 98291. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CO223_3 deposited with the ATCC under accession number 98291. In yet other preferred embodiments, the present invention provides a

polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:168 from amino acid 1 to amino acid 80. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:168 having biological activity, the fragment preferably comprising eight (more preferably
5 twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:168, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:168 having biological activity, the fragment comprising the amino acid sequence from amino acid 52 to amino acid 61 of SEQ ID NO:168.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID
10 NO:167.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X
15 SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:167, but excluding the poly(A) tail at the 3' end of SEQ ID NO:167; and
 - (ab) the nucleotide sequence of the cDNA insert of clone
20 CO223_3 deposited with the ATCC under accession number 98291;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- 25 (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (ba) SEQ ID NO:167, but excluding the poly(A) tail at the 3'
30 end of SEQ ID NO:167; and
 - (bb) the nucleotide sequence of the cDNA insert of clone CO223_3 deposited with the ATCC under accession number 98291;
 - (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
 - 35 (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:167, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:167 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:167, but excluding the poly(A) tail at the 3' end of SEQ ID NO:167. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:167 from nucleotide 176 to nucleotide 520, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:167 from nucleotide 176 to nucleotide 520, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:167 from nucleotide 176 to nucleotide 520. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:167 from nucleotide 317 to nucleotide 520, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:167 from nucleotide 317 to nucleotide 520, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:167 from nucleotide 317 to nucleotide 520. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:167 from nucleotide 118 to nucleotide 413, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:167 from nucleotide 118 to nucleotide 413, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:167 from nucleotide 118 to nucleotide 413.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:168;
- (b) the amino acid sequence of SEQ ID NO:168 from amino acid 1 to amino acid 80;
- (c) a fragment of the amino acid sequence of SEQ ID NO:168, the fragment comprising eight contiguous amino acids of SEQ ID NO:168; and
- (d) the amino acid sequence encoded by the cDNA insert of clone CO223_3 deposited with the ATCC under accession number 98291;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:168 or the amino acid sequence of SEQ ID NO:168 from amino acid 1 to amino acid 80. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:168 having biological activity, the fragment preferably comprising eight (more preferably

twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:168, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:168 having biological activity, the fragment comprising the amino acid sequence from amino acid 52 to amino acid 61 of SEQ ID NO:168.

5 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:169;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:169 from nucleotide 303 to nucleotide 542;
- 10 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:169 from nucleotide 1 to nucleotide 435;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CO310_2 deposited with the ATCC under accession number 98279;
- 15 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CO310_2 deposited with the ATCC under accession number 98279;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CO310_2 deposited with the ATCC under accession number 98279;
- 20 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CO310_2 deposited with the ATCC under accession number 98279;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:170;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:170 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:170;
- 25 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- 30 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:169.
- 35

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:169 from nucleotide 303 to nucleotide 542; the nucleotide sequence of SEQ ID NO:169 from nucleotide 1 to nucleotide 435; the nucleotide sequence of the full-length protein coding sequence of clone CO310_2 deposited with the ATCC under accession number 98279; or the nucleotide
5 sequence of a mature protein coding sequence of clone CO310_2 deposited with the ATCC under accession number 98279. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CO310_2 deposited with the ATCC under accession number 98279. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID
10 NO:170 from amino acid 1 to amino acid 44. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:170 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:170, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ
15 ID NO:170 having biological activity, the fragment comprising the amino acid sequence from amino acid 34 to amino acid 43 of SEQ ID NO:170.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:169.

Further embodiments of the invention provide isolated polynucleotides produced
20 according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - 25 (aa) SEQ ID NO:169, but excluding the poly(A) tail at the 3' end of SEQ ID NO:169; and
 - (ab) the nucleotide sequence of the cDNA insert of clone CO310_2 deposited with the ATCC under accession number 98279;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions
30 at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:169, but excluding the poly(A) tail at the 3' end of SEQ ID NO:169; and

(bb) the nucleotide sequence of the cDNA insert of clone CO310_2 deposited with the ATCC under accession number 98279;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:169, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:169 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:169, but excluding the poly(A) tail at the 3' end of SEQ ID NO:169. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:169 from nucleotide 303 to nucleotide 542, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:169 from nucleotide 303 to nucleotide 542, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:169 from nucleotide 303 to nucleotide 542. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:169 from nucleotide 1 to nucleotide 435, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:169 from nucleotide 1 to nucleotide 435, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:169 from nucleotide 1 to nucleotide 435.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:170;

(b) the amino acid sequence of SEQ ID NO:170 from amino acid 1 to amino acid 44;

(c) a fragment of the amino acid sequence of SEQ ID NO:170, the fragment comprising eight contiguous amino acids of SEQ ID NO:170; and

(d) the amino acid sequence encoded by the cDNA insert of clone CO310_2 deposited with the ATCC under accession number 98279;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:170 or the amino acid sequence of SEQ ID NO:170 from amino acid 1 to amino acid 44. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:170 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:170, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:170 having biological activity, the fragment comprising the amino acid sequence from amino acid 34 to amino acid 43 of SEQ ID NO:170.

10 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:171;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:171 from nucleotide 40 to nucleotide 455;
- 15 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:171 from nucleotide 85 to nucleotide 455;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:171 from nucleotide 265 to nucleotide 515;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CP258_3 deposited with the ATCC under accession number 98279;
- 20 (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CP258_3 deposited with the ATCC under accession number 98279;
- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CP258_3 deposited with the ATCC under accession number 98279;
- 25 (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CP258_3 deposited with the ATCC under accession number 98279;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:172;
- 30 (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:172 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:172;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h)
- 35 above;

(l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and

5 (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:171.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:171 from nucleotide 40 to nucleotide 455; the nucleotide sequence of SEQ ID NO:171 from nucleotide
10 85 to nucleotide 455; the nucleotide sequence of SEQ ID NO:171 from nucleotide 265 to nucleotide 515; the nucleotide sequence of the full-length protein coding sequence of clone CP258_3 deposited with the ATCC under accession number 98279; or the nucleotide sequence of a mature protein coding sequence of clone CP258_3 deposited with the ATCC under accession number 98279. In other preferred embodiments, the polynucleotide encodes the full-length or a
15 mature protein encoded by the cDNA insert of clone CP258_3 deposited with the ATCC under accession number 98279. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:172 from amino acid 64 to amino acid 138. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence
20 of SEQ ID NO:172 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:172, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:172 having biological activity, the fragment comprising the amino acid sequence from amino acid 64 to amino acid 73 of SEQ ID NO:172.

25 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:171.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
- 30 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
- (aa) SEQ ID NO:171, but excluding the poly(A) tail at the 3' end of SEQ ID NO:171; and

- (ab) the nucleotide sequence of the cDNA insert of clone CP258_3 deposited with the ATCC under accession number 98279;
- (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
- 5 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
- 10 consisting of:
- (ba) SEQ ID NO:171, but excluding the poly(A) tail at the 3' end of SEQ ID NO:171; and
- (bb) the nucleotide sequence of the cDNA insert of clone CP258_3 deposited with the ATCC under accession number 98279;
- 15 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).
- Preferably the polynucleotide isolated according to the above process comprises a nucleotide
- 20 sequence corresponding to the cDNA sequence of SEQ ID NO:171, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:171 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:171, but excluding the poly(A) tail at the 3' end of SEQ ID NO:171. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:171
- 25 from nucleotide 40 to nucleotide 455, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:171 from nucleotide 40 to nucleotide 455, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:171 from nucleotide 40 to nucleotide 455. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ
- 30 ID NO:171 from nucleotide 85 to nucleotide 455, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:171 from nucleotide 85 to nucleotide 455, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:171 from nucleotide 85 to nucleotide 455. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA
- 35 sequence of SEQ ID NO:171 from nucleotide 265 to nucleotide 515, and extending contiguously

from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:171 from nucleotide 265 to nucleotide 515, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:171 from nucleotide 265 to nucleotide 515.

In other embodiments, the present invention provides a composition comprising a protein,
5 wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:172;
- (b) the amino acid sequence of SEQ ID NO:172 from amino acid 64 to amino acid 138;
- (c) a fragment of the amino acid sequence of SEQ ID NO:172, the fragment
10 comprising eight contiguous amino acids of SEQ ID NO:172; and
- (d) the amino acid sequence encoded by the cDNA insert of clone CP258_3 deposited with the ATCC under accession number 98279;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:172 or the amino acid sequence of SEQ ID
15 NO:172 from amino acid 64 to amino acid 138. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:172 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:172, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:172 having biological activity,
20 the fragment comprising the amino acid sequence from amino acid 64 to amino acid 73 of SEQ ID NO:172.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:173;
- 25 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:173 from nucleotide 105 to nucleotide 1007;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:173 from nucleotide 801 to nucleotide 1007;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:173
30 from nucleotide 1 to nucleotide 352;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CW1155_3 deposited with the ATCC under accession number 98279;
- 35 (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CW1155_3 deposited with the ATCC under accession number 98279;

- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CW1155_3 deposited with the ATCC under accession number 98279;
- 5 (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CW1155_3 deposited with the ATCC under accession number 98279;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:174;
- 10 (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:174 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:174;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;
- 15 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and
- (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:173.
- 20 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:173 from nucleotide 105 to nucleotide 1007; the nucleotide sequence of SEQ ID NO:173 from nucleotide 801 to nucleotide 1007; the nucleotide sequence of SEQ ID NO:173 from nucleotide 1 to nucleotide 352; the nucleotide sequence of the full-length protein coding sequence of clone CW1155_3 deposited with the ATCC under accession number 98279; or the nucleotide sequence
- 25 of a mature protein coding sequence of clone CW1155_3 deposited with the ATCC under accession number 98279. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CW1155_3 deposited with the ATCC under accession number 98279. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID
- 30 NO:174 from amino acid 1 to amino acid 83. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:174 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:174, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ

ID NO:174 having biological activity, the fragment comprising the amino acid sequence from amino acid 145 to amino acid 154 of SEQ ID NO:174.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:173.

5 Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

10 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:173, but excluding the poly(A) tail at the 3' end of SEQ ID NO:173; and

(ab) the nucleotide sequence of the cDNA insert of clone CW1155_3 deposited with the ATCC under accession number 98279;

15 (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

20 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:173, but excluding the poly(A) tail at the 3' end of SEQ ID NO:173; and

25 (bb) the nucleotide sequence of the cDNA insert of clone CW1155_3 deposited with the ATCC under accession number 98279;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

30 (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:173, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:173 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:173, but excluding the poly(A) tail at the 3' end of SEQ ID NO:173. Also preferably the polynucleotide isolated according to the above

35

process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:173 from nucleotide 105 to nucleotide 1007, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:173 from nucleotide 105 to nucleotide 1007, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:173 from nucleotide 105 to nucleotide 1007. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:173 from nucleotide 801 to nucleotide 1007, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:173 from nucleotide 801 to nucleotide 1007, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:173 from nucleotide 801 to nucleotide 1007. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:173 from nucleotide 1 to nucleotide 352, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:173 from nucleotide 1 to nucleotide 352, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:173 from nucleotide 1 to nucleotide 352.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:174;
 - (b) the amino acid sequence of SEQ ID NO:174 from amino acid 1 to amino acid 83;
 - (c) a fragment of the amino acid sequence of SEQ ID NO:174, the fragment comprising eight contiguous amino acids of SEQ ID NO:174; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone CW1155_3 deposited with the ATCC under accession number 98279;
- the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:174 or the amino acid sequence of SEQ ID NO:174 from amino acid 1 to amino acid 83. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:174 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:174, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:174 having biological activity, the fragment comprising the amino acid sequence from amino acid 145 to amino acid 154 of SEQ ID NO:174.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:175;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:175 from nucleotide 11 to nucleotide 1699;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:175 from nucleotide 1682 to nucleotide 1699;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:175 from nucleotide 737 to nucleotide 1134;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CZ247_2 deposited with the ATCC under accession number 98279;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CZ247_2 deposited with the ATCC under accession number 98279;
- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CZ247_2 deposited with the ATCC under accession number 98279;
- (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CZ247_2 deposited with the ATCC under accession number 98279;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:176;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:176 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:176;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and
- (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:175.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:175 from nucleotide 11 to nucleotide 1699; the nucleotide sequence of SEQ ID NO:175 from nucleotide 1682 to nucleotide 1699; the nucleotide sequence of SEQ ID NO:175 from nucleotide 737 to nucleotide 1134; the nucleotide sequence of the full-length protein coding sequence of

clone CZ247_2 deposited with the ATCC under accession number 98279; or the nucleotide sequence of a mature protein coding sequence of clone CZ247_2 deposited with the ATCC under accession number 98279. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CZ247_2 deposited with the ATCC under accession number 98279. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:176 from amino acid 298 to amino acid 374. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:176 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:176, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:176 having biological activity, the fragment comprising the amino acid sequence from amino acid 276 to amino acid 285 of SEQ ID NO:176.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:175.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:175, but excluding the poly(A) tail at the 3' end of SEQ ID NO:175; and
 - (ab) the nucleotide sequence of the cDNA insert of clone CZ247_2 deposited with the ATCC under accession number 98279;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (ba) SEQ ID NO:175, but excluding the poly(A) tail at the 3' end of SEQ ID NO:175; and

- (bb) the nucleotide sequence of the cDNA insert of clone CZ247_2 deposited with the ATCC under accession number 98279;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- 5 (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:175, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:175 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:175, but excluding the poly(A) tail at the 3' end of SEQ ID NO:175. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:175 from nucleotide 11 to nucleotide 1699, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:175 from nucleotide 11 to nucleotide 1699, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:175 from nucleotide 11 to nucleotide 1699. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:175 from nucleotide 1682 to nucleotide 1699, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:175 from nucleotide 1682 to nucleotide 1699, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:175 from nucleotide 1682 to nucleotide 1699. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:175 from nucleotide 737 to nucleotide 1134, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:175 from nucleotide 737 to nucleotide 1134, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:175 from nucleotide 737 to nucleotide 1134.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 30 (a) the amino acid sequence of SEQ ID NO:176;
- (b) the amino acid sequence of SEQ ID NO:176 from amino acid 298 to amino acid 374;
- (c) a fragment of the amino acid sequence of SEQ ID NO:176, the fragment comprising eight contiguous amino acids of SEQ ID NO:176; and

(d) the amino acid sequence encoded by the cDNA insert of clone CZ247_2 deposited with the ATCC under accession number 98279; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:176 or the amino acid sequence of SEQ ID NO:176 from amino acid 298 to amino acid 374. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:176 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:176, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:176 having biological activity, the fragment comprising the amino acid sequence from amino acid 276 to amino acid 285 of SEQ ID NO:176.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:177;
- 15 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:177 from nucleotide 918 to nucleotide 1262;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:177 from nucleotide 999 to nucleotide 1262;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:177 from nucleotide 928 to nucleotide 1134;
- 20 (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AM666_1 deposited with the ATCC under accession number 98292;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AM666_1 deposited with the ATCC under accession number 98292;
- 25 (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone AM666_1 deposited with the ATCC under accession number 98292;
- (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone AM666_1 deposited with the ATCC under accession number 98292;
- 30 (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:178;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:178 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:178;
- 35

- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;
- 5 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and
- (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:177.
- 10 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:177 from nucleotide 918 to nucleotide 1262; the nucleotide sequence of SEQ ID NO:177 from nucleotide 999 to nucleotide 1262; the nucleotide sequence of SEQ ID NO:177 from nucleotide 928 to nucleotide 1134; the nucleotide sequence of the full-length protein coding sequence of clone AM666_1 deposited with the ATCC under accession number 98292; or the nucleotide
- 15 sequence of a mature protein coding sequence of clone AM666_1 deposited with the ATCC under accession number 98292. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone AM666_1 deposited with the ATCC under accession number 98292. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID
- 20 NO:178 from amino acid 5 to amino acid 72. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:178 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:178, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ
- 25 ID NO:178 having biological activity, the fragment comprising the amino acid sequence from amino acid 52 to amino acid 61 of SEQ ID NO:178.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:177.

Further embodiments of the invention provide isolated polynucleotides produced

30 according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

- (aa) SEQ ID NO:177, but excluding the poly(A) tail at the 3' end of SEQ ID NO:177; and
- (ab) the nucleotide sequence of the cDNA insert of clone AM666_1 deposited with the ATCC under accession number 98292;
- 5 (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
- (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
- 10 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
- (ba) SEQ ID NO:177, but excluding the poly(A) tail at the 3' end of SEQ ID NO:177; and
- 15 (bb) the nucleotide sequence of the cDNA insert of clone AM666_1 deposited with the ATCC under accession number 98292;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- (iii) amplifying human DNA sequences; and
- 20 (iv) isolating the polynucleotide products of step (b)(iii).
- Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:177, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:177 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:177, but excluding the poly(A) tail at the 3' end of SEQ ID NO:177. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:177 from nucleotide 918 to nucleotide 1262, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:177 from nucleotide 918 to nucleotide 1262, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:177 from nucleotide 918 to nucleotide 1262. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:177 from nucleotide 999 to nucleotide 1262, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:177 from nucleotide 999 to nucleotide 1262, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:177 from nucleotide 999 to nucleotide 1262. Also preferably the
- 25
- 30
- 35

polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:177 from nucleotide 928 to nucleotide 1134, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:177 from nucleotide 928 to nucleotide 1134, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:177 from nucleotide 928 to nucleotide 1134.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:178;
- 10 (b) the amino acid sequence of SEQ ID NO:178 from amino acid 5 to amino acid 72;
- (c) a fragment of the amino acid sequence of SEQ ID NO:178, the fragment comprising eight contiguous amino acids of SEQ ID NO:178; and
- (d) the amino acid sequence encoded by the cDNA insert of clone AM666_1
- 15 deposited with the ATCC under accession number 98292;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:178 or the amino acid sequence of SEQ ID NO:178 from amino acid 5 to amino acid 72. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:178 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:178, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:178 having biological activity, the fragment comprising the amino acid sequence from amino acid 52 to amino acid 61 of SEQ ID NO:178.

25 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:179;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:179 from nucleotide 751 to nucleotide 906;
- 30 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:179 from nucleotide 829 to nucleotide 906;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:179 from nucleotide 556 to nucleotide 831;

- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BN387_3 deposited with the ATCC under accession number 98292;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BN387_3 deposited with the ATCC under accession number 98292;
- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BN387_3 deposited with the ATCC under accession number 98292;
- (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone BN387_3 deposited with the ATCC under accession number 98292;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:180;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:180 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:180;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and
- (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:179.
- Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:179 from nucleotide 751 to nucleotide 906; the nucleotide sequence of SEQ ID NO:179 from nucleotide 829 to nucleotide 906; the nucleotide sequence of SEQ ID NO:179 from nucleotide 556 to nucleotide 831; the nucleotide sequence of the full-length protein coding sequence of clone BN387_3 deposited with the ATCC under accession number 98292; or the nucleotide sequence of a mature protein coding sequence of clone BN387_3 deposited with the ATCC under accession number 98292. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BN387_3 deposited with the ATCC under accession number 98292. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:180 from amino acid 1 to amino acid 27. In further preferred embodiments, the present invention provides

a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:180 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:180, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:180 having biological activity, the fragment comprising the amino acid sequence from amino acid 21 to amino acid 30 of SEQ ID NO:180.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:179.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:179, but excluding the poly(A) tail at the 3' end of SEQ ID NO:179; and

(ab) the nucleotide sequence of the cDNA insert of clone BN387_3 deposited with the ATCC under accession number 98292;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:179, but excluding the poly(A) tail at the 3' end of SEQ ID NO:179; and

(bb) the nucleotide sequence of the cDNA insert of clone BN387_3 deposited with the ATCC under accession number 98292;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:179, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:179 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:179, but excluding the poly(A) tail at the 3' end of SEQ ID NO:179. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:179 from nucleotide 751 to nucleotide 906, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:179 from nucleotide 751 to nucleotide 906, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:179 from nucleotide 751 to nucleotide 906. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:179 from nucleotide 829 to nucleotide 906, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:179 from nucleotide 829 to nucleotide 906, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:179 from nucleotide 829 to nucleotide 906. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:179 from nucleotide 556 to nucleotide 831, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:179 from nucleotide 556 to nucleotide 831, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:179 from nucleotide 556 to nucleotide 831.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:180;
- (b) the amino acid sequence of SEQ ID NO:180 from amino acid 1 to amino acid 27;
- (c) a fragment of the amino acid sequence of SEQ ID NO:180, the fragment comprising eight contiguous amino acids of SEQ ID NO:180; and
- (d) the amino acid sequence encoded by the cDNA insert of clone BN387_3 deposited with the ATCC under accession number 98292;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:180 or the amino acid sequence of SEQ ID NO:180 from amino acid 1 to amino acid 27. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:180 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:180, or a protein

comprising a fragment of the amino acid sequence of SEQ ID NO:180 having biological activity, the fragment comprising the amino acid sequence from amino acid 21 to amino acid 30 of SEQ ID NO:180.

In one embodiment, the present invention provides a composition comprising an isolated
5 polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:181;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:181 from nucleotide 139 to nucleotide 765;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:181
10 from nucleotide 1 to nucleotide 416;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BQ135_2 deposited with the ATCC under accession number 98292;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA
15 insert of clone BQ135_2 deposited with the ATCC under accession number 98292;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone BQ135_2 deposited with the ATCC under accession number 98292;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert
20 of clone BQ135_2 deposited with the ATCC under accession number 98292;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:182;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:182 having biological activity, the fragment comprising
25 eight contiguous amino acids of SEQ ID NO:182;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of
30 the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:181.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:181 from nucleotide 139 to nucleotide 765; the nucleotide sequence of SEQ ID NO:181 from nucleotide 1 to nucleotide 416; the nucleotide sequence of the full-length protein coding sequence of clone BQ135_2 deposited with the ATCC under accession number 98292; or the nucleotide
5 sequence of a mature protein coding sequence of clone BQ135_2 deposited with the ATCC under accession number 98292. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone BQ135_2 deposited with the ATCC under accession number 98292. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID
10 NO:182 from amino acid 1 to amino acid 93. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:182 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:182, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ
15 ID NO:182 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID NO:182.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:181.

Further embodiments of the invention provide isolated polynucleotides produced
20 according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
25 (aa) SEQ ID NO:181, but excluding the poly(A) tail at the 3' end of SEQ ID NO:181; and
(ab) the nucleotide sequence of the cDNA insert of clone BQ135_2 deposited with the ATCC under accession number 98292;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions
30 at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);

and

- (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

- 5 (ba) SEQ ID NO:181, but excluding the poly(A) tail at the 3' end of SEQ ID NO:181; and
- (bb) the nucleotide sequence of the cDNA insert of clone BQ135_2 deposited with the ATCC under accession number 98292;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- 10 (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:181, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:181 to a nucleotide

15 sequence corresponding to the 3' end of SEQ ID NO:181, but excluding the poly(A) tail at the 3' end of SEQ ID NO:181. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:181 from nucleotide 139 to nucleotide 765, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:181 from nucleotide 139 to nucleotide

20 765, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:181 from nucleotide 139 to nucleotide 765. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:181 from nucleotide 1 to nucleotide 416, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:181 from nucleotide 1 to

25 nucleotide 416, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:181 from nucleotide 1 to nucleotide 416.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:182;
- 30 (b) the amino acid sequence of SEQ ID NO:182 from amino acid 1 to amino acid 93;
- (c) a fragment of the amino acid sequence of SEQ ID NO:182, the fragment comprising eight contiguous amino acids of SEQ ID NO:182; and
- (d) the amino acid sequence encoded by the cDNA insert of clone BQ135_2
- 35 deposited with the ATCC under accession number 98292;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:182 or the amino acid sequence of SEQ ID NO:182 from amino acid 1 to amino acid 93. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:182 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:182, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:182 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID NO:182.

10 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:183;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:183 from nucleotide 214 to nucleotide 714;
- 15 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:183 from nucleotide 151 to nucleotide 531;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CR678_1 deposited with the ATCC under accession number 98292;
- 20 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CR678_1 deposited with the ATCC under accession number 98292;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CR678_1 deposited with the ATCC under accession number 98292;
- 25 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CR678_1 deposited with the ATCC under accession number 98292;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:184;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:184 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:184;
- 30 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- 35

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:183.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:183 from nucleotide 214 to nucleotide 714; the nucleotide sequence of SEQ ID NO:183 from nucleotide 151 to nucleotide 531; the nucleotide sequence of the full-length protein coding sequence of clone CR678_1 deposited with the ATCC under accession number 98292; or the nucleotide sequence of a mature protein coding sequence of clone CR678_1 deposited with the ATCC under accession number 98292. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CR678_1 deposited with the ATCC under accession number 98292. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:184 from amino acid 1 to amino acid 106. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:184 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:184, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:184 having biological activity, the fragment comprising the amino acid sequence from amino acid 78 to amino acid 87 of SEQ ID NO:184.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:183.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:183, but excluding the poly(A) tail at the 3' end of SEQ ID NO:183; and

(ab) the nucleotide sequence of the cDNA insert of clone CR678_1 deposited with the ATCC under accession number 98292;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in

5 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:183, but excluding the poly(A) tail at the 3' end of SEQ ID NO:183; and

10 (bb) the nucleotide sequence of the cDNA insert of clone CR678_1 deposited with the ATCC under accession number 98292;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

15 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:183, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:183 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:183, but excluding the poly(A) tail at the 3' end of SEQ ID NO:183. Also preferably the polynucleotide isolated according to the above
20 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:183 from nucleotide 214 to nucleotide 714, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:183 from nucleotide 214 to nucleotide 714, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:183 from nucleotide 214 to nucleotide 714. Also preferably the polynucleotide isolated according to
25 the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:183 from nucleotide 151 to nucleotide 531, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:183 from nucleotide 151 to nucleotide 531, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:183 from nucleotide 151 to nucleotide 531.

30 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:184;

(b) the amino acid sequence of SEQ ID NO:184 from amino acid 1 to amino acid 106;

- (c) a fragment of the amino acid sequence of SEQ ID NO:184, the fragment comprising eight contiguous amino acids of SEQ ID NO:184; and
- (d) the amino acid sequence encoded by the cDNA insert of clone CR678_1 deposited with the ATCC under accession number 98292;
- 5 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:184 or the amino acid sequence of SEQ ID NO:184 from amino acid 1 to amino acid 106. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:184 having biological activity, the fragment preferably comprising eight (more preferably
- 10 twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:184, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:184 having biological activity, the fragment comprising the amino acid sequence from amino acid 78 to amino acid 87 of SEQ ID NO:184.

In one embodiment, the present invention provides a composition comprising an isolated

15 polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:185;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:185 from nucleotide 116 to nucleotide 4498;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:185
- 20 from nucleotide 1221 to nucleotide 1711;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CW420_2 deposited with the ATCC under accession number 98292;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA
- 25 insert of clone CW420_2 deposited with the ATCC under accession number 98292;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CW420_2 deposited with the ATCC under accession number 98292;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert
- 30 of clone CW420_2 deposited with the ATCC under accession number 98292;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:186;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:186 having biological activity, the fragment comprising
- 35 eight contiguous amino acids of SEQ ID NO:186;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

5 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:185.

10 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:185 from nucleotide 116 to nucleotide 4498; the nucleotide sequence of SEQ ID NO:185 from nucleotide 1221 to nucleotide 1711; the nucleotide sequence of the full-length protein coding sequence of clone CW420_2 deposited with the ATCC under accession number 98292; or the nucleotide sequence of a mature protein coding sequence of clone CW420_2 deposited with the
15 ATCC under accession number 98292. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CW420_2 deposited with the ATCC under accession number 98292. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:186 from amino acid 370 to amino acid 532. In further preferred
20 embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:186 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:186, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:186 having biological activity, the fragment comprising the
25 amino acid sequence from amino acid 725 to amino acid 734 of SEQ ID NO:186.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:185.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

30 (a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:185, but excluding the poly(A) tail at the 3'
35 end of SEQ ID NO:185; and

- (ab) the nucleotide sequence of the cDNA insert of clone CW420_2 deposited with the ATCC under accession number 98292;
- (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
- 5 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
- 10 consisting of:
- (ba) SEQ ID NO:185, but excluding the poly(A) tail at the 3' end of SEQ ID NO:185; and
- (bb) the nucleotide sequence of the cDNA insert of clone CW420_2 deposited with the ATCC under accession number 98292;
- 15 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide

20 sequence corresponding to the cDNA sequence of SEQ ID NO:185, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:185 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:185, but excluding the poly(A) tail at the 3' end of SEQ ID NO:185. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:185

25 from nucleotide 116 to nucleotide 4498, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:185 from nucleotide 116 to nucleotide 4498, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:185 from nucleotide 116 to nucleotide 4498. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of

30 SEQ ID NO:185 from nucleotide 1221 to nucleotide 1711, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:185 from nucleotide 1221 to nucleotide 1711, to a nucleotide sequence corresponding to the 3' end of said sequence f SEQ ID NO:185 from nucleotide 1221 to nucleotide 1711.

In other embodiments, the present invention provides a composition comprising a protein,

35 wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:186;
- (b) the amino acid sequence of SEQ ID NO:186 from amino acid 370 to amino acid 532;
- (c) a fragment of the amino acid sequence of SEQ ID NO:186, the fragment comprising eight contiguous amino acids of SEQ ID NO:186; and
- (d) the amino acid sequence encoded by the cDNA insert of clone CW420_2 deposited with the ATCC under accession number 98292;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:186 or the amino acid sequence of SEQ ID NO:186 from amino acid 370 to amino acid 532. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:186 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:186, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:186 having biological activity, the fragment comprising the amino acid sequence from amino acid 725 to amino acid 734 of SEQ ID NO:186.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:187;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:187 from nucleotide 119 to nucleotide 2176;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:187 from nucleotide 1 to nucleotide 529;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CW795_2 deposited with the ATCC under accession number 98292;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CW795_2 deposited with the ATCC under accession number 98292;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CW795_2 deposited with the ATCC under accession number 98292;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone CW795_2 deposited with the ATCC under accession number 98292;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:188;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:188 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:188;

5 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

10 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:187.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:187 from nucleotide 119 to nucleotide 2176; the nucleotide sequence of SEQ ID NO:187 from
15 nucleotide 1 to nucleotide 529; the nucleotide sequence of the full-length protein coding sequence of clone CW795_2 deposited with the ATCC under accession number 98292; or the nucleotide sequence of a mature protein coding sequence of clone CW795_2 deposited with the ATCC under accession number 98292. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CW795_2 deposited with the
20 ATCC under accession number 98292. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:188 from amino acid 1 to amino acid 137. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:188 having biological activity, the fragment preferably comprising eight
25 (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:188, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:188 having biological activity, the fragment comprising the amino acid sequence from amino acid 338 to amino acid 347 of SEQ ID NO:188.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID
30 NO:187.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:187, but excluding the poly(A) tail at the 3' end of SEQ ID NO:187; and

(ab) the nucleotide sequence of the cDNA insert of clone CW795_2 deposited with the ATCC under accession number 98292;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:187, but excluding the poly(A) tail at the 3' end of SEQ ID NO:187; and

(bb) the nucleotide sequence of the cDNA insert of clone CW795_2 deposited with the ATCC under accession number 98292;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:187, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:187 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:187, but excluding the poly(A) tail at the 3' end of SEQ ID NO:187. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:187 from nucleotide 119 to nucleotide 2176, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:187 from nucleotide 119 to nucleotide 2176, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:187 from nucleotide 119 to nucleotide 2176. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:187 from nucleotide 1 to nucleotide 529, and extending contiguously from a

nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:187 from nucleotide 1 to nucleotide 529, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:187 from nucleotide 1 to nucleotide 529.

In other embodiments, the present invention provides a composition comprising a protein,
5 wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:188;
- (b) the amino acid sequence of SEQ ID NO:188 from amino acid 1 to amino acid 137;
- (c) a fragment of the amino acid sequence of SEQ ID NO:188, the fragment
10 comprising eight contiguous amino acids of SEQ ID NO:188; and
- (d) the amino acid sequence encoded by the cDNA insert of clone CW795_2 deposited with the ATCC under accession number 98292;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:188 or the amino acid sequence of SEQ ID
15 NO:188 from amino acid 1 to amino acid 137. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:188 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:188, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:188 having biological activity,
20 the fragment comprising the amino acid sequence from amino acid 338 to amino acid 347 of SEQ ID NO:188.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:189;
- 25 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:189 from nucleotide 401 to nucleotide 589;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:189 from nucleotide 258 to nucleotide 627;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length
30 protein coding sequence of clone CW823_3 deposited with the ATCC under accession number 98292;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CW823_3 deposited with the ATCC under accession number 98292;

- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone CW823_3 deposited with the ATCC under accession number 98292;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert
5 of clone CW823_3 deposited with the ATCC under accession number 98292;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:190;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:190 having biological activity, the fragment comprising
10 eight contiguous amino acids of SEQ ID NO:190;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of
15 the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:189.
- 20 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:189 from nucleotide 401 to nucleotide 589; the nucleotide sequence of SEQ ID NO:189 from nucleotide 258 to nucleotide 627; the nucleotide sequence of the full-length protein coding sequence of clone CW823_3 deposited with the ATCC under accession number 98292; or the nucleotide sequence of a mature protein coding sequence of clone CW823_3 deposited with the
25 ATCC under accession number 98292. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone CW823_3 deposited with the ATCC under accession number 98292. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:190 having biological activity, the fragment preferably
30 comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:190, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:190 having biological activity, the fragment comprising the amino acid sequence from amino acid 26 to amino acid 35 of SEQ ID NO:190.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID
35 NO:189.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:189, but excluding the poly(A) tail at the 3' end of SEQ ID NO:189; and

(ab) the nucleotide sequence of the cDNA insert of clone CW823_3 deposited with the ATCC under accession number 98292;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:189, but excluding the poly(A) tail at the 3' end of SEQ ID NO:189; and

(bb) the nucleotide sequence of the cDNA insert of clone CW823_3 deposited with the ATCC under accession number 98292;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:189, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:189 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:189, but excluding the poly(A) tail at the 3' end of SEQ ID NO:189. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:189 from nucleotide 401 to nucleotide 589, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:189 from nucleotide 401 to nucleotide 589, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:189

from nucleotide 401 to nucleotide 589. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:189 from nucleotide 258 to nucleotide 627, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:189 from nucleotide 258 to nucleotide 627, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:189 from nucleotide 258 to nucleotide 627.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:190;
- 10 (b) a fragment of the amino acid sequence of SEQ ID NO:190, the fragment comprising eight contiguous amino acids of SEQ ID NO:190; and
- (c) the amino acid sequence encoded by the cDNA insert of clone CW823_3 deposited with the ATCC under accession number 98292;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:190. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:190 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:190, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:190 having biological activity, the fragment comprising the amino acid sequence from amino acid 26 to amino acid 35 of SEQ ID NO:190.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:191;
- 25 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:191 from nucleotide 548 to nucleotide 868;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:191 from nucleotide 590 to nucleotide 868;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone DF989_3 deposited with the ATCC under accession number 98292;
- 30 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone DF989_3 deposited with the ATCC under accession number 98292;

- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone DF989_3 deposited with the ATCC under accession number 98292;
- 5 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone DF989_3 deposited with the ATCC under accession number 98292;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:192;
- 10 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:192 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:192;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- 15 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:191.
- 20 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:191 from nucleotide 548 to nucleotide 868; the nucleotide sequence of SEQ ID NO:191 from nucleotide 590 to nucleotide 868; the nucleotide sequence of the full-length protein coding sequence of clone DF989_3 deposited with the ATCC under accession number 98292; or the nucleotide sequence of a mature protein coding sequence of clone DF989_3 deposited with the
- 25 ATCC under accession number 98292. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone DF989_3 deposited with the ATCC under accession number 98292. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:192 from amino acid 75 to amino acid 107. In further preferred
- 30 embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:192 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:192, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:192 having biological activity, the fragment comprising the
- 35 amino acid sequence from amino acid 48 to amino acid 57 of SEQ ID NO:192.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:191 and SEQ ID NO:193.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 5 (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
- 10 (aa) SEQ ID NO:191;
- (ab) SEQ ID NO:193, but excluding the poly(A) tail at the 3' end of SEQ ID NO:193; and
- (ac) the nucleotide sequence of the cDNA insert of clone DF989_3 deposited with the ATCC under accession number 98292;
- 15 (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
- (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that hybridize in
- 20 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
- (ba) SEQ ID NO:191;
- (bb) SEQ ID NO:193, but excluding the poly(A) tail at the 3' end of SEQ ID NO:193; and
- 25 (bc) the nucleotide sequence of the cDNA insert of clone DF989_3 deposited with the ATCC under accession number 98292;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- (iii) amplifying human DNA sequences; and
- 30 (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequences of SEQ ID NO:191 and SEQ ID NO:193, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:191 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:193, but excluding

35 the poly(A) tail at the 3' end of SEQ ID NO:193. Also preferably the polynucleotide isolated

according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:191, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:191 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:191. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:191 from nucleotide 548 to nucleotide 868, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:191 from nucleotide 548 to nucleotide 868, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:191 from nucleotide 548 to nucleotide 868. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:191 from nucleotide 590 to nucleotide 868, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:191 from nucleotide 590 to nucleotide 868, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:191 from nucleotide 590 to nucleotide 868.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:192;
- (b) the amino acid sequence of SEQ ID NO:192 from amino acid 75 to amino acid 107;
- (c) a fragment of the amino acid sequence of SEQ ID NO:192, the fragment comprising eight contiguous amino acids of SEQ ID NO:192; and
- (d) the amino acid sequence encoded by the cDNA insert of clone DF989_3 deposited with the ATCC under accession number 98292;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:192 or the amino acid sequence of SEQ ID NO:192 from amino acid 75 to amino acid 107. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:192 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:192, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:192 having biological activity, the fragment comprising the amino acid sequence from amino acid 48 to amino acid 57 of SEQ ID NO:192.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:194;

- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:194 from nucleotide 251 to nucleotide 787;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:194 from nucleotide 371 to nucleotide 787;
- 5 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone DL162_1 deposited with the ATCC under accession number 98292;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone DL162_1 deposited with the ATCC under accession number 98292;
- 10 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone DL162_1 deposited with the ATCC under accession number 98292;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone DL162_1 deposited with the ATCC under accession number 98292;
- 15 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:195;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:195 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:195;
- 20 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of
- 25 the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:194.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:194

30 from nucleotide 251 to nucleotide 787; the nucleotide sequence of SEQ ID NO:194 from nucleotide 371 to nucleotide 787; the nucleotide sequence of the full-length protein coding sequence of clone DL162_1 deposited with the ATCC under accession number 98292; or the nucleotide sequence of a mature protein coding sequence of clone DL162_1 deposited with the ATCC under accession number 98292. In other preferred embodiments, the polynucleotide

35 encodes the full-length or a mature protein encoded by the cDNA insert of clone DL162_1

deposited with the ATCC under accession number 98292. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:195 from amino acid 38 to amino acid 170. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a
5 fragment of the amino acid sequence of SEQ ID NO:195 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:195, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:195 having biological activity, the fragment comprising the amino acid sequence from amino acid 84 to amino acid 93 of SEQ ID NO:195.

10 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:194.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:
15 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:194, but excluding the poly(A) tail at the 3' end of SEQ ID NO:194; and
20 (ab) the nucleotide sequence of the cDNA insert of clone DL162_1 deposited with the ATCC under accession number 98292;
(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
(iii) isolating the DNA polynucleotides detected with the probe(s);

25 and

(b) a process comprising the steps of:
(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

30 (ba) SEQ ID NO:194, but excluding the poly(A) tail at the 3' end of SEQ ID NO:194; and
(bb) the nucleotide sequence of the cDNA insert of clone DL162_1 deposited with the ATCC under accession number 98292;
(ii) hybridizing said primer(s) to human genomic DNA in conditions
35 at least as stringent as 4X SSC at 50 degrees C;

- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:194, and extending contiguously
5 from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:194 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:194, but excluding the poly(A) tail at the 3' end of SEQ ID NO:194. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:194 from nucleotide 251 to nucleotide 787, and extending contiguously from a nucleotide sequence
10 corresponding to the 5' end of said sequence of SEQ ID NO:194 from nucleotide 251 to nucleotide 787, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:194 from nucleotide 251 to nucleotide 787. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:194 from nucleotide 371 to nucleotide 787, and extending contiguously from a nucleotide
15 sequence corresponding to the 5' end of said sequence of SEQ ID NO:194 from nucleotide 371 to nucleotide 787, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:194 from nucleotide 371 to nucleotide 787.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 20 (a) the amino acid sequence of SEQ ID NO:195;
- (b) the amino acid sequence of SEQ ID NO:195 from amino acid 38 to amino acid 170;
- (c) a fragment of the amino acid sequence of SEQ ID NO:195, the fragment comprising eight contiguous amino acids of SEQ ID NO:195; and
- 25 (d) the amino acid sequence encoded by the cDNA insert of clone DL162_1 deposited with the ATCC under accession number 98292;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:195 or the amino acid sequence of SEQ ID NO:195 from amino acid 38 to amino acid 170. In further preferred embodiments, the present
30 invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:195 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:195, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:195 having biological activity, the fragment comprising the amino acid sequence from amino acid 84 to amino acid 93 of SEQ
35 ID NO:195.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:196;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:196
5 from nucleotide 121 to nucleotide 3345;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:196
from nucleotide 160 to nucleotide 3345;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:196
from nucleotide 2592 to nucleotide 3318;
- 10 (e) a polynucleotide comprising the nucleotide sequence of the full-length
protein coding sequence of clone DL162_2 deposited with the ATCC under accession
number 98292;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA
insert of clone DL162_2 deposited with the ATCC under accession number 98292;
- 15 (g) a polynucleotide comprising the nucleotide sequence of a mature protein
coding sequence of clone DL162_2 deposited with the ATCC under accession number
98292;
- (h) a polynucleotide encoding a mature protein encoded by the cDNA insert
of clone DL162_2 deposited with the ATCC under accession number 98292;
- 20 (i) a polynucleotide encoding a protein comprising the amino acid sequence
of SEQ ID NO:197;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino
acid sequence of SEQ ID NO:197 having biological activity, the fragment comprising
eight contiguous amino acids of SEQ ID NO:197;
- 25 (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h)
above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i)
or (j) above ;
- (m) a polynucleotide that hybridizes under stringent conditions to any one of
30 the polynucleotides specified in (a)-(j); and
- (n) a polynucleotide that hybridizes under stringent conditions to any one of
the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the
length of SEQ ID NO:196.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:196
35 from nucleotide 121 to nucleotide 3345; the nucleotide sequence of SEQ ID NO:196 from

nucleotide 160 to nucleotide 3345; the nucleotide sequence of SEQ ID NO:196 from nucleotide 2592 to nucleotide 3318; the nucleotide sequence of the full-length protein coding sequence of clone DL162_2 deposited with the ATCC under accession number 98292; or the nucleotide sequence of a mature protein coding sequence of clone DL162_2 deposited with the ATCC under
5 accession number 98292. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone DL162_2 deposited with the ATCC under accession number 98292. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:197 from amino acid 860 to amino acid 1066. In further preferred embodiments, the present
10 invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:197 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:197, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:197 having biological activity, the fragment comprising the amino acid sequence from
15 amino acid 532 to amino acid 541 of SEQ ID NO:197.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:196.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 20 (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:196, but excluding the poly(A) tail at the 3'
25 end of SEQ ID NO:196; and
 - (ab) the nucleotide sequence of the cDNA insert of clone DL162_2 deposited with the ATCC under accession number 98292;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - 30 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
35 consisting of:

(ba) SEQ ID NO:196, but excluding the poly(A) tail at the 3' end of SEQ ID NO:196; and

(bb) the nucleotide sequence of the cDNA insert of clone DL162_2 deposited with the ATCC under accession number 98292;

5 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide
10 sequence corresponding to the cDNA sequence of SEQ ID NO:196, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:196 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:196, but excluding the poly(A) tail at the 3' end of SEQ ID NO:196. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:196
15 from nucleotide 121 to nucleotide 3345, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:196 from nucleotide 121 to nucleotide 3345, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:196 from nucleotide 121 to nucleotide 3345. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of
20 SEQ ID NO:196 from nucleotide 160 to nucleotide 3345, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:196 from nucleotide 160 to nucleotide 3345, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:196 from nucleotide 160 to nucleotide 3345. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence
25 corresponding to the cDNA sequence of SEQ ID NO:196 from nucleotide 2592 to nucleotide 3318, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:196 from nucleotide 2592 to nucleotide 3318, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:196 from nucleotide 2592 to nucleotide 3318.

30 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:197;

(b) the amino acid sequence of SEQ ID NO:197 from amino acid 860 to amino acid 1066;

- (c) a fragment of the amino acid sequence of SEQ ID NO:197, the fragment comprising eight contiguous amino acids of SEQ ID NO:197; and
- (d) the amino acid sequence encoded by the cDNA insert of clone DL162_2 deposited with the ATCC under accession number 98292;
- 5 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:197 or the amino acid sequence of SEQ ID NO:197 from amino acid 860 to amino acid 1066. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:197 having biological activity, the fragment preferably comprising eight (more preferably
- 10 twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:197, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:197 having biological activity, the fragment comprising the amino acid sequence from amino acid 532 to amino acid 541 of SEQ ID NO:197.

In one embodiment, the present invention provides a composition comprising an isolated

15 polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:198;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:198 from nucleotide 117 to nucleotide 2600;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:198
- 20 from nucleotide 2130 to nucleotide 2600;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:198 from nucleotide 1 to nucleotide 506;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone EC172_1 deposited with the ATCC under accession
- 25 number 98292;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone EC172_1 deposited with the ATCC under accession number 98292;
- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone EC172_1 deposited with the ATCC under accession number
- 30 98292;
- (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone EC172_1 deposited with the ATCC under accession number 98292;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:199;

(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:199 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:199;

5 (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;

(l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and

10 (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:198.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:198 from nucleotide 117 to nucleotide 2600; the nucleotide sequence of SEQ ID NO:198 from
15 nucleotide 2130 to nucleotide 2600; the nucleotide sequence of SEQ ID NO:198 from nucleotide 1 to nucleotide 506; the nucleotide sequence of the full-length protein coding sequence of clone EC172_1 deposited with the ATCC under accession number 98292; or the nucleotide sequence of a mature protein coding sequence of clone EC172_1 deposited with the ATCC under accession number 98292. In other preferred embodiments, the polynucleotide encodes the full-length or a
20 mature protein encoded by the cDNA insert of clone EC172_1 deposited with the ATCC under accession number 98292. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:199 from amino acid 1 to amino acid 130. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ
25 ID NO:199 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:199, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:199 having biological activity, the fragment comprising the amino acid sequence from amino acid 409 to amino acid 418 of SEQ ID NO:199.

30 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:198.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:198, but excluding the poly(A) tail at the 3' end of SEQ ID NO:198; and

(ab) the nucleotide sequence of the cDNA insert of clone EC172_1 deposited with the ATCC under accession number 98292;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:198, but excluding the poly(A) tail at the 3' end of SEQ ID NO:198; and

(bb) the nucleotide sequence of the cDNA insert of clone EC172_1 deposited with the ATCC under accession number 98292;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:198, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:198 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:198, but excluding the poly(A) tail at the 3' end of SEQ ID NO:198. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:198 from nucleotide 117 to nucleotide 2600, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:198 from nucleotide 117 to nucleotide 2600, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:198 from nucleotide 117 to nucleotide 2600. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:198 from nucleotide 2130 to nucleotide 2600, and extending contiguously from a

nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:198 from nucleotide 2130 to nucleotide 2600, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:198 from nucleotide 2130 to nucleotide 2600. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence
5 corresponding to the cDNA sequence of SEQ ID NO:198 from nucleotide 1 to nucleotide 506, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:198 from nucleotide 1 to nucleotide 506, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:198 from nucleotide 1 to nucleotide 506.

In other embodiments, the present invention provides a composition comprising a protein,
10 wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:199;
- (b) the amino acid sequence of SEQ ID NO:199 from amino acid 1 to amino acid 130;
- (c) a fragment of the amino acid sequence of SEQ ID NO:199, the fragment
15 comprising eight contiguous amino acids of SEQ ID NO:199; and
- (d) the amino acid sequence encoded by the cDNA insert of clone EC172_1 deposited with the ATCC under accession number 98292;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:199 or the amino acid sequence of SEQ ID
20 NO:199 from amino acid 1 to amino acid 130. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:199 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:199, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:199 having biological activity,
25 the fragment comprising the amino acid sequence from amino acid 409 to amino acid 418 of SEQ ID NO:199.

In certain preferred embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions. Also provided by the
30 present invention are organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein.

Processes are also provided for producing a protein, which comprise:

- (a) growing a culture of the host cell transformed with such polynucleotide compositions in a suitable culture medium; and
 - (b) purifying the protein from the culture.
- 35

The protein produced according to such methods is also provided by the present invention.

Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier. Compositions comprising an antibody which specifically reacts with such protein are also provided by the present invention.

5 Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.

10 BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B are schematic representations of the pED6 and pNOTs vectors, respectively, used for deposit of clones disclosed herein.

DETAILED DESCRIPTION

15 ISOLATED PROTEINS AND POLYNUCLEOTIDES

Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and protein disclosed in the present application. The nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone in accordance with known methods. The predicted amino acid sequence (both full-length and mature forms) can then be
20 determined from such nucleotide sequence. The amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have determined to be the reading frame best identifiable with sequence information available at the time of filing.

25 As used herein a "secreted" protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence. "Secreted" proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g., receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported
30 across the membrane of the endoplasmic reticulum.

Clone "AX65_22"

A polynucleotide of the present invention has been identified as clone "AX65_22". AX65_22 was isolated from a human adult testes cDNA library using methods which are selective
35 for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding

a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. AX65_22 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "AX65_22 protein").

5 The nucleotide sequence of the 5' portion of AX65_22 as presently determined is reported in SEQ ID NO:1. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:2. The predicted amino acid sequence of the AX65_22 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:2. Amino acids 8 to 20 of SEQ ID NO:2 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 21. Due to the hydrophobic nature of the predicted
10 leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the AX65_22 protein. Additional nucleotide sequence from the 3' portion of AX65_22, including a poly(A) tail, is reported in SEQ ID NO:3.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone
15 AX65_22 should be approximately 3500 bp.

The nucleotide sequence disclosed herein for AX65_22 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. AX65_22 demonstrated at least some similarity with sequences identified as T08476 (Eukaryotic expression vector pAPEX-3p) and U46493 (Cloning vector pFlp recombinase
20 gene, complete cds). The predicted AX65_22 protein demonstrated at least some homology with sequences identified as J01969 (DNA polymerase [Human adenovirus type 5]), R07640 (Deduced protein sequence of p170-2 comprising T4), and X57205 (fibroblast growth factor receptor [Homo sapiens]). Based upon sequence similarity, AX65_22 proteins and each similar protein or peptide may share at least
25 some activity.

Clone "BD335_14"

A polynucleotide of the present invention has been identified as clone "BD335_14". BD335_14 was isolated from a human fetal kidney cDNA library using methods which are
30 selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BD335_14 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BD335_14 protein").

The nucleotide sequence of BD335_14 as presently determined is reported in SEQ ID
35 NO:4, and includes a poly(A) tail. What applicants presently believe to be the proper reading

frame and the predicted amino acid sequence of the BD335_14 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:5.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BD335_14 should be approximately 3000 bp.

5 The nucleotide sequence disclosed herein for BD335_14 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. The predicted BD335_14 protein demonstrated at least some similarity with sequences identified as U83511 (APXL [Homo sapiens]). Based upon sequence similarity, BD335_14 proteins and each homologous protein or peptide may share at least some activity. The
10 TopPredII computer program predicts three potential transmembrane domains within the BD335_14 protein sequence, one centered around amino acid 80, another around amino acid 320, and a third around amino acid 700 of SEQ ID NO:5.

Clone "BG241_1"

15 A polynucleotide of the present invention has been identified as clone "BG241_1". BG241_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BG241_1 is a full-length clone, including the entire coding sequence of
20 a secreted protein (also referred to herein as "BG241_1 protein").

 The nucleotide sequence of the 5' portion of BG241_1 as presently determined is reported in SEQ ID NO:6. An additional internal nucleotide sequence from BG241_1 as presently determined is reported in SEQ ID NO:7. What applicants believe is the proper reading frame and the predicted amino acid sequence encoded by such internal sequence is reported in SEQ ID NO:8.
25 Additional nucleotide sequence from the 3' portion of BG241_1, including a poly(A) tail, is reported in SEQ ID NO:9.

 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BG241_1 should be approximately 800 bp.

 The nucleotide sequence disclosed herein for BG241_1 was searched against the GenBank
30 and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BG241_1 demonstrated at least some similarity with sequences identified as AI082187 (ox75f01.x1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE 1662169 3' similar to contains element MSR1 repetitive element; mRNA sequence), W38781 (zb27g08.r1 Soares parathyroid tumor NbHPA Homo sapiens), and Y12781 (Homo sapiens
35 mRNA for transducin (beta) like 1 protein). The predicted BG241_1 protein demonstrated at

least some similarity to sequences identified as Y12781 (transducin (beta) like 1 protein [Homo sapiens]) and other beta-transducin-like proteins (see GenBank accession numbers L28125 and T86738). Based upon sequence similarity, BG241_1 proteins and each similar protein or peptide may share at least some activity.

5

Clone "BL187_4"

A polynucleotide of the present invention has been identified as clone "BL187_4". BL187_4 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding
10 a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BL187_4 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BL187_4 protein").

The nucleotide sequence of BL187_4 as presently determined is reported in SEQ ID NO:10, and includes a poly(A) tail. What applicants presently believe to be the proper reading
15 frame and the predicted amino acid sequence of the BL187_4 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:11. Amino acids 17 to 29 of SEQ ID NO:11 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 30. Due to the hydrophobic nature of the predicted leader/signal
20 sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the BL187_4 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BL187_4 should be approximately 2300 bp.

The nucleotide sequence disclosed herein for BL187_4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search
25 protocols. BL187_4 demonstrated at least some similarity with sequences identified as AA476210 (zw35g01.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone 771312 3', mRNA sequence), AA868505 (ak43b04.s1 Soares testis NHT Homo sapiens cDNA clone IMAGE 1408687 3' similar to SW PLZF_HUMAN Q05516 ZINC FINGER PROTEIN PLZF; mRNA sequence), AA927876 (om18b09.s1 Soares NFL T GBC S1
30 Homo sapiens cDNA clone IMAGE:1541369 3', mRNA sequence), AD000671 (Homo sapiens DNA from chromosome 19-cosmid f24109 containing HRX2, genomic sequence), H48938 (EST0010 Homo sapiens cDNA clone HTN-6-15), and Z63958 (H.sapiens CpG DNA, clone 93d10, forward read cpg93d10.ft1a). The predicted amino acid sequence disclosed herein for BL187_4 was searched against the GenPept and GeneSeq amino acid

sequence databases using the BLASTX search protocol. The predicted BL187_4 protein demonstrated at least some similarity to sequences identified as R95242 (HIC-1 polypeptide), Z19002 (kruppel-like zinc finger protein [Homo sapiens]), and a number of other zinc-finger proteins. Based upon sequence similarity, BL187_4 proteins and each similar protein or peptide may share at least some activity. Motifs analysis indicates the presence of two zinc-finger (C2H2 type) domains centered around amino acids 375 and 430 of SEQ ID NO:11, respectively. The TopPredII computer program predicts two potential transmembrane domains within the BL187_4 protein sequence, one centered around amino acid 30 and another around amino acid 260 of SEQ ID NO:11. BL187_4 protein appears to be a novel secreted or membrane-associated zinc-finger protein.

Clone "BL249_18"

A polynucleotide of the present invention has been identified as clone "BL249_18". BL249_18 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BL249_18 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BL249_18 protein").

The nucleotide sequence of BL249_18 as presently determined is reported in SEQ ID NO:12, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BL249_18 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:13. Amino acids 32 to 44 of SEQ ID NO:13 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 45. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the BL249_18 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BL249_18 should be approximately 2300 bp.

The nucleotide sequence disclosed herein for BL249_18 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BL249_18 demonstrated at least some similarity with sequences identified as AA034864 (mi53f01.r1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone 467257 5'), AA115100 (zl02h12.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 491207 3'), AA219365 (zr04c06.r1 Stratagene NT2 neuronal precursor 937230 Homo sapiens cDNA clone 650506 5'), AA399095 (zt59b06.r1 Soares

testis NHT Homo sapiens cDNA clone 726611 5'), R82633 (yj20a05.s1 Homo sapiens cDNA clone 149264 3'), and T22047 (Human gene signature HUMGS03590). The predicted amino acid sequence disclosed herein for BL249_18 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted
5 BL249_18 protein demonstrated at least some similarity to sequences identified as AC003673 (unknown protein (AAC09020.1) [Arabidopsis thaliana]) and Z98598 (hypothetical protein [Schizosaccharomyces pombe]). Based upon sequence similarity, BL249_18 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the BL249_18 protein sequence, one
10 centered around amino acid 45 and another around amino acid 680 of SEQ ID NO:13.

Clone "BO71_1"

A polynucleotide of the present invention has been identified as clone "BO71_1". BO71_1 was isolated from a human adult retina cDNA library using methods which are selective
15 for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BO71_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BO71_1 protein").

The nucleotide sequence of the 5' portion of BO71_1 as presently determined is reported
20 in SEQ ID NO:14. An additional internal nucleotide sequence from BO71_1 as presently determined is reported in SEQ ID NO:15. What applicants believe is the proper reading frame and the predicted amino acid sequence encoded by such internal sequence is reported in SEQ ID NO:16. Additional nucleotide sequence from the 3' portion of BO71_1, including a poly(A) tail, is reported in SEQ ID NO:17.

25 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BO71_1 should be approximately 2000 bp.

The nucleotide sequence disclosed herein for BO71_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BO71_1 demonstrated at least some similarity with sequences identified as X86809
30 (H.sapiens mRNA for major astrocytic phosphoprotein PEA-15). The predicted amino acid sequence disclosed herein for BO71_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BO71_1 protein demonstrated at least some similarity to sequences identified as U06144 (cellular disintegrin-related protein [Mus musculus]). Based upon sequence similarity, BO71_1
35 proteins and each similar protein or peptide may share at least some activity.

Clone "BO365_2"

A polynucleotide of the present invention has been identified as clone "BO365_2". BO365_2 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding
5 a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BO365_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BO365_2 protein").

The nucleotide sequence of BO365_2 as presently determined is reported in SEQ ID NO:18, and includes a poly(A) tail. What applicants presently believe to be the proper reading
10 frame and the predicted amino acid sequence of the BO365_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:19.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BO365_2 should be approximately 2800 bp.

The nucleotide sequence disclosed herein for BO365_2 was searched against the GenBank
15 and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BO365_2 demonstrated at least some similarity with sequences identified as D63876 (Human mRNA for KIAA0154 gene, partial cds) and Z83844 (Human DNA sequence *** SEQUENCING IN PROGRESS *** from clone 37E16; HTGS phase 1). The predicted amino acid sequence disclosed herein for BO365_2 was searched against the GenPept and
20 GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BO365_2 protein demonstrated at least some similarity to sequences identified as D10250 (alpha-fetoprotein enhancer binding protein [Homo sapiens]), D63876 (KIAA0154 gene product is related to mouse gamma adaptin [Homo sapiens]), and R23962 (AFP-1). Based upon sequence similarity, BO365_2 proteins and each similar protein or peptide may share at least
25 some activity. The TopPredII computer program predicts three potential transmembrane domains within the BO365_2 protein sequence, centered around amino acids 70, 140, and 180 of SEQ ID NO:19, respectively.

Clone "BV51_1"

30 A polynucleotide of the present invention has been identified as clone "BV51_1". BV51_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BV51_1 is a full-length clone, including the entire coding sequence of a
35 secreted protein (also referred to herein as "BV51_1 protein").

The nucleotide sequence of the 5' portion of BV51_1 as presently determined is reported in SEQ ID NO:20. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:21. The predicted amino acid sequence of the BV51_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:21. Additional
5 nucleotide sequence from the 3' portion of BV51_1, including a poly(A) tail, is reported in SEQ ID NO:22.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BV51_1 should be approximately 970 bp.

The nucleotide sequence disclosed herein for BV51_1 was searched against the GenBank
10 and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BV51_1 demonstrated at least some similarity with sequences identified as AB012130 (Homo sapiens SBC2 mRNA for sodium bicarbonate cotransporter2, complete cds) and U46493 (Cloning vector pFlp recombinase gene, complete cds). The predicted amino acid sequence disclosed herein for BV51_1 was searched against the GenPept and GeneSeq amino acid
15 sequence databases using the BLASTX search protocol. The predicted BV51_1 protein demonstrated at least some similarity to sequences identified as AB01213 (sodium bicarbonate cotransporter2 [Homo sapiens]). Based upon sequence similarity, BV51_1 proteins and each similar protein or peptide may share at least some activity.

20 Clone "BV140_3"

A polynucleotide of the present invention has been identified as clone "BV140_3". BV140_3 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence
25 of the encoded protein. BV140_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BV140_3 protein").

The nucleotide sequence of the 5' portion of BV140_3 as presently determined is reported in SEQ ID NO:23. An additional internal nucleotide sequence from BV140_3 as presently determined is reported in SEQ ID NO:24. What applicants believe is the proper reading frame
30 and the predicted amino acid sequence encoded by such internal sequence is reported in SEQ ID NO:25. Additional nucleotide sequence from the 3' portion of BV140_3, including a poly(A) tail, is reported in SEQ ID NO:26.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BV140_3 should be approximately 3500 bp.

The nucleotide sequence disclosed herein for BV140_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BV140_3 demonstrated at least some similarity with sequences identified as H72799 (yu07d10.r1 Homo sapiens cDNA clone 233107 5') and T94057 (ye33g08.r1 Homo sapiens cDNA clone 119582 5'). Based upon sequence similarity, BV140_3 proteins and each similar protein or peptide may share at least some activity.

Clone "BV141_2"

A polynucleotide of the present invention has been identified as clone "BV141_2". BV141_2 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BV141_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BV141_2 protein").

The nucleotide sequence of BV141_2 as presently determined is reported in SEQ ID NO:27, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BV141_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:28.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BV141_2 should be approximately 1100 bp.

The nucleotide sequence disclosed herein for BV141_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BV141_2 demonstrated at least some similarity with sequences identified as L26860 (Mus musculus (C6e) heavy chain immunoglobulin variable region gene). Based upon sequence similarity, BV141_2 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the BV141_2 protein sequence, one centered around amino acid 34 and another around amino acid 65 of SEQ ID NO:28. The nucleotide sequence of BV141_2 indicates that it may contain one or more of the following repetitive element(s): L1 repeat.

Clone "CC194_4"

A polynucleotide of the present invention has been identified as clone "CC194_4". CC194_4 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence

of the encoded protein. CC194_4 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CC194_4 protein").

The nucleotide sequence of the 5' portion of CC194_4 as presently determined is reported in SEQ ID NO:29. What applicants presently believe is the proper reading frame for the coding
5 region is indicated in SEQ ID NO:30. The predicted amino acid sequence of the CC194_4 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:30. Amino acids 88 to 100 of SEQ ID NO:30 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 101. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted
10 leader/signal sequence not be separated from the remainder of the CC194_4 protein. Additional nucleotide sequence from the 3' portion of CC194_4, including a poly(A) tail, is reported in SEQ ID NO:31.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CC194_4 should be approximately 3300 bp.

15 The nucleotide sequence disclosed herein for CC194_4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CC194_4 demonstrated at least some similarity with sequences identified as AA722214 (zh20f10.s1 Soares pineal gland N3HPG Homo sapiens cDNA clone 412651 3', mRNA sequence), H11476 (ym10h08.s1 Homo sapiens cDNA clone 47781 3'), H11581
20 (ym10h08.r1 Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE:47781 5' similar to SP:C36E8.3 CE00911; mRNA sequence), H23044 (ym51d07.r1 Homo sapiens cDNA clone 52058 5' similar to SP:C36E8.3 CE00911), N93789 (zb64g05.s1 Soares fetal lung NbHL19W Homo sapiens cDNA clone 308408 3'), and W54544 (mc99a01.r1 Soares mouse embryo NbME13.5 14.5 Mus musculus). The predicted amino acid sequence disclosed
25 herein for CC194_4 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CC194_4 protein demonstrated at least some similarity to sequences identified as M38561 (CAD [Homo sapiens]). Based upon sequence similarity, CC194_4 proteins and each similar protein or peptide may share at least some activity.

30

Clone "DA136_11"

A polynucleotide of the present invention has been identified as clone "DA136_11".
35 DA136_11 was isolated from a human adult placenta cDNA library using methods which are

selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. DA136_11 includes at least a portion of the coding sequence of a secreted protein (also referred to herein as "DA136_11 protein").

5 The nucleotide sequence of DA136_11 as presently determined is reported in SEQ ID NO:32, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the DA136_11 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:33.

10 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone DA136_11 should be approximately 3800 bp.

15 The nucleotide sequence disclosed herein for DA136_11 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. DA136_11 demonstrated at least some similarity with sequences identified as AA523414 (ng30a07.s1 NCI_CGAP_Co3 Homo sapiens cDNA clone 936276), H89334 (yw25h09.r1 Homo sapiens cDNA clone 253313 5'), R59925 (yh11b12.s1 Homo sapiens cDNA clone 42891 3), T66165 (Human interleukin-12 receptor alpha chain NR4 DNA), Y09328 (H.sapiens mRNA for IL13 receptor alpha-1 chain), and Y10659 (H.sapiens IL-13Ra mRNA). The predicted amino acid sequence disclosed herein for DA136_11 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX
20 search protocol. The predicted DA136_11 protein demonstrated at least some similarity to sequences identified as L08960 (cell adhesion molecule [Gallus gallus]), M34083 (lactogen receptor precursor [Rattus norvegicus]), M59941 (GM-CSF receptor beta chain [Homo sapiens]), W09822 (Human interleukin-12 receptor alpha chain NR4), X61178 (interleukin-5 receptor type 3 [Homo sapiens]), and Y10659 (IL-13Ra [Homo sapiens]).
25 Based upon sequence similarity, DA136_11 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the DA136_11 protein sequence, centered around amino acid 215 of SEQ ID NO:33.

30 Clone "AR415_4"

A polynucleotide of the present invention has been identified as clone "AR415_4". AR415_4 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence

of the encoded protein. AR415_4 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "AR415_4 protein").

The nucleotide sequence of AR415_4 as presently determined is reported in SEQ ID NO:34, and includes a poly(A) tail. What applicants presently believe to be the proper reading
5 frame and the predicted amino acid sequence of the AR415_4 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:35. Amino acids 14 to 26 of SEQ ID NO:35 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 27. Due to the hydrophobic nature of the predicted leader/signal
10 sequence not be separated from the remainder of the AR415_4 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone AR415_4 should be approximately 1500 bp.

The nucleotide sequence disclosed herein for AR415_4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search
15 protocols. AR415_4 demonstrated at least some similarity with sequences identified as AA100799 (zm26d01.s1 Stratagene pancreas (#937208) Homo sapiens cDNA clone 526753 3'), AA100852 (zm26d01.r1 Stratagene pancreas (#937208) Homo sapiens cDNA clone 526753 5' similar to SW CO02_HUMAN P19075 TUMOR-ASSOCIATED ANTIGEN CO-029), AA146605 (zo35c09.r1 Stratagene colon (#937204) Homo sapiens cDNA clone 588880 5' similar to
20 SW:CO02_HUMAN P19075 TUMOR-ASSOCIATED ANTIGEN CO-029), AA224847 (nc33c12.s1 NCI CGAP Pr2 Homo sapiens cDNA clone 4079 similar to SW:CO02_HUMAN P19075 TUMOR-ASSOCIATED ANTIGEN CO-029), AA225191 (nc21h08.s1 NCI CGAP Pr1 Homo sapiens cDNA clone 2968), AA593864 (nn19f08.s1 NCI CGAP Co12 Homo sapiens cDNA clone IMAGE:1084359), D26483 (Mouse mRNA for PE31/TALLA), M33680 (Human
25 26-kDa cell surface protein TAPA-1 mRNA, complete cds), T14726 (Human CD53 antigen cDNA), and T23814 (Human gene signature HUMGS05723). The predicted amino acid sequence disclosed herein for AR415_4 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted AR415_4 protein demonstrated at least some sequence similarity with sequences identified as D29808 (TALLA-1
30 [Homo sapiens]), M35252 (tumor-associated antigen [Homo sapiens]), and R22360 (CO-029 tumour associated antigen protein). Based upon sequence similarity, AR415_4 proteins and each homologous protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the AR415_4 protein sequence centered around amino acid 100 of SEQ ID NO:35.

Clone "AS63_29"

A polynucleotide of the present invention has been identified as clone "AS63_29". AS63_29 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding
5 a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. AS63_29 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "AS63_29 protein").

The nucleotide sequence of the 5' portion of AS63_29 as presently determined is reported in SEQ ID NO:36. What applicants presently believe is the proper reading frame for the coding
10 region is indicated in SEQ ID NO:37. The predicted amino acid sequence of the AS63_29 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:37. Amino acids 28 to 40 of SEQ ID NO:37 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 41. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted
15 leader/signal sequence not be separated from the remainder of the AS63_29 protein. Additional nucleotide sequence from the 3' portion of AS63_29, including a poly(A) tail, is reported in SEQ ID NO:38.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone AS63_29 should be approximately 1700 bp.

20 The nucleotide sequence disclosed herein for AS63_29 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. AS63_29 demonstrated at least some similarity with sequences identified as L26877 (Mus musculus (B20c) heavy chain immunoglobulin variable region gene), T09146 (EST07039 Homo sapiens cDNA clone HIBBP68 5' end), T23466 (seq3050 Homo sapiens cDNA clone
25 Hy18-Ch13-Charon40-cDNA-100 3'), and W55739 (ma35f05.r1 Life Tech mouse brain Mus musculus cDNA clone 312705 5'). The predicted amino acid sequence disclosed herein for AS63_29 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted AS63_29 protein demonstrated at least some sequence similarity with sequences identified as R04032 (Full length T4 encoded by plasmid
30 pBG381). Based upon sequence similarity, AS63_29 proteins and each homologous protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the AS63_29 protein sequence, near the amino terminus.

Clone "AY304_14"

A polynucleotide of the present invention has been identified as clone "AY304_14". AY304_14 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. AY304_14 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "AY304_14 protein").

The nucleotide sequence of AY304_14 as presently determined is reported in SEQ ID NO:39, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the AY304_14 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:40.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone AY304_14 should be approximately 2200 bp.

The nucleotide sequence disclosed herein for AY304_14 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. AY304_14 demonstrated at least some similarity with sequences identified as AA127688 (zk92f05.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 490305 3'), AA179609 (zp49g11.r1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone 612836 5'), AA276253 (vc40f05.r1 Barstead MPLRB1 Mus musculus cDNA clone 777057 5'), H15545 (ym27d04.s1 Homo sapiens cDNA clone 49495 3' similar to contains PTR5 repetitive element), L08441 (Human autonomously replicating sequence (ARS) mRNA), N34949 (yy49h09.s1 Homo sapiens cDNA clone 276929 3'), R48594 (yj65d07.s1 Homo sapiens cDNA clone 153613 3'), T21160 (Human gene signature HUMGS02466), U43284 (Cloning vector phGFP-S65T, complete sequence, green fluorescent protein (gfp) gene, complete cds), and Z45151 (H. sapiens partial cDNA sequence; clone c-2hh04). The predicted amino acid sequence disclosed herein for AY304_14 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted AY304_14 protein demonstrated at least some sequence similarity with sequences identified as D86984 (similar to yeast adenylate cyclase (S56776) [Homo sapiens]), J01415 (cytochrome oxidase subunit 3 [Homo sapiens]), V00662 (cytochrome oxidase III [Homo sapiens]), and X68948 (envelope glycoprotein [Spleen focus-forming virus]). Based upon sequence similarity, AY304_14 proteins and each homologous protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the AY304_14 protein sequence, one centered around amino acid 81 and another around amino acid 120 of SEQ ID NO:40.

A polynucleotide of the present invention has been identified as clone "BG160_1". BG160_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BG160_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BG160_1 protein").

The nucleotide sequence of BG160_1 as presently determined is reported in SEQ ID NO:41, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BG160_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:42. Amino acids 588 to 600 of SEQ ID NO:42 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 601. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the BG160_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BG160_1 should be approximately 2300 bp.

The nucleotide sequence disclosed herein for BG160_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BG160_1 demonstrated at least some similarity with sequences identified as A60021 (tropomyosin-related protein, neuronal - rat ;contains element MER27 repetitive element), AA081525 (zn20e02.r1 Stratagene neuroepithelium NT2RAMI 937234 Homo sapiens cDNA clone 547994 5'), AA092565 (ll5773.seq.F Fetal heart, Lambda ZAP Express Homo sapiens cDNA 5'), D56138 (Human fetal brain cDNA 5'-end GEN-416H11), D61090 (Human fetal brain cDNA 5'-end GEN-155A07), D61184 (Human fetal brain cDNA 5'-end GEN-165A01), L10335 (Homo sapiens neuro-endocrine-specific protein C (NSP) mRNA, complete cds), N21304 (yx53f07.s1 Homo sapiens cDNA clone 265477 3' similar to SP:A60021 A60021 TROPOMYOSIN-RELATED PROTEIN, NEURONAL), and W95814 (ze07f11.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 358317 5' similar to PIR:A60021). The predicted amino acid sequence disclosed herein for BG160_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BG160_1 protein demonstrated at least some sequence similarity with sequences identified as L10334 (neuroendocrine-specific protein B [Homo sapiens]), L10335 (neuroendocrine-specific protein C [Homo sapiens]). Based upon sequence similarity, BG160_1 proteins and each homologous protein or peptide may share at least some activity. The TopPredII computer

program predicts three potential transmembrane domains within the BG160_1 protein sequence, centered around amino acids 84, 484, and 595 of SEQ ID NO:42, respectively.

BG160_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 110 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

Clone "BO432_4"

A polynucleotide of the present invention has been identified as clone "BO432_4". BO432_4 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BO432_4 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BO432_4 protein").

The nucleotide sequence of the 5' portion of BO432_4 as presently determined is reported in SEQ ID NO:43. An additional internal nucleotide sequence from BO432_4 as presently determined is reported in SEQ ID NO:44. What applicants believe is the proper reading frame and the predicted amino acid sequence encoded by such internal sequence is reported in SEQ ID NO:45. Additional nucleotide sequence from the 3' portion of BO432_4, including a poly(A) tail, is reported in SEQ ID NO:46.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BO432_4 should be approximately 1700 bp.

The nucleotide sequence disclosed herein for BO432_4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BO432_4 demonstrated at least some similarity with sequences identified as AA283626 (zt15e09.s1 Soares NbHTGBC Homo sapiens cDNA clone 713224 3'), AA406486 (zv12g02.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 753458 5' similar to WP F35G2.2 CE05809 E.COLI YCAC LIKE), AA570446 (nk62c12.s1 NCI_CGAP_Sch1 Homo sapiens cDNA clone IMAGE:1018102), N55855 (J3389F Homo sapiens cDNA clone J3389 5'), Q10613 (Rianodin receptor gene), T62691 (yc70d10.r1 Homo sapiens cDNA clone 86035 5'), and W90766 (zh79h04.s1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 418327 3'). The predicted amino acid sequence disclosed herein for BO432_4 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BO432_4 protein demonstrated at least some sequence similarity with sequences identified as Z69637 (F35G2.2 [Caenorhabditis elegans]). Based upon sequence similarity, BO432_4 proteins and each homologous protein or peptide may share at least some activity. The TopPredII

computer program predicts a potential transmembrane domain at the amino terminus of the BO432_4 protein sequence. The BO432_4 protein may also contain the bacterial lysR family signature, a motif found in bacterial transcriptional regulators and which is possibly indicative of a helix-turn-helix structure.

5

Clone "BO538_2"

A polynucleotide of the present invention has been identified as clone "BO538_2". BO538_2 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding
10 a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BO538_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BO538_2 protein").

The nucleotide sequence of the 5' portion of BO538_2 as presently determined is reported in SEQ ID NO:47. What applicants presently believe is the proper reading frame for the coding
15 region is indicated in SEQ ID NO:48. The predicted amino acid sequence of the BO538_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:48. Additional nucleotide sequence from the 3' portion of BO538_2, including a poly(A) tail, is reported in SEQ ID NO:49.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone
20 BO538_2 should be approximately 3000 bp.

The nucleotide sequence disclosed herein for BO538_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BO538_2 demonstrated at least some similarity with sequences identified as AA503100 (ne44h01.s1 NCI_CGAP_Co3 Homo sapiens cDNA clone 900241), R44035
25 (yg21g09.s1 Homo sapiens cDNA clone 33167 3'), T21630 (Human gene signature HUMGS03066), and W64854 (me06d12.r1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone 386711 5' similar to PIR S40989 S40989 hypothetical protein F55H2.6 - Caenorhabditis elegans). The predicted amino acid sequence disclosed herein for BO538_2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX
30 search protocol. The predicted BO538_2 protein demonstrated at least some sequence similarity with sequences identified as M60525 (nerve growth factor inducible protein [Rattus norvegicus]), R28916 (Type III procollagen), and Z27080 (F55H2.6 [Caenorhabditis elegans]). Based upon sequence similarity, BO538_2 proteins and each homologous protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains
35 within the BO538_2 protein sequence.

Clone "BR595_4"

A polynucleotide of the present invention has been identified as clone "BR595_4". BR595_4 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding
5 a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BR595_4 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BR595_4 protein").

The nucleotide sequence of the 5' portion of BR595_4 as presently determined is reported in SEQ ID NO:50. What applicants presently believe is the proper reading frame for the coding
10 region is indicated in SEQ ID NO:51. The predicted amino acid sequence of the BR595_4 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:51. Additional nucleotide sequence from the 3' portion of BR595_4, including a poly(A) tail, is reported in SEQ ID NO:52.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone
15 BR595_4 should be approximately 3000 bp.

The nucleotide sequence disclosed herein for BR595_4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BR595_4 demonstrated at least some similarity with sequences identified as AA443742 (zw95b02.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 784683 3'),
20 AA600820 (np45b08.s1 NCI_CGAP_Br1.1 Homo sapiens cDNA clone IMAGE:1129239), T19410 (Human gene signature HUMGS00435), W87465 (zh67c04.s1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 417126 3'), and Z33587 (H. sapiens partial cDNA sequence; clone HEA89P; single read). Based upon sequence similarity, BR595_4 proteins and each homologous protein or peptide may share at least some activity.

25

Clone "CI490_2"

A polynucleotide of the present invention has been identified as clone "CI490_2". CI490_2 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding
30 a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CI490_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CI490_2 protein").

The nucleotide sequence of CI490_2 as presently determined is reported in SEQ ID NO:53, and includes a poly(A) tail. What applicants presently believe to be the proper reading
35 frame and the predicted amino acid sequence of the CI490_2 protein corresponding to the

foregoing nucleotide sequence is reported in SEQ ID NO:54. Amino acids 64 to 76 of SEQ ID NO:54 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 77. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CI490_2 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CI490_2 should be approximately 1200 bp.

The nucleotide sequence disclosed herein for CI490_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CI490_2 demonstrated at least some similarity with sequences identified as H30751 (yo79a04.r1 Homo sapiens cDNA clone 184110 5'), H49766 (yo24f01.r1 Homo sapiens cDNA clone 178873 5' similar to SP:S19586 N-METHYL-D-ASPARTATE RECEPTOR GLUTAMATE-BINDING CHAIN), H51158 (yo32d04.r1 Homo sapiens cDNA clone 179623 5'), R85211 (yo41d11.s1 Homo sapiens cDNA clone 180501 3' similar to SP S19586 N-METHYL-D-ASPARTATE RECEPTOR GLUTAMATE-BINDING CHAIN), S19586 (N-METHYL-D-ASPARTATE RECEPTOR GLUTAMATE-BINDING CHAIN), S61973 (NMDA receptor glutamate-binding subunit [rat, mRNA]), T01031 (Human leucine zipper protein-kinase cDNA sequence), and W56893 (zc01g05.r1 Soares parathyroid tumor NbHPA Homo sapiens cDNA clone 321080 5' similar to PIR S19586 S19586 N-methyl-D-aspartate receptor glutamate-binding chain - rat). The predicted amino acid sequence disclosed herein for CI490_2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CI490_2 protein demonstrated at least some sequence similarity with sequences identified as S61973 (NMDA receptor glutamate-binding subunit [Rattus sp.]) and U08020 (collagen pro-alpha-1 type I chain [Mus musculus]). Based upon sequence similarity, CI490_2 proteins and each homologous protein or peptide may share at least some activity. The TopPredII computer program predicts six potential transmembrane domains within the CI490_2 protein sequence, with the most amino-terminal transmembrane domain centered around amino acid 77 of SEQ ID NO:54.

30 Clone "CI522_1"

A polynucleotide of the present invention has been identified as clone "CI522_1". CI522_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence

of the encoded protein. CI522_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CI522_1 protein").

The nucleotide sequence of the 5' portion of CI522_1 as presently determined is reported in SEQ ID NO:55. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:56. The predicted amino acid sequence of the CI522_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:56. Amino acids 7 to 19 of SEQ ID NO:56 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 20. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CI522_1 protein. Additional nucleotide sequence from the 3' portion of CI522_1, including a poly(A) tail, is reported in SEQ ID NO:57.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CI522_1 should be approximately 1400 bp.

The nucleotide sequence disclosed herein for CI522_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CI522_1 demonstrated at least some similarity with sequences identified as AA028557 (m18g05.r1 Soares mouse p3NMF19.5 Mus musculus cDNA clone 463928 5'), H32238 (EST107136 Rattus sp. cDNA 5' end), T33525 (EST58140 Homo sapiens cDNA 5' end similar to None), U66468 (Human cell growth regulator CGR11 mRNA, complete cds), and X00525 (Mouse 28S ribosomal RNA). The predicted amino acid sequence disclosed herein for CI522_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CI522_1 protein demonstrated at least some sequence similarity with sequences identified as U66468 (cell growth regulator CGR11 [Homo sapiens]). Based upon sequence similarity, CI522_1 proteins and each homologous protein or peptide may share at least some activity.

Clone "CN238_1"

A polynucleotide of the present invention has been identified as clone "CN238_1". CN238_1 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CN238_1 includes at least a portion of the coding sequence of a secreted protein (also referred to herein as "CN238_1 protein").

The nucleotide sequence of CN238_1 as presently determined is reported in SEQ ID NO:58, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CN238_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:59.

5 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CN238_1 should be approximately 2190 bp.

 The nucleotide sequence disclosed herein for CN238_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CN238_1 demonstrated at least some similarity with sequences identified as
10 AA044097 (zk51b02.r1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 486315 5'),
AA044287 (zk51b02.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 486315 3'),
AA045440 (zk67c03.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 487876 3'),
AA143007 (zl48f01.r1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 505177 5'),
D51196 (Human fetal brain cDNA 3'-end GEN-016G05), D60310 (Human fetal brain cDNA
15 3'-end GEN-098A09), N69344 (yz43e04.s1 Homo sapiens cDNA clone 285822 3' similar to
gb:K00558 TUBULIN ALPHA-1 CHAIN (HUMAN)), W22250 (64B8 Human retina cDNA
Tsp509I-cleaved sublibrary Homo), and X01703 (Human gene for alpha-tubulin (b alpha 1)). The
predicted amino acid sequence disclosed herein for CN238_1 was searched against the GenPept
and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted
20 CN238_1 protein demonstrated at least some sequence similarity with sequences identified as
K00557 (alpha-tubulin [Homo sapiens]) and U51583 (zinc finger homeodomain enhancer-binding
protein-1 [Rattus norvegicus]). Based upon sequence similarity, CN238_1 proteins and each
homologous protein or peptide may share at least some activity.

25 Clone "CO390_1"

 A polynucleotide of the present invention has been identified as clone "CO390_1".
CO390_1 was isolated from a human adult brain cDNA library using methods which are selective
for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding
a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence
30 of the encoded protein. CO390_1 is a full-length clone, including the entire coding sequence of
a secreted protein (also referred to herein as "CO390_1 protein").

 The nucleotide sequence of CO390_1 as presently determined is reported in SEQ ID
NO:60, and includes a poly(A) tail. What applicants presently believe to be the proper reading
frame and the predicted amino acid sequence of the CO390_1 protein corresponding to the
35 foregoing nucleotide sequence is reported in SEQ ID NO:61.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CO390_1 should be approximately 2300 bp.

The nucleotide sequence disclosed herein for CO390_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CO390_1 demonstrated at least some similarity with sequences identified as H84353 (yv85a11.r1 Homo sapiens cDNA clone 249500 5'), L35532 (Pan troglodytes Alu repeat region), N80616 (Genomic clone encoding SAP(Phe)), R53922 (yi03h10.s1 Homo sapiens cDNA clone 138211 3' similar to contains Alu repetitive element; contains TAR1 repetitive element), X75335 (H.sapiens Alu insertion in COL3A1 gene), X95882 (R.norvegicus mRNA for ATP ligand gated ion channel), and Y09561 (H.sapiens mRNA for P2X7 receptor). The predicted amino acid sequence disclosed herein for CO390_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CO390_1 protein demonstrated at least some sequence similarity with sequences identified as U45448 (P2x1 receptor [Homo sapiens]), W04216 (Rat superior cervical ganglion p2x receptor), X83688 (ATP receptor [Homo sapiens]), X95882 (P2X7 gene product [Rattus norvegicus]), and Y09561 (ATP receptor [Homo sapiens]). Based upon sequence similarity, CO390_1 proteins and each homologous protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the CO390_1 protein sequence, centered around amino acid 249 of SEQ ID NO:61. The nucleotide sequence of CO390_1 may contain an Alu repetitive element.

CO390_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 75 kDa was detected in conditioned medium using SDS polyacrylamide gel electrophoresis.

25

Clone "AJ20_2"

A polynucleotide of the present invention has been identified as clone "AJ20_2". AJ20_2 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. AJ20_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "AJ20_2 protein").

The nucleotide sequence of the 5' portion of AJ20_2 as presently determined is reported in SEQ ID NO:62. What applicants presently believe is the proper reading frame for the coding

35

region is indicated in SEQ ID NO:63. The predicted amino acid sequence of the AJ20_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:63. Amino acids 8 to 20 of SEQ ID NO:63 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 21. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the AJ20_2 protein. Additional nucleotide sequence from the 3' portion of AJ20_2, including a poly(A) tail, is reported in SEQ ID NO:64.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone AJ20_2 should be approximately 850 bp.

The nucleotide sequence disclosed herein for AJ20_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database.

Clone "AR440_1"

A polynucleotide of the present invention has been identified as clone "AR440_1". AR440_1 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637); or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. AR440_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "AR440_1 protein").

The partial nucleotide sequence of AR440_1, including its 3' end and a poly(A) tail, as presently determined is reported in SEQ ID NO:66. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:67. The predicted amino acid sequence of the AR440_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:67. Additional nucleotide sequence from the 5' portion of AR440_1 is reported in SEQ ID NO:65.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone AR440_1 should be approximately 1400 bp.

The nucleotide sequence disclosed herein for AR440_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database. The nucleotide sequence of AR440_1 indicates that it may contain an Alu repetitive element.

Clone "AS164_1"

A polynucleotide of the present invention has been identified as clone "AS164_1". AS164_1 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. AS164_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "AS164_1 protein").

The nucleotide sequence of AS164_1 as presently determined is reported in SEQ ID NO:68, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the AS164_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:69.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone AS164_1 should be approximately 1600 bp.

The nucleotide sequence disclosed herein for AS164_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. AS164_1 demonstrated at least some similarity with sequences identified as H24668 (yl40h10.r1 Homo sapiens cDNA clone 160771 5'), N29757 (yw90h10.s1 Homo sapiens cDNA clone 259555 3'), T62184 (yb96d08.r1 Homo sapiens cDNA clone 79023 5'), Z69706 (Human DNA sequence from cosmid COS12 from a contig from the tip of the short arm of chromosome 16, spanning 2Mb of 16p13.3. Contains ESTs, Flanking sequences of 3' alpha globin H), and Z69890 (Human DNA sequence from cosmid RJ14 from a contig from the tip of the short arm of chromosome 16, spanning 2Mb of 16p13.3. Contains ESTs and CpG island). The predicted amino acid sequence disclosed herein for AS164_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted AS164_1 protein demonstrated at least some similarity to sequences identified as A20359_1 (ryanodine receptor gene product [Homo sapiens]) and U78866 (putative arginine-aspartate-rich RNA binding protein [Arabidopsis thaliana]). Based upon sequence similarity, AS164_1 proteins and each similar protein or peptide may share at least some activity. The predicted AS164_1 protein sequence also contains repeated Asp-Arg RNA-binding motifs.

30 Clone "AX8_1"

A polynucleotide of the present invention has been identified as clone "AX8_1". AX8_1 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence

of the encoded protein. AX8_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "AX8_1 protein").

The nucleotide sequence of AX8_1 as presently determined is reported in SEQ ID NO:70, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the AX8_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:71. Amino acids 106 to 118 of SEQ ID NO:71 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 119. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the AX8_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone AX8_1 should be approximately 2300 bp.

The nucleotide sequence disclosed herein for AX8_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database. The TopPredII computer program predicts three potential transmembrane domains within the AX8_1 protein sequence, centered around amino acids 111, 144, and 182 of SEQ ID NO:71, respectively.

AX8_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 35 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.

Clone "BD176_3"

A polynucleotide of the present invention has been identified as clone "BD176_3". BD176_3 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BD176_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BD176_3 protein").

The nucleotide sequence of the 5' portion of BD176_3 as presently determined is reported in SEQ ID NO:72. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:73. The predicted amino acid sequence of the BD176_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:73. Amino acids 2 to 14 of SEQ ID NO:73 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 15. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted

leader/signal sequence not be separated from the remainder of the BD176_3 protein. Additional nucleotide sequence from the 3' portion of BD176_3, including a poly(A) tail, is reported in SEQ ID NO:74.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone
5 BD176_3 should be approximately 1300 bp.

The nucleotide sequence disclosed herein for BD176_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BD176_3 demonstrated at least some similarity with sequences identified as AA029679 (ze94g10.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 366690 5'),
10 D45913 (Mouse NLRR-1 mRNA for leucine-rich-repeat protein, complete cds), R55610 (yg88h08.r1 Homo sapiens cDNA clone 40606 5'), and T07640 (EST05530 Homo sapiens cDNA clone HFBEM16). The predicted amino acid sequence disclosed herein for BD176_3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BD176_3 protein demonstrated at least some similarity to
15 sequences identified as D45913 (leucine-rich-repeat protein [Mus musculus]) and M59472 (asparagine-rich antigen Pfa55-6 [Plasmodium falciparum]). Based upon sequence similarity, BD176_3 proteins and each similar protein or peptide may share at least some activity.

Clone "BD339_1"

20 A polynucleotide of the present invention has been identified as clone "BD339_1". BD339_1 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BD339_1 is a full-length clone, including the entire coding
25 sequence of a secreted protein (also referred to herein as "BD339_1 protein").

The nucleotide sequence of BD339_1 as presently determined is reported in SEQ ID NO:75, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BD339_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:76.

30 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BD339_1 should be approximately 650 bp.

The nucleotide sequence disclosed herein for BD339_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BD339_1 demonstrated at least some similarity with sequences identified as H82422
35 (yu80d08.s1 Homo sapiens cDNA clone 240111 3), N62058 (EST53c05 Homo sapiens cDNA

clone), U21730 Human 5'-nucleotidase (CD73)), W01979 (za30h09.r1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 294113 5'), and W02015 (za32b11.r1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 294237 5'). Based upon sequence similarity, BD339_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII
5 computer program predicts three potential transmembrane domains within the BD339_1 protein sequence, centered around amino acids 14, 46, and 76 of SEQ ID NO:76, respectively.

Clone "BD427_1"

A polynucleotide of the present invention has been identified as clone "BD427_1".
10 BD427_1 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BD427_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BD427_1 protein").

15 The nucleotide sequence of BD427_1 as presently determined is reported in SEQ ID NO:77, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BD427_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:78.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone
20 BD427_1 should be approximately 1810 bp.

The nucleotide sequence disclosed herein for BD427_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BD427_1 demonstrated at least some similarity with sequences identified as BD427_1 demonstrated at least some similarity with sequences identified as AA027122 (zk04a03.r1 Soares
25 pregnant uterus NbHPU Homo sapiens cDNA clone 469516 5'), N24735 (yx56b02.s1 Homo sapiens cDNA clone 265707 3'), and W84644 (zd91a06.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 356818 5'). Based upon sequence similarity, BD427_1 proteins and each similar protein or peptide may share at least some activity.

Clone "BL229_22"

A polynucleotide of the present invention has been identified as clone "BL229_22". BL229_22 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino

acid sequence of the encoded protein. BL229_22 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BL229_22 protein").

The nucleotide sequence of the 5' portion of BL229_22 as presently determined is reported in SEQ ID NO:79. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:80. The predicted amino acid sequence of the BL229_22 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:80. Additional nucleotide sequence from the 3' portion of BL229_22, including a poly(A) tail, is reported in SEQ ID NO:81.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BL229_22 should be approximately 870 bp.

The nucleotide sequence disclosed herein for BL229_22 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database.

Clone "BV123_16"

A polynucleotide of the present invention has been identified as clone "BV123_16". BV123_16 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BV123_16 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BV123_16 protein").

The nucleotide sequence of BV123_16 as presently determined is reported in SEQ ID NO:82, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BV123_16 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:83.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BV123_16 should be approximately 1080 bp.

The nucleotide sequence disclosed herein for BV123_16 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BV123_16 demonstrated at least some similarity with sequences identified as H29610 (ym61e03.s1 Homo sapiens cDNA clone 52653 3'), H52374 (yq81b12.r1 Homo sapiens cDNA clone 202175 5'), H66213 (yu16h10.s1 Homo sapiens cDNA), L08092 (Homo sapiens dystrophin (DMD) gene, intron 7, transposon-like sequence), L35670 (Homo sapiens (subclone H8 10_g5 from P1 35 H5 C8) DNA sequence), M62716 (Human CSP-B gene flanking sequence), N46985 (yy83a05.s1 Homo sapiens cDNA clone 280112 3'), R94603 (yq38a04.s1 Homo sapiens

cDNA clone 198030 3'), U91321 (Human chromosome 16p13 BAC clone CIT987SK-363E6, complete sequence), and Z82200 (Human DNA sequence from clone J333E231). Based upon sequence similarity, BV123_16 proteins and each similar protein or peptide may share at least some activity.

5

Clone "CH377_1"

A polynucleotide of the present invention has been identified as clone "CH377_1". CH377_1 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CH377_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CH377_1 protein").

The nucleotide sequence of CH377_1 as presently determined is reported in SEQ ID NO:84, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CH377_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:85. Amino acids 5 to 17 of SEQ ID NO:85 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 18. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CH377_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CH377_1 should be approximately 570 bp.

The nucleotide sequence disclosed herein for CH377_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CH377_1 demonstrated at least some similarity with sequences identified as AA507382 (nh73b01.s1 NCI_CGAP_Br1.1 Homo sapiens cDNA clone IMAGE 964105) and N70479 (za74f12.s1 Homo sapiens cDNA clone 298319 3'). Based upon sequence similarity, CH377_1 proteins and each similar protein or peptide may share at least some activity.

30

Clone "BD441_1"

A polynucleotide of the present invention has been identified as clone "BD441_1". BD441_1 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino

35

acid sequence of the encoded protein. BD441_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BD441_1 protein").

The nucleotide sequence of the 5' portion of BD441_1 as presently determined is reported in SEQ ID NO:86. An additional internal nucleotide sequence from BD441_1 as presently
5 determined is reported in SEQ ID NO:87. What applicants believe is the proper reading frame and the predicted amino acid sequence encoded by such internal sequence is reported in SEQ ID NO:88. Additional nucleotide sequence from the 3' portion of BD441_1, including a poly(A) tail, is reported in SEQ ID NO:89.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone
10 BD441_1 should be approximately 2400 bp.

The predicted amino acid sequence disclosed herein for BD441_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BD441_1 protein demonstrated at least some similarity to sequences identified as X61615 (leukemia inhibitory factor receptor [Homo sapiens]). Based upon sequence similarity,
15 BD441_1 proteins and each similar protein or peptide may share at least some activity.

Clone "BD441_2"

A polynucleotide of the present invention has been identified as clone "BD441_2". BD441_2 was isolated from a human fetal kidney cDNA library using methods which are
20 selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BD441_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BD441_2 protein").

The nucleotide sequence of the 5' portion of BD441_2 as presently determined is reported
25 in SEQ ID NO:90. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:91. The predicted amino acid sequence of the BD441_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:91. Additional nucleotide sequence from the 3' portion of BD441_2, including a poly(A) tail, is reported in SEQ ID NO:92.

30 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BD441_2 should be approximately 1200 bp.

The predicted amino acid sequence disclosed herein for BD441_2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BD441_2 protein demonstrated at least some similarity to sequences identified as

X61615 (leukemia inhibitory factor receptor [Homo sapiens]). Based upon sequence similarity, BD441_2 proteins and each similar protein or peptide may share at least some activity.

Clone "BG102_3"

5 A polynucleotide of the present invention has been identified as clone "BG102_3". BG102_3 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BG102_3 is a full-length clone, including the entire coding sequence of
10 a secreted protein (also referred to herein as "BG102_3 protein").

The nucleotide sequence of BG102_3 as presently determined is reported in SEQ ID NO:93, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BG102_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:94. Amino acids 11 to 23 of SEQ ID
15 NO:94 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 24. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the BG102_3 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone
20 BG102_3 should be approximately 1100 bp.

The nucleotide sequence disclosed herein for BG102_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BG102_3 demonstrated at least some similarity with sequences identified as AC002078 (Human BAC clone RG111H14 from 7q22, complete sequence), L11910 (Human
25 retinoblastoma susceptibility gene exons 1-27, complete cds), U62317 (Chromosome 22q13 BAC Clone CIT987SK-384D8 complete sequence), Z54147 (Human DNA sequence from cosmid L129H7, Huntington's Disease Region, chromosome 4p16.3 contains CpG island), Z75747 (Human DNA sequence from cosmid U96H1, between markers DXS366 and DXS87 on chromosome X *), and Z80899 (Human DNA sequence from cosmid F1121 on chromosome 6).

30 The predicted amino acid sequence disclosed herein for BG102_3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BG102_3 protein demonstrated at least some similarity to sequences identified as M13100 (unknown protein [Rattus norvegicus]) and U15647 (reverse transcriptase [Mus musculus]). Based upon sequence similarity, BG102_3 proteins and each similar protein or

peptide may share at least some activity. The nucleotide sequence of BG102_3 indicates that it may contain an L1 repetitive element.

BG102_3 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 55 kDa was detected in conditioned medium using SDS polyacrylamide gel electrophoresis.

Clone "BK158_1"

A polynucleotide of the present invention has been identified as clone "BK158_1". BK158_1 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BK158_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BK158_1 protein").

The nucleotide sequence of BK158_1 as presently determined is reported in SEQ ID NO:95, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BK158_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:96.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BK158_1 should be approximately 1150 bp.

The nucleotide sequence disclosed herein for BK158_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BK158_1 demonstrated at least some similarity with sequences identified as N39195 (yv26e08.s1 Homo sapiens cDNA clone 243878 3') and N45263 (yv26e08.r1 Homo sapiens cDNA clone 243878 5'). Based upon sequence similarity, BK158_1 proteins and each similar protein or peptide may share at least some activity.

BK158_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 28 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.

Clone "BP163_1"

A polynucleotide of the present invention has been identified as clone "BP163_1". BP163_1 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence

of the encoded protein. BP163_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BP163_1 protein").

The nucleotide sequence of the 5' portion of BP163_1 as presently determined is reported in SEQ ID NO:97. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:98. The predicted amino acid sequence of the BP163_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:98. Additional nucleotide sequence from the 3' portion of BP163_1, including a poly(A) tail, is reported in SEQ ID NO:99.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BP163_1 should be approximately 1240 bp.

The nucleotide sequence disclosed herein for BP163_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BP163_1 demonstrated at least some similarity with sequences identified as AA187086 (zp58h06.r1 Stratagene endothelial cell 937223 Homo sapiens cDNA clone 624443 5' similar to TR G285943 G285943 ORF, COMPLETE CDS), AA301506 (EST14475 Testis tumor Homo sapiens cDNA 5' end similar to hypothetical protein (GB D14659)), D14659 (Human mRNA for KIAA0103 gene, complete cds), and W57328 (ma26d10.r1 Life Tech mouse brain Mus musculus cDNA clone). The predicted amino acid sequence disclosed herein for BP163_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BP163_1 protein demonstrated at least some similarity to sequences identified as D14659 (KIAA0103 [Homo sapiens]). Based upon sequence similarity, BP163_1 proteins and each similar protein or peptide may share at least some activity.

Clone "BZ16_3"

A polynucleotide of the present invention has been identified as clone "BZ16_3". BZ16_3 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BZ16_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BZ16_3 protein").

The partial nucleotide sequence of BZ16_3, including its 3' end and a poly(A) tail, as presently determined is reported in SEQ ID NO:101. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:102. The predicted amino acid sequence of the BZ16_3 protein corresponding to the foregoing nucleotide sequence is

reported in SEQ ID NO:102. Additional nucleotide sequence from the 5' portion of BZ16_3 is reported in SEQ ID NO:100.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BZ16_3 should be approximately 2120 bp.

5 The nucleotide sequence disclosed herein for BZ16_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BZ16_3 demonstrated at least some similarity with sequences identified as F06886 (*H. sapiens* partial cDNA sequence; clone c-1nf02), F06870 (*H. sapiens* partial cDNA sequence; clone c-1nc11), N53511 (yz26b08.s1 *Homo sapiens* cDNA clone 284151 3'), T65313 (yc79g12.s1
10 *Homo sapiens* cDNA clone 22132 3'), U00084 (*Haemophilus influenzae*), W44815 (zc21d01.s1 *Soares* senescent fibroblasts NbHSF *Homo sapiens* cDNA clone 322945 3'), and Z49128 (*Caenorhabditis elegans* cosmid M03C11). The predicted amino acid sequence disclosed herein for BZ16_3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BZ16_3 protein demonstrated at least some
15 similarity to sequences identified as D26185 (cell division protein [*Bacillus subtilis*]), L46096 (HEAHI1465_1 cell division protein [*Haemophilus influenzae*]), and Z49128 (CEM03C11_5 M03C11.5 [*Caenorhabditis elegans*]). The BZ16_3 protein demonstrated at least some similarity to ATP-dependent proteases such as ftsH. Based upon sequence similarity, BZ16_3 proteins and each similar protein or peptide may share at least some activity.

20

Clone "CC182_1"

A polynucleotide of the present invention has been identified as clone "CC182_1". CC182_1 was isolated from a human adult brain cDNA library using methods which are selective
25 for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CC182_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CC182_1 protein").

The nucleotide sequence of CC182_1 as presently determined is reported in SEQ ID
30 NO:103, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CC182_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:104. Amino acids 26 to 38 of SEQ ID NO:104 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 39. Due to the hydrophobic nature of the predicted leader/signal

sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CC182_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CC182_1 should be approximately 1600 bp.

5 The nucleotide sequence disclosed herein for CC182_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CC182_1 demonstrated at least some similarity with sequences identified as H61159 (yu37f08.s1 Homo sapiens cDNA clone 236007 3' similar to contains L1 repetitive element), L09709 (Human lysosomal-associated membrane glycoprotein-2 (LAMP2) gene, 5' end of CDS
10 and flanking region), W44797 (zb98e10.s1 Soares parathyroid tumor NbHPA Homo sapiens cDNA clone 320874 3' similar to contains Alu repetitive element), and X62167 (H.sapiens mRNA for P2 protein of peripheral myelin). Based upon sequence similarity, CC182_1 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of CC182_1 indicates that it may contain an L1 repetitive element and/or a MER42C repetitive element.

15

Clone "CG109_1"

A polynucleotide of the present invention has been identified as clone "CG109_1". CG109_1 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding
20 a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CG109_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CG109_1 protein").

The nucleotide sequence of CG109_1 as presently determined is reported in SEQ ID NO:105, and includes a poly(A) tail. What applicants presently believe to be the proper reading
25 frame and the predicted amino acid sequence of the CG109_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:106.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CG109_1 should be approximately 600 bp.

The nucleotide sequence disclosed herein for CG109_1 was searched against the GenBank
30 and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database.

Clone "CJ397_1"

A polynucleotide of the present invention has been identified as clone "CJ397_1".
35 CJ397_1 was isolated from a human fetal brain cDNA library using methods which are selective

for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CJ397_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CJ397_1 protein").

5 The nucleotide sequence of the 5' portion of CJ397_1 as presently determined is reported in SEQ ID NO:107. An additional internal nucleotide sequence from CJ397_1 as presently determined is reported in SEQ ID NO:108. What applicants believe is the proper reading frame and the predicted amino acid sequence encoded by such internal sequence is reported in SEQ ID NO:109. Additional nucleotide sequence from the 3' portion of CJ397_1, including a poly(A)
10 tail, is reported in SEQ ID NO:110.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CJ397_1 should be approximately 1900 bp.

The nucleotide sequence disclosed herein for CJ397_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search
15 protocols. CJ397_1 demonstrated at least some similarity with sequences identified as H18685 (yn52b08.s1 Homo sapiens cDNA clone 172023 3'), H46001 (yo13f06.s1 Homo sapiens cDNA clone 177827 3'), and T77612 (yc91f06.r1 Homo sapiens cDNA clone 23298 5'). Based upon sequence similarity, CJ397_1 proteins and each similar protein or peptide may share at least some activity.

20

Clone "AM795_4"

A polynucleotide of the present invention has been identified as clone "AM795_4". AM795_4 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified
25 as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. AM795_4 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "AM795_4 protein").

The nucleotide sequence of AM795_4 as presently determined is reported in SEQ ID NO:111, and includes a poly(A) tail. What applicants presently believe to be the proper reading
30 frame and the predicted amino acid sequence of the AM795_4 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:112. Amino acids 9 to 21 of SEQ ID NO:112 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 22. Amino acids 138 to 150 of SEQ ID NO:112 are a possible leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid
35 151. Due to the hydrophobic nature of the predicted and the possible leader/signal sequences,

each of such sequences may act as a transmembrane domain should that leader/signal sequence not be separated from the remainder of the AM795_4 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone AM795_4 should be approximately 1900 bp.

5 The nucleotide sequence disclosed herein for AM795_4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. AM795_4 demonstrated at least some similarity with sequences identified as AF002700 (Homo sapiens GDNF family receptor alpha 2 (GFRalpha2) mRNA, complete cds), H05619 (yl70a10.s1 Homo sapiens cDNA clone 43207 3'), U46493 (Cloning vector pFlp recombina-
10 se gene, complete cds), U59486 (Rattus norvegicus GDNF receptor alpha mRNA, complete cds), V00248 (Human Ret ligand retL2 cDNA), W73633 (zd55h01.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 344593 3', mRNA sequence), and W73681 (zd55h01.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 344593 5', mRNA sequence). The predicted amino acid sequence disclosed herein for AM795_4 was searched against the GenPept
15 and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted AM795_4 protein demonstrated at least some similarity to sequences identified as AF002700 (GDNF family receptor alpha 2 (GFRalpha2) [Homo sapiens]), U59486 (GDNF receptor alpha [Rattus norvegicus]), and W37460 (Human Ret ligand retL2 cDNA). A receptor complex comprised of TrnR1 (GDNFR alpha) and Ret was found to be capable of mediating both GDNF
20 and NTN signaling. The receptor called TrnR2, identified based on homology to TrnR1, is 48% identical to TrnR1 and is encoded by a gene located on the short arm of chromosome 8. TrnR2 is attached to the cell surface via a GPI-linkage, and can mediate both NTN and GDNF signaling through Ret *in vitro* (Baloh *et al.*, 1997, *Neuron* 18(5): 793-802, which is incorporated by reference herein). Based upon sequence similarity, AM795_4 proteins and each similar protein
25 or peptide may share at least some activity.

AM795_4 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 76 kDa was detected in conditioned media fractions using SDS polyacrylamide gel electrophoresis.

30 Clone "AT340_1"

A polynucleotide of the present invention has been identified as clone "AT340_1". AT340_1 was isolated from a human adult blood (lymphocytes and dendritic cells treated with mixed lymphocyte reaction) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or
35 transmembrane protein on the basis of computer analysis of the amino acid sequence of the

encoded protein. AT340_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "AT340_1 protein").

The partial nucleotide sequence of AT340_1, including its 3' end and a poly(A) tail, as presently determined is reported in SEQ ID NO:114. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:115. The predicted amino acid sequence of the AT340_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:115. Amino acids 12 to 24 of SEQ ID NO:115 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 25. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the AT340_1 protein. Additional nucleotide sequence from the 5' portion of AT340_1 is reported in SEQ ID NO:113.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone AT340_1 should be approximately 1100 bp.

The nucleotide sequence disclosed herein for AT340_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. AT340_1 demonstrated at least some similarity with sequences identified as AA039343 (zk39g04.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 485238 3'), R68951 (yi43g06.r1 Homo sapiens cDNA clone 142042 5' similar to SP:C35D10.1 CE01190), R77532 (yi76c01.r1 Homo sapiens cDNA), R92619 (yq04a04.r1 Homo sapiens cDNA clone 195918 5' similar to SP:C35D10.1 CE01190), and W60997 (zc99f09.s1 Pancreatic Islet Homo sapiens cDNA clone 339305 3'). The predicted amino acid sequence disclosed herein for AT340_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted AT340_1 protein demonstrated at least some similarity to sequences identified as U21324 (similar to S. cerevisiae hypothetical protein YKL166 [Caenorhabditis elegans]). Based upon sequence similarity, AT340_1 proteins and each similar protein or peptide may share at least some activity.

Clone "BG132_1"

A polynucleotide of the present invention has been identified as clone "BG132_1". BG132_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BG132_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BG132_1 protein").

The nucleotide sequence of the 5' portion of BG132_1 as presently determined is reported in SEQ ID NO:116. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:117. The predicted amino acid sequence of the BG132_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:117.

5 Amino acids 121 to 133 of SEQ ID NO:117 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 134. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the BG132_1 protein. Additional nucleotide sequence from the 3' portion of BG132_1, including a poly(A) tail,
10 is reported in SEQ ID NO:118.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BG132_1 should be approximately 2000 bp.

The nucleotide sequence disclosed herein for BG132_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search
15 protocols. BG132_1 demonstrated at least some similarity with sequences identified as AA078587 (7P05H12 Chromosome 7 Placental cDNA Library Homo sapiens cDNA clone 7P05H12), H14301 (ym63c04.r1 Homo sapiens cDNA clone 163590 5' similar to gb:U03642_cds1 PROBABLE G PROTEIN-COUPLED RECEPTOR APJ (HUMAN)), L09249 (putative G-protein coupled receptor, rhodopsin family), S79811 (adrenomedullin receptor [rats,
20 lung, mRNA]), T36034 (rchd523 gene differentially expressed in cardiovascular disease), U58828 (Human IL8-related receptor (DRY12) mRNA, complete cds), and Y08162 (H.sapiens mRNA for heptahelix receptor). The predicted amino acid sequence disclosed herein for BG132_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BG132_1 protein demonstrated at least some similarity to
25 sequences identified as L06109 (G protein-coupled receptor [Gallus gallus]), L34339 (galanin receptor [Homo sapiens]), U30290 (galanin receptor GALR1 [Rattus norvegicus]), U58828 (IL8-related receptor [Homo sapiens]), W03739 (rchd523 gene product (G protein-coupled receptor)), X98510 (G protein-coupled receptor [Homo sapiens]), and Y08162 (heptahelix receptor [Homo sapiens]). Based upon sequence similarity, BG132_1 proteins and each similar
30 protein or peptide may share at least some activity.

Clone "BG219_2"

A polynucleotide of the present invention has been identified as clone "BG219_2". BG219_2 was isolated from a human adult brain cDNA library using methods which are selective
35 for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding

a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BG219_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BG219_2 protein").

5 The nucleotide sequence of BG219_2 as presently determined is reported in SEQ ID NO:119, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BG219_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:120.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BG219_2 should be approximately 700 bp.

10 The nucleotide sequence disclosed herein for BG219_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BG219_2 demonstrated at least some similarity with sequences identified as AA210695 (zr88b05.s1 Soares NbHTGBC Homo sapiens cDNA clone 682737 3'), C01459 (HUMGS0008450, Human Gene Signature, 3'-directed cDNA sequence), N22628 (EST49p115
15 Homo sapiens cDNA clone 49p115), and T26211 (Human gene signature HUMGS08450). Based upon sequence similarity, BG219_2 proteins and each similar protein or peptide may share at least some activity.

Clone "BG366_2"

20 A polynucleotide of the present invention has been identified as clone "BG366_2". BG366_2 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BG366_2 is a full-length clone, including the entire coding sequence of
25 a secreted protein (also referred to herein as "BG366_2 protein").

The nucleotide sequence of BG366_2 as presently determined is reported in SEQ ID NO:121, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BG366_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:122. The amino acid sequence of
30 another protein that could be encoded by BG366_2 is reported in SEQ ID NO:283.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BG366_2 should be approximately 3000 bp.

The nucleotide sequence disclosed herein for BG366_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search
35 protocols. BG366_2 demonstrated at least some similarity with sequences identified as N39453

(yy49h03.s1 Homo sapiens cDNA clone 276917 3'). Based upon sequence similarity, BG366_2 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the BG366_2 protein sequence centered around amino acid 92 of SEQ ID NO:122.

5

Clone "BV172_2"

A polynucleotide of the present invention has been identified as clone "BV172_2". BV172_2 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding
10 a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BV172_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BV172_2 protein").

The nucleotide sequence of BV172_2 as presently determined is reported in SEQ ID NO:123, and includes a poly(A) tail. What applicants presently believe to be the proper reading
15 frame and the predicted amino acid sequence of the BV172_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:124.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BV172_2 should be approximately 1650 bp.

The nucleotide sequence disclosed herein for BV172_2 was searched against the GenBank
20 and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BV172_2 demonstrated at least some similarity with sequences identified as No significant hits were found in the database. The TopPredII computer program predicts a potential transmembrane domain within the BV172_2 protein sequence centered around amino acid 19 of SEQ ID NO:124. The nucleotide sequence of BV172_2 indicates that it may contain one or more
25 of the following types of repetitive elements: an element similar to chicken CR1, human L1, Mer33.

30

Clone "CC247_10"

A polynucleotide of the present invention has been identified as clone "CC247_10". CC247_10 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino

acid sequence of the encoded protein. CC247_10 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CC247_10 protein").

The nucleotide sequence of CC247_10 as presently determined is reported in SEQ ID NO:125, and includes a poly(A) tail. What applicants presently believe to be the proper reading
5 frame and the predicted amino acid sequence of the CC247_10 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:126. Amino acids 1 to 8 of SEQ ID NO:126 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 9. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be
10 separated from the remainder of the CC247_10 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CC247_10 should be approximately 550 bp.

The nucleotide sequence disclosed herein for CC247_10 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA
15 search protocols. CC247_10 demonstrated at least some similarity with sequences identified as AA291226 (zs47d03.r1 NCI_CGAP_GCB1 Homo sapiens cDNA clone 700613 5'), T05738 (EST03627 Homo sapiens cDNA clone HFBDF64), W51195 (ma14b04.r1 Life Tech mouse brain Mus musculus cDNA clone 304495 5'), and W93640 (zd95d09.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 357233 3'). The predicted amino acid sequence disclosed herein for
20 CC247_10 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CC247_10 protein demonstrated at least some similarity to sequences identified as M62424 (thrombin receptor [Homo sapiens]). The predicted CC247_10 protein is highly hydrophobic. Based upon sequence similarity, CC247_10 proteins and each similar protein or peptide may share at least some activity.

25

Clone "CI480_9"

A polynucleotide of the present invention has been identified as clone "CI480_9". CI480_9 was isolated from a human adult brain cDNA library using methods which are selective
30 for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CI480_9 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CI480_9 protein").

The nucleotide sequence of CI480_9 as presently determined is reported in SEQ ID
35 NO:127, and includes a poly(A) tail. What applicants presently believe to be the proper reading

frame and the predicted amino acid sequence of the CI480_9 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:128. Amino acids 39 to 51 of SEQ ID NO:128 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 52. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CI480_9 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CI480_9 should be approximately 1940 bp.

The nucleotide sequence disclosed herein for CI480_9 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CI480_9 demonstrated at least some similarity with sequences identified as N99342 (IMAGE:20093 Homo sapiens cDNA clone 20093), R89725 (ym99d09.r1 Homo sapiens cDNA clone 167057 5'), and U60644 (Human HU-K4 mRNA, complete cds). The predicted amino acid sequence disclosed herein for CI480_9 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CI480_9 protein demonstrated at least some similarity to sequences identified as U60644 (HU-K4 [Homo sapiens]). Based upon sequence similarity, CI480_9 proteins and each similar protein or peptide may share at least some activity.

CI480_9 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 63 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

Clone "CO722_1"

A polynucleotide of the present invention has been identified as clone "CO722_1". CO722_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CO722_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CO722_1 protein").

The nucleotide sequence of CO722_1 as presently determined is reported in SEQ ID NO:129, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CO722_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:130. Amino acids 17 to 29 of SEQ ID NO:130 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 30. Due to the hydrophobic nature of the predicted leader/signal

sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CO722_1 protein.

The EcoRI/N tI restriction fragment obtainable from the deposit containing clone CO722_1 should be approximately 6800 bp.

5 The nucleotide sequence disclosed herein for CO722_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CO722_1 demonstrated at least some similarity with sequences identified as AA186616 (zp71a08.s1 Stratagene endothelial cell 937223 Homo sapiens cDNA clone 625622 3' similar to contains Alu repetitive element), H10376 (ym08a03.s1 Homo sapiens cDNA clone 10 47067 3'), N86013 (J5997F Fetal heart, Lambda ZAP Express Homo sapiens cDNA), U55258 (Human hBRAVO/Nr-CAM precursor (hBRAVO/ Nr-CAM) gene, complete cds), W19770 (zb39d01.r1 Soares parathyroid tumor NbHPA Homo sapiens), W31608 (zb91d09.r1 Soares parathyroid tumor NbHPA Homo sapiens cDNA clone), and X58482 (Chicken mRNA for neuronal transmembrane protein Nr-CAM, ng-CAM related). The predicted amino acid sequence 15 disclosed herein for CO722_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CO722_1 protein demonstrated at least some similarity to sequences identified as AB002341 (KIAA0343 [Homo sapiens]) and X58482 (Nr-CAM protein [Gallus gallus]). Based upon sequence similarity, CO722_1 proteins and each similar protein or peptide may share at least some activity. The 20 TopPredII computer program predicts two potential transmembrane domains within the CO722_1 protein sequence, centered around amino acids 610 and 1070 of SEQ ID NO:130, respectively.

CO722_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 160 kDa was detected in conditioned media fractions using SDS polyacrylamide gel electrophoresis.

25

Clone "CT748_2"

A polynucleotide of the present invention has been identified as clone "CT748_2". CT748_2 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding 30 a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CT748_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CT748_2 protein").

The nucleotide sequence of CT748_2 as presently determined is reported in SEQ ID NO:131, and includes a poly(A) tail. What applicants presently believe to be the proper reading 35 frame and the predicted amino acid sequence of the CT748_2 protein corresponding to the

foregoing nucleotide sequence is reported in SEQ ID NO:132. Amino acids 281 to 293 of SEQ ID NO:132 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 294. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal
5 sequence not be separated from the remainder of the CT748_2 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CT748_2 should be approximately 5500 bp.

The nucleotide sequence disclosed herein for CT748_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search
10 protocols. CT748_2 demonstrated at least some similarity with sequences identified as T48063 (yb24f03.s1 Homo sapiens cDNA clone 72125 3') and X54175 (Human specific Alu element (HS C4N2) DNA). The predicted amino acid sequence disclosed herein for CT748_2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CT748_2 protein demonstrated at least some similarity to sequences
15 identified as Z36714 (cyclin F [Homo sapiens]). Based upon sequence similarity, CT748_2 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of CT748_2 indicates that it may contain an Alu repetitive element.

Clone "AJ1_1"

20 A polynucleotide of the present invention has been identified as clone "AJ1_1". AJ1_1 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. AJ1_1 is a full-length clone, including the entire coding sequence of a
25 secreted protein (also referred to herein as "AJ1_1 protein").

The nucleotide sequence of the 5' portion of AJ1_1 as presently determined is reported in SEQ ID NO:133. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:134. The predicted amino acid sequence of the AJ1_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:134. Additional
30 nucleotide sequence from the 3' portion of AJ1_1, including a poly(A) tail, is reported in SEQ ID NO:135.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone AJ1_1 should be approximately 925 bp.

The predicted amino acid sequence disclosed herein for AJ1_1 was searched against the
35 GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The

predicted AJ1_1 protein demonstrated at least some similarity to sequences identified as U39060 (GRIP1 [Mus musculus]). Based upon sequence similarity, AJ1_1 proteins and each similar protein or peptide may share at least some activity.

5 Clone "AQ73_3"

A polynucleotide of the present invention has been identified as clone "AQ73_3". AQ73_3 was isolated from a human adult ovary (PA-1 teratocarcinoma, untreated tissue pooled with retinoic-acid-treated and activin-treated tissue) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified
10 as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. AQ73_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "AQ73_3 protein").

The nucleotide sequence of AQ73_3 as presently determined is reported in SEQ ID NO:136, and includes a poly(A) tail. What applicants presently believe to be the proper reading
15 frame and the predicted amino acid sequence of the AQ73_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:137.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone AQ73_3 should be approximately 2800 bp.

The nucleotide sequence disclosed herein for AQ73_3 was searched against the GenBank
20 and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. AQ73_3 demonstrated at least some similarity with sequences identified as AA514474 (nf57g01.s1 NCI_CGAP_Co3 Homo sapiens cDNA clone 924048), T47520 (Human hepatoma-derived growth factor (HDGF-2) cDNA), W24708 (zb62e08.r1 Soares fetal lung NbHL19W Homo sapiens cDNA clone 308198 5'), and W45513 (zc27g08.s1 Soares senescent
25 fibroblasts NbHSF Homo sapiens cDNA clone 323582 3'). The predicted amino acid sequence disclosed herein for AQ73_3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted AQ73_3 protein demonstrated at least some similarity to sequences identified as D16431 (hepatoma-derived GF [Homo sapiens]), D63707 (mouse hepatoma derived growth factor (HDGF) [Mus musculus]), R66727 (Human
30 hepatoma derived growth factor), U18997 (ORF_f299 [Escherichia coli]), U97193 (similar to S. cerevisiae SIR2 (SP P06700) and mouse hepatoma derived growth factor HDGF (NID g945418) [Caenorhabditis elegans]), and W09404 (Human hepatoma-derived growth factor (HDGF-2)). Based upon sequence similarity, AQ73_3 proteins and each similar protein or peptide may share at least some activity.

AQ73_3 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 67 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

5 Clone "BG142_1"

A polynucleotide of the present invention has been identified as clone "BG142_1". BG142_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence
10 of the encoded protein. BG142_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BG142_1 protein").

The nucleotide sequence of BG142_1 as presently determined is reported in SEQ ID NO:138, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BG142_1 protein corresponding to the
15 foregoing nucleotide sequence is reported in SEQ ID NO:139.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BG142_1 should be approximately 1100 bp.

The nucleotide sequence disclosed herein for BG142_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search
20 protocols. BG142_1 demonstrated at least some similarity with sequences identified as AA170261 (ms87h11.r1 Soares mouse 3NbMS Mus musculus cDNA clone 618597 5' similar to TR E245601 E245601 G-RICH BOX-BINDING PROTEIN), L04282 (Human CACCC box-binding protein mRNA, complete cds), N27696 (yx51h12.r1 Homo sapiens cDNA clone 265319 5'), W96110 (ze09a11.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone
25 358460 5'), and W96111 (ze09a11.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 358460 3'). The predicted amino acid sequence disclosed herein for BG142_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BG142_1 protein demonstrated at least some similarity to sequences identified as U80078 (transcription factor BFCOL1 [Mus musculus]) and X98096 (G-rich
30 box-binding protein [Mus musculus]). Based upon sequence similarity, BG142_1 proteins and each similar protein or peptide may share at least some activity.

Clone "BV66_1"

A polynucleotide of the present invention has been identified as clone "BV66_1".
35 BV66_1 was isolated from a human adult brain cDNA library using methods which are selective

for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BV66_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BV66_1 protein").

5 The nucleotide sequence of BV66_1 as presently determined is reported in SEQ ID NO:140, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BV66_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:141.

10 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BV66_1 should be approximately 870 bp.

 The nucleotide sequence disclosed herein for BV66_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database. The nucleotide sequence of BV66_1 indicates that it may contain a TAAA1 simple repeat element.

15

Clone "BV291_3"

 A polynucleotide of the present invention has been identified as clone "BV291_3". BV291_3 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding
20 a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BV291_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BV291_3 protein").

 The nucleotide sequence of BV291_3 as presently determined is reported in SEQ ID NO:142, and includes a poly(A) tail. What applicants presently believe to be the proper reading
25 frame and the predicted amino acid sequence of the BV291_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:143.

 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BV291_3 should be approximately 2000 bp.

 The nucleotide sequence disclosed herein for BV291_3 was searched against the GenBank
30 and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BV291_3 demonstrated at least some similarity with sequences identified as H10954 (ym06e09.r1 Homo sapiens cDNA clone 47034 5'), H10955 (ym06e09.s1 Homo sapiens cDNA clone 47034 3'), N25300 (yw52c10.s1 Homo sapiens cDNA clone 255858 3'), T25940 (Human gene signature HUMGS08173), T68890 (yc30g11.s1 Homo sapiens cDNA clone 82244 3'),
35 T78286 (yc99a08.r1 Homo sapiens cDNA clone 24033 5'), Z39987 (H. sapiens partial cDNA

sequence; clone c-1oh05), and Z47073 (Caenorhabditis elegans cosmid ZC506). The predicted amino acid sequence disclosed herein for BV291_3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted BV291_3 protein demonstrated at least some similarity to sequences identified as X02155 (BTTGR_1 thyroglobulin [Bos taurus]). Based upon sequence similarity, BV291_3 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the BV291_3 protein sequence centered around amino acid 48 of SEQ ID NO:143.

BV291_3 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 30 kDa was detected in conditioned medium using SDS polyacrylamide gel electrophoresis.

Clone "CK201_1"

A polynucleotide of the present invention has been identified as clone "CK201_1". CK201_1 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CK201_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CK201_1 protein").

The nucleotide sequence of CK201_1 as presently determined is reported in SEQ ID NO:144, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CK201_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:145.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CK201_1 should be approximately 1080 bp.

The nucleotide sequence disclosed herein for CK201_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CK201_1 demonstrated at least some similarity with sequences identified as AA129133 (zo09h12.s1 Stratagene neuroepithelium NT2RAMI 937234 Homo sapiens cDNA clone 567239 3' similar to contains Alu repetitive element), D81444 (Human fetal brain cDNA 5'-end GEN-164G10), R36326 (yg69h09.r1 Homo sapiens cDNA clone 38821 5'), T08553 (Oncogene R-ras mutant cDNA (exons 2-6)), T31595 (Probe (BLUR13) for Alu repeat sequence), X03273 (Human Alu-family cluster 5' of alpha(1)-acid glycoprotein gene), and X69907 (H.sapiens gene for mitochondrial ATP synthase c subunit). The predicted amino acid sequence disclosed herein for CK201_1 was searched against the GenPept and GeneSeq amino acid

sequence databases using the BLASTX search protocol. The predicted CK201_1 protein demonstrated at least some similarity to sequences identified as D21827 (major surface glycoprotein [Pneumocystis carinii]). Based upon sequence similarity, CK201_1 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of
5 CK201_1 indicates that it may contain an Alu repetitive element.

CK201_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 40 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.

10 Clone "CQ331_2"

A polynucleotide of the present invention has been identified as clone "CQ331_2". CQ331_2 was isolated from a human adult heart cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence
15 of the encoded protein. CQ331_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CQ331_2 protein").

The nucleotide sequence of CQ331_2 as presently determined is reported in SEQ ID NO:146, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CQ331_2 protein corresponding to the
20 foregoing nucleotide sequence is reported in SEQ ID NO:147. Amino acids 7 to 19 of SEQ ID NO:147 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 20. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CQ331_2 protein.

25 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CQ331_2 should be approximately 1600 bp.

The nucleotide sequence disclosed herein for CQ331_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CQ331_2 demonstrated at least some similarity with sequences identified as J03766
30 (Canine cardiac calsequestrin mRNA, complete cds), L29766 (Homo sapiens epoxide hydrolase (EPHX) gene, complete cds), N83601 (KK1173F Homo sapiens cDNA clone KK1173 5' similar to CALSEQUESTRIN (CARDIAC)), T99646 (ye73f12.s1 Homo sapiens cDNA clone 123407 3' similar to contains Alu repetitive element; contains PTR5 repetitive element), and W76326 (zd60d04.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 345031 5' similar to
35 contains Alu repetitive element). The predicted amino acid sequence disclosed herein for

CQ331_2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CQ331_2 protein demonstrated at least some similarity to sequences identified as J03766 (DOGCAL_1 Canine cardiac calsequestrin mRNA, complete cds [Canis canis]) and X55040 (calsequestrin [Oryctolagus cuniculus]). Based upon
5 sequence similarity, CQ331_2 proteins and each similar protein or peptide may share at least some activity.

Clone "CT550_1"

A polynucleotide of the present invention has been identified as clone "CT550_1".
10 CT550_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CT550_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CT550_1 protein").

15 The nucleotide sequence of CT550_1 as presently determined is reported in SEQ ID NO:148, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CT550_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:149.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone
20 CT550_1 should be approximately 1070 bp.

The nucleotide sequence disclosed herein for CT550_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database. The TopPredII computer program predicts a potential transmembrane domain within the CT550_1 protein sequence centered around amino
25 acid 25 of SEQ ID NO:149.

CT550_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 7 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

Clone "CT585_1"

30 A polynucleotide of the present invention has been identified as clone "CT585_1". CT585_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence

of the encoded protein. CT585_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CT585_1 protein").

The nucleotide sequence of CT585_1 as presently determined is reported in SEQ ID NO:150, and includes a poly(A) tail. What applicants presently believe to be the proper reading
5 frame and the predicted amino acid sequence of the CT585_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:151. Amino acids 2 to 14 of SEQ ID NO:151 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 15. Due to the hydrophobic nature of the predicted leader/signal
10 sequence not be separated from the remainder of the CT585_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CT585_1 should be approximately 2710 bp.

The nucleotide sequence disclosed herein for CT585_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search
15 protocols. CT585_1 demonstrated at least some similarity with sequences identified as AA069442 (zf74b02.s1 Soares pineal gland N3HPG Homo sapiens cDNA clone 382635 3'), L38961 (Homo sapiens putative transmembrane protein (B5) mRNA, complete cds), N34932 (yy49b10.s1 Homo sapiens cDNA clone 276859 3'), N60101 (TgESTzy11f10.r1 Toxoplasma gondii cDNA clone tgzy11f10.r1 5'), and U13019 (Caenorhabditis elegans cosmid T12A2). The predicted amino acid
20 sequence disclosed herein for CT585_1 was searched against the GenPept, GeneSeq, and SwissProt amino acid sequence databases using the BLASTX search protocol. The predicted CT585_1 protein demonstrated at least some similarity to sequences identified as L34260 (transmembrane protein [Mus musculus]), L38961 (transmembrane protein [Homo sapiens]), P46975 (Caenorhabditis elegans oligosaccharyl transferase stt3 [Caenorhabditis elegans]), and
25 U13019 (Caenorhabditis elegans cosmid T12A2 [Caenorhabditis elegans]). Based upon sequence similarity, CT585_1 proteins and each similar protein or peptide may share at least some activity.

Clone "CT797_3"

A polynucleotide of the present invention has been identified as clone "CT797_3".
30 CT797_3 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CT797_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CT797_3 protein").

The nucleotide sequence of CT797_3 as presently determined is reported in SEQ ID NO:152, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CT797_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:153.

5 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CT797_3 should be approximately 3300 bp.

 The nucleotide sequence disclosed herein for CT797_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CT797_3 demonstrated at least some similarity with sequences identified as AA573847
10 (nk08d06.s1 NCI_CGAP_Co2 Homo sapiens cDNA clone IMAGE:1012907). The predicted amino acid sequence disclosed herein for CT797_3 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CT797_3 protein demonstrated at least some similarity to sequences identified as U18309 (chromokinesin [Gallus gallus]) and Z82271 (T01G1.1 [Caenorhabditis elegans]). Based upon
15 sequence similarity, CT797_3 proteins and each similar protein or peptide may share at least some activity.

 CT797_3 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 80 kDa was detected in conditioned medium using SDS polyacrylamide gel electrophoresis.

20

Clone "CB107_1"

 A polynucleotide of the present invention has been identified as clone "CB107_1". CB107_1 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding
25 a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CB107_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CB107_1 protein").

 The nucleotide sequence of the 5' portion of CB107_1 as presently determined is reported in SEQ ID NO:154. An additional internal nucleotide sequence from CB107_1 as presently
30 determined is reported in SEQ ID NO:155. What applicants believe is the proper reading frame and the predicted amino acid sequence encoded by such internal sequence is reported in SEQ ID NO:156. Additional nucleotide sequence from the 3' portion of CB107_1, including a poly(A) tail, is reported in SEQ ID NO:157.

 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone
35 CB107_1 should be approximately 3300 bp.

The nucleotide sequence disclosed herein for CB107_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CB107_1 demonstrated at least some similarity with sequences identified as AA121485 (zn80a02.s1 Stratagene lung carcinoma 937218 Homo sapiens cDNA clone 564458 3'),
5 AA428192 (zw51b08.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 773559 3'), D83018 (Human mRNA for nel-related protein 2, complete cds), F10919 (H. sapiens partial cDNA sequence; clone c-3lg01), H15375 (ym28d09.r1 Homo sapiens cDNA clone 49527 5' similar to SP A54105 A54105 FIBRILLIN-2 PRECURSOR), U48245 (Rattus norvegicus protein kinase C-binding protein Nel mRNA, complete cds), U59230 (Mus musculus mel (MEL91)
10 mRNA, complete cds), and W28387 (46c5 Human retina cDNA randomly primed sublibrary Homo sapiens cDNA). The predicted amino acid sequence disclosed herein for CB107_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted CB107_1 protein demonstrated at least some similarity to sequences identified as D83018 (nel-related protein 2 [Homo sapiens]), R05222 (Antigen
15 GX5401FL encoded by Eimeria tenella genomic DNA), R79964 (Connective tissue growth factor), U48245 (RNU48245_1 protein kinase C-binding protein Nel [Rattus norvegicus]), and U59230 (mel [Mus musculus]). Based upon sequence similarity, CB107_1 proteins and each similar protein or peptide may share at least some activity.

20

Clone "CG300_3"

A polynucleotide of the present invention has been identified as clone "CG300_3". CG300_3 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding
25 a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CG300_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CG300_3 protein").

The nucleotide sequence of CG300_3 as presently determined is reported in SEQ ID NO:158, and includes a poly(A) tail. What applicants presently believe to be the proper reading
30 frame and the predicted amino acid sequence of the CG300_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:159. Amino acids 30 to 42 of SEQ ID NO:159 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 43. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal
35 sequence not be separated from the remainder of the CG300_3 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CG300_3 should be approximately 1800 bp.

The nucleotide sequence disclosed herein for CG300_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CG300_3 demonstrated at least some similarity with sequences identified as N40185 (yy44d08.s1 Homo sapiens cDNA clone 276399 3') and W01791 (za72d06.r1 Soares fetal lung NbHL19W Homo sapiens cDNA clone 298091 5'). Based upon sequence similarity, CG300_3 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts four potential transmembrane domains within the CG300_3 protein sequence, centered around amino acids 34, 98, 151, and 179 of SEQ ID NO:159, respectively.

CG300_3 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 29 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

15

Clone "CJ145_1"

A polynucleotide of the present invention has been identified as clone "CJ145_1". CJ145_1 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CJ145_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CJ145_1 protein").

The nucleotide sequence of CJ145_1 as presently determined is reported in SEQ ID NO:160, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CJ145_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:161. Amino acids 6 to 18 of SEQ ID NO:161 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 19. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CJ145_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CJ145_1 should be approximately 3600 bp.

The nucleotide sequence disclosed herein for CJ145_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search

35

protocols. CJ145_1 demonstrated at least some similarity with sequences identified as R43655 (yc86b04.s1 Homo sapiens cDNA clone 22829 3'), R50995 (yg63f06.s1 Homo sapiens cDNA clone 37377 3' similar to c ntains MER22 repetitive element), and W92748 (zd92h03.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 356981 3'). Based upon sequence similarity, CJ145_1 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of CJ145_1 indicates that it may contain a CA simple repeat element.

Clone "CJ160_11"

A polynucleotide of the present invention has been identified as clone "CJ160_11". CJ160_11 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CJ160_11 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CJ160_11 protein").

The nucleotide sequence of CJ160_11 as presently determined is reported in SEQ ID NO:162, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CJ160_11 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:163. Amino acids 17 to 29 of SEQ ID NO:163 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 30. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CJ160_11 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CJ160_11 should be approximately 1700 bp.

The nucleotide sequence disclosed herein for CJ160_11 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CJ160_11 demonstrated at least some similarity with sequences identified as AA024511 (ze76e04.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 364926 3') and AC000074 (00884; HTGS phase 3, complete sequence). Based upon sequence similarity, CJ160_11 proteins and each similar protein or peptide may share at least some activity.

CJ160_11 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 96 kDa was detected in conditioned medium using SDS polyacrylamide gel electrophoresis.

Clone "CO20_1"

A polynucleotide of the present invention has been identified as clone "CO20_1". CO20_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CO20_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CO20_1 protein").

The nucleotide sequence of the 5' portion of CO20_1 as presently determined is reported in SEQ ID NO:164. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:165. The predicted amino acid sequence of the CO20_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:165. Amino acids 17 to 29 of SEQ ID NO:165 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 30. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CO20_1 protein. Additional nucleotide sequence from the 3' portion of CO20_1, including a poly(A) tail, is reported in SEQ ID NO:166.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CO20_1 should be approximately 2400 bp.

The nucleotide sequence disclosed herein for CO20_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CO20_1 demonstrated at least some similarity with sequences identified as AA045770 (zl68b10.s1 Stratagene colon (#937204) Homo sapiens cDNA clone 509755 3' similar to SW:R13A_HUMAN P40429 60S RIBOSOMAL PROTEIN L13A), AA070899 (zm66c01.s1 Stratagene neuroepithelium (#937231) Homo sapiens cDNA clone 530592 3' similar to contains Alu repetitive element), AA325205 (EST28155 Cerebellum II Homo sapiens cDNA 5' end), N22253 (yw36a08.s1 Homo sapiens cDNA clone 254294 3' similar to SP S29539 S29539 BASIC PROTEIN, 23K), R01933 (ye85g07.s1 Homo sapiens cDNA clone 124572 3' similar to SP:S29539 S29539 BASIC PROTEIN, 23K), R12008 (yf51f04.r1 Homo sapiens cDNA clone 25456 5'), R39848 (yf51f04.s1 Homo sapiens cDNA clone 25456 3' similar to contains Alu repetitive element;contains PTR5 repetitive element), R56565 (yg91c12.r1 Homo sapiens cDNA clone 40891 5'), T19487 (Human gene signature HUMGS00543), T30988 (EST25695 Homo sapiens cDNA 5' end similar to None), U37026 (Rattus norvegicus brain sodium channel beta 2 subunit (SCNB2) mRNA, complete cds), and X56932 (H.sapiens mRNA for 23 kD highly basic protein). The predicted amino acid sequence disclosed herein for CO20_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol.

The predicted CO20_1 protein demonstrated at least some similarity to sequences identified as U37026 (sodium channel beta 2 subunit [Rattus norvegicus]), U58658 (unknown [Homo sapiens]), and X56932 (23 kD highly basic protein [Homo sapiens]). The sodium channel beta 2 subunit is a glycoprotein with an extracellular domain containing an immunoglobulin-like fold with
5 similarity to the neural cell adhesion molecule contactin. Based upon sequence similarity, CO20_1 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of CO20_1 indicates that it may contain an Alu repetitive element.

Clone "CO223_3"

10 A polynucleotide of the present invention has been identified as clone "CO223_3". CO223_3 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CO223_3 is a full-length clone, including the entire coding sequence of
15 a secreted protein (also referred to herein as "CO223_3 protein").

The nucleotide sequence of CO223_3 as presently determined is reported in SEQ ID NO:167, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CO223_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:168. Amino acids 35 to 47 of SEQ ID
20 NO:168 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 48. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CO223_3 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone
25 CO223_3 should be approximately 700 bp.

The nucleotide sequence disclosed herein for CO223_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CO223_3 demonstrated at least some similarity with sequences identified as AA004498 (zh87b06.r1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 428243
30 5' similar to gb M62505 C5A ANAPHYLATOXIN CHEMOTACTIC RECEPTOR (HUMAN);contains L1.t1 L1 repetitive element) and U47924 (Human chromosome 12p13 gene cluster, surface antigen CD4 (CD4), A, B, G-protein beta-3 subunit (GNB3), isopeptidase T (ISOT) and triosephosphate isomerase (TPI) genes, complete cds). Based upon sequence similarity, CO223_3 proteins and each similar protein or peptide may share at least some activity.

The 3' end of the CO223_3 polynucleotide sequence contains a 54-bp sequence that is repeated three times in the clone; these repeats begin at positions 314, 368, and 422 of SEQ ID NO:167 and encode amino acids 47 to 64, 65 to 82, and 83 to 99 of SEQ ID NO:168, respectively.

5 Clone "CO310_2"

A polynucleotide of the present invention has been identified as clone "CO310_2". CO310_2 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence
10 of the encoded protein. CO310_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CO310_2 protein").

The nucleotide sequence of CO310_2 as presently determined is reported in SEQ ID NO:169, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CO310_2 protein corresponding to the
15 foregoing nucleotide sequence is reported in SEQ ID NO:170.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CO310_2 should be approximately 1400 bp.

The nucleotide sequence disclosed herein for CO310_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search
20 protocols. No hits were found in the database. The nucleotide sequence of CO310_2 indicates that it may contain an L1 repetitive element.

Clone "CP258_3"

A polynucleotide of the present invention has been identified as clone "CP258_3".
25 CP258_3 was isolated from a human adult salivary gland cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CP258_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CP258_3 protein").

30 The nucleotide sequence of CP258_3 as presently determined is reported in SEQ ID NO:171, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CP258_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:172. Amino acids 3 to 15 of SEQ ID NO:172 are a predicted leader/signal sequence, with the predicted mature amino acid sequence
35 beginning at amino acid 16. Due to the hydrophobic nature of the predicted leader/signal

sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CP258_3 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CP258_3 should be approximately 560 bp.

5 The nucleotide sequence disclosed herein for CP258_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database.

CP258_3 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 26 kDa was detected in conditioned medium and membrane fractions using
10 SDS polyacrylamide gel electrophoresis.

Clone "CW1155_3"

A polynucleotide of the present invention has been identified as clone "CW1155_3". CW1155_3 was isolated from a human fetal brain cDNA library using methods which are
15 selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CW1155_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CW1155_3 protein").

The nucleotide sequence of CW1155_3 as presently determined is reported in SEQ ID
20 NO:173, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CW1155_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:174. Amino acids 220 to 232 of SEQ ID NO:174 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 233. Due to the hydrophobic nature of the predicted leader/signal
25 sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the CW1155_3 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CW1155_3 should be approximately 1170 bp.

The nucleotide sequence disclosed herein for CW1155_3 was searched against the
30 GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CW1155_3 demonstrated at least some similarity with sequences identified as AA169043 (ms36h08.r1 Stratagene mouse heart (#937316) Mus musculus cDNA clone 613695 5'), D86145 (Rat mRNA), and H29261 (ym32b03.s1 Homo sapiens cDNA clone 49733 3'). Based upon sequence similarity, CW1155_3 proteins and each similar protein or peptide may share at
35 least some activity.

Clone "CZ247_2"

A polynucleotide of the present invention has been identified as clone "CZ247_2". CZ247_2 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding
5 a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CZ247_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CZ247_2 protein").

The nucleotide sequence of CZ247_2 as presently determined is reported in SEQ ID NO:175, and includes a poly(A) tail. What applicants presently believe to be the proper reading
10 frame and the predicted amino acid sequence of the CZ247_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:176. Amino acids 545 to 557 of SEQ ID NO:176 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 558. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal
15 sequence not be separated from the remainder of the CZ247_2 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CZ247_2 should be approximately 2300 bp.

The nucleotide sequence disclosed herein for CZ247_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search
20 protocols. CZ247_2 demonstrated at least some similarity with sequences identified as T09256 (Human ara Kb beta-galactosidase fusion protein coding sequence), W27222 (26h9 Human retina cDNA randomly primed sublibrary Homo sapiens cDNA), and W72736 (zd71e02.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 346106 3'). The predicted amino acid sequence disclosed herein for CZ247_2 was searched against the GenPept and GeneSeq amino acid
25 sequence databases using the BLASTX search protocol. The predicted CZ247_2 protein demonstrated at least some similarity to sequences identified as R88069 (Human ara Kb beta-galactosidase fusion protein). Based upon sequence similarity, CZ247_2 proteins and each similar protein or peptide may share at least some activity.

Clone "AM666_1"

A polynucleotide of the present invention has been identified as clone "AM666_1". AM666_1 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino

acid sequence of the encoded protein. AM666_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "AM666_1 protein").

The nucleotide sequence of AM666_1 as presently determined is reported in SEQ ID NO:177, and includes a poly(A) tail. What applicants presently believe to be the proper reading
5 frame and the predicted amino acid sequence of the AM666_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:178. Amino acids 15 to 27 of SEQ ID NO:178 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 28. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal
10 sequence not be separated from the remainder of the AM666_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone AM666_1 should be approximately 1300 bp.

The nucleotide sequence disclosed herein for AM666_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA
15 search protocols. AM666_1 demonstrated at least some similarity with sequences identified as AA493985 (nh07g08.s1 NCI_CGAP_Thy1 Homo sapiens cDNA clone). Based upon sequence similarity, AM666_1 proteins and each similar protein or peptide may share at least some activity.

AM666_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 17 kDa was detected in membrane fractions using SDS polyacrylamide gel
20 electrophoresis.

Clone "BN387_3"

A polynucleotide of the present invention has been identified as clone "BN387_3". BN387_3 was isolated from a human adult placenta cDNA library using methods which are
25 selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BN387_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BN387_3 protein").

The nucleotide sequence of BN387_3 as presently determined is reported in SEQ ID
30 NO:179, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BN387_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:180. Amino acids 14 to 26 of SEQ ID NO:180 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 27. Due to the hydrophobic nature of the predicted leader/signal

sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the BN387_3 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BN387_3 should be approximately 2000 bp.

5 The nucleotide sequence disclosed herein for BN387_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. BN387_3 demonstrated at least some similarity with sequences identified as H16912 (ym39d01.r1 Homo sapiens cDNA clone 50771 5'). Based upon sequence similarity, BN387_3 proteins and each similar protein or peptide may share at least some activity.

10 BN387_3 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 30 kDa was detected in conditioned medium using SDS polyacrylamide gel electrophoresis.

Clone "BQ135_2"

15 A polynucleotide of the present invention has been identified as clone "BQ135_2". BQ135_2 was isolated from a human adult colon (adenocarcinoma Caco2) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. BQ135_2 is a full-length clone,
20 including the entire coding sequence of a secreted protein (also referred to herein as "BQ135_2 protein").

The nucleotide sequence of BQ135_2 as presently determined is reported in SEQ ID NO:181, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the BQ135_2 protein corresponding to the
25 foregoing nucleotide sequence is reported in SEQ ID NO:182.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone BQ135_2 should be approximately 1200 bp.

The nucleotide sequence disclosed herein for BQ135_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search
30 protocols. BQ135_2 demonstrated at least some similarity with sequences identified as AA023751 (mh81f01.r1 Soares mouse placenta 4NbMP13.5 14.5 Mus musculus cDNA clone 457369 5'), AA105433 (ml83g01.r1 Stratagene mouse kidney (#937315) Mus musculus cDNA clone 518640 5'), D64061 (Rat brain mRNA for annexin V-binding protein (ABP-7), partial cds), and N67257 (yz49b08.s1 Homo sapiens cDNA clone 286359 3'). The predicted amino acid
35 sequence disclosed herein for BQ135_2 was searched against the GenPept and GeneSeq amino

acid sequence databases using the BLASTX search protocol. The predicted BQ135_2 protein demonstrated at least some similarity to sequences identified as D64061 (annexin V-binding protein (ABP-7) [Rattus norvegicus]). Annexins associate with membranes and act as ion channels, they can also act as an autocrine factor that enhances osteoclast formation and bone resorption. Annexins have been localized in nucleoli and mitochondria but also in the cytoplasm, plasma (i.e. blood) and in association with vesicles. They are probably involved in fusing vesicles to each other and to plasma membranes causing secretion of vesicular contents. Specifically they have a calcium-dependent ability to bind phospholipids. Thus they are membrane associated. It is possible that annexin-binding proteins are also membrane associated even though they are highly hydrophilic through the same mechanism (electrostatic interaction with phospholipids of membranes). Based upon sequence similarity, BQ135_2 proteins and each similar protein or peptide may share at least some activity.

Clone "CR678_1"

A polynucleotide of the present invention has been identified as clone "CR678_1". CR678_1 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CR678_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CR678_1 protein").

The nucleotide sequence of CR678_1 as presently determined is reported in SEQ ID NO:183, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CR678_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:184.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CR678_1 should be approximately 870 bp.

The nucleotide sequence disclosed herein for CR678_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CR678_1 demonstrated at least some similarity with sequences identified as X85232 (H.sapiens chromosome 3 sequences). Based upon sequence similarity, CR678_1 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of CR678_1 indicates that it may contain an Alu repetitive element.

Clone "CW420_2"

A polynucleotide of the present invention has been identified as clone "CW420_2". CW420_2 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CW420_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CW420_2 protein").

The nucleotide sequence of CW420_2 as presently determined is reported in SEQ ID NO:185, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CW420_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:186.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CW420_2 should be approximately 5100 bp.

The nucleotide sequence disclosed herein for CW420_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. CW420_2 demonstrated at least some similarity with sequences identified as T55440 (yb38e09.s1 Homo sapiens cDNA clone 73480 3'). Based upon sequence similarity, CW420_2 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the CW420_2 protein sequence centered around amino acids 500 and 1270 of SEQ ID NO:186, respectively.

Clone "CW795_2"

A polynucleotide of the present invention has been identified as clone "CW795_2". CW795_2 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CW795_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CW795_2 protein").

The nucleotide sequence of CW795_2 as presently determined is reported in SEQ ID NO:187, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CW795_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:188.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CW795_2 should be approximately 3000 bp.

The nucleotide sequence disclosed herein for CW795_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA

search protocols. CW795_2 demonstrated at least some similarity with sequences identified as AA115676 (zl86a09.s1 Stratagene colon (#937204) Homo sapiens cDNA clone 511480 3'), N22955 (yw44h07.s1 Homo sapiens cDNA clone 255133 3'), and W56804 (zd16g06.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 340858 3'). The predicted amino acid sequence disclosed herein for CW795_2 was searched against the GenPept, GeneSeq, and SwissProt amino acid sequence databases using the BLASTX search protocol. The predicted CW795_2 protein demonstrated at least some similarity to sequences identified as X81068 (probable mitochondrial protein) and the yeast proteins rca1 and afg3 (tat-binding homologues). Based upon sequence similarity, CW795_2 proteins and each similar protein or peptide may share at least some activity.

10 The TopPredII computer program predicts two potential transmembrane domains within the CW795_2 protein sequence centered around amino acids 60 and 170 of SEQ ID NO:188, respectively.

CW795_2 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 10 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

15

Clone "CW823_3"

A polynucleotide of the present invention has been identified as clone "CW823_3". CW823_3 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. CW823_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "CW823_3 protein").

20

The nucleotide sequence of CW823_3 as presently determined is reported in SEQ ID NO:189, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the CW823_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:190.

25

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone CW823_3 should be approximately 600 bp.

30 The nucleotide sequence disclosed herein for CW823_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database.

Clone "DF989_3"

A polynucleotide of the present invention has been identified as clone "DF989_3". DF989_3 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding
5 a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. DF989_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "DF989_3 protein").

The nucleotide sequence of the 5' portion of DF989_3 as presently determined is reported in SEQ ID NO:191. What applicants presently believe is the proper reading frame for the coding
10 region is indicated in SEQ ID NO:192. The predicted amino acid sequence of the DF989_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:192. Amino acids 2 to 14 of SEQ ID NO:192 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 15. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the
15 predicted leader/signal sequence not be separated from the remainder of the DF989_3 protein. Additional nucleotide sequence from the 3' portion of DF989_3, including a poly(A) tail, is reported in SEQ ID NO:193.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone DF989_3 should be approximately 1800 bp.

20 The nucleotide sequence disclosed herein for DF989_3 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. DF989_3 demonstrated at least some similarity with sequences identified as R24724 (yg43c05.r1 Homo sapiens cDNA clone 35337 5') and T33717 (EST58870 Homo sapiens cDNA 5' end similar to None). Based upon sequence similarity, DF989_3 proteins and each similar
25 protein or peptide may share at least some activity.

Clone "DL162_1"

A polynucleotide of the present invention has been identified as clone "DL162_1". DL162_1 was isolated from a human adult brain cDNA library using methods which are selective
30 for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. DL162_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "DL162_1 protein").

The nucleotide sequence of DL162_1 as presently determined is reported in SEQ ID
35 NO:194, and includes a poly(A) tail. What applicants presently believe to be the proper reading

frame and the predicted amino acid sequence of the DL162_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:195. Amino acids 28 to 40 of SEQ ID NO:195 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 41. Due to the hydrophobic nature of the predicted leader/signal
5 sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the DL162_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone DL162_1 should be approximately 875 bp.

The nucleotide sequence disclosed herein for DL162_1 was searched against the GenBank
10 and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the database.

Clone "DL162_2"

A polynucleotide of the present invention has been identified as clone "DL162_2".
15 DL162_2 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. DL162_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "DL162_2 protein").

20 The nucleotide sequence of DL162_2 as presently determined is reported in SEQ ID NO:196, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the DL162_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:197. Amino acids 1 to 13 of SEQ ID NO:197 are a predicted leader/signal sequence, with the predicted mature amino acid sequence
25 beginning at amino acid 14. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the DL162_2 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone DL162_2 should be approximately 4000 bp.

30 The predicted amino acid sequence disclosed herein for DL162_2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted DL162_2 protein demonstrated at least some similarity to sequences identified as AB002309 (KIAA0311 protein [Homo sapiens]). The TopPredII computer program predicts a potential transmembrane domains within the DL162_2 protein sequence near the carboxyl
35 terminus of SEQ ID NO:197.

DL162_2 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 160 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

5 Clone "EC172_1"

A polynucleotide of the present invention has been identified as clone "EC172_1". EC172_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. EC172_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "EC172_1 protein").

The nucleotide sequence of EC172_1 as presently determined is reported in SEQ ID NO:198, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the EC172_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:199. Amino acids 659 to 671 of SEQ ID NO:199 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 672. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the EC172_1 protein.

20 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone EC172_1 should be approximately 4000 bp.

The nucleotide sequence disclosed herein for EC172_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. EC172_1 demonstrated at least some similarity with sequences identified as H31192 (EST104991 Rattus sp. cDNA 3' end similar to C.elegans hypothetical protein ZK1098.10) and U29585 (Streptococcus pyogenes emm18.1). The predicted amino acid sequence disclosed herein for EC172_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted EC172_1 protein demonstrated at least some similarity to sequences identified as Z22176 (ZK1098.10 [Caenorhabditis elegans]). Based upon sequence similarity, EC172_1 proteins and each similar protein or peptide may share at least some activity.

Deposit of Clones

Clones AX65_22, BD335_14, BG241_1, BL187_4, BL249_18, BO71_1, BO365_2, BV51_1, BV140_3, BV141_2, CC194_4, and DA136_11 were deposited on October 3, 1996 with

the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98196, from which each clone comprising a particular polynucleotide is obtainable.

5 Clones AR415_4, AS63_29, BG160_1, BO432_4, BO538_2, BR595_4, CI490_2, CI522_1, CN238_1, CO390_1, and AY304_1 (an additional isolate of clone AY304_14) were deposited on October 25, 1996 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98232, from which each clone comprising
10 a particular polynucleotide is obtainable. Clone AY304_14 was deposited on October 23, 1997 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and was given the accession number 98561.

Clones AJ20_2, AR440_1, AS164_1, AX8_1, BD176_3, BD339_1, BD427_1, BL229_22, BV123_16, and CH377_1 were deposited on November 15, 1996 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98261, from which each clone comprising a particular polynucleotide is obtainable.

Clones BD441_1, BD441_2, BG102_3, BK158_1, BP163_1, BZ16_3, CC182_1, CG109_1 and CJ397_1 were deposited on November 20, 1996 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98264, from which each clone comprising a particular polynucleotide is obtainable.

Clones AM795_4, AT340_1, BG132_1, BG219_2, BG366_2, BV172_2, CC247_10, CI480_9, CO722_1, and CT748_2 were deposited on December 5, 1996 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98271, from which each clone comprising a particular polynucleotide is obtainable.

Clones AJ1_1, AQ73_3, BG142_1, BV66_1, BV291_3, CK201_1, CQ331_2, CT550_1, CT585_1 and CT797_3 were deposited on December 13, 1996 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98278, from which each clone comprising a particular polynucleotide is obtainable.

Clones CB107_1, CG300_3, CJ145_1, CJ160_11, CO20_1, CO223_1, CO310_2, CP258_3, CW1155_3 and CZ247_2 were deposited on December 17, 1996 with the ATCC

(American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98279, from which each clone comprising a particular polynucleotide is obtainable. Clone CO223_3 was deposited on January 9, 1997 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and was given the accession number 98291.

Clones AM666_1, BN387_3, BQ135_2, CR678_1, CW420_2, CW795_2, CW823_3, DF989_3, DL162_2, DL162_1, and EC172_1 were deposited on January 10, 1997 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98292, from which each clone comprising a particular polynucleotide is obtainable.

All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent, except for the requirements specified in 37 C.F.R. § 1.808(b), and the term of the deposit will comply with 37 C.F.R. § 1.806.

Each clone has been transfected into separate bacterial cells (*E. coli*) in this composite deposit. Each clone can be removed from the vector in which it was deposited by performing an EcoRI/NotI digestion (5' site, EcoRI; 3' site, NotI) to produce the appropriate fragment for such clone. Each clone was deposited in either the pED6 or pNOTs vector depicted in Figures 1A and 1B, respectively. The pED6dpc2 vector ("pED6") was derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning (Kaufman *et al.*, 1991, *Nucleic Acids Res.* 19: 4485-4490); the pNOTs vector was derived from pMT2 (Kaufman *et al.*, 1989, *Mol. Cell. Biol.* 9: 946-958) by deletion of the DHFR sequences, insertion of a new polylinker, and insertion of the M13 origin of replication in the ClaI site. In some instances, the deposited clone can become "flipped" (i.e., in the reverse orientation) in the deposited isolate. In such instances, the cDNA insert can still be isolated by digestion with EcoRI and NotI. However, NotI will then produce the 5' site and EcoRI will produce the 3' site for placement of the cDNA in proper orientation for expression in a suitable vector. The cDNA may also be expressed from the vectors in which they were deposited.

Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:

An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences provided herein, or from a combination of those sequences. The sequence of an oligonucleotide probe that was used to isolate or to sequence each full-length clone is identified below, and should be most reliable in isolating the clone of interest.

	<u>Clone</u>	<u>Probe Sequence</u>
	AX65_22	SEQ ID NO:200
	BD335_14	SEQ ID NO:201
	BG241_1	SEQ ID NO:202
5	BL187_4	SEQ ID NO:203
	BL249_18	SEQ ID NO:204
	BO71_1	SEQ ID NO:205
	BO365_2	SEQ ID NO:206
	BV51_1	SEQ ID NO:207
10	BV140_3	SEQ ID NO:208
	BV141_2	SEQ ID NO:209
	CC194_4	SEQ ID NO:210
	DA136_11	SEQ ID NO:211
	AR415_4	SEQ ID NO:212
15	AS63_29	SEQ ID NO:213
	AY304_14	SEQ ID NO:214
	BG160_1	SEQ ID NO:215
	BO432_4	SEQ ID NO:216
	BO538_2	SEQ ID NO:217
20	BR595_4	SEQ ID NO:218
	CI490_2	SEQ ID NO:219
	CI522_1	SEQ ID NO:220
	CN238_1	SEQ ID NO:221
	CO390_1	SEQ ID NO:222
25	AJ20_2	SEQ ID NO:223
	AR440_1	SEQ ID NO:224
	AS164_1	SEQ ID NO:225
	AX8_1	SEQ ID NO:226
	BD176_3	SEQ ID NO:227
30	BD339_1	SEQ ID NO:228
	BD427_1	SEQ ID NO:229
	BL229_22	SEQ ID NO:230
	BV123_16	SEQ ID NO:231
	CH377_1	SEQ ID NO:232
35	BD441_1	SEQ ID NO:233

	BD441_2	SEQ ID NO:234
	BG102_3	SEQ ID NO:235
	BK158_1	SEQ ID NO:236
	BP163_1	SEQ ID NO:237
5	BZ16_3	SEQ ID NO:238
	CC182_1	SEQ ID NO:239
	CG109_1	SEQ ID NO:240
	CJ397_1	SEQ ID NO:241
	AM795_4	SEQ ID NO:242
10	AT340_1	SEQ ID NO:243
	BG132_1	SEQ ID NO:244
	BG219_2	SEQ ID NO:245
	BG366_2	SEQ ID NO:246
	BV172_2	SEQ ID NO:247
15	CC247_10	SEQ ID NO:248
	CI480_9	SEQ ID NO:249
	CO722_1	SEQ ID NO:250
	CT748_2	SEQ ID NO:251
	AJ1_1	SEQ ID NO:252
20	AQ73_3	SEQ ID NO:253
	BG142_1	SEQ ID NO:254
	BV66_1	SEQ ID NO:255
	BV291_3	SEQ ID NO:256
	CK201_1	SEQ ID NO:257
25	CQ331_2	SEQ ID NO:258
	CT550_1	SEQ ID NO:259
	CT585_1	SEQ ID NO:260, SEQ ID NO:262
	CT797_3	SEQ ID NO:261
	CB107_1	SEQ ID NO:263
30	CG300_3	SEQ ID NO:264
	CJ145_1	SEQ ID NO:265
	CJ160_11	SEQ ID NO:266
	CO20_1	SEQ ID NO:267
	CO223_3	SEQ ID NO:268
35	CO310_2	SEQ ID NO:269

	CP258_3	SEQ ID NO:270
	CW1155_3	SEQ ID NO:271
	CZ247_2	SEQ ID NO:272
	AM666_1	SEQ ID NO:273
5	BN387_3	SEQ ID NO:274
	BQ135_2	SEQ ID NO:275
	CR678_1	SEQ ID NO:276
	CW420_2	SEQ ID NO:277
	CW795_2	SEQ ID NO:278
10	CW823_3	SEQ ID NO:279
	DF989_3	SEQ ID NO:280
	DL162_1, DL162_2	SEQ ID NO:281
	EC172_1	SEQ ID NO:282

15 In the sequences listed above which include an N at position 2, that position is occupied in preferred probes/primers by a biotinylated phosphoramidite residue rather than a nucleotide (such as, for example, that produced by use of biotin phosphoramidite (1-dimethoxytrityloxy-2-(N-biotinyl-4-aminobutyl)-propyl-3-O-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite) (Glen Research, cat. no. 10-1953)).

20 The design of the oligonucleotide probe should preferably follow these parameters:

- (a) It should be designed to an area of the sequence which has the fewest ambiguous bases ("N's"), if any;
- (b) It should be designed to have a T_m of approx. 80 ° C (assuming 2° for each A or T and 4 degrees for each G or C).

25 The oligonucleotide should preferably be labeled with γ -³²P ATP (specific activity 6000 Ci/mmole) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a
30 scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4e+6 dpm/pmole.

The bacterial culture containing the pool of full-length clones should preferably be thawed and 100 μ l of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100 μ g/ml. The culture should preferably be grown to saturation at 37° C,
35 and the saturated culture should preferably be diluted in fresh L-broth. Aliquots of these dilutions

should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100 µg/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37°C. Other known methods of obtaining distinct, well-separated colonies can also be employed.

Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose filters and lyse, denature and bake them.

The filter is then preferably incubated at 65°C for 1 hour with gentle agitation in 6X SSC (20X stock is 175.3 g NaCl/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100 µg/ml of yeast RNA, and 10 mM EDTA (approximately 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at a concentration greater than or equal to 1e+6 dpm/mL. The filter is then preferably incubated at 65°C with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2X SSC/0.5% SDS at room temperature without agitation, preferably followed by 500 mL of 2X SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes. A third wash with 0.1X SSC/0.5% SDS at 65°C for 30 minutes to 1 hour is optional. The filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.

The positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing.

Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H.U. Saragovi, *et al.*, *Bio/Technology* 10, 773-778 (1992) and in R.S. McDowell, *et al.*, *J. Amer. Chem. Soc.* 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may be fused through "linker" sequences to the Fc portion of an immunoglobulin. For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions. For example, a protein - IgM fusion would generate a decavalent form of the protein of the invention.

The present invention also provides both full-length and mature forms of the disclosed proteins. The full-length form of the such proteins is identified in the sequence listing by translation of the nucleotide sequence of each disclosed clone. The mature form(s) of such protein

may be obtained by expression of the disclosed full-length polynucleotide (preferably those deposited with the ATCC) in a suitable mammalian cell or other host cell. The sequence(s) of the mature form(s) of the protein may also be determinable from the amino acid sequence of the full-length form.

5 The present invention also provides genes corresponding to the polynucleotide sequences disclosed herein. "Corresponding genes" are the regions of the genome that are transcribed to produce the mRNAs from which cDNA polynucleotide sequences are derived and may include contiguous regions of the genome necessary for the regulated expression of such genes. Corresponding genes may therefore include but are not limited to coding sequences, 5' and 3'
10 untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. An "isolated gene"
15 is a gene that has been separated from the adjacent coding sequences, if any, present in the genome of the organism from which the gene was isolated.

 The chromosomal location corresponding to the polynucleotide sequences disclosed herein may also be determined, for example by hybridizing appropriately labeled polynucleotides of the present invention to chromosomes *in situ*. It may also be possible to determine the
20 corresponding chromosomal location for a disclosed polynucleotide by identifying significantly similar nucleotide sequences in public databases, such as expressed sequence tags (ESTs), that have already been mapped to particular chromosomal locations. For at least some of the polynucleotide sequences disclosed herein, public database sequences having at least some similarity to the polynucleotide of the present invention have been listed by database accession
25 number. Searches using the GenBank accession numbers of these public database sequences can then be performed at an Internet site provided by the National Center for Biotechnology Information having the address <http://www.ncbi.nlm.nih.gov/UniGene/>, in order to identify "UniGene clusters" of overlapping sequences. Many of the "UniGene clusters" so identified will already have been mapped to particular chromosomal sites.

30 Organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein are provided. The desired change in gene expression can be achieved through the use of antisense polynucleotides or ribozymes that bind and/or cleave the mRNA transcribed from the gene (Albert and Morris, 1994, *Trends Pharmacol. Sci.* 15(7): 250-254; Lavarosky *et al.*, 1997, *Biochem. Mol. Med.* 62(1): 11-22; and
35 Hampel, 1998, *Prog. Nucleic Acid Res. Mol. Biol.* 58: 1-39; all of which are incorporated by

reference herein). The desired change in gene expression can also be achieved through the use of double-stranded ribonucleotide molecules having some complementarity to the mRNA transcribed from the gene, and which interfere with the transcription, stability, or expression of the mRNA ("RNA interference" or "RNAi"; Fire *et al.*, 1998, *Nature* 391 (6669): 806-811; 5 Montgomery *et al.*, 1998, *Proc. Natl. Acad. Sci. USA* 95 (26): 15502-15507; and Sharp, 1999, *Genes Dev.* 13 (2): 139-141; all of which are incorporated by reference herein). Transgenic animals that have multiple copies of the gene(s) corresponding to the polynucleotide sequences disclosed herein, preferably produced by transformation of cells with genetic constructs that are stably maintained within the transformed cells and their progeny, are provided. Transgenic 10 animals that have modified genetic control regions that increase or reduce gene expression levels, or that change temporal or spatial patterns of gene expression, are also provided (see European Patent No. 0 649 464 B1, incorporated by reference herein). In addition, organisms are provided in which the gene(s) corresponding to the polynucleotide sequences disclosed herein have been partially or completely inactivated, through insertion of extraneous sequences into the 15 corresponding gene(s) or through deletion of all or part of the corresponding gene(s). Partial or complete gene inactivation can be accomplished through insertion, preferably followed by imprecise excision, of transposable elements (Plasterk, 1992, *Bioessays* 14(9): 629-633; Zwaal *et al.*, 1993, *Proc. Natl. Acad. Sci. USA* 90(16): 7431-7435; Clark *et al.*, 1994, *Proc. Natl. Acad. Sci. USA* 91(2): 719-722; all of which are incorporated by reference herein), or through 20 homologous recombination, preferably detected by positive/negative genetic selection strategies (Mansour *et al.*, 1988, *Nature* 336: 348-352; U.S. Patent Nos. 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,614,396; 5,616,491; and 5,679,523; all of which are incorporated by reference herein). These organisms with altered gene expression are preferably eukaryotes and more preferably are mammals. Such organisms are useful for the development of non-human models 25 for the study of disorders involving the corresponding gene(s), and for the development of assay systems for the identification of molecules that interact with the protein product(s) of the corresponding gene(s).

Where the protein of the present invention is membrane-bound (e.g., is a receptor), the present invention also provides for soluble forms of such protein. In such forms, part or all of the 30 intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed. The intracellular and transmembrane domains of proteins of the invention can be identified in accordance with known techniques for determination of such domains from sequence information. For example, the TopPredII computer program can be used to predict the location of transmembrane domains in an amino acid sequence, domains

which are described by the location of the center of the transmembrane domain, with at least ten transmembrane amino acids on each side of the reported central residue(s).

Proteins and protein fragments of the present invention include proteins with amino acid sequence lengths that are at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Also included in the present invention are proteins and protein fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins.

In particular, sequence identity may be determined using WU-BLAST (Washington University BLAST) version 2.0 software, which builds upon WU-BLAST version 1.4, which in turn is based on the public domain NCBI-BLAST version 1.4 (Altschul and Gish, 1996, Local alignment statistics, Doolittle *ed.*, *Methods in Enzymology* 266: 460-480; Altschul *et al.*, 1990, Basic local alignment search tool, *Journal of Molecular Biology* 215: 403-410; Gish and States, 1993, Identification of protein coding regions by database similarity search, *Nature Genetics* 3: 266-272; Karlin and Altschul, 1993, Applications and statistics for multiple high-scoring segments in molecular sequences, *Proc. Natl. Acad. Sci. USA* 90: 5873-5877; all of which are incorporated by reference herein). WU-BLAST version 2.0 executable programs for several UNIX platforms can be downloaded from <ftp://blast.wustl.edu/blast/executables>. The complete suite of search programs (BLASTP, BLASTN, BLASTX, TBLASTN, and TBLASTX) is provided at that site, in addition to several support programs. WU-BLAST 2.0 is copyrighted and may not be sold or redistributed in any form or manner without the express written consent of the author; but the posted executables may otherwise be freely used for commercial, nonprofit, or academic purposes. In all search programs in the suite -- BLASTP, BLASTN, BLASTX, TBLASTN and TBLASTX -- the gapped alignment routines are integral to the database search itself, and thus yield much better sensitivity and selectivity while producing the more easily interpreted output. Gapping can optionally be turned off in all of these programs, if desired. The default penalty (Q) for a gap of length one is Q=9 for proteins

and BLASTP, and Q=10 for BLASTN, but may be changed to any integer value including zero, one through eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. The default per-residue penalty for extending a gap (R) is R=2 for proteins and BLASTP, and R=10 for BLASTN, but may be changed to any integer value including zero, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. Any combination of values for Q and R can be used in order to align sequences so as to maximize overlap and identity while minimizing sequence gaps. The default amino acid comparison matrix is BLOSUM62, but other amino acid comparison matrices such as PAM can be utilized.

Species homologues of the disclosed polynucleotides and proteins are also provided by the present invention. As used herein, a "species homologue" is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide. Preferably, polynucleotide species homologues have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, and protein species homologues have at least 30% sequence identity (more preferably, at least 45% identity; most preferably at least 60% identity) with the given protein, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides or the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Species homologues may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species. Preferably, species homologues are those isolated from mammalian species. Most preferably, species homologues are those isolated from certain mammalian species such as, for example, *Pan troglodytes*, *Gorilla gorilla*, *Pongo pygmaeus*, *Hylobates concolor*, *Macaca mulatta*, *Papio papio*, *Papio hamadryas*, *Cercopithecus aethiops*, *Cebus capucinus*, *Aotus trivirgatus*, *Sanguinus oedipus*, *Microcebus murinus*, *Mus musculus*, *Rattus norvegicus*, *Cricetulus griseus*, *Felis catus*, *Mustela vison*, *Canis familiaris*, *Oryctolagus cuniculus*, *Bos taurus*, *Ovis aries*, *Sus scrofa*, and *Equus caballus*, for which genetic maps have been created allowing the identification of syntenic relationships between the genomic organization of genes in one species and the genomic organization of the related genes in another species (O'Brien and Seuánez, 1988, *Ann. Rev. Genet.* 22: 323-351; O'Brien *et al.*, 1993, *Nature Genetics* 3:103-112; Johansson *et al.*, 1995, *Genomics* 25: 682-690; Lyons *et al.*, 1997, *Nature Genetics* 15: 47-56; O'Brien *et al.*, 1997, *Trends in Genetics* 13(10): 393-399; Carver and Stubbs, 1997, *Genome Research* 7:1123-1137; all of which are incorporated by reference herein).

The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotides which also encode proteins which are identical or have significantly similar sequences to those encoded by the disclosed polynucleotides. Preferably, allelic variants have at least 60% sequence identity
5 (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps. Allelic variants may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic
10 acid source from individuals of the appropriate species.

The invention also includes polynucleotides with sequences complementary to those of the polynucleotides disclosed herein.

The present invention also includes polynucleotides that hybridize under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent
15 conditions, to polynucleotides described herein. Examples of stringency conditions are shown in the table below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

Stringency Condition	Polynucleotide Hybrid	Hybrid Length (bp) [‡]	Hybridization Temperature and Buffer [†]	Wash Temperature and Buffer [†]
5	A	≥ 50	65°C; 1xSSC -or- 42°C; 1xSSC, 50% formamide	65°C; 0.3xSSC
	B	<50	T _B *; 1xSSC	T _B *; 1xSSC
	C	≥ 50	67°C; 1xSSC -or- 45°C; 1xSSC, 50% formamide	67°C; 0.3xSSC
	D	<50	T _D *; 1xSSC	T _D *; 1xSSC
	E	≥ 50	70°C; 1xSSC -or- 50°C; 1xSSC, 50% formamide	70°C; 0.3xSSC
	F	<50	T _F *; 1xSSC	T _F *; 1xSSC
10	G	≥ 50	65°C; 4xSSC -or- 42°C; 4xSSC, 50% formamide	65°C; 1xSSC
	H	<50	T _H *; 4xSSC	T _H *; 4xSSC
	I	≥ 50	67°C; 4xSSC -or- 45°C; 4xSSC, 50% formamide	67°C; 1xSSC
	J	<50	T _J *; 4xSSC	T _J *; 4xSSC
	K	≥ 50	70°C; 4xSSC -or- 50°C; 4xSSC, 50% formamide	67°C; 1xSSC
	L	<50	T _L *; 2xSSC	T _L *; 2xSSC
15	M	≥ 50	50°C; 4xSSC -or- 40°C; 6xSSC, 50% formamide	50°C; 2xSSC
	N	<50	T _N *; 6xSSC	T _N *; 6xSSC
	O	≥ 50	55°C; 4xSSC -or- 42°C; 6xSSC, 50% formamide	55°C; 2xSSC
	P	<50	T _P *; 6xSSC	T _P *; 6xSSC
	Q	≥ 50	60°C; 4xSSC -or- 45°C; 6xSSC, 50% formamide	60°C; 2xSSC
	R	<50	T _R *; 4xSSC	T _R *; 4xSSC

[‡]: The hybrid length is that anticipated for the hybridized region(s) of the hybridizing polynucleotides. When hybridizing a polynucleotide to a target polynucleotide of unknown sequence, the hybrid length is assumed to be that of the hybridizing polynucleotide. When polynucleotides of known sequence are hybridized, the hybrid length can be determined by aligning the sequences of the polynucleotides and identifying the region or regions of optimal sequence complementarity.

[†]: SSPE (1xSSPE is 0.15M NaCl, 10mM NaH₂PO₄, and 1.25mM EDTA, pH 7.4) can be substituted for SSC (1xSSC is 0.15M NaCl and 15mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes after hybridization is complete.

*T_B - T_R: The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature (T_m) of the hybrid, where T_m is determined according to the following equations. For hybrids less than 18 base pairs in length, T_m(°C) = 2(# of A + T bases) + 4(# of G + C bases). For hybrids between 18 and 49 base pairs in length, T_m(°C) = 81.5 + 16.6(log₁₀[Na⁺]) + 0.41(%G+C) - (600/N), where N is the number of bases in the hybrid, and [Na⁺] is the concentration of sodium ions in the hybridization buffer ([Na⁺] for 1xSSC = 0.165 M).

35

Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E.F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning: A Laboratory*

Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11, and *Current Protocols in Molecular Biology*, 1995, F.M. Ausubel et al., eds., John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.

5 Preferably, each such hybridizing polynucleotide has a length that is at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as
10 to maximize overlap and identity while minimizing sequence gaps.

The isolated polynucleotide encoding the protein of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman *et al.*, *Nucleic Acids Res.* 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General
15 methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, *Methods in Enzymology* 185, 537-566 (1990). As defined herein "operably linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

20 A number of types of cells may act as suitable host cells for expression of the protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from *in vitro* culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK
25 or Jurkat cells.

Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include
30 *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium*, or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.

The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, *e.g.*, Invitrogen, San Diego, California, U.S.A. (the
5 MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."

The protein of the invention may be prepared by culturing transformed host cells under
10 culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (*i.e.*, from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-
15 toyopearl® or Cibacrom blue 3GA Sepharose®; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.

Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of
20 maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLabs (Beverly, MA), Pharmacia (Piscataway, NJ) and Invitrogen Corporation (Carlsbad, CA), respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available
25 from the Eastman Kodak Company (New Haven, CT).

Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, *e.g.*, silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially
30 homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."

The protein of the invention may also be expressed as a product of transgenic animals, *e.g.*, as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized
35 by somatic or germ cells containing a nucleotide sequence encoding the protein.

The protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means, are known to those skilled in the art. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess
5 biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

The proteins provided herein also include proteins characterized by amino acid sequences
10 similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues
15 may be deleted or replaced with another amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Patent No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein.

Other fragments and derivatives of the sequences of proteins which would be expected
20 to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are believed to be encompassed by the present invention.

USES AND BIOLOGICAL ACTIVITY

25 The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction
30 of DNA).

Research Uses and Utilities

The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein
35 for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding

protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, those described in Gyuris *et al.*, 1993, *Cell* 75: 791-803 and in Rossi *et al.*, 1997, *Proc. Natl. Acad. Sci. USA* 94: 8405-8410, all of which are incorporated by reference herein) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.

The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E.F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R. Kimmel eds., 1987.

Nutritional Uses

Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate.

5 In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.

10

Cytokine and Cell Proliferation/Differentiation Activity

A protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. Many protein factors discovered to date,

15 including all known cytokines, have exhibited activity in one or more factor-dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DA1, 123, T1165, HT2,

20 CTLL2, TF-1, Mo7e and CMK. The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for T-cell or thymocyte proliferation include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In

25 Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Bertagnolli et al., J. Immunol. 145:1706-1712, 1990; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Bertagnolli, et al., J. Immunol. 149:3778-3783, 1992; Bowman et al., J. Immunol. 152: 1756-1761, 1994.

Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or

30 thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A.M. and Shevach, E.M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon γ , Schreiber, R.D. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991;

5 deVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al., Nature 336:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci. U.S.A. 80:2931-2938, 1983; Measurement of mouse and human interleukin 6 - Nordan, R. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., Proc. Natl. Acad. Sci. U.S.A. 83:1857-1861, 1986; Measurement of human Interleukin 11 - Bennett, F., Giannotti, J., Clark,

10 S.C. and Turner, K. J. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Measurement of mouse and human Interleukin 9 - Ciarletta, A., Giannotti, J., Clark, S.C. and Turner, K.J. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

Assays for T-cell clone responses to antigens (which will identify, among others, proteins

15 that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic

20 studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.

Immune Stimulating or Suppressing Activity

25 A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells

30 and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases caused by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as

candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, *i.e.*, in the treatment of cancer.

Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, 5 rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein of the present invention may also to be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression 10 is desired (including, for example, organ transplantation), may also be treatable using a protein of the present invention.

Using the proteins of the invention it may also be possible to regulate immune responses in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The 15 functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists 20 after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as, for example, B7)), *e.g.*, preventing high level 25 lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule 30 which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (*e.g.*, B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the 35 corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter

prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins *in vivo* as described in Lenschow *et al.*, Science 257:789-792 (1992) and Turka *et al.*, Proc. Natl. Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function *in vivo* on the development of that disease.

Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in MRL/lpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).

Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral

diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.

Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells *in vitro* with viral antigen-pulsed
5 APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the *in vitro* activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and
10 reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells *in vivo*.

In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a
15 nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected *ex vivo* with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7-3-like
20 activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection *in vivo*.

The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells
25 to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I α chain protein and β_2 microglobulin protein or an MHC class II α chain protein and an MHC
30 class II β chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant
35 chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B

lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, *In Vitro* assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., *Proc. Natl. Acad. Sci. USA* 78:2488-2492, 1981; Herrmann et al., *J. Immunol.* 128:1968-1974, 1982; Handa et al., *J. Immunol.* 135:1564-1572, 1985; Takai et al., *J. Immunol.* 137:3494-3500, 1986; Takai et al., *J. Immunol.* 140:508-512, 1988; Herrmann et al., *Proc. Natl. Acad. Sci. USA* 78:2488-2492, 1981; Herrmann et al., *J. Immunol.* 128:1968-1974, 1982; Handa et al., *J. Immunol.* 135:1564-1572, 1985; Takai et al., *J. Immunol.* 137:3494-3500, 1986; Bowman et al., *J. Virology* 61:1992-1998; Takai et al., *J. Immunol.* 140:508-512, 1988; Bertagnolli et al., *Cellular Immunology* 133:327-341, 1991; Brown et al., *J. Immunol.* 153:3079-3092, 1994.

Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, *J. Immunol.* 144:3028-3033, 1990; and Assays for B cell function: *In vitro* antibody production, Mond, J.J. and Brunswick, M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, *In Vitro* assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., *J. Immunol.* 137:3494-3500, 1986; Takai et al., *J. Immunol.* 140:508-512, 1988; Bertagnolli et al., *J. Immunol.* 149:3778-3783, 1992.

Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., *J. Immunol.* 134:536-544, 1995; Inaba et al., *Journal of Experimental Medicine* 173:549-559, 1991; Macatonia et al., *Journal of Immunology* 154:5071-5079, 1995; Porgador et al., *Journal of Experimental Medicine* 182:255-260, 1995; Nair et al., *Journal of Virology*

67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.

Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992.

Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad Sci. USA 88:7548-7551, 1991.

Hematopoiesis Regulating Activity

A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either *in-vivo* or *ex-vivo* (i.e., in conjunction with bone marrow

transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.

The activity of a protein of the invention may, among other means, be measured by the following methods:

5 Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. *Cellular Biology* 15:141-151, 1995; Keller et al., *Molecular and*
10 *Cellular Biology* 13:473-486, 1993; McClanahan et al., *Blood* 81:2903-2915, 1993.

Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hirayama et al.,
15 *Proc. Natl. Acad. Sci. USA* 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I.K. and Briddell, R.A. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, NY. 1994; Neben et al., *Experimental Hematology* 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R.E. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 1-21,
20 Wiley-Liss, Inc., New York, NY. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, NY. 1994; Long term culture initiating cell assay, Sutherland, H.J. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, NY. 1994.

25

Tissue Growth Activity

A protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.

30 A protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. *De novo* bone formation induced by an

osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming
5 cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

10 Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a
15 tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also
20 useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors *ex vivo* for return *in vivo* to effect tissue repair. The compositions of the invention
25 may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, *i.e.* for the treatment of central and peripheral
30 nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral
35 sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with

the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.

Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity.

A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium).

Assays for wound healing activity include, without limitation, those described in: Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71:382-84 (1978).

Activin/Inhibin Activity

A protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin α family, may be useful as a contraceptive based on the ability of

inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin- β group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, United States Patent 4,798,885. A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., *Endocrinology* 91:562-572, 1972; Ling et al., *Nature* 321:779-782, 1986; Vale et al., *Nature* 321:776-779, 1986; Mason et al., *Nature* 318:659-663, 1985; Forage et al., *Proc. Natl. Acad. Sci. USA* 83:3091-3095, 1986.

Chemotactic/Chemokinetic Activity

A protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.

A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation,

those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al. APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25: 1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153: 1762-1768, 1994.

Hemostatic and Thrombolytic Activity

A protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.

Receptor/Ligand Activity

A protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for receptor-ligand activity include without limitation those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 1995.

10

Anti-Inflammatory Activity

Proteins of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions, including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.

25

Cadherin/Tumor Invasion Suppressor Activity

Cadherins are calcium-dependent adhesion molecules that appear to play major roles during development, particularly in defining specific cell types. Loss or alteration of normal cadherin expression can lead to changes in cell adhesion properties linked to tumor growth and metastasis. Cadherin malfunction is also implicated in other human diseases, such as pemphigus vulgaris and pemphigus foliaceus (auto-immune blistering skin diseases), Crohn's disease, and some developmental abnormalities.

The cadherin superfamily includes well over forty members, each with a distinct pattern of expression. All members of the superfamily have in common conserved extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule. The

35

cadherin domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the first cadherin domain provide the basis for homophilic adhesion; modification of this recognition site can change the specificity of a cadherin so that instead of recognizing only itself, the mutant molecule can now also bind to a different cadherin. In addition, some cadherins engage in heterophilic adhesion with other cadherins.

E-cadherin, one member of the cadherin superfamily, is expressed in epithelial cell types. Pathologically, if E-cadherin expression is lost in a tumor, the malignant cells become invasive and the cancer metastasizes. Transfection of cancer cell lines with polynucleotides expressing E-cadherin has reversed cancer-associated changes by returning altered cell shapes to normal, restoring cells' adhesiveness to each other and to their substrate, decreasing the cell growth rate, and drastically reducing anchorage-independent cell growth. Thus, reintroducing E-cadherin expression reverts carcinomas to a less advanced stage. It is likely that other cadherins have the same invasion suppressor role in carcinomas derived from other tissue types. Therefore, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to treat cancer. Introducing such proteins or polynucleotides into cancer cells can reduce or eliminate the cancerous changes observed in these cells by providing normal cadherin expression.

Cancer cells have also been shown to express cadherins of a different tissue type than their origin, thus allowing these cells to invade and metastasize in a different tissue in the body. Proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be substituted in these cells for the inappropriately expressed cadherins, restoring normal cell adhesive properties and reducing or eliminating the tendency of the cells to metastasize.

Additionally, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to generate antibodies recognizing and binding to cadherins. Such antibodies can be used to block the adhesion of inappropriately expressed tumor-cell cadherins, preventing the cells from forming a tumor elsewhere. Such an anti-cadherin antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be detected by the use of a cadherin-binding antibody.

Fragments of proteins of the present invention with cadherin activity, preferably a polypeptide comprising a decapeptide of the cadherin recognition site, and polynucleotides of the present invention encoding such protein fragments, can also be used to block cadherin function by binding to cadherins and preventing them from binding in ways that produce undesirable effects. Additionally, fragments of proteins of the present invention with cadherin activity,

preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer patients, and polynucleotides encoding such protein fragments, can be used to disturb proper cell-cell adhesion.

Assays for cadherin adhesive and invasive suppressor activity include, without limitation, those described in: Hortsch et al. J Biol Chem 270 (32): 18809-18817, 1995; Miyaki et al. Oncogene 11: 2547-2552, 1995; Ozawa et al. Cell 63: 1033-1038, 1990.

Tumor Inhibition Activity

In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via antibody-dependent cell-mediated cytotoxicity (ADCC)). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.

Other Activities

A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an

immune response against such protein or another material or entity which is cross-reactive with such protein.

ADMINISTRATION AND DOSING

5 A protein of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources) may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable"

10 means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN, TNF0, TNF1, TNF2,

15 G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. The pharmaceutical composition may further contain other agents which either enhance the activity of the protein or compliment its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein of the invention, or to minimize side effects. Conversely, protein of the present invention may be included in

20 formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.

 A protein of the present invention may be active in multimers (e.g., heterodimers or

25 homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.

 The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will

30 respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with

35 co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind

surface immunoglobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.

The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No. 4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.

As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated. Protein of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.

Administration of protein of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous,

intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred.

When a therapeutically effective amount of protein of the present invention is administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and preferably from about 25 to 90% protein of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention.

When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

The amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 μ g

to about 100 mg (preferably about 0.1 mg to about 10 mg, more preferably about 0.1 μ g to about 1 mg) of protein of the present invention per kg body weight.

The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.

Protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the protein. As used herein, the term "antibody" includes without limitation a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a single-chain antibody, a CDR-grafted antibody, a humanized antibody, or fragments thereof which bind to the indicated protein. Such term also includes any other species derived from an antibody or antibody sequence which is capable of binding the indicated protein.

Antibodies to a particular protein can be produced by methods well known to those skilled in the art. For example, monoclonal antibodies can be produced by generation of antibody-producing hybridomas in accordance with known methods (see for example, Goding, 1983, *Monoclonal antibodies: principles and practice*, Academic Press Inc., New York; and Yokoyama, 1992, "Production of Monoclonal Antibodies" in *Current Protocols in Immunology*, Unit 2.5, Greene Publishing Assoc. and John Wiley & Sons). Polyclonal sera and antibodies can be produced by inoculation of a mammalian subject with the relevant protein or fragments thereof in accordance with known methods. Fragments of antibodies, receptors, or other reactive peptides can be produced from the corresponding antibodies by cleavage of and collection of the desired fragments in accordance with known methods (see for example, Goding, *supra*; and Andrew et al., 1992, "Fragmentation of Immunoglobulins" in *Current Protocols in Immunology*, Unit 2.8, Greene Publishing Assoc. and John Wiley & Sons). Chimeric antibodies and single chain antibodies can also be produced in accordance with known recombinant methods (see for example, 5,169,939, 5,194,594, and 5,576,184). Humanized antibodies can also be made from corresponding murine antibodies in accordance with well known methods (see for

example, U.S. Patent Nos. 5,530,101, 5,585,089, and 5,693,762). Additionally, human antibodies may be produced in non-human animals such as mice that have been genetically altered to express human antibody molecules (see for example Fishwild *et al.*, 1996, *Nature Biotechnology* 14: 845-851; Mendez *et al.*, 1997, *Nature Genetics* 15: 146-156
5 (erratum *Nature Genetics* 16: 410); and U.S. Patents 5,877,397 and 5,625,126). Such antibodies may be obtained using either the entire protein or fragments thereof as an immunogen. The peptide immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Methods for synthesizing such peptides are known in the art, for example, as in R.P. Merrifield, J.
10 Amer.Chem.Soc. 85, 2149-2154 (1963); J.L. Krstenansky, *et al.*, FEBS Lett. 211, 10 (1987).

Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved.
15 In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the protein may be useful in detecting and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.

For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device. When administered, the therapeutic
20 composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein of the
25 invention which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing composition to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and
30 optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical applications.

The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular application of the compositions will define the appropriate formulation. Potential matrices for the compositions may
35 be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite,

polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.

Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns. In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix.

A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorption of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.

In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF- α and TGF- β), and insulin-like growth factor (IGF).

The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins of the present invention.

The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue

(e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final
5 composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline labeling.

Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either *in vivo* or *ex vivo* into cells for expression in a
10 mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA).

Cells may also be cultured *ex vivo* in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can
15 then be introduced *in vivo* for therapeutic purposes.

Patent and literature references cited herein are incorporated by reference as if fully set forth.

What is claimed is:

1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:41;
- (b) the nucleotide sequence of SEQ ID NO:41 from nucleotide 102 to nucleotide 2027;
- (c) the nucleotide sequence of SEQ ID NO:41 from nucleotide 1902 to nucleotide 2027;
- (d) the nucleotide sequence of SEQ ID NO:41 from nucleotide 1 to nucleotide 431;
- (e) the nucleotide sequence of the full-length protein coding sequence of clone BG160_1 deposited with the ATCC under accession number 98232;
- (f) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone BG160_1 deposited with the ATCC under accession number 98232;
- (g) the nucleotide sequence of a mature protein coding sequence of clone BG160_1 deposited with the ATCC under accession number 98232;
- (h) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone BG160_1 deposited with the ATCC under accession number 98232;
- (i) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:42;
- (j) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42, the fragment comprising eight contiguous amino acids of SEQ ID NO:42;
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(h); and
- (l) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(h), and that has a length that is at least 25% of the length of SEQ ID NO:41.

2. The polynucleotide of claim 1 wherein said polynucleotide is operably linked to at least one expression control sequence.

3. A host cell transformed with the polynucleotide of claim 2.

4. The host cell of claim 3, wherein said cell is a mammalian cell.
5. A process for producing a protein encoded by the polynucleotide of claim 2, which process comprises:
 - (a) growing a culture of a host cell in a suitable culture medium, wherein the host cell has been transformed with the polynucleotide of claim 2; and
 - (b) purifying said protein from the culture.
6. A protein produced according to the process of claim 5.
7. An isolated polynucleotide encoding the protein of claim 6.
8. The polynucleotide of claim 7, wherein the polynucleotide comprises the cDNA insert of clone BG160_1 deposited with the ATCC under accession number 98232.
9. A protein comprising an amino acid sequence selected from the group consisting of:
 - (a) the amino acid sequence of SEQ ID NO:42;
 - (b) the amino acid sequence of SEQ ID NO:42 from amino acid 1 to amino acid 110;
 - (c) a fragment of the amino acid sequence of SEQ ID NO:42, the fragment comprising eight contiguous amino acids of SEQ ID NO:42; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone BG160_1 deposited with the ATCC under accession number 98232;the protein being substantially free from other mammalian proteins.
10. The protein of claim 9, wherein said protein comprises the amino acid sequence of SEQ ID NO:42.
11. A composition comprising the protein of claim 9 and a pharmaceutically acceptable carrier.
12. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
 - (a) the nucleotide sequence of SEQ ID NO:129;

- (b) the nucleotide sequence of SEQ ID NO:129 from nucleotide 383 to nucleotide 3958;
- (c) the nucleotide sequence of SEQ ID NO:129 from nucleotide 470 to nucleotide 3958;
- (d) the nucleotide sequence of SEQ ID NO:129 from nucleotide 271 to nucleotide 488;
- (e) the nucleotide sequence of the full-length protein coding sequence of clone CO722_1 deposited with the ATCC under accession number 98271;
- (f) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone CO722_1 deposited with the ATCC under accession number 98271;
- (g) the nucleotide sequence of a mature protein coding sequence of clone CO722_1 deposited with the ATCC under accession number 98271;
- (h) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone CO722_1 deposited with the ATCC under accession number 98271;
- (i) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:130;
- (j) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:130, the fragment comprising eight contiguous amino acids of SEQ ID NO:130;
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(h); and
- (l) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(h), and that has a length that is at least 25% of the length of SEQ ID NO:129.

13. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:130;
- (b) the amino acid sequence of SEQ ID NO:130 from amino acid 1 to amino acid 34;
- (c) a fragment of the amino acid sequence of SEQ ID NO:130, the fragment comprising eight contiguous amino acids of SEQ ID NO:130; and

(d) the amino acid sequence encoded by the cDNA insert of clone CO722_1 deposited with the ATCC under accession number 98271; the protein being substantially free from other mammalian proteins.




Fig. 1A




Fig. 1B

SEQUENCE LISTING

<110> Jacobs, Kenneth
McCoy, John M.
LaVallie, Edward R.
Collins-Racie, Lisa A.
Evans, Cheryl
Merberg, David
Treacy, Maurice
Bowman, Michael R.
Spaulding, Vikki
Agostino, Michael J.
Genetics Institute, Inc.

<120> SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

<130> GI 6011-18X

<140>
<141>

<160> 283

<170> PatentIn Ver. 2.0

<210> 1
<211> 565
<212> DNA
<213> Homo sapiens

<220>
<221> unsure
<222> (20)

<220>
<221> unsure
<222> (49)

<220>
<221> unsure
<222> (58)

<220>
<221> unsure
<222> (144)

<220>
<221> unsure
<222> (178)

<220>
<221> unsure
<222> (215)

<220>
<221> unsure
<222> (218)

<220>
<221> unsure

<222> (228)

<220>

<221> unsure

<222> (239)

<220>

<221> unsure

<222> (541)

<400> 1

```

gattgtcagt ttccaaaaan gaggaggatt tgatattcac ttggcccgng gtgatgcntt 60
tgagggtggc cgcgtccatc tggtcagaaa agacaatctt tttgttgtca agcttgaggt 120
gtggcaggct tgagatcttg ccanacactt gaggacaat gacatccact ttgctttntc 180
tccacagggtg tccactccca ggtccaactg cagantnga attcggcntt catggcctnt 240
gaatagagac ttctggactc tatagaacct actgcctcct gatgaagtcc ctactgttca 300
cccttgcagt ttttatgctc ctggcccaat tggcttcagg taattggtat gtgaaaaagt 360
gtctaaacga cgttggaatt tgcaagaaga agtgcaaacc tgaagagatg catacaaaga 420
ctacaagaat ttcaacagta acagcaacaa cagtcaacaa caactttgat gatgactact 480
gcttcgatgt cttcgatggc tcttaccgtt ttctcccact ggtggaacat tcccagcctc 540
ngtctcctgc tctaggatcc cgcac                                     565

```

<210> 2

<211> 94

<212> PRT

<213> Homo sapiens

<220>

<221> UNSURE

<222> (87)

<400> 2

```

Met Lys Ser Leu Leu Phe Thr Leu Ala Val Phe Met Leu Leu Ala Gln
 1              5              10              15

Leu Val Ser Gly Asn Trp Tyr Val Lys Lys Cys Leu Asn Asp Val Gly
      20              25              30

Ile Cys Lys Lys Lys Cys Lys Pro Glu Glu Met His Thr Lys Thr Thr
      35              40              45

Arg Ile Ser Thr Val Thr Ala Thr Thr Val Asn Asn Asn Phe Asp Asp
      50              55              60

Asp Tyr Cys Phe Asp Val Phe Asp Gly Ser Tyr Pro Phe Leu Pro Leu
      65              70              75              80

Val Glu His Ser Gln Pro Xaa Ser Pro Ala Leu Gly Ser Pro
      85              90

```

<210> 3

<211> 92

<212> DNA

<213> Homo sapiens

<400> 3

```

aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 60
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa                                     92

```

<210> 4
 <211> 2949
 <212> DNA
 <213> Homo sapiens

<400> 4

```

acctgctgga acgctcggac gtccttgagg gccctgtcca tgtgaggtcc aggtcatctc 60
ccgccaccgc agacaagcgc caggatgtgc ttttggggca agacagtggc tttggtcttg 120
tgaaggatcc atgttatattg gctggtcctg gatctaggtc actcagttgt tcagaaagag 180
gccaagaaga gatgctgccg ctcttccacc atctcaccac tcgttggggg gggttcaggct 240
gcaaagccat tgggtgattcc tccgttccta gtgaatgtcc tggaaccctg gaccatcaga 300
ggcaagccag taggacaccc tgccccaggc caccactggc aggaacgcaa gggctgggtca 360
cagacaccag ggctgcaccc ctgaccccaa ttggcacccc tctgccttca gccattccct 420
ctggctactg ctcacaggac ggtcagacag ggcgacagcc tctcccgcct tacaccctg 480
ccatgatgca cagaagcaat ggtcacaccc tgaccagacc tcccgggtcca agaggctgtg 540
agggcgatgg cccagagcat ggggtagaag agggaaacag gaagaggggt tcgctgcctc 600
agtggccacc tccttctcga gcaaagtggg cccacgcagc cagagaggac agccttcctg 660
aggaatcctc agcccctgat tttgcaaacc tgaagcacta tcaaaaacag cagagtcttc 720
caagtctatg cagcacttct gaccagaca cactctctgg ggcccgcagc actccaggga 780
ggatctccct ccgaatatct gagtctgtcc tgcgggactc cccgccacct catgaggatt 840
atgaagacga agtgtttgtg agggatccgc accccaaggc cagctccagc cccacatttg 900
aacctcttcc cccaccccca cctcctccac cgagtcagga aaccccggtg tatakcatgg 960
atgacttccc tccacctcct cccacactg tatgtgaggc gcagctggac agtgaggatc 1020
ccgagggggc acgcccagc ttcaacaac tttctaaagt gacaattgca agggaaaggc 1080
acatgcctgg tgcagcccat gtggtaggta gtcagacacc ggcttccaga ctccaaactt 1140
ctatcaaggg ttcagaggct gagtccacac caccctcctc catgagcgtt cagcccaac 1200
ttgctgggtc tcttgggtgg cagccagcac ccatccagac tcaaagcctc agccatgatc 1260
cagtcagtgg aactcagggt ttagaaaaga aagtcagtcc tgatcctcag aagagttcag 1320
aagacatcag aacagaggct ttggccaagg aaattgtcca ccaagacaaa tctctagcag 1380
acattttgga tccagactcc aggtgaaga caacaatgga cctgatggaa gggtttgttc 1440
cccagatgtg gaacttgctg aagggaaaaca gtgtaaagag gaaggccata cagagaactg 1500
tcagctcttc aggatgtgaa ggcaagagga atgaagacaa ggaagcagtg agcatgttgg 1560
ttaactgccc tgcctactac agtgtgtctg ctcccaaggc tgagctactg aacaaaatca 1620
aagagatgcc agcagaagtg aatgaggaag aggaacaggc agatgtcaat gaaaagaagg 1680
ctgagctcat tggaaagtct acccacaagc tggagacctt ccaggaggcg aaggggagcc 1740
tgctcacgga catcaagctc aacaacgccc tgggagaaga ggtggaggct ctgatcagcg 1800
agctctgcaa gcccaatgag ttgacaagt ataggatgtt cataggggat ttggacaagg 1860
tgggtcaacct gctgctctcc ctctcggggc gtctagcccg tgttgagaat gtccttagcg 1920
gccttggtga agatgccagt aatgaagaaa ggagctctct ttacgagaaa aggaagatcc 1980
tggctgggtc gcatgaggat gccggggagc tgaaggagaa cctggatcgc agggagcgag 2040
tagtgctggg catcttggcc aattacctt cagaggagca gctccaggac taccagcact 2100
tcgtgaaaat gaagtccacg ctctcattg agcaacggaa gctggatgac aagatcaagc 2160
tggggccagga gcagggtcaag tgtctgctgg agagcctgcc ctcagatttc attcccaagg 2220
ctggggccct ggctctgccc ccaaacctca cgagtgaagg cattcctgct gggggctgta 2280
ctttcagtggt tattttccca acattaacct ctccacttta acctcttcta aaatacccaa 2340
ccaaaagatc actgtttctc tcaacactat ttaatctgaa aaatgtttca gtacaaacca 2400
ctgtttgaac tatctgggtt attggtgttt gttcctgatg aaaggaaaaa aattctctcc 2460
aggaggaagc ctttttcctt cttgcccttc ctgattgatc ttctgagagc tcgaatgctg 2520
ctggacacgt accccttcta ttattacttt gtagtagaaa gaaagttaat gaaactgaga 2580
actgattgga ggggtgtttga tcatttagtt tttaacaggc tgaggcaaca tggatcagtg 2640
tgtgtccccc tcaggaatgt atccacagtg gccttccttg ctggtgggca gtgtatcctg 2700
atggcagggt acaagtacca ttaatgaagg gtctgcaaca taaagcctta aaaagacaca 2760
cactaagaaa actgtaaaac cttgaacatt gttatttata ttttttaaaa tggaaaagat 2820
cactatgttt gttgtgctaa ccacttattt gattctgttt tgtggtggac atagatgatt 2880
acgtttgagc tttgtatttt gtgaaaacct taatgaaatg aattccaaag ataaaaaaaa 2940
aaaaaaaaa 2949

```

<210> 5
 <211> 709
 <212> PRT

<213> Homo sapiens

<220>

<221> UNSURE

<222> (255)

<400> 5

Met Leu Pro Leu Phe His His Leu Thr Pro Arg Trp Gly Gly Ser Gly
 1 5 10 15

Cys Lys Ala Ile Gly Asp Ser Ser Val Pro Ser Glu Cys Pro Gly Thr
 20 25 30

Leu Asp His Gln Arg Gln Ala Ser Arg Thr Pro Cys Pro Arg Pro Pro
 35 40 45

Leu Ala Gly Thr Gln Gly Leu Val Thr Asp Thr Arg Ala Ala Pro Leu
 50 55 60

Thr Pro Ile Gly Thr Pro Leu Pro Ser Ala Ile Pro Ser Gly Tyr Cys
 65 70 75 80

Ser Gln Asp Gly Gln Thr Gly Arg Gln Pro Leu Pro Pro Tyr Thr Pro
 85 90 95

Ala Met Met His Arg Ser Asn Gly His Thr Leu Thr Gln Pro Pro Gly
 100 105 110

Pro Arg Gly Cys Glu Gly Asp Gly Pro Glu His Gly Val Glu Glu Gly
 115 120 125

Thr Arg Lys Arg Val Ser Leu Pro Gln Trp Pro Pro Pro Ser Arg Ala
 130 135 140

Lys Trp Ala His Ala Ala Arg Glu Asp Ser Leu Pro Glu Glu Ser Ser
 145 150 155 160

Ala Pro Asp Phe Ala Asn Leu Lys His Tyr Gln Lys Gln Gln Ser Leu
 165 170 175

Pro Ser Leu Cys Ser Thr Ser Asp Pro Asp Thr Pro Leu Gly Ala Pro
 180 185 190

Ser Thr Pro Gly Arg Ile Ser Leu Arg Ile Ser Glu Ser Val Leu Arg
 195 200 205

Asp Ser Pro Pro Pro His Glu Asp Tyr Glu Asp Glu Val Phe Val Arg
 210 215 220

Asp Pro His Pro Lys Ala Thr Ser Ser Pro Thr Phe Glu Pro Leu Pro
 225 230 235 240

Pro Pro Pro Pro Pro Pro Pro Ser Gln Glu Thr Pro Val Tyr Xaa Met
 245 250 255

Asp Asp Phe Pro Pro Pro Pro Pro His Thr Val Cys Glu Ala Gln Leu
 260 265 270

Asp Ser Glu Asp Pro Glu Gly Pro Arg Pro Ser Phe Asn Lys Leu Ser
 275 280 285

Lys Val Thr Ile Ala Arg Glu Arg His Met Pro Gly Ala Ala His Val
 290 295 300
 Val Gly Ser Gln Thr Leu Ala Ser Arg Leu Gln Thr Ser Ile Lys Gly
 305 310 315 320
 Ser Glu Ala Glu Ser Thr Pro Pro Ser Phe Met Ser Val His Ala Gln
 325 330 335
 Leu Ala Gly Ser Leu Gly Gly Gln Pro Ala Pro Ile Gln Thr Gln Ser
 340 345 350
 Leu Ser His Asp Pro Val Ser Gly Thr Gln Gly Leu Glu Lys Lys Val
 355 360 365
 Ser Pro Asp Pro Gln Lys Ser Ser Glu Asp Ile Arg Thr Glu Ala Leu
 370 375 380
 Ala Lys Glu Ile Val His Gln Asp Lys Ser Leu Ala Asp Ile Leu Asp
 385 390 395 400
 Pro Asp Ser Arg Leu Lys Thr Thr Met Asp Leu Met Glu Gly Leu Phe
 405 410 415
 Pro Arg Asp Val Asn Leu Leu Lys Glu Asn Ser Val Lys Arg Lys Ala
 420 425 430
 Ile Gln Arg Thr Val Ser Ser Ser Gly Cys Glu Gly Lys Arg Asn Glu
 435 440 445
 Asp Lys Glu Ala Val Ser Met Leu Val Asn Cys Pro Ala Tyr Tyr Ser
 450 455 460
 Val Ser Ala Pro Lys Ala Glu Leu Leu Asn Lys Ile Lys Glu Met Pro
 465 470 475 480
 Ala Glu Val Asn Glu Glu Glu Gln Ala Asp Val Asn Glu Lys Lys
 485 490 495
 Ala Glu Leu Ile Gly Ser Leu Thr His Lys Leu Glu Thr Leu Gln Glu
 500 505 510
 Ala Lys Gly Ser Leu Leu Thr Asp Ile Lys Leu Asn Asn Ala Leu Gly
 515 520 525
 Glu Glu Val Glu Ala Leu Ile Ser Glu Leu Cys Lys Pro Asn Glu Phe
 530 535 540
 Asp Lys Tyr Arg Met Phe Ile Gly Asp Leu Asp Lys Val Val Asn Leu
 545 550 555 560
 Leu Leu Ser Leu Ser Gly Arg Leu Ala Arg Val Glu Asn Val Leu Ser
 565 570 575
 Gly Leu Gly Glu Asp Ala Ser Asn Glu Glu Arg Ser Ser Leu Tyr Glu
 580 585 590
 Lys Arg Lys Ile Leu Ala Gly Gln His Glu Asp Ala Arg Glu Leu Lys
 595 600 605

Glu Asn Leu Asp Arg Arg Glu Arg Val Val Leu Gly Ile Leu Ala Asn
 610 615 620
 Tyr Leu Ser Glu Glu Gln Leu Gln Asp Tyr Gln His Phe Val Lys Met
 625 630 635 640
 Lys Ser Thr Leu Leu Ile Glu Gln Arg Lys Leu Asp Asp Lys Ile Lys
 645 650 655
 Leu Gly Gln Glu Gln Val Lys Cys Leu Leu Glu Ser Leu Pro Ser Asp
 660 665 670
 Phe Ile Pro Lys Ala Gly Ala Leu Ala Leu Pro Pro Asn Leu Thr Ser
 675 680 685
 Glu Pro Ile Pro Ala Gly Gly Cys Thr Phe Ser Gly Ile Phe Pro Thr
 690 695 700
 Leu Thr Ser Pro Leu
 705

<210> 6
 <211> 190
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (4)

<220>
 <221> unsure
 <222> (30)

<220>
 <221> unsure
 <222> (97)

<220>
 <221> unsure
 <222> (154)

<220>
 <221> unsure
 <222> (174)

<400> 6
 cgangcgtct gcacccacac gctcacgaan catcaggagc ctgtctatag cgtatctttc 60
 agccctgatg ggaagtactt ggccagtgga tccttcnaca agtgcgcca tatctggaat 120
 actcagagtg gaaatcttgt ccacagctac cgangcactg gcggcatctt ccangtgtgc 180
 tggaacgcc 190

<210> 7
 <211> 391
 <212> DNA
 <213> Homo sapiens

<400> 7

gagtggaaag gcagggggag gggcagggag caacagaagg aagagacaac aagcccaaga 60
 cagcttccat ttcagacgga aggccccag aagatagaat tccagccgac tgaaaaacca 120
 cccaatgaac aaagaagatt ttagaaaata gaaagctgtt gggattacaa agttgcgcgt 180
 ttcacggtta caaactgggtc tttgaacctc ctttgtgaga gcaattgtag tgtccaaatt 240
 gttagggaaa acaaaaaaaaaa aaaatcccaa ggaggagggt ttttccccct tccctgtttg 300
 gttatcaca gcattttgtt ttttttttgg cacagctttt tacgtttctt tccattcagc 360
 catcacagag cctgttccgg gtggaaacca a 391

<210> 8
 <211> 62
 <212> PRT
 <213> Homo sapiens

<400> 8
 Thr Ser Phe Val Arg Ala Ile Val Val Ser Lys Leu Leu Gly Lys Thr
 1 5 10 15
 Lys Lys Lys Asn Pro Lys Glu Glu Gly Phe Ser Pro Phe Pro Val Trp
 20 25 30
 Phe Ile Thr Ala Phe Cys Phe Phe Phe Gly Thr Ala Phe Tyr Val Ser
 35 40 45
 Phe His Ser Ala Ile Thr Glu Pro Val Pro Gly Gly Asn Gln
 50 55 60

<210> 9
 <211> 267
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (21)

<400> 9
 tctctctctc tctccctctg nacctttctc atagttgctt cagatcttag gtctcaaggg 60
 cactttggcg cgtagtaagt gctttatgta agaaggcagg gcaggggggc tttttacagg 120
 agaaaaaaaa atgacttata agagaaagag cctggagtat ttttgaaaaa aaaaataata 180
 tttttatgtt aaaacaattt taaaatctta aaatggccat cagacataga gagctttgtg 240
 tgattcatgt tttaaaaaaaa aaaaaaa 267

<210> 10
 <211> 2178
 <212> DNA
 <213> Homo sapiens

<400> 10
 cttttaacgg tcaactcggcc ttaarccgtc ctgggtgtat gtgaggctga aaggggaagga 60
 rgaacagggg ctgggcccgt gtgtgctctg ccgtcatctc taaraaacia ccataccact 120
 gaatgtact gtgtacttac aaaccacact catattcgtc acgtcatttc atcttcaccc 180
 ccacctcaa atgaggcttg aaatgaagat gaagatgttc ctcctcccc tttcaaccat 240
 ggacctcaca ctgtggactt cctcttagag cctctgagtt aggtacccaa gccaaaggac 300
 aatgtccctg cccccataa gactgcccag cccctatggc tctgatcggc tggtagagct 360
 agcagccagg ctccggccag cactctgtga tactctgate accgtaggga gccaggagtt 420
 ccccgccac agcctgggtg tagcagggtg cagccagcag ctgggcccga ggggccagt 480
 ggctctggga gaaggcatca gcccttctac ctttgcccag ctctgaact ttgtgtatgg 540
 ggagagtgtg gagctgcagc ctggagagct aaggccccct caggaggcgg ccagggcctt 600
 gggagtgcag tccctggaag aggcattgctg gagggctcga ggggacaggg ctaaaaagcc 660

```

agatccaggc ctgaagaaac atcaggagga gccagagaaa ccctcaagga atcctgagag 720
agaactgggg gaccctggag agaagcagaa accagaacag gtttctagaa ctggtgggag 780
agaacaggag atgttgcaca agcactcgcc accaagaggc agacccgaga tggcaggagc 840
aacgcaggag gctcagcagg aacagaccag gtcaaaggag aaacgcctcc aagcccctgt 900
tggccaaagg ggagcagatg ggaagcatgg agtgctcacg tggttgaggg aaaatccagg 960
gggctctgag gaaagtctgc gcaagctccc tggccccctt ccccagcag gctccctgca 1020
aaccagcgtc acccctaggc cctcgtgggc tgaggccctt tggttggtgg gggggccagcc 1080
tgccctgtgg agcatcctgc tgatgccgcc cagatatggc attcccttct accatagcac 1140
ccccaccact ggagcctggc aggaggtctg gcgggaacag aggatccac tgtccctaaa 1200
tgccccaaa gggctctgga gccagaacca gttggcctcc tccagcccta cccagggttc 1260
cctccccagc ggccccgcac agctcagccc tggggagatg gaagagtctg atcaggggca 1320
cacaggcgca cttgcaacct gtgcgggtca tgaggacaag gcaggctgcc cacctcgccc 1380
gcaccctccc ccggccccctc ctgctcggtc tcggccctat gcgtgctctg tctgtggaaa 1440
gaggttttca ctcaagcatc agatggagac gcactaccga gtccacacag gagagaagcc 1500
cttctcctgt agcctttgtc ctcagcgctc ccgggacttc tcggccatga ccaagcacct 1560
gcggacacac gggggccgctc cgtaccgctg ctccctgtgc ggggcccgtt gtcccagcct 1620
ggcctccatg caggcgcaca tgcgcgggtca ctgcgccagc caactcccgc ccggatggac 1680
catecgctcc accttcctct actcctcctc gaggcgctct cggccctcga cctctccctg 1740
ttgtccttct tcctccacca cctgacgggg tgtcggtagc gtcttagcca agagtccaat 1800
taaagaacga aaagcggggc ggctcgggtt ctgacctggc accgctgcta cggcggccta 1860
gcaaattccg ccccagaagc gcccaggaa gggcgccgag tgccctctcc tggacgatcg 1920
cgggtcgcag aagcccaggc cagcgagccc tacagagtga ggacactgaa gtgtgcagga 1980
gcgaaggtta acagtagggg agattgtcga tctcatcacc ataataaaga gtttcctgtt 2040
gccctccctt caaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2100
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2160
aaaaaaaaaa aaaaaaaa 2178

```

<210> 11

<211> 487

<212> PRT

<213> Homo sapiens

<400> 11

```

Met Ser Leu Pro Pro Ile Arg Leu Pro Ser Pro Tyr Gly Ser Asp Arg
  1             5             10             15

Leu Val Gln Leu Ala Ala Arg Leu Arg Pro Ala Leu Cys Asp Thr Leu
      20             25             30

Ile Thr Val Gly Ser Gln Glu Phe Pro Ala His Ser Leu Val Leu Ala
    35             40             45

Gly Val Ser Gln Gln Leu Gly Arg Arg Gly Gln Trp Ala Leu Gly Glu
    50             55             60

Gly Ile Ser Pro Ser Thr Phe Ala Gln Leu Leu Asn Phe Val Tyr Gly
    65             70             75             80

Glu Ser Val Glu Leu Gln Pro Gly Glu Leu Arg Pro Leu Gln Glu Ala
      85             90             95

Ala Arg Ala Leu Gly Val Gln Ser Leu Glu Glu Ala Cys Trp Arg Ala
    100            105            110

Arg Gly Asp Arg Ala Lys Lys Pro Asp Pro Gly Leu Lys Lys His Gln
    115            120            125

Glu Glu Pro Glu Lys Pro Ser Arg Asn Pro Glu Arg Glu Leu Gly Asp
    130            135            140

```

Pr Gly Glu Lys Gln Lys Pro Glu Gln Val Ser Arg Thr Gly Gly Arg
 145 150 155 160
 Glu Gln Glu Met Leu His Lys His Ser Pro Pro Arg Gly Arg Pro Glu
 165 170 175
 Met Ala Gly Ala Thr Gln Glu Ala Gln Gln Glu Gln Thr Arg Ser Lys
 180 185 190
 Glu Lys Arg Leu Gln Ala Pro Val Gly Gln Arg Gly Ala Asp Gly Lys
 195 200 205
 His Gly Val Leu Thr Trp Leu Arg Glu Asn Pro Gly Gly Ser Glu Glu
 210 215 220
 Ser Leu Arg Lys Leu Pro Gly Pro Leu Pro Pro Ala Gly Ser Leu Gln
 225 230 235 240
 Thr Ser Val Thr Pro Arg Pro Ser Trp Ala Glu Ala Pro Trp Leu Val
 245 250 255
 Gly Gly Gln Pro Ala Leu Trp Ser Ile Leu Leu Met Pro Pro Arg Tyr
 260 265 270
 Gly Ile Pro Phe Tyr His Ser Thr Pro Thr Thr Gly Ala Trp Gln Glu
 275 280 285
 Val Trp Arg Glu Gln Arg Ile Pro Leu Ser Leu Asn Ala Pro Lys Gly
 290 295 300
 Leu Trp Ser Gln Asn Gln Leu Ala Ser Ser Ser Pro Thr Pro Gly Ser
 305 310 315 320
 Leu Pro Gln Gly Pro Ala Gln Leu Ser Pro Gly Glu Met Glu Glu Ser
 325 330 335
 Asp Gln Gly His Thr Gly Ala Leu Ala Thr Cys Ala Gly His Glu Asp
 340 345 350
 Lys Ala Gly Cys Pro Pro Arg Pro His Pro Pro Pro Ala Pro Pro Ala
 355 360 365
 Arg Ser Arg Pro Tyr Ala Cys Ser Val Cys Gly Lys Arg Phe Ser Leu
 370 375 380
 Lys His Gln Met Glu Thr His Tyr Arg Val His Thr Gly Glu Lys Pro
 385 390 395 400
 Phe Ser Cys Ser Leu Cys Pro Gln Arg Ser Arg Asp Phe Ser Ala Met
 405 410 415
 Thr Lys His Leu Arg Thr His Gly Ala Ala Pro Tyr Arg Cys Ser Leu
 420 425 430
 Cys Gly Ala Gly Cys Pro Ser Leu Ala Ser Met Gln Ala His Met Arg
 435 440 445
 Gly His Ser Pro Ser Gln Leu Pro Pro Gly Trp Thr Ile Arg Ser Thr
 450 455 460

Phe Leu Tyr Ser Ser Ser Arg Pro Ser Arg Pro Ser Thr Ser Pro Cys
 465 470 475 480

Cys Pro Ser Ser Ser Thr Thr
 485

<210> 12

<211> 2436

<212> DNA

<213> Homo sapiens

<400> 12

```

caacaaccat ctacagctgt attcctgttc ccttgatggc acaattaaac tgtgggacta 60
tatagatggc atcttaataa agactttcat agttggatgt aaacttcatg ccctctttac 120
tcttgcccaa gctgaggatt ctgtctttgt tatagtgaat aaagaaaaac cagatatatt 180
tcagctgggt tcagtgaaac tgccaaaatc ctcaagccag gaagtagaag ccaaggagct 240
gtcctttgtt ttggattaca taaaccagtc acccaagtgc attgcctttg gaaacgaggg 300
agtatatgtt gctgcagtac ggggaattta cttgtctgtt tattttttca aaaagaaaaac 360
aacatcaagg ttactttat catcatcaag aaataagaag catgctaaaa acaattttac 420
gtgtgtagca tgtcacccaa cggaagactg catcgcatct ggtcacatgg atggcaaaat 480
tcgtcttttg aggaattttt atgatgataa gaaatatacg tacacatgtt tacattggca 540
ccatgatatg gttatggatt tggctttttc agtgacaggc accagtctgc tgagtggcgg 600
tcgtgaatct gtactttagt agtggcgcca tgcaacagag aagaataagg agtttctccc 660
gcgtttagga gctactatg aacatatctc agtctcgccc gcaggagatt tattctgcac 720
ttctcactct gataataaga taataattat tcaccgaaac cttgaagcat ccgcagtaat 780
tcaaggccta gtgaaagata ggagtatctt cactgggttg atgattgatc caagaactaa 840
agctttgggt ttgaatggaa aacctggcca cctgcagctt tattctctcc agagtataa 900
acagttatac aatttagata ttatacagca agaataatatt aatgattatg gtctgatcca 960
aattgaacta acaaaggctg catttggctg ctttggtaac tggcttgcaa cagtggaaac 1020
gcggcaagaa aaggaaactg agcttgaatt gcaaatgaaa ctgtggatgt ataataagaa 1080
aacacaaggg ttattctta acactaaaat taacatgcca cacgaagact gcattacagc 1140
tctctgttcc tgtaatgcag aaaaatctga acagcccacc ttgggttacag ctagcaaaga 1200
tggttacttc aaagtatgga tattaacaga tgactctgac atatacaaaa aagctgttgg 1260
ctggacctgt gactttgttg gtagttatca caagtatcaa gcaactaact gttgtttctc 1320
cgaagatggc tctttactag cagttagttt tgaggaaata gtcacaatat gggattctgt 1380
aacatgggaa cttaaatgta cattttgcca acgagctggg aaaataaggc acctttgctt 1440
tgggagattg acgtgttcaa agtatctact tgggtgctact gaaaatggca ttctttgctg 1500
ttggaatctg ctgagctgtg cattggagtg gaatgcaaaa ttaaagtgtta gagttatgga 1560
acccgatcct aattcagaga atattgctgc aatctctcag tcttcagtgg gttcagactt 1620
gtttgtattt aaacctagtg agccaaggcc attgtatatt caaaagggta tctccagaga 1680
gaaagtccag tggggagtgt ttgttccacg agatgtccct gaatccttca cctcagaagc 1740
ttaccagtgg ctaaatagat ccagtttta cttcctaaca aaatcacaga gtttattgac 1800
attcagtaca aagtctccag aagaaaaact cacaccaaca agcaaacagc tgctagcaga 1860
agaaagtctt cccacaaccc cattttattt catattggga aaacacaggc aacagcagga 1920
tgaaaaacta aacgaaactt tagagaatga gctgggtacaa ctacccttaa cagaaaacat 1980
acccgcaatt agtgagcttc ttcacactcc agcccatgtc ctgccatctg ctgctttcct 2040
gtgctccatg tttgtaaatt cattgctgct gtctaaagag actaagagtg ctaaggaaat 2100
tcctgaagat gtagatatgg aagaagaaaa agaaagtga gattcagatg aagaaaatga 2160
ttttaccgaa aaagtccagg atacaagtaa cacaggttta ggagaagaca ttatacatca 2220
gttgtaaaaa tctgaagaaa aagaactgag aaaatttagg aaaatagact acagctggat 2280
agctgccctt taagccttgg agatggggag gatccttgga ctttgtgttt ttgattgtat 2340
gttgatattc taaaaacatc tattttaatg ttatttctgt tctaaaaata agataataaa 2400
tattaacaaa ctttaaaaaa aaaaaaaaaa aaaaaa 2436

```

<210> 13

<211> 763

<212> PRT

<213> Homo sapiens

<400> 13

Asn Asn His Leu Gln Leu Tyr Ser Cys Ser Leu Asp Gly Thr Ile Lys
 1 5 10 15
 Leu Trp Asp Tyr Ile Asp Gly Ile Leu Ile Lys Thr Phe Ile Val Gly
 20 25 30
 Cys Lys Leu His Ala Leu Phe Thr Leu Ala Gln Ala Glu Asp Ser Val
 35 40 45
 Phe Val Ile Val Asn Lys Glu Lys Pro Asp Ile Phe Gln Leu Val Ser
 50 55 60
 Val Lys Leu Pro Lys Ser Ser Ser Gln Glu Val Glu Ala Lys Glu Leu
 65 70 75 80
 Ser Phe Val Leu Asp Tyr Ile Asn Gln Ser Pro Lys Cys Ile Ala Phe
 85 90 95
 Gly Asn Glu Gly Val Tyr Val Ala Ala Val Arg Glu Phe Tyr Leu Ser
 100 105 110
 Val Tyr Phe Phe Lys Lys Lys Thr Thr Ser Arg Phe Thr Leu Ser Ser
 115 120 125
 Ser Arg Asn Lys Lys His Ala Lys Asn Asn Phe Thr Cys Val Ala Cys
 130 135 140
 His Pro Thr Glu Asp Cys Ile Ala Ser Gly His Met Asp Gly Lys Ile
 145 150 155 160
 Arg Leu Trp Arg Asn Phe Tyr Asp Asp Lys Lys Tyr Thr Tyr Thr Cys
 165 170 175
 Leu His Trp His His Asp Met Val Met Asp Leu Ala Phe Ser Val Thr
 180 185 190
 Gly Thr Ser Leu Leu Ser Gly Gly Arg Glu Ser Val Leu Val Glu Trp
 195 200 205
 Arg Asp Ala Thr Glu Lys Asn Lys Glu Phe Leu Pro Arg Leu Gly Ala
 210 215 220
 Thr Ile Glu His Ile Ser Val Ser Pro Ala Gly Asp Leu Phe Cys Thr
 225 230 235 240
 Ser His Ser Asp Asn Lys Ile Ile Ile Ile His Arg Asn Leu Glu Ala
 245 250 255
 Ser Ala Val Ile Gln Gly Leu Val Lys Asp Arg Ser Ile Phe Thr Gly
 260 265 270
 Leu Met Ile Asp Pro Arg Thr Lys Ala Leu Val Leu Asn Gly Lys Pro
 275 280 285
 Gly His Leu Gln Phe Tyr Ser Leu Gln Ser Asp Lys Gln Leu Tyr Asn
 290 295 300
 Leu Asp Ile Ile Gln Gln Glu Tyr Ile Asn Asp Tyr Gly Leu Ile Gln
 305 310 315 320

Ile Glu Leu Thr Lys Ala Ala Phe Gly Cys Phe Gly Asn Trp Leu Ala
 325 330 335
 Thr Val Glu Gln Arg Gln Glu Lys Glu Thr Glu Leu Glu Leu Gln Met
 340 345 350
 Lys Leu Trp Met Tyr Asn Lys Lys Thr Gln Gly Phe Ile Leu Asn Thr
 355 360 365
 Lys Ile Asn Met Pro His Glu Asp Cys Ile Thr Ala Leu Cys Phe Cys
 370 375 380
 Asn Ala Glu Lys Ser Glu Gln Pro Thr Leu Val Thr Ala Ser Lys Asp
 385 390 395 400
 Gly Tyr Phe Lys Val Trp Ile Leu Thr Asp Asp Ser Asp Ile Tyr Lys
 405 410 415
 Lys Ala Val Gly Trp Thr Cys Asp Phe Val Gly Ser Tyr His Lys Tyr
 420 425 430
 Gln Ala Thr Asn Cys Cys Phe Ser Glu Asp Gly Ser Leu Leu Ala Val
 435 440 445
 Ser Phe Glu Glu Ile Val Thr Ile Trp Asp Ser Val Thr Trp Glu Leu
 450 455 460
 Lys Cys Thr Phe Cys Gln Arg Ala Gly Lys Ile Arg His Leu Cys Phe
 465 470 475 480
 Gly Arg Leu Thr Cys Ser Lys Tyr Leu Leu Gly Ala Thr Glu Asn Gly
 485 490 495
 Ile Leu Cys Cys Trp Asn Leu Leu Ser Cys Ala Leu Glu Trp Asn Ala
 500 505 510
 Lys Leu Asn Val Arg Val Met Glu Pro Asp Pro Asn Ser Glu Asn Ile
 515 520 525
 Ala Ala Ile Ser Gln Ser Ser Val Gly Ser Asp Leu Phe Val Phe Lys
 530 535 540
 Pro Ser Glu Pro Arg Pro Leu Tyr Ile Gln Lys Gly Ile Ser Arg Glu
 545 550 555 560
 Lys Val Gln Trp Gly Val Phe Val Pro Arg Asp Val Pro Glu Ser Phe
 565 570 575
 Thr Ser Glu Ala Tyr Gln Trp Leu Asn Arg Ser Gln Phe Tyr Phe Leu
 580 585 590
 Thr Lys Ser Gln Ser Leu Leu Thr Phe Ser Thr Lys Ser Pro Glu Glu
 595 600 605
 Lys Leu Thr Pro Thr Ser Lys Gln Leu Leu Ala Glu Glu Ser Leu Pro
 610 615 620
 Thr Thr Pro Phe Tyr Phe Ile Leu Gly Lys His Arg Gln Gln Gln Asp
 625 630 635 640

Glu Lys Leu Asn Glu Thr Leu Glu Asn Glu Leu Val Gln Leu Pro Leu
 645 650 655
 Thr Glu Asn Ile Pro Ala Ile Ser Glu Leu Leu His Thr Pro Ala His
 660 665 670
 Val Leu Pro Ser Ala Ala Phe Leu Cys Ser Met Phe Val Asn Ser Leu
 675 680 685
 Leu Leu Ser Lys Glu Thr Lys Ser Ala Lys Glu Ile Pro Glu Asp Val
 690 695 700
 Asp Met Glu Glu Glu Lys Glu Ser Glu Asp Ser Asp Glu Glu Asn Asp
 705 710 715 720
 Phe Thr Glu Lys Val Gln Asp Thr Ser Asn Thr Gly Leu Gly Glu Asp
 725 730 735
 Ile Ile His Gln Leu Ser Lys Ser Glu Glu Lys Glu Leu Arg Lys Phe
 740 745 750
 Arg Lys Ile Asp Tyr Ser Trp Ile Ala Ala Leu
 755 760

<210> 14
 <211> 137
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (2)

<220>
 <221> unsure
 <222> (18)

<220>
 <221> unsure
 <222> (29) .. (30)

<220>
 <221> unsure
 <222> (36)

<220>
 <221> unsure
 <222> (44)

<220>
 <221> unsure
 <222> (49)

<220>
 <221> unsure
 <222> (62)

<220>

<221> unsure
<222> (67)

<220>
<221> unsure
<222> (80)

<220>
<221> unsure
<222> (93)

<220>
<221> unsure
<222> (99)

<220>
<221> unsure
<222> (108)

<220>
<221> unsure
<222> (112)

<220>
<221> unsure
<222> (121)

<400> 14
gngggggagg atgaatantc ggaagctggn gcggcngcgg gganccaang aagaggttcc 60
gnaccnngct tacgaaccgn ggactcttga ctneccacnc cctgaacnct cncctccaaa 120
ngcgtcatgg atggaat 137

<210> 15
<211> 539
<212> DNA
<213> Homo sapiens

<400> 15
gtggagggag agtgaattct ggaatctct cagcagcttt ttgccaaaca gatggggccag 60
gagccgcgga accaggctga ggaatgttgc ctacgatct ctcatatcca ttcctggcac 120
ccaccagccc agggaaatgcc tctaccagtt gtcagcgaga ggcttacaca gcatcttaaa 180
taaaagggat tattgaacca agaggccagg gactgatgga aatgcccacc ttgctggctc 240
attgaaaaag tttggcaagg ttgtcaggag acatgaatta gatgggcttg ggtcttgtgc 300
cctttgctaa accaagtgtc gtattgggaa agagacgggg agagaagtgt tggagatgct 360
ctttagtcag gcctgagtc cttgcccac cctggagttg gagttgggga tggagccagg 420
atctccaaac cacatgcccc tagagtttca gggaaaatat ggattgtgaa ttgaagatgg 480
ggggtgatgt aaggcagaca aggacagaaa atccctcttc cagctgtgat ttggctgtg 539

<210> 16
<211> 27
<212> PRT
<213> Homo sapiens

<400> 16
Met Asp Cys Glu Leu Lys Met Gly Gly Asp Val Arg Gln Thr Arg Thr
1 5 10 15

Glu Asn Pro Ser Ser Ser Cys Asp Leu Ala Val
20 25

<210> 17
 <211> 99
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (50)

<220>
 <221> unsure
 <222> (55)..(56)

<220>
 <221> unsure
 <222> (62).

<220>
 <221> unsure
 <222> (64)

<220>
 <221> unsure
 <222> (84)

<400> 17
 agagaggcag atccccaatg aggggtcagg acgggtctctg gctgcacatn ctggmntcat 60
 antnatccca tggggagcag cacnttatga aaaaaaaaaa 99

<210> 18
 <211> 2608
 <212> DNA
 <213> Homo sapiens

<400> 18
 attagccact gcacctggct ggtgtctcca ttttacagat gaggetgtca ccccccaata 60
 tcacacagcc aagtggcaga gttgtgttca aatgctggca gtcaggccat gctctgtctg 120
 artccaract ctgccacttt ctarctgtgt gttctcgggc aggttattta ccaactttga 180
 agtccatttt cttatcccta aaagagggct gagaagctca cccctacctt tgaaggttgt 240
 ttgaggatta agcaagacca gcactctgaag ggcctgaagc atctagggca tcatcagtgc 300
 actttatctc tggcctctaa gaagtgcac tagaaggac cactgtcac agcttcctgg 360
 tacccttgcc tttgcctgtc aggtagcact tcggtttgga cctcactttt tcaggatttg 420
 ttggaaacaa gatcccttat cttctctagg tcagatttgg ggtgaacttg gctgacagta 480
 ttccagggca ggcagaggtc aggctggctg gtgacctgct gcctccttcc catcggcagc 540
 tagttctagg gccatccaca gggatcccca gccctccata gtaccagtga gcctcactgg 600
 catgtgccag ggccaagagg gccttcagcg tcgcctccag tccagccctg tcctcgattt 660
 cttggggaca ctgtgggtca gccagcacag tgcctagccc acagtcaccc agcaggcgtc 720
 cctcgagtgg gccagtggca ggcacagagc tgctctcccc ttgcctggat gcgtgaggaa 780
 aggaactctt ctccctgcag cccagccctg caggctctct gctgccagat gacgagtga 840
 gatgaaagtc ctgatgtcta ttgtctgtgt gcacagagct ttggagtggc ctggccagga 900
 agaggggaag cgtgtgtggg gtcagcaciaa ggggttgccg ggatcttggg tactggttct 960
 gctctgctgc tggttccctc tgaaaatgtg ggtttctccc ctccgtgctg agcctcagaa 1020
 aggggcaggg agcccatgc cagcacacat ggccctcgg ctctctggcc tctgcagggt 1080
 cagcccagct ccttcacctc tctcctgctt tccctcagg cctcagtgc cccacacccc 1140
 cttcaggccc aagcctggat ggtaccggat ggaacagctt ccagtcgtcg gatgccactg 1200
 agccccccag cccctgctct ggcccaggcc cccagtatgg aaagccgacc cccagcgcag 1260
 acatccctgc cagcaagcag cggctctggac gacctagacc tcctggggaa gaccctcctg 1320
 cagcagtcgc tgccccggga atcccagcaa gtgcgggtgg agaagcagca gccaaacccc 1380
 cggctcacac tccgggacct gcagaataag agcagcagct gcagctcccc cagctccagc 1440

```

gccaccagcc ttctccacac cgtgtcccca gagcccccca ggcctccgca gcagcccgta 1500
ccaaccgagc tctcactggc cagcatcact gtgcccctgg agtccatcaa acccagcaac 1560
atcctgcccg tgactgtgta tgaccagcac ggcttccgca tcctcttcca ttttggccgg 1620
gaccactgc cagggcgctc cgacgtgctg gtggtggtgg tttccatgct gagcaccgcc 1680
ccccagccca tccgcaacat cgtgttccag tcagctgtcc ccaaggttat gaaggtgaag 1740
ctgcagccac cctcgggcac ggagctgcca gcttttaacc ccatcgcca cccctcagca 1800
atcaccagg tctgtgtgct tgccaacccc cagaaggaga aggttcgcct ccgctacaag 1860
ctcaccttca ccatgggtga ccagacctac aacgagatgg gggatgtgga ccagttcccc 1920
ccacctgaaa cctggggtag cctctagaac agaggggctg gggagaggaa ggggcagagg 1980
gaccggtcac tgtccagcct ggagggaggc attggtggcc aaggacacc tttgttgccc 2040
atggccatc acccccaggc ctggtgcttc tccccacacc cctgtaggcc tcaagtgact 2100
cttccccctc ctgctccggc cccgcccctg ctgagccaaa cccagtagga ggctgggcct 2160
gggtttgtgc cgctggggtc tccatcaccg ggacctggag agggaggggc tgtgtagcct 2220
tggaagaact tgggtcatgg ggaggaagca cagctgttgg ggaagggcca ggacctcagg 2280
cccagcccca accccagctg ggggtggggtc tttcccacct gtctcttatg ccttatggga 2340
aggcccagcc ataactcggg ggccatgctc gagctgggga ccagcttagg cctcctatgg 2400
gtgtcttacg tctgtccatc catctgtccg tggtcagaag tggggtcagt gtgtgagtga 2460
gagcaggagt atttatgaaa ataaaacgtc gtttttcctg gaaaaaaaaa aaaaaaaaaa 2520
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2580
aaaaaaaaa aaaaaaaaaa aaaaaaaa 2608

```

<210> 19

<211> 236

<212> PRT

<213> Homo sapiens

<400> 19

```

Met Glu Ser Arg Pro Pro Ala Gln Thr Ser Leu Pro Ala Ser Ser Gly
  1              5              10              15

```

```

Leu Asp Asp Leu Asp Leu Leu Gly Lys Thr Leu Leu Gln Gln Ser Leu
      20              25              30

```

```

Pro Pro Glu Ser Gln Gln Val Arg Trp Glu Lys Gln Gln Pro Thr Pro
      35              40              45

```

```

Arg Leu Thr Leu Arg Asp Leu Gln Asn Lys Ser Ser Ser Cys Ser Ser
      50              55              60

```

```

Pro Ser Ser Ser Ala Thr Ser Leu Leu His Thr Val Ser Pro Glu Pro
      65              70              75              80

```

```

Pro Arg Pro Pro Gln Gln Pro Val Pro Thr Glu Leu Ser Leu Ala Ser
      85              90              95

```

```

Ile Thr Val Pro Leu Glu Ser Ile Lys Pro Ser Asn Ile Leu Pro Val
      100             105             110

```

```

Thr Val Tyr Asp Gln His Gly Phe Arg Ile Leu Phe His Phe Ala Arg
      115             120             125

```

```

Asp Pro Leu Pro Gly Arg Ser Asp Val Leu Val Val Val Val Ser Met
      130             135             140

```

```

Leu Ser Thr Ala Pro Gln Pro Ile Arg Asn Ile Val Phe Gln Ser Ala
      145             150             155             160

```

```

Val Pro Lys Val Met Lys Val Lys Leu Gln Pro Pro Ser Gly Thr Glu
      165             170             175

```

Leu Pro Ala Phe Asn Pro Ile Val His Pro Ser Ala Ile Thr Gln Val
 180 185 190

Leu Leu Leu Ala Asn Pro Gln Lys Glu Lys Val Arg Leu Arg Tyr Lys
 195 200 205

Leu Thr Phe Thr Met Gly Asp Gln Thr Tyr Asn Glu Met Gly Asp Val
 210 215 220

Asp Gln Phe Pro Pro Pro Glu Thr Trp Gly Ser Leu
 225 230 235

<210> 20
 <211> 328
 <212> DNA
 <213> Homo sapiens

<400> 20
 agacttcgaa ttcggccttc atggcctara aaaactgatt cacctggcag agacctaccc 60
 catccacatg cacagccagc tggaccacct tagcctctat tactgcaggt gtactctgcc 120
 agagaatcca aacaatcaca cctccagta ctggaaggac cacaacatcg tgacagcaga 180
 agtccactgg gctaacctga ctgtcagtga atgccaggag atgcatggag agttcatggg 240
 atctgcgtgc ggccatcatg gacctacac tctgatgtc ctcttttggt cctgtattct 300
 ctttttcacc accttcaccc tctcaagc 328

<210> 21
 <211> 87
 <212> PRT
 <213> Homo sapiens

<400> 21
 Met His Ser Gln Leu Asp His Leu Ser Leu Tyr Tyr Cys Arg Cys Thr
 1 5 10 15

Leu Pro Glu Asn Pro Asn Asn His Thr Leu Gln Tyr Trp Lys Asp His
 20 25 30

Asn Ile Val Thr Ala Glu Val His Trp Ala Asn Leu Thr Val Ser Glu
 35 40 45

Cys Gln Glu Met His Gly Glu Phe Met Gly Ser Ala Cys Gly His His
 50 55 60

Gly Pro Tyr Thr Pro Asp Val Leu Phe Trp Ser Cys Ile Leu Phe Phe
 65 70 75 80

Thr Thr Phe Ile Leu Ser Ser
 85

<210> 22
 <211> 326
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (1)

<220>
 <221> unsure
 <222> (31)

<220>
 <221> unsure
 <222> (82)

<220>
 <221> unsure
 <222> (84)

<220>
 <221> unsure
 <222> (129)

<400> 22
 naaatgtatt tatatgtatg tcttattata nacaaggcag atttcccctg gaataaaaagt 60
 ctagaatgta ctgcttaatt tnanacatgt gtgcaggcaa tattatctgt gagtgaaaag 120
 tggaataana cgtggattgg gtcaactgat tatcagcttg ttaggagtcc tctgtgtgag 180
 acatgggtggg ataattgtga agttctcact gtatgtggat gttcatgtga aagatagtac 240
 tttcttcccg taaatatctt ttgatttcca tttgtatgga atcccaatga atgtatcttt 300
 ggaaaacaaa aaaaaaaaaa aaaaaa 326

<210> 23
 <211> 194
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (55)

<220>
 <221> unsure
 <222> (73)

<220>
 <221> unsure
 <222> (119)

<220>
 <221> unsure
 <222> (126)

<220>
 <221> unsure
 <222> (137)

<220>
 <221> unsure
 <222> (174)

<400> 23
 aagtctcatt ctcaagagtg atgctgcaaa accccttttg ggccatgatg ctgtnatcca 60
 ggcttttagca canaaaggte tttatgtcac tgaccaggaa aaattggtaa ctgaacgana 120
 tctccncaag aaaccntac agatgagtg acatttgggc catgatcgat accncatgat 180
 ggcttatact gtat 194

<210> 24

<211> 396
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (139)

<400> 24
 ttcatttttta ctgtcctgat gttgtcagat tagaggatat ttgtttgaaa gaaactatgt 60
 ctttggtga tagcctgtat aatctgcagc tgattcaaga attttgccaa gaatacttga 120
 accagtgttg ccatttcant ctggaagata tgctctatgc tgcttcatcc ataaagagta 180
 attatttggg gttcatggcg gaactgttct ggtgggttga agtgggtgaag ccgtcttttg 240
 tacagcctcg tggtgttcgt ccacaaggag ctgaacctgt aaaagatatg ccttcaattc 300
 ctgtcttgaa tgctgccaaa agaaatgtct tagatagtag ttctgacttc ccttcaagtg 360
 gggaaggagc tacatttaca cagtctcatc tcgagg 396

<210> 25
 <211> 113
 <212> PRT
 <213> Homo sapiens

<220>
 <221> UNSURE
 <222> (28)

<400> 25
 Met Ser Leu Ala Asp Ser Leu Tyr Asn Leu Gln Leu Ile Gln Glu Phe
 1 5 10 15
 Cys Gln Glu Tyr Leu Asn Gln Cys Cys His Phe Xaa Leu Glu Asp Met
 20 25 30
 Leu Tyr Ala Ala Ser Ser Ile Lys Ser Asn Tyr Leu Val Phe Met Ala
 35 40 45
 Glu Leu Phe Trp Trp Phe Glu Val Val Lys Pro Ser Phe Val Gln Pro
 50 55 60
 Arg Val Val Arg Pro Gln Gly Ala Glu Pro Val Lys Asp Met Pro Ser
 65 70 75 80
 Ile Pro Val Leu Asn Ala Ala Lys Arg Asn Val Leu Asp Ser Ser Ser
 85 90 95
 Asp Phe Pro Ser Ser Gly Glu Gly Ala Thr Phe Thr Gln Ser His Leu
 100 105 110
 Glu

<210> 26
 <211> 336
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (87)

<220>
<221> unsure
<222> (123)

<400> 26
aatttgatga tgaccagaaa gtatgctgtg gttctttttt aaggatgac aaaaagcaga 60
aatgatatg gcaatgaaac gggcagnttt gttggagaaa agattaagaa gggaaaagga 120
aantcagctc cggaacaac agttggaagc agaaatggag cataagaagg aggaaacaag 180
gcgtaaaact gaggaagaac gtcagaagaa agaagatgag agagcacgca gagaatttat 240
taggcaagaa tatatgagge ggaaacaact gaaactaatg gaagatatgg atacagtaat 300
taaaccctgt cctcaagtag taaaaaaaaa aaaaaa 336

<210> 27
<211> 917
<212> DNA
<213> Homo sapiens

<400> 27
cacctggatt atctcagtag tttcccaact ggtttccttg tttccattct tgcctccttc 60
tgtctactct caatataaca gctagaacaa tcctttttaca atggaattca gatcatgttt 120
acccctctgt tcaaattctc cagtgacttt ccagttttta catgatctgg ctctactac 180
ctgtctcact gtgttttcta ctactctcct gccctttctc ctcttaataa acactgggct 240
catgggtgtt cctttaacat gccaggcatg cttgaccctg tctgtctca gggccctgct 300
gttcctctg cctggaacat tcttcccata gtgtctgcat ggctcgctct ctactgctt 360
tggattgctg ctcaaaagtc accttatcaa aggcctttcc caaaggttta aaaatcattc 420
tactataaag acacatgcat acatatgttt attgcagcac tattcacaat aacaagact 480
tggaaccaac ccaaatgccc atcaatgata gactggataa agaaaatatg gcacgtaagc 540
accatggaat actatgcagc cataaaaaag aatgagttca tgccttttgc agggacatgg 600
atgaagctgg aaaccattat tctcagcaaa ctaacacagg aacagaaaac caaacaccgc 660
atgttctcac tcataagtgg gagttgaaca atgagaacat acgggcacag tggggggaac 720
atcacacacc agggcctgtc ggggggtgag aggcaaggga agtgatagca ttaagagaaa 780
tacctaattg agattatggg ttgatggggg cagcaaacca ccatggcaca tgtgtacct 840
tgtaacaaac ctgcacattc tgcacatata tcccagaact taaagtataa ttaagaaaa 900
agaaaaaaaa aaaaaa 917

<210> 28
<211> 76
<212> PRT
<213> Homo sapiens

<400> 28
Met Glu Phe Arg Ser Cys Leu Pro Leu Cys Ser Asn Ser Pro Val Thr
1 5 10 15
Phe Gln Phe Leu His Asp Leu Ala Pro Thr Thr Cys Leu Thr Val Phe
20 25 30
Pro Thr Thr Leu Leu Pro Phe Leu Leu Leu Ile Asn Thr Gly Leu Met
35 40 45
Val Phe Pro Leu Thr Cys Gln Ala Cys Leu Thr Leu Ser Cys Leu Arg
50 55 60
Ala Leu Leu Phe Pro Leu Pro Gly Thr Phe Phe Pro
65 70 75

<210> 29
<211> 351

<212> DNA

<213> Homo sapiens

<400> 29

```

ggctttgacc gctatcgcca ggagtggatg gactatggct gtgcacagga ggcagagggc 60
aggatgtgcg aggactteca ggatgaggac cagactcag cctcccctga cacttccttc 120
agcccctatg atggagacct caccamtacc tcctcctccc tcctcatcga cagcctcacc 180
acagaagatg acaccaagtt gaatccctat gcaggaggag acggccttca gaacaacctg 240
tcccccaaga caaagggcac tcctgtgcac ctgggcacca tcgtgggcat cgtgctggca 300
gtcctcctcg tggcggccat catcctggct ggaatttaca tcaatggcca c          351

```

<210> 30

<211> 108

<212> PRT

<213> Homo sapiens

<220>

<221> UNSURE

<222> (40)

<400> 30

```

Met Asp Tyr Gly Cys Ala Gln Glu Ala Glu Gly Arg Met Cys Glu Asp
 1              5              10              15
Phe Gln Asp Glu Asp His Asp Ser Ala Ser Pro Asp Thr Ser Phe Ser
          20              25              30
Pro Tyr Asp Gly Asp Leu Thr Xaa Thr Ser Ser Ser Leu Phe Ile Asp
      35              40              45
Ser Leu Thr Thr Glu Asp Asp Thr Lys Leu Asn Pro Tyr Ala Gly Gly
      50              55              60
Asp Gly Leu Gln Asn Asn Leu Ser Pro Lys Thr Lys Gly Thr Pro Val
      65              70              75              80
His Leu Gly Thr Ile Val Gly Ile Val Leu Ala Val Leu Leu Val Ala
          85              90              95
Ala Ile Ile Leu Ala Gly Ile Tyr Ile Asn Gly His
      100              105

```

<210> 31

<211> 179

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (24)

<220>

<221> unsure

<222> (33)

<220>

<221> unsure

<222> (56)

<220>

<221> unsure

<222> (82)

<220>

<221> unsure

<222> (93)

<220>

<221> unsure

<222> (99)

<220>

<221> unsure

<222> (117)

<220>

<221> unsure

<222> (137)

<400> 31

gttgctcagcc ccttcctttc ccengaccta aanataaaag acaaggcaaa gcccgntataa 60
 ttttaagacg gtttttttagg anattagtcc acnattttnt tggtttgatg gttttcngaa 120
 ataaagtccc tttcctngct ccaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 179

<210> 32

<211> 3906

<212> DNA

<213> Homo sapiens

<400> 32

ggaaactcag ccacctgtga caaatttgag tgtctctgtt gaaaacctct gcacagtaat 60
 atggacatgg aatccacccg agggagccag ctcaaattgt agtctatggc atttttagtca 120
 ttttggcgac aaacaagata agaaaatagc tccggaaact cgtcgttcaa tagaagtacc 180
 cctgaatgag aggatttgtc tgcaagtggg gtcccagtggt agcaccaatg agagtggagaa 240
 gcctagcatt ttggttgaaa aatgcattct acccccagaa ggtgatcctg agtctgctgt 300
 gactgagctt caatgcattt ggcacaacct gagctacatg aagtgttctt ggctccctgg 360
 aaggaatacc agtcccagca ctaactatac tctctactat tggcacagaa gcctggaaaa 420
 aattcatcaa tgtgaaaaca tcttttagaga aggccaatac ttgggttggt cctttgatct 480
 gaccaaagtg aaggattcca gttttgaaca acacagtggt caaataatgg tcaaggataa 540
 tgcaggaaaa attaaaccat ccttcaatat agtgccttta acttcccgtg tgaaacctga 600
 tcctccacat attaaaaacc tctccttcca caatgatgac ctatatgtgc aatgggagaa 660
 tccacagaat tttattagca gatgcctatt ttatgaagta gaagtcaata acagccaaac 720
 tgagacacat aatgttttct acgtccaaga ggctaaatgt gagaatccag aatttgagag 780
 aaatgtggag aatacatctt gtttcatggc ccctgggtgt cttcctgata ctttgaacac 840
 agtcagaata agagtcaaaa caaataagtt atgctatgag gatgacaaac tctggagtaa 900
 ttggagccaa gaaatgagta taggtaagaa gcgcaattcc acactctaca taaccatgtt 960
 actcattgtt ccagtcacgt tgcaggtgac aatcatagta ctctgtttt acctaaaaag 1020
 gctcaagatt attatatctc ctccaattcc tgatcctggc aagattttta aagaaatgtt 1080
 tggagaccag aatgatgata ctctgcactg gaagaagtac gacatctatg agaagcaaac 1140
 caaggaggaa accgactctg tagtgctgat agaaaacctg aagaaagcct ctcatgtatg 1200
 gagataattt atttttacct tcaactgtgac cttgagaaga ttcttcccat tctccatttg 1260
 ttatctggga acttattaaa tggaaactga aactactgca ccatttataaa acaggcagct 1320
 cataagagcc acaggtcttt atgttgagtc gcgcaccgaa aaactaaaaa taatgggcgc 1380
 tttggagaag agtgtggagt cattctcatt gaattataaa agccagcagg cttcaaacta 1440
 ggggacaaag caaaaagtga tgatactggg ggagttaatc ttatcaagag ttgtgacaac 1500
 ttcctgaggg atctatactt gctttgtgtt ctttgtgtca acatgacaa attttatttg 1560
 taggggaact catttggggg gcaaattgcta atgtcaaact tgagtcacaa agaacatgta 1620
 gaaaacaaaa tggataaaat ctgatatgta ttgtttggga tcctattgaa ccattgttgt 1680
 ggctattaaa actcttttaa cagtcctgggc tgggtccggc ggctcacgcc tgtaatccca 1740

```

gcaatttggg agtccgaggc gggcggatca ctcgaggtca ggagttccag accagcctga 1800
ccaaaatggg gaaacctcct ctctactaaa actacaaaaa ttaactgggt gtggtggcgc 1860
gtgcctgtaa tcccagctac tcgggaagct gaggcaggtg aattgtttga acctgggagg 1920
tggaggttgc agtgagcaga gatcacacca ctgcactcta gcctgggtga cagagcaaga 1980
ctctgtctaa aaaacaaaac aaaacaaaac aaaacaaaaa aacctcttaa tattctggag 2040
tcatcattcc ctctgacagc attttctctt gctttgaaag cccagaaat cagtgttggc 2100
catgatgaca actacagaaa aaccagaggc agcttctttg ccaagacctt tcaaagccat 2160
tttaggctgt taggggcagt ggaggtagaa tgactccttg ggtattagag ttcaaccat 2220
gaagtctcta acaatgtatt ttcttcacct ctgctactca agtagcattt actgtgtctt 2280
tggtttgtgc tagggccccc ggtgtgaagc acagaccctt tccaggggtt tacagtctat 2340
ttgagactcc tcagttcttg ccactttttt tttaatctcc accagtcatt ttccagacct 2400
tttaactcct caattccaac actgatttcc ctttttgcac tctccctcct tcccttcctt 2460
gtagcctttt gactttcatt ggaaattagg atgtaaatct gctcaggaga cctggaggag 2520
cagaggataa ttagcatctc aggttaagtg tgagtaatct gagaaacaat gactaattct 2580
tgcataattt gtaacttcca tgtgaggggt ttcagcattg atatttgtgc attttctaaa 2640
cagagatgag gtggtatctt cacgtagaac attggtattc gcttgagaaa aaaagaatag 2700
ttgaacctat ttctctttct ttacaagatg ggtccaggat tcctcttttc tctgccataa 2760
atgattaatt aaatagcttt tgtgtcttac attggtagcc agccagccaa ggctctgttt 2820
atgcttttgg ggggcatata ttgggttcca ttctcaccta tccacacaac atatccgtat 2880
atatcccctc tactcttact tcccccaat ttaaagaagt atgggaaatg agaggcattt 2940
ccccacccc atttctctcc tcacacacag actcatatta ctggtaggaa cttgagaact 3000
ttatttccaa gttgttcaaa catttaccaa tcatattaat acaatgatgc tatttgcaat 3060
tcctgtcctt aggggagggg agataagaaa ccctcactct ctacagggtt gggtagaagt 3120
ggcaacctgc ttccatggcc gtgtagaagc atgggtgccct ggcttctctg aggaagctgg 3180
ggttcatgac aatggcagat gtaaagtatt tcttgaagtc agattgaggc tgggagacag 3240
ccgtagtaga tgttctactt tgttctgctg ttctctagaa agaataattg gtttctctgt 3300
ataggaatga gattaattcc ttccaggtta tttataatt ctgggaagca aaacctatgc 3360
ctccccctag ccattttttac tgttatccta ttagatggc catgaagagg atgctgtgaa 3420
attcccaaca aacattgatg ctgacagtca tgcagtctgg gagtggggaa gtgatctttt 3480
gttcccatcc tcttctttta gcagtaaaat agctgagggg aaagggaggg aaaaggaagt 3540
tatgggaata cctgtggtgg ttgtgatccc taggtcttgg gagctcttgg aggtgtctgt 3600
atcagtggat ttcccatccc ctgtgggaaa ttagtaggct catttactgt tttaggtcta 3660
gcctatgtgg attttttctt aacatacyta agcaaaccce gtgtcaggat ggtaattctt 3720
attctttcgt tcagtttaagt ttttcccttc atctgggcac tgaagggata tgtgaaacaa 3780
tgttaacatt tttggtagtc ttcaaccagg gattgtttct gtttaacttc ttataggaaa 3840
gcttgagtaa aataaatatt gtcttttctg atgtcaccca aaaaaaaaaa aaaaaaaaaa 3900
aaaaaa 3906

```

<210> 33

<211> 286

<212> PRT

<213> Homo sapiens

<400> 33

```

Met Lys Cys Ser Trp Leu Pro Gly Arg Asn Thr Ser Pro Asp Thr Asn
  1             5             10             15

```

```

Tyr Thr Leu Tyr Tyr Trp His Arg Ser Leu Glu Lys Ile His Gln Cys
      20             25             30

```

```

Glu Asn Ile Phe Arg Glu Gly Gln Tyr Leu Gly Cys Ser Phe Asp Leu
      35             40             45

```

```

Thr Lys Val Lys Asp Ser Ser Phe Glu Gln His Ser Val Gln Ile Met
      50             55             60

```

```

Val Lys Asp Asn Ala Gly Lys Ile Lys Pro Ser Phe Asn Ile Val Pro
      65             70             75             80

```

```

Leu Thr Ser Arg Val Lys Pro Asp Pro Pro His Ile Lys Asn Leu Ser

```

85	90	95
Phe His Asn Asp Asp Leu Tyr Val Gln Trp Glu Asn Pro Gln Asn Phe 100 105 110		
Ile Ser Arg Cys Leu Phe Tyr Glu Val Glu Val Asn Asn Ser Gln Thr 115 120 125		
Glu Thr His Asn Val Phe Tyr Val Gln Glu Ala Lys Cys Glu Asn Pro 130 135 140		
Glu Phe Glu Arg Asn Val Glu Asn Thr Ser Cys Phe Met Val Pro Gly 145 150 155 160		
Val Leu Pro Asp Thr Leu Asn Thr Val Arg Ile Arg Val Lys Thr Asn 165 170 175		
Lys Leu Cys Tyr Glu Asp Asp Lys Leu Trp Ser Asn Trp Ser Gln Glu 180 185 190		
Met Ser Ile Gly Lys Lys Arg Asn Ser Thr Leu Tyr Ile Thr Met Leu 195 200 205		
Leu Ile Val Pro Val Ile Val Ala Gly Ala Ile Ile Val Leu Leu Leu 210 215 220		
Tyr Leu Lys Arg Leu Lys Ile Ile Ile Phe Pro Pro Ile Pro Asp Pro 225 230 235 240		
Gly Lys Ile Phe Lys Glu Met Phe Gly Asp Gln Asn Asp Asp Thr Leu 245 250 255		
His Trp Lys Lys Tyr Asp Ile Tyr Glu Lys Gln Thr Lys Glu Glu Thr 260 265 270		
Asp Ser Val Val Leu Ile Glu Asn Leu Lys Lys Ala Ser Gln 275 280 285		

<210> 34

<211> 1605

<212> DNA

<213> Homo sapiens

<400> 34

```

acgctgacca tcacaggcac acagaggcac atccacctca catccacctc atacttgtgt 60
actctcaggg ttcagtcttt catcctatcc ctctctgate tgtgcctccc aataccttcc 120
aagatgttta cagagaccct tctccctgtg cagttaggag tgtaaggcaa gagagcccct 180
acttcatggg gcagatcaag agctgagacc aaagatgggc tatgttgcct acettgtcct 240
gtcctcctgc tgtcttaaac tatgatccct gctgcgggtca ctgaagcctt tccctgtgag 300
cagtgggtgtg tgagagccag gcgtccctct gcctgcccac tcagtggcaa caccggggag 360
ctgttttgtc ctttgtggag cctcagcagt tccctctttc agaactcact gccaagagcc 420
ctgaacagga gccaccatgc agtgcttcag cttcattaag accatgatga tcctcttcaa 480
tttgtcatc tttctgtgtg gtgcagccct gttggcagtg ggcattctggg tgtcaatcga 540
tggggcatcc tttctgaaga tcttcgggcc actgtcgtcc agtgccatgc agtttgtcaa 600
cgtgggctac ttcctcatcg cagccggcgt tgtggctctt gctcttggtt tcctgggctg 660
ctatgggtgct aagactgaga gcaagtgtgc cctcgtgacg ttcttcttca tcctcctcct 720
catcttcatt gctgaggttg cagctgctgt ggtcgccttg gtgtacacca caatggctga 780
gcacttctg acgttgctgg tagtgctgc catcaagaaa gattatggtt cccaggaaga 840
cttcactcaa gtgtggaaca ccaccatgaa agggctcaag tgctgtggct tcaccaacta 900

```



```

tacggatttt gaggactcac cctacttcaa agagaacagt gcctttcccc cattctgttg 960
caatgacaac gtcaccaaca cagccaatga aacctgcacc aagcaaaagg ctcacgacca 1020
aaaagtagag ggttgcttca atcagctttt gtatgacatc cgaactaatg cagtcaccgt 1080
gggtggtgtg gcagctggaa ttgggggcct cgagctggct gccatgattg tgtccatgta 1140
tctgtactgc aatctacaat aagtccactt ctgcctctgc cactactgct gccacatggg 1200
aactgtgaag aggcaccctg gcaagcagca gtgattgggg gaggggacag gatctaacaa 1260
tgtcacttgg gccagaatgg acctgccctt tctgctccag acttgggggt agatagggac 1320
cactcctttt aggcgatgcc tgactttcct tccattgggt ggtggatggg tggggggcat 1380
tccagagcct ctaaggtagc cagttctgtt gccattccc ccagtctatt aaacccttga 1440
tatgccccct aggcctagtg gtgatcccag tgctctactg ggggatgaga gaaaggcatt 1500
ttatagcctg ggcataagtg aaatcagcag agcctctggg tggatgtgta gaaggcactt 1560
caaatgcat aaacctgtta caatgttgaa aaaaaaaaaa aaaaa 1605

```

<210> 35

<211> 241

<212> PRT

<213> Homo sapiens

<400> 35

```

Met Gln Cys Phe Ser Phe Ile Lys Thr Met Met Ile Leu Phe Asn Leu
  1             5             10             15

```

```

Leu Ile Phe Leu Cys Gly Ala Ala Leu Leu Ala Val Gly Ile Trp Val
          20             25             30

```

```

Ser Ile Asp Gly Ala Ser Phe Leu Lys Ile Phe Gly Pro Leu Ser Ser
          35             40             45

```

```

Ser Ala Met Gln Phe Val Asn Val Gly Tyr Phe Leu Ile Ala Ala Gly
          50             55             60

```

```

Val Val Val Phe Ala Leu Gly Phe Leu Gly Cys Tyr Gly Ala Lys Thr
          65             70             75             80

```

```

Glu Ser Lys Cys Ala Leu Val Thr Phe Phe Phe Ile Leu Leu Leu Ile
          85             90             95

```

```

Phe Ile Ala Glu Val Ala Ala Ala Val Val Ala Leu Val Tyr Thr Thr
          100            105            110

```

```

Met Ala Glu His Phe Leu Thr Leu Leu Val Val Pro Ala Ile Lys Lys
          115            120            125

```

```

Asp Tyr Gly Ser Gln Glu Asp Phe Thr Gln Val Trp Asn Thr Thr Met
          130            135            140

```

```

Lys Gly Leu Lys Cys Cys Gly Phe Thr Asn Tyr Thr Asp Phe Glu Asp
          145            150            155            160

```

```

Ser Pro Tyr Phe Lys Glu Asn Ser Ala Phe Pro Pro Phe Cys Cys Asn
          165            170            175

```

```

Asp Asn Val Thr Asn Thr Ala Asn Glu Thr Cys Thr Lys Gln Lys Ala
          180            185            190

```

```

His Asp Gln Lys Val Glu Gly Cys Phe Asn Gln Leu Leu Tyr Asp Ile
          195            200            205

```

```

Arg Thr Asn Ala Val Thr Val Gly Gly Val Ala Ala Gly Ile Gly Gly
          210            215            220

```

Leu Glu Leu Ala Ala Met Ile Val Ser Met Tyr Leu Tyr Cys Asn Leu
 225 230 235 240

Gln

<210> 36
 <211> 377
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (346)

<400> 36
 caacctcgtg gtcaccgcac cggggctgat caaggggtgac gcctgcttca catctctaata 60
 gaacaccctc atgacgtcgc taccagcact agtgcagcaa caggggaaggc tgcttctggc 120
 tgctaattgtg gccaccctgg ggctcctcat ggcccggctc cttagcacct ctccagctct 180
 tcaggggaaca ccagcattccc gaggggttctt cgcagctgcc atcctcttcc taccacagtc 240
 ccacgtggcg cgggccaccc cgggctcaga ccaggcagtg ctagccctgt cccctgagta 300
 tgagggcata tgggccgacc tgcaggagct ctgggtcctg ggcattcaag ccttcaccgg 360
 ctgtgtgcct ctgctgc 377

<210> 37
 <211> 106
 <212> PRT
 <213> Homo sapiens

<220>
 <221> UNSURE
 <222> (96)

<400> 37
 Met Asn Thr Leu Met Thr Ser Leu Pro Ala Leu Val Gln Gln Gln Gly
 1 5 10 15
 Arg Leu Leu Leu Ala Ala Asn Val Ala Thr Leu Gly Leu Leu Met Ala
 20 25 30
 Arg Leu Leu Ser Thr Ser Pro Ala Leu Gln Gly Thr Pro Ala Ser Arg
 35 40 45
 Gly Phe Phe Ala Ala Ala Ile Leu Phe Leu Ser Gln Ser His Val Ala
 50 55 60
 Arg Ala Thr Pro Gly Ser Asp Gln Ala Val Leu Ala Leu Ser Pro Glu
 65 70 75 80
 Tyr Glu Gly Ile Trp Ala Asp Leu Gln Glu Leu Trp Phe Leu Gly Xaa
 85 90 95
 Gln Ala Phe Thr Gly Cys Val Pro Leu Leu
 100 105

<210> 38
 <211> 245

<212> DNA
<213> Homo sapiens

<220>
<221> unsure
<222> (3)

<220>
<221> unsure
<222> (17)

<220>
<221> unsure
<222> (34)

<220>
<221> unsure
<222> (46)

<220>
<221> unsure
<222> (65)

<220>
<221> unsure
<222> (71)

<220>
<221> unsure
<222> (142)

<220>
<221> unsure
<222> (214)

<400> 38
tangaactcct ctctgcngag acgcgactgg cggntccagc agggantacc ttttttataa 60
accnnggggg nccacacaca cacacacaca cacacacaca cacacacaca cacacacaca 120
catttttgat cccttgcttc cntccccag tgcgttctgt gatcgccaag ttcaaagctg 180
tgcacatgtg gacactcaat aaatgttcat tggngacaaa aaaaaaaaaa aaaaaaaaaa 240
aaaaa 245

<210> 39
<211> 2384
<212> DNA
<213> Homo sapiens

<400> 39
ccaaaacatg ctcaaagta gaacattttg tttcaatatt aggaaagtgc tttgaatccc 60
cttgagcagac aaaagcgcttg tctgagacag catgcgaaga ctgagaggaa aacaagcaga 120
gaataacagg tgcccagact ctaccaaagc atgtttctac cagcagtgat gaagggagcc 180
ccagtgccag tacaccaatg atcaataaaa ctggctttta attttcagct gagaagcctg 240
tgattgaagt tcccagcatg acaatcctgg ataaaaagga tggagagcag gccaaagccc 300
tgtttgagaa agtgaggaag ttccgtgccc atgtggaaga tagtgacttg atctataaac 360
tctatgtggt ccaaacagtt atcaaaacag ccaagttcat ttttattctc tgctatacag 420
cgaactttgt caacgcaatc agctttgaac acgtctgcaa gcccaaagtt gagcatctga 480
ttggttatga ggtatttgag tgcacccaca atatggctta catgttgaaa aagcttctca 540
tcagttacat atccattatt tgtgtttatg gctttatctg cctctacact ctcttctggt 600
tattcaggat acctttgaag gaatattctt tcgaaaaagt cagagaagag agcagtttta 660
gtgacattcc agatgtcaaa aacgattttg cgttccttct tcacatggta gaccagtatg 720

```

accagctata ttccaagcgt tttggtgtgt tcttgtcaga agttagttaa aataaactta 780
gggaaattag tttgaaccat gagtggacat ttgaaaaact caggcagcac atttcacgca 840
acgcccagga caagcaggag ttgcatctgt tcatgctgtc gggggtgcc gatgctgtct 900
ttgacctcac agacctggat gtgctaaagc ttgaactaat tccagaagct aaaattcctg 960
ctaagatttc tcaaattgact aacctccaag agctccacct ctgccactgc cctgcaaaag 1020
ttgaacagac tgcttttagc tttcttcgcg atcacttgag atgccttcac gtgaagttca 1080
ctgatgtggc tgaaattcct gcctgggtgt atttgcctca aaaccttcga gagttgtact 1140
taataggcaa tttgaactct gaaaacaata agatgatagg acttgaatct ctccgagagt 1200
tgcggcacct taagattctc cacgtgaaga gcaatttgac caaagttccc tccaacatta 1260
cagatgtggc tccacatctt acaaagttag tcattcataa tgacggcact aaactccttg 1320
tactgaacag ccttaagaaa atgatgaatg tcgctgagct ggaactccag aactgtgagc 1380
tagagagaat cccacatgct attttcagcc tctctaattt acaggaactg gatttaaagt 1440
ccaataacat tcgcacaatt gaggaaatca tcagtttcca gcatttaaaa cgactgactt 1500
gtttaaaatt atggcataac aaaattgtta ctattcctcc ctctattacc catgtcaaaa 1560
acttgagtc actttatttc tctaacaaca agctcgaatc cttaccagtg gcagtattta 1620
gtttacagaa actcagatgc ttagatgtga gctacaacaa catttcaatg attccaatag 1680
aaataggatt gcttcagaac ctgcagcatt tgcatatcac tgggaacaaa gtggacattc 1740
tgccaaaaca attgttttaa tgcataaagt tgaggacttt gaatctggga cagaactgca 1800
tcacctcact cccagagaaa gttggtcagc tctcccagct cactcagctg gagctgaagg 1860
ggaactgctt ggaccgctg ccagcccagc tgggcccagt tcggatgctc aagaaaagcg 1920
ggcttggtgt ggaagatcac ctttttgata ccctgccact cgaagtcaaa gaggcattga 1980
atcaagacat aaatattccc tttgcaaagt ggatttamac taagataata tatgcacagt 2040
gatgtgcagg aacaacttcc tagattgcaa gtgctcacgt acaagttatt acaagataat 2100
gcatttttag agtagataca tcttttaaaa taaaacagag aggatgcata gaaggctgat 2160
agaagacata actgaatgtt caatgtttgt aggggtttta gtcattcatt tccaaatcat 2220
tttttttttt cttttgggga aagggaagga aaaattataa tcactaatct tggttctttt 2280
taaattgttt gtaacttgga tgctgccgct actgaatgtt taaaaattgc ttgcctgcta 2340
aagtaaataa ttaaatgac attttcttac tataaaaaaa aaaa 2384

```

<210> 40

<211> 614

<212> PRT

<213> Homo sapiens

<220>

<221> UNSURE

<222> (607)

<400> 40

```

Met Ile Asn Lys Thr Gly Phe Lys Phe Ser Ala Glu Lys Pro Val Ile
  1             5             10             15

```

```

Glu Val Pro Ser Met Thr Ile Leu Asp Lys Lys Asp Gly Glu Gln Ala
          20             25             30

```

```

Lys Ala Leu Phe Glu Lys Val Arg Lys Phe Arg Ala His Val Glu Asp
          35             40             45

```

```

Ser Asp Leu Ile Tyr Lys Leu Tyr Val Val Gln Thr Val Ile Lys Thr
          50             55             60

```

```

Ala Lys Phe Ile Phe Ile Leu Cys Tyr Thr Ala Asn Phe Val Asn Ala
          65             70             75             80

```

```

Ile Ser Phe Glu His Val Cys Lys Pro Lys Val Glu His Leu Ile Gly
          85             90             95

```

```

Tyr Glu Val Phe Glu Cys Thr His Asn Met Ala Tyr Met Leu Lys Lys
          100            105            110

```

Leu Leu Ile Ser Tyr Ile Ser Ile Ile Cys Val Tyr Gly Phe Ile Cys
 115 120 125
 Leu Tyr Thr Leu Phe Trp Leu Phe Arg Ile Pro Leu Lys Glu Tyr Ser
 130 135 140
 Phe Glu Lys Val Arg Glu Glu Ser Ser Phe Ser Asp Ile Pro Asp Val
 145 150 155 160
 Lys Asn Asp Phe Ala Phe Leu Leu His Met Val Asp Gln Tyr Asp Gln
 165 170 175
 Leu Tyr Ser Lys Arg Phe Gly Val Phe Leu Ser Glu Val Ser Glu Asn
 180 185 190
 Lys Leu Arg Glu Ile Ser Leu Asn His Glu Trp Thr Phe Glu Lys Leu
 195 200 205
 Arg Gln His Ile Ser Arg Asn Ala Gln Asp Lys Gln Glu Leu His Leu
 210 215 220
 Phe Met Leu Ser Gly Val Pro Asp Ala Val Phe Asp Leu Thr Asp Leu
 225 230 235 240
 Asp Val Leu Lys Leu Glu Leu Ile Pro Glu Ala Lys Ile Pro Ala Lys
 245 250 255
 Ile Ser Gln Met Thr Asn Leu Gln Glu Leu His Leu Cys His Cys Pro
 260 265 270
 Ala Lys Val Glu Gln Thr Ala Phe Ser Phe Leu Arg Asp His Leu Arg
 275 280 285
 Cys Leu His Val Lys Phe Thr Asp Val Ala Glu Ile Pro Ala Trp Val
 290 295 300
 Tyr Leu Leu Lys Asn Leu Arg Glu Leu Tyr Leu Ile Gly Asn Leu Asn
 305 310 315 320
 Ser Glu Asn Asn Lys Met Ile Gly Leu Glu Ser Leu Arg Glu Leu Arg
 325 330 335
 His Leu Lys Ile Leu His Val Lys Ser Asn Leu Thr Lys Val Pro Ser
 340 345 350
 Asn Ile Thr Asp Val Ala Pro His Leu Thr Lys Leu Val Ile His Asn
 355 360 365
 Asp Gly Thr Lys Leu Leu Val Leu Asn Ser Leu Lys Lys Met Met Asn
 370 375 380
 Val Ala Glu Leu Glu Leu Gln Asn Cys Glu Leu Glu Arg Ile Pro His
 385 390 395 400
 Ala Ile Phe Ser Leu Ser Asn Leu Gln Glu Leu Asp Leu Lys Ser Asn
 405 410 415
 Asn Ile Arg Thr Ile Glu Glu Ile Ile Ser Phe Gln His Leu Lys Arg
 420 425 430

Leu Thr Cys Leu Lys Leu Trp His Asn Lys Ile Val Thr Ile Pro Pro
 435 440 445

Ser Ile Thr His Val Lys Asn Leu Glu Ser Leu Tyr Phe Ser Asn Asn
 450 455 460

Lys Leu Glu Ser Leu Pro Val Ala Val Phe Ser Leu Gln Lys Leu Arg
 465 470 475 480

Cys Leu Asp Val Ser Tyr Asn Asn Ile Ser Met Ile Pro Ile Glu Ile
 485 490 495

Gly Leu Leu Gln Asn Leu Gln His Leu His Ile Thr Gly Asn Lys Val
 500 505 510

Asp Ile Leu Pro Lys Gln Leu Phe Lys Cys Ile Lys Leu Arg Thr Leu
 515 520 525

Asn Leu Gly Gln Asn Cys Ile Thr Ser Leu Pro Glu Lys Val Gly Gln
 530 535 540

Leu Ser Gln Leu Thr Gln Leu Glu Leu Lys Gly Asn Cys Leu Asp Arg
 545 550 555 560

Leu Pro Ala Gln Leu Gly Gln Cys Arg Met Leu Lys Lys Ser Gly Leu
 565 570 575

Val Val Glu Asp His Leu Phe Asp Thr Leu Pro Leu Glu Val Lys Glu
 580 585 590

Ala Leu Asn Gln Asp Ile Asn Ile Pro Phe Ala Asn Gly Ile Xaa Thr
 595 600 605

Lys Ile Ile Tyr Ala Gln
 610

<210> 41

<211> 2386

<212> DNA

<213> Homo sapiens

<400> 41

ccaaaacatc aaaccctttt cttgtagcag cacaggattc tgagacagat tatgtcacia 60
 cagataattt aacaaaggtg actgaggaag tcgtggcaaa catgcctgaa ggcctgactc 120
 cagatttagt acaggaagca tgtgaaagt aattgaatga agttactggt acaaagattg 180
 cttatgaaac aaaaatggac ttggttcaaa catcagaagt tatgcaagag tcaactctatc 240
 ctgcagcaca gctttgccca tcatttgaag agtcagaagc tactccttca ccagttttgc 300
 ctgacattgt tatggaagca ccattgaatt ctgcagttcc tagtgctggt gcttccgtga 360
 tacagcccag ctcatcacca ttagaagctt cttcagttaa ttatgaaagc ataaaacatg 420
 agcctgaaaa cccccacca tatgaagagg ccatgagtgt atcactaaaa aaagtatcag 480
 gaataaagga agaaattaaa gagcctgaaa atattaatgc agctcttcaa gaaacagaag 540
 ctccttatat atctattgca tgtgatttaa ttaaagaaac aaagctttct gctgaaccag 600
 ctccggattt ctctgattat tcagaaatgg caaaagttga acagccagt cctgatcatt 660
 ctgagctagt tgaagattcc tcacctgatt ctgaaccagt tgacttattt agtgatgatt 720
 caatacctga cgttccacia aaacaagatg aaactgtgat gcttgtgaaa gaaagtctca 780
 ctgagacttc atttgagtca atgatagaat atgaaaataa ggaaaaactc agtgctttgc 840
 cacctgaggg aggaaagcca tatttggaat cttttaagct cagtttagat aacacaaaag 900
 ataccctgtt acctgatgaa gtttcaacat tgagcaaaaa ggagaaaatt cttttgcaga 960
 tggaggagct cagtactgca gtttattcaa atgatgactt atttatttct aaggaagcac 1020

```

agataagaga aactgaaacg ttttcagatt catctccaat tgaaattata gatgagtcc 1080
ctacattgat cagttctaaa actgattcat tttctaaatt agccagggaa tatactgacc 1140
tagaagtatc ccacaaaagt gaaattgcta atgccccgga tggagctggg tcattgcctt 1200
gcacagaatt gcccacatgac ctttctttga agaacataca acccaaagtt gaagagaaaa 1260
tcagtttttc agatgacttt tctaaaaatg ggtctgctac atcaaagggtg ctcttattgc 1320
ctccagatgt ttctgctttg gccactcaag cagagataga gagcatagtt aaacccaaag 1380
ttcttgtaga agaagctgag aaaaaacttc cttccgatac agaaaaagag gacagatcac 1440
catctgctat attttcagca gagctgagta aaacttcagt tgttgacctc ctgtactgga 1500
gagacattaa gaagactgga gtggtgtttg gtgccagcct attcctgctg ctttcattga 1560
cagtattcag cattgtgagc gtaacagcct acattgcctt ggccctgctc tctgtgacca 1620
tcagcttttag gatatacaag ggtgtgatcc aagctatcca gaaatcagat gaaggccacc 1680
cattcagggg agttgctata tctgaggagt tggttcagaa gtacagtaat tctgctcttg 1740
gtcatgtgaa ctgcacgata aaggaactca ggcgcctctt cttagttagt gatttagttg 1800
attctctgaa gtttgtagtg ttgatgtggg tatttaccta tgttggtgcc ttgtttaatg 1860
gtctgacact actgattttg gctctcattt cactcttcag tgttcctgtt atttatgaac 1920
ggcatcaggc acagatagat cattatctag gacttgcaaa taagaatgtt aaagatgcta 1980
tggctaaaat ccaagcaaaa atccctggat tgaagcgcaa agctgaatga aaacgcccac 2040
aataattagt aggagttcat ctttaaaggg gatattcatt tgattatacg ggggagggtc 2100
agggagaac gaaccttgac gttgcagtgc agtttcacag atcggttgta gatctttatt 2160
tttagccatg cactgttggt agggaaaaat acctgtcttg actgccatgt gttcatcatc 2220
ttaagtattg taagctgcta tgtatggatt taaaccgtaa tcatatcttt ttctatctg 2280
aggcactggg ggaataaaaa acctgtatat ttactttgtg tgcagatagt cttgccgcat 2340
cttggcaagt tgcagagatg gtggagctag aaaaaaaaaa aaaaaa 2386

```

<210> 42

<211> 642

<212> PRT

<213> Homo sapiens

<400> 42

```

Met Pro Glu Gly Leu Thr Pro Asp Leu Val Gln Glu Ala Cys Glu Ser
 1             5             10             15
Glu Leu Asn Glu Val Thr Gly Thr Lys Ile Ala Tyr Glu Thr Lys Met
          20             25             30
Asp Leu Val Gln Thr Ser Glu Val Met Gln Glu Ser Leu Tyr Pro Ala
          35             40             45
Ala Gln Leu Cys Pro Ser Phe Glu Glu Ser Glu Ala Thr Pro Ser Pro
          50             55             60
Val Leu Pro Asp Ile Val Met Glu Ala Pro Leu Asn Ser Ala Val Pro
          65             70             75             80
Ser Ala Gly Ala Ser Val Ile Gln Pro Ser Ser Ser Pro Leu Glu Ala
          85             90             95
Ser Ser Val Asn Tyr Glu Ser Ile Lys His Glu Pro Glu Asn Pro Pro
          100            105            110
Pro Tyr Glu Glu Ala Met Ser Val Ser Leu Lys Lys Val Ser Gly Ile
          115            120            125
Lys Glu Glu Ile Lys Glu Pro Glu Asn Ile Asn Ala Ala Leu Gln Glu
          130            135            140
Thr Glu Ala Pro Tyr Ile Ser Ile Ala Cys Asp Leu Ile Lys Glu Thr
          145            150            155            160

```

Lys Leu Ser Ala Glu Pro Ala Pro Asp Phe Ser Asp Tyr Ser Glu Met
 165 170 175
 Ala Lys Val Glu Gln Pr Val Pro Asp His Ser Glu Leu Val Glu Asp
 180 185 190
 Ser Ser Pr Asp Ser Glu Pro Val Asp Leu Phe Ser Asp Asp Ser Ile
 195 200 205
 Pro Asp Val Pro Gln Lys Gln Asp Glu Thr Val Met Leu Val Lys Glu
 210 215 220
 Ser Leu Thr Glu Thr Ser Phe Glu Ser Met Ile Glu Tyr Glu Asn Lys
 225 230 235 240
 Glu Lys Leu Ser Ala Leu Pro Pro Glu Gly Gly Lys Pro Tyr Leu Glu
 245 250 255
 Ser Phe Lys Leu Ser Leu Asp Asn Thr Lys Asp Thr Leu Leu Pro Asp
 260 265 270
 Glu Val Ser Thr Leu Ser Lys Lys Glu Lys Ile Pro Leu Gln Met Glu
 275 280 285
 Glu Leu Ser Thr Ala Val Tyr Ser Asn Asp Asp Leu Phe Ile Ser Lys
 290 295 300
 Glu Ala Gln Ile Arg Glu Thr Glu Thr Phe Ser Asp Ser Ser Pro Ile
 305 310 315 320
 Glu Ile Ile Asp Glu Phe Pro Thr Leu Ile Ser Ser Lys Thr Asp Ser
 325 330 335
 Phe Ser Lys Leu Ala Arg Glu Tyr Thr Asp Leu Glu Val Ser His Lys
 340 345 350
 Ser Glu Ile Ala Asn Ala Pro Asp Gly Ala Gly Ser Leu Pro Cys Thr
 355 360 365
 Glu Leu Pro His Asp Leu Ser Leu Lys Asn Ile Gln Pro Lys Val Glu
 370 375 380
 Glu Lys Ile Ser Phe Ser Asp Asp Phe Ser Lys Asn Gly Ser Ala Thr
 385 390 395 400
 Ser Lys Val Leu Leu Leu Pro Pro Asp Val Ser Ala Leu Ala Thr Gln
 405 410 415
 Ala Glu Ile Glu Ser Ile Val Lys Pro Lys Val Leu Val Lys Glu Ala
 420 425 430
 Glu Lys Lys Leu Pro Ser Asp Thr Glu Lys Glu Asp Arg Ser Pro Ser
 435 440 445
 Ala Ile Phe Ser Ala Glu Leu Ser Lys Thr Ser Val Val Asp Leu Leu
 450 455 460
 Tyr Trp Arg Asp Ile Lys Lys Thr Gly Val Val Phe Gly Ala Ser Leu
 465 470 475 480

Phe Leu Leu Leu Ser Leu Thr Val Phe Ser Ile Val Ser Val Thr Ala
 485 490 495
 Tyr Ile Ala Leu Ala Leu Leu Ser Val Thr Ile Ser Phe Arg Ile Tyr
 500 505 510
 Lys Gly Val Ile Gln Ala Ile Gln Lys Ser Asp Glu Gly His Pro Phe
 515 520 525
 Arg Glu Val Ala Ile Ser Glu Glu Leu Val Gln Lys Tyr Ser Asn Ser
 530 535 540
 Ala Leu Gly His Val Asn Cys Thr Ile Lys Glu Leu Arg Arg Leu Phe
 545 550 555 560
 Leu Val Asp Asp Leu Val Asp Ser Leu Lys Phe Ala Val Leu Met Trp
 565 570 575
 Val Phe Thr Tyr Val Gly Ala Leu Phe Asn Gly Leu Thr Leu Leu Ile
 580 585 590
 Leu Ala Leu Ile Ser Leu Phe Ser Val Pro Val Ile Tyr Glu Arg His
 595 600 605
 Gln Ala Gln Ile Asp His Tyr Leu Gly Leu Ala Asn Lys Asn Val Lys
 610 615 620
 Asp Ala Met Ala Lys Ile Gln Ala Lys Ile Pro Gly Leu Lys Arg Lys
 625 630 635 640

Ala Glu

<210> 43
 <211> 344
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (13)

<220>
 <221> unsure
 <222> (39)

<220>
 <221> unsure
 <222> (185)

<220>
 <221> unsure
 <222> (260)

<400> 43
 ggcggctgcg ganccggcgg tccttgcgct ccccaacanc ggcgccgagg gcgcgggggc 60
 gccgtcgggc acagtcccgg tgctcttctg tttctcagtc ttcgcgcgac cctcgtcggc 120
 gccacacggg gcgggctaca agctgctcat ccagaagttc ctcagcctgt acggcgacca 180
 gatcnacatg caccgcaaat tcgtggtgca gctgttcgcc gaggagtggg gccagtacgt 240

ggacttgccc aagggcttcn cgggtgagcga gcgctgcaag gtgcgcctcg tgccgctgca 300
tateccagctc actaccctgg gaaatcttac accttcaagc actg 344

<210> 44
<211> 631
<212> DNA
<213> Homo sapiens

<220>
<221> unsure
<222> (73)

<220>
<221> unsure
<222> (369)

<400> 44
acatgattca gagtcctgtg ggtaaattca tatgcaataa tcttattcca atcaatctgt 60
aaagtaaaag cantacatcc acattaacat tataacatct tacagtaata taaaagccaa 120
atcattgttg gtacgtcatt ttcttttaaag tgaacaattt aagaaaactt cacaagagtc 180
tgcacttttg aaagatacga tcagagtaca cagtagagac aaaacaggca tcttcattgt 240
aatttttttt aataaataaa agcacattaa caaaaaagga aggtaagcag caccggaagc 300
ctttgacgtt tgtaactaaa tgctgggtact caattgaatc gagctgggta agtttcacta 360
ggaggcgcn aaaaaggagcc gtttttgact taacatttta attctagtag agataagaag 420
agcttgtgtg ggcttacagt ccttcacctg actgtccttc accagtgagt agcataccag 480
ttcttcaaat gtctataact ttggaaagca gaccgcactc tggagcactc gccttaatta 540
gattctgaat ttccttgaat tttggatggc ccttatcagc taccagctga agcagaacag 600
cctcactcgt ggtcactatg atcccgggtc g 631

<210> 45
<211> 22
<212> PRT
<213> Homo sapiens

<400> 45
Met Val Leu Ile Ser Tyr Gln Leu Lys Gln Asn Ser Leu Thr Arg Gly
1 5 10 15
His Tyr Asp Pro Gly Ser
20

<210> 46
<211> 70
<212> DNA
<213> Homo sapiens

<400> 46
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 60
aaaaaaaaaa 70

<210> 47
<211> 428
<212> DNA
<213> Homo sapiens

<400> 47
agcacgcggt cctgcccgtg gacggggcaa cgctggcaga tgtgatgcgc cagcggggca 60
tcaacatgcg ctacctgggc aaggtgctgg agctgggtgct gcggarcccg gcccgccacc 120
agctggacca cgtctttaa atcggcattg gagaactcat caccgctcg sccaagcaca 180

tcttcaagac gtacttacag ggagtcgagc tctccggcct ctcagccgcc atcagccact 240
 tcctgaactg cttcctgagc tcctacccaa acccctggc ccacctgccc gccgacgagc 300
 tggctctccaa gaagcggaat aagaggagga aaaaccggcc cccgggggct gcagataaca 360
 cagcctgggc tgtcatgacc cccagggagc tctggaagaa catctgccag gaggccaaga 420
 actacttt 428

<210> 48
 <211> 128
 <212> PRT
 <213> Homo sapiens

<220>
 <221> UNSURE
 <222> (21)

<220>
 <221> UNSURE
 <222> (43)

<400> 48
 Met Arg Gln Arg Gly Ile Asn Met Arg Tyr Leu Gly Lys Val Leu Glu
 1 5 10 15
 Leu Val Leu Arg Xaa Pro Ala Arg His Gln Leu Asp His Val Phe Lys
 20 25 30
 Ile Gly Ile Gly Glu Leu Ile Thr Arg Ser Xaa Lys His Ile Phe Lys
 35 40 45
 Thr Tyr Leu Gln Gly Val Glu Leu Ser Gly Leu Ser Ala Ala Ile Ser
 50 55 60
 His Phe Leu Asn Cys Phe Leu Ser Ser Tyr Pro Asn Pro Val Ala His
 65 70 75 80
 Leu Pro Ala Asp Glu Leu Val Ser Lys Lys Arg Asn Lys Arg Arg Lys
 85 90 95
 Asn Arg Pro Pro Gly Ala Ala Asp Asn Thr Ala Trp Ala Val Met Thr
 100 105 110
 Pro Gln Glu Leu Trp Lys Asn Ile Cys Gln Glu Ala Lys Asn Tyr Phe
 115 120 125

<210> 49
 <211> 245
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (46)

<220>
 <221> unsure
 <222> (138)

<220>
 <221> unsure

<222> (147)

<400> 49

tgggtggggga ggatgtgccc accctgagac cgggaggaga cgggcntttg cctggggtttg 60
 cggagagccg cttatgggtg tgggtccgtcc agacaccttg tttcaagggg gatgggcgtg 120
 agcgggcaag cagagcancc ccaccgntga gcaagaactt ttttttgttt ttaaaccatc 180
 acgtcctcat ttcacattgg aataaagtga gtttttgaaa aaaaaaaaaa aaaaaaaaaa 240
 aaaaaa 245

<210> 50

<211> 566

<212> DNA

<213> Homo sapiens

<400> 50

cagtgaagccc tttgaaaaat aaacatccag atgaagatgc tgtggaagct gaggggcatg 60
 aggtaaaaag actcaggttt gacaaagaag gtgaagtcag agaaacagcc agtcaaacga 120
 cttccagcga aatttcttca gttatggtag gagaaacaga agcatcatct tcatctcagg 180
 ataaagacaa agatagccgt tgtwcccgcc agcactgtwc agaagaggat gaagaagagg 240
 atgaagagga agaagaagag tcttttatga catcaagaga aatgatccca gaaagaaaaa 300
 atcaagaaaa agaattctgat gatgccttaa ctgtgaatga agagacttct gaggaaaata 360
 atcaaatgga ggaattctgat gtgtctcaag ctgagaaaga tttgctacat tctgaaggta 420
 gtgaaaacga aggccttgta agtagtagtt cttctgactg ccgtgaaaca gaagaattag 480
 taggatccaa ttccagtaaa actggagaga ttctttcaga atcatccatg gaaaatgatg 540
 acgaagccac agaagtcacc gatgaa 566

<210> 51

<211> 141

<212> PRT

<213> Homo sapiens

<220>

<221> UNSURE

<222> (21)

<220>

<221> UNSURE

<222> (26)

<400> 51

Met Val Gly Glu Thr Glu Ala Ser Ser Ser Ser Gln Asp Lys Asp Lys
 1 5 10 15
 Asp Ser Arg Cys Xaa Arg Gln His Cys Xaa Glu Glu Asp Glu Glu Glu
 20 25 30
 Asp Glu Glu Glu Glu Glu Glu Ser Phe Met Thr Ser Arg Glu Met Ile
 35 40 45
 Pro Glu Arg Lys Asn Gln Glu Lys Glu Ser Asp Asp Ala Leu Thr Val
 50 55 60
 Asn Glu Glu Thr Ser Glu Glu Asn Asn Gln Met Glu Glu Ser Asp Val
 65 70 75 80
 Ser Gln Ala Glu Lys Asp Leu Leu His Ser Glu Gly Ser Glu Asn Glu
 85 90 95
 Gly Pro Val Ser Ser Ser Ser Ser Asp Cys Arg Glu Thr Glu Glu Leu
 100 105 110

Val Gly Ser Asn Ser Ser Lys Thr Gly Glu Ile Leu Ser Glu Ser Ser
 115 120 125

Met Glu Asn Asp Asp Glu Ala Thr Glu Val Thr Asp Glu
 130 135 140

<210> 52

<211> 531

<212> DNA

<213> Homo sapiens

<400> 52

```
tcatcatggc tataaatacc aaaacgattt ggatccattt atgtttgtag gataatatac 60
tactgactga cttgactgtc aggttcacaa cagctagatg atatatattat gactatgtct 120
aatagttgaa ataaaatctg aatattgatt tactataccc aagaggggag aaaaattaac 180
cattgtaaat ttttaaaaat tttttcaaaa atgttaaaat gaggcaaatt taagtttaca 240
aattttgaaa ttttcttttg aatatttatg aaattgtcag taaacttacc taagatcctg 300
tgaccttttg atatttttta ttttaattgt agtgccatgg accatttgta aacaaattga 360
tttacttttg ttggttgtaa gttgaagatt tagcattatg actttgaggt ctgtggtttt 420
atgtgtaaac ttgcaattgc tatatttgca agggcaaattg tatttcttta ttaaataaag 480
tacaataatg gtgaatgtac caaaatgaca tcacttaaaa aaaaaaaaaa a 531
```

<210> 53

<211> 1163

<212> DNA

<213> Homo sapiens

<400> 53

```
kctggaacca cgcggargaa ggaagagacg caggcaggct gcggttacct aagcggscac 60
ccgggcctca gggacccttc cccgagagac ggcaccatga cccagggaaa gctctccgtg 120
gctaacaagc ccctgggacc gaggggacgc agcakgtgca tggcgagaag aaggagctcc 180
agcagtgcct tcagccccac cctcctatga ggaaccacct ctggggaggg gatgaaggca 240
ggggccttcc ccccagcccc cacagcgggtg cctctccacc ctagctgggc ctatgtggac 300
cccagcagca gctccagcta tgacaacggt tccccaccg gagaccatga gctcttcacc 360
actttcagct gggatgacca gaaagtctgt cgagtctttg tcagaaaggc ctacaccatc 420
ctgctgattc agctgctggg gaccttggct gtcgtggctc tctttacttt ctgtgacctc 480
gtcaaggact atgtccaggc caaccagggc tggtagtggg catcctatgc tgtgttcttt 540
gcaacctacc tgacctggc ttgctgttct ggacctcagg ggcatttccc ctggaacctg 600
attctcctga ccgtctttac cctgtccatg gcctacctca ctgggatgct gtccagctac 660
tacaacacca cctccgtgct gctgtgcttg ggcacacagg ccttgtctg cctctcagtc 720
accgtcttca gcttccagac caagtctgac ttcacctcct gccagggcgt gctcttcgtg 780
cttctcatga ctcttttctt cagcggactc atcctggcca tctcctacc cttccaatat 840
gtgccctggc tccatgcagt ttatgcagca ctgggagcgg gtgtatttac attgttcctg 900
gcacttgaca cccagttgct gatgggtaac cgacgccact cgctgagccc tgaggagtat 960
atttttggag ccctcaacat ttacctagac atcatctata tcttcacctt cttcctgcag 1020
ctttttggca ctaaccgaga atgaggagcc ctccctgccc caccgtcctc cagagaatgc 1080
gcccctcctg gttccctgtc cctccctgct gctcctgcga gaccagatat aaaactagct 1140
gccaacccaa aaaaaaaaaa aaa 1163
```

<210> 54

<211> 270

<212> PRT

<213> Homo sapiens

<400> 54

Met Lys Ala Gly Ala Phe Pro Pro Ala Pro Thr Ala Val Pro Leu His
 1 5 10 15

Pro Ser Trp Ala Tyr Val Asp Pro Ser Ser Ser Ser Ser Tyr Asp Asn
 20 25 30
 Gly Phe Pro Thr Gly Asp His Glu Leu Phe Thr Thr Phe Ser Trp Asp
 35 40 45
 Asp Gln Lys Val Arg Arg Val Phe Val Arg Lys Val Tyr Thr Ile Leu
 50 55 60
 Leu Ile Gln Leu Leu Val Thr Leu Ala Val Val Ala Leu Phe Thr Phe
 65 70 75 80
 Cys Asp Pro Val Lys Asp Tyr Val Gln Ala Asn Pro Gly Trp Tyr Trp
 85 90 95
 Ala Ser Tyr Ala Val Phe Phe Ala Thr Tyr Leu Thr Leu Ala Cys Cys
 100 105 110
 Ser Gly Pro Arg Arg His Phe Pro Trp Asn Leu Ile Leu Leu Thr Val
 115 120 125
 Phe Thr Leu Ser Met Ala Tyr Leu Thr Gly Met Leu Ser Ser Tyr Tyr
 130 135 140
 Asn Thr Thr Ser Val Leu Leu Cys Leu Gly Ile Thr Ala Leu Val Cys
 145 150 155 160
 Leu Ser Val Thr Val Phe Ser Phe Gln Thr Lys Phe Asp Phe Thr Ser
 165 170 175
 Cys Gln Gly Val Leu Phe Val Leu Leu Met Thr Leu Phe Phe Ser Gly
 180 185 190
 Leu Ile Leu Ala Ile Leu Leu Pro Phe Gln Tyr Val Pro Trp Leu His
 195 200 205
 Ala Val Tyr Ala Ala Leu Gly Ala Gly Val Phe Thr Leu Phe Leu Ala
 210 215 220
 Leu Asp Thr Gln Leu Leu Met Gly Asn Arg Arg His Ser Leu Ser Pro
 225 230 235 240
 Glu Glu Tyr Ile Phe Gly Ala Leu Asn Ile Tyr Leu Asp Ile Ile Tyr
 245 250 255
 Ile Phe Thr Phe Phe Leu Gln Leu Phe Gly Thr Asn Arg Glu
 260 265 270

<210> 55
 <211> 624
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (123)

<400> 55
 cgcacccccct ccggccgcgg gcgcakcggg ggcgctggtg gakctgmga gggccasgtc 60

cggcgggagg ggcggcggtt ggcactggct ccggactctg cccggccagg gcggcggttc 120
 canccgggag ggcgacgtgg agcggccack tggakeggcc cgggggargc tggcgggcgg 180
 akcgagggcg cgggcgggcg akcakccakg agcgcccacg gagstggacc cccagakccg 240
 cgcggcgccg cagcagttcc aggaaggatg ttacctttga cgatgacagt gttaatcctg 300
 ctgctgctcc ccacgggtca ggctgccccca aaggatggag tcacaaggcc agaattctgaa 360
 gtgcagcatc agctcctgcc caacccttc cagccaggcc aggagcagct cggacttctg 420
 cagagctacc taaagggact aggaaggaca gaagtgaac tggagcatct gagccgggag 480
 caggttctcc tctacctctt tgccctccat gactatgacc agagtggaca gctggatggc 540
 ctggagctgc tgtccatgtt gacagctgct ctggcccctg gagctgcaa ctctcctacc 600
 accaaccggt tgatcttgat agtg 624

<210> 56

<211> 119

<212> PRT

<213> Homo sapiens

<400> 56

Met Leu Pro Leu Thr Met Thr Val Leu Ile Leu Leu Leu Leu Pro Thr
 1 5 10 15

Gly Gln Ala Ala Pro Lys Asp Gly Val Thr Arg Pro Glu Ser Glu Val
 20 25 30

Gln His Gln Leu Leu Pro Asn Pro Phe Gln Pro Gly Gln Glu Gln Leu
 35 40 45

Gly Leu Leu Gln Ser Tyr Leu Lys Gly Leu Gly Arg Thr Glu Val Gln
 50 55 60

Leu Glu His Leu Ser Arg Glu Gln Val Leu Leu Tyr Leu Phe Ala Leu
 65 70 75 80

His Asp Tyr Asp Gln Ser Gly Gln Leu Asp Gly Leu Glu Leu Leu Ser
 85 90 95

Met Leu Thr Ala Ala Leu Ala Pro Gly Ala Ala Asn Ser Pro Thr Thr
 100 105 110

Asn Pro Val Ile Leu Ile Val
 115

<210> 57

<211> 80

<212> DNA

<213> Homo sapiens

<400> 57

aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 60
 aaaaaaaaaa aaaaaaaaaa 80

<210> 58

<211> 2160

<212> DNA

<213> Homo sapiens

<400> 58

agacagggaa tactttattc aaaacccatc acagaaatgg acagcttggg tctgtaacaa 60
 agcattcatg ttttagagca taggtcagta attgtatatg agagcatata ctgctacata 120
 caaattaact gatcagacca caacttttca atgttttaaaa cagaataagc ttcctgttaa 180


```

aagcagcacc tttgtgacgt ttttaacttta gtatttctct ccttcttctt caccctctcc 240
ttcaacagaa tccacaccaa cctcctcata atccttcttc gcagcacatg aatcacaggt 300
attcctactg caagcgggag gcgaggagc gggaagcggc ggagcgcgag gcgcgcgaga 360
aagggcactt ggaacccacc gagctgctga tgaaccgggc ttacttgcag agcattaccc 420
ctcaggggta ctctgactcg gaggagaggg agagtatgcc gagggatggc gagagcgaga 480
aggagcacga gaaagaaggc gaggatggct acgggaagct gggcagacag gatggcgacg 540
aggagttcga ggaggaagag gaagaaagtg aaaataaaag tatggatacg gatcccgaaa 600
cgatacgaga tgaagaagag actggagatc actccatgga cgatagtctg gaggatggga 660
aaatggaaac caaatcagac cacgaggaag acaatatgga agatggcatg taataaacta 720
ctgcatttta agcttcttat ttttttttcc agtagtattg ttacctgctt gaaaacactg 780
ctgtgttaag ctgttcatgc acgtgcctga cgcttccagg aagctgtaga gagggacaga 840
aggggcgggt cagccaagac agatgtagac ggagttggag ctgggtattg ttaaaaactg 900
cattatgcaa aaattttgta cagtgttaag gcctaaaaac tgtgtggttc agagactaat 960
tcctgtgttt aatagcattt atactttaag cacaactaga aaattgtaag aattgcactc 1020
tacttatgta tcactacaaa ctttaaaaaa ctatgtctaa tttatattaa tacattttta 1080
aaaggtgccc gcactaccat acatcagtat ttttattatt attattgtta ttccttttta 1140
atttaaatgt ctcgcactac aatgcacag tattatgatt cctctgtact ttcctttcgc 1200
tattcatcaa tttcccatct tttttttcag cttaagtaac cacacaattt taggcctcaa 1260
tttttttttt tctgtgaagg aacttgaagt gatgcatgtg tgaatttaag ataccgaagt 1320
cttaaagtga cctggacgtg aaggaaaaag taagatgaga aataaagaaa gcctttgtaa 1380
gggtggtttt aaagccttat atgcaaacct tttaatctgt gtttctgcaa gtgccatcct 1440
tgtacagtgt taagagggtg acatgggtta cctttgcacc agcttcagt ttaagctcac 1500
cctgttcttt gaagcaccca tgtcagtatt agaagaatag gcagcagttc cttagtttac 1560
atatgtttgt gcaattattt tctgtacttt tttgttcatt aattttgtca gtattacacc 1620
aaactgtttt tgcaacaaaa aaattttttt tgcattcatt taattttagg tcaaataaca 1680
ttttatttat gtggctcatt ttatatctcc taattttatt tatttcatac tgtagtgtac 1740
agtattatag ttcttcaata tatagatata ttttagtaaa aaaggaacat gacgttgatc 1800
atttgggcaa attttacgta aagagaagag catttattgt gttttggaac attaatgtg 1860
agatgggatt tttcaatttt attattttat ttttgttttt ttccaattac tggaaattcc 1920
aaatttggga acttttgata cgatcttgtg aaaacactgt attttcgact gaaaattcca 1980
ctttcttcac ctgttttttt agctaaaaag agggactgtt aaatacaatg tatgatacca 2040
tgacaaaaat ctttcttgaa ttgtctttgt aaaagtatta ttgaattttc aatttgtaat 2100
ttcttttgaa aatgaccatg ctgcaataaa aatgtagcca aactaaaaaa aaaaaaaaaa 2160

```

<210> 59

<211> 141

<212> PRT

<213> Homo sapiens

<400> 59

```

Met Asn His Arg Tyr Ser Tyr Cys Lys Arg Glu Ala Glu Glu Arg Glu
  1              5              10              15

```

```

Ala Ala Glu Arg Glu Ala Arg Glu Lys Gly His Leu Glu Pro Thr Glu
      20              25              30

```

```

Leu Leu Met Asn Arg Ala Tyr Leu Gln Ser Ile Thr Pro Gln Gly Tyr
  35              40              45

```

```

Ser Asp Ser Glu Glu Arg Glu Ser Met Pro Arg Asp Gly Glu Ser Glu
  50              55              60

```

```

Lys Glu His Glu Lys Glu Gly Glu Asp Gly Tyr Gly Lys Leu Gly Arg
  65              70              75              80

```

```

Gln Asp Gly Asp Glu Glu Phe Glu Glu Glu Glu Glu Ser Glu Asn
      85              90              95

```

```

Lys Ser Met Asp Thr Asp Pro Glu Thr Ile Arg Asp Glu Glu Glu Thr
  100             105             110

```

Gly Asp His Ser Met Asp Asp Ser Ser Glu Asp Gly Lys Met Glu Thr
 115 120 125

Lys Ser Asp His Glu Glu Asp Asn Met Glu Asp Gly Met
 130 135 140

<210> 60

<211> 2168

<212> DNA

<213> Homo sapiens

<400> 60

```
gcagttactg ggaggggggct tgctgtggcc ctgtcaggaa gagtagagct ctggtccagc 60
tccgcgcagg gagggaggct gtcaccatgc cggcctgctg cagctgcagt gatgttttcc 120
agtatgagac gaacaaagtc actcggatcc agagcatgaa ttatggcacc attaatgtgt 180
tcttcacagt gatcatcttt tcctacgttt gctttgctc- ggtgagtgac aagctgtacc 240
agcggaaaga gcctgtcatc agttctgtgc acaccaaggc gaaggggata gcagaggtga 300
aagaggagat cgtggagaat ggagtgaaga agttgggtgca cagtgtcttt gacaccgcag 360
actacacctt ccctttgcag gggaactctt tcttcgtgat gacaaacttt ctcaaacag 420
aaggccaaga gcagcgggtg tgteccagag atcccaccgc caggacgctc tgttcctctg 480
accgaggttg taaaaaggga tggatggacc cgcagagcaa aggaattcag accggaaggt 540
gtgtagtgca tgaagggaac cagaagacct gtgaagtctc tgcctgggtg cccatcgagg 600
cagtggaaaga ggccccccgg cctgctctct tgaacagtgc cgaaaacttc actgtgctca 660
tcaagaacaa tatcgacttc cccggccaca actacaccac gagaaacatc ctgccagggt 720
taaacatcac ttgtaccttc cacaagactc agaatccaca gtgtccatt ttccgactag 780
gagacatctt ccgagaaaca ggcgataatt ttccagatgt ggcaattcag ggcggaataa 840
tgggcattga gatctactgg gactgcaacc tagaccgttg gtcccatcac tgccatccca 900
aatacagttt ccgtcgcctt gacgacaaga ccaccaacgc- gtccctgtac cctgggtaca 960
acttcagata cgccaagtac tacaaggaaa acaatgttga gaaacggact ctgataaaaag 1020
tcttcgggat ccgttttgac atcctgggtt ttggcaccgg aggaaaattt gacattatcc 1080
agctgggtgt gtacatcggc tcaaccctct cctacttcgg tctggccgct gtgttcacg 1140
acttcctcat cgacacttac tccagtaact gctgtcgcct ccataattat ccctgggtgca 1200
agtgtgtca gccctgtgtg gtcaacgaat actactacag gaagaagtgc gagtccattg 1260
tggagccaaa gccgacatta aagtatgtgt ccttcgtgga tgaatccac attaggatgg 1320
tgaaccagca gctactaggg agaagtctgc aagatgtcaa gggccaagaa gtcccaagac 1380
ctgcgatgga cttcacagat ttgtccaggc tgccccctgg cctccatgac acacccccga 1440
ttcctggaca accagaggag atacagctgc ttagaaagga ggcgactcct agatccaggg 1500
atagccccgt ctggtgccag tgtggaagct gcctcccatc tcaactccct gagagccaca 1560
ggtgcctgga ggagctgtgc tgccggaaaa agccgggggc ctgcatcacc acctcagagc 1620
tgttcaggaa gctggtcctg tccagacacg tcctgcagtc- cctcctgctc taccaggagc 1680
ccttgctggc gctggatgtg gattccacca acagccggc- gcggcactgt gcctacaggt 1740
gctacgccac ctggcgcttc ggctcccagg acatggctga ctttgccatc ctgcccagct 1800
gctgccgctg gaggatccgg aaagagtttc cgaagagtga agggcagtac agtggcttca 1860
agagtcctta ctgaagccag gcgccgtggc tcacgtctgt aatcccagcg ctttgggagg 1920
ccgaggcagg cagatcacct gaggtcggga gttggagacc cgcctggcta acaaggcgaa 1980
atcctgtctg tactaaaaat acaaaaatca gccagacatg gtggcatgca cctgcaatcc 2040
cagctactcg ggaggctgag gcacaagaat cacttgaacc cgggaggcag aggttgtagt 2100
gagcccagat tgtgccactg ctctccagcc tgggaggcac agcaaactgt ccccaaaaaa 2160
aaaaaaaaa 2168
```

<210> 61

<211> 595

<212> PRT

<213> Homo sapiens

<400> 61

Met Pro Ala Cys Cys Ser Cys Ser Asp Val Phe Gln Tyr Glu Thr Asn
 1 5 10 15

Lys Val Thr Arg Ile Gln Ser Met Asn Tyr Gly Thr Ile Lys Trp Phe
 20 25 30
 Phe His Val Ile Ile Phe Ser Tyr Val Cys Phe Ala Leu Val Ser Asp
 35 40 45
 Lys Leu Tyr Gln Arg Lys Glu Pro Val Ile Ser Ser Val His Thr Lys
 50 55 60
 Val Lys Gly Ile Ala Glu Val Lys Glu Glu Ile Val Glu Asn Gly Val
 65 70 75 80
 Lys Lys Leu Val His Ser Val Phe Asp Thr Ala Asp Tyr Thr Phe Pro
 85 90 95
 Leu Gln Gly Asn Ser Phe Phe Val Met Thr Asn Phe Leu Lys Thr Glu
 100 105 110
 Gly Gln Glu Gln Arg Leu Cys Pro Glu Tyr Pro Thr Arg Arg Thr Leu
 115 120 125
 Cys Ser Ser Asp Arg Gly Cys Lys Lys Gly Trp Met Asp Pro Gln Ser
 130 135 140
 Lys Gly Ile Gln Thr Gly Arg Cys Val Val His Glu Gly Asn Gln Lys
 145 150 155 160
 Thr Cys Glu Val Ser Ala Trp Cys Pro Ile Glu Ala Val Glu Glu Ala
 165 170 175
 Pro Arg Pro Ala Leu Leu Asn Ser Ala Glu Asn Phe Thr Val Leu Ile
 180 185 190
 Lys Asn Asn Ile Asp Phe Pro Gly His Asn Tyr Thr Thr Arg Asn Ile
 195 200 205
 Leu Pro Gly Leu Asn Ile Thr Cys Thr Phe His Lys Thr Gln Asn Pro
 210 215 220
 Gln Cys Pro Ile Phe Arg Leu Gly Asp Ile Phe Arg Glu Thr Gly Asp
 225 230 235 240
 Asn Phe Ser Asp Val Ala Ile Gln Gly Gly Ile Met Gly Ile Glu Ile
 245 250 255
 Tyr Trp Asp Cys Asn Leu Asp Arg Trp Phe His His Cys His Pro Lys
 260 265 270
 Tyr Ser Phe Arg Arg Leu Asp Asp Lys Thr Thr Asn Val Ser Leu Tyr
 275 280 285
 Pro Gly Tyr Asn Phe Arg Tyr Ala Lys Tyr Tyr Lys Glu Asn Asn Val
 290 295 300
 Glu Lys Arg Thr Leu Ile Lys Val Phe Gly Ile Arg Phe Asp Ile Leu
 305 310 315 320
 Val Phe Gly Thr Gly Gly Lys Phe Asp Ile Ile Gln Leu Val Val Tyr
 325 330 335

Ile Gly Ser Thr Leu Ser Tyr Phe Gly Leu Ala Ala Val Phe Ile Asp
 340 345 350
 Phe Leu Ile Asp Thr Tyr Ser Ser Asn Cys Cys Arg Ser His Ile Tyr
 355 360 365
 Pro Trp Cys Lys Cys Cys Gln Pro Cys Val Val Asn Glu Tyr Tyr Tyr
 370 375 380
 Arg Lys Lys Cys Glu Ser Ile Val Glu Pro Lys Pro Thr Leu Lys Tyr
 385 390 395 400
 Val Ser Phe Val Asp Glu Ser His Ile Arg Met Val Asn Gln Gln Leu
 405 410 415
 Leu Gly Arg Ser Leu Gln Asp Val Lys Gly Gln Glu Val Pro Arg Pro
 420 425 430
 Ala Met Asp Phe Thr Asp Leu Ser Arg Leu Pro Leu Ala Leu His Asp
 435 440 445
 Thr Pro Pro Ile Pro Gly Gln Pro Glu Glu Ile Gln Leu Leu Arg Lys
 450 455 460
 Glu Ala Thr Pro Arg Ser Arg Asp Ser Pro Val Trp Cys Gln Cys Gly
 465 470 475 480
 Ser Cys Leu Pro Ser Gln Leu Pro Glu Ser His Arg Cys Leu Glu Glu
 485 490 495
 Leu Cys Cys Arg Lys Lys Pro Gly Ala Cys Ile Thr Thr Ser Glu Leu
 500 505 510
 Phe Arg Lys Leu Val Leu Ser Arg His Val Leu Gln Phe Leu Leu Leu
 515 520 525
 Tyr Gln Glu Pro Leu Leu Ala Leu Asp Val Asp Ser Thr Asn Ser Arg
 530 535 540
 Leu Arg His Cys Ala Tyr Arg Cys Tyr Ala Thr Trp Arg Phe Gly Ser
 545 550 555 560
 Gln Asp Met Ala Asp Phe Ala Ile Leu Pro Ser Cys Cys Arg Trp Arg
 565 570 575
 Ile Arg Lys Glu Phe Pro Lys Ser Glu Gly Gln Tyr Ser Gly Phe Lys
 580 585 590
 Ser Pro Tyr
 595

<210> 62

<211> 430

<212> DNA

<213> Homo sapiens

<400> 62

taaagatctg tgttcagagt cataactgaay agagacttct ggactctata gaaccactg 60

cctcctgatg aagtcacctac tgttcaccct tgcagttttt atgctcctgg cccaattggt 120
 ctcaggtaat tggatgtga aaaagtgtct aaacgacgtt ggaatttgca agaagaagtg 180
 caaacctgaa gagatgcatg taaagaatgg ttgggcaatg tgcggcaaac aaagggactg 240
 ctgtgttcca gctgacagac gtgctaatta tcctgttttc tgtgtccaga caaagactac 300
 aagaatttca acagtaacag caacaacagc aacaacaact ttgatgatga ctactgtctc 360
 gatgtcttcg atggctccta cccgtttctc ccactggttg aacattccag cctctgtctc 420
 ctgctctagg 430

<210> 63

<211> 121

<212> PRT

<213> Homo sapiens

<400> 63

Met Lys Ser Leu Leu Phe Thr Leu Ala Val Phe Met Leu Leu Ala Gln
 1 5 10 15

Leu Val Ser Gly Asn Trp Tyr Val Lys Lys Cys Leu Asn Asp Val Gly
 20 25 30

Ile Cys Lys Lys Lys Cys Lys Pro Glu Glu Met His Val Lys Asn Gly
 35 40 45

Trp Ala Met Cys Gly Lys Gln Arg Asp Cys Cys Val Pro Ala Asp Arg
 50 55 60

Arg Ala Asn Tyr Pro Val Phe Cys Val Gln Thr Lys Thr Thr Arg Ile
 65 70 75 80

Ser Thr Val Thr Ala Thr Thr Ala Thr Thr Thr Leu Met Met Thr Thr
 85 90 95

Ala Ser Met Ser Ser Met Ala Pro Thr Arg Phe Ser His Trp Leu Asn
 100 105 110

Ile Pro Ala Ser Val Ser Cys Ser Arg
 115 120

<210> 64

<211> 112

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (8)

<220>

<221> unsure

<222> (12)

<220>

<221> unsure

<222> (36)

<220>

<221> unsure

<222> (41)

<220>

<221> unsure

<222> (44)

<400> 64

tttcctgntt tnggatcccc gattcattaa agcaangggg nttnaaaaaa aaaaaaaaaa 60
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 112

<210> 65

<211> 324

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (1)

<220>

<221> unsure

<222> (69)

<220>

<221> unsure

<222> (74)

<220>

<221> unsure

<222> (125)

<220>

<221> unsure

<222> (159)

<400> 65

nctaccccaa cctgtgtggc tgggccgcgg tctccctca agggcctggg gccgtgcctc 60
gggtgtacnc gtanggtct gtgtgctggg ggtggctcac cgggcagcgt gggtgagcgg 120
cgcanccggc gcagcggaga acgagagagg ggagcagana cagaatcgcc taagctgaag 180
tgtattggcg ccattcatggc tcaactgcggc ctccggctcc ttggctcggg tgattctcct 240
gcctgagcct ccctagtagc taggactaca gtgctgtaga agaaaatcac atgattgggtg 300
ccctcaaaaa attggtgccca cttg 324

<210> 66

<211> 794

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (61)

<220>

<221> unsure

<222> (82)

<220>

<221> unsure

<222> (108)..(120)

<220>

<221> unsure

<222> (184)

<220>

<221> unsure

<222> (754)

<400> 66

cattatttca tcaccagaga atacacatgc agcaaatagc attgtgagtc aaactattcc 60
naaagcacag attcagcaat cnacacacac tcattctggat atctcacnnn nnnnnnnnnn 120
ttaactgatg aaaaaagtaa tggaacaatt gcccttgtgg atgattctga ggatcctgga 180
gccnatgtat ctaacataca gcttcagcaa aaaatttcaa gtctggagat taaactcaaa 240
gtatctgaag aagaaaaaca gagaattaaa caggatgtgg aakcattgat ggaaaagcat 300
aatgtcttag aaaaaggctt tctaaaagaa aaagagcaag aggccatttc ttttcaagat 360
agatacaaag aacttcagga aaaacataaa caagaattgg aagacatgag gaaagctggg 420
cacgaagccc tcagcattat tgtggatgaa tataaggcac tactgcagtc ttcagttaag 480
caacaagtag aagctattga aaaacagtac atttctgcaa ttgagaaaca ggcacacaag 540
tgtgaggagt tgctaaatgc tcagcatcag aggctccttg aagtgctaga tacagagaag 600
gaactgttaa aagaaaaaat aaaggaagct ttgattcagc aatctcaaga acagaaggaa 660
atattggaaa agtgttttga ggaagaaagg caaagaaata aagaggcatt agtatccgct 720
gcaaagcttg aaaaagaacc agtgaaggat gcanttttaa aattcgtaga agaagaaaga 780
aaaaaaaaaa aaaa 794

<210> 67

<211> 164

<212> PRT

<213> Homo sapiens

<220>

<221> UNSURE

<222> (156)

<400> 67

Met Glu Lys His Asn Val Leu Glu Lys Gly Phe Leu Lys Glu Lys Glu
1 5 10 15
Gln Glu Ala Ile Ser Phe Gln Asp Arg Tyr Lys Glu Leu Gln Glu Lys
20 25 30
His Lys Gln Glu Leu Glu Asp Met Arg Lys Ala Gly His Glu Ala Leu
35 40 45
Ser Ile Ile Val Asp Glu Tyr Lys Ala Leu Leu Gln Ser Ser Val Lys
50 55 60
Gln Gln Val Glu Ala Ile Glu Lys Gln Tyr Ile Ser Ala Ile Glu Lys
65 70 75 80
Gln Ala His Lys Cys Glu Glu Leu Leu Asn Ala Gln His Gln Arg Leu
85 90 95
Leu Glu Val Leu Asp Thr Glu Lys Glu Leu Leu Lys Glu Lys Ile Lys
100 105 110
Glu Ala Leu Ile Gln Gln Ser Gln Glu Gln Lys Glu Ile Leu Glu Lys
115 120 125
Cys Leu Glu Glu Glu Arg Gln Arg Asn Lys Glu Ala Leu Val Ser Ala
130 135 140
Ala Lys Leu Glu Lys Glu Pro Val Lys Asp Ala Xaa Leu Lys Phe Val

145

150

155

160

Glu Glu Glu Arg

<210> 68

<211> 1494

<212> DNA

<213> Homo sapiens

<400> 68

```

cgtttgctga cgccgctgcc accgcctgcc tgagagaagt cgtcgcggcc gaccccgctcg 60
cctccgccgg ctaccatgtc cgcccaggcg cagatgcggg ccttgctgga ccagctcatg 120
ggcacggctc gggacggaga cgaaaccaga cagagggtca agtttacaga tgaccgtgtc 180
tgcaagagtc accttctgga ctgctgcccc catgacatcc tggctgggac gcgcatggat 240
ttaggagaat gtacaaaaat ccacgacttg gccctccgag cagattatga gattgcaagt 300
aaagaaagag acctgttttt tgaattagat gcaatggatc acttgaggtc ctttattgct 360
gaatgtgatc ggagaactga gctcgccaag aagcggtctg cagaaacaca ggaggaaatc 420
agtgcggaag tttctgcaaa ggcaggaaaa gtacatgagt taaatgaaga aataggaaaa 480
ctccttgcta aagccgaaca gctaggggct gaaggtaatg tggatgaatc ccagaagatt 540
cttatggaag tggaaaaagt tctgtcgaag aaaaaagaag ctgaggaaga atacagaaat 600
tccatgcctg catccagttt tcagcagcaa aagctgcgtg tctgcgaggt ctgttcagcc 660
taccttggtc tccatgacaa tgaccgtcgc ctggcagacc acttcggtgg caagttacac 720
ttgggggttca ttcagatccg agagaagctt gatcagttga ggaaaactgt cgctgaaaag 780
caggagaaga gaaatcagga tcgcttgagg aggagagagg agaggggaac ggaggagcgt 840
ctgagcagga ggtcgggatc aagaaccaga gatcgagga ggtcacgctc ccgggatcgg 900
cgtcggaggc ggtcaagatc tacctcccga gagcgacgga aattgtcccg gtcccgggtc 960
cgagatagac atcggcgcca ccgcagccgt tcccggagcc acagccgggg acatcgctcg 1020
gcttcccggg accgaagtgc gaaatacaag taactactct gactccttcg gtagctgcaa 1080
ccaggagttc tccagagagc gggcatccag agaggagtcc tgggagagcg ggcggagcga 1140
gcgagggccc ccgactgga ggcttgagag ctccaacggg aagatggctt cacggaggtc 1200
agaagagaag gaggccggcg agatctgaac ccgtctcccg ggtgctgtaa atagtctgat 1260
aaacgttcac acagtcctaa attacccttt atatttctg aatacaactc atcttttgta 1320
gtttaaaatt tctattgttt tggagctagc tgtgagtttc tagaagtgtg cagagttgct 1380
cctgtgttcc cgggtcatgt tgagtaggaa taaataaatc tgatgctgcc tcctggaaaa 1440
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 1494

```

<210> 69

<211> 325

<212> PRT

<213> Homo sapiens

<400> 69

```

Met Ser Ala Gln Ala Gln Met Arg Ala Leu Leu Asp Gln Leu Met Gly
 1             5             10             15

Thr Ala Arg Asp Gly Asp Glu Thr Arg Gln Arg Val Lys Phe Thr Asp
      20             25             30

Asp Arg Val Cys Lys Ser His Leu Leu Asp Cys Cys Pro His Asp Ile
      35             40             45

Leu Ala Gly Thr Arg Met Asp Leu Gly Glu Cys Thr Lys Ile His Asp
      50             55             60

Leu Ala Leu Arg Ala Asp Tyr Glu Ile Ala Ser Lys Glu Arg Asp Leu
      65             70             75             80

Phe Phe Glu Leu Asp Ala Met Asp His Leu Glu Ser Phe Ile Ala Glu

```

85					90					95						
Cys	Asp	Arg	Arg	Thr	Glu	Leu	Ala	Lys	Lys	Arg	Leu	Ala	Glu	Thr	Gln	
100					105					110						
Glu	Glu	Ile	Ser	Ala	Glu	Val	Ser	Ala	Lys	Ala	Gly	Lys	Val	His	Glu	
115					120					125						
Leu	Asn	Glu	Glu	Ile	Gly	Lys	Leu	Leu	Ala	Lys	Ala	Glu	Gln	Leu	Gly	
130					135					140						
Ala	Glu	Gly	Asn	Val	Asp	Glu	Ser	Gln	Lys	Ile	Leu	Met	Glu	Val	Glu	
145					150					155					160	
Lys	Val	Arg	Ala	Lys	Lys	Lys	Glu	Ala	Glu	Glu	Glu	Tyr	Arg	Asn	Ser	
165					170					175						
Met	Pro	Ala	Ser	Ser	Phe	Gln	Gln	Gln	Lys	Leu	Arg	Val	Cys	Glu	Val	
180					185					190						
Cys	Ser	Ala	Tyr	Leu	Gly	Leu	His	Asp	Asn	Asp	Arg	Arg	Leu	Ala	Asp	
195					200					205						
His	Phe	Gly	Gly	Lys	Leu	His	Leu	Gly	Phe	Ile	Gln	Ile	Arg	Glu	Lys	
210					215					220						
Leu	Asp	Gln	Leu	Arg	Lys	Thr	Val	Ala	Glu	Lys	Gln	Glu	Lys	Arg	Asn	
225					230					235					240	
Gln	Asp	Arg	Leu	Arg	Arg	Arg	Glu	Glu	Arg	Glu	Arg	Glu	Glu	Arg	Leu	
245					250					255						
Ser	Arg	Arg	Ser	Gly	Ser	Arg	Thr	Arg	Asp	Arg	Arg	Arg	Ser	Arg	Ser	
260					265					270						
Arg	Asp	Arg	Arg	Arg	Arg	Arg	Ser	Arg	Ser	Thr	Ser	Arg	Glu	Arg	Arg	
275					280					285						
Lys	Leu	Ser	Arg	Ser	Arg	Ser	Arg	Asp	Arg	His	Arg	Arg	His	Arg	Ser	
290					295					300						
Arg	Ser	Arg	Ser	His	Ser	Arg	Gly	His	Arg	Arg	Ala	Ser	Arg	Asp	Arg	
305					310					315					320	
Ser	Ala	Lys	Tyr	Lys												
325																

<210> 70

<211> 1761

<212> DNA

<213> Homo sapiens

<400> 70

```

caaggggaagt tctgaggggt gagaggttgc tcattcgtca gagcgtgctg cccaccctcc 60
acccttgcac ggcagaaact gtgcagggga cgaggccaag gaatcaggag acccagagge 120
aggggtggcc cggagacggt gaagaaacca agacgcagag aggccaagcc ccttgccttg 180
ggtcacacag ccaaaggagg cagagccaga actcacaacc agatccagag gcaacaggga 240
catggccacc tgggacgaaa aggcagtcac ccgcagggcc aaggtggctc ccgctgagag 300
gatgagcaag ttcttaaggc acttcacggt cgtgggagac gactaccatg cctggaacat 360

```

```

caactacaag aaatgggaga atgaagagga ggaggaggag gaggagcagc caccacccac 420
accagtctca ggcgaggaag gcagagctgc agccccctgac gttgcccctg cccctggccc 480
cgcacccagg gcccccttg acttcagggg catgttgagg aaactgttca gctcccacag 540
gtttcaggtc atcatcatct gcttggtggt tctggatgcc ctcttggtgc ttgctgagct 600
catcctggac ctgaagatca tccagcccga caagaataac tatgctgcca tggatttcca 660
ctacatgagc atcaccatct tggctctttt tatgatggag atcatcttta aattatttgt 720
cttccgcttg gagttctttc accacaagtt tgagatcctg gatgccgtcg tgggtggtggt 780
ctcattcatc ctgacattg tctcctgtt ccaggagcac cagtttgagg ctctgggcct 840
gctgattctg ctccggctgt ggcgggtggc ccggatcatc aatgggatta tcatctcagt 900
taagacacgt tcagaacggc aactcttaag gttaaaacag atgaatgtac aattggccgc 960
caagattcaa caccttgagt tcagctgctc tgagaaggaa caagaaattg aaagacttaa 1020
caaaactattg cgacagcatg gacttcttgg tgaagtgaac tagaccgga ccagctcccc 1080
tcaaaaagaa gacactgtct catgggcctg tgctgtcacg agaggaacag ctgcccctcc 1140
tgggcccgtt ggtgagaggt ttggtttgat acctctgctt cctcctgcc agcatggatt 1200
ctgggtggac acagccttgt ggaaggtcca gtaccaccaa gagctgcca tccactcca 1260
ccccacactg tatcaaatgt atcacatttt ctcattgtga acacttttagc ctttaattgaa 1320
aatgagcaac aaagctggac aattgctagt tgtatataaa atttaatctc accgaatgta 1380
cagttttcaa atttcacgtg tatattaagg aactgatgca tctgagcatt ctgaaagaaa 1440
gaaaaagaag ctacttttagc tgccacccca ttctagaaaa gtctcttatt ttcaagctgt 1500
tctaaatagc ttcgtctcag tttccccaaa aggggtaccc aggccctcc tctgtgtgcc 1560
ccagctgcat cagccagctt ctaggtggct ccattgtttt ctgccacctg acaacatttt 1620
tcctcaatta ctgtacaact actgtataaa ataaaacaac tactgtataa aataaactct 1680
ctcttttccc tggaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1740
aaaaaaaaaa aaaaaaaaaa a 1761

```

<210> 71

<211> 273

<212> PRT

<213> Homo sapiens

<400> 71

```

Met Ala Thr Trp Asp Glu Lys Ala Val Thr Arg Arg Ala Lys Val Ala
  1              5              10              15

```

```

Pro Ala Glu Arg Met Ser Lys Phe Leu Arg His Phe Thr Val Val Gly
      20              25              30

```

```

Asp Asp Tyr His Ala Trp Asn Ile Asn Tyr Lys Lys Trp Glu Asn Glu
    35              40              45

```

```

Glu Glu Glu Glu Glu Glu Glu Gln Pro Pro Pro Thr Pro Val Ser Gly
    50              55              60

```

```

Glu Glu Gly Arg Ala Ala Ala Pro Asp Val Ala Pro Ala Pro Gly Pro
    65              70              75              80

```

```

Ala Pro Arg Ala Pro Leu Asp Phe Arg Gly Met Leu Arg Lys Leu Phe
      85              90              95

```

```

Ser Ser His Arg Phe Gln Val Ile Ile Ile Cys Leu Val Val Leu Asp
    100              105              110

```

```

Ala Leu Leu Val Leu Ala Glu Leu Ile Leu Asp Leu Lys Ile Ile Gln
    115              120              125

```

```

Pro Asp Lys Asn Asn Tyr Ala Ala Met Val Phe His Tyr Met Ser Ile
    130              135              140

```

```

Thr Ile Leu Val Phe Phe Met Met Glu Ile Ile Phe Lys Leu Phe Val
    145              150              155              160

```


Phe Arg Leu Glu Phe Phe His His Lys Phe Glu Ile Leu Asp Ala Val
 165 170 175
 Val Val Val Val Ser Phe Ile Leu Asp Ile Val Leu Leu Phe Gln Glu
 180 185 190
 His Gln Phe Glu Ala Leu Gly Leu Leu Ile Leu Leu Arg Leu Trp Arg
 195 200 205
 Val Ala Arg Ile Ile Asn Gly Ile Ile Ile Ser Val Lys Thr Arg Ser
 210 215 220
 Glu Arg Gln Leu Leu Arg Leu Lys Gln Met Asn Val Gln Leu Ala Ala
 225 230 235 240
 Lys Ile Gln His Leu Glu Phe Ser Cys Ser Glu Lys Glu Gln Glu Ile
 245 250 255
 Glu Arg Leu Asn Lys Leu Leu Arg Gln His Gly Leu Leu Gly Glu Val
 260 265 270

Asn

<210> 72
 <211> 928
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (367)

<220>
 <221> unsure
 <222> (448)

<220>
 <221> unsure
 <222> (467)

<220>
 <221> unsure
 <222> (508)

<220>
 <221> unsure
 <222> (539)

<400> 72
 aatcgaggagt cctggaaagt taattccaat gtcacgacgt caaacttaaa atgggtcgtct 60
 gccaccatga agattgataa ccctcacata acatatactg ccagggtccc agtcgatgtc 120
 catgaataca acctaacgca tctgcagcct tccacagatt atgaagtgtg tctcacagt 180
 tccaatattc atcagcagac tcaaaagtca tgcgtaaatg tcacaaccaa aaatgccgcc 240
 ttcgcagtg acatctctga tcaagaaacc agtacagccc ttgctgcagt aatgggggtmt 300
 atgtttgccg tcattagcct tgcgtccatt gctgtgtgtac tttgccaaaa gatttaagag 360
 aaaaaantac caccactcat taaaaaagta tatgcaaaaa acctcttcaa tcccactaaa 420
 tgagctgtac ccaccactca ttaacctntg ggaagggtgac agcgagnaag acaaagatgg 480

ttttgcagac accaagccaa cccaggtna cacatccaga aggtattaca tgtggtaant 540
 cagaggatat tttgcttctg gtagtaagga gcacaaagac gtttttgcct tattctgcaa 600
 aagtgaacaa gttgaagact tttgtatttt tgactttgct agtttgtggc agagtggaga 660
 ggacgggtgg atatttcaaa tttttttagt atagcgtatc gcaagggttt gacacggctg 720
 ccagcgactc taggcttcca gtctgtgttt gggtttttatc cttatcatta ttatgattgt 780
 tattatatta ttattttatt ttagttgttg tgctaaactc aataatgctg ttctaactac 840
 agtgctcaat aaaatgatta atgacaggat ggggttcccc tgtgctttta ccagtagcat 900
 gacccttcct gaagccatcc gtagaaag 928

<210> 73

<211> 52

<212> PRT

<213> Homo sapiens

<400> 73

Met Ile Val Ile Ile Leu Leu Phe Tyr Phe Ser Cys Cys Ala Lys Leu
 1 5 10 15

Asn Asn Ala Val Leu Thr Thr Val Leu Asn Lys Met Ile Asn Asp Arg
 20 25 30

Met Gly Phe Pro Cys Ala Phe Thr Ser Ser Met Thr Leu Pro Glu Ala
 35 40 45

Ile Arg Arg Lys
 50

<210> 74

<211> 49

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (9)

<400> 74

aaattaaana aaaaaaaaaa aaaaaaaaaa aaataaagaa aaaaaaaaaa 49

<210> 75

<211> 597

<212> DNA

<213> Homo sapiens

<400> 75

attctacaag ataacttccc agtactttaaa aaaagtctca aagtcataaa caagaaagaa 60
 ctgagggact attgcatatt ggagcgatct aaagaagtat tacaatttgt ggaattcttg 120
 attaaatcct ggaccagcaa aaggacatta gtgggaaatc tgatgaaatt caaatgagat 180
 cttatattga agttaattgt gtcagtgtac atttcctggc tttcataatt gcaagtgtat 240
 atgtaagggtt tgtaaatatt aggagcagct gggtaaaggc tatacaaaaa ctctataacta 300
 tttttgcatt tttttctgta agtttaaaac attttccaac taaaaagttg aaaacacatg 360
 tattagagac acatgcgtat gtgtctctaa taatcttaaa tatatttaag atgatagaag 420
 gaattcttga gatagtaaaa tgaagtcacc aaaaaacaaa caaagaaaca aaacgaaatc 480
 accaaaaatct atcaataaat ttcaggtaat acttttggca gattcattcc tttgagatgg 540
 agtctcactc ccagtctggg caacgagcga aactccgtct aaaaaaaaaa aaaaaaa 597

<210> 76

<211> 89

<212> PRT

<213> Homo sapiens

<400> 76

Met Arg Ser Tyr Ile Glu Val Asn Cys Val Ser Val His Phe Leu Val
 1 5 10 15

Phe Ile Ile Ala Ser Asp Tyr Val Arg Phe Val Asn Ile Arg Ser Ser
 20 25 30

Trp Val Lys Val Ile Gln Lys Leu Tyr Thr Ile Phe Ala Phe Phe Ser
 35 40 45

Val Ser Leu Lys His Phe Pro Thr Lys Lys Leu Lys Thr His Val Leu
 50 55 60

Glu Thr His Ala Tyr Val Ser Leu Ile Ile Leu Asn Ile Phe Lys Met
 65 70 75 80

Ile Glu Gly Ile Leu Glu Ile Val Lys
 85

<210> 77

<211> 1804

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (1794)

<400> 77

ggagttcatt aggccagtgg cactgattttt tccttcccat catagctatt tattctagta 60
 agaggataat aaaagaaatt tcctatacaa gaactgaaat tttccatttg tatggatcta 120
 gtcactttca gatttcaatt tgaggttaag tatataaagc acatcccaat tttatatgct 180
 gccttgagaa aattacagga tgcacggcaa tttgtaggaa tttcaaattgg gatcatttaa 240
 acatttgaaa aattatttta aaaaccatct agtttgcttc tggatttttag acattaaagc 300
 ctatgttgtc ttgttaacag ggggtggaatg tataaccatc agattcagca tgtgatttca 360
 cctttgaatc tgagtatttc tccctatctc tctttgagtc atttttggag cagactgtca 420
 ccagtattga taactaagca ttaaaggga aagttgcatt gcaactatgc attggtttcc 480
 tggaagaact tttcttttgt tttagtgaat gaagaggctt gatgggatca cttactgtaa 540
 ctcttctac ataaggacc cttctgcaag cagaacacaa aagaacatgc tcaaggagta 600
 tcccattttc tggataaatt gaagaagttt gctagtaatg tctttatact agcgtcttcc 660
 ttgtatccct ttgctggcaa gggaatacaa ggcgtcaaga ccacagatca aaacacccca 720
 catttgagtg gagtcttatt ttaactccaa gagcagttat tcccttctag tctaaaattg 780
 gcagtttttt ctttttttta ataaaatttt taaaatattc ccaaaccagt ggaacacaga 840
 cactggctgc acttagtact gccaaaagcc aaggtcattt gcacatattc catcaacctg 900
 tcgagaatta ggcctcactt tataacccaa ggcattggaag tgcattgcat ctcttagctg 960
 ggcaaacaat tatactgtag ttgtgataca acacatgttg cttttatttg tactgcacat 1020
 atccactgta cagccacttg ggagtatcgt ggtagcttg cagcaactgc tgtctgcatt 1080
 tatactgttt attgcatatt cttttccctg gaagtgaag agaaatgttt tctttgttgc 1140
 attgattaca ttttataaat ttgcttagct ggaaagcttg ggaaaagagg cctgtttgtc 1200
 aattgtacaa ccgattgtga agctctagt tgaatatttt tacgtctgta ttagacattt 1260
 tctttgcaa tctattgttc gattgaaatg taaatgaaat taaagatggg gtacacccat 1320
 catgtaaaaa gcaggcacca tctctaagat ggatttaatg ctcatTTTTA aggcataatac 1380
 tcagcttcta tttaaaacta taattttaaaa taattctgta caatgaaatg gggaatatat 1440
 atgggaataa attctattcc atttatttca atttgaattt ccaaattgta atgtttccct 1500
 ttgtgctata ggaataggat taaatggggg aagactagga tttataaggc ctgtatatgg 1560
 ggggagggca gagatggaac aatgaggggt gtgatgatag tgaatagcaa agagtgaatt 1620
 ctgtgtgttt ttgctgtagc actgaagtga agagatatta gctttggctg ttcacaaaat 1680

agagcatcat gattttcagt gtttgagaga aaattgatgg aaaaagtttg cagtacttga 1740
 catgtatttg catgcacaaa ataaaattat ttgtccacct taataaaaaa aaanaaaaaa 1800
 aaaa 1804

<210> 78
 <211> 37
 <212> PRT
 <213> Homo sapiens

<400> 78
 Met Lys Arg Leu Asp Gly Ile Thr Tyr Cys Asn Ser Phe Tyr Ile Arg
 1 5 10 15

Thr Pro Ser Ala Ser Arg Thr Gln Lys Asn Met Leu Lys Glu Tyr Pro
 20 25 30

Ile Phe Trp Ile Asn
 35

<210> 79
 <211> 360
 <212> DNA
 <213> Homo sapiens

<400> 79
 agaataccaa gactgtgtgt acacgcagat gtcagtggca gagaatgaag atcagcttcg 60
 tgcaaagggt tatgacaaaa caccagactt cattttacaa gtaccagttg ctgtagaagg 120
 gcacataatt cactggattg aaagcaaagc ctcatttggt gatgaatgta gccaccacgc 180
 ctacctgcat gaccagttct ggagctactg gaatagggtc ccaatataac agacaaatgg 240
 tgaaacagag ggatactcac taggaaacag atttgggcca ggcttagtca tctattggta 300
 tggatttatc caggagctgg actgcaaccg ggaaaggggc atcctgctca aagcctgttt 360

<210> 80
 <211> 20
 <212> PRT
 <213> Homo sapiens

<400> 80
 Met Asp Leu Ser Arg Ser Trp Thr Ala Thr Gly Lys Gly Ala Ser Cys
 1 5 10 15

Ser Lys Pro Val
 20

<210> 81
 <211> 202
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (136)

<220>
 <221> unsure
 <222> (138)

<400> 81

```

aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 60
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 120
aaaaaaaaa aaaaantnaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 180
aaaaaaaaa aaaaaaaaaa aa 202

```

<210> 82
 <211> 1189
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (1155)

```

<400> 82
ggccttcacg gcctaatacag atttttagtgg caagacaggt gatgataggg agaaagaaag 60
agtccctgcct gtcaaaagtg gctgtgctat ataratgaac cctcacaggt agcacctctc 120
agagagaata ratggtaaat gtttcttttc aggtctttta aagtgtcagg ctatcagtta 180
acctctccta gatctcagaa atgcctagaa agagaagtcc tggctacatc aatggaaatt 240
ctccacagat gcaaattttc tctacaaaag atggctttgc agagccacct cagtctgttg 300
tccctgtagc agccattttc aattatgtca aagagatata ttttggggta aaatattttg 360
attatcttca ttagtatatc tcaattttgt caatacaaac ctgagagtta tagtcagagg 420
ttgaattttc atttcaaaat gttttcctag ttttttttct cttttttgtt ttattgtaag 480
ttgacaattt ataattgtat aaaagtatga ggtacaaagt gatgttatag cttaagaata 540
cagtatggta tgattaaatc aagttattaa cctatccttc acgttaaagt cttaaatttt 600
ttgatgagaa catttgaaat ttactcttgg aaggtaaaaa aaaatctcag gaccccccaa 660
attaaagcca tgaagctgaa ttgtgcaaca tcctcttcca aatggaagct tgtcttccag 720
gtacagaaca aaaacaagac tcattttctc acctgcctaa agatgtgcac ataattggct 780
cctcctttac tccctttttc tcttctaaca ttcattatat cttgtgtaaa atgtagattt 840
actggacact aactaaaatt tcacaggggt gtaccattt gccttactgc ctacctacct 900
gtyttcctac gtaccttytc cccactttaa ggaatgcata catattaaac ctcccaaaaa 960
cytytttaga aaaatagcca caggtttatc tgtggctggg gtgtttccct agatgcacty 1020
taaagctggc ttaataaacc tcagtgtatg aaacttatgc ctcaatcact cattttgggt 1080
gtcactgtct taccaatttg aaatgtaaaa tattytacta ctaattatat ttaccacatt 1140
gtgcaacaga actcnaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1189

```

<210> 83
 <211> 56
 <212> PRT
 <213> Homo sapiens

```

<400> 83
Met Arg Thr Phe Glu Ile Tyr Ser Trp Lys Val Lys Lys Asn Leu Arg
  1             5             10             15

Thr Pro Gln Ile Lys Ala Met Lys Leu Asn Cys Ala Thr Ser Ser Ser
          20             25             30

Lys Trp Lys Leu Val Phe Gln Val Gln Asn Lys Asn Lys Thr His Phe
          35             40             45

Phe Thr Cys Leu Lys Met Cys Thr
          50             55

```

<210> 84
 <211> 525
 <212> DNA
 <213> Homo sapiens

<400> 84

cataacagcg tcagagagaa agaactgact gaaacgtttg agatgaagaa agttctcctc 60
 ctgatcacag ccattcttggc agtggctggt gggtttcccag tctctcaaga ccaggaacga 120
 gaaaaaagaa gtatcagtga cagcgatgaa ttagcttcag gggtttttgt gttcccttac 180
 ccatatccat ttcgcccact tccaccaatt ccatttccaa gatttccatg gtttagacgt 240
 aattttccta ttccaatacc tgaatctgcc cctacaactc cccttcctag cgaaaagtaa 300
 acaagaagga aaagtcacga taaacctggt cacctgaaat tgaaattgag ccacttcctt 360
 gaagaatcaa aattcctggt aataaaagaa aaacaaatgt aattgaaata gcacacagca 420
 ttctctagtc aatatcttta gtgatytyt ttaataaaca tgraagcaaa graaaaaaaa 480
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 525

<210> 85

<211> 85

<212> PRT

<213> Homo sapiens

<400> 85

Met Lys Lys Val Leu Leu Leu Ile Thr Ala Ile Leu Ala Val Ala Val
 1 5 10 15
 Gly Phe Pro Val Ser Gln Asp Gln Glu Arg Glu Lys Arg Ser Ile Ser
 20 25 30
 Asp Ser Asp Glu Leu Ala Ser Gly Phe Phe Val Phe Pro Tyr Pro Tyr
 35 40 45
 Pro Phe Arg Pro Leu Pro Pro Ile Pro Phe Pro Arg Phe Pro Trp Phe
 50 55 60
 Arg Arg Asn Phe Pro Ile Pro Ile Pro Glu Ser Ala Pro Thr Thr Pro
 65 70 75 80
 Leu Pro Ser Glu Lys
 85

<210> 86

<211> 349

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (9)

<220>

<221> unsure

<222> (159)

<220>

<221> unsure

<222> (188)

<220>

<221> unsure

<222> (230)

<220>

<221> unsure

<222> (232)

<220>

<221> unsure

<222> (270)

<400> 86

```

acttcgcanc ccatcccggc tggacgcgac cgggggagtgc agcagcccgt tcccctcctc 60
ggtgccgcct ctgcccagcg tttgcttggc tgggctacca cctgcgctcg gacggcgctc 120
ggaggggtcct cgcccccggc ctgcctacct gaaaaccana actgatggct ctatttgcag 180
tctttcanac aacattcttc ttaacattgc tgtccttgag gacttaccan antgaagtct 240
tggctgaacg tttaccattg actcctgttn tcacttaaag tttccaccaa ttctacgcgt 300
cagagtttgc acttacaatg gactgtccac aaccttcctt atcatcagg 349

```

<210> 87

<211> 563

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (63)

<220>

<221> unsure

<222> (83)

<220>

<221> unsure

<222> (116)

<220>

<221> unsure

<222> (177)

<220>

<221> unsure

<222> (183)

<220>

<221> unsure

<222> (228)

<220>

<221> unsure

<222> (240)

<400> 87

```

tccattccag caccagccaa cagcacaaaa ttaatccttg acagggtgttc ctaccaaatt 60
tgngtcatag ccaacaacag tgnnggtgct tctcctgctt ctgtaatagt catttntgca 120
gaccccgaaa acaaagaggt tgaggaagaa agaattgcag gcacagaggg tggattnttt 180
ttnttttggg aaccccaacc tggagatggt atagggttatg ttgtggantg gtgtgaccan 240
acccaggatg tgcctcggtg atttccagtg gaagaatgta ggtcccaata ccacaagcac 300
agtcattagc acagatgctt ttaggccagg agttcgatat gacttcagaa tttatgggtt 360
atctacaaaa aggattgctt gtttattaga gaaaaaaaaac aggatactct caggaacttg 420
ctccttcaga caaccctcac gtgctggtgg atacattgac atcccactcc ttcactctga 480
gttggaagaa ttactctact gaatctcaac ctggttttat acaagggtac catgtctatc 540
tgaaatccaa ggcgaggcag tgc 563

```

<210> 88

<211> 58

<212> PRT

<213> Homo sapiens

<400> 88

Arg Lys Lys Thr Gly Tyr Ser Gln Glu Leu Ala Pro Ser Asp Asn Pro
 1 5 10 15

His Val Leu Val Asp Thr Leu Thr Ser His Ser Phe Thr Leu Ser Trp
 20 25 30

Lys Asp Tyr Ser Thr Glu Ser Gln Pro Gly Phe Ile Gln Gly Tyr His
 35 40 45

Val Tyr Leu Lys Ser Lys Ala Arg Gln Cys
 50 55

<210> 89

<211> 361

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (102)

<220>

<221> unsure

<222> (105)

<220>

<221> unsure

<222> (153)

<220>

<221> unsure

<222> (186)

<220>

<221> unsure

<222> (191)

<220>

<221> unsure

<222> (252)..(253)

<400> 89

gaaaaggcag ttctttcaga tgggttcagaa tggttgcaaatacaaaaattga caaccgcggaa 60
 gaaaaggcat tgattgtgga caacctaaag ccagaatcct tntangagtt tttcatcact 120
 ccattcacta gtgctggtga aggcccccagt gcnacgttca cgaagggtcac gactccggat 180
 gaacantcct ngatgctgat tcatatccta ctgcccattgg ttttctgcgt cttgctcatc 240
 atgggtcatgt gnnacttgaa aagtcagtgg atcaaggaga cctgttatcc tgacatccct 300
 gacccttaca agagcagcat cctgtcatta ataaaattca aggtaaaaaa aaaaaaaaaa 360
 a 361

<210> 90

<211> 756

<212> DNA

<213> Homo sapiens

<220>
 <221> unsure
 <222> (37)

<220>
 <221> unsure
 <222> (54)

<220>
 <221> unsure
 <222> (376)

<220>
 <221> unsure
 <222> (433)

<400> 90
 attgaattct agacctgcgg ccgctgctcc ctcagangcc cctgatgtct gganaattgt 60
 gagcttggag ccaggaaatc atactgtgac cttattctgg aagccattat caaaactgca 120
 tgccaatgga aagatcctgt tctataatgt agttgtagaa aacctagaca aaccatccag 180
 ttcagagctc cattccattc cagcaccagc caacagcaca aaactaatcc ttgacagggtg 240
 ttcctaccaa atctgcgtca tagccaacaa cagtgtgggt gcttctcctg cttctgtaat 300
 agtcatytct gcagaccccg aaaacaaaga gggtgaggaa gaaagaattg caggcacaga 360
 ggggtggattt tttttntttt ggaaacccca acctggagat gttatagggt atgttgtgga 420
 ctggtgtgac canacccagg atgtgcctcg gtgatttcca gtggaagaat gtaggtccca 480
 ataccacaag cacagtcatt agcacagatg cttttaggcc aggagttcga tatgacttca 540
 gaatttatgg gttatctaca aaaaggattg cttgtttatt agagaaaaaa aacaggatac 600
 tctcaggaac ttgctccttc agacaaccct cacgtgctgg tggatacatt gacatccac 660
 tccttcactc tgagttggaa agattactct actgaatctc aacctgggtt tatacaaggg 720
 taccatgtct atctgaaatc caaggcgagg cagtgc 756

<210> 91
 <211> 58
 <212> PRT
 <213> Homo sapiens

<400> 91
 Arg Lys Lys Thr Gly Tyr Ser Gln Glu Leu Ala Pro Ser Asp Asn Pro
 1 5 10 15
 His Val Leu Val Asp Thr Leu Thr Ser His Ser Phe Thr Leu Ser Trp
 20 25 30
 Lys Asp Tyr Ser Thr Glu Ser Gln Pro Gly Phe Ile Gln Gly Tyr His
 35 40 45
 Val Tyr Leu Lys Ser Lys Ala Arg Gln Cys
 50 55

<210> 92
 <211> 79
 <212> DNA
 <213> Homo sapiens

<400> 92
 tcattaataa aattcaaggt aaatgttaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 60
 aaaaaaaaaa aaaaaaaaaa 79

<210> 93

<211> 1939

<212> DNA

<213> Homo sapiens

<400> 93

```

attggttttc aaatattaaa ccagcatttt attttaaaat aaacccact tagttatgat 60
attttatctt ttttatataa tgtgggattt gatttgccga tattttatta aagatttttg 120
catcatgttc tttttctgaa attttatttt gttctaattg cataaaataa gttggaaatt 180
atcctctcta tctctacttt gtgaaagaat ttatattaca ttggtattat ttcttccttg 240
aatgtttgat agactatact agtgaagca tctgggcta gggttttctc tgtggaagat 300
tttcagttac aaattcaatt ttactgagtc aggtttgata agttacattt ctcaaggaat 360
ttatctattt aatcattgaa tgtattgaac attcatttgt ttataatttt gttttgttat 420
tgaaaatgtc tgtaagattt atagtgatgt tcccttttct attcctgaca ttgttaattt 480
gtgttctctc tccctccatc cctctctcac tctctcttgt cagctggtct gtgggattat 540
cacctttatt aatcttttca gagaaccact ttttatttct ttgatttcct ttattgtttg 600
ttaacttttc agtttattga ttccctctct tagctttatt acttcccttc ttctacttag 660
taagagttaa atttgccctc atttttttag cttcttaagg taggaaattt gatttatatt 720
taaacttaaa aaaacttaaa gctataaaat tccctttaag cactgtttta gctgaattct 780
acatattttg attgggtatg ttttcatcat tcaattaaaa acatagtctc taatttttct 840
ttgcaatttc ttctttaacc catagggtat ttggcagttt gctgctgaat ttcaaagtgc 900
ttgggaggtt ttatagctat cttgttaaaa attgatttct aatttaattt tgtcagagaa 960
catactttgt atgacttaaa tcttttaaaa tacgttcaga ctgatttagg gtccagcata 1020
tggtacgtct tagtgaatgt aatataatgcc attggaaatg atgcacattc tgcaattgtt 1080
gggtgtaatg tgctataaat gtcaaccagg ttaacttggt tgatagtatt gttgaattcc 1140
tgtgttccaa atgatatatt ttgtctgttt attctatcaa ttaatgagaa aggtttatta 1200
aaatctccaa ccattgttgt gcatttattt ctatttcttc agttctgttg atttttgttt 1260
tatatatatt gaagctctga gtacatctcc ctgatgagtt gaccctttta tcattatgaa 1320
atgtcattct ttctctgtaa tgcttatctt aaaatctact ttgtttgata tgaatgtagc 1380
cacttaagct ttcttatgca tactgtttgc aaagtgtgtg tgtgtgtgtg tgtgtgtgtg 1440
tgtatctatc tcaatccttt agtttccgcc tatctctgtc tttttattta aagtgtgttt 1500
ttgcaggtag tgtataactt ggatcttggt tttatattca gtctgacaat ttatgcttct 1560
tgattattgt gtttagttta tttgcatagt gtgtagtcca ttgacatttg gcataatatt 1620
gataatttgt gttggagcgt attgtcttca tttctgattg tcccatctgg ttttgttget 1680
gttttgttgt tctctgttc cacacttttt gtcttctttt gggttaatca aatattcttt 1740
ggctttgcat cttatgtctt ctgttggatt tttatctata ccttgctgta tttttcttta 1800
gtggtttctc taggggttac actatacatt attaactaat catagtccat ttagaattaa 1860
tattgtacac ttacataaaa atgtaaaaca ttgtcacag tataaagtct attccttcca 1920
aaaaaaaaa aaaaaaaaaa

```

1939

<210> 94

<211> 52

<212> PRT

<213> Homo sapiens

<400> 94

```

Met Ser Val Arg Phe Ile Val Met Phe Pro Phe Leu Phe Leu Thr Leu
 1           5           10          15
Leu Ile Cys Val Leu Ser Pro Ser Ile Pro Leu Ser Leu Ser Leu Val
          20          25          30
Ser Trp Ser Val Gly Leu Ser Pro Leu Leu Ile Phe Ser Glu Asn His
          35          40          45
Phe Leu Phe Leu
          50

```

<210> 95

<211> 1252

<212> DNA

<213> Homo sapiens

<400> 95

```

gtagaaatcc caaaaagatt tggacagagg cagagcctat gtcactacac cttaaaggat 60
aacaagggtt' atatcaagac tcatggtgaa catgtaggtt ttagaatttt catggatgcc 120
atactacttt ctttgactag aaagggtgaag atgccagatg tggagctctt tgttaatttg 180
ggagactggc ctttggaata aaagaaatcc aattcaaaca tccatccgat cttttcctgg 240
tgtggctcca cagattccaa ggatatcgtg atgcctacgt acgatttgac tgattctgtt 300
ctggaaacca tgggcccggg aagtctggat atgatgtccg tgcaagctaa cacgggtcct 360
ccctgggaaa gcaaaaattc cactgccgtc tggagagggc gagacagccg caaagagaga 420
ctcgagctgg ttaaactcag tagaaaacac ccagaactca tagacgctgt tttcaccaac 480
tttttcttct ttaaacacga tgaaaacctg tatggtccca ttgtgaaaca tatttcattt 540
tttgatttct tcaagcataa gtatcaaata aatatcgatg gcactgtagc agcttatcgc 600
ctgccatatt tgctagttag tgacagtgtt gtgctgaagc aggattccat ctactatgaa 660
cattttttaca atgagctgca gccctggaaa cactacattc cagttaagag caacctgagc 720
gatctgctag aaaaacttaa atgggcgaaa gatcacgatg aagaggccaa aaagatagca 780
aaagcaggac aagaatttgc aagaaataat ctcatgggag atgacatatt ctgttattat 840
ttcaaacttt tccaggaata tgccaattta caagtgaag agccccaaat ccgagagggc 900
atgaaaaggg tagaaccaca gactgaggac gacctcttcc cttgtacttg ccataggaaa 960
aagaccaaag atgaactctg atatgcaaaa taacttctat tagaataatg gtgctctgaa 1020
gactcttctt aactaaaaag aagaattttt ttaagtatta attccatgga caatataaaa 1080
tctgtgtgat tgtttgcagt atgaagacac atttctactt atgcagtatt ctcagtactg 1140
tactttaaag tacattttta gaattttata ataaaaccac ctttatttta aaggaaaaaa 1200
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 1252

```

<210> 96

<211> 289

<212> PRT

<213> Homo sapiens

<400> 96

```

Met Asp Ala Ile Leu Leu Ser Leu Thr Arg Lys Val Lys Met Pro Asp
 1             5             10             15

Val Glu Leu Phe Val Asn Leu Gly Asp Trp Pro Leu Glu Lys Lys Lys
      20             25             30

Ser Asn Ser Asn Ile His Pro Ile Phe Ser Trp Cys Gly Ser Thr Asp
      35             40             45

Ser Lys Asp Ile Val Met Pro Thr Tyr Asp Leu Thr Asp Ser Val Leu
      50             55             60

Glu Thr Met Gly Arg Val Ser Leu Asp Met Met Ser Val Gln Ala Asn
      65             70             75             80

Thr Gly Pro Pro Trp Glu Ser Lys Asn Ser Thr Ala Val Trp Arg Gly
      85             90             95

Arg Asp Ser Arg Lys Glu Arg Leu Glu Leu Val Lys Leu Ser Arg Lys
      100            105            110

His Pro Glu Leu Ile Asp Ala Ala Phe Thr Asn Phe Phe Phe Phe Lys
      115            120            125

His Asp Glu Asn Leu Tyr Gly Pro Ile Val Lys His Ile Ser Phe Phe
      130            135            140

Asp Phe Phe Lys His Lys Tyr Gln Ile Asn Ile Asp Gly Thr Val Ala

```

145	150	155	160
Ala Tyr Arg Leu Pro Tyr Leu Leu Val Gly Asp Ser Val Val Leu Lys			
	165	170	175
Gln Asp Ser Ile Tyr Tyr Glu His Phe Tyr Asn Glu L u Gln Pro Trp			
	180	185	190
Lys His Tyr Ile Pro Val Lys Ser Asn Leu Ser Asp Leu Leu Glu Lys			
	195	200	205
Leu Lys Trp Ala Lys Asp His Asp Glu Glu Ala Lys Lys Ile Ala Lys			
	210	215	220
Ala Gly Gln Glu Phe Ala Arg Asn Asn Leu Met Gly Asp Asp Ile Phe			
	225	230	235
Cys Tyr Tyr Phe Lys Leu Phe Gln Glu Tyr Ala Asn Leu Gln Val Ser			
	245	250	255
Glu Pro Gln Ile Arg Glu Gly Met Lys Arg Val Glu Pro Gln Thr Glu			
	260	265	270
Asp Asp Leu Phe Pro Cys Thr Cys His Arg Lys Lys Thr Lys Asp Glu			
	275	280	285

Leu

<210> 97
 <211> 492
 <212> DNA
 <213> Homo sapiens

<400> 97
 ctaggttctg ggaagatggc gaaggtctca gagctttacg atgtcacttg ggaagaaatg 60
 agagataaaa tgagaaaatg gagagaagaa aactcaagaa atagttagca aattgtggaa 120
 gttggagaag aattaattaa tgaatatgct tctaagctgg gagatgatat ttggatcata 180
 tatgaacagg tgatgattgc agcactagac tatggctcggg atgacttggc attgttttgt 240
 cttcaagagc tgagaagaca gttccctggc agtcacagag tcaagcgatt aacaggcatg 300
 agatttgaag ccatggaaag atatgatgat gctatacagc tatatgatag gattttacaa 360
 gaagatccaa ctaacactgc tgcaagaaag cgtaagattg ccattcgaaa agcccagggg 420
 aaaaatgtgg aggccattcg ggagctgaat gagtatctgg aacaatttgt tggagaccaa 480
 gaagcctggc at 492

<210> 98
 <211> 159
 <212> PRT
 <213> Homo sapiens

<400> 98
 Met Ala Lys Val Ser Glu Leu Tyr Asp Val Thr Trp Glu Glu Met Arg
 1 5 10 15
 Asp Lys Met Arg Lys Trp Arg Glu Glu Asn Ser Arg Asn Ser Glu Gln
 20 25 30
 Ile Val Glu Val Gly Glu Glu Leu Ile Asn Glu Tyr Ala Ser Lys Leu
 35 40 45

Gly Asp Asp Il Trp Ile Ile Tyr Glu Gln Val Met Ile Ala Ala Leu
 50 55 60
 Asp Tyr Gly Arg Asp Asp Leu Ala Leu Phe Cys Leu Gln Glu Leu Arg
 65 70 75 80
 Arg Gln Phe Pro Gly Ser His Arg Val Lys Arg Leu Thr Gly Met Arg
 85 90 95
 Phe Glu Ala Met Glu Arg Tyr Asp Asp Ala Ile Gln Leu Tyr Asp Arg
 100 105 110
 Ile Leu Gln Glu Asp Pro Thr Asn Thr Ala Ala Arg Lys Arg Lys Ile
 115 120 125
 Ala Ile Arg Lys Ala Gln Gly Lys Asn Val Glu Ala Ile Arg Glu Leu
 130 135 140
 Asn Glu Tyr Leu Glu Gln Phe Val Gly Asp Gln Glu Ala Trp His
 145 150 155

<210> 99
 <211> 85
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (20)

<220>
 <221> unsure
 <222> (27)

<400> 99
 ccttggttaa taaaccatgn tgatttntta aacttgccaa aaaaaaaaaa aaaaaaaaaa 60
 aaaaaaaaaa aaaaaaaaaa aaaaaa 85

<210> 100
 <211> 313
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (68)

<220>
 <221> unsure
 <222> (108)

<220>
 <221> unsure
 <222> (137)

<220>
 <221> unsure
 <222> (288)

<400> 100

```

ccttggatta tctgaactaa aaattggaca gattgatcag ctggtaaaaa atctacttcc 60
tggatttngt aaaggcaaaa acatttcttc ccattggcat acatcccntg tctctgcaca 120
atccttcttt gaaaatnaat atggtaactt aaatatattt agtacattac gtccctcttg 180
cttgatcga catcattcaa aagctcttca aagcatttgt tcaaactctt agtactggcc 240
agttttcata cagtctcggg gttttaaaac tttgaaatca aggacacnac gtctccagtc 300
tacctccgag aga 313

```

<210> 101

<211> 964

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (395)

<400> 101

```

gcttttccgg agcagagttg gagaatcttg tgaaccaggc tgcattaaaa gcagctgttg 60
atggaaaaga aatgggttacc atgaaggagc tggagttttc caaagacaaa attctaattg 120
ggcctgaaag aagaagtgtg gaaattgata acaaaaacaa aaccatcaca gcatatcatg 180
aatctggtca tgccattatt gcatattaca caaaagatgc aatgcctatc aacaaagcta 240
caatcatgcc acggggggcca acacttggac atgtgtccct gttacctgag aatgacagat 300
ggaatgaaac tagagcccag ctgcttgcac aaatggatgt tagtatggga ggaagagtgg 360
cagaggagct tatatttgga accgaccata ttacnacagg tgcttccagt gattttgata 420
atgccactaa aatagcaaag cggatrgyta ccaaatttgg aatgagtga aagcttggag 480
ttatgaccta cagtataca ggggaaacta agtccagaaa cccaatctgc catcgaacaa 540
gaaataagaa tccttctaag ggactcatat gaacgagcaa aacatatctt gaaaactcat 600
gcaaaggagc ataagaatct cgcagaagct ttattgacct atgagacttt ggatgccaaa 660
gagattcaaa ttgttctkga ggggaaaaag ttggaagtga gatgataact ctctkgatat 720
ggatgcttgc tggttttatt gcaagaatat aagtagcatt gcagtagtct acttttacia 780
cgctttcccc tcattcttga tgtggtgtaa ttgaagggtg tgaaatgctt tgtcaatcat 840
ttgtcacatt tatccagttt gggttattct cattaggaca cctattgcaa attagcatcc 900
catggcaaat atattttgaa aaaataaaga actatcagga ttgaaaaaaa aaaaaaaaaa 960
aaaa 964

```

<210> 102

<211> 166

<212> PRT

<213> Homo sapiens

<220>

<221> UNSURE

<222> (125)..(126)

<400> 102

```

Met Val Thr Met Lys Glu Leu Glu Phe Ser Lys Asp Lys Ile Leu Met
  1              5              10              15

Gly Pro Glu Arg Arg Ser Val Glu Ile Asp Asn Lys Asn Lys Thr Ile
          20              25              30

Thr Ala Tyr His Glu Ser Gly His Ala Ile Ile Ala Tyr Tyr Thr Lys
          35              40              45

Asp Ala Met Pro Ile Asn Lys Ala Thr Ile Met Pro Arg Gly Pro Thr
          50              55              60

Leu Gly His Val Ser Leu Leu Pro Glu Asn Asp Arg Trp Asn Glu Thr

```

65	70	75	80
Arg Ala Gln Leu Leu Ala Gln Met Asp Val Ser Met Gly Gly Arg Val			
85	90	95	
Ala Glu Glu Leu Ile Phe Gly Thr Asp His Ile Thr Thr Gly Ala Ser			
100	105	110	
Ser Asp Phe Asp Asn Ala Thr Lys Ile Ala Lys Arg Xaa Xaa Thr Lys			
115	120	125	
Phe Gly Met Ser Glu Lys Leu Gly Val Met Thr Tyr Ser Asp Thr Gly			
130	135	140	
Glu Thr Lys Ser Arg Asn Pro Ile Cys His Arg Thr Arg Asn Lys Asn			
145	150	155	160
Pro Ser Lys Gly Leu Ile			
165			

<210> 103
 <211> 1362
 <212> DNA
 <213> Homo sapiens

<400> 103

cttttcatat	ccttttattt	tcccaattca	tataggaaag	ataagtattt	tccctttcat	60
tttcaaaatt	gattggtaca	ctaacctcct	ccatagtaac	caatttgtat	ttttttatta	120
tgaactcatg	aatttaaaca	tttgatgttg	tttcagttca	ttgcagtcac	tatccttatt	180
gattctcaaa	gtgttttatt	tttgacaaat	aagtcttcca	aattagttag	ttattttgat	240
agtgacctta	atagtctttg	ctagctttcca	tccttgtatg	gcataacaaa	acattccagg	300
cccctttagt	acatttcctg	tcccagacct	ggtattagtc	atctaattctg	gaagccctgc	360
tttctttctg	tgggaaacat	tatttcaaga	cattagggat	aagaatgccca	gttgctactg	420
agttggttat	tgtttcaagg	atttatcaat	acatagagca	aataattatg	ttttgctttg	480
tcttattttt	atttctttac	tttagaaaca	gtacagctac	ttacaaatca	agtttagaac	540
tctcagggtta	tcttaaactc	gaagcttcta	ccttcctaag	aacaaaacac	cggaatgatg	600
agatgtcata	taaatatcca	tttattttat	ttcacaatac	atacattgac	ctattgtatg	660
tatgattagt	acaaatgggt	taaattggct	tggtgtgctt	tgctttgttt	ttgcagtttt	720
tttttgtcat	tagattttat	ctcactagaa	atgtatagtc	aaatttctgt	gttctaaagt	780
cacttgaagt	agtttttctg	tttgtagtaa	tgttaccagt	tggacacatt	aggttcattt	840
atttttggga	attgcttttg	ttcccattta	aatttttatt	tatcttgcgt	atcttggatt	900
aacggtaata	gaccatatac	aatttttctc	actttttttc	attkgagagt	ttcctcattt	960
attttgtttt	cggatgcaaa	gtatttcatt	gtatgaatta	ccagtttggt	caattagttt	1020
tctttgataa	catttggggt	gcttctagtc	ttttgttatw	acagagtctt	gcaatgaata	1080
gtcttatgct	tatatgtttt	gtggtttctg	gcaaggattt	caacgtaatt	taaggctatc	1140
ctctacttaa	gttatggcca	attaagtgtc	tgattaaatg	tctgtaataa	tttaaaaata	1200
acaatactta	atttaaaaga	gcttataata	cataattatt	cattagagag	atgcagcaaa	1260
ccaccatggc	aaatgtattc	ctatgtaaca	aacctgcacg	ttcagcaagt	gtatcccagc	1320
actgaaagta	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aa		1362

<210> 104
 <211> 86
 <212> PRT
 <213> Homo sapiens

<400> 104

Met Pro Val Ala Thr Glu Leu Val Ile Val Ser Arg Ile Tyr Gln Tyr
1 5 10 15

Ile Glu Gln Ile Ile Met Phe Cys Phe Val Leu Phe Leu Phe Leu Tyr
 20 25 30

Phe Arg Asn Ser Thr Ala Thr Tyr Lys Ser Ser Leu Glu Leu Ser Gly
 35 40 45

Tyr Leu Lys Ser Glu Ala Ser Thr Phe Leu Arg Thr Lys His Arg Asn
 50 55 60

Asp Glu Met Ser Tyr Lys Tyr Pro Phe Ile Leu Phe His Asn Thr Tyr
 65 70 75 80

Ile Asp Leu Leu Tyr Val
 85

<210> 105
 <211> 479
 <212> DNA
 <213> Homo sapiens

<400> 105
 ctggcttctt cggagctgtg taktcttaat ttgctttgct gctggetggc tgacagctga 60
 tgggggactc ctcaggacgg actcccttcc agatgcaccc atctccatcc ttctcaactc 120
 cccaaccttt gtcctcccca ctcttcgctc gcgcggcggt ctgagaccac caggaccagt 180
 ttcaggggtt tccttctcca gcgagacttg gcagaacagg ctttaaaagc aaaggaggca 240
 gcggaagact gtgaattcct ttggacaatt gatgatattc atcattgtgc ccagtttcta 300
 caaataaaag atgggtggat tattttctcg atggaggaca aaaccttcaa ctgtagaagt 360
 tctagaaagt atagataagg aaattcaagc attggaagaa tttagggaaa aaaaaaaaaa 420
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 479

<210> 106
 <211> 33
 <212> PRT
 <213> Homo sapiens

<400> 106
 Met Gly Gly Leu Phe Ser Arg Trp Arg Thr Lys Pro Ser Thr Val Glu
 1 5 10 15

Val Leu Glu Ser Ile Asp Lys Glu Ile Gln Ala Leu Glu Glu Phe Arg
 20 25 30

Glu

<210> 107
 <211> 333
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (70)

<220>
 <221> unsure
 <222> (156)

<220>
 <221> unsure
 <222> (184)

<220>
 <221> unsure
 <222> (207)

<220>
 <221> unsure
 <222> (308)

<400> 107
 ctgacttact aataactaaag aagtgggggg agctcgagag ccagacggcc agacaggcag 60
 acccctccan aggcccgcca ggtgggcatg gtccccatt ttctttaagg cagcacctgg 120
 agtggagaga ggccactccc tctccagccc ccgatntgga cccgggggag gggaggctga 180
 tgcntttggc cccggcctgg ccaaaanagc ccateccccag ggcagtttca ggtgccggct 240
 gggccctgaa tgtcaaggat aatatatagc ccgctcctgg gtcctggagc tgtggccctt 300
 tgtactcntg ttgtgtccat tgtgtgtgtg cgt 333

<210> 108
 <211> 611
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (62)

<220>
 <221> unsure
 <222> (185)

<220>
 <221> unsure
 <222> (192)

<220>
 <221> unsure
 <222> (249)

<220>
 <221> unsure
 <222> (290)

<400> 108
 gtccattgtg tgtgtgcgtg gggacagagg cctggaaatg cggaggacta tacagagaag 60
 gnagggttttg tgaaggccag gcagggttgg aggccggggg tgtgagagga gaggcccata 120
 gggctgagtg gggtcgggtg aggcagaggt cagaaacaga agagctgcag ttgctggagc 180
 tgggntgaga antgggctgc ctectgceat cccccgtct cctccccctt tccccttggt 240
 gccccctnt gctcagaatc tgaagtagtt ccctcctcag caatttcatt tcttgaacac 300
 tgactcacac cttttaggca cctactgtgt gcatagcatt ccaccaggac tcatctccct 360
 tccttctcag ggggtcccgga gccccgacta gctttgccct aactccttca tcaaaagacc 420
 ccccgccagc ttcccacacc tcatacgcag ccacatctgc cctattctcc atgctttcca 480
 gcttgcctgc ccttcctcat ctctccctgc ctgtgcagac ctccaccctt ctttcctcca 540
 cccctccatc ccccaatgct tgtagacctt ccattcatte cgtctcatcg tgcgtggtct 600
 ctgatcgtcc a 611

<210> 109
 <211> 47

<212> PRT

<213> Homo sapiens

<400> 109

Met Leu Ser Ser Leu Pro Ala Leu Pro His Leu Ser Leu Pro Val Gln
 1 5 10 15

Thr Ser Thr Leu Leu Ser Ser Thr Pro Pro Ser Pro Asn Ala Cys Arg
 20 25 30

Pro Ser Ile His Ser Val Ser Ser Cys Val Val Ser Asp Arg Pro
 35 40 45

<210> 110

<211> 274

<212> DNA

<213> Homo sapiens

<400> 110

atccagggcg tggggagacc attggcattt gggaaccatt ttccttcgaa cggcttcccc 60
 ttgagctgag cattctgctt gctgcagtag acgggtcgcc ttttgcccat accgaaattt 120
 tctgaaatta aatcgcacac ccccaccatt tcctctcccc tgggatctgg aggaacatca 180
 tacatagtag gtgaatcgtt ttgtagagtg aagaatgcta atgtaaagca aatagtcacc 240
 cacgttcctt tgtaaattcca aaaaaaaaaa aaaa 274

<210> 111

<211> 1646

<212> DNA

<213> Homo sapiens

<400> 111

catcgggtgg actagctggg atctccgcat tggatttggg gctgattacc actgcttgcc 60
 tattattatt gttgttggtta ctactattat ttttttttac ccaagggaga aagacaaaaa 120
 aacgggtggga tttatttaac atgatcttgg caaacgtctt ctgcctcttc ttctttctag 180
 acgagaccct ccgctctttg gccagccctt cctccctgca gggccccgag ctccacggct 240
 ggcgcccccc agtggactgt gtccgggcca atgagctgtg tgccgcccga tccaactgca 300
 gctctcgcta ccgcaactctg cggcagtgcc tggcaggccg cgaccgcaac accatgctgg 360
 ccaacaagga gtgccaggcg gccttgaggg tcttgccagg gagcccgctg tacgactgcc 420
 gctgcaagcg gggcatgaag aaggagctgc agtgtctgca gatctactgg agcatccacc 480
 tggggctgac cgaggggtgag gagttctacg aagcctcccc ctatgagccg gtgacctccc 540
 gcctctcgga catcttcagg cttgcttcaa tcttctcagg gacaggggca gaccgggtgg 600
 tcagcgccaa gagcaaccat tgcctggatg ctgccaaggc ctgcaacctg aatgacaact 660
 gcaagaagct gcgctcctcc tacatctcca tctgcaaccg cgagatctcg cccaccgagc 720
 gctgcaaccg ccgcaagtgc cacaaggccc tgcgccagtt cttcgaccgg gtgccagcg 780
 agtacacctt ccgcatgctc ttctgtctct gccaaagacca ggcgtgctgt gagcgccgcc 840
 ggcaaaccat cctgcccagc tgctcctatg aggacaagga gaagcccaac tgcctggacc 900
 tgcgtggcgt gtgccggact gaccacctgt gtcgggtccc gctggccgac ttccatgcca 960
 attgtcgagc ctctaccag acggtcacca gctgccctgc ggacaattac caggcgtgtc 1020
 tgggctctta tgctggcatg attgggtttg acatgacacc taactatgtg gactccagcc 1080
 ccactggcat cgtggtgtcc ccctggtgca gctgtcgtgg cagcgggaac atggaggagg 1140
 agtgtgagaa gttcctcagg gacttcaccg agaaccctat cctccggaac gccatccagg 1200
 cctttggcaa cggcacggac gtgaacgtgt ccccaaaagg cccctcgttc caggccaccc 1260
 aggccctcgt ggtggagaag acgccttctt tgccagatga cctcagtgc agtaccagct 1320
 tggggaccag tgtcatcacc acctgcacct ctgtccagga gcaggggctg aaggccaaca 1380
 actccaaaga gttaagcatg tgcttcacag agctcacgac aaatatcatc ccaggagta 1440
 acaaggtgat caaacctaac tcaggcccca gcagagccag accgtcggct gccttgaccg 1500
 tgctgtctgt cctgatgctg aaacaggcct tgtaggctgt gggaaccgag tcagaagatt 1560
 tttgaaagct acgcagacaa gaacagccgc ctgacgaaat ggaaacacac acagacacac 1620
 acacaccttg caaaaaaaaaa aaaaaa 1646

<210> 112

<211> 464

<212> PRT

<213> H m sapiens

<400> 112

Met Ile Leu Ala Asn Val Phe Cys Leu Phe Phe Phe Leu Asp Glu Thr
 1 5 10 15

Leu Arg Ser Leu Ala Ser Pro Ser Ser Leu Gln Gly Pro Glu Leu His
 20 25 30

Gly Trp Arg Pro Pro Val Asp Cys Val Arg Ala Asn Glu Leu Cys Ala
 35 40 45

Ala Glu Ser Asn Cys Ser Ser Arg Tyr Arg Thr Leu Arg Gln Cys Leu
 50 55 60

Ala Gly Arg Asp Arg Asn Thr Met Leu Ala Asn Lys Glu Cys Gln Ala
 65 70 75 80

Ala Leu Glu Val Leu Gln Glu Ser Pro Leu Tyr Asp Cys Arg Cys Lys
 85 90 95

Arg Gly Met Lys Lys Glu Leu Gln Cys Leu Gln Ile Tyr Trp Ser Ile
 100 105 110

His Leu Gly Leu Thr Glu Gly Glu Glu Phe Tyr Glu Ala Ser Pro Tyr
 115 120 125

Glu Pro Val Thr Ser Arg Leu Ser Asp Ile Phe Arg Leu Ala Ser Ile
 130 135 140

Phe Ser Gly Thr Gly Ala Asp Pro Val Val Ser Ala Lys Ser Asn His
 145 150 155 160

Cys Leu Asp Ala Ala Lys Ala Cys Asn Leu Asn Asp Asn Cys Lys Lys
 165 170 175

Leu Arg Ser Ser Tyr Ile Ser Ile Cys Asn Arg Glu Ile Ser Pro Thr
 180 185 190

Glu Arg Cys Asn Arg Arg Lys Cys His Lys Ala Leu Arg Gln Phe Phe
 195 200 205

Asp Arg Val Pro Ser Glu Tyr Thr Tyr Arg Met Leu Phe Cys Ser Cys
 210 215 220

Gln Asp Gln Ala Cys Ala Glu Arg Arg Arg Gln Thr Ile Leu Pro Ser
 225 230 235 240

Cys Ser Tyr Glu Asp Lys Glu Lys Pro Asn Cys Leu Asp Leu Arg Gly
 245 250 255

Val Cys Arg Thr Asp His Leu Cys Arg Ser Arg L u Ala Asp Phe His
 260 265 270

Ala Asn Cys Arg Ala Ser Tyr Gln Thr Val Thr Ser Cys Pro Ala Asp
 275 280 285

Asn Tyr Gln Ala Cys Leu Gly Ser Tyr Ala Gly Met Ile Gly Phe Asp
 290 295 300
 Met Thr Pro Asn Tyr Val Asp Ser Ser Pro Thr Gly Il Val Val Ser
 305 310 315 320
 Pro Trp Cys Ser Cys Arg Gly Ser Gly Asn Met Glu Glu Glu Cys Glu
 325 330 335
 Lys Phe Leu Arg Asp Phe Thr Glu Asn Pro Cys Leu Arg Asn Ala Ile
 340 345 350
 Gln Ala Phe Gly Asn Gly Thr Asp Val Asn Val Ser Pro Lys Gly Pro
 355 360 365
 Ser Phe Gln Ala Thr Gln Ala Pro Arg Val Glu Lys Thr Pro Ser Leu
 370 375 380
 Pro Asp Asp Leu Ser Asp Ser Thr Ser Leu Gly Thr Ser Val Ile Thr
 385 390 395 400
 Thr Cys Thr Ser Val Gln Glu Gln Gly Leu Lys Ala Asn Asn Ser Lys
 405 410 415
 Glu Leu Ser Met Cys Phe Thr Glu Leu Thr Thr Asn Ile Ile Pro Gly
 420 425 430
 Ser Asn Lys Val Ile Lys Pro Asn Ser Gly Pro Ser Arg Ala Arg Pro
 435 440 445
 Ser Ala Ala Leu Thr Val Leu Ser Val Leu Met Leu Lys Gln Ala Leu
 450 455 460

<210> 113
 <211> 355
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (133)

<220>
 <221> unsure
 <222> (151)

<220>
 <221> unsure
 <222> (196)

<220>
 <221> unsure
 <222> (228)

<400> 113
 ctctcatttt tcctttcgaa gtgatatcca ctcgaacgag atcaaattctg taagctggag 60
 atacaacttc cactacataa gatccagaag gtatatcatg aaccacaaaa ctcccatctg 120
 tcttaaggaa acngacgtgc tcttctccgt ntaccagcac tcgggcccgc gagatccagt 180

cctgaggctt caccntgga acaactgcac gcccctcaat cttgaagnga tctcctatgc 240
 cgacccact ccctcccgat ccctcagcag cagccccggg cacctccgag ttctggacat 300
 cccccgatag cagcagcagc agcaggacgg gaaagaagcc ccacagagcg gccgc 355

<210> 114
 <211> 587
 <212> DNA
 <213> Homo sapiens

<400> 114
 ggctggacag acttttctaata gaaccaatg gttatgatga tggttcttcc tttattgata 60
 tttgtgcttc tgcctaaagt ggtcaacaca agtgatcctg acatgagacg ggaaatggag 120
 cagtcaatga atatgctgaa ttccaacat gagttgcctg atgtttctga gttcatgaca 180
 agactcttct cttcaaaatc atctggcaaa tctagcagcg gcagcagtaa aacaggcaaa 240
 agtggggctg gcaaaaggag gtagtcagcg cgtccaragc tggcatttgc acaaacacgg 300
 caacactggg tggcatccaa gtcttgga aa accgtgtgaa gcaactacta taaacttgag 360
 tcatcccgac gttgatctct tacaactgtg tatgttaact ttttagcaca tgttttgtac 420
 ttggtacacg agaaaaccca gctttcatct tttgtctgta tgaggatcaat attgatgtca 480
 ctgaattaat tacagtgtcc tatagaaaat gccattaata aattatatga actactatac 540
 attatgtata ttaattaaaa catcttaatc cagaaaaaaa aaaaaaa 587

<210> 115
 <211> 81
 <212> PRT
 <213> Homo sapiens

<400> 115
 Met Asn Pro Met Val Met Met Met Val Leu Pro Leu Leu Ile Phe Val
 1 5 10 15
 Leu Leu Pro Lys Val Val Asn Thr Ser Asp Pro Asp Met Arg Arg Glu
 20 25 30
 Met Glu Gln Ser Met Asn Met Leu Asn Ser Asn His Glu Leu Pro Asp
 35 40 45
 Val Ser Glu Phe Met Thr Arg Leu Phe Ser Ser Lys Ser Ser Gly Lys
 50 55 60
 Ser Ser Ser Gly Ser Ser Lys Thr Gly Lys Ser Gly Ala Gly Lys Arg
 65 70 75 80
 Arg

<210> 116
 <211> 601
 <212> DNA
 <213> Homo sapiens

<400> 116
 gatgtaccta ggcaccgcgc agcctgcggc ccccaacacc acctcccccg agctcaacct 60
 gtcccacccg ctccctgggca ccgccctggc caatgggaca ggtgagctct cggagcacca 120
 gcagtacgtg atcggcctgt tcctctcgtg cctctacacc atcttcctct tccccatcgg 180
 ctttgtgggc aacatcctga tcctgggtgg gaacatcagc ttccgcgaga agatgaccat 240
 ccccgacctg tacttcatca acctggcggt ggcggacctc atcctgggtgg ccgactccct 300
 cattgaggtg ttcaacctgc acgagcggta ctacgacatc gccgtcctgt gcaccttcat 360
 gtcgctcttc ctgcaggtca acatgtacag cagcgtcttc ttcctcacct ggatgagctt 420
 cgaccgctac atcgccctgg ccagggccat gcgctgcagc ctgttccgca ccaagcacca 480

cgcccggtg agctgtggcc tcactctggat ggcacccgtg tcagccacgc tggtagccctt 540
 caccgcccgtg cacctgcagc acaccgacga ggcctgcttc tgtttcgcgg atgtccggga 600
 g 601

<210> 117
 <211> 200
 <212> PRT
 <213> Homo sapiens

<400> 117
 Met Tyr Leu Gly Thr Ala Gln Pro Ala Ala Pro Asn Thr Thr Ser Pro
 1 5 10 15
 Glu Leu Asn Leu Ser His Pro Leu Leu Gly Thr Ala Leu Ala Asn Gly
 20 25 30
 Thr Gly Glu Leu Ser Glu His Gln Gln Tyr Val Ile Gly Leu Phe Leu
 35 40 45
 Ser Cys Leu Tyr Thr Ile Phe Leu Phe Pro Ile Gly Phe Val Gly Asn
 50 55 60
 Ile Leu Ile Leu Val Val Asn Ile Ser Phe Arg Glu Lys Met Thr Ile
 65 70 75 80
 Pro Asp Leu Tyr Phe Ile Asn Leu Ala Val Ala Asp Leu Ile Leu Val
 85 90 95
 Ala Asp Ser Leu Ile Glu Val Phe Asn Leu His Glu Arg Tyr Tyr Asp
 100 105 110
 Ile Ala Val Leu Cys Thr Phe Met Ser Leu Phe Leu Gln Val Asn Met
 115 120 125
 Tyr Ser Ser Val Phe Phe Leu Thr Trp Met Ser Phe Asp Arg Tyr Ile
 130 135 140
 Ala Leu Ala Arg Ala Met Arg Cys Ser Leu Phe Arg Thr Lys His His
 145 150 155 160
 Ala Arg Leu Ser Cys Gly Leu Ile Trp Met Ala Ser Val Ser Ala Thr
 165 170 175
 Leu Val Pro Phe Thr Ala Val His Leu Gln His Thr Asp Glu Ala Cys
 180 185 190
 Phe Cys Phe Ala Asp Val Arg Glu
 195 200

<210> 118
 <211> 419
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (80)

<220>

<221> unsure

<222> (178)

<400> 118

```

acgcctgagc gtcctccatc ttccaggatg gcagcaatgg cgctgtgagg cctcaccagg 60
cccacgagga gcagcagcgn tcggccccgga gcagcaggaa ggcccttttg tggagcgccc 120
gccgtctgct ccgggggtgt tcagtcactg cttgttgaca tcaacatggc aattgcantc 180
atgtggactg ggaccgtgag agctgccgtg tgggttagtc gggtgccagg acaatgaaat 240
actccagcac gtgtggctga cgaatttgtt ttacagaaa taacagctgg ggacaactgc 300
ggatgatgat taaaaacctt cccataaaat gtaagaaaag ctgatgaggc tggtgacgtt 360
cagcctttgt caataaacct gtcatgtgag gaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 419

```

<210> 119

<211> 714

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (646)

<220>

<221> unsure

<222> (649)

<400> 119

```

agccattggg acaggaaatg ccaaacaaca cccagataag gttgctgaag ccataattga 60
tgccattgaa gactttgtcc agaaaggatc agcccagtct gtgaaaaaag ttaaagtgtg 120
tatctttctg cctcaagtac tggatgtgtt ttatgccaac atgaagaaaa gagaaggggac 180
tcagctttct tcccaacagy ctartswtsy ytwmytthy akcatttttg ggcttttcaa 240
agcaatctcc ccaaaaaaag aatcatttgg ttttggaaaa gaaaacagaa tcagcaactt 300
ttcgggtgtg tggtgaaaat gtcacgtgtg tgggaatagc tatctcctgg ctacaagacc 360
tgattgaaaa agaacagtgt ccttacacca gtgaagatga gtgcatcaa gactttgatg 420
aaaaggagta tcaggagtgt aatgagctgc agaagaagt aaatattaac atttccctgg 480
accataagag acctttgatc aaggttttgg gaattagcag agatgtgatg caggctagag 540
atgaaattga ggcgatgatc aagagagttc gattggccaa agaacaggaa tcccgggcag 600
attgtatcag tgagtttata gaatggcagt ataatgacaa taacanttnt cattgtttta 660
acaaaatgac caatctgaaa ttagaggatg caaggagaga aaaaaaaaaa aaaa 714

```

<210> 120

<211> 159

<212> PRT

<213> Homo sapiens

<220>

<221> UNSURE

<222> (141)..(142)

<400> 120

```

Phe Leu Gly Phe Ser Lys Gln Ser Pro Gln Lys Lys Asn His Leu Val
  1             5             10             15

Leu Glu Lys Lys Thr Glu Ser Ala Thr Phe Arg Val Cys Gly Glu Asn
      20             25             30

Val Thr Cys Val Glu Tyr Ala Ile Ser Trp Leu Gln Asp Leu Ile Glu
      35             40             45

Lys Glu Gln Cys Pro Tyr Thr Ser Glu Asp Glu Cys Ile Lys Asp Phe
      50             55             60

```

Asp Glu Lys Glu Tyr Gln Glu Leu Asn Glu Leu Gln Lys Lys Leu Asn
65 70 75 80

Ile Asn Ile Ser Leu Asp His Lys Arg Pro Leu Ile Lys Val Leu Gly
85 90 95

Ile Ser Arg Asp Val Met Gln Ala Arg Asp Glu Ile Glu Ala Met Ile
100 105 110

Lys Arg Val Arg Leu Ala Lys Glu Gln Glu Ser Arg Ala Asp Cys Ile
115 120 125

Ser Glu Phe Ile Glu Trp Gln Tyr Asn Asp Asn Asn Xaa Xaa His Cys
130 135 140

Phe Asn Lys Met Thr Asn Leu Lys Leu Glu Asp Ala Arg Arg Glu
145 150 155

<210> 121

<211> 2681

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (2656)

<400> 121

cataacttcc aatcttcttg gcctggcact aaggacctac tacagactgg cactgaaata 60
tcttccctac cttatcattc cttgtgcttc tccacaagcc cactcttccc cttcatcata 120
catgtgccga cctttcctgt ctcttttact ttgcagcacc aaatgctttc tactttgttg 180
tctaggagga acacatgtca cttttgtaag ctgctcgaaa gcaggggcca caccttcac 240
cttgttttcc acacaacacc aagcacttag tagacacca ataaatcatt gctgaatgaa 300
tgtattcagc ctggaattgc actaggattt tttggccaac acattgtatt cttactgat 360
accagacttc caatcaaata aaatccttaa gcctttttca tagtctttaa ttaactact 420
tctcttccat tatttccctt tgcctacttt tgaactgata ttcagaactt ttctgttaat 480
gtttaatttt catccattat tcttgtctgt acagatcttc ttgatttttg actctcttat 540
ctagtttttt tttttttttt ttggcttccc gttgtgttat ccacaggcac aatgggtata 600
ttgactatcg ttcattgaag ttgttgatac aaatggtgaa caggagaaaa accagtagct 660
tgccaacttg gcacctcatt ctctagcttg acagtaatcc cttatctagt agtttttaga 720
tatggttatt taatcaaata tcactagctt ctaattttgt tataattcat tcatgtatac 780
agacaatgaa gaatcatctt tcttcattca acacatttat tgggaaccaa tcattgtcca 840
aggcaatatg ctaggcattg tgtaatagaa agcgattaag cttttacccc tgctctctt 900
ggcctgcaaa gagcaggtaa gattcatgca cagacaaatg tagtaccagg taaatagtga 960
ggccaaacac aagaggcagg tcaaagggtc ttggattcag aggatggaga agctcttct 1020
aggctggtga aatatttgca gaatgagtag gctcataagt ggaggtgagg tacaggctaa 1080
gctgctgtaa gaaagagtcc aaaatgcaaa ggatttacca caatgcagtt aatttttctc 1140
acaacggtcg aggtaggcag gtggtccaag tccagttaat cagccctcct caacacaagg 1200
cttccccttg taagctcagg atgaccgctc cagtctcat catctcccag gcagaaaaac 1260
gggagaaaga gaactagacg taccaccag tcattttaag gacatagcca ggccagggtg 1320
agtgactcac atctgtaatc caagcacttt gggagggtcg aggctggagg atagctcgaa 1380
gccaggagtt tgagaccagc ttggataaga aagcaagacc ttgtctctac aaaaaattta 1440
aaaattaacc atgtgtggtg gtgtgcacct atagtcccag ctactcagga ggctgagggt 1500
gaaggatcac ttgagcacag gagttggagg atacagttag ccatgatcac accacctcac 1560
tccagcctgg gcaacatagt gagaccccat ctctttaaaa aacaaaacaa aaaaacatca 1620
ccaggaagtt gcttacatgt cttctattcc tataacatcg gcctgagctt agtcacatgg 1680
ccacaccag cagaaagaac tctaggaaat atgggtcttat gctaggtaac cccaaacca 1740
gctaaaactg ttgcttttga agaagggtga aacagacaat gtggaggaga attaccagtc 1800

tgccacaaag agaaagaatt ctatgtgagg aaaacgctct agaagagggga gctgattaat 1860
 tagttatata tcagccgaga ggatgttatg agaaacacag atttgggttt aatagaaaaa 1920
 cttagaaccc ttcaagaagg aatgggagga cttgagagtg tcctccgctt ctgaaaatga 1980
 tcaagaaaaa tggtaagaat gtacacctca aggggtggatg gtaaagggtca gcctttaagc 2040
 ctcaatggcg gtgtggttgt aggtggggtg ggggtggagg cccgaagac aggcagacta 2100
 ccacagtagc cccgatggaa gcagtggaga tgaactggaa ggagcggctg tgggagcgac 2160
 aacgtgatga gaataaaccc ggcttggtc tgccctgtgc acacacaggt gagctgtgtg 2220
 cccccggatg tgtcagctgg tatatgcgtc tgtcagaagg cagctgggga gcactgttag 2280
 ctcagagact aagaggcaga cccaggaagc ccttctttgc attggtcagg gtttgcgtga 2340
 ttttcccaag cccaggaaat ggaacccagt tcttcttctt tctgtgtaaa ataataagca 2400
 tcacaatagg ctgtgctcat gagaacgcat tttgtttcca cagaaatgtt ttttctcact 2460
 ctgtcctgat tttgatttct gttaaactca gtaaacacat taccaaattt taaaataagg 2520
 tgacttggtt tccccaaact acagttcacc aaagggtatt catctgtttg ttctgaaaat 2580
 gcagctgctg tctagattta tgtgtgctct gacaagaaat gttttgtgta acaataaaaa 2640
 tcatttcctt tgatgnaaaa aaaaaaaaaa aaaaaaaaaa a 2681

<210> 122

<211> 132

<212> PRT

<213> Homo sapiens

<400> 122

Met Glu Ala Val Arg Met Asn Trp Lys Glu Arg Leu Trp Glu Arg Gln
 1 5 10 15

Arg Asp Glu Asn Lys Pro Gly Leu Ala Leu Pro Cys Ala His Thr Gly
 20 25 30

Glu Leu Cys Ala Pro Gly Cys Val Ser Trp Tyr Met Arg Leu Ser Glu
 35 40 45

Gly Ser Trp Gly Ala Leu Leu Ala Gln Arg Leu Arg Gly Arg Pro Arg
 50 55 60

Lys Pro Phe Phe Ala Leu Val Arg Val Cys Cys Ile Phe Pro Ser Pro
 65 70 75 80

Gly Asn Gly Thr Gln Phe Phe Phe Phe Leu Cys Lys Ile Ile Ser Ile
 85 90 95

Thr Ile Gly Cys Ala His Glu Asn Ala Phe Cys Phe His Arg Asn Val
 100 105 110

Phe Ser His Ser Val Leu Ile Leu Ile Ser Val Lys Leu Ser Lys His
 115 120 125

Ile Thr Lys Phe
 130

<210> 123

<211> 1585

<212> DNA

<213> Homo sapiens

<400> 123

ctaagctatt tgattctagg tctagaatgt tatctcttat tagaggatat gttaattttc 60
 ctgcatttta ttcatttatt aacttaacat ctctgattgc ctaccatgtg tcaggctctg 120
 tactaaggat tgaggaccca aagatgaaca aaacatgggg cctaattcaa agatttcaca 180
 atctggagag aaagtcagcc acatacaaaa aattataagg tagaatgtgc tataaaaaat 240


```

gatttaggta cagtggaagt ttagaaaggc ttcactaaag atgtcgtatt tgaattgggt 300
ctgagcatga attagtcttc aggtgaggga ggggggttaa gaaaactcta atgaaggaac 360
tctagtatgt gtgaaggcaa ggaggctggt gtgttttaggt tgcagcaaac caagtacaac 420
caggcttgga cttgagtgc tggaaagaca ggaagatgcc atgctgagaa aaactgcca 480
tgccaagctg agaaatgttc agcagaaaca taagggtgagc tgcatatgtc atttaaaatg 540
ttctaggagc cacattttta aaaaatcaaa attaacaagt caaaaaataa aaagcaatgg 600
ggggagatta aatgcatatt actaagtga agaagccaat caaaaaaggc tacatacctg 660
tatgattcca actatatgac attctgaaaa aggccaaact atagagacag taaatgatca 720
gtggttgcca ggagttaggg aggagggagg gatgaacagg cagagcacag aagattttta 780
gagcagtaga actattttgt atgatattat aatattgtag atacatatca ttataaattt 840
gtccaaaccc atagaatgta caccaagagt gaactctaata gtaaactgtg gactttgggt 900
gataatgatg tgtcagtgtg gattgatcag ttgtaacaaa tgtaccattc tgggtggggaa 960
tgttgataat ggagtaggct atgcatgtgt ggggcagtgg gtatatggga aatatctata 1020
ccttctggct agttttgctg tgaacttgat ctaaaaataa gcctactaag aaacacaagt 1080
caaattaatt ttaataatac attttattta acccaattta tcagaaatac taatatttta 1140
acatgtaatt gatataaaag ttattaacta gatattttac ttttttggt actgagtctt 1200
tgaaatctgg tctgtatttt acatttacag tacatctcaa ttcacattag ccacatttca 1260
gatactcagt acatacatga gtacctatgg ctagtggctg ctgtgttgga cagggcaggt 1320
cttgaaacct ggacttgctt gactcagaag cctcaattct cagccacagt gatatcctgc 1380
tccctaagta ctataatgat aaacacaaga ggagaggagc tttcagatga tcatctaata 1440
ccatgacgtt agctgttget ctccacactg cccgggtggc ccagtctgaa gcacttaggc 1500
agtgtgttcc aacagaaata caatgagagc caatacgtga taagtgtcct atgggccaca 1560
ttgaaacagt aaaaaaaaaa aaaaaa 1585

```

<210> 124

<211> 63

<212> PRT

<213> Homo sapiens

<400> 124

```

Met Leu Ser Leu Ile Arg Gly Tyr Val Asn Phe Pro Ala Phe Tyr Ser
  1             5             10             15

```

```

Phe Ile Asn Leu Thr Ser Leu Ile Ala Tyr His Val Ser Gly Ser Val
      20             25             30

```

```

Leu Arg Ile Glu Asp Pro Lys Met Asn Lys Thr Trp Gly Leu Ile Gln
      35             40             45

```

```

Arg Phe His Asn Leu Glu Arg Lys Ser Ala Thr Tyr Lys Lys Leu
      50             55             60

```

<210> 125

<211> 625

<212> DNA

<213> Homo sapiens

<400> 125

```

gatccacca gttctgcctg gcttctctcca tccccagagg cactaaaagc agtatttttaa 60
ggttggtgtc ttactccctg gaagcctgaa atgggtggaa tagcggtaag gcttgagtaa 120
aactagggga cagaggttct tatttgctga ttttatttta taatttgacc acagcatctg 180
aactccctct ctccctggaa taagtatttt tcccacattt ttggatatat gtatggtaga 240
caattttttt ttaagacaca gagataaatg ttttcttget ttggttacct ttcctttccc 300
ctttaaaagg aattagctat agaactgctt tgtaaagatg cttcttgata ttttactttt 360
gttccttttc cctaatacatt ccctttttct cccactcctc cagaaggcat aacccttctc 420
tccacacccc ctacccccac cccgctccta ggctcccatc ctttccatca agaccttcat 480
tagcttatga tatttgctgc cgagatgtta taacaaggac tcgttcatgt atataagcta 540
tttcttgatc catttaaaag gaattgtaca ttgtgttaga aaaaaaaaaa aaaaaaaaaa 600
aaaaaaaaaa aaaaaaaaaa aaaaaa 625

```

<210> 126
 <211> 24
 <212> PRT
 <213> Homo sapiens

<400> 126
 Met Leu Leu Asp Ile Leu Leu Leu Phe Leu Phe Pro Asn His Ser Leu
 1 5 10 15
 Phe Ser Pro Leu Leu Gln Lys Ala
 20

<210> 127
 <211> 1946
 <212> DNA
 <213> Homo sapiens

<400> 127
 gaagctggggg cccagcggag gtagcagcag acgcctgaga gcgaggccga ggcccctcag 60
 ggttttggaga ccctgacaca cccaccttct cacctgggct ctgcgtatcc cccagccttg 120
 agggaagatg aagcctaaac tgatgtacca ggagctgaag gtgcctgcag aggagcccgc 180
 caatgagctg cccatgaatg agattgagga gtggaaggct gcggaaaaga aagcccgcctg 240
 ggtcctgctg gtcctcattc tggcgggtgt gggcttcgga gccctgatga ctcagctgtt 300
 tctatgggaa tacggcgact tgcattctct tgggcccac cagcgcccag ccccttgcta 360
 tgacccttgc gaarcagtgc tgggtggaag cattcctgar ggctgggact tccccaatgc 420
 ctccacgggg aacccttcca ccagccaggc ctggctgggc ctgctcgccg gtgcgcacag 480
 cagcctggac atcgctcct tctactggac cctcaccaac aatgacaccc acacgcagga 540
 gccctctgcc cagcaggggtg aggaggtcct ccggcagctg cagaccctgg caccaaaggg 600
 cgtgaacgtc cgcacgctg tgagcaagcc cagcgggccc cagccacagg cggacctgca 660
 ggctctgctg cagagcgggtg cccaggtccg catgggtggac atgcagaagc tgacctatgg 720
 cgtcctgcat accaagtctt ggggtgggtgga ccagaccac ttctacctgg gcagtgccaa 780
 catggactgg cgttctactga cccaggtcaa ggagctgggc gtgggtcatgt acaactgcag 840
 ctgcctggct cgagacctga ccaagatctt tgaggcctac tggttcctgg gccaggcagg 900
 cagctccatc ccatcaactt ggccccggtt ctatgacacc cgctacaacc aagagacacc 960
 aatggagatc tgcctcaatg gaaccctgc tctggcctac ctggcgagtg cggccccacc 1020
 cctgtgtcca agtggccgca ctccagacct gaaggctcta ctcaacgtgg tggacaatgc 1080
 ccggagtctt atctacgtcg ctgtcatgaa ctacctgcc actctggagt tctcccacc 1140
 tcacaggctt tggcctgcca ttgacgatgg gctgcggcgg gccacctacg agcgtggcgt 1200
 caaggtgcgc ctgctcatca gctgctgggg acactcggag ccatccatgc gggccttcct 1260
 gctctctctg gctgccctgc gtgacaacca taccactct gacatccagg tgaaactctt 1320
 tgtgggtccc gcggatgagg cccaggctcg aatcccatat gcccggtgca accacaacaa 1380
 gtacatggtg actgaacgcg ccacctacat cggaacctcc aactggctctg gcaactactt 1440
 cacggagacg gcgggcacct cgctgctggg gacgcagaat gggagggggcg gcctgcggag 1500
 ccagctggag gccattttcc tgagggactg ggactccctt tacagccatg accttgacac 1560
 ytcagytgac agsgtgggca acgcctgccg cytgytctga ggcccgatcc agtgggcagg 1620
 ccaaggcctg ctgggccccg gcggaccacg gtgytctggg tcacgggtccc tgtecccgca 1680
 ccccgtytty tgytgcccc attgtggctc ctcaggytyt ytccctgyt ctcccaccty 1740
 tacctccacc cccaccggcc tgacgctgtg gccccgggac ccagcagagc tggggggagg 1800
 atcagcccc aaagaaatgg ggggtgcatg tgggcctggc cccctggccc acccccaytt 1860
 ttcagggcaa aaagggccca ggggtataat aagtaaataa cttgtctgta aaaaaaaaaa 1920
 aaaaaaaaaa aaaaaaaaaa aaaaaa 1946

<210> 128
 <211> 490
 <212> PRT
 <213> Homo sapiens

<220>

<221> UNSURE

<222> (83)

<220>

<221> UNSURE

<222> (480)

<220>

<221> UNSURE

<222> (482)

<220>

<221> UNSURE

<222> (490)

<400> 128

Met Lys Pro Lys Leu Met Tyr Gln Glu Leu Lys Val Pro Ala Glu Glu
 1 5 10 15

Pro Ala Asn Glu Leu Pro Met Asn Glu Ile Glu Ala Trp Lys Ala Ala
 20 25 30

Glu Lys Lys Ala Arg Trp Val Leu Leu Val Leu Ile Leu Ala Val Val
 35 40 45

Gly Phe Gly Ala Leu Met Thr Gln Leu Phe Leu Trp Glu Tyr Gly Asp
 50 55 60

Leu His Leu Phe Gly Pro Asn Gln Arg Pro Ala Pro Cys Tyr Asp Pro
 65 70 75 80

Cys Glu Xaa Val Leu Val Glu Ser Ile Pro Glu Gly Leu Asp Phe Pro
 85 90 95

Asn Ala Ser Thr Gly Asn Pro Ser Thr Ser Gln Ala Trp Leu Gly Leu
 100 105 110

Leu Ala Gly Ala His Ser Ser Leu Asp Ile Ala Ser Phe Tyr Trp Thr
 115 120 125

Leu Thr Asn Asn Asp Thr His Thr Gln Glu Pro Ser Ala Gln Gln Gly
 130 135 140

Glu Glu Val Leu Arg Gln Leu Gln Thr Leu Ala Pro Lys Gly Val Asn
 145 150 155 160

Val Arg Ile Ala Val Ser Lys Pro Ser Gly Pro Gln Pro Gln Ala Asp
 165 170 175

Leu Gln Ala Leu Leu Gln Ser Gly Ala Gln Val Arg Met Val Asp Met
 180 185 190

Gln Lys Leu Thr His Gly Val Leu His Thr Lys Phe Trp Val Val Asp
 195 200 205

Gln Thr His Phe Tyr Leu Gly Ser Ala Asn Met Asp Trp Arg Ser Leu
 210 215 220

Thr Gln Val Lys Glu Leu Gly Val Val Met Tyr Asn Cys Ser Cys Leu
 225 230 235 240

Ala Arg Asp Leu Thr Lys Ile Phe Glu Ala Tyr Trp Phe Leu Gly Gln
 245 250 255
 Ala Gly Ser Ser Ile Pro Ser Thr Trp Pro Arg Phe Tyr Asp Thr Arg
 260 265 270
 Tyr Asn Gln Glu Thr Pro Met Glu Ile Cys Leu Asn Gly Thr Pro Ala
 275 280 285
 Leu Ala Tyr Leu Ala Ser Ala Pro Pro Pro Leu Cys Pro Ser Gly Arg
 290 295 300
 Thr Pro Asp Leu Lys Ala Leu Leu Asn Val Val Asp Asn Ala Arg Ser
 305 310 315 320
 Phe Ile Tyr Val Ala Val Met Asn Tyr Leu Pro Thr Leu Glu Phe Ser
 325 330 335
 His Pro His Arg Phe Trp Pro Ala Ile Asp Asp Gly Leu Arg Arg Ala
 340 345 350
 Thr Tyr Glu Arg Gly Val Lys Val Arg Leu Leu Ile Ser Cys Trp Gly
 355 360 365
 His Ser Glu Pro Ser Met Arg Ala Phe Leu Leu Ser Leu Ala Ala Leu
 370 375 380
 Arg Asp Asn His Thr His Ser Asp Ile Gln Val Lys Leu Phe Val Val
 385 390 395 400
 Pro Ala Asp Glu Ala Gln Ala Arg Ile Pro Tyr Ala Arg Val Asn His
 405 410 415
 Asn Lys Tyr Met Val Thr Glu Arg Ala Thr Tyr Ile Gly Thr Ser Asn
 420 425 430
 Trp Ser Gly Asn Tyr Phe Thr Glu Thr Ala Gly Thr Ser Leu Leu Val
 435 440 445
 Thr Gln Asn Gly Arg Gly Gly Leu Arg Ser Gln Leu Glu Ala Ile Phe
 450 455 460
 Leu Arg Asp Trp Asp Ser Pro Tyr Ser His Asp Leu Asp Thr Ser Xaa
 465 470 475 480
 Asp Xaa Val Gly Asn Ala Cys Arg Leu Xaa
 485 490

<210> 129

<211> 6254

<212> DNA

<213> Homo sapiens

<400> 129

agggctccagg gcagtcgcgc cagagctgag cggagggcgc ggccgcgagaa cgaatctttg 60
 tgacattctc tctcagcatt ctttatcccc tgtttgctga agacttcgac caaagctggt 120
 cttagctgtt ggcattctcc tgagaaaagg atagcttcag aaatcagaaa aacattttggg 180
 aggtgtctag cccagtggac cttctgaaga gcaatgctaa gaagacgttt ggtttaaaga 240

```

attaaaagga agaacaactt aagagcttct tcaaagttcc ccgcatgaaa attacttaaa 300
cgttgcacac aacgtttcac aaaatctttt gtgaaagaag aaaaggaaat tcagtgtgtg 360
agtctcagea ggagttaagc taatgcagct taacatcatg ccgacaaaga agcgcttctc 420
tgccgggcaga gtgcccctga ttctcttctt gtgccagatg attagtgcac tggaaagtacc 480
tcttgatcca aaacttcttg aagacttggt acagcctcca accatcaccc aacagtctcc 540
aaaagattac attattgacc ctccgggagaa tattgtaatc cagtgtgaag ccaaagggaa 600
accgccccca agcttttctt ggacccgtaa tgggactcat tttgacatcg ataaagaccc 660
tctggtcacc atgaagcctg gcacaggaac gtcataatt aacatcatga gcgaagggaa 720
agctgagacc tatgaaggag tctatcagtg tacagcaagg aacgaacgcg gagctgcagt 780
ttctaataac attgttgtcc gcccatccag atcaccattg tggaccaaaag aaaaacttga 840
accaatcaca cttcaaagtg gtcagtcttt agtacttccc tgcagacccc caattggatt 900
accaccacct ataatatctt ggatggataa ttcttttcaa agacttccac aaagtgaagag 960
agtttctcaa ggtttgaatg gggaccttta tttttccaat gtcctcccag aggacacccg 1020
cgaagactat atctgttatg ctagatttaa tcatactcaa accatacagc agaagcaacc 1080
tatttctgtg aaggtgattt cagctaaatc aagtagagag aggccaccaa catttttaac 1140
tccagaaggc aatgcaagta acaaagagga attaagagga aatgtgcttt cactggagtg 1200
cattgcagaa ggactgccta ccccaattat ttactgggca aaggaagatg gaatgtctac 1260
caaaaacagg acagtttata agaactttga gaaaaccttg cagatcatte atgtttcaga 1320
agcagactct ggaaattacc aatgtatagc aaaaaatgca ttaggagcca tccaccatac 1380
catttctgtc agagttaaag cggtccata ctggatcaca gcccctcaa atcttgtgt 1440
gtccccagga gaggatggga ccttgatctg cagagctaat ggcaaccca aaccagaat 1500
tagctggtta acaaatggag tcccaataga aattgcccct gatgaccca gcagaaaaat 1560
agatggcgat accattattt ttcaaagt tcaagaaaga tcaagtgcag tatatcagt 1620
caatgcctct aatgaatatg gatatttact ggcaaacgca tttgtaaatg tgctggctga 1680
gccaccacga atcctcacac ctgcaaacac actctaccag gtcattgcaa acaggcctgc 1740
tttactagac tgtgccttct ttgggtctcc tctcccaacc atcagtggtt ttaaaggagc 1800
taaaggaagt gctcttcatg aagatatcta tgttttacat gaaaatggaa ctttggaaat 1860
tcctgtggcc caaaaggaca gtacaggaac ttatacgtgt gttgcaagga ataaattagg 1920
gatggcaaag aatgaagttc acttagaaat caaagatgct acatggatcg ttaaacagcc 1980
cgaatatgca gttgtgcaa gagggagcat ggtgtccttt gaatgcaaag tgaaacatga 2040
tcacacctta tccctcactg tcctgtggct gaaggacaac agggaaactgc ccagtgatga 2100
aaggttcact gttgacaagg atcatctagt ggtagctgat gtcagtgcag atgacagcgg 2160
gacctacacg tgtgtggcca acaccactct ggacagcgtc tccgccagcg ctgtgcttag 2220
cgttgttgct cctactccaa ctccagctcc cgtttacgat gtcccaaate ctccctttga 2280
cttagaactg acagatcaac ttgacaaaag tgttcagctg tcatggaccc caggcgatga 2340
caacaatagc cccattacaa aattcatcat cgaatatgaa gatgcaatgc acaagccagg 2400
gctgtggcac caccaaaactg aagtttcttg aacacagacc acagcccagc tgaagctgtc 2460
tccttacgtg aactactcct tccgcgtgat ggcagtgaac agcattggga agagcttgcc 2520
cagcgaggcc tctgagcagt atttgacgaa agcctcagaa ccagataaaa accccacagc 2580
tgtggaagga ctgggatcag agcctgataa tttggtgatt acgtggaagc ccttgaatgg 2640
tttcgaatct aatgggccag gccttcagta caaagttagc tggcgccaga aagatggtga 2700
tgatgaatgg acatctgtgg ttgtggcaaa tgtatccaaa tatattgtct caggcacgcc 2760
aacctttgtt ccatacctga tcaaagttca ggccctgaat gacatggggg ttgccccga 2820
gccagctgta gtcattgggac attctggaga agacctcca atggtggctc ctgggaacgt 2880
gcgtgtgaat gtggtgaaca gtaccttagc cgaggtgcac tgggacccag tacctctgaa 2940
aagcatccga ggacacctac aaggctatcg gatttactat tggagaccc agagtctatc 3000
taaaagaaac agacgtcaca ttgagaaaaa gatcctcacc ttccaaggca gcaagactca 3060
tggcatgttg ccggggctag agccctttag ccactacaca ctgaatgtcc gagtggctca 3120
tgggaaaggg gagggcccag ccagccctga cagagtcttt aatactccag aaggagtccc 3180
cagtgtctcc tcgtctttga agattgtgaa tccaacactg gactctctca ctttggaatg 3240
ggatccaccg agccaccga atggcatctt gacagagtac acctaaagt atcagccaat 3300
taacagcaca catgaattag gccctctggt agatttgaaa attcctgcca acaagacacg 3360
gtggacttta aaaaatttaa atttcagcac tcgatataag ttttatttct atgcacaaac 3420
atcagcagga tcaggaagtc aaattacaga ggaagcagta acaactgtgg atgaagctgg 3480
tattcttcca cctgatgtag gtgcaggcaa agcgatggca agccggcagg tggatattgc 3540
aactcagggc tggttcattg gtctgatgtg tgctgttgct ctcttatct taattttgct 3600
gattgtttgc ttcattcagaa gaaacaaggg tggtaaatat ccagttaaag aaaaggaaga 3660
tgcccatgct gacctgaaa tccagcctat gaaggaagat gatgggacat ttggagaata 3720
cagtgatgca gaagaccaca agcctttgaa aaaaggaagt cgaactcctt cagacaggac 3780
cgtgaaaaaa gaagatagtg acgacagcct agttgactat ggagaagggg ttaatggcca 3840

```



```

gttcaatgag gatggctcct ttattggaca atacagtggc aagaaagaga aagagccggc 3900
tgaaggaaac gaaagctcag aggcaccttc tcctgtcaac gccatgaatt cctttgttta 3960
atTTTTaagc tctttgcaa tattccattt ctctagaatg tttatcctaa gcacttggtt 4020
gtcagccctc tcatactatg aacatatggg tagagagtat attttctgct gtatgttagt 4080
attatgagaa tagttacagc aaaaacataa ctcaagtcaa tgatatgtta atatgaactg 4140
gaatgcaaag tgcatacttt ttcattcaaa atgggtattc ttgatttcct cagaactgat 4200
aaaaaataat gcaacatcac caacagatcc tgttatttcc tctgcaggat acagttcaat 4260
atgatgcatg aaaaatgctc cacattttaa ggacataccc gtgtatgtta tgaaaacatg 4320
gtttgatact ttgtttatac taccctcagc tgaacccta tatatgaatt ccgttttcat 4380
tgtcaagaat gttactgtag tattctctag aacttcaatg tctttgtgga cattgttgtg 4440
aaattggtga ctatgtatag ctgtcgttag tctttttggg agactgttag gaacagtttg 4500
tacagtatat acttgctaaa tgagttcatt atgacagtca cattgctgat gcttactgag 4560
aactattacc tactcttggc tcctgttact ccgtaggctt cttaatcttc caggcattac 4620
agcagcacag tgttctactt ttacatcat ttctatgttc gggtgttttt aggcataaac 4680
aatgtgtatt gcagtgcatt tcggcatttg tgccatactg aaagaatcaa aaacaaatca 4740
tccaaattaa atttcaaaca ttatttcaga gaacacaggg caagacacat acagtgcctt 4800
cagatattaa gcattccaca acatcgtgca ttctgtatca gctgggtccag tccattcttg 4860
gtcctagatt actgtcattg tctaaaagta acttttataa agcagagttc atgaaaactg 4920
caatgctggg aaaagaagga aacatgaaaa taaaaataag acagtttatt agaaatagca 4980
tttctcata agcataaaaa gaaatctttg ttgccaactg aagcacatgg gattttgtgg 5040
tcctttatgg tttctataac attcagtaag aaagatgtca acatgctaga aaattaattt 5100
taaaaactaag ttattccaac actaaaagca tacaacagca tgccaacagt aatatattat 5160
tctccaagac tttacctatg taagtgttca aaactctgca gcattaaaca acgtgtatgc 5220
aaattgttat ggatacattt cagaatctaa gaaatcaggc aagtgttaa aaggccaacg 5280
gtccaaggga ttacatctgc agtttaaaaa gtaaatatat attctatcgt attcataaac 5340
aatatctatc aaatgggtta cctccaaata tgaaaatcta taacaaccta tgggtgaagg 5400
aatgctcagt ttcatttgcc aataaattgg tttctcataa cttgcatcaa gtttaatttt 5460
aagtaaagct ttttatatgt agatatcttg ttgaatttgt aaatacactt aaaatgtaga 5520
tgctatatgc ttataggtgt tacatacaaa taaacatgca atgtttatgt tgtactgtat 5580
aagaggtaag ctaattaatg cagtgaatgg gattggaaag catctactta aatatctatt 5640
gggttcccc cttccccac cttttttgct gtgaaactga aatagtgaac ttttctacgt 5700
attgacagca gatttttcga tgaaatcttc agagctttgc ctatggggca cagtaggcc 5760
agtaacctgg catgtttgat atatgtaggt aaagcataat ttaaagtaat cccaggtaaa 5820
gatggcccta aatactttca tgtctctata ttcatttttc acagatccac ctgtctcttg 5880
aaaatataaa aagacaaaac aggtttgcct tggcatcaga gagcaciaag attaaaagtt 5940
actttaaatt tgccaatatt ttgggagaac aataaaaacta cattttttcy tyttccatac 6000
tggtagatgc gaaatttatc tgtgcatgaa agggtcactt ctgtaatagt gcacagattt 6060
ggtattaaaa attaaatgtg gttttaaaag ttcctytytc ttttgtaatt tatgttccca 6120
attgagtgtg aatgtccaag taatgggtgta tgtaatggta caggcaaatg tgactggatt 6180
tccctcaaaa aagtaactat taaacagtyt tgatctcaaa aaaaaaaaaa aaaaaaaaaa 6240
aaaaaaaaaa aaaa 6254

```

<210> 130

<211> 1192

<212> PRT

<213> Homo sapiens

<400> 130

```

Met Gln Leu Asn Ile Met Pro Thr Lys Lys Arg Leu Ser Ala Gly Arg
  1             5             10             15

```

```

Val Pro Leu Ile Leu Phe Leu Cys Gln Met Ile Ser Ala Leu Glu Val
      20             25             30

```

```

Pro Leu Asp Pro Lys Leu Leu Glu Asp Leu Val Gln Pro Pro Thr Ile
    35             40             45

```

```

Thr Gln Gln Ser Pro Lys Asp Tyr Ile Ile Asp Pro Arg Glu Asn Ile
    50             55             60

```

Val Ile Gln Cys Glu Ala Lys Gly Lys Pro Pro Pro Ser Phe Ser Trp
 65 70 75 80
 Thr Arg Asn Gly Thr His Phe Asp Ile Asp Lys Asp Pro Leu Val Thr
 85 90 95
 Met Lys Pro Gly Thr Gly Thr Leu Ile Ile Asn Ile Met Ser Glu Gly
 100 105 110
 Lys Ala Glu Thr Tyr Glu Gly Val Tyr Gln Cys Thr Ala Arg Asn Glu
 115 120 125
 Arg Gly Ala Ala Val Ser Asn Asn Ile Val Val Arg Pro Ser Arg Ser
 130 135 140
 Pro Leu Trp Thr Lys Glu Lys Leu Glu Pro Ile Thr Leu Gln Ser Gly
 145 150 155 160
 Gln Ser Leu Val Leu Pro Cys Arg Pro Pro Ile Gly Leu Pro Pro Pro
 165 170 175
 Ile Ile Phe Trp Met Asp Asn Ser Phe Gln Arg Leu Pro Gln Ser Glu
 180 185 190
 Arg Val Ser Gln Gly Leu Asn Gly Asp Leu Tyr Phe Ser Asn Val Leu
 195 200 205
 Pro Glu Asp Thr Arg Glu Asp Tyr Ile Cys Tyr Ala Arg Phe Asn His
 210 215 220
 Thr Gln Thr Ile Gln Gln Lys Gln Pro Ile Ser Val Lys Val Ile Ser
 225 230 235 240
 Ala Lys Ser Ser Arg Glu Arg Pro Pro Thr Phe Leu Thr Pro Glu Gly
 245 250 255
 Asn Ala Ser Asn Lys Glu Glu Leu Arg Gly Asn Val Leu Ser Leu Glu
 260 265 270
 Cys Ile Ala Glu Gly Leu Pro Thr Pro Ile Ile Tyr Trp Ala Lys Glu
 275 280 285
 Asp Gly Met Leu Pro Lys Asn Arg Thr Val Tyr Lys Asn Phe Glu Lys
 290 295 300
 Thr Leu Gln Ile Ile His Val Ser Glu Ala Asp Ser Gly Asn Tyr Gln
 305 310 315 320
 Cys Ile Ala Lys Asn Ala Leu Gly Ala Ile His His Thr Ile Ser Val
 325 330 335
 Arg Val Lys Ala Ala Pro Tyr Trp Ile Thr Ala Pro Gln Asn Leu Val
 340 345 350
 Leu Ser Pro Gly Glu Asp Gly Thr Leu Ile Cys Arg Ala Asn Gly Asn
 355 360 365
 Pro Lys Pro Arg Ile Ser Trp Leu Thr Asn Gly Val Pro Ile Glu Ile
 370 375 380

Ala Pro Asp Asp Pro Ser Arg Lys Ile Asp Gly Asp Thr Ile Ile Phe
 385 390 395 400
 Ser Asn Val Gln Glu Arg Ser Ser Ala Val Tyr Gln Cys Asn Ala Ser
 405 410 415
 Asn Glu Tyr Gly Tyr Leu Leu Ala Asn Ala Phe Val Asn Val Leu Ala
 420 425 430
 Glu Pro Pro Arg Ile Leu Thr Pro Ala Asn Thr Leu Tyr Gln Val Ile
 435 440 445
 Ala Asn Arg Pro Ala Leu Leu Asp Cys Ala Phe Phe Gly Ser Pro Leu
 450 455 460
 Pro Thr Ile Glu Trp Phe Lys Gly Ala Lys Gly Ser Ala Leu His Glu
 465 470 475 480
 Asp Ile Tyr Val Leu His Glu Asn Gly Thr Leu Glu Ile Pro Val Ala
 485 490 495
 Gln Lys Asp Ser Thr Gly Thr Tyr Thr Cys Val Ala Arg Asn Lys Leu
 500 505 510
 Gly Met Ala Lys Asn Glu Val His Leu Glu Ile Lys Asp Ala Thr Trp
 515 520 525
 Ile Val Lys Gln Pro Glu Tyr Ala Val Val Gln Arg Gly Ser Met Val
 530 535 540
 Ser Phe Glu Cys Lys Val Lys His Asp His Thr Leu Ser Leu Thr Val
 545 550 555 560
 Leu Trp Leu Lys Asp Asn Arg Glu Leu Pro Ser Asp Glu Arg Phe Thr
 565 570 575
 Val Asp Lys Asp His Leu Val Val Ala Asp Val Ser Asp Asp Asp Ser
 580 585 590
 Gly Thr Tyr Thr Cys Val Ala Asn Thr Thr Leu Asp Ser Val Ser Ala
 595 600 605
 Ser Ala Val Leu Ser Val Val Ala Pro Thr Pro Thr Pro Ala Pro Val
 610 615 620
 Tyr Asp Val Pro Asn Pro Pro Phe Asp Leu Glu Leu Thr Asp Gln Leu
 625 630 635 640
 Asp Lys Ser Val Gln Leu Ser Trp Thr Pro Gly Asp Asp Asn Asn Ser
 645 650 655
 Pro Ile Thr Lys Phe Ile Ile Glu Tyr Glu Asp Ala Met His Lys Pro
 660 665 670
 Gly Leu Trp His His Gln Thr Glu Val Ser Gly Thr Gln Thr Thr Ala
 675 680 685
 Gln Leu Lys Leu Ser Pro Tyr Val Asn Tyr Ser Phe Arg Val Met Ala
 690 695 700

Val	Asn	Ser	Ile	Gly	Lys	Ser	Leu	Pro	Ser	Glu	Ala	Ser	Glu	Gln	Tyr		
705					710					715					720		
Leu	Thr	Lys	Ala	Ser	Glu	Pro	Asp	Lys	Asn	Pro	Thr	Ala	Val	Glu	Gly		
				725					730					735			
Leu	Gly	Ser	Glu	Pro	Asp	Asn	Leu	Val	Ile	Thr	Trp	Lys	Pro	Leu	Asn		
			740					745					750				
Gly	Phe	Glu	Ser	Asn	Gly	Pro	Gly	Leu	Gln	Tyr	Lys	Val	Ser	Trp	Arg		
		755					760					765					
Gln	Lys	Asp	Gly	Asp	Asp	Glu	Trp	Thr	Ser	Val	Val	Val	Ala	Asn	Val		
	770					775					780						
Ser	Lys	Tyr	Ile	Val	Ser	Gly	Thr	Pro	Thr	Phe	Val	Pro	Tyr	Leu	Ile		
785					790					795					800		
Lys	Val	Gln	Ala	Leu	Asn	Asp	Met	Gly	Phe	Ala	Pro	Glu	Pro	Ala	Val		
				805					810					815			
Val	Met	Gly	His	Ser	Gly	Glu	Asp	Leu	Pro	Met	Val	Ala	Pro	Gly	Asn		
			820					825						830			
Val	Arg	Val	Asn	Val	Val	Asn	Ser	Thr	Leu	Ala	Glu	Val	His	Trp	Asp		
		835					840					845					
Pro	Val	Pro	Leu	Lys	Ser	Ile	Arg	Gly	His	Leu	Gln	Gly	Tyr	Arg	Ile		
	850					855					860						
Tyr	Tyr	Trp	Lys	Thr	Gln	Ser	Ser	Ser	Lys	Arg	Asn	Arg	Arg	His	Ile		
865					870					875					880		
Glu	Lys	Lys	Ile	Leu	Thr	Phe	Gln	Gly	Ser	Lys	Thr	His	Gly	Met	Leu		
			885						890					895			
Pro	Gly	Leu	Glu	Pro	Phe	Ser	His	Tyr	Thr	Leu	Asn	Val	Arg	Val	Val		
		900						905					910				
Asn	Gly	Lys	Gly	Glu	Gly	Pro	Ala	Ser	Pro	Asp	Arg	Val	Phe	Asn	Thr		
		915					920					925					
Pro	Glu	Gly	Val	Pro	Ser	Ala	Pro	Ser	Ser	Leu	Lys	Ile	Val	Asn	Pro		
	930					935					940						
Thr	Leu	Asp	Ser	Leu	Thr	Leu	Glu	Trp	Asp	Pro	Pro	Ser	His	Pro	Asn		
945				950						955					960		
Gly	Ile	Leu	Thr	Glu	Tyr	Thr	Leu	Lys	Tyr	Gln	Pro	Ile	Asn	Ser	Thr		
			965						970					975			
His	Glu	Leu	Gly	Pro	Leu	Val	Asp	Leu	Lys	Ile	Pro	Ala	Asn	Lys	Thr		
		980						985					990				
Arg	Trp	Thr	Leu	Lys	Asn	Leu	Asn	Phe	Ser	Thr	Arg	Tyr	Lys	Phe	Tyr		
		995				1000						1005					
Phe	Tyr	Ala	Gln	Thr	Ser	Ala	Gly	Ser	Gly	Ser	Gln	Ile	Thr	Glu	Glu		
1010						1015					1020						

Ala Val Thr Thr Val Asp Glu Ala Gly Ile Leu Pro Pro Asp Val Gly
1025 1030 1035 1040

Ala Gly Lys Ala Met Ala Ser Arg Gln Val Asp Ile Ala Thr Gln Gly
1045 1050 1055

Trp Phe Ile Gly Leu Met Cys Ala Val Ala Leu Leu Ile Leu Ile Leu
1060 1065 1070

Leu Ile Val Cys Phe Ile Arg Arg Asn Lys Gly Gly Lys Tyr Pro Val
1075 1080 1085

Lys Glu Lys Glu Asp Ala His Ala Asp Pro Glu Ile Gln Pro Met Lys
1090 1095 1100

Glu Asp Asp Gly Thr Phe Gly Glu Tyr Ser Asp Ala Glu Asp His Lys
1105 1110 1115 1120

Pro Leu Lys Lys Gly Ser Arg Thr Pro Ser Asp Arg Thr Val Lys Lys
1125 1130 1135

Glu Asp Ser Asp Asp Ser Leu Val Asp Tyr Gly Glu Gly Val Asn Gly
1140 1145 1150

Gln Phe Asn Glu Asp Gly Ser Phe Ile Gly Gln Tyr Ser Gly Lys Lys
1155 1160 1165

Glu Lys Glu Pro Ala Glu Gly Asn Glu Ser Ser Glu Ala Pro Ser Pro
1170 1175 1180

Val Asn Ala Met Asn Ser Phe Val
1185 1190

<210> 131

<211> 4253

<212> DNA

<213> Homo sapiens

<400> 131

```

gcgatcagaa gactgaggca gtgctgcagg tgaacatggc tgtagcctac caatccttca 60
ttttggctga cttcataatt gaacctgctc actgccaccc agtcgttcac atggcaaacc 120
ccagtgttcc ttaagtgggc tgaaaagaat ggaatcctag acctgtcttg ttagagtara 180
agctcattga gctgcctgcc cttccatatt gcttgtggac ctatgaatgg tgctctttaa 240
aatgtcagtg tagagggact gggaatcctg tattcctgcc ctatcattct gtaactttga 300
gaagcatgtg ggctcagtg aractactta tttttagttc tgttagaaca ggatttttaa 360
gaaaccatct gaacagaaga aataaagcgg aaggtaagct cagctcatgt gcccatcaag 420
ctgcataaat ctccatctgc tctgggaaac attcatggga acagaaggat tcttcttctc 480
gagaatgttg ttttcattat ataatcatag atacagcatg tgggtgattt ctgtgtacaa 540
atactttacc catgagaaat gtatagctgt tagatatgtg tgggctcaca catatatgca 600
atagatgcta tacatagcga tgtgcatgtg tatttgtata tatttatgtt catattttaa 660
catatgaaac atgaaataga agtataatat tatttttgta tccaaatagt taacagagca 720
gatgccctta gattctaata tgttgttcag tcttgaagat agccaagtta aatataaaaa 780
caggagaaga ggaanaataa aaktccattg agaaggaata gagagaaaga acrggtcttg 840
tgaatgagaa kttcatttgg atcaacacag catttcctar aatgagctcg cactgtgctt 900
tttgcarara craatgggct ccgtaggctc tccacggctt ttgatggcar atgakttgct 960
tctgtttcar atgaktcaag ctccagtcct ggaaggcaga tgctctctc cgatggtggg 1020
ccaccgggcc agtcaracac agacagctcc cgtggaggag agcgacttcg acaccatgcc 1080
agacattgag agtgataaaa acatcatccg gaccaagatg ttcctttacc tgtcagattt 1140
gtccaggaag gaccggagaa ttgtcagcaa aaaatataaa atttattttt ggaacatcat 1200

```



```

caccattgct gtgttttacg cgctgcccgat gatccagctg gtcattacct atcagacagt 1260
ggtaaagtgc actggcaacc aggacatctg ttactacaac ttcctctgtg ctcacccctt 1320
gggctgcctg agtgccttca acaacattct cagcaatctg ggccacgtgc ttctgggctt 1380
cctcttccctg ctgatagtct tgcgccgca catcctccat cggagagccc tggaagccaa 1440
ggacatcttt gctgtggagt acgggattcc caaacacttt ggtctcttct acgctatggg 1500
cattgcatctg atgatggaag ggggtgctcag tgcttgctac catgtctgcc ctaattattc 1560
caacttccaa ttcgacacct ccttcattga catgatcgct ggctgtgca tgctgaagct 1620
ctatcagacc cgccaccag acatcaatgc cagcgctac tctgcctatg cctcctttgc 1680
tgtggtcac atggtcaccg tccttggagt ggtgttctga aaaaatgacg tatggttctg 1740
ggtcattctt tctgcaatcc acgttctggc ctcgctagcc ctcagcacc aaatatatta 1800
tatgggtcgt tcaagatag atgtgtctga cacagatttg ggaattttcc ggcgggctgc 1860
catggtgttc tacacagact gtatccagca gtgtagccga cctctatata tggatagaat 1920
ggtgttgctg gttgtgggga atctgggttaa ctggtccttc gccctctttg gattgatata 1980
ccgccccagg gactttgctt cctacatgct gggcatcttc atctgtaacc ttttgctgta 2040
cctggccttt tacatcatca tgaagctccg cagctctgaa aaggctctcc cagctccgct 2100
cttctgcac gtggccaccg ctgtgatgtg ggctgccgcc ctatattttt tcttccagaa 2160
tctcagcagc tgggaggga ctccggccga atccgggag aagaaccgag agtgcattct 2220
gctggatttc ttcgatgacc atgacatctg gcacttcttc tctgctactg ctctgttttt 2280
ctcattcttg gttttgttaa ctttggatga tgacctgat gtggttcgga gagaccagat 2340
ccctgtcttc tgaacctcca acattaagag aggggaggga gcgatcaatc ttggtgctgt 2400
ttcacaaaaa ttacagtac cacagcaaa taaccactgc cagatgctcc actcaccctc 2460
tgtagagcca actctgcatt cacacaggaa ggagaggggc tgcgggagat ttaaacctgc 2520
aagaaaggag gcagaagggg agccatgttt tgaggacaga cgcaaacctg aggagctgag 2580
aaacacttgc tccttccatc tgcagctttg ggagtgcac agggataggc actgcatcca 2640
agtcaactca ccatcttggg gtccctccca ccctcacgga gacttgccag caatggcaga 2700
atgctgctgc acacttccct ccagttgtca ccctgccag aaaggccagc agcttggact 2760
tcctgccag aaactgtgtt ggcccccttc acacctctgc aacacctgct gctccagcaa 2820
gaggatgtga ttcttttaga tatggcgggg aggtgacccc aggcctgcc ctactgggat 2880
agatgtttta atggcaccag ctagtcacct ccagaagaa actctgtata tttccccag 2940
gtttctgatg ccatcagaag ggctcaggag tggggtttgt cacacattcc tcttaacaag 3000
taactgtcac tgggaccgag tcctgggtgc ttacatattc ctctgtgtct tcatctcact 3060
gacctgtgtg gacctcatca ctctgactct gccttcttgg aaaggccctg tcaactccaca 3120
gatgtctggc cagcttcaag gcagaaggaa aaacaggaaa agctctttta acagcagcag 3180
gaacaagaga aatgactaac cataactaaa gactggtaac agcagcagca gccagacagg 3240
cctcacctta aggacttggg ctgccagagc aaattcagca gagcttattt ggcctcccat 3300
tcacacagct cagttctgtg cccacatcac ctttggggaa gaaatcagca ttctaatacag 3360
ggacactact tcaggagtcc tccacagcga gtccgtcatc tgtcacttta tgtagatcag 3420
ggttctagac ttcttccctg aggttctcag aagcagctct caggatgaac gtattgtcct 3480
cttccccctt tcttgcaaa tgcacagcta atctaattgt gtctctcggt tgcacctgac 3540
attctctccc cagtaagggtg ttggcaagct cagcatctgg gttccactct cacactgtct 3600
ggcagctctg tgtctgagaa gttctacatt gaccaggccc ccttgttggc tggagtatga 3660
cgtaatcaga aaatagacgt ataaatgtgc acatgcgtat gtatttgctt gtgaaattaa 3720
agtcacctct tgcctctgct ttcctgatca ttcgttagag aaatggatca ggcatttttt 3780
taaattatta ttctttctct aaactatttg cattgtgttc aaaaacccat tttagaagtt 3840
tgaacagcaa gcttttccctg attttaaaaa cacaaagttg ctttcaatga aatattttgt 3900
gattttttta aagtccecaa atgtgtactt agccttctgt tattccttat tctttaagca 3960
gtgttggctt ccattgacca tatgaaggcc accaattaa tggttgtgtt aatccaacat 4020
gtaaaaaact ttttggcagg gcacagtggc tcacgcctgt aatcccaaca ctttgggagg 4080
ctgaggcagg aggatcamtt gagcccagga gattgacgcc gcagtgaact atgattgtgc 4140
ccctgcactc cagcctggat gacagagtga gaccccatyt yttaaaaaat aaaaaaaaat 4200
aaaaatttga acctgtttca aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 4253

```

<210> 132

<211> 479

<212> PRT

<213> Homo sapiens

<220>

<221> UNSURE

<222> (13) .. (14)

<220>

<221> UNSURE

<222> (21)

<400> 132

Met	Gly	Ser	Val	Gly	Ser	Pro	Arg	Leu	Leu	Met	Ala	Xaa	Xaa	Leu	Ser
1				5				10						15	
Leu	Phe	Gln	Met	Xaa	Gln	Ala	Pro	Val	Leu	Glu	Gly	Arg	Cys	Pro	Pro
			20					25					30		
Pro	Met	Val	Gly	His	Arg	Ala	Ser	Gln	Thr	Gln	Thr	Ala	Pro	Val	Glu
		35					40					45			
Glu	Ser	Asp	Phe	Asp	Thr	Met	Pro	Asp	Ile	Glu	Ser	Asp	Lys	Asn	Ile
		50				55					60				
Ile	Arg	Thr	Lys	Met	Phe	Leu	Tyr	Leu	Ser	Asp	Leu	Ser	Arg	Lys	Asp
65					70				75						80
Arg	Arg	Ile	Val	Ser	Lys	Lys	Tyr	Lys	Ile	Tyr	Phe	Trp	Asn	Ile	Ile
				85					90					95	
Thr	Ile	Ala	Val	Phe	Tyr	Ala	Leu	Pro	Val	Ile	Gln	Leu	Val	Ile	Thr
			100					105					110		
Tyr	Gln	Thr	Val	Val	Asn	Val	Thr	Gly	Asn	Gln	Asp	Ile	Cys	Tyr	Tyr
		115					120					125			
Asn	Phe	Leu	Cys	Ala	His	Pro	Leu	Gly	Val	Leu	Ser	Ala	Phe	Asn	Asn
		130				135					140				
Ile	Leu	Ser	Asn	Leu	Gly	His	Val	Leu	Leu	Gly	Phe	Leu	Phe	Leu	Leu
145					150					155					160
Ile	Val	Leu	Arg	Arg	Asp	Ile	Leu	His	Arg	Arg	Ala	Leu	Glu	Ala	Lys
				165					170					175	
Asp	Ile	Phe	Ala	Val	Glu	Tyr	Gly	Ile	Pro	Lys	His	Phe	Gly	Leu	Phe
			180					185					190		
Tyr	Ala	Met	Gly	Ile	Ala	Leu	Met	Met	Glu	Gly	Val	Leu	Ser	Ala	Cys
		195					200					205			
Tyr	His	Val	Cys	Pro	Asn	Tyr	Ser	Asn	Phe	Gln	Phe	Asp	Thr	Ser	Phe
		210				215					220				
Met	Tyr	Met	Ile	Ala	Gly	Leu	Cys	Met	Leu	Lys	Leu	Tyr	Gln	Thr	Arg
225					230					235					240
His	Pro	Asp	Ile	Asn	Ala	Ser	Ala	Tyr	Ser	Ala	Tyr	Ala	Ser	Phe	Ala
				245				250						255	
Val	Val	Ile	Met	Val	Thr	Val	Leu	Gly	Val	Val	Phe	Gly	Lys	Asn	Asp
			260					265					270		
Val	Trp	Phe	Trp	Val	Ile	Phe	Ser	Ala	Ile	His	Val	Leu	Ala	Ser	Leu
			275				280					285			

Ala Leu Ser Thr Gln Ile Tyr Tyr Met Gly Arg Phe Lys Ile Asp Val
 290 295 300

Ser Asp Thr Asp Leu Gly Ile Phe Arg Arg Ala Ala Met Val Phe Tyr
 305 310 315 320

Thr Asp Cys Ile Gln Gln Cys Ser Arg Pro Leu Tyr Met Asp Arg Met
 325 330 335

Val Leu Leu Val Val Gly Asn Leu Val Asn Trp Ser Phe Ala Leu Phe
 340 345 350

Gly Leu Ile Tyr Arg Pro Arg Asp Phe Ala Ser Tyr Met Leu Gly Ile
 355 360 365

Phe Ile Cys Asn Leu Leu Leu Tyr Leu Ala Phe Tyr Ile Ile Met Lys
 370 375 380

Leu Arg Ser Ser Glu Lys Val Leu Pro Val Pro Leu Phe Cys Ile Val
 385 390 395 400

Ala Thr Ala Val Met Trp Ala Ala Ala Leu Tyr Phe Phe Phe Gln Asn
 405 410 415

Leu Ser Ser Trp Glu Gly Thr Pro Ala Glu Ser Arg Glu Lys Asn Arg
 420 425 430

Glu Cys Ile Leu Leu Asp Phe Phe Asp Asp His Asp Ile Trp His Phe
 435 440 445

Leu Ser Ala Thr Ala Leu Phe Phe Ser Phe Leu Val Leu Leu Thr Leu
 450 455 460

Asp Asp Asp Leu Asp Val Val Arg Arg Asp Gln Ile Pro Val Phe
 465 470 475

<210> 133

<211> 462

<212> DNA

<213> Homo sapiens

<400> 133

gtggaaggag tggataataa aatgagtcag tgcaccagct ccaccattcc tagctcaagt 60
 caagagaaag accctaaaat taagacagag acaagtgaag agggatctgg agacttggat 120
 aatctagatg ctattcttgg tgatctgact agttctgact ttacaataa ttccatatcc 180
 tcaaattggta gtcattctggg gactaagcaa caggtgtttc aaggaactaa ttctctgggt 240
 ttgaaaagtt cacagtctgt gcagtctatt cgtcctccat ataaccgagc agtgtctctg 300
 gatagccctg tttctgttgg ctcaagtcct ccagtaaaaa atatcagtgc tttcccatg 360
 ttaccaaagc aacctatgtt ggggtgggaat ccaagaatga tggatagtca rgaaaattat 420
 ggctcaagta tgggagactg gggcttacca aactcaaagg cc 462

<210> 134

<211> 147

<212> PRT

<213> Homo sapiens

<400> 134

Met Ser Gln Cys Thr Ser Ser Thr Ile Pro Ser Ser Ser Gln Glu Lys
 1 5 10 15

Asp Pro Lys Ile Lys Thr Glu Thr Ser Glu Glu Gly Ser Gly Asp Leu
20 25 30

Asp Asn Leu Asp Ala Ile Leu Gly Asp Leu Thr Ser Ser Asp Phe Tyr
35 40 45

Asn Asn Ser Ile Ser Ser Asn Gly Ser His Leu Gly Thr Lys Gln Gln
50 55 60

Val Phe Gln Gly Thr Asn Ser Leu Gly Leu Lys Ser Ser Gln Ser Val
65 70 75 80

Gln Ser Ile Arg Pro Pro Tyr Asn Arg Ala Val Ser Leu Asp Ser Pro
85 90 95

Val Ser Val Gly Ser Ser Pro Pro Val Lys Asn Ile Ser Ala Phe Pro
100 105 110

Met Leu Pro Lys Gln Pro Met Leu Gly Gly Asn Pro Arg Met Met Asp
115 120 125

Ser Gln Glu Asn Tyr Gly Ser Ser Met Gly Asp Trp Gly Leu Pro Asn
130 135 140

Ser Lys Ala
145

<210> 135

<211> 119

<212> DNA

<213> Homo sapiens

<400> 135

aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 60
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 119

<210> 136

<211> 3316

<212> DNA

<213> Homo sapiens

<400> 136

ggtaagatgg cggctgtgag tctgcggctc ggcgacttgg tgtgggggaa actcggccga 60
tattctcctt ggccaggaaa gattgttaat ccaccaaagg acttgaagaa acctcgcgga 120
aagaaatgct tctttgtgaa attttttggga acagaagatc atgcctggat caaagtggaa 180
cagctgaagc catatcatgc tcataaagag gaaatgataa aaattaacaa gggtaaacga 240
ttccagcaag cggtagatgc tgcgaagag ttcctcagga gagccaaagg gaaagaccag 300
acgtcatccc acaattcttc tgatgacaag aatcgacgta attccagtga ggagagaagt 360
aggccaaact caggtgatga gaagcgcaaa cttagcctgt ctgaagggaa ggtgaagaag 420
aacatgggag aaggaaagaa gaggggtgtc tcaggctctt cagagagagg ctccaaatcc 480
cctctgaaaa gagcccaaga gcaaagtccc cggaagcggg gtcggccccc aaaggatgag 540
aaggatctca ccattcccga gtctagtacc gtgaagggga tgatggccgg accgatggcc 600
gcgttttaaat ggcagccaac cgcaagcgag cctgttaaag atgcagatcc tcatttccat 660
catttctctg taagccaaac agagaagcca gctgtctgtt accaggcaat cacgaagaag 720
ttgaaaatat gtgaagagga aactggctcc acctccatcc aggcagctga cagcacagcc 780
gtgaatggca gcatcacacc cacagacaaa aagataggat ttttgggcct tggctctcatg 840
ggaagtggaa tcgtctccaa cttgctaaaa atgggtcaca cagtgactgt ctggaaccgc 900
actgcagaga aagagggggc ccgtctggga agaaccctcg ctgaagtcgt ctcaacctgc 960

```

gacatcactt tcgcctgcgt gtcggatccc aaggcggcca aggacctggt gctgggcccc 1020
agtgggtgtc tgcaagggat ccgccctggg aagtgtctac tggacatgtc aacagtggac 1080
gctgacaccg tctactgagct ggcccagggt atttgttcca ggggggggcg ctttctggaa 1140
gcccccgctt cagggaatca gcagctgtct aatgacggga tgttggtgat cttagcggct 1200
ggagacaggg gcttatatga ggactgcagc agctgtctcc aggcgatggg gaagacctcc 1260
ttcttcctag gtgaagtggg caatgcagcc aagatgatgc tgatcgtgaa catgggtccaa 1320
gggagcttca tggccactat tgccgagggg ctgacctggg cccagggtgac aggccagtcc 1380
cagcagacac tcttggaatc cctcaatcag ggacagtggg ccagcatctt cctggaccag 1440
aagtgcctaa atatcctgca aggaaacttt aagcctgatt tctacctgaa atacattcag 1500
aaggatctcc gcttagccat tgcgctgggt gatgcggtca accatccgac tcccatggca 1560
gctgcagcaa atgaggtgta caaaagagcc aaggcgtggg accagtctga caacgatatg 1620
tccgccgtgt accgagccta catacactaa gctgtcgaca ccccgccctc accctccaa 1680
tccccctctt gacccccctt tcttcacatg gggctcggggg cctgggagtt cattctggac 1740
cagcccacct atctccattt ccttttatac agactttgag acttgccatc agcacagcac 1800
acagcagcac ccttccccctg aggcgggtgg ggaggggaca agtgtcagca ggattggcgt 1860
gtgggaaagc tcttgagctg ggcactggcc ccccgagcga ggtggctgtg tgttcacaca 1920
cacacacaca cacacacaca cacaggctct cgcccagga tagaagctgc ccagaaactg 1980
ctgcctggct ttttttcttc cgagcttgtc ttatctcaaa ccccttcag tcaaggaact 2040
agaatcagca acgagagttg gaagccttcc cacagcttcc cccagagcga agaggctgta 2100
gtcatgtccc catccccac tggattccct acaaggagag gccttgggccc cagatgagcc 2160
agtacagact ccagacagag gggcccttgg ggcctccaa cctcagggtg tgagctgaga 2220
aagatgttca cgtctaagcg tccagtgtgc acccagcgt ccatagacgc ctttgtgaac 2280
tgaaaagaga ctggcagagt cccgagaaga tggggccctg gctttccagg gagtgcagca 2340
agcagccggc ctgcagaccc agcctgacca acgatgagca tttcttaggc tcagctcttg 2400
atacggaac gagtgtcttc actccagcca gcatcatggt cttcgggtgt tcccgggccc 2460
ggggtctgtc gggaggggag agaactgggc ctgacctacc tgaactgact ggccctccga 2520
ggtgggtctg ggacatccta gaggccttac atttgtcctt ggatagggga ccgggggggg 2580
cttggaatgt tgcaaaaaaa aaagttaacc aagggatgtc agttttttat ccctctgcat 2640
gggttggatt ttccaaaatc ataatttgca gaaggaaggc cagcatttac gatgcaatat 2700
gtaattatat atagggtggc cacactaggg cgggggtcct ccccccctac agctttggcc 2760
cctttcagag attagaaact gggttagagg attgcagaag acgagtgggg ggagggcagg 2820
gaagatgcct gtcgggtttt tagcacagtt catttctact ggattttgaa gcatttctgt 2880
ctggacacaa agcctgttct agtcctggcg gaacacactg ggggtggggg cgggggaaga 2940
tgcggtaatg aaaccgggta gtcaattttg tcttaatat gttgacaatt ctgtaaagt 3000
cctttttatg aatatttctg tttaagctat ttcaccttcc ttttgaaate cttccctttt 3060
aaggagaaaa tgtgacactt gtgaaaaagc ttgtaagaaa gccctccct tttttcttta 3120
aaccttttaa tgacaaatct aggtaatata ggttgtgaat ttttattttt gctttgtttt 3180
taatgaacat ttgtctttca gaataggatt gtgtgataat gtttaaatgg caaaaacaaa 3240
acatgatttt gtgcaattaa caaagctact gcaagaaaaa taaaacactt cttggttaaca 3300
caaaaaaaaa aaaaaa 3316

```

<210> 137

<211> 547

<212> PRT

<213> Homo sapiens

<400> 137

```

Met Ala Ala Val Ser Leu Arg Leu Gly Asp Leu Val Trp Gly Lys Leu
  1             5             10             15

```

```

Gly Arg Tyr Pro Pro Trp Pro Gly Lys Ile Val Asn Pro Pro Lys Asp
          20             25             30

```

```

Leu Lys Lys Pro Arg Gly Lys Lys Cys Phe Phe Val Lys Phe Phe Gly
          35             40             45

```

```

Thr Glu Asp His Ala Trp Ile Lys Val Glu Gln Leu Lys Pro Tyr His
          50             55             60

```

```

Ala His Lys Glu Glu Met Ile Lys Ile Asn Lys Gly Lys Arg Phe Gln

```


65		70		75		80									
Gln	Ala	Val	Asp	Ala	Val	Glu	Glu	Phe	Leu	Arg	Arg	Ala	Lys	Gly	Lys
		85						90						95	
Asp	Gln	Thr	Ser	Ser	His	Asn	Ser	Ser	Asp	Asp	Lys	Asn	Arg	Arg	Asn
		100						105					110		
Ser	Ser	Glu	Glu	Arg	Ser	Arg	Pro	Asn	Ser	Gly	Asp	Glu	Lys	Arg	Lys
		115					120					125			
Leu	Ser	Leu	Ser	Glu	Gly	Lys	Val	Lys	Lys	Asn	Met	Gly	Glu	Gly	Lys
		130				135					140				
Lys	Arg	Val	Ser	Ser	Gly	Ser	Ser	Glu	Arg	Gly	Ser	Lys	Ser	Pro	Leu
145					150					155					160
Lys	Arg	Ala	Gln	Glu	Gln	Ser	Pro	Arg	Lys	Arg	Gly	Arg	Pro	Pro	Lys
				165					170					175	
Asp	Glu	Lys	Asp	Leu	Thr	Ile	Pro	Glu	Ser	Ser	Thr	Val	Lys	Gly	Met
			180					185					190		
Met	Ala	Gly	Pro	Met	Ala	Ala	Phe	Lys	Trp	Gln	Pro	Thr	Ala	Ser	Glu
		195					200					205			
Pro	Val	Lys	Asp	Ala	Asp	Pro	His	Phe	His	His	Phe	Leu	Leu	Ser	Gln
		210				215					220				
Thr	Glu	Lys	Pro	Ala	Val	Cys	Tyr	Gln	Ala	Ile	Thr	Lys	Lys	Leu	Lys
225					230					235					240
Ile	Cys	Glu	Glu	Glu	Thr	Gly	Ser	Thr	Ser	Ile	Gln	Ala	Ala	Asp	Ser
				245					250					255	
Thr	Ala	Val	Asn	Gly	Ser	Ile	Thr	Pro	Thr	Asp	Lys	Lys	Ile	Gly	Phe
			260					265					270		
Leu	Gly	Leu	Gly	Leu	Met	Gly	Ser	Gly	Ile	Val	Ser	Asn	Leu	Leu	Lys
		275					280					285			
Met	Gly	His	Thr	Val	Thr	Val	Trp	Asn	Arg	Thr	Ala	Glu	Lys	Glu	Gly
		290				295					300				
Ala	Arg	Leu	Gly	Arg	Thr	Pro	Ala	Glu	Val	Val	Ser	Thr	Cys	Asp	Ile
305					310					315					320
Thr	Phe	Ala	Cys	Val	Ser	Asp	Pro	Lys	Ala	Ala	Lys	Asp	Leu	Val	Leu
			325						330				335		
Gly	Pro	Ser	Gly	Val	Leu	Gln	Gly	Ile	Arg	Pro	Gly	Lys	Cys	Tyr	Val
			340					345					350		
Asp	Met	Ser	Thr	Val	Asp	Ala	Asp	Thr	Val	Thr	Glu	Leu	Ala	Gln	Val
		355					360					365			
Ile	Val	Ser	Arg	Gly	Gly	Arg	Phe	Leu	Glu	Ala	Pro	Val	Ser	Gly	Asn
		370				375					380				
Gln	Gln	Leu	Ser	Asn	Asp	Gly	Met	Leu	Val	Ile	Leu	Ala	Ala	Gly	Asp

385 390 395 400
 Arg Gly Leu Tyr Glu Asp Cys Ser Ser Cys Phe Gln Ala Met Gly Lys
 405 410 415
 Thr Ser Phe Phe Leu Gly Glu Val Gly Asn Ala Ala Lys Met Met Leu
 420 425 430
 Ile Val Asn Met Val Gln Gly Ser Phe Met Ala Thr Ile Ala Glu Gly
 435 440 445
 Leu Thr Leu Ala Gln Val Thr Gly Gln Ser Gln Gln Thr Leu Leu Asp
 450 455 460
 Ile Leu Asn Gln Gly Gln Leu Ala Ser Ile Phe Leu Asp Gln Lys Cys
 465 470 475 480
 Gln Asn Ile Leu Gln Gly Asn Phe Lys Pro Asp Phe Tyr Leu Lys Tyr
 485 490 495
 Ile Gln Lys Asp Leu Arg Leu Ala Ile Ala Leu Gly Asp Ala Val Asn
 500 505 510
 His Pro Thr Pro Met Ala Ala Ala Ala Asn Glu Val Tyr Lys Arg Ala
 515 520 525
 Lys Ala Leu Asp Gln Ser Asp Asn Asp Met Ser Ala Val Tyr Arg Ala
 530 535 540
 Tyr Ile His
 545

<210> 138
 <211> 1097
 <212> DNA
 <213> Homo sapiens

<400> 138
 attggttcaa gaagaaaatt tgagcccagg cacccaaaca ccttcaaattg ataaagcaag 60
 tatgttgcaa gaatactcca aatacctcca acaggctttt gaaaaatcca ctaatgcaag 120
 ttttactctt ggacacgggtt tccaatttgt cagtttgtct tcacctctcc acaaccacac 180
 tttgtttcca gaaaaacaaa tatacactac gtctcctttg gagtgtggtt tcggccaatc 240
 tgttacctca gtgttgccat cttcattgcc aaagcctcct tttgggatgt tgtttggatc 300
 tcagccaggt ctttatttgt ctgctttgga tgctacacat cagcagttga caccttccca 360
 ggagctggat gatctgatag attctcagaa gaacttagag acttcacag cttccagtc 420
 ctcatctcag aaattgacta gccagaagga acagaaaaac ttagagtctt caacaggctt 480
 tcagattcca tctcaggagt tagctagcca gatagatcct cagaaagaca tagagcctag 540
 aacaacgtat cagattgaga actttgcaca agcgttttgt tctcagttta agtcgggcag 600
 cagggtgcca atgaccttta tctaactc taatggagaa gtggaccata gagtaaggac 660
 ttcagtgtca gatttctcag ggtatacaaa tatgatgtct gatgtaagt agccatgtag 720
 tacaagagta aagacacca ccagccagag ttacaggtaa ggtcccaaaa gtggccaggc 780
 tggaggtttt ttaatgtaat tttgttttat tttgagaaca ctgccattgg aatgttttta 840
 cacgatccta ttaagaataa tgtgatgcc tttcaatgca acttttcata ttagtattat 900
 tttgttagcg tgatttttagc tctgtttgta ttatgatctt taatcaaat caatagatta 960
 aaaatagttt gacattcaaa gtgacaatgt ttagcaatca aatttacatg tatagattgt 1020
 cagggaaatag cccaaatgtt ttaaacgcaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1080
 aaaaaaaaaa aaaaaaa 1097

<210> 139

<211> 232

<212> PRT

<213> Homo sapiens

<400> 139

Met Leu Gln Glu Tyr Ser Lys Tyr Leu Gln Gln Ala Phe Glu Lys Ser
 1 5 10 15

Thr Asn Ala Ser Phe Thr Leu Gly His Gly Phe Gln Phe Val Ser Leu
 20 25 30

Ser Ser Pro Leu His Asn His Thr Leu Phe Pro Glu Lys Gln Ile Tyr
 35 40 45

Thr Thr Ser Pro Leu Glu Cys Gly Phe Gly Gln Ser Val Thr Ser Val
 50 55 60

Leu Pro Ser Ser Leu Pro Lys Pro Pro Phe Gly Met Leu Phe Gly Ser
 65 70 75 80

Gln Pro Gly Leu Tyr Leu Ser Ala Leu Asp Ala Thr His Gln Gln Leu
 85 90 95

Thr Pro Ser Gln Glu Leu Asp Asp Leu Ile Asp Ser Gln Lys Asn Leu
 100 105 110

Glu Thr Ser Ser Ala Phe Gln Ser Ser Ser Gln Lys Leu Thr Ser Gln
 115 120 125

Lys Glu Gln Lys Asn Leu Glu Ser Ser Thr Gly Phe Gln Ile Pro Ser
 130 135 140

Gln Glu Leu Ala Ser Gln Ile Asp Pro Gln Lys Asp Ile Glu Pro Arg
 145 150 155 160

Thr Thr Tyr Gln Ile Glu Asn Phe Ala Gln Ala Phe Gly Ser Gln Phe
 165 170 175

Lys Ser Gly Ser Arg Val Pro Met Thr Phe Ile Thr Asn Ser Asn Gly
 180 185 190

Glu Val Asp His Arg Val Arg Thr Ser Val Ser Asp Phe Ser Gly Tyr
 195 200 205

Thr Asn Met Met Ser Asp Val Ser Glu Pro Cys Ser Thr Arg Val Lys
 210 215 220

Thr Pro Thr Ser Gln Ser Tyr Arg
 225 230

<210> 140

<211> 775

<212> DNA

<213> Homo sapiens

<400> 140

gtgtcacata ccactcttgt aggtgtcctc aataatcccc ttttcccaca aaatacacag 60
 ggtgtattat ctttctcttt attcaccccc acttttgctga actgaagtta attacatagc 120
 ctttcttcta acctccttag taatgaacct tcacataaag tgtatttaca gcgtctgtgg 180

```

tagccagccc ttctctctct actttctagg aggggatagc caataactag gaatttaatg 240
acagattttt ttttcttttg aaataaatgg ccagagtttc tccatttttag aattttgttg 300
tcctccttaa tcactctgctt acctagtcac tactcaatct gcagaaactt cataaaggaa 360
aagtgcctgca ttgtttttac aaataacagt ttgtagggaa aatatgacaa acctcaacta 420
tgaggagtgt ccacaataca aaattttgaa aaaacattac atagtataa tatcatactt 480
ggttgttagg cttgttgctt ccccatca gaggcattca atgatttatt ttttgaatt 540
gctgtgaact tttttaata agccatttag tgtgaaattg tcatgtatca aatggctatt 600
ggaaatggac ttactcaat tttaattcca ctgcattca gccggagtga cagagtaaga 660
ctctgtctca aaaataata aataataaaa taaataata aataataaaa taaataaaaa 720
ataataatac aagttttcat aaggaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 775

```

<210> 141

<211> 44

<212> PRT

<213> Homo sapiens

<400> 141

```

Met Thr Asn Leu Asn Tyr Gly Ser Cys Pro Gln Tyr Lys Ile Leu Lys
  1             5             10             15

```

```

Lys His Tyr Ile Val Ile Ile Ser Tyr Leu Val Val Arg Leu Val Ala
          20             25             30

```

```

Ser Pro His Gln Arg His Leu Met Ile Tyr Leu Leu
          35             40

```

<210> 142

<211> 2060

<212> DNA

<213> Homo sapiens

<400> 142

```

gaaaaagaag acaaagctca ccttcaggcg gaggtgcagc acctgcgaga ggacaacctg 60
aggctacagg aggagtecca gaacgcctcg gacaagctga agaagttcac agaatgggtc 120
ttcaacacca tagacatgag ctagggaagg ctgaggagga caggagaagg gccagacac 180
tcctccagt gagtgctctg cagcccttat tccctccata gaaagcatcc tcagagcacc 240
ttcctgggt tcctactctg cccctttctg gggagtgcac aacacaatag ttgcagatca 300
acaatcatca cctgcctttt gtagaaaaga aaaacaaaaa aagtaataaa aaattttaaa 360
cagtaaaata aaagttaaac tgctaaaatg tgaatgtctt tatttttttg cacaatatct 420
ttatctgtta tgtatttaag aagaaactgg gccttgacc agggcgcccc ctggcccatc 480
cgctctatt cccatcagct ttcttatcaa cttcaggtaa cccaagcttt cccttggtat 540
tctaacaaat atcattattc ctgaaaaaag aatgttttta taacttggtt ggggagtaga 600
gagggatatt tccttacctt cttccctaaa atgcctggag agggagtgtc tttgagaaaa 660
tgctacctc ccttgatga ctctgcatg agctagtgtt gtctgtacct gtctccaga 720
gatcagcagg accggagtta aatatttaac agcaagtctg taaaccagag cagctctgac 780
agtgcctgca ggccacaccc cttctcagtc ctgcattgtg aggtcatttc ctgcttctcc 840
ctttccccag gaagatgggt ccacttggtg tgcaagactc tttttgttt ggcttaattg 900
agccccacta aattggaatc aatctctctt acagcttctt ggctccaaac attaatgat 960
ttcagaattc ccccaaacta aaaccttatt tgtctgcatt ttgaatgcat tttgggtcaa 1020
agtatacgtt ttaaagattt ttaaagataa aatgtgggca caactgggtt ttttagcttg 1080
ctgaaaatga ccatatctct aaattaatct ttctctccag agcaagactt caccagtatt 1140
tgtaactagg agaagctaa tgaaatgtta attgtgaatt ttaatcattg cttgttagga 1200
ataatgactg tgatactaga atgggctttt gaaacctgca tgtccagtg tgaaatttca 1260
gcaeggcatt ttctgcatcc ttctatggcc atccaaagga ttccgctgca gaaattattg 1320
atgtgctatt tttgctgtct tgtgatgcag gctgcttttg gccctgggt cactcttcca 1380
aggctgctgt agagcacaga gacatggggc tggccagtgt tgactgacct gaggagacct 1440
ctttgtttgt tgcttcata actgtcacta aaccgacccc tctgccctt cagtggcaac 1500
tctggtctaa gggaacattc agcactctag cggcattctg ttggaagttc cctcacccaa 1560
gtaatctcaa ttcttctctc tctccatccc tgaaagaaac aggatggatt ttcctctctt 1620

```

```

ctccctgcta cattcactac cagatTTTTta tgctacagtt tcattcttga ttgtgatttc 1680
tccatggaat tttttttttc tgggtgacatt tctatcatgg aaataggaag atttcggagt 1740
gctttgtgaa gatttcaatt gtctgtctct ttctctcttt gacttgtagt aaggagattg 1800
tacattgcct gatattctct tgtaaagag aaatattgct aacatccaag cattctgaag 1860
tcttgcttat ccttctgagt ttagttctca ttttgTTTTa cattttgttt ggggacttgg 1920
ggcaagctat ttattagagt ttgcaacag agttcttgtt tgaagcctct aaagactacc 1980
tgtaaaattc aaagaataaa attcatttta aacgctcttt taaaaaaaaa aaaaaaaaaa 2040
aaaaaaaaaa aaaaaaaaaa                                     2060

```

<210> 143
 <211> 62
 <212> PRT
 <213> Homo sapiens

<400> 143
 Met Thr Val Ile Leu Glu Trp Ala Phe Glu Thr Cys Met Ser Gln Cys
 1 5 10 15
 Glu Ile Ser Ala Arg His Phe Leu His Pro Phe Met Ala Ile Gln Arg
 20 25 30
 Ile Pro Leu Gln Lys Leu Leu Met Cys Tyr Phe Cys Cys Leu Val Met
 35 40 45
 Gln Ala Ala Leu Gly Pro Trp Val Thr Leu Pro Arg Leu Leu
 50 55 60

<210> 144
 <211> 1160
 <212> DNA
 <213> Homo sapiens

<400> 144
 gattattttc agtaggcaga catctaatacg gaatcttgcct cttgttgccc aggctggagt 60
 gtaatggcac aatctcggct tactgcaacc tctgcctcct ggattcaagt gattctcctg 120
 cctcagcctc ccaagtagct gggattacag ccctgaaaac cactcgcttg cagagcgctg 180
 gatcagcaat gcctactagt tcttcattca aacaccggat taaagagcag gaagactaca 240
 tccgagattg gactgctcat cgagaagaga tagccaggat cagccaagat cttgctctca 300
 ttgctcggga gatcaacgat gtagcaggag agatagattc agtgacttca tcaggcaactg 360
 cccctagtac cacagtaagc actgctgcca ccacccctgg ctctgccata gacactagag 420
 aagagttggt tgatcgtggt tttgatgaaa gcctcaactt ccaaagatt cctccattag 480
 ttcattccaa aacaccagaa ggaaacaacg gtcgatctgg tgatccaaga cctcaagcag 540
 cagagcctcc cgatcactta acaattacaa ggcggagaac ctggagcagg gatgaagtca 600
 tgggagataa tctgctgctg tcatccgtct ttcagttctc targaagata agacaatcta 660
 tagataagac agctggaaag atcagaatat tatttaaaaga caaagatcgg aattgggatg 720
 acatagaaaag caaattaaga gccgaaagtg aagtccttat tgtgaaaacc tcgagcatgg 780
 agattttctc tatcttacag gaactgaaaa gagtagaaaa gcagctacaa gcaatcaatg 840
 ctatgattga tcctgatgga actttggagg ctctgaacaa catgggattt ccagtgcta 900
 tgttgccatc tccaccgaaa cagaagtcca gccctgtgaa taaccaccac agcccgggtc 960
 agacaccaac acttggccaa ccagaagcta gggctcttca tcctgctgct gtttcagccg 1020
 cagctgaatt tgagaatgct gaatctgagg ctgatttcag tatacatttc aatagagtca 1080
 accctgatgg ggaagaggaa gatgttacag taacataaat gactttctct tgattgttga 1140
 aaaaaaaaaa aaaaaaaaaa 1160

<210> 145
 <211> 309
 <212> PRT
 <213> Homo sapiens

<220>

<221> UNSURE

<222> (152)

<400> 145

Met Pro Thr Ser Ser Ser Phe Lys His Arg Ile Lys Glu Gln Glu Asp
 1 5 10 15

Tyr Ile Arg Asp Trp Thr Ala His Arg Glu Glu Ile Ala Arg Ile Ser
 20 25 30

Gln Asp Leu Ala Leu Ile Ala Arg Glu Ile Asn Asp Val Ala Gly Glu
 35 40 45

Ile Asp Ser Val Thr Ser Ser Gly Thr Ala Pro Ser Thr Thr Val Ser
 50 55 60

Thr Ala Ala Thr Thr Pro Gly Ser Ala Ile Asp Thr Arg Glu Glu Leu
 65 70 75 80

Val Asp Arg Val Phe Asp Glu Ser Leu Asn Phe Gln Lys Ile Pro Pro
 85 90 95

Leu Val His Ser Lys Thr Pro Glu Gly Asn Asn Gly Arg Ser Gly Asp
 100 105 110

Pro Arg Pro Gln Ala Ala Glu Pro Pro Asp His Leu Thr Ile Thr Arg
 115 120 125

Arg Arg Thr Trp Ser Arg Asp Glu Val Met Gly Asp Asn Leu Leu Leu
 130 135 140

Ser Ser Val Phe Gln Phe Ser Xaa Lys Ile Arg Gln Ser Ile Asp Lys
 145 150 155 160

Thr Ala Gly Lys Ile Arg Ile Leu Phe Lys Asp Lys Asp Arg Asn Trp
 165 170 175

Asp Asp Ile Glu Ser Lys Leu Arg Ala Glu Ser Glu Val Pro Ile Val
 180 185 190

Lys Thr Ser Ser Met Glu Ile Ser Ser Ile Leu Gln Glu Leu Lys Arg
 195 200 205

Val Glu Lys Gln Leu Gln Ala Ile Asn Ala Met Ile Asp Pro Asp Gly
 210 215 220

Thr Leu Glu Ala Leu Asn Asn Met Gly Phe Pro Ser Ala Met Leu Pro
 225 230 235 240

Ser Pro Pro Lys Gln Lys Ser Ser Pro Val Asn Asn His His Ser Pro
 245 250 255

Gly Gln Thr Pro Thr Leu Gly Gln Pro Glu Ala Arg Ala Leu His Pro
 260 265 270

Ala Ala Val Ser Ala Ala Ala Glu Phe Glu Asn Ala Glu Ser Glu Ala
 275 280 285

Asp Phe Ser Ile His Phe Asn Arg Val Asn Pro Asp Gly Glu Glu Glu

290

295

300

Asp Val Thr Val Thr
305

<210> 146
<211> 1536
<212> DNA
<213> Homo sapiens

<220>
<221> unsure
<222> (317)

<400> 146
gaagagagaa aatcagcctg tctgctctct ccttggctca acaaggcctc taacagtctt 60
ctgtcctcta ttctgcacac ggcataattg ggaacgagaa acaaaagttt tcccaaatga 120
agagaactca cttgtttatt gtggggattt attttctgtc ctcttgcagg gcagaagagg 180
ggcttaattt cccacatat gatgggaagg accgagtggg aagtctttcc gagaagaact 240
tcaagcaggt tttaaagaaa tatgacttgc tttgcctcta ctaccatgag ccggtgtctt 300
cagataagggt cacgcanaaa cagttccaac tgaaagaaat cgtgcttgag cttgtggccc 360
acgtccttga acataaagct ataggctttg tgatgggtga tgccaagaaa gaagccaagc 420
ttgccaagaa actgggtttt gatgaagaag gaagcctgta tattcttaag ggtgatcgca 480
caatagagtt tgatggcgag tttgcagctg atgtcttggg ggagttcctc ttggatctaa 540
ttgaagaccc agtggagatc atcagcagca aactggaagt ccaagccttc gaacgcattg 600
aagactacat caaactcatt ggcttttttca agagtgagga ctcagaatac tacaaggctt 660
ttgaagaagc agctgaacac ttccagcctt acatcaaatt ctttgccacc ttgacaaaag 720
gggttgcaaa gaaattatct ttgaagatga atgaggttga cttctatgag ccatttatgg 780
atgagcccat tgccatcccc aacaaacctt acacagaaga ggagctgggtg gagtttgtga 840
aggaacacca aaggtgcctg agatggcatg tgggggctgg gggcctgggg tctggggaat 900
ggagaggagc ctctctgtgc taacatttca gacctgcaa gagcaacaac ctagttagta 960
ccccagcagt acagaactca gtagtatggc tttgttgatc agtaatgact agcagggatg 1020
ttattacttc tgaatctaag tctgcacctg caagcagagt ttgataaatc cctcagtcag 1080
caaatcccct caaagccagg gcaagatata aataaaaattc tatactagga atgagagcaa 1140
tttagtgaaa gttcccatat accaataacc atgccagtg ctttagggaa actattttat 1200
ctaattctca accttaggga gtaattatta ttatcccaat tttacagatc aaggaattgg 1260
actcaatagt taagtaactt agccaaggat gaacactcta tgcatagaac ttctgggaga 1320
gaaatgcttg ataccactta gtgtagctcc agcatggatc agcaaacttt ttctgtaaag 1380
aacaatatgg taaatatctt aggttctgtg ggccagatgg cgtctgtagc aactacttaa 1440
ctgcggctgt ggcataaag cagccatgga tcatgtataa acaaatgggt gtggctgtgt 1500
accagtaaaa gtttatctag gaaaaaaaaa aaaaaa 1536

<210> 147
<211> 268
<212> PRT
<213> Homo sapiens

<220>
<221> UNSURE
<222> (67)

<400> 147
Met Lys Arg Thr His Leu Phe Ile Val Gly Ile Tyr Phe Leu Ser Ser
1 5 10 15
Cys Arg Ala Glu Glu Gly Leu Asn Phe Pro Thr Tyr Asp Gly Lys Asp
20 25 30
Arg Val Val Ser Leu Ser Glu Lys Asn Phe Lys Gln Val Leu Lys Lys

35	40	45
Tyr Asp Leu Leu Cys Leu Tyr Tyr His Glu Pro Val Ser Ser Asp Lys		
50	55	60
Val Thr Xaa Lys Gln Phe Gln Leu Lys Glu Ile Val Leu Glu Leu Val		
65	70	75 80
Ala His Val Leu Glu His Lys Ala Ile Gly Phe Val Met Val Asp Ala		
85	90	95
Lys Lys Glu Ala Lys Leu Ala Lys Lys Leu Gly Phe Asp Glu Glu Gly		
100	105	110
Ser Leu Tyr Ile Leu Lys Gly Asp Arg Thr Ile Glu Phe Asp Gly Glu		
115	120	125
Phe Ala Ala Asp Val Leu Val Glu Phe Leu Leu Asp Leu Ile Glu Asp		
130	135	140
Pro Val Glu Ile Ile Ser Ser Lys Leu Glu Val Gln Ala Phe Glu Arg		
145	150	155 160
Ile Glu Asp Tyr Ile Lys Leu Ile Gly Phe Phe Lys Ser Glu Asp Ser		
165	170	175
Glu Tyr Tyr Lys Ala Phe Glu Glu Ala Ala Glu His Phe Gln Pro Tyr		
180	185	190
Ile Lys Phe Phe Ala Thr Phe Asp Lys Gly Val Ala Lys Lys Leu Ser		
195	200	205
Leu Lys Met Asn Glu Val Asp Phe Tyr Glu Pro Phe Met Asp Glu Pro		
210	215	220
Ile Ala Ile Pro Asn Lys Pro Tyr Thr Glu Glu Glu Leu Val Glu Phe		
225	230	235 240
Val Lys Glu His Gln Arg Cys Leu Arg Trp His Val Gly Ala Gly Gly		
245	250	255
Leu Gly Ser Gly Glu Trp Arg Gly Ala Ser Leu Cys		
260	265	

<210> 148

<211> 1009

<212> DNA

<213> Homo sapiens

<400> 148

```

gaattcggcc ttcattgcgc tgcaggaaag aatctgacat catcacactg tgttttcctt 60
aacttgacag gaagtcaact tcaagcagat tgacttgaaa cgggatctca tttaggaagc 120
ataagtgtcc aatcaaaaac tgtgtatttt tttaaatttg gaaaatactc aagttccagt 180
tgcttatcat tctccttcac tttctgaaaa cctggcaatc ccatgtggac ttctggtaga 240
atgagcaatg caaagaactg gcttggaactt ggcattgtcct tgtacttctg ggggctgatg 300
gaccttacga ccaccgttct ctcggacacc ccaacaccac aagggtgaatt agaagcactc 360
ctgtcagaca agccacagtc acatcagcgg accaagarga gctgggtttg gaaccagttt 420
ttcgttctgg aagagtacac tgggaccgac cctttgtatg tcggcaaggt aagaaatgcc 480
aagtagaaat gaccgggta gtggatattg aaattgaata tgaattgagt atcaaagttg 540

```

acctagcctt tatytgagac ctgagaaaaa ctagaacaag tggtagctta cttgacacct 600
 agctaaaatg taacttctgc tttgtcagag accagtctga aaggaaagat ttatttcctt 660
 gtccatgtct ctggtatgaa tgggaaaaag tgggaattgg gatttggagg aaaaggctca 720
 gaccctgcaa gagctattca agtcctaaaa gaggcagcag cagctgtctg ggaatgacag 780
 aatgggggag agggaaactt ggaaatacaa gaagagtaca gagttttttg ctttgtgttt 840
 ttatgggggt tttttcagag catttccaga ggtattgcct gaggtgcaaa tttaataaaa 900
 aaaataaaaa taaaacattt ttcatttcag aagatcctag catgtgcttt aggatagttg 960
 gagacaataa atatatttat aaatgttaaa aaaaaaaaaa aaaaaaaaaa 1009

<210> 149

<211> 87

<212> PRT

<213> Homo sapiens

<220>

<221> UNSURE

<222> (59)

<400> 149

Met Trp Thr Ser Gly Arg Met Ser Asn Ala Lys Asn Trp Leu Gly Leu
 1 5 10 15

Gly Met Ser Leu Tyr Phe Trp Gly Leu Met Asp Leu Thr Thr Thr Val
 20 25 30

Leu Ser Asp Thr Pro Thr Pro Gln Gly Glu Leu Glu Ala Leu Leu Ser
 35 40 45

Asp Lys Pro Gln Ser His Gln Arg Thr Lys Xaa Ser Trp Val Trp Asn
 50 55 60

Gln Phe Phe Val Leu Glu Glu Tyr Thr Gly Thr Asp Pro Leu Tyr Val
 65 70 75 80

Gly Lys Val Arg Asn Ala Lys
 85

<210> 150

<211> 2546

<212> DNA

<213> Homo sapiens

<400> 150

aaaagaaacc aaggaaattt gtatgataag gcaggtaaag tgaggaaaca tgcaactgaa 60
 caggaaaaaa ctgaagaggg attaggccct aatataaaaa gcattgtcac catgttgatg 120
 ctgatgctat tgatgatgtt tgctgtccac tgtacctggg tcacaagcaa tgcctactct 180
 agtccaagtg tagtcctggc ctcatacaat catgatggca ccaggaatat cttagatgat 240
 tttagagaag cttacttttg gctaaggcaa aatacagatg aacatgcacg agtaatgtct 300
 tgggtgggatt atggctatca gatagctgga atggctaata gaactacgtt ggtggataat 360
 aacacctgga ataacagcca catagcactg gtgggaaaag ctatgtcttc taatgaaaca 420
 gcagcctata aaatcatgag gactctagat gtagattatg ttttggttat ttttgagggg 480
 gttattggct attctgggta tgatatcaac aaatttctct ggatgggttag gatagctgaa 540
 ggagaacatc ccaaagacat tcgggaaagt gactatttta cccacaggg agaattccgt 600
 gtagacaaag caggatcccc tactttgttg aattgcctta tgtataaaat gtcatactac 660
 agatttgag aaatgcagct ggattttcgt acacccccag gttttgaccg aacacgtaat 720
 gctgagattg gaaataagga cattaaattc aaacatttgg aagaagcctt tacatcagaa 780
 cactggcttg ttaggatata taaagtataa gcacctgata acaggagagac attagatcac 840
 aaacctcgag tcaccaacat tttcccaaaa cagaagtatt tgtcaaagaa gactaccaa 900
 aggaagcgtg gctacattaa aaataagctg gtttttaaga aaggcaagaa aatatctaag 960

```

aagactgttt aaatgcactg ttctgggtcc taacttgaag cagttgtcct tgtgagaacc 1020
ggctctttgcc ttttagctcat gtcgtgtttc acagcaaaga gggtagagaa ccatcactgg 1080
tccagggttaa tgtacaaaat tttctggcaa tgcctgatta aaaaaataaa attggcttgt 1140
tgagaacagc tgttttcgat ttctaattgtg aagcaagaca gagcactgct gtaaattgtct 1200
agcagcagat ttttttttta ttggtagata ttatccttca aatctgagaa tttggactaa 1260
ctgcacaaaa gaaccttcta atttgggtccc tggcacatgc atacttgtca atgtttttat 1320
tctcttacia gacctgcatt ttatttgaat taccgaata gcaatatgta aaatacaagt 1380
gacaaaatgt gatgagagct tcttgaaccg gtaaactagt acaggtctga gaaagacata 1440
ttagaagaat cattatactt ccctgaatta tattttatctt catgtttctc taatgcaaag 1500
aatgtttcat caaatgtata tttctgttg cttactgtt gctctgagaa gaagctgctg 1560
tttcaaagat ggacctctga gtagctaatt gattcaagta gtttttttat gttgacacat 1620
tattactgct gtttagcagtc gttttcacca ggtacttaca gagcagattt catacatcat 1680
tcattcaagg gctaaattta tatttttttg aaatcatggc aactacacag gatgttgctt 1740
accaggacgg agttttggta tcttagtact gaagtttagca ctatgtttac atgcaaaaga 1800
ttaaggaaaa aacctttaa gtggacaggt atccaaagtt cattttctgt gactcatcaa 1860
agtgcacaaa gacttgtaac aactttgcct ggactttttt cattttacia cagttcatcc 1920
attcacaatg attttgttct ctgctccata ttttttaate ccttaagcat ttgatgaaac 1980
actcttttagt gctatatgca ttttcttact tttgttaaaa atgtgacaat tgtcaaaaaa 2040
tgcactaaaa tgtaaatgga gattgaacaa gttcacttcc cagcttatag gcaactttat 2100
acagacttga acattttctc cagttgttta gtaaaagtga aagagaaagg gtttttctctg 2160
ccacaggata taactttttt ttatataaca agcataaac accactgctt ttgggtggaaa 2220
agtgcagaat agtatgtacc ttttatgaag aaaaatgtaa tttacaatat tcagtgagaa 2280
tgttactgct gattttcttt tccaagggtg agaatactt ttgatttata gaattcattt 2340
ttgaccacaga tgatgggttcc tttacagaac aataaaatgg ctgaacattt tcacaaatag 2400
agtgtaacga agtctggatt tctgatacct tgcatttgg gggattttat tttactttgt 2460
tgcttttaaaa ttcaatgcag agaagttgtt gactgtaggg gaaataaagt taattcaaat 2520
tttgaaaaaa aaaaaaaaaa aaaaaa 2546

```

<210> 151

<211> 286

<212> PRT

<213> Homo sapiens

<400> 151

```

Met Leu Met Leu Met Leu Leu Met Met Phe Ala Val His Cys Thr Trp
 1              5              10              15

Val Thr Ser Asn Ala Tyr Ser Ser Pro Ser Val Val Leu Ala Ser Tyr
      20              25              30

Asn His Asp Gly Thr Arg Asn Ile Leu Asp Asp Phe Arg Glu Ala Tyr
      35              40              45

Phe Trp Leu Arg Gln Asn Thr Asp Glu His Ala Arg Val Met Ser Trp
      50              55              60

Trp Asp Tyr Gly Tyr Gln Ile Ala Gly Met Ala Asn Arg Thr Thr Leu
      65              70              75              80

Val Asp Asn Asn Thr Trp Asn Asn Ser His Ile Ala Leu Val Gly Lys
      85              90              95

Ala Met Ser Ser Asn Glu Thr Ala Ala Tyr Lys Ile Met Arg Thr Leu
      100             105             110

Asp Val Asp Tyr Val Leu Val Ile Phe Gly Gly Val Ile Gly Tyr Ser
      115             120             125

Gly Asp Asp Ile Asn Lys Phe Leu Trp Met Val Arg Ile Ala Glu Gly
      130             135             140

```


Glu His Pro Lys Asp Ile Arg Glu Ser Asp Tyr Phe Thr Pro Gln Gly
 145 150 155 160
 Glu Phe Arg Val Asp Lys Ala Gly Ser Pro Thr Leu Leu Asn Cys Leu
 165 170 175
 Met Tyr Lys Met Ser Tyr Tyr Arg Phe Gly Glu Met Gln Leu Asp Phe
 180 185 190
 Arg Thr Pro Pro Gly Phe Asp Arg Thr Arg Asn Ala Glu Ile Gly Asn
 195 200 205
 Lys Asp Ile Lys Phe Lys His Leu Glu Glu Ala Phe Thr Ser Glu His
 210 215 220
 Trp Leu Val Arg Ile Tyr Lys Val Lys Ala Pro Asp Asn Arg Glu Thr
 225 230 235 240
 Leu Asp His Lys Pro Arg Val Thr Asn Ile Phe Pro Lys Gln Lys Tyr
 245 250 255
 Leu Ser Lys Lys Thr Thr Lys Arg Lys Arg Gly Tyr Ile Lys Asn Lys
 260 265 270
 Leu Val Phe Lys Lys Gly Lys Lys Ile Ser Lys Lys Thr Val
 275 280 285

<210> 152

<211> 4061

<212> DNA

<213> Homo sapiens

<400> 152

aagcaattga agaaattgca gcaggatgtg atggaaatga aaaaaacaaa ggttcgccta 60
 atgaaacaaa tgaaagaaga acaagagaaa gccagactga ctgagtctag aagaaacaga 120
 gagattgctc agttgaaaaa ggatcaacgt aaaagagatc atcmacttag acttctggaa 180
 gcccaaaaaa gaaaccaaga agtggttcta cgtcgcaaaa ctgaagaggt tacggctctt 240
 cgtcggcaag taagacccat gtcagataaa gtggctggga aagttactcg gaagctgagt 300
 tcatctgatg cacctgctca ggacacaggt tccagtgcag ctgctgtcga aacagatgca 360
 tcaaggacag gagcccagca gaaaatgaga attcctgtgg cgagagtcca ggccttacca 420
 acgccggcaa caaatggaaa caggaaaaaa tatcagagga aaggattgac tggccgagtg 480
 tttatttcca agacagctcg catgaagtgg cagctccttg agcgcagggg cacagacatc 540
 atcatgcaga agatgaccat ttccaacatg gaggcagata tgaatagact cctcaagcaa 600
 cgggaggaac tcacaaaaag acgagagaaa ctttcaaaaa gaaggagaa gatagtcaag 660
 gagaatggag agggagataa aaatgtggct aatatcaatg aagagatgga gtcactgact 720
 gctaatatcg attacatcaa tgacagtatt tctgattgtc aggccaacat aatgcagatg 780
 gaagaagcaa aggaagaagg tgagacattg gatgttactg cagtcattaa tgcctgcacc 840
 cttacagaag cccgatacct gctagatcac ttctgttcaa tgggcatcaa taagggtctt 900
 caggctgccc agaaagaggc tcaaattaaa gtactggaag gtcgactcaa acaaacagaa 960
 ataaccagtg ctacccaaaa ccagctctta ttccatatgt tgaaagagaa ggcagaatta 1020
 aatcctgagc tagatgcttt actaggccat gctttacaag atctagatag cgtaccatta 1080
 gaaaatgtag aggatagtac tgatgaggat gctcctttta acagcccagg atcagaagga 1140
 agcacgctgt cttcagatct catgaagctt tgtggtgaag tgaaacctaa gaacaaggcc 1200
 cgaaggagaa ccaccactca gatggaattg ctgtatgcag atagcagtga actagcttca 1260
 gacactagta caggagatgc ctcttgcct ggccctctca cacctgttgc agaagggcaa 1320
 gagattggaa tgaatacaga gacaagtggc acttctgcta gggaaaaaga gctctctccc 1380
 ccacctggct taccttctaa gataggcagc atttccaggc agtcattctt atcagaaaaa 1440
 aaaattccag agccttctcc tgtaacaagg agaaaggcat atgagaaagc agaaaaatca 1500

```

aaggccaagg aacaaaagca ctcagattct ggaacttcag aggctagtct ttcacctcct 1560
tcttccccac caagccggcc ccgtaatgaa ctgaatgttt ttaatcgtct tactgtttct 1620
cagggaacaa catcagttca gcaggataag tctgatgaaa gtgactcctc tctctcggag 1680
gtacacagca gatcctccag aaggggcata atcaacccat ttcctgcttc aaaaggaatc 1740
agagcttttc cacttcagtg tattcacata gctgaagggc atacaaaagc tgtgctctgt 1800
gtggattcta ctgatgatct cctcttcact ggatcaaaaag atcgtacttg taaagtatgg 1860
aatctgggtga ctgggcagga aataatgtca ctgggggggc atcccaacaa tgtcgtgtct 1920
gtaaaatact gtaattatac cagtttggtc ttcactgtat caacatctta tattaagggtg 1980
tgggatatca gagattcagc aaagtgcatt cgaacactaa cgtcttcagg tcaagttact 2040
cttggagatg cttgttctgc aagtaccagt cgaacagtag ctattccttc tggagagAAC 2100
cagatcaatc aaattgccct aaaccaact ggcaccttc tctatgctgc ttctggaaat 2160
gctgtcagga tgtgggatct taaaagggtt cagtctacag gaaagttaac aggacaccta 2220
ggccctgtta tgtgccttac tgtggatcag atttccagtg gacaagatct aatcatcact 2280
ggctccaagg atcattacat caaaatgttt gatgttacag aaggagctct tgggactgtg 2340
agtcccaccc acaattttga accccctcat tatgatggca tagaagcact aaccattcaa 2400
ggggataacc tatttagtgg gtctagagat aatggaatca agaaatggga cttaactcaa 2460
aaagaccttc ttcagcaagt tccaaatgca cataaggatt gggctctgtgc cctgggagtg 2520
gtgccagacc acccagtttt gctcagtggc tgcagagggg gcattttgaa agtctggaac 2580
atggatactt ttatgccagt gggagagatg aagggtcatg atagtcctat caatgccata 2640
tgtgttaatt ccacccacat ttttactgca gctgatgatc gaactgtgag aatttggaag 2700
gctcgcaatt tgcaagatgg tcagatctct gacacaggag atctggggga agatattgcc 2760
agtaattaaa catgaatgaa gatagggtgt aaactgaatg ctgtgataat actctgtatt 2820
ctttatggaa aatgttgtcc tgtacttact aggcaaacg tatgaatcgg attaactgga 2880
aaatatatct gaattcaact gctgactata aatgggtatt taataaaatt gtgtactatc 2940
ctgtgtgctt agttttaaga tcaaccaata gatacatatc ctacaattga tatattgctt 3000
tattcacact tttattgtgg ctgaattttt gtgcctatct ataaaacaca ctttcaaatt 3060
atttgaatta ccaagacgtc tgcttttgtg acagtcagaa aacacacctg gaatacgtg 3120
cagcccacca ttaactcatt catgtagttt attcaagtga tttatgtatt taaactaaat 3180
attgaaaatg tcagtcaaat tgcggtttgc ttgtcaggta tttatatcag tctgtagtgg 3240
attcccaaat ttcaaagctc ttttaatgta atggacaaaa ataagatatg agaataattat 3300
tgatgaattt tcataagggtg gaattgatct taatctacta acagagaagg gtagacagtt 3360
tgtgttaaat gttggcattt acttgtattg accaaagctt tgcagctcta ctatattctg 3420
tgctcaggac taaaatgctg ttaatttttt tttttttttt tccagtgtgtg tgcataatatt 3480
ctgtgatggg aaacattgtt gatgtcctaa cagaaatata ttttgatcta ttttcctatg 3540
gagttgtttc tattatgacc atttaatttt gtttttattt aatagtagta tttccttccc 3600
ttttatctaa ttttttatat gctgctaaat atatttttaa tatactatgt ttgcgaacct 3660
tggtagctat gatgagagct attatcatct gtgggtgggaa aagctatgta aataggtaga 3720
ttgtatagag agactatctt gtgttgtgcc tgtatgaatt tttaaaagtt gttgactgga 3780
ttttgcaaaa ggatgtataa tatttctgtc tgctcagaat attaatattgt aaattctgca 3840
agtttaattt ttatgtagat ggtataacat ttgaaaatat tgtcttatgt gattttttcc 3900
cctgaaaata tttgcttgta aatgaaaact tagctagggc ttaaataaac atgttgctat 3960
gaaatkraaa aaaaaaaaaa aaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 4020
aaraaaaaaa aaaaaaaaaa aaaaaaaaa aaaaaaaaaa a 4061

```

<210> 153

<211> 910

<212> PRT

<213> Homo sapiens

<220>

<221> UNSURE

<222> (43)

<400> 153

```

Met Lys Lys Thr Lys Val Arg Leu Met Lys Gln Met Lys Glu Glu Gln
  1             5             10             15

```

```

Glu Lys Ala Arg Leu Thr Glu Ser Arg Arg Asn Arg Glu Ile Ala Gln
          20             25             30

```

Leu Lys Lys Asp Gln Arg Lys Arg Asp His Xaa Leu Arg Leu Leu Glu
 35 40 45
 Ala Gln Lys Arg Asn Gln Glu Val Val Leu Arg Arg Lys Thr Glu Glu
 50 55 60
 Val Thr Ala Leu Arg Arg Gln Val Arg Pro Met Ser Asp Lys Val Ala
 65 70 75 80
 Gly Lys Val Thr Arg Lys Leu Ser Ser Ser Asp Ala Pro Ala Gln Asp
 85 90 95
 Thr Gly Ser Ser Ala Ala Ala Val Glu Thr Asp Ala Ser Arg Thr Gly
 100 105 110
 Ala Gln Gln Lys Met Arg Ile Pro Val Ala Arg Val Gln Ala Leu Pro
 115 120 125
 Thr Pro Ala Thr Asn Gly Asn Arg Lys Lys Tyr Gln Arg Lys Gly Leu
 130 135 140
 Thr Gly Arg Val Phe Ile Ser Lys Thr Ala Arg Met Lys Trp Gln Leu
 145 150 155 160
 Leu Glu Arg Arg Val Thr Asp Ile Ile Met Gln Lys Met Thr Ile Ser
 165 170 175
 Asn Met Glu Ala Asp Met Asn Arg Leu Leu Lys Gln Arg Glu Glu Leu
 180 185 190
 Thr Lys Arg Arg Glu Lys Leu Ser Lys Arg Arg Glu Lys Ile Val Lys
 195 200 205
 Glu Asn Gly Glu Gly Asp Lys Asn Val Ala Asn Ile Asn Glu Glu Met
 210 215 220
 Glu Ser Leu Thr Ala Asn Ile Asp Tyr Ile Asn Asp Ser Ile Ser Asp
 225 230 235 240
 Cys Gln Ala Asn Ile Met Gln Met Glu Glu Ala Lys Glu Glu Gly Glu
 245 250 255
 Thr Leu Asp Val Thr Ala Val Ile Asn Ala Cys Thr Leu Thr Glu Ala
 260 265 270
 Arg Tyr Leu Leu Asp His Phe Leu Ser Met Gly Ile Asn Lys Gly Leu
 275 280 285
 Gln Ala Ala Gln Lys Glu Ala Gln Ile Lys Val Leu Glu Gly Arg Leu
 290 295 300
 Lys Gln Thr Glu Ile Thr Ser Ala Thr Gln Asn Gln Leu Leu Phe His
 305 310 315 320
 Met Leu Lys Glu Lys Ala Glu Leu Asn Pro Glu Leu Asp Ala Leu Leu
 325 330 335
 Gly His Ala Leu Gln Asp Leu Asp Ser Val Pro Leu Glu Asn Val Glu
 340 345 350

Asp Ser Thr Asp Glu Asp Ala Pro Leu Asn Ser Pro Gly Ser Glu Gly
 355 360 365
 Ser Thr Leu Ser Ser Asp Leu Met Lys Leu Cys Gly Glu Val Lys Pro
 370 375 380
 Lys Asn Lys Ala Arg Arg Arg Thr Thr Thr Gln Met Glu Leu Leu Tyr
 385 390 395 400
 Ala Asp Ser Ser Glu Leu Ala Ser Asp Thr Ser Thr Gly Asp Ala Ser
 405 410 415
 Leu Pro Gly Pro Leu Thr Pro Val Ala Glu Gly Gln Glu Ile Gly Met
 420 425 430
 Asn Thr Glu Thr Ser Gly Thr Ser Ala Arg Glu Lys Glu Leu Ser Pro
 435 440 445
 Pro Pro Gly Leu Pro Ser Lys Ile Gly Ser Ile Ser Arg Gln Ser Ser
 450 455 460
 Leu Ser Glu Lys Lys Ile Pro Glu Pro Ser Pro Val Thr Arg Arg Lys
 465 470 475 480
 Ala Tyr Glu Lys Ala Glu Lys Ser Lys Ala Lys Glu Gln Lys His Ser
 485 490 495
 Asp Ser Gly Thr Ser Glu Ala Ser Leu Ser Pro Pro Ser Ser Pro Pro
 500 505 510
 Ser Arg Pro Arg Asn Glu Leu Asn Val Phe Asn Arg Leu Thr Val Ser
 515 520 525
 Gln Gly Asn Thr Ser Val Gln Gln Asp Lys Ser Asp Glu Ser Asp Ser
 530 535 540
 Ser Leu Ser Glu Val His Ser Arg Ser Ser Arg Arg Gly Ile Ile Asn
 545 550 555 560
 Pro Phe Pro Ala Ser Lys Gly Ile Arg Ala Phe Pro Leu Gln Cys Ile
 565 570 575
 His Ile Ala Glu Gly His Thr Lys Ala Val Leu Cys Val Asp Ser Thr
 580 585 590
 Asp Asp Leu Leu Phe Thr Gly Ser Lys Asp Arg Thr Cys Lys Val Trp
 595 600 605
 Asn Leu Val Thr Gly Gln Glu Ile Met Ser Leu Gly Gly His Pro Asn
 610 615 620
 Asn Val Val Ser Val Lys Tyr Cys Asn Tyr Thr Ser Leu Val Phe Thr
 625 630 635 640
 Val Ser Thr Ser Tyr Ile Lys Val Trp Asp Ile Arg Asp Ser Ala Lys
 645 650 655
 Cys Ile Arg Thr Leu Thr Ser Ser Gly Gln Val Thr Leu Gly Asp Ala
 660 665 670

Cys Ser Ala Ser Thr Ser Arg Thr Val Ala Ile Pro Ser Gly Glu Asn
 675 680 685
 Gln Ile Asn Gln Ile Ala Leu Asn Pro Thr Gly Thr Phe Leu Tyr Ala
 690 695 700
 Ala Ser Gly Asn Ala Val Arg Met Trp Asp Leu Lys Arg Phe Gln Ser
 705 710 715 720
 Thr Gly Lys Leu Thr Gly His Leu Gly Pro Val Met Cys Leu Thr Val
 725 730 735
 Asp Gln Ile Ser Ser Gly Gln Asp Leu Ile Ile Thr Gly Ser Lys Asp
 740 745 750
 His Tyr Ile Lys Met Phe Asp Val Thr Glu Gly Ala Leu Gly Thr Val
 755 760 765
 Ser Pro Thr His Asn Phe Glu Pro Pro His Tyr Asp Gly Ile Glu Ala
 770 775 780
 Leu Thr Ile Gln Gly Asp Asn Leu Phe Ser Gly Ser Arg Asp Asn Gly
 785 790 795 800
 Ile Lys Lys Trp Asp Leu Thr Gln Lys Asp Leu Leu Gln Gln Val Pro
 805 810 815
 Asn Ala His Lys Asp Trp Val Cys Ala Leu Gly Val Val Pro Asp His
 820 825 830
 Pro Val Leu Leu Ser Gly Cys Arg Gly Gly Ile Leu Lys Val Trp Asn
 835 840 845
 Met Asp Thr Phe Met Pro Val Gly Glu Met Lys Gly His Asp Ser Pro
 850 855 860
 Ile Asn Ala Ile Cys Val Asn Ser Thr His Ile Phe Thr Ala Ala Asp
 865 870 875 880
 Asp Arg Thr Val Arg Ile Trp Lys Ala Arg Asn Leu Gln Asp Gly Gln
 885 890 895
 Ile Ser Asp Thr Gly Asp Leu Gly Glu Asp Ile Ala Ser Asn
 900 905 910

<210> 154

<211> 372

<212> DNA

<213> Homo sapiens

<400> 154

aatcgcacct gtccaacttg caatgacttc catggacttg tgcagaaaat catggagcta 60
 caggatattt tagccaaaac atcagccaag ctgtctcgag ctgaacagcg aatgaataga 120
 ttggatcagt gctattgtga aaggacttgc accatgaagg gaaccaccta ccgagaattt 180
 gagtcctgga tagacggctg taagaactgc acatgcctga atggaaccat ccagtgtgaa 240
 actctaattc gcccaaattc tgactgcca cttaagtccg ctcttgcgta tgtggatggc 300
 aaatgctgta aggaatgcaa atcgatatcc caatttcaag gacgaaccta ctttgaagga 360
 gaaagaaata ca 372

<210> 155
 <211> 761
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (108)

<220>
 <221> unsure
 <222> (191)

<220>
 <221> unsure
 <222> (268)

<220>
 <221> unsure
 <222> (299)

<400> 155
 ttctggagta tgtgttctct atgagtgcaa ggaccagacc atgaaatttg ttgagagttc 60
 aggctgtcca gctttggatt gtccagagtc tcatcagata accttgntc acagctgttg 120
 caaagtttgt aaagggttatg atttttgttt tgaaaggcat aactgcatgg agaattccat 180
 ctgcagaaat ntgaatgaca gggctgtttg tagctgtcga gatggtttta gggtttttcg 240
 agaggataat gcctactgtg aagacatnga tgagtgtgct gaagggcgcc attactgtng 300
 tgaaaataca atgtgtgtca acaccccggg ttcttttatg tgcattctgca aaactggata 360
 catcagaatt gatgattatt catgtacaga acatgatgag tgtatcacia atcagcacag 420
 ctgtgatgaa aatgctttat gcttcaacac tgttggagga cacaactgtg tttgcaagcc 480
 gggctataca gggaatggaa cgacatgcaa agcattttgc aaagatggct gtaggaatgg 540
 aggagcctgt attgccgcta atgtgtgtgc ctgcccacia ggcttcactg gaccagctg 600
 tgaaacggac attgatgaat gctctgatgg ttttgttcaa tgtgacagtc gtgctaattg 660
 cattaacctg cctggatggg accactgtga gtgcagagat ggctaccatg acaatgggat 720
 gttttcacca agtggagaat cgtgtgaaga tattgatgag t 761

<210> 156
 <211> 240
 <212> PRT
 <213> Homo sapiens

<220>
 <221> UNSURE
 <222> (23)

<220>
 <221> UNSURE
 <222> (51)

<220>
 <221> UNSURE
 <222> (76)

<220>
 <221> UNSURE
 <222> (87)

<400> 156
 Met Lys Phe Val Glu Ser Ser Gly Cys Pro Ala Leu Asp Cys Pro Glu
 1 5 10 15

Ser His Gln Ile Thr Leu Xaa His Ser Cys Cys Lys Val Cys Lys Gly
 20 25 30
 Tyr Asp Phe Cys Phe Glu Arg His Asn Cys Met Glu Asn Ser Ile Cys
 35 40 45
 Arg Asn Xaa Asn Asp Arg Ala Val Cys Ser Cys Arg Asp Gly Phe Arg
 50 55 60
 Val Phe Arg Glu Asp Asn Ala Tyr Cys Glu Asp Xaa Asp Glu Cys Ala
 65 70 75 80
 Glu Gly Arg His Tyr Cys Xaa Glu Asn Thr Met Cys Val Asn Thr Pro
 85 90 95
 Gly Ser Phe Met Cys Ile Cys Lys Thr Gly Tyr Ile Arg Ile Asp Asp
 100 105 110
 Tyr Ser Cys Thr Glu His Asp Glu Cys Ile Thr Asn Gln His Ser Cys
 115 120 125
 Asp Glu Asn Ala Leu Cys Phe Asn Thr Val Gly Gly His Asn Cys Val
 130 135 140
 Cys Lys Pro Gly Tyr Thr Gly Asn Gly Thr Thr Cys Lys Ala Phe Cys
 145 150 155 160
 Lys Asp Gly Cys Arg Asn Gly Gly Ala Cys Ile Ala Ala Asn Val Cys
 165 170 175
 Ala Cys Pro Gln Gly Phe Thr Gly Pro Ser Cys Glu Thr Asp Ile Asp
 180 185 190
 Glu Cys Ser Asp Gly Phe Val Gln Cys Asp Ser Arg Ala Asn Cys Ile
 195 200 205
 Asn Leu Pro Gly Trp Tyr His Cys Glu Cys Arg Asp Gly Tyr His Asp
 210 215 220
 Asn Gly Met Phe Ser Pro Ser Gly Glu Ser Cys Glu Asp Ile Asp Glu
 225 230 235 240

<210> 157
 <211> 342
 <212> DNA
 <213> Homo sapiens

<400> 157
 gcagaaaatt ttcctctaga tcagaatctt caagaatcag ttaggttcct cactgcaaga 60
 aataaaatgt caggcagtga atgaattata ttttaagaag taaagcaaag aagctataac 120
 atgttatgta cagtacactc tgaaaagaaa tctgaaacaa gttattgtaa tgataaaaat 180
 aatgcacagg catggttact taatattttc taacaggaaa agtcattcct atttccttgt 240
 tttactgcac ttaatatatt ttggttgaat ttgttcagta taagttcggt ccttgtgcaa 300
 aattaaataa atatttttct taccttaaaa aaaaaaaaaa aa 342

<210> 158
 <211> 1445
 <212> DNA

<213> Homo sapiens

<400> 158

```

gtgcgcatgg ggacgctata gcaattcggt tgcgtgcctt cctctccttc gaagatgaca 60
aggcctacca tcgtttcttc ctgcctttgg gccgtcaggg agttgggttg gaccgctcc 120
aaccctcggg tcttcctgca atacagtggg tacaatttgt catggctact ctgagataag 180
accacttttt tatctgagct tctgtgacct gctcctggga ctttgctggc tcacggagac 240
acttctctat ggagcttcag tagcaaataa ggacatcate tgctataacc tacaagcagt 300
tggacagata ttctacattt cctcatttct ctacaccgtc aattacatct ggtatttgta 360
cacagagctg aggatgaaac acacccaaag tggacagagc acatctccac tggatgata 420
ttatacttgt cgattttgtc aaatggcctt tgttttctca agcctgatac ctctgctatt 480
gatgacacct gtattctgtc tgggaaatac tagtgaatgt ttccaaaact tcagtcagag 540
ccacaattgt atcttgatgc actcaccacc atcagccatg gctgaacttc caccttctgc 600
caacacatct gtctgtagca cactttatct ttatgggtat gccatttttc tgggcagctt 660
tgtactcagc ctcttacca ttatgggtct acttatccga gccagacat tgtataagaa 720
gtttgtgaag tcaactggct ttctggggag tgaacagtgg gcagtgatc acattgtgga 780
ccaacgggtg cgcttctacc cagtggcctt cttttgctgc tggggcccag ctgtcattct 840
aatgatcata aagctgacta agccacagga caccaagctt cacatggccc tttatgttct 900
ccaggctcta acggcaacat ctcagggtct actcaactgt ggagtatatg gctggacgca 960
gcacaaattc caccaactaa agcaggaggc tggcgtgat gcagataccc agacaccatt 1020
attatgctca cagaagagat tctatagcag gggcttaaact tcaactggaat ccaccctgac 1080
tttctctgcc agtacttcta ccattttttg aaactacaat actggaacat ccaggaactg 1140
gagttattct acgctaattg attggaaaga atgttgggaa aggacatctt aaatcttttc 1200
taactatgcc ctaactgca gaactcaaag gaaatatagt gccattgtta gtagtcattc 1260
tagatgaatt gggagtatct ctccagttat tcccagattc actagtgate cttaaagtct 1320
ctattcaggg agaggaagac actttccatc tcagagatag actcgtgtta cttgatgga 1380
tattggattt gtctaagtct cttctagaaa aaataaattc tagattatta aaaaaaaaaa 1440
aaaaa 1445

```

<210> 159

<211> 245

<212> PRT

<213> Homo sapiens

<400> 159

```

Met Lys His Thr Gln Ser Gly Gln Ser Thr Ser Pro Leu Val Ile Asp
 1             5             10             15

Tyr Thr Cys Arg Phe Cys Gln Met Ala Phe Val Phe Ser Ser Leu Ile
      20             25             30

Pro Leu Leu Leu Met Thr Pro Val Phe Cys Leu Gly Asn Thr Ser Glu
      35             40             45

Cys Phe Gln Asn Phe Ser Gln Ser His Asn Cys Ile Leu Met His Ser
      50             55             60

Pro Pro Ser Ala Met Ala Glu Leu Pro Pro Ser Ala Asn Thr Ser Val
      65             70             75             80

Cys Ser Thr Leu Tyr Phe Tyr Gly Ile Ala Ile Phe Leu Gly Ser Phe
      85             90             95

Val Leu Ser Leu Leu Thr Ile Met Val Leu Leu Ile Arg Ala Gln Thr
      100            105            110

Leu Tyr Lys Lys Phe Val Lys Ser Thr Gly Phe Leu Gly Ser Glu Gln
      115            120            125

Trp Ala Val Ile His Ile Val Asp Gln Arg Val Arg Phe Tyr Pro Val

```

130	135	140
Ala Phe Phe Cys Cys Trp Gly Pro Ala Val Ile Leu Met Ile Ile Lys		
145	150	155 160
Leu Thr Lys Pro Gln Asp Thr Lys Leu His Met Ala Leu Tyr Val Leu		
	165	170 175
Gln Ala Leu Thr Ala Thr Ser Gln Gly Leu Leu Asn Cys Gly Val Tyr		
	180	185 190
Gly Trp Thr Gln His Lys Phe His Gln Leu Lys Gln Glu Ala Arg Arg		
	195	200 205
Asp Ala Asp Thr Gln Thr Pro Leu Leu Cys Ser Gln Lys Arg Phe Tyr		
	210	215 220
Ser Arg Gly Leu Asn Ser Leu Glu Ser Thr Leu Thr Phe Pro Ala Ser		
225	230	235 240
Thr Ser Thr Ile Phe		
	245	

<210> 160

<211> 3550

<212> DNA

<213> Homo sapiens

<400> 160

```

ccccctcgata atggattact aaatgggata cagctgtac cagttcgctc cgagccccgg 60
ccgcctgtcc gtcgatgcac cgaaaagggt gaagtagaga aataaagtct ccccgctgaa 120
ctactatgag gtcagaagcc ttgctgctat atttcacact gctacacttt gctggggctg 180
gtttcccaga agattctgag ccaatcagta tttcgcatgg caactataca aaacagtatc 240
cgggtgtttgt gggccacaag ccaggacgga acaccacaca gaggcacagg ctggacatcc 300
agatgattat gatcatgaac ggaaccctct acattgctgc tagggaccat atttatactg 360
ttgatataga cacatcacac acsgaagaaa tttattgtag caaaaaactg acatggaaat 420
ctagacaggc cgatgtagac acatgcagaa tgaagggaaa acataaggat gagtgccaca 480
actttattaa agttcttcta aagaaaaacg atgatgcatt gtttgtctgt ggaactaatg 540
ccttcaaccc ttcctgcaga aactataaga tggatacatt ggaaccattc ggggatgaat 600
tcagcggaat ggccagatgc ccatatgatg ccaaacatgc caacgttgca ctgtttgcag 660
atggaaaact atactcagcc acagtgactg acttccttgc cattgacgca gtcatttacc 720
ggagtcttgg agaaagccct accctgcgga ccgtcaagca cgattcaaaa tggttgaaag 780
aaccatactt tgttcaagcc gtggattacg gagattatat ctacttcttc ttcagggaaa 840
tagcagtgga gtataacacc atgggaaagg tagttttccc aagagtggct caggtttgta 900
agaatgatat gggaggatct caaagagtcc tggagaaaca gtggacgtcg ttcctgaagg 960
cgcgcttgaa ctgctcagtt cctggagact ctcattttta tttcaacatt ctccaggcag 1020
ttacagatgt gattcgtatc aacgggcgtg atgttgcctt ggcaacgttt tctacacctt 1080
ataacagcat ccctgggtct gcagtctgtg cctatgacat gcttgacatt gccagtgttt 1140
ttactgggag attcaaggaa cagaagtctc ctgattccac ctggacacca gttectgatg 1200
aacgagttcc taagcccagg ccaggttgct gtgctggctc atcctcctta gaaagatatg 1260
caacctccaa tgagttccct gatgataccc tgaacttcat caagacgcac ccgctcatgg 1320
atgaggcagt gccctccatc ttcaacaggc catggttcct gagaacaatg gtcagatacc 1380
gccttaccaa aattgcagtg gacacagctg ctgggccata tcagaatcac actgtgggtt 1440
ttctgggatc agagaaggga atcatcttga agtttttggc cagaatagga aatagtggtt 1500
ttctaaatga cagccttttc ctggaggaga tgagtgttta caactctgaa aaatgcagct 1560
atgatggagt cgaagacaaa aggatcatgg gcatgcagct ggacagagca agcagctctc 1620
tgtatgttgc gttctctacc tgtgtgataa aggttcccct tggccggtgt gaacgacatg 1680
ggaagtgtaa aaaaacctgt attgcctcca gagaccata ttgtggatgg ataaaggaag 1740
gtggtgcctg cagccattta tcaccaaca gcagactgac ttttgagcag gacatagagc 1800

```

```

gtggcaatac agatggtctg ggggactgtc acaattcctt tgtggcactg aatggagtga 1860
ttcgggaaag ttacctcaaa ggccacgacc agctggttcc cgtcacctc ttggccattg 1920
cagtcacctt ggctttctgc atgggggccc tcttctcggg catcacctc tactgcgtct 1980
gtgatcatcg gcgcaaagac gtggctgtgg tgcagcgcaa ggagaaggag ctcacccact 2040
cgcgccgggg ctccatgagc agcgtcacca agctcagcgg cctcttttggg gacactcaat 2100
ccaaagaccc aaagccggag gccatcctca cgccactcat gcacaacggc aagctcgcca 2160
ctcccggaac cacggccaag atgctcatta aagcagacca gcaccacctg gacctgacgg 2220
ccctccccac ccagagtca accccaacgc tgcagcagaa gcggaagccc agccgcggca 2280
gccgcgagtg ggagaggaac cagaacctca tcaatgcctg cacaaaggac atgcccccca 2340
tgggctcccc tgtgattccc acggacctgc ccctgcgggc ctccccccagc cacatcccca 2400
gcgtggtggt cctgcccatac acgcagcagg gctaccagca tgagtacgtg gaccagccca 2460
aaatgagcga ggtggcccag atggcgctgg aggaccaggc cgccacactg gagtataaga 2520
ccatcaagga acatttcagc agcaagagtc ccaaccatgg ggtgaacctt gtggagaacc 2580
tggacagcct gccccccaaa gtctccacagc gggaggcctc cctgggtccc ccgggagcct 2640
ccctgtttca gaccggttta agcaagcggc tggaaatgca ccactccttt tcctacgggg 2700
ttgactataa gaggagctac ccacgaact cgctcacgag aagccaccag gccaccactc 2760
tcaaaagaaa caacactaac tcctccaatt cctctcacct ctccagaaac cagagctttg 2820
gcaggggaga caaccgccc cccgccccgc agagggtgga ctccatccag gtgcacagct 2880
cccagccatc tggccaggcc gtgactgtct cgaggcagcc cagcctcaac gcctacaact 2940
cactgacaag gtcggggctg aagcgtacgc cctcgctaaa gccggacgta cccccaaaac 3000
catcctttgc tcccctttcc acatccatga agcccaatga tgcgtgtaca taatcccagg 3060
gggagggggg caggtgtcga accagcaggc aaggcgaggt gcccgctcag ctcagcaagg 3120
ttctcaactg cctcgagtac ccaccagacc aagaaggcct gcggcagagc cgaggacgct 3180
gggtcctcct ctctgggaca caggggtact cacgaaaact gggccgctg gtttggtgaa 3240
ggtttgcaac ggcggggact caccttcatt ctcttccttc actttccccc acaccctaca 3300
acaggtcgga cccacaaaag acttcagtta tcatcacaaa catgagccaa aagcacatac 3360
atacccatc cccaccccc acacacacac acacatgcac acaacacata cacacacacg 3420
cacagaggtg aacagaaaact gaaacatttt gtccacaact tcacgggacg tggccagact 3480
gggtttgcgt tccaacctgc aaaacacaaa tacatttttt aaaatcaaga aaatttaaaa 3540
aaaaaaaaaa 3550

```

<210> 161

<211> 975

<212> PRT

<213> Homo sapiens

<400> 161

```

Met Arg Ser Glu Ala Leu Leu Leu Tyr Phe Thr Leu Leu His Phe Ala
  1             5             10             15

```

```

Gly Ala Gly Phe Pro Glu Asp Ser Glu Pro Ile Ser Ile Ser His Gly
      20             25             30

```

```

Asn Tyr Thr Lys Gln Tyr Pro Val Phe Val Gly His Lys Pro Gly Arg
      35             40             45

```

```

Asn Thr Thr Gln Arg His Arg Leu Asp Ile Gln Met Ile Met Ile Met
      50             55             60

```

```

Asn Gly Thr Leu Tyr Ile Ala Ala Arg Asp His Ile Tyr Thr Val Asp
      65             70             75             80

```

```

Ile Asp Thr Ser His Thr Glu Glu Ile Tyr Cys Ser Lys Lys Leu Thr
      85             90             95

```

```

Trp Lys Ser Arg Gln Ala Asp Val Asp Thr Cys Arg Met Lys Gly Lys
      100            105            110

```

```

His Lys Asp Glu Cys His Asn Phe Ile Lys Val Leu Leu Lys Lys Asn
      115            120            125

```

Asp	Asp	Ala	Leu	Phe	Val	Cys	Gly	Thr	Asn	Ala	Phe	Asn	Pro	Ser	Cys	130	135	140	
Arg	Asn	Tyr	Lys	Met	Asp	Thr	Leu	Glu	Pro	Phe	Gly	Asp	Glu	Phe	Ser	145	150	155	160
Gly	Met	Ala	Arg	Cys	Pro	Tyr	Asp	Ala	Lys	His	Ala	Asn	Val	Ala	Leu	165	170	175	
Phe	Ala	Asp	Gly	Lys	Leu	Tyr	Ser	Ala	Thr	Val	Thr	Asp	Phe	Leu	Ala	180	185	190	
Ile	Asp	Ala	Val	Ile	Tyr	Arg	Ser	Leu	Gly	Glu	Ser	Pro	Thr	Leu	Arg	195	200	205	
Thr	Val	Lys	His	Asp	Ser	Lys	Trp	Leu	Lys	Glu	Pro	Tyr	Phe	Val	Gln	210	215	220	
Ala	Val	Asp	Tyr	Gly	Asp	Tyr	Ile	Tyr	Phe	Phe	Phe	Arg	Glu	Ile	Ala	225	230	235	240
Val	Glu	Tyr	Asn	Thr	Met	Gly	Lys	Val	Val	Phe	Pro	Arg	Val	Ala	Gln	245	250	255	
Val	Cys	Lys	Asn	Asp	Met	Gly	Gly	Ser	Gln	Arg	Val	Leu	Glu	Lys	Gln	260	265	270	
Trp	Thr	Ser	Phe	Leu	Lys	Ala	Arg	Leu	Asn	Cys	Ser	Val	Pro	Gly	Asp	275	280	285	
Ser	His	Phe	Tyr	Phe	Asn	Ile	Leu	Gln	Ala	Val	Thr	Asp	Val	Ile	Arg	290	295	300	
Ile	Asn	Gly	Arg	Asp	Val	Val	Leu	Ala	Thr	Phe	Ser	Thr	Pro	Tyr	Asn	305	310	315	320
Ser	Ile	Pro	Gly	Ser	Ala	Val	Cys	Ala	Tyr	Asp	Met	Leu	Asp	Ile	Ala	325	330	335	
Ser	Val	Phe	Thr	Gly	Arg	Phe	Lys	Glu	Gln	Lys	Ser	Pro	Asp	Ser	Thr	340	345	350	
Trp	Thr	Pro	Val	Pro	Asp	Glu	Arg	Val	Pro	Lys	Pro	Arg	Pro	Gly	Cys	355	360	365	
Cys	Ala	Gly	Ser	Ser	Ser	Leu	Glu	Arg	Tyr	Ala	Thr	Ser	Asn	Glu	Phe	370	375	380	
Pro	Asp	Asp	Thr	Leu	Asn	Phe	Ile	Lys	Thr	His	Pro	Leu	Met	Asp	Glu	385	390	395	400
Ala	Val	Pro	Ser	Ile	Phe	Asn	Arg	Pro	Trp	Phe	Leu	Arg	Thr	Met	Val	405	410	415	
Arg	Tyr	Arg	Leu	Thr	Lys	Ile	Ala	Val	Asp	Thr	Ala	Ala	Gly	Pro	Tyr	420	425	430	
Gln	Asn	His	Thr	Val	Val	Phe	Leu	Gly	Ser	Glu	Lys	Gly	Ile	Ile	Leu	435	440	445	

Lys Phe Leu Ala Arg Ile Gly Asn Ser Gly Phe Leu Asn Asp Ser Leu
 450 455 460
 Phe Leu Glu Glu Met Ser Val Tyr Asn Ser Glu Lys Cys Ser Tyr Asp
 465 470 475 480
 Gly Val Glu Asp Lys Arg Ile Met Gly Met Gln Leu Asp Arg Ala Ser
 485 490 495
 Ser Ser Leu Tyr Val Ala Phe Ser Thr Cys Val Ile Lys Val Pro Leu
 500 505 510
 Gly Arg Cys Glu Arg His Gly Lys Cys Lys Lys Thr Cys Ile Ala Ser
 515 520 525
 Arg Asp Pro Tyr Cys Gly Trp Ile Lys Glu Gly Gly Ala Cys Ser His
 530 535 540
 Leu Ser Pro Asn Ser Arg Leu Thr Phe Glu Gln Asp Ile Glu Arg Gly
 545 550 555 560
 Asn Thr Asp Gly Leu Gly Asp Cys His Asn Ser Phe Val Ala Leu Asn
 565 570 575
 Gly Val Ile Arg Glu Ser Tyr Leu Lys Gly His Asp Gln Leu Val Pro
 580 585 590
 Val Thr Leu Leu Ala Ile Ala Val Ile Leu Ala Phe Val Met Gly Ala
 595 600 605
 Val Phe Ser Gly Ile Thr Val Tyr Cys Val Cys Asp His Arg Arg Lys
 610 615 620
 Asp Val Ala Val Val Gln Arg Lys Glu Lys Glu Leu Thr His Ser Arg
 625 630 635 640
 Arg Gly Ser Met Ser Ser Val Thr Lys Leu Ser Gly Leu Phe Gly Asp
 645 650 655
 Thr Gln Ser Lys Asp Pro Lys Pro Glu Ala Ile Leu Thr Pro Leu Met
 660 665 670
 His Asn Gly Lys Leu Ala Thr Pro Gly Asn Thr Ala Lys Met Leu Ile
 675 680 685
 Lys Ala Asp Gln His His Leu Asp Leu Thr Ala Leu Pro Thr Pro Glu
 690 695 700
 Ser Thr Pro Thr Leu Gln Gln Lys Arg Lys Pro Ser Arg Gly Ser Arg
 705 710 715 720
 Glu Trp Glu Arg Asn Gln Asn Leu Ile Asn Ala Cys Thr Lys Asp Met
 725 730 735
 Pro Pro Met Gly Ser Pro Val Ile Pro Thr Asp Leu Pro Leu Arg Ala
 740 745 750
 Ser Pro Ser His Ile Pro Ser Val Val Val Leu Pro Ile Thr Gln Gln
 755 760 765

Gly Tyr Gln His Glu Tyr Val Asp Gln Pro Lys Met Ser Glu Val Ala
 770 775 780
 Gln Met Ala Leu Glu Asp Gln Ala Ala Thr Leu Glu Tyr Lys Thr Ile
 785 790 795 800
 Lys Glu His Phe Ser Ser Lys Ser Pro Asn His Gly Val Asn Leu Val
 805 810 815
 Glu Asn Leu Asp Ser Leu Pro Pro Lys Val Pro Gln Arg Glu Ala Ser
 820 825 830
 Leu Gly Pro Pro Gly Ala Ser Leu Phe Gln Thr Gly Leu Ser Lys Arg
 835 840 845
 Leu Glu Met His His Ser Phe Ser Tyr Gly Val Asp Tyr Lys Arg Ser
 850 855 860
 Tyr Pro Thr Asn Ser Leu Thr Arg Ser His Gln Ala Thr Thr Leu Lys
 865 870 875 880
 Arg Asn Asn Thr Asn Ser Ser Asn Ser Ser His Leu Ser Arg Asn Gln
 885 890 895
 Ser Phe Gly Arg Gly Asp Asn Pro Pro Pro Ala Pro Gln Arg Val Asp
 900 905 910
 Ser Ile Gln Val His Ser Ser Gln Pro Ser Gly Gln Ala Val Thr Val
 915 920 925
 Ser Arg Gln Pro Ser Leu Asn Ala Tyr Asn Ser Leu Thr Arg Ser Gly
 930 935 940
 Leu Lys Arg Thr Pro Ser Leu Lys Pro Asp Val Pro Pro Lys Pro Ser
 945 950 955 960
 Phe Ala Pro Leu Ser Thr Ser Met Lys Pro Asn Asp Ala Cys Thr
 965 970 975

<210> 162

<211> 1723

<212> DNA

<213> Homo sapiens

<400> 162

ctgcagactt tggggtcacc ggccagccac acaggcaccg ttttcagatg tccacttctc 60
 attgggtaca tcaatctttt aacttttgggg gtcacagttt tagccacctt tcgggggggtg 120
 actggagcag taggaggtgt ggggtcattt tatgaatata ataaaatgga gctgactatg 180
 gacrrrgact wagtgtgggg gagaggggac gatacagggt gtgtgtcttg gagtgccttg 240
 gggacaggga cccccgggtg gtcctatggc aggatgagaa rggagggact tggctcccc 300
 agagccccgt ggaagctact gttctctcca gtgtctcgag cgtagccaaa ataaggtttg 360
 gaggtctccg gcctgtctgc tgtggtctga gctggctgca agcccagggt ggggagcgag 420
 tctgggaaga ttggctttga ctctctgttg ccagaggaga tgccatccca gcacggcccc 480
 cactgtagtc caggctcgtg gtggcagcgg gggcaagggg aggggcaagg ctgccccac 540
 cccacgcacc aagtcacgcc aagtctcagc aggtaaaagc acgtgagcct agggcgagcg 600
 gagggagtcc tgggtggcccc gcaggtcagg agggaaagca gggtcagag ggcacgttg 660
 ccccaggga gggctctacc tgggggtcag gagcaccttg gtcttgatga ttgattgatt 720
 gatagaatgg agctgggtct gagcctccca ggcttgagct cctgggagtt cttgtgcggt 780

gagctgggca gctcctgggt aggtccgggc accaagcagg ccctgatgtg gacagagtcc 840
 catcagaggg agctgatgaa gaatgggtccc tgtaagtaag tctactaggtt caacaactgc 900
 ctggccgagc actcagcccg tggagctcag gccaacacca gagccccggg tttagggggcc 960
 aggagagcag gtgaccaatt atttggggag tcttgggtag aattttccgcc acacattctc 1020
 cccagggctg caggggtctt ccgaggcagg gcggtggagc aggattcagg atgtggtggg 1080
 aatagagtga ggggcagtgg gtgggcagac ctgggcgtca gaggtcctga tgggaaagga 1140
 ggcaggggct acccagagag gggggctcgt gtggcacagc cccaccgac tccgccgtcc 1200
 ccttcccttg tgagccccgg gggctgtaca tactctactc catcccttg tccatccctg 1260
 agaccacccc cgccgccctt gcgtcgactt agcaaccacc tcataggccc acccacctcg 1320
 ggatccgagc caaccatccc acatcacaaa ctttgggttg ggggacttta cgttcgttta 1380
 atttctcatt ttgtacggag aaatattctt ttcaaaagcg tcttttgact gaagtaactt 1440
 tcctggtgct gttgttaact cgttcctttt tttaatttat tccccaccc caggcagccc 1500
 tcctggttcc tactcaccct cccccctcc cccaccctcc gtcccatctg aaccatttgt 1560
 ttcttttctt tccgtcagat tttggaaaaa ttctcctctc ctecccgccc cctccacacc 1620
 atcctcccs g atttaaatat agtcactgct acaagtaaca gatgcactgt gaagattcca 1680
 gtattaataa aggtgtactg taattaacaa aaaaaaaaaa aaa 1723

<210> 163

<211> 101

<212> PRT

<213> Homo sapiens

<220>

<221> UNSURE

<222> (49)

<220>

<221> UNSURE

<222> (51)

<220>

<221> UNSURE

<222> (81)

<400> 163

Val Phe Arg Cys Pro Leu Leu Ile Gly Tyr Ile Asn Leu Leu Thr Leu
 1 5 10 15

Gly Val Thr Val Leu Ala Thr Phe Arg Gly Val Thr Gly Ala Val Gly
 20 25 30

Gly Val Gly Ser Phe Tyr Glu Tyr Asn Lys Met Glu Leu Thr Met Asp
 35 40 45

Xaa Asp Xaa Val Trp Gly Arg Gly Asp Asp Thr Gly Cys Val Ser Gly
 50 55 60

Ser Ala Trp Gly Thr Gly Thr Pro Arg Trp Ser Tyr Gly Arg Met Arg
 65 70 75 80

Xaa Glu Gly Leu Gly Ser Pro Arg Ala Arg Trp Lys Leu Leu Phe Ser
 85 90 95

Pro Val Ser Arg Ala
 100

<210> 164

<211> 469

<212> DNA

<213> Homo sapiens

<400> 164

```

gcaacataca agccgggcat attagagaga tggaaataaa gcttccttaa tgttgtatat 60
gtctttgaag tacatccgtg catttttttt tagcatccaa ccattcctcc cttgtagttc 120
tcgccccctc aaatcaccct ctcccgtagc ccacccgact aacatctcag tctctgaaaa 180
tgcacagaga tgcctggcta cctcgccctg ccttcagcct cacggggctc agtctctttt 240
tctctttggt gccaccagga cggagcatgg aggtcacagt acctgccacc ctcaacgtcc 300
tcaatggctc tgacgcccgc ctgccctgca ctttcaactc ctgctacaca gtgaaccaca 360
aacagttctc cctgaactgg acttaccagg agtgcaacaa ctgctctgag gagatgttcc 420
tccagttccg catgaagatc attaacctga agctggagcg gtttcaaga 469

```

<210> 165

<211> 96

<212> PRT

<213> Homo sapiens

<400> 165

```

Met His Arg Asp Ala Trp Leu Pro Arg Pro Ala Phe Ser Leu Thr Gly
  1           5           10           15

Leu Ser Leu Phe Phe Ser Leu Val Pro Pro Gly Arg Ser Met Glu Val
           20           25           30

Thr Val Pro Ala Thr Leu Asn Val Leu Asn Gly Ser Asp Ala Arg Leu
  35           40           45

Pro Cys Thr Phe Asn Ser Cys Tyr Thr Val Asn His Lys Gln Phe Ser
  50           55           60

Leu Asn Trp Thr Tyr Gln Glu Cys Asn Asn Cys Ser Glu Glu Met Phe
  65           70           75           80

Leu Gln Phe Arg Met Lys Ile Ile Asn Leu Lys Leu Glu Arg Phe Gln
           85           90           95

```

<210> 166

<211> 454

<212> DNA

<213> Homo sapiens

<400> 166

```

tggttttttg ctacagagag ggaagggaaa gcctgaggcc ggcataaggg gaggccttgg 60
aacctgagct gccaatgcca gccctgtccc atctgcggcc acgatactcg ctctctctcc 120
aacaactcct ttggtgggga caaaagtgac aattgtaggc caggcacagt ggctcacgcc 180
tgtaatccca gcactttggg aggccaaggc ggggtggatta cctccatctg tttagtagaa 240
atgggcaaaa ccccatTTTT actaaaaata caagaattag ctgggcgtgg tggcgtgtgc 300
ctgtaatccc agctatttgg gaggtgagg caggagaatc gcttgagccc gggaagcaga 360
ggttgcaagt aactgagata gtgatagtgc cactgcaatt cagcctgggt gacatagaga 420
gactccatct caaaaaaaaaa aaaaaaaaaa aaaa 454

```

<210> 167

<211> 736

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (680)

<220>

<221> unsure

<222> (704)

<400> 167

```

gtttttaaac attatgttct acatgataaa tacatataat agtatgtcta tttaaataat 60
taaatttgaa aaaaactaat caaatattat cataagtaat gataaaaacc acaatttctt 120
ttgcagcaaa ctaataacac ctggatttct caatttatta agttgtactt acctgatgct 180
gatgatgatt actgtattta cacattgtct cagagctcac tcttgaggag gttgtggcct 240
cgaaaatgcc ttgttgctcc tctggaatct gtcttttcag cttcatctcc tcctcctcac 300
ctcctgctgt ggtgcacaga tacctatagg caggctccat ctcctcctcc ccagctcctc 360
ccctagtga cagataccta taggcaggct tcctcctcct ctcctcctcct tctcctcctag 420
tgcacagata cctataggca ggctccatct cctcctcccc agctcctccc ctartgcaca 480
gacacctata ggcaagctcc atctcctcct ctttagctag cctccccatc tcatcacac 540
gcatgtctgt gaccttttgt aatcatttac agtgccacac ggaaccctgt attttgcaca 600
cagcaaaaca aacaatgttt agcttttatt atggtatttg atgactgtaa atggaaataa 660
atattgttct ttattttttt aaaaaaaaaa aaaaaaaaaa aaanaaaaaa aaaaaaaaaa 720
aaaaaaaaa aaaaaa

```

<210> 168

<211> 114

<212> PRT

<213> Homo sapiens

<220>

<221> UNSURE

<222> (100)

<400> 168

```

Met Leu Met Met Ile Thr Val Phe Thr His Cys Leu Arg Ala His Ser
  1              5              10              15

Cys Gly Gly Cys Gly Leu Glu Asn Ala Leu Leu Ser Leu Trp Asn Leu
      20              25              30

Ser Phe Gln Leu His Leu Leu Leu Leu Thr Ser Cys Cys Gly Ala Gln
      35              40              45

Ile Pro Ile Gly Arg Leu His Leu Leu Leu Pro Ser Ser Ser Pro Ser
      50              55              60

Ala Gln Ile Pro Ile Gly Arg Leu His Leu Leu Leu Pro Ser Phe Ser
      65              70              75              80

Pro Ser Ala Gln Ile Pro Ile Gly Arg Leu His Leu Leu Leu Pro Ser
      85              90              95

Ser Ser Pro Xaa Ala Gln Thr Pro Ile Gly Lys Leu His Leu Leu Leu
      100              105              110

Phe Ser

```

<210> 169

<211> 1427

<212> DNA

<213> Homo sapiens

<400> 169

```

gtagttacta actccaacac ctaatagcat tggtagaaag cttataaatg cagttattta 60
gcctcgacta agatTTTTtct gatacctagt ttcactTTTTt aatgccctct gaaagTTTTt 120
tgatcagttg tttaatggga gatctgaaat gttaaactca gaccagaaag aagagaacct 180
gttttctaga aattaggttt ttaatccaag taagatgcaa gcttttgctt ttttaataac 240
ttgtatagct aaaaacttga cggtgaaaag ctctcagatc aaagctgac cttctgtcag 300
taatgattct aaaaataagc aagattttta tggggaatat attttatttc attcttatct 360
caaacctagg tactgtgggc gttttgagtt catttcgagg cattttcaat gtgcctcagg 420
ccacatccaa cctctycca gggccagatt taatgttcag ctcataaag gttatcatag 480
ttttaacatt taagtactat tttgcagtgg gtatatacca aaatttgcta atagtaagat 540
aaccttagtt atatatcatt cacgttagtt ctatcttggg ggcaataaac atttcttggt 600
caagaaattc atgttctatc ttggaggcaa taaacaaaca ttttttggtc aaaattaggg 660
ctaccctatt gtccttatgt cttttcctga tctgtggtea aacatttttc ttagtcattt 720
agaaattttc tatgttggtt taaattttct ttaaacttag aatggagtat gtgaccaata 780
ctttcctttg gaatgggatg gacatttgaa atagagccca ttctttataa agtataaaat 840
atgtttaatg ctagtatttt taactaaact ttgagaaac tagattcaca tgctgttgta 900
agaaataata cagagacctc ttcgtgttac ctttcacttt gtttccaca cagtgaacat 960
ctttcaaaac tgtcatacaa tatcataccc aggatactga cactgggtata gctaagatag 1020
agaacgtttc cacacagAAC tttttctagc acagggatcc ctcatcttgc ttttgatgac 1080
cataccactc tcaactcccat ccctactccc ttcttaaccc ttggcaacca taatctgttc 1140
tccattttta tagttttttt tttttcattt caataaagct gtataactgg aatcataata 1200
atatgtaacc ttttgggatt ggcttttttt catttagcat gattttctgg aggttaatcc 1260
agcttattat gtgtatcaag tctattgaca ggtacttttt agtgtgaata gaatcccata 1320
gtatagatgt accacagttt gttaaactgt tcacctgctg agagacattg ggccagtttt 1380
tggtactat aaataaagtt gctataaaca aaaaaaaaaa aaaaaaa 1427

```

<210> 170

<211> 79

<212> PRT

<213> Homo sapiens

<220>

<221> UNSURE

<222> (45)

<400> 170

```

Met Ile Leu Lys Ile Ser Lys Ile Leu Met Gly Asn Ile Phe Tyr Phe
 1             5             10             15

Ile Leu Ile Ser Asn Leu Gly Thr Val Val Val Leu Ser Ser Phe Arg
          20             25             30

Gly Ile Phe Asn Val Pro Gln Ala Thr Ser Asn Leu Xaa Pro Gly Pro
          35             40             45

Asp Leu Met Phe Ser Leu Ile Lys Val Ile Ile Val Leu Thr Phe Lys
          50             55             60

Tyr Tyr Phe Ala Val Gly Ile Tyr Gln Asn Leu Leu Ile Val Arg
          65             70             75

```

<210> 171

<211> 572

<212> DNA

<213> Homo sapiens

<400> 171

```

tgcagattct gtggttatac tcactcctca tcccaaagaa tgaaatttac cactctcctc 60
ctcttggcag ctgtagcagg ggccctgggc tatgctgaag atgcctcctc tgactcgacg 120

```


ggtgctgac ctgcccagga agctgggacc tctaagccta atgaagagat ctcaggtcca 180
 gcagaaccag cttcaccccc agagacaacc acaacagccc aggagacttc ggcggcagca 240
 gttcagggga cagccaaggt cacctcaagc aggcaggaac taaaccccct gaaatccata 300
 gtggagaaaa gtatcttact aacagaacaa gcccttgcaa aagcaggaaa aggaatgcac 360
 ggaggcgtgc caggtggaaa acaattcatc gaaaatggaa gtgaatttgc aaaaaatta 420
 ctgaagaaat tcagtctatt aaaaccatgg gcatgagaag ctgaaaagaa tgggatcatt 480
 ggacttaaag ccttaaatac ccttgtagcc cagagytatt aaaacgaaag catccaaaaa 540
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 572

<210> 172

<211> 138

<212> PRT

<213> Homo sapiens

<400> 172

Met Lys Phe Thr Thr Leu Leu Phe Leu Ala Ala Val Ala Gly Ala Leu
 1 5 10 15

Val Tyr Ala Glu Asp Ala Ser Ser Asp Ser Thr Gly Ala Asp Pro Ala
 20 25 30

Gln Glu Ala Gly Thr Ser Lys Pro Asn Glu Glu Ile Ser Gly Pro Ala
 35 40 45

Glu Pro Ala Ser Pro Pro Glu Thr Thr Thr Thr Ala Gln Glu Thr Ser
 50 55 60

Ala Ala Ala Val Gln Gly Thr Ala Lys Val Thr Ser Ser Arg Gln Glu
 65 70 75 80

Leu Asn Pro Leu Lys Ser Ile Val Glu Lys Ser Ile Leu Leu Thr Glu
 85 90 95

Gln Ala Leu Ala Lys Ala Gly Lys Gly Met His Gly Gly Val Pro Gly
 100 105 110

Gly Lys Gln Phe Ile Glu Asn Gly Ser Glu Phe Ala Gln Lys Leu Leu
 115 120 125

Lys Lys Phe Ser Leu Leu Lys Pro Trp Ala
 130 135

<210> 173

<211> 1223

<212> DNA

<213> Homo sapiens

<400> 173

ccttgttcca cgtagctggc aaggtcttca ttcacttgcc actgctagtc ttccaaccct 60
 tctggacttt ctttgctctt gtcttgtttt ggggtgtactg gatcatgaca cttctttttc 120
 ttggcactac cggcagtcct gttcagaatg agcaaggctt tgtggagttc aaaattttctg 180
 ggctcttgca gtacatgtgg tggtagcatg tggtagggcct gatttggatc agtgaattta 240
 ttctagcatg tcagcagatg acagtggcag gagctgtggt aacatactat tttactaggg 300
 ataaaaggaa tttgccattt acacctattt tggcatcagt aaatcgcctt atycgttacc 360
 acctaggtac ggtggcaaaa ggatctttta ttatcacatt agtcaaaatt ccgcgaatga 420
 tccttatgta tattcacagt cagctcaaag gaaaggaaaa tgcttgtgca cgatgtgtgc 480
 tgaaatcttg catttgttgc ctttggtgtc ttgaaaagtg cctaaattat ttaaatcaga 540
 atgcatacac agccacagct atcaacagca ccaacttctg cacctcagca aaggatgcct 600
 ttgtcattct ggtggagaat gctttgcgag tggctaccat caacacagta ggagatttta 660

```

tggtattcct tggcaaggtg ctgatagtct gcagcacagg tttagctggg attatgctgc 720
tcaactacca gcaggactac acagtatggg tgctgcctct gatcatcgtc tgcctctttg 780
ctttcctagt cgttcattgc ttcctgtcta tttatgaaat ggtagtggat gtattattct 840
kgkgttttgc cattgawaca aaatacaatg atgggmgccc tggcagagaa ttctatatgg 900
ataaagtgct gatggagttt gtggaaaaca gtaggaaagc aatgaaagaa gctggtaagg 960
gaggcgctgc tgattccaga gagctaaagc cgatgctgaa gaaaagggtga ctgggtctcat 1020
gagccctgaa gaatgaactc agaggaggtt gtttacatga ggttctccca ctcaccagct 1080
gttgagagtc tgcgattatg aagagcagga tcttattact tcaatgaaag catgtaacaa 1140
gtttctcaaa ccaccaacag ccaagtggat ttggtacagt gcggctgtct aataaataat 1200
caaaagcaaa aaaaaaaaaa aaa 1223

```

<210> 174
 <211> 301
 <212> PRT
 <213> Homo sapiens

<220>
 <221> UNSURE
 <222> (246)..(247)

<220>
 <221> UNSURE
 <222> (251)

<220>
 <221> UNSURE
 <222> (258)

<400> 174
 Met Thr Leu Leu Phe Leu Gly Thr Thr Gly Ser Pro Val Gln Asn Glu
 1 5 10 15
 Gln Gly Phe Val Glu Phe Lys Ile Ser Gly Pro Leu Gln Tyr Met Trp
 20 25 30
 Trp Tyr His Val Val Gly Leu Ile Trp Ile Ser Glu Phe Ile Leu Ala
 35 40 45
 Cys Gln Gln Met Thr Val Ala Gly Ala Val Val Thr Tyr Tyr Phe Thr
 50 55 60
 Arg Asp Lys Arg Asn Leu Pro Phe Thr Pro Ile Leu Ala Ser Val Asn
 65 70 75 80
 Arg Leu Ile Arg Tyr His Leu Gly Thr Val Ala Lys Gly Ser Phe Ile
 85 90 95
 Ile Thr Leu Val Lys Ile Pro Arg Met Ile Leu Met Tyr Ile His Ser
 100 105 110
 Gln Leu Lys Gly Lys Glu Asn Ala Cys Ala Arg Cys Val Leu Lys Ser
 115 120 125
 Cys Ile Cys Cys Leu Trp Cys Leu Glu Lys Cys Leu Asn Tyr Leu Asn
 130 135 140
 Gln Asn Ala Tyr Thr Ala Thr Ala Ile Asn Ser Thr Asn Phe Cys Thr
 145 150 155 160
 Ser Ala Lys Asp Ala Phe Val Ile Leu Val Glu Asn Ala Leu Arg Val

165	170	175
Ala Thr Ile Asn Thr Val Gly Asp Phe Met Leu Phe Leu Gly Lys Val		
180	185	190
Leu Ile Val Cys Ser Thr Gly Leu Ala Gly Ile Met Leu Leu Asn Tyr		
195	200	205
Gln Gln Asp Tyr Thr Val Trp Val Leu Pro Leu Ile Ile Val Cys Leu		
210	215	220
Phe Ala Phe Leu Val Ala His Cys Phe Leu Ser Ile Tyr Glu Met Val		
225	230	235
Val Asp Val Leu Phe Xaa Xaa Phe Ala Ile Xaa Thr Lys Tyr Asn Asp		
245	250	255
Gly Xaa Pro Gly Arg Glu Phe Tyr Met Asp Lys Val Leu Met Glu Phe		
260	265	270
Val Glu Asn Ser Arg Lys Ala Met Lys Glu Ala Gly Lys Gly Gly Val		
275	280	285
Ala Asp Ser Arg Glu Leu Lys Pro Met Leu Lys Lys Arg		
290	295	300

<210> 175

<211> 2460

<212> DNA

<213> Homo sapiens

<400> 175

```

gagaagcgcg atgacggcta cgaggccgct gccagctcca aaactagctc aggcgatgcc 60
tcctcactca gcatcgaggg agactaaca actccgggca aagttggggc tgaaaccctt 120
ggagggttaat gccatcaaga aggaggcggg caccaaggag gagcccgtga cagctgatgt 180
catcaaccct atggccttgc gacagcgaga ggagctgcgg gagaagctgg cggctgccaa 240
ggagaagcgc ctgctgaacc aaaagctggg gaagataaag accctaggag aggatgaccc 300
ctggctggac gacactgcag cctggatcga gaggagccgg cagctgcaga aggagaagga 360
cctggcagag aagagggcca agttactgga ggagatggac caaaagtttg gtgtcagcac 420
tctggtggag gaggagtctg ggcagaggcg gcaggacctg tacagtgcc gggacctgca 480
gggcctcact gtggagcatg ccattgattc cttccgagaa ggggagacaa tgattcttac 540
cctcaaggac aaaggcgtgc tgcaggagga ggaggacgtg ctggtgaacg tgaacctggt 600
ggataaggag cgggcagaga aaaatgtgga gctgcggaag aagaagcctg actacctgcc 660
ctatgccgag gacgagagcg tggacgacct ggcgcagcaa aaacctcgct ctatcctgtc 720
caagtatgac gaaaagcttg aaggggagcg gccacattcc ttccgcttgg agcagggcgg 780
cacggctgat ggcctgcggg agcgggagct ggaggagatc cgggccaagc tgcggctgca 840
ggctcagtcc ctgagcacag tggggccccg gctggcctcc gaatacctca cgcctgagga 900
gatggtgacc tttaaaaaga ccaagcggag ggtgaagaaa atccgcaaga aggagaagga 960
ggtagtagtg cgggcagatg acttgctgcc tctcggggac cagactcagg atggggactt 1020
tggttccaga ctgcggggac ggggtcgccg ccgagtgtcc gaagtggagg aggagaagga 1080
gcctgtgcct cagcccctgc cgtcggacga cacccgagtg gagaacatgg acatcagtga 1140
tgaggaggaa ggtggagctc caccgccggg gtcccccgag gtgctggagg aggacgaggc 1200
ggagctggag ctgcagaagc agctggagaa gggacgccgg ctgcgacagt tacagcagct 1260
acagcagctg cgagacagtg gcgagaaggt ggtggagatt gtgaagaagc tggagtctcg 1320
ccagcggggc tgggaggagg atgaggatcc cgagcgggaag ggggccatcg tgttcaacgc 1380
cacgtccgag ttctgccgca ccttggggga gatccccacc tacgggctgg ctggcaatcg 1440
cgaggagcag gaggagctca tggactttga acgggatgag gagcgctcag ccaacggtgg 1500
ctccgaatct gacggggagg agaacatcgg ctggagcacg gtgaacctgg acgaggagaa 1560
gcagcagcag gatgtgaggg ccacgccgct ggggggtggg cgtttggggg tgctcaagct 1620

```

ggagatgagc accgggctcg gtgtccagag cctcagcctc ctcattccaga gtgggctctg 1680
 cagacctccc agggcgatct gaggagtaaa tgaggaaatt aaatgttgtg gagggctggt 1740
 gcctggcagg tggtagaccag tgggtggggc tgagaagagc cggtagggcc tgctaaccac 1800
 ccccgccacg tgtcccgtag ttctctgctt cctccaccac catcctggac gaggaaccga 1860
 tcgtgaatag ggggctggca gctgccctgc tcctgtgtca gaacaaaggc ctgctggaga 1920
 ccacagtga gaaggtggcc cgggtgaagg cccccaacaa gtcgctgccc tcagccgtgt 1980
 actgcacga ggataagatg gccatcgatg acaagtacag ccggaggag gaataccgag 2040
 gcttcacaca ggacttcaag gagaaggacg gtacaaaccc gacgttaaga tcgaatacgt 2100
 ggatgagacg ggccggaaac tcacacccaa ggaggcttcc cggcagctgt cgcaccgctt 2160
 ccatggcaag ggctcaggca agatgaagac agagcggcgg atgaagaagc tggacgagga 2220
 ggcgctcctg aagaagatga gctccagsga cacgcccctg ggcaccgtgg ccctgytcca 2280
 ggagaagcag aaggctcaga agaccccta catygtgttc agcggcagcg gcaagagcat 2340
 gaacgcgaac accatcacca agtgacagcg ccctcccgcg ccggccctgc ctcaaccttc 2400
 atattaaata aagctccctc cttaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2460

<210> 176

<211> 563

<212> PRT

<213> Homo sapiens

<400> 176

Met Thr Ala Thr Arg Pro Leu Pro Ala Pro Lys Leu Ala Gln Ala Met
1 5 10 15

Pro Pro His Ser Ala Ser Arg Glu Thr Asn Lys Leu Arg Ala Lys Leu
20 25 30

Gly Leu Lys Pro Leu Glu Val Asn Ala Ile Lys Lys Glu Ala Gly Thr
35 40 45

Lys Glu Glu Pro Val Thr Ala Asp Val Ile Asn Pro Met Ala Leu Arg
50 55 60

Gln Arg Glu Glu Leu Arg Glu Lys Leu Ala Ala Ala Lys Glu Lys Arg
65 70 75 80

Leu Leu Asn Gln Lys Leu Gly Lys Ile Lys Thr Leu Gly Glu Asp Asp
85 90 95

Pro Trp Leu Asp Asp Thr Ala Ala Trp Ile Glu Arg Ser Arg Gln Leu
100 105 110

Gln Lys Glu Lys Asp Leu Ala Glu Lys Arg Ala Lys Leu Leu Glu Glu
115 120 125

Met Asp Gln Lys Phe Gly Val Ser Thr Leu Val Glu Glu Glu Phe Gly
130 135 140

Gln Arg Arg Gln Asp Leu Tyr Ser Ala Arg Asp Leu Gln Gly Leu Thr
145 150 155 160

Val Glu His Ala Ile Asp Ser Phe Arg Glu Gly Glu Thr Met Ile Leu
165 170 175

Thr Leu Lys Asp Lys Gly Val Leu Gln Glu Glu Glu Asp Val Leu Val
180 185 190

Asn Val Asn Leu Val Asp Lys Glu Arg Ala Glu Lys Asn Val Glu Leu
195 200 205

Arg	Lys	Lys	Lys	Pro	Asp	Tyr	Leu	Pro	Tyr	Ala	Glu	Asp	Glu	Ser	Val	210	215	220
Asp	Asp	Leu	Ala	Gln	Gln	Lys	Pro	Arg	Ser	Ile	Leu	Ser	Lys	Tyr	Asp	225	230	235 240
Glu	Lys	Leu	Glu	Gly	Glu	Arg	Pro	His	Ser	Phe	Arg	Leu	Glu	Gln	Gly	245	250	255
Gly	Thr	Ala	Asp	Gly	Leu	Arg	Glu	Arg	Glu	Leu	Glu	Glu	Ile	Arg	Ala	260	265	270
Lys	Leu	Arg	Leu	Gln	Ala	Gln	Ser	Leu	Ser	Thr	Val	Gly	Pro	Arg	Leu	275	280	285
Ala	Ser	Glu	Tyr	Leu	Thr	Pro	Glu	Glu	Met	Val	Thr	Phe	Lys	Lys	Thr	290	295	300
Lys	Arg	Arg	Val	Lys	Lys	Ile	Arg	Lys	Lys	Glu	Lys	Glu	Val	Val	Val	305	310	315 320
Arg	Ala	Asp	Asp	Leu	Leu	Pro	Leu	Gly	Asp	Gln	Thr	Gln	Asp	Gly	Asp	325	330	335
Phe	Gly	Ser	Arg	Leu	Arg	Gly	Arg	Gly	Arg	Arg	Arg	Val	Ser	Glu	Val	340	345	350
Glu	Glu	Glu	Lys	Glu	Pro	Val	Pro	Gln	Pro	Leu	Pro	Ser	Asp	Asp	Thr	355	360	365
Arg	Val	Glu	Asn	Met	Asp	Ile	Ser	Asp	Glu	Glu	Glu	Gly	Gly	Ala	Pro	370	375	380
Pro	Pro	Gly	Ser	Pro	Gln	Val	Leu	Glu	Glu	Asp	Glu	Ala	Glu	Leu	Glu	385	390	395 400
Leu	Gln	Lys	Gln	Leu	Glu	Lys	Gly	Arg	Arg	Leu	Arg	Gln	Leu	Gln	Gln	405	410	415
Leu	Gln	Gln	Leu	Arg	Asp	Ser	Gly	Glu	Lys	Val	Val	Glu	Ile	Val	Lys	420	425	430
Lys	Leu	Glu	Ser	Arg	Gln	Arg	Gly	Trp	Glu	Glu	Asp	Glu	Asp	Pro	Glu	435	440	445
Arg	Lys	Gly	Ala	Ile	Val	Phe	Asn	Ala	Thr	Ser	Glu	Phe	Cys	Arg	Thr	450	455	460
Leu	Gly	Glu	Ile	Pro	Thr	Tyr	Gly	Leu	Ala	Gly	Asn	Arg	Glu	Glu	Gln	465	470	475 480
Glu	Glu	Leu	Met	Asp	Phe	Glu	Arg	Asp	Glu	Glu	Arg	Ser	Ala	Asn	Gly	485	490	495
Gly	Ser	Glu	Ser	Asp	Gly	Glu	Glu	Asn	Ile	Gly	Trp	Ser	Thr	Val	Asn	500	505	510
Leu	Asp	Glu	Glu	Lys	Gln	Gln	Gln	Asp	Val	Arg	Ala	Thr	Pro	Leu	Gly	515	520	525

Gly Gly Arg Leu Gly Val Leu Lys Leu Glu Met Ser Thr Gly Leu Gly
530 535 540

Val Gln Ser Leu Ser Leu Leu Ile Gln Ser Gly Leu Cys Arg Pro Pro
545 550 555 560

Arg Ala Ile

<210> 177

<211> 1790

<212> DNA

<213> Homo sapiens

<400> 177

```

ctgggtaccca cccctgtctc tggacttctt tatgaacact gagtatttga ctccccaccc 60
ttcatgggtca gtccttttta acaccctaga tatcattgct gtccttttca ttgacatgct 120
agagacattt ccaattttca tgggagtcag taagatagag atgatgaaa ttcagagtgt 180
tcaaagaaag aggaggcctc atcagttgat agaataaca acagattgtc taatctcagt 240
tttcttcact tttctaccca ttacagtgga aaaaagaacc cttaaggaag ccagtgcctc 300
tcaacattgg ttacaaaacc atcagtgccg gacttaatt taaaatcttc tgaaaatcca 360
tcagttgggt ttcatgtctc actctaaact cagctccaac caggctgctt cctagattct 420
tgtctgtgtg tgtttctgtt ttggtctctt gttacttctt tctgtaaact taagtaaact 480
cagtttggtg acctagtga ttgattcttt ccattttcta tactattcac cagcatatca 540
aagatgcttc ttcctaactc tgatttccag agtaactgtg ctatcagctt ttcataacta 600
gaactagggt tttacctttt cacatttctt gcctcctacc cagttcgtaa gccaaattag 660
actcgtactc ttgtgaagtg ccctttagat actagtgtaa aatatactgc gtaattctcc 720
attgccctac atatattaac cctttaagaa aatatatcac cagtctatct tatcttcgca 780
gaacttgccc aggtatgagc cagcatttat taccactcat tctagaaggt gccagttagg 840
tagctatcca ggtttacatt ttaaggcagt cgagacctta ttcacgtggt atataaaca 900
ccacatttct cttttatatg gaacaagact tttcatttgc ggctggcctt ctcactagct 960
tatgcttttt ttttttaaga ctttcttag cactcgctga actcctcccc ctcacaatca 1020
atctcagcaa ctcagcagag tcgcttcagt tcacagctct taatccttca ctccagacta 1080
aagctaactt tatgtcctca aacagctaca actcactgtt atcacagttc cgactgcaga 1140
gactccattt aagaggaaat ttaaaaaata aacaatgctc tatttctgtc cacatcaaag 1200
gtacctctaa cagaaacttg tctttgcttc tgtctctctg ctactggact ctcagctcaa 1260
ggtaatgtaa gatgatctca tagatgcact ttagcctctt gatgttagca gttgagtcct 1320
ccctgcgcac aaaatacatt tgtggtaatg aatgcccaga atctcactgg cacaccaag 1380
agtagttaa ctaaaattgc tactaacaca acattgtaga attcgttgcc ttaatggatg 1440
tgatcttcta ggcttactgt gtcttaacaa gcagctttat atatatttat cttgcccaga 1500
aagtacactt gtagaattta acatttgctc ctttctccaa acagattaaa ggttatgcag 1560
ctgaatgatt ctgtgtccca ttttaaaggc ccaggctatc ccctagattt agattagttc 1620
ctaaaaaatc ttccagtctg aatcctgaca aatggatagc taaattaatt tccactcctc 1680
ttctctcttg cactgttttg tacattacag ccaccattag ctttaaaagc tgcagcagcc 1740
aaattcgggt acagtaacat aaagcctgag ctttaaaaaa aaaaaaaaaa 1790

```

<210> 178

<211> 115

<212> PRT

<213> Homo sapiens

<400> 178

Met Glu Gln Asp Phe Ser Phe Ala Ala Gly Leu Leu Thr Ser Leu Cys
1 5 10 15

Phe Phe Phe Leu Arg Pro Phe Leu Ala Leu Ala Glu Leu Leu Pro Leu
20 25 30

Thr Ile Asn Leu Ser Asn Ser Ala Glu Ser Leu Gln Phe Thr Ala Leu

35 40 45
 Asn Pro Ser Leu Gln Thr Lys Ala Asn Leu Met Ser Ser Asn Ser Tyr
 50 55 60
 Asn Ser Leu Leu Ser Gln Phe Arg Leu Gln Arg Leu His Leu Arg Gly
 65 70 75 80
 Asn Leu Lys Asn Lys Gln Cys Ser Ile Ser Val His Ile Lys Gly Thr
 85 90 95
 Ser Asn Arg Asn Leu Ser Leu Leu Leu Ser Leu Cys Tyr Trp Thr Leu
 100 105 110
 Ser Ser Arg
 115

<210> 179

<211> 2026

<212> DNA

<213> Homo sapiens

<400> 179

cattgagttg ccctaacaac attgtctcca gtgtcagaac catattaagg ttcgtttctc 60
 agattgggag cctgcaacac catacagcca acattgcctt tgccacgcca ctgccaccat 120
 cccaccatt gccctatggt gggcagatga attccagaaa ccttcaggga gccaggataa 180
 ttaggcaacc catctgaatt ggccacgtaa gtgacaggca cttatctctc gggttcttgc 240
 ttttgcagac tccagggaag tccgtcttag aggtcgatgg cagagactcc tactctttcc 300
 catgaggggt tgataggaat caaattggga ttctctggc ttgggtttt gtctttttgt 360
 tgttgttttt ggttttcagt ttgttttttg gtgtatgggg ggtgattttg tttctgaata 420
 agaaaaagaa gaggcaacca tggcccttat gtgggtttat cctttttgag caatgtttta 480
 gccacaagta aggaatcttg aaagtctttt gtccagcaag cagtcttaaa aatgtttttc 540
 ctaactcctt ttgcaggtga ctaagtacaa aaaaatagtt ttctcattgt attcaaaata 600
 gtgagtaggt tccctggata atacacagtg gtagttagaca tattttctca aaacacaacc 660
 agaaaaccca cttccggtat ttgtaaatca cttttcaagg gaaaaagtga acacgtattc 720
 cctgtatttc tagtttgatt accaaacctg atgttacaaa gaaacctccg ttctgtagac 780
 agaattttct ttatttttct tcttttactc ctcaaatca ctttcccagt gccatcacca 840
 tctataaggt ctgagagcag aggattatc atggtaataa gtgggggtgt ggtgcagcca 900
 ttccagtaac acccacaaga ggacagctgt tctgaatgtc cccaccacc cctctttcag 960
 tacaggtgag acattttcag ttcatgagct ccagaccaa tcccaggcca gcccttgac 1020
 caaaagcctt ttttagaagg cttatcagtc tattaggaat gtctcaggaa agatgagcca 1080
 tttctttggg gagaaatata ttacagatg gaagtgtgt actgcgtgtc tgtgtgtgtg 1140
 tgtggtgtgt gtggtcacgt gagtgcgtgt gtctatctat gtgcatttca cttccataaa 1200
 gaccagccc aagctgctgg gaaccatgtg ttctgagta ttctcagagg ttaaacaagt 1260
 gacaagtgag cttctgaaat tagtgtctca gcaagctggc tttaggaatg agccccattt 1320
 tatcaagcag agaaaaaaaa taacagcaga aaagataaag ataaaccaa aatataatac 1380
 cccaatgga aaataatgtt gattcagcaa ttcccatagg atgtattaca tgctctaatt 1440
 tattatatta ttatttatct gtctttgatc tttgcccatt gtactcttaa aaagatgttg 1500
 ggatgttgat tgcgattttt aaacaactag ataatgtata aatcagcagt ggaaatcagt 1560
 tttaatgtgt ggatgtgtct gattattgtt aaatgcctct ttttttactt tttttttttt 1620
 tagatgtata atgtttcata aacctggca ctggtcacaa agctcagctg tgaaaatgaa 1680
 atttgtagta tttttaaaca tgaatgtcaa tttcaagtgt atttgaaatg gttcctccag 1740
 gagagatatt tgtgcaccat taggaaaatc ttctctgcag aggaagtagc cttcttttga 1800
 gaaaatggaa aatgggttct gatatgtgat ctgagagtag cccatttcct agggcaccat 1860
 ggaaaacaca aatgtgatct ttaagtatac ctcttcccca gtttggggag gaaaggactc 1920
 agtttgcacc ctttttgtat gtaaaataaa atgtcttacc tttcttggct aaaaaaaaaa 1980
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 2026

<210> 180

<211> 52

<212> PRT

<213> Homo sapiens

<400> 180

Met Leu Gln Arg Asn Leu Arg Ser Val Asp Arg Ile Ser Phe Ile Phe
 1 5 10 15

Leu Leu Leu Leu Leu Thr Ile Thr Phe Pro Val Pro Ser Pro Ser Ile
 20 25 30

Arg Ser Gln Ser Arg Gly Leu Phe Met Val Ile Ser Gly Gly Val Val
 35 40 45

Gln Pro Phe Gln
 50

<210> 181

<211> 1138

<212> DNA

<213> Homo sapiens

<400> 181

gggtctgtgg agagccgggt gcgagcggcg gcagcacgag gggaaaagag ctgagcggag 60
 accaaagtca gccgggagac agtgggtctg tgagagaccg aatagagggg ctggggccac 120
 gagcgccatt gacaagcaat ggggaagaaa cagaaaaaca agagcgaaga cagcaccaag 180
 gatgacattg atcttgatgc cttggctgca gaaatagaag gagctggtgc tgccaaagaa 240
 caggagcctc aaaagtcaaa agggaaaaag aaaaaagaga aaaaaagca ggactttgat 300
 gaagatgata tcttgaaaga actggaagaa ttgtctttgg aagctcaagg catcaaagct 360
 gacagagaaa ctgttgcaagt gaagccaaca gaaaacaatg aagaggaatt cacctcaaaa 420
 gataaaaaaa agaaaggaca gaagggcaaa aaacagagtt ttgatgataa tgatagcgaa 480
 gaattggaag ataaagattc aaaatcaaaa aagactgcaa aaccgaaagt ggaaatgtac 540
 tctgggagtg atgatgatga tgattttaac aaacttccta aaaaagctaa agggaaagct 600
 caaaaatcaa ataagaagtg ggatgggtca gaggaggatg aggataacag taaaaaatt 660
 aaagagcgtt caagaataaa ttcttctggt gaaagtgggt atgaatcaga tgaatttttg 720
 caatctaaaa ggacagaaaa aaaatcagaa aaacaagcca ggtcctaaca tagaaagtgg 780
 gaatgaagat gatgacgctt ccttcaaaat taagacagtg gcccacaaaga aggcagaaaa 840
 gaaggagcgc gagagaaaaa agcgagatga agaaaaagcg aaactgcgga agctgaaaga 900
 aaaagaagag ttagaaacag gtaaaaagga tcagagtaaa caaaaggaat ctcaaaggaa 960
 atttgaagaa gaaactgtaa aatccaaagt gactgttgat actggagtaa ttcctgcctc 1020
 tgaagagaaa gcagagactc ccacagctgc agaagatgac aatgaaggag acaaaaagaa 1080
 gaaagataag aagaaaaaga aaggagaaaa ggaagaaaaa gagaaaaaaa aaaaaaaa 1138

<210> 182

<211> 209

<212> PRT

<213> Homo sapiens

<400> 182

Met Gly Lys Lys Gln Lys Asn Lys Ser Glu Asp Ser Thr Lys Asp Asp
 1 5 10 15

Ile Asp Leu Asp Ala Leu Ala Ala Glu Ile Glu Gly Ala Gly Ala Ala
 20 25 30

Lys Glu Gln Glu Prc Gln Lys Ser Lys Gly Lys Lys Lys Lys Glu Lys
 35 40 45

Lys Lys Gln Asp Phe Asp Glu Asp Asp Ile Leu Lys Glu Leu Glu Glu

50	55	60
Leu Ser Leu Glu Ala Gln Gly Ile Lys Ala Asp Arg Glu Thr Val Ala		
65	70	75 80
Val Lys Pro Thr Glu Asn Asn Glu Glu Glu Phe Thr Ser Lys Asp Lys		
	85	90 95
Lys Lys Lys Gly Gln Lys Gly Lys Lys Gln Ser Phe Asp Asp Asn Asp		
	100	105 110
Ser Glu Glu Leu Glu Asp Lys Asp Ser Lys Ser Lys Lys Thr Ala Lys		
	115	120 125
Pro Lys Val Glu Met Tyr Ser Gly Ser Asp Asp Asp Asp Asp Phe Asn		
	130	135 140
Lys Leu Pro Lys Lys Ala Lys Gly Lys Ala Gln Lys Ser Asn Lys Lys		
	145	150 155 160
Trp Asp Gly Ser Glu Glu Asp Glu Asp Asn Ser Lys Lys Ile Lys Glu		
	165	170 175
Arg Ser Arg Ile Asn Ser Ser Gly Glu Ser Gly Asp Glu Ser Asp Glu		
	180	185 190
Phe Leu Gln Ser Lys Arg Thr Glu Lys Lys Ser Glu Lys Gln Ala Arg		
	195	200 205

Ser

<210> 183
 <211> 912
 <212> DNA
 <213> Homo sapiens

<400> 183
 atccagctct ttcagagaga agagatggga ataagataag aacatcattt cctgaagagt 60
 ttactaagtt gatgttttct tttggtgaag ggcaatgtgg aatttaaatac atatagttca 120
 tgtgtgcacc tgtcctgcag tttgaggcag atgattttaa accagcatct atagacactt 180
 cctgtgaagg agagcttcaa gttggcaaag gagatgaagt cacaattaca ctgccacata 240
 tccctagctg agggcagcag taaaatccag gcccgaaatgg aacagcagcc cactcgtcct 300
 ccacagacgt cacagccacc accacctcca ccacctatgc cattcagagc tccaacgaag 360
 cctccagttg gacccaaaac ttctcccttg aaagataacc cgtcacctga acctcagttg 420
 gatgacatca aaagagagct gagggctgaa gttgacatta ttgaacaaat gagcagcagc 480
 agtgggagca gctcttcaga ctctgagagc tcttcgggaa gtgatgacga tagctccagc 540
 agtggagsg aggamaatgg ccagcytct cytccgcagc yttmacacca gcagccytac 600
 aacagtaggc ctgccgttgc caatggaacc agccggccac aaggaagcaa ccagytyatg 660
 aacaccctca gaaatgactt gcagttgagt gagtytgga gtgacagtga tgactagtgc 720
 tggatytttc gaaacctact ttttgggtgca caaacatgcc gcaagactga gctacttttg 780
 ccgtggagtc cattgcaaga ggaaaatggt atggatcagt gactgtagta ggagtttgag 840
 gctytggaac tctcacatat tcaagtcttt aacttagtgg tgatgggtga aaaaaaaaaa 900
 aaaaaaaaaa aa 912

<210> 184
 <211> 167
 <212> PRT
 <213> Homo sapiens

<220>

<221> UNSURE

<222> (114)

<220>

<221> UNSURE

<222> (120)

<220>

<221> UNSURE

<222> (123) .. (124)

<220>

<221> UNSURE

<222> (148)

<220>

<221> UNSURE

<222> (161)

<400> 184

Met	Lys	Ser	Gln	Leu	His	Cys	His	Ile	Ser	Leu	Ala	Glu	Gly	Ser	Ser
1				5				10						15	

Lys	Ile	Gln	Ala	Arg	Met	Glu	Gln	Gln	Pro	Thr	Arg	Pro	Pro	Gln	Thr
		20						25					30		

Ser	Gln	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Met	Pro	Phe	Arg	Ala	Pro	Thr
		35					40					45			

Lys	Pro	Pro	Val	Gly	Pro	Lys	Thr	Ser	Pro	Leu	Lys	Asp	Asn	Pro	Ser
	50					55					60				

Pro	Glu	Pro	Gln	Leu	Asp	Asp	Ile	Lys	Arg	Glu	Leu	Arg	Ala	Glu	Val
65					70					75					80

Asp	Ile	Ile	Glu	Gln	Met	Ser	Ser	Ser	Ser	Gly	Ser	Ser	Ser	Ser	Asp
				85					90					95	

Ser	Glu	Ser	Ser	Ser	Gly	Ser	Asp	Asp	Asp	Ser	Ser	Ser	Ser	Gly	Gly
			100					105					110		

Glu	Xaa	Asn	Gly	Pro	Ala	Ser	Xaa	Pro	Gln	Xaa	Xaa	His	Gln	Gln	Pro
		115					120					125			

Tyr	Asn	Ser	Arg	Pro	Ala	Val	Ala	Asn	Gly	Thr	Ser	Arg	Pro	Gln	Gly
	130					135					140				

Ser	Asn	Gln	Xaa	Met	Asn	Thr	Leu	Arg	Asn	Asp	Leu	Gln	Leu	Ser	Glu
145					150					155					160

Xaa	Gly	Ser	Asp	Ser	Asp	Asp
				165		

<210> 185

<211> 4582

<212> DNA

<213> Homo sapiens

<400> 185

```

ggtgaagcta atcaaactctg gttcctatgt agctcttact gttcagggac gccacactgg 60
gtcgccccag attccacttg cegactctga agtagagccg tcagtcattg gacatatgtc 120
tcccatcatg acatctcttc attcacctgg agcatctggg aatatggaga gaatcactag 180
tctgtgtgct atgggggagg aaaacaatgt ggttcataac cagaaagtag aaattctgag 240
aaaaatgtta cagaaagaac aggaacggct acagttattg caggaagatt acaaccgaac 300
acctgcccac agattgctaa aagagatcca agaggccaag aaacacattc ctcagctgca 360
agagcagtta tccaaagcca caggctctgc tcaggatgga gctgtagtta caccctccag 420
accttttaggg gacaccctaa cagtcagtga ggcagaaaca gatcctggag atgtactggg 480
caggactgac tgtagcagtg gagatgcttc tcggcccagt agtgacaatg cagatagtcc 540
caagagtggc ccaaaagaga gaatttatct agaggaaaac ccagagaaaa gtgaaacaat 600
tcaggacact gacactcaat cacttgctcg aagtcctca acccgatatag cacctcatat 660
tattggagca gaagatgatg attttggtac tgaacatgaa cagatcaatg gacagtgcag 720
ctgtttccag agcattgaat tactaaaatc tcgcccggct catttggtg ttttcttaca 780
ccatgtagtt tcacaatttg accctgcgac ttgtctctgt tatctctatt cagacctgta 840
taaacatacc aattccaaag aaactcgtcg catcttcctt gagtttcatc agttctttct 900
aaatcgatca gcacacctga aagtttctgt tcctgatgaa atgtctgcag atctagaaaa 960
gagaagacct gagctcattc ctgaggatct gcacgcccac tatatccaaa ctatgcaaga 1020
aagagtccat ccagaagttc aaaggcactt aaaagatttt cggcagaaac gtagtatggg 1080
actgaccttg gctgaaagcg agctgactaa acttgatgca gagcgagaca aggaccgatt 1140
gactttggag aaggagcgga catgtgcaga acagattggt gccaaaattg aagaagtatt 1200
gatgaytgct caggctgtar aggaagataa gagctccacc atgcagtatg ttattctcat 1260
gtatatgaag catttgggag taaaagtga agagcctcga aatttggagc acaaacgggg 1320
tcggattgga tttcttccca aaatcaagca aagtatgaag aaagataaag aaggggaaga 1380
aaaagggaag cgaagaggat tccccagcat cctgggaccc ccacggagac caagccgtca 1440
tgacaacagt gcaattggca gagccatgga actacagaag gcgcgccacc ctaagcactt 1500
atccacaccc tcactctgtg gtcctgaacc tcaggactct gccaaagttgc gccagagtgg 1560
gttagcaaat gaaggaacag acgctggata cctgcctgcc aattccatgt cttctgtagc 1620
ttcagggggc tctttttccc aggaaggagg gaaagagaat gatacaggat caaagcaagt 1680
tgagaaaca tcagcacctg gagacacctt agatggcaca cctcgtactc tcaatactgt 1740
ctttgatctc ccaccacctc cattagacca agtgcaggag gaggaatgtg aagtagaaag 1800
ggtgactgaa catgggacac caaagccctt tcgaaagtgt gacagtgtag cttttggaga 1860
aagtcaaagt gaggatgaac aatttgaaaa tgacttagag acagatccac ccaactggca 1920
gcagcttggt agtcgagaag tgttactggg actaaaacct tgtgaaatca aaagacagga 1980
agtgattaat gaattgttct acactgaaag agctcatgtt cgaacactga aggttcttga 2040
tcaagtgttc tatcagcgag tatccagaga aggaattctg tcaccctcag agctacggaa 2100
aattttttca aacttggag atattcttca acttcatatt ggattgaatg aacaaatgaa 2160
ggctgttcga aagagaaatg agacctctgt tatcgatcag attggggaag atttgctgac 2220
atgggttcagc ggaccaggag aggagaaatt gaaacatgct gctgctacct tttgcagtaa 2280
ccaacctttc gccctggaaa tgatcaaatt tcgtcagaaa aaggattctc gatttcagac 2340
ttttgtgcaa gatgctgaaa gtaatccacc gtgtcgtcgt cttcaactga aggatattat 2400
tcccactcaa atgcaaaggc ttactaagta cccacttctg ttggataata ttgccaaata 2460
cacagaatgg ccaacagaaa gggagaaggc gaagaaagct gcagatcact gtcgtcagat 2520
cttaaatatt gtaaatcagg ctgtcaagga ggcagaaaac aagcagcgcc tagaagatta 2580
tcagcgctgc cttgatacct ccagcctgaa gttgtcagag tacccaaatg ttgaagagct 2640
caggaatttg gatttaacaa aaaggaagat gattcatgaa gggccatttg tttggaaggc 2700
gaatagagat aaaactattg atttatcac gttgtctgct gaagacattc ttgtattgtt 2760
acaaaagcag gatgatagac tggttttaag gtgtcatagt aagattctgg catctacagc 2820
tgatagcaaa cacacgttta gccctgtcat taagttgagt acagtgttg ttcgacaagt 2880
ggcaacagat acaaaagctt tattcgtcat ttccatgtca gacaatggcg ctcagattta 2940
tgaactggtg gcacagacag tttctgaaaa gactgtctgg caggacctaa cctgtcggat 3000
ggctgcatca gtgaaggagc aatccacaaa gccgattcca ttaccacagt caaacctgg 3060
cgaaggagat aatgatgaag aagatccttc aaaattaaaa gaggagcagc atggcatttc 3120
agtcactggt ttgcagagtc cagacagaga tttgggatta gaatctacct taatatcgct 3180
aaaacctcag tctcattcac tgagtacctc tgggaaatca gaggtacgtg atctgtttgt 3240
ggctgagaga cagtttgcaa aggaacaaca tacagatggg aactaaagg aagttggaga 3300
agattatcaa atcgcaatcc cagattcaca cctgcctgtc tcagaagaac ggtgggcatt 3360
ggatgacta agaaatttg gtttgttgaa gcagttgctg gtgcaacagc taggtttgac 3420
tgagaagagc gttcaggaag actggcaaca tttcccaaga tacagaacag cctctcaggg 3480

```



```

gccgcagaca gacagtgtca tccagaactc tgaaaatatt aaggcctatc attctggtga 3540
aggacatatg cccttttagaa ctggaactgg tgacattgca acttggtaca gtccacggac 3600
ttcaactgaa tcttttgctc cacgggattc agtgggactg gcaccccagg atagccaggc 3660
aagtaacatt ttagtaatgg accacatgat tatgacccca gagatgccta ccatggagcc 3720
agaaggggggt cttgatgaca gtggagagca cttttttgat gcccgtgaag cacatagtga 3780
tgagaatcca tcagaagggtg atggagcagt taacaaggaa gagaaggatg ttaatttacg 3840
catctcagga aactatattga tccttgatgg ctatgaccca gtgcaggaga gttccacaga 3900
tgaggagggtt gcttcctcac ttaccctgca gcccatgaca ggcacccctg ctgtggaatc 3960
caccaccag cagcaacatt ctctcagaa tactactcc gatggggcaa tttcaccatt 4020
cacccccga tttctggtcc agcagcgctg gggagctatg gagtattcct gttttgagat 4080
ccagagtccc tcctcttggtg cagattcaca gagccagatc atggagtaca ttcataagat 4140
agaggctgac cttgaacact taaaggaagg tggaggaaag ttaacacat tctttgccaa 4200
aggctggctg gatcagccct cacagacaag cactcagata aaagttagag ccgcatgtcc 4260
tggagggtgac tgcaggttgt tggatttggg gtatcggccg tgtctacca catcctggct 4320
ccagtgtgga tgcagagaga gtgtgacaga ggatctgcct gtgaaccacc tgggattagt 4380
caagtcccaa ggtgcccaaga gtgggactag ttyttcacag tgtggcagct gcactaatct 4440
gtttgtgagg gaatatccat tccctcactc tactctcctc actatcgga attcattttg 4500
attcagaata aaaacaaat gtatagagct ttgggttgta ggatatgaaa ttgtacttag 4560
atttaagaaa aaaaaaaaaa aa 4582

```

<210> 186
 <211> 1461
 <212> PRT
 <213> Homo sapiens

<220>
 <221> UNSURE
 <222> (364)

<220>
 <221> UNSURE
 <222> (369)

<220>
 <221> UNSURE
 <222> (1433)

<400> 186
 Met Ser Pro Ile Met Thr Ser Pro His Ser Pro Gly Ala Ser Gly Asn
 1 5 10 15
 Met Glu Arg Ile Thr Ser Pro Val Leu Met Gly Glu Glu Asn Asn Val
 20 25 30
 Val His Asn Gln Lys Val Glu Ile Leu Arg Lys Met Leu Gln Lys Glu
 35 40 45
 Gln Glu Arg Leu Gln Leu Leu Gln Glu Asp Tyr Asn Arg Thr Pro Ala
 50 55 60
 Gln Arg Leu Leu Lys Glu Ile Gln Glu Ala Lys Lys His Ile Pro Gln
 65 70 75 80
 Leu Gln Glu Gln Leu Ser Lys Ala Thr Gly Ser Ala Gln Asp Gly Ala
 85 90 95
 Val Val Thr Pro Ser Arg Pro Leu Gly Asp Thr Leu Thr Val Ser Glu
 100 105 110
 Ala Glu Thr Asp Pro Gly Asp Val Leu Gly Arg Thr Asp Cys Ser Ser

115					120					125									
Gly	Asp	Ala	Ser	Arg	Pro	Ser	Ser	Asp	Asn	Ala	Asp	Ser	Pro	Lys	Ser				
130					135					140									
Gly	Pro	Lys	Glu	Arg	Ile	Tyr	Leu	Glu	Glu	Asn	Pro	Glu	Lys	Ser	Glu				
145					150					155					160				
Thr	Ile	Gln	Asp	Thr	Asp	Thr	Gln	Ser	Leu	Val	Gly	Ser	Pro	Ser	Thr				
165					170					175									
Arg	Ile	Ala	Pro	His	Ile	Ile	Gly	Ala	Glu	Asp	Asp	Asp	Phe	Gly	Thr				
180					185					190									
Glu	His	Glu	Gln	Ile	Asn	Gly	Gln	Cys	Ser	Cys	Phe	Gln	Ser	Ile	Glu				
195					200					205									
Leu	Leu	Lys	Ser	Arg	Pro	Ala	His	Leu	Ala	Val	Phe	Leu	His	His	Val				
210					215					220									
Val	Ser	Gln	Phe	Asp	Pro	Ala	Thr	Leu	Leu	Cys	Tyr	Leu	Tyr	Ser	Asp				
225					230					235					240				
Leu	Tyr	Lys	His	Thr	Asn	Ser	Lys	Glu	Thr	Arg	Arg	Ile	Phe	Leu	Glu				
245					250					255									
Phe	His	Gln	Phe	Phe	Leu	Asn	Arg	Ser	Ala	His	Leu	Lys	Val	Ser	Val				
260					265					270									
Pro	Asp	Glu	Met	Ser	Ala	Asp	Leu	Glu	Lys	Arg	Arg	Pro	Glu	Leu	Ile				
275					280					285									
Pro	Glu	Asp	Leu	His	Arg	His	Tyr	Ile	Gln	Thr	Met	Gln	Glu	Arg	Val				
290					295					300									
His	Pro	Glu	Val	Gln	Arg	His	Leu	Lys	Asp	Phe	Arg	Gln	Lys	Arg	Ser				
305					310					315					320				
Met	Gly	Leu	Thr	Leu	Ala	Glu	Ser	Glu	Leu	Thr	Lys	Leu	Asp	Ala	Glu				
325					330					335									
Arg	Asp	Lys	Asp	Arg	Leu	Thr	Leu	Glu	Lys	Glu	Arg	Thr	Cys	Ala	Glu				
340					345					350									
Gln	Ile	Val	Ala	Lys	Ile	Glu	Glu	Val	Leu	Met	Xaa	Ala	Gln	Ala	Val				
355					360					365									
Xaa	Glu	Asp	Lys	Ser	Ser	Thr	Met	Gln	Tyr	Val	Ile	Leu	Met	Tyr	Met				
370					375					380									
Lys	His	Leu	Gly	Val	Lys	Val	Lys	Glu	Pro	Arg	Asn	Leu	Glu	His	Lys				
385					390					395					400				
Arg	Gly	Arg	Ile	Gly	Phe	Leu	Pro	Lys	Ile	Lys	Gln	Ser	Met	Lys	Lys				
405					410					415									
Asp	Lys	Glu	Gly	Glu	Glu	Lys	Gly	Lys	Arg	Arg	Gly	Phe	Pro	Ser	Ile				
420					425					430									
Leu	Gly	Pro	Pro	Arg	Arg	Pro	Ser	Arg	His	Asp	Asn	Ser	Ala	Ile	Gly				

435	440	445
Arg Ala Met Glu Leu Gln Lys	Ala Arg His Pro Lys His Leu Ser Thr	
450	455	460
Pro Ser Ser Val Ser Pro Glu Pro Gln Asp Ser Ala Lys Leu Arg Gln		
465	470	475 480
Ser Gly Leu Ala Asn Glu Gly Thr Asp Ala Gly Tyr Leu Pro Ala Asn		
485	490	495
Ser Met Ser Ser Val Ala Ser Gly Ala Ser Phe Ser Gln Glu Gly Gly		
500	505	510
Lys Glu Asn Asp Thr Gly Ser Lys Gln Val Gly Glu Thr Ser Ala Pro		
515	520	525
Gly Asp Thr Leu Asp Gly Thr Pro Arg Thr Leu Asn Thr Val Phe Asp		
530	535	540
Phe Pro Pro Pro Pro Leu Asp Gln Val Gln Glu Glu Glu Cys Glu Val		
545	550	555 560
Glu Arg Val Thr Glu His Gly Thr Pro Lys Pro Phe Arg Lys Phe Asp		
565	570	575
Ser Val Ala Phe Gly Glu Ser Gln Ser Glu Asp Glu Gln Phe Glu Asn		
580	585	590
Asp Leu Glu Thr Asp Pro Pro Asn Trp Gln Gln Leu Val Ser Arg Glu		
595	600	605
Val Leu Leu Gly Leu Lys Pro Cys Glu Ile Lys Arg Gln Glu Val Ile		
610	615	620
Asn Glu Leu Phe Tyr Thr Glu Arg Ala His Val Arg Thr Leu Lys Val		
625	630	635 640
Leu Asp Gln Val Phe Tyr Gln Arg Val Ser Arg Glu Gly Ile Leu Ser		
645	650	655
Pro Ser Glu Leu Arg Lys Ile Phe Ser Asn Leu Glu Asp Ile Leu Gln		
660	665	670
Leu His Ile Gly Leu Asn Glu Gln Met Lys Ala Val Arg Lys Arg Asn		
675	680	685
Glu Thr Ser Val Ile Asp Gln Ile Gly Glu Asp Leu Leu Thr Trp Phe		
690	695	700
Ser Gly Pro Gly Glu Glu Lys Leu Lys His Ala Ala Ala Thr Phe Cys		
705	710	715 720
Ser Asn Gln Pro Phe Ala Leu Glu Met Ile Lys Ser Arg Gln Lys Lys		
725	730	735
Asp Ser Arg Phe Gln Thr Phe Val Cln Asp Ala Glu Ser Asn Pro Leu		
740	745	750
Cys Arg Arg Leu Gln Leu Lys Asp Ile Ile Pro Thr Gln Met Gln Arg		

755					760					765					
Leu	Thr	Lys	Tyr	Pro	Leu	Leu	Leu	Asp	Asn	Ile	Ala	Lys	Tyr	Thr	Glu
770					775					780					
Trp	Pro	Thr	Glu	Arg	Glu	Lys	Val	Lys	Lys	Ala	Ala	Asp	His	Cys	Arg
785					790					795					800
Gln	Ile	Leu	Asn	Tyr	Val	Asn	Gln	Ala	Val	Lys	Glu	Ala	Glu	Asn	Lys
			805						810					815	
Gln	Arg	Leu	Glu	Asp	Tyr	Gln	Arg	Arg	Leu	Asp	Thr	Ser	Ser	Leu	Lys
			820					825					830		
Leu	Ser	Glu	Tyr	Pro	Asn	Val	Glu	Glu	Leu	Arg	Asn	Leu	Asp	Leu	Thr
		835					840					845			
Lys	Arg	Lys	Met	Ile	His	Glu	Gly	Pro	Leu	Val	Trp	Lys	Val	Asn	Arg
		850				855					860				
Asp	Lys	Thr	Ile	Asp	Leu	Tyr	Thr	Leu	Leu	Leu	Glu	Asp	Ile	Leu	Val
865					870					875					880
Leu	Leu	Gln	Lys	Gln	Asp	Asp	Arg	Leu	Val	Leu	Arg	Cys	His	Ser	Lys
				885					890					895	
Ile	Leu	Ala	Ser	Thr	Ala	Asp	Ser	Lys	His	Thr	Phe	Ser	Pro	Val	Ile
			900					905					910		
Lys	Leu	Ser	Thr	Val	Leu	Val	Arg	Gln	Val	Ala	Thr	Asp	Asn	Lys	Ala
		915					920					925			
Leu	Phe	Val	Ile	Ser	Met	Ser	Asp	Asn	Gly	Ala	Gln	Ile	Tyr	Glu	Leu
	930					935					940				
Val	Ala	Gln	Thr	Val	Ser	Glu	Lys	Thr	Val	Trp	Gln	Asp	Leu	Ile	Cys
945					950					955					960
Arg	Met	Ala	Ala	Ser	Val	Lys	Glu	Gln	Ser	Thr	Lys	Pro	Ile	Pro	Leu
				965					970					975	
Pro	Gln	Ser	Thr	Pro	Gly	Glu	Gly	Asp	Asn	Asp	Glu	Glu	Asp	Pro	Ser
			980					985					990		
Lys	Leu	Lys	Glu	Glu	Gln	His	Gly	Ile	Ser	Val	Thr	Gly	Leu	Gln	Ser
		995					1000					1005			
Pro	Asp	Arg	Asp	Leu	Gly	Leu	Glu	Ser	Thr	Leu	Ile	Ser	Ser	Lys	Pro
	1010					1015					1020				
Gln	Ser	His	Ser	Leu	Ser	Thr	Ser	Gly	Lys	Ser	Glu	Val	Arg	Asp	Leu
1025				1030					1035					1040	
Phe	Val	Ala	Glu	Arg	Gln	Phe	Ala	Lys	Glu	Gln	His	Thr	Asp	Gly	Thr
			1045					1050					1055		
Leu	Lys	Glu	Val	Gly	Glu	Asp	Tyr	Gln	Ile	Ala	Ile	Pro	Asp	Ser	His
		1060					1065					1070			
Leu	Pro	Val	Ser	Glu	Glu	Arg	Trp	Ala	Leu	Asp	Ala	Leu	Arg	Asn	Leu

1075	1080	1085
Gly Leu Leu Lys Gln Leu Leu Val Gln Gln Leu Gly Leu Thr Glu Lys 1090	1095	1100
Ser Val Gln Glu Asp Trp Gln His Phe Pro Arg Tyr Arg Thr Ala Ser 1105	1110	1115 1120
Gln Gly Pro Gln Thr Asp Ser Val Ile Gln Asn Ser Glu Asn Ile Lys 1125	1130	1135
Ala Tyr His Ser Gly Glu Gly His Met Pro Phe Arg Thr Gly Thr Gly 1140	1145	1150
Asp Ile Ala Thr Cys Tyr Ser Pro Arg Thr Ser Thr Glu Ser Phe Ala 1155	1160	1165
Pro Arg Asp Ser Val Gly Leu Ala Pro Gln Asp Ser Gln Ala Ser Asn 1170	1175	1180
Ile Leu Val Met Asp His Met Ile Met Thr Pro Glu Met Pro Thr Met 1185	1190	1195 1200
Glu Pro Glu Gly Gly Leu Asp Asp Ser Gly Glu His Phe Phe Asp Ala 1205	1210	1215
Arg Glu Ala His Ser Asp Glu Asn Pro Ser Glu Gly Asp Gly Ala Val 1220	1225	1230
Asn Lys Glu Glu Lys Asp Val Asn Leu Arg Ile Ser Gly Asn Tyr Leu 1235	1240	1245
Ile Leu Asp Gly Tyr Asp Pro Val Gln Glu Ser Ser Thr Asp Glu Glu 1250	1255	1260
Val Ala Ser Ser Leu Thr Leu Gln Pro Met Thr Gly Ile Pro Ala Val 1265	1270	1275 1280
Glu Ser Thr His Gln Gln Gln His Ser Pro Gln Asn Thr His Ser Asp 1285	1290	1295
Gly Ala Ile Ser Pro Phe Thr Pro Glu Phe Leu Val Gln Gln Arg Trp 1300	1305	1310
Gly Ala Met Glu Tyr Ser Cys Phe Glu Ile Gln Ser Pro Ser Ser Cys 1315	1320	1325
Ala Asp Ser Gln Ser Gln Ile Met Glu Tyr Ile His Lys Ile Glu Ala 1330	1335	1340
Asp Leu Glu His Leu Lys Glu Gly Gly Gly Lys Leu Thr Pro Phe Phe 1345	1350	1355 1360
Ala Lys Gly Trp Leu Asp Gln Pro Ser Gln Thr Ser Thr Gln Ile Lys 1365	1370	1375
Val Arg Ala Ala Cys Pro Gly Gly Asp Cys Arg Leu Leu Asp Leu Glu 1380	1385	1390
Tyr Arg Pro Cys Leu Thr Thr Ser Trp Leu Gln Cys Gly Cys Arg Glu		

1395 1400 1405
 Ser Val Thr Glu Asp Leu Pro Val Asn His Leu Gly Leu Val Lys Ser
 1410 1415 1420
 Gln Gly Ala Gln Ser Gly Thr Ser Xaa Ser Gln Cys Gly Ser Cys Thr
 1425 1430 1435 1440
 Asn Leu Phe Val Arg Glu Tyr Pro Phe Pro His Ser Thr Leu Leu Thr
 1445 1450 1455
 Ile Gly Asn Ser Phe
 1460

<210> 187
 <211> 2837
 <212> DNA
 <213> Homo sapiens

<400> 187
 tcttttgaca gatataattg ctgcttatca aagattctgt tctcgacccc caaaaggatt 60
 tgaaaaatac tttcctaattg gaaaaaatgg aaaaaagct agtgaaccta aagaagttat 120
 gggagagaaa aaagaatcaa agccagctgc taccacacgc tcttctggag gaggaggtgg 180
 tggcgggtgga aaacgaggtg gcaagaaaga tgattctcac tgggtgtcca ggtttcagaa 240
 ggggtgacatt ccatgggacg acaaggattt caggatgttc ttctcttga ctgctctgtt 300
 ctgggggtgga gtcattgttt acttgctgct caagagatcc gggagagaaa tcacttggaa 360
 ggactttgtc aataactatc ttcaaaaagg agtagtagac agattggaag tcgtcaacaa 420
 gcgttttgtt cgagtgcctt ttacaccagg aaaaactcct gttgatgggc aatacgtttg 480
 gtttaatatc ggcagtgtgg acacctttga acggaatctg gaaactttac agcaggaatt 540
 gggcatagaa ggagaaaatc ggggtgcctgt tgtctacatt gctgaaagtg atggctcttt 600
 tctgctgagc atgctgccta cggtgctcat catcgccctc ttgctctaca ccatcagaag 660
 agggcctgct ggcattggcc ggacaggccg agggatgggc ggactcttca gtgtcggaga 720
 aaccactgcc aaggtcttaa aggatgaaat tgatgtgaag ttcaaagatg tggctggctg 780
 tgaggaggcc aagctagaga tcatggaatt tgtgaatttc ttgaaaaacc caaagcagta 840
 tcaagaccta ggagcaataa tcccaaaggg tgccattctc actggctctc caggcactgg 900
 gaagacgctg ctagctaagg ccacagccgg agaagccaat gtcccccttca tcaccgctag 960
 tggatctgag tttttggaga tgttcgttgg tgtgggcccc gctagagtcc gagacttatt 1020
 tgcccttgct cggaagaatg ccccttgcat cctcttcac gatgaaatcg atgagggtgg 1080
 aaggaagaga ggaagaggca actttggagg gcagagttag caggagaaca cactcaacca 1140
 gctgctgggt gagatggatg gttttaatac aacaacaaat gtcgtcattt tggccggcac 1200
 caatcgacca ggaccaccag acataaaaagg aagagcttct attttcaaag ttcattctcc 1260
 accgctaaaa ctggacagta ccctggagaa ggataaattg gcaagaaaac tggcatcttt 1320
 aactccaggg ttttcagggt ctgatgttgc taatgtctgt aatgaagctg cgttgattgc 1380
 tgcaaggcat ctgtcagatt ccataaatca gaaacacttt gaacaggcaa ttgagcgagt 1440
 gattgggtggc ttaaagaaaa aaacgcaggt tctgcagccc gaggagaaaa agactgtggc 1500
 ataccacgaa gcaggccatg cggttgccgg ctggtatctg gagcacgcag acccgctttt 1560
 aaaggtatcc atcatcccac gtggcaaagg actagggttat gctcagtatt taccaaaaga 1620
 acaatacctc tataccaaag agcagctctt ggataggatg tgtatgactt taggtggctg 1680
 agtctctgaa gaaatcttct ttggaagaat tacaactggt gctcaagatg acttgagaaa 1740
 agtaactcag agtgcataatg cccaaattgt tcagtttggc atgaatgaaa aggttgggca 1800
 aatctccttt gacctcccac gtcaggggga catggtattg gagaaacctt acagtgaagc 1860
 cactgcaaga tcatagatg atgaagtacg aatacttatt aatgatgctt ataaaagaac 1920
 agtagctctt ctacagaaa agaaagctga cgtggagaag gttgctcttc tgttggtaga 1980
 aaaagaagta ttagataaga atgatatggt tgaacttttg ggcccagac catttgcgga 2040
 aaaatctacc tatgaagaat ttgtggaagg cactggcagc ttggatgagg acacctcact 2100
 tccagaaggc ctaaggact ggaacaagga gcgggaaaag gagaaagagg agccccggg 2160
 tgagaaagtt gccaaactaga ggcccagagg gaggccatct cagtctgtcc actgtggttt 2220
 cagctgggtg attatctcag ctgtggcttt cagaagaatg ggaatgctgc gctgatttta 2280
 gccagccact ggcccagctg aaatgatggg gaaaggagtc cttagtcctt tcagcctcag 2340

aggtcacagt ggggtggcagg tgactttccg gaggccttga gggaaatgca cactgtccca 2400
 tagcctcatt gggttcccag acgtgctgga aaggttgagc ccagagtggc cgaggctgga 2460
 ccctgtggca ccaagtgggg tcggctgacc gtgtggcagg gattgttgca mtggawtttt 2520
 ggcgtgtggg aagggatgct ttttttttgt cgcccayttt tcattcctgt ttttcctcag 2580
 ttcccckgkg cagatgggct gtgaaattaa attggagttt tgataagaac attttaattt 2640
 gacttaatat tttaaagatt gaatccagat cacttggttc tgttttaatt gaatgggttt 2700
 ttacaggagc tgtaacatam ttaaaaatat gaatgtatta tgtaaatatg gcttccttac 2760
 ataaaaaata aaatgtcaac actgtaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2820
 aaaaaaaaaa aaaaaaa 2837

<210> 188

<211> 686

<212> PRT

<213> Homo sapiens

<400> 188

Met Gly Glu Lys Lys Glu Ser Lys Pro Ala Ala Thr Thr Arg Ser Ser
 1 5 10 15

Gly Gly Gly Gly Gly Gly Gly Gly Lys Arg Gly Gly Lys Lys Asp Asp
 20 25 30

Ser His Trp Trp Ser Arg Phe Gln Lys Gly Asp Ile Pro Trp Asp Asp
 35 40 45

Lys Asp Phe Arg Met Phe Phe Leu Trp Thr Ala Leu Phe Trp Gly Gly
 50 55 60

Val Met Phe Tyr Leu Leu Leu Lys Arg Ser Gly Arg Glu Ile Thr Trp
 65 70 75 80

Lys Asp Phe Val Asn Asn Tyr Leu Ser Lys Gly Val Val Asp Arg Leu
 85 90 95

Glu Val Val Asn Lys Arg Phe Val Arg Val Thr Phe Thr Pro Gly Lys
 100 105 110

Thr Pro Val Asp Gly Gln Tyr Val Trp Phe Asn Ile Gly Ser Val Asp
 115 120 125

Thr Phe Glu Arg Asn Leu Glu Thr Leu Gln Gln Glu Leu Gly Ile Glu
 130 135 140

Gly Glu Asn Arg Val Pro Val Val Tyr Ile Ala Glu Ser Asp Gly Ser
 145 150 155 160

Phe Leu Leu Ser Met Leu Pro Thr Val Leu Ile Ile Ala Phe Leu Leu
 165 170 175

Tyr Thr Ile Arg Arg Gly Pro Ala Gly Ile Gly Arg Thr Gly Arg Gly
 180 185 190

Met Gly Gly Leu Phe Ser Val Gly Glu Thr Thr Ala Lys Val Leu Lys
 195 200 205

Asp Glu Ile Asp Val Lys Phe Lys Asp Val Ala Gly Cys Glu Glu Ala
 210 215 220

Lys Leu Glu Ile Met Glu Phe Val Asn Phe Leu Lys Asn Pro Lys Gln
 225 230 235 240

Tyr Gln Asp Leu Gly Ala Ile Ile Pro Lys Gly Ala Ile Leu Thr Gly
 245 250 255
 Pro Pro Gly Thr Gly Lys Thr Leu Leu Ala Lys Ala Thr Ala Gly Glu
 260 265 270
 Ala Asn Val Pro Phe Ile Thr Val Ser Gly Ser Glu Phe Leu Glu Met
 275 280 285
 Phe Val Gly Val Gly Pro Ala Arg Val Arg Asp Leu Phe Ala Leu Ala
 290 295 300
 Arg Lys Asn Ala Pro Cys Ile Leu Phe Ile Asp Glu Ile Asp Ala Val
 305 310 315 320
 Gly Arg Lys Arg Gly Arg Gly Asn Phe Gly Gly Gln Ser Glu Gln Glu
 325 330 335
 Asn Thr Leu Asn Gln Leu Leu Val Glu Met Asp Gly Phe Asn Thr Thr
 340 345 350
 Thr Asn Val Val Ile Leu Ala Gly Thr Asn Arg Pro Gly Pro Pro Asp
 355 360 365
 Ile Lys Gly Arg Ala Ser Ile Phe Lys Val His Leu Arg Pro Leu Lys
 370 375 380
 Leu Asp Ser Thr Leu Glu Lys Asp Lys Leu Ala Arg Lys Leu Ala Ser
 385 390 395 400
 Leu Thr Pro Gly Phe Ser Gly Ala Asp Val Ala Asn Val Cys Asn Glu
 405 410 415
 Ala Ala Leu Ile Ala Ala Arg His Leu Ser Asp Ser Ile Asn Gln Lys
 420 425 430
 His Phe Glu Gln Ala Ile Glu Arg Val Ile Gly Gly Leu Lys Lys Lys
 435 440 445
 Thr Gln Val Leu Gln Pro Glu Glu Lys Lys Thr Val Ala Tyr His Glu
 450 455 460
 Ala Gly His Ala Val Ala Gly Trp Tyr Leu Glu His Ala Asp Pro Leu
 465 470 475 480
 Leu Lys Val Ser Ile Ile Pro Arg Gly Lys Gly Leu Gly Tyr Ala Gln
 485 490 495
 Tyr Leu Pro Lys Glu Gln Tyr Leu Tyr Thr Lys Glu Gln Leu Leu Asp
 500 505 510
 Arg Met Cys Met Thr Leu Gly Gly Arg Val Ser Glu Glu Ile Phe Phe
 515 520 525
 Gly Arg Ile Thr Thr Gly Ala Gln Asp Asp Leu Arg Lys Val Thr Gln
 530 535 540
 Ser Ala Tyr Ala Gln Ile Val Gln Phe Gly Met Asn Glu Lys Val Gly
 545 550 555 560

Gln Ile Ser Phe Asp Leu Pro Arg Gln Gly Asp Met Val Leu Glu Lys
565 570 575

Pro Tyr Ser Glu Ala Thr Ala Arg Leu Ile Asp Asp Glu Val Arg Ile
580 585 590

Leu Ile Asn Asp Ala Tyr Lys Arg Thr Val Ala Leu Leu Thr Glu Lys
595 600 605

Lys Ala Asp Val Glu Lys Val Ala Leu Leu Leu Leu Glu Lys Glu Val
610 615 620

Leu Asp Lys Asn Asp Met Val Glu Leu Leu Gly Pro Arg Pro Phe Ala
625 630 635 640

Glu Lys Ser Thr Tyr Glu Glu Phe Val Glu Gly Thr Gly Ser Leu Asp
645 650 655

Glu Asp Thr Ser Leu Pro Glu Gly Leu Lys Asp Trp Asn Lys Glu Arg
660 665 670

Glu Lys Glu Lys Glu Glu Pro Pro Gly Glu Lys Val Ala Asn
675 680 685

<210> 189

<211> 627

<212> DNA

<213> Homo sapiens

<400> 189

gattggagtt cttttcttaa atatccaaat aagattatag ctatgttttt accaaatggt 60
tgtgcggtaa atagagagt gatggaaatt aaccctagaa aggatagtg taacttttaa 120
aaagttgatt aactatttcg tgtgctaatt tgagtttttc tgaatactcc aatatgggtt 180
cctttaacac ctgctctcag tttaacaatca cctaacttcc cagcgttggt gtctttttct 240
ctgtctgacc ctgtcttatt tctcctacaa agacatatcc tgcgctgtac ttcagatact 300
tttttcgagg aacatttgtg atttgtggca taaagtaact gtctaaagga aatcttctga 360
gaggatctgg tcattttatg aaaggggcaa ttaaggggaa atggaagcag atctttttaa 420
gaaggagcat ttgaaattag cccaggaatc atgtccggcg agtcctgctc ttttgtacct 480
gggcataata gtcagccaca cagagctaga gttagttcaa gaattgtctt tcctgatcgt 540
gctatatttt tggaaacacg ttagatacag aggtaagatg tcaaaattct gaaatacaca 600
caatatagga tcaaaaaaaaa aaaaaaa 627

<210> 190

<211> 63

<212> PRT

<213> Homo sapiens

<400> 190

Met Glu Ala Asp Leu Leu Lys Lys Glu His Leu Lys Leu Ala Gln Glu
1 5 10 15

Ser Cys Pro Ala Ser Pro Ala Leu Leu Tyr Leu Gly Ile Ile Val Ser
20 25 30

His Thr Glu Leu Glu Leu Val Gln Glu Leu Ser Phe Leu Ile Val Leu
35 40 45

Tyr Phe Trp Lys His Val Arg Tyr Arg Gly Lys Met Ser Lys Phe

50

55

60

<210> 191
 <211> 868
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (733)

<400> 191
 attctgtccc tgccttaga aaacctaata taccaagggt gtcattgttg caactccctg 60
 cccagtcctg cacaagcct tggctgtgtg tggcaccctt tgcctcctac cccagagcag 120
 ctggctccat tggcttctcc ctgcaccagc cctgtcctca ggggtcagga aaaagcacac 180
 agctttcttt cctctcctcc agaggcctgg aaggagggtg gaggtccagt aagggcctgg 240
 ctgccttgga tttcttggtc ctgccttgcc aactgcaccc tgtagctcct gctccctgtg 300
 accccagaac agagggtgctg ccttccctgt ctcttagaca aagcacaag ggatgccctg 360
 cttggcttga gcctgcccac ctgaaggatt ttctctgccc caggacctt ccatccctga 420
 atacaaggct ctaggcaact tctctctggg tggtagacac tagaatgctt ggcattagcc 480
 ctagaaagga gggtggggtg tatgggtagt gagctagggt gggagaaagg tgggtgctgaa 540
 aggacagatg ctagttgtag ttctactcac tcattcattc attagtcaa cagtactgag 600
 caccacctgc actagaggca gagggtgtaa caagataccc ttttgcttgg ggggacgtcc 660
 acttcccatg gggttggtta ttccaggaa agccctcag tcctcctccc tgttctggct 720
 gtgtgtgaag gangtgtgtg agcaggccca atcctttgca gcaagaatga gaggtcagag 780
 tattccattg cacacgcacc ctggggctga cagacttgtg ccccttagcc ttcattgcatg 840
 cccaagcact ggcagctttg cagccctt 868

<210> 192
 <211> 107
 <212> PRT
 <213> Homo sapiens

<220>
 <221> UNSURE
 <222> (62)

<400> 192
 Met Leu Val Val Val Ser Leu Thr His Ser Phe Ile Ser Ala Thr Val
 1 5 10 15
 Leu Ser Thr Thr Cys Thr Arg Gly Arg Gly Val Asn Lys Ile Pro Phe
 20 25 30
 Cys Leu Gly Gly Arg Pro Leu Pro Met Gly Leu Ala Ile Ser Arg Lys
 35 40 45
 Ala Pro Gln Ser Ser Ser Leu Phe Trp Leu Cys Val Lys Xaa Val Cys
 50 55 60
 Glu Gln Ala Gln Ser Phe Ala Ala Arg Met Arg Gly Gln Ser Ile Pro
 65 70 75 80
 Leu His Thr His Pro Gly Ala Asp Arg Leu Val Pro Pro Ser Leu His
 85 90 95
 Ala Cys Pro Ser Thr Gly Ser Phe Ala Ala Pro
 100 105

<210> 193
 <211> 467
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (57)

<220>
 <221> unsure
 <222> (254)

<400> 193
 tggctatccc tagaagcact tcatccatct taaccacccc aaacgggac ccttcanatc 60
 tcatacccag taagatgcaa gaaaggaata tttgagagca agcagccctg ttccaggggc 120
 cccaggtatg tgtagaggcc cagtgggggt ggccacttgg tgtttctacc accccctgcc 180
 atccagtctg gccaggtacc tacctgggag gttggtgtac ttggcttaag tacttcatgc 240
 tttattcagg ctgnttcccc acagcaccgg caggaaatga aggtgcactt atatgcatcc 300
 ctgcaggaat aaagagtggg tggcctgccc agcccagcac cacagccttt ccccagccag 360
 gagagaccac ctaaggatca aggcagctcc tgttttcttg gttctgtgac actcgagtct 420
 gagccagccc ctgaggaatt gcctcaaaaag agaaaaaaaa aaaaaaa 467

<210> 194
 <211> 1035
 <212> DNA
 <213> Homo sapiens

<400> 194
 aatctttttg ttgtcaagct tgagggtgtg caggcttgag atctggccat acacttgagt 60
 gacaatgaca tccactttgc ctttctctcc acagggtgtcc actcccagggt ccaactgcag 120
 acttcgaatt cggccttcat ggcctagatg attgcaagtc aatggaagga gctgcagagg 180
 caaatcaaac ggcagcacag ctggattctc agggctcttg ataccatcaa agccgagata 240
 ctggctactg atgtgtctgt ggaggatgag gaagggactg gaagcccaa ggctgaggtt 300
 caactatgct acctggaagc acaaagagat gctgttgagc agatgtccct caagctgtrc 360
 agcgagcagt ataccagcag cagcaagcga aaggaagagt ttgctgatat gtcaaaagtt 420
 tcattcagtg ggaagcaatg ggcttctgga ctttgattca gaatatcmgg agctctggga 480
 ttggctgatt gacatggagt cccttgatgac ggacagccac gacctgatga tgtcagagga 540
 gcagcagcag catctttaca agcgatacag tgtggaaatg tccatcagac acctgaaaaa 600
 gacggagctg cttagtaagg ttgaagcttt gaagaaagggt ggcgttttac taccaaatga 660
 tctccttgaa aaagtggatt caattaatga aaaatgggaa ctrcttgggg tattttgcatt 720
 tttattactg tttgtagggt atgtgtacat tttttgcgta gtgaagtact ctgtccgatt 780
 tctaatttga ggcacaaata tctctctctt tcaattcact acctacgttt caaacaagct 840
 attcatgcta ttatgggaaa gacactgctt ttctctctct gttgattttt tttttttctg 900
 agcttgtccc ctctcagatt ttaataattt tggttcttta atacatgaaa aagtaagtaa 960
 aatatgccat gtattatggg tatgcaccaa gtcaactata atacagtata tctgatatat 1020
 aaaaaaaaaa aaaaa 1035

<210> 195
 <211> 179
 <212> PRT
 <213> Homo sapiens

<220>
 <221> UNSURE
 <222> (37)

<220>
 <221> UNSURE

<222> (73)

<400> 195

Met Cys Leu Trp Arg Met Arg Lys Gly Leu Glu Ala Pro Arg Leu Arg
 1 5 10 15

Phe Asn Tyr Ala Thr Trp Lys His Lys Glu Met Leu Leu Ser Arg Cys
 20 25 30

Pro Ser Ser Cys Xaa Ala Ser Ser Ile Pro Ala Ala Ala Ser Glu Arg
 35 40 45

Lys Ser Leu Leu Ile Cys Gln Lys Phe His Ser Val Gly Ser Asn Gly
 50 55 60

Leu Leu Asp Phe Asp Ser Glu Tyr Xaa Glu Leu Trp Asp Trp Leu Ile
 65 70 75 80

Asp Met Glu Ser Leu Val Met Asp Ser His Asp Leu Met Met Ser Glu
 85 90 95

Glu Gln Gln Gln His Leu Tyr Lys Arg Tyr Ser Val Glu Met Ser Ile
 100 105 110

Arg His Leu Lys Lys Thr Glu Leu Leu Ser Lys Val Glu Ala Leu Lys
 115 120 125

Lys Gly Gly Val Leu Leu Pro Asn Asp Leu Leu Glu Lys Val Asp Ser
 130 135 140

Ile Asn Glu Lys Trp Glu Leu Leu Gly Val Phe Ala Phe Leu Leu Leu
 145 150 155 160

Phe Val Gly Tyr Val Tyr Ile Phe Cys Val Val Lys Tyr Ser Val Arg
 165 170 175

Phe Leu Ile

<210> 196

<211> 3831

<212> DNA

<213> Homo sapiens

<400> 196

gcagcagggtc aaacaaggca tctcctagta ttgcatecta cagatgtgct gtaaacaatca 60
 aaagaagacg gtgggatcag gagatgctgt tttggaaaga agtgagggtt agacttctcc 120
 atgttaacca tgagcgtgac actttccccc ctgagggtcac aggacctgga tcccatggct 180
 actgatgctt caccatggc catcaacatg acaccactg tggagcaggg tgagggagaa 240
 gaggcaatga aggacatgga ctctgaccag cagtatgaaa agccaccccc actacacaca 300
 ggggctgact ggaagattgt cctccactta cctgaaattg agacctggct ccggatgacc 360
 tcagagaggg tccgagacct aacctattca gtccagcagg attcggacag caagcatgtg 420
 gatgtacatc tagttcaact aaaggacatt tgtgaagata tttctgatca tgttgagcaa 480
 atccatgcc tcttgaaac agagttctcc cttaaagctgc tgtcttactc tgtcaacgtg 540
 atagtggaca tccacgcagt gcagctcctc tggcaccagc ttcgagtctc agtactgggt 600
 ctgcgggagc gcattctgca aggtctgcag gacgccaatg gcaactacac taggcagacg 660
 gacattctgc aagctttctc tgaagagaca aaagagggcc ggcttgattc tctaacagaa 720
 gtggatgact caggacaatt aaccatcaaa tgtttctcaa attacttgtc tctggattgt 780
 ggcattactg cattcgaact gtctgactac agtccaagtg aggatttgct cagtgggcta 840

```

ggtgacatga cctctagcca agtcaaaacc aaaccctttg actcttggag ctacagttag 900
atggaaaagg agtttcctga gcttatccga agtggtggtt tacttacggg agctgctgac 960
tctatctcta ccaatggcag tgaagcagtt actgaggagg tatctcaagt atctctctca 1020
gtagacgaca aaggtggatg tgaggaagac aatgcttctg cagtcgaaga gcaaccaggc 1080
ttaacactgg ggggtgtcatc atcttcagga gaagctctga caaatgctgc tcaacctcc 1140
tctgagactg tgcagcaaga atccagttcc tcctcccatc atgatgcaa gaatcagcag 1200
cctgttcctt gtgaaaatgc aacccccaaa cgaaccatca gagattgctt taattataac 1260
gaggactctc ccacacagcc tacattgcca aaaagaggac tttttcttaa agaggaaact 1320
tttaagaatg atctgaaagg caatgggtga aagaggcaaa tgggtgatct aaagcctgag 1380
atgagcagaa gcaccccttc gctagtagat cctcctgaca gatccaaact ttgcctggta 1440
ttgcagtctt cttaccccaa cagcccttct gctgccagcc agtcttatga gtgtttacac 1500
aaggtgggga atgggaacct tgaaaacaca gtcaaatttc acattaaaga aatttcttcc 1560
agcctgggaa ggcttaacga ctgctataaa gagaaatctc gacttaaaaa gccacacaag 1620
acctcagaag aggtgcctcc atgccgaaca cctaaacggg ggactgggtc aggcaaacaa 1680
gctaaaaata caaagagctc agcagtgcc aatggagagc tttcttatac ttccaaggcc 1740
atagaggggc cacaacaaaa ttctgcttcc acatcctcac ttgagccttg taatcagaga 1800
agtttgaatg ccaaattgca attgcagtca gaaacatcca gtaccacagc ttttactcag 1860
agcagtgaat cctctgttgg ctcagacaac atcatgtctc cgggtgccact tctttcaaaa 1920
cacaaaagca aaaaaggcca agcctcctct ccaagtcacg tcactaggaa tgggtgaggtt 1980
gtggaggcct ggtatggctc tgatgaatac ctagcactgc cctctcacct taagcagaca 2040
gaagtattgg ctttgaagtt ggaaaacctc acaaagcttc tgcctcagaa acccagagga 2100
gaaaccatcc agaattattga tgactgggaa ctgtctgaaa tgaattcaga ttctgaaatc 2160
tatccaacct atcatgtcaa aaagaagcat acaaggctag gcaggggtgc tccaagctca 2220
tctagtgaac tagcctcttc actaggggag agcattgaat ctggggccct gagtgacatt 2280
ctttctgatg aggagtccag tatgcctctc gctggcatga aaaagtatgc tgatgagaag 2340
tcagaaagag cttcatcctc tgagaaaaat gagagccatt ctgccactaa atcagcttta 2400
attcagaaac tgatgcaaga tattcagcac caagacaact atgaagccat atgggaaaaa 2460
atagaggggt ttgtaaacaa actggatgaa ttcattcaat gggtaaatga agccatggaa 2520
actacagaga attggactcc ccctaaagca gagatggatg accttaaact gtatctggag 2580
acacacttga gttttaagtt gaatgtagac agtcattgtg ctctcaagga agctgtggag 2640
gaggaaggac accaacttct tgagcttatt gcattctaca aagcaggact gaaggacatg 2700
ctgcggatga ttgcaagtca atggaaggag ctgcagaggc aaatcaaacg gcagcacagc 2760
tggtattctca gggctctgga taccatcaaa gccgagatac tggctactga tgtgtctgtg 2820
gaggatgagg aagggactgg aagccccaag gctgagggtc aactatgcta cctggaagca 2880
caaagagatg ctgttgagca gatgtccctc aagctgtaca gcgagcagta taccagcagc 2940
agcaagcgaa aggaagagtt tgctgatatg tcaaaaagttc attcagtggg aagcaatggg 3000
cttctggact ttgattcaga atatcaggag ctctgggatt ggctgattga catggagtcc 3060
cttgtgatgg acagccacga cctgatgatg tcagaggagc agcagcagca tctttacaag 3120
cgatacagtg tggaaatgtc catcagacac ctgaaaaaga cggagctgct tagtaagggt 3180
gaagctttga agaaagggtg cgttttacta ccaaagatc tccttgaaaa agtggattca 3240
attaatgaaa aatgggaact gcttggggta tttgcatttt tattactgtt tgtaggttat 3300
gtgtacattt tttgcgtagt gaagtactct gtccgatttc taatttgagg cacaaatatc 3360
tctctcttct aattcactac ctacgtttca aacaagctat tcatgctatt atgggaaaga 3420
cactgctttt cctcttctgt tgattttttt tttttctgag cttgtccctt ctcagatttt 3480
aataattttg gttctttaat acatgaaaaa gtaagtaaaa tatgccatgt attatgggta 3540
tgcaccaagt caactataat acagtataat tgatatatac tgactgtcat gcttgaatga 3600
atgttaatag aatttattct gaaggtacat gtgagagaca tctactgttt aactattttac 3660
tgtaccctta agatgaaaag tggagttgtc actacagctt tcaagtcaca ctaaagccac 3720
caaaacaaag atgcaaatct gacccaaatc tgaattgcag aattgaatca gcctgtgttt 3780
tgtgcctcaa tttccagctc acttttaaca aaagccaaaa aaaaaaaaaa a 3831

```

<210> 197

<211> 1075

<212> PRT

<213> Homo sapiens

<400> 197

Met Leu Thr Met Ser Val Thr Leu Ser Pro Leu Arg Ser Gln Asp Leu

1

5

10

15

Asp Pro Met Ala Thr Asp Ala Ser Pro Met Ala Ile Asn Met Thr Pro
 20 25 30
 Thr Val Glu Gln Gly Glu Gly Glu Glu Ala Met Lys Asp Met Asp Ser
 35 40 45
 Asp Gln Gln Tyr Glu Lys Pro Pro Pro Leu His Thr Gly Ala Asp Trp
 50 55 60
 Lys Ile Val Leu His Leu Pro Glu Ile Glu Thr Trp Leu Arg Met Thr
 65 70 75 80
 Ser Glu Arg Val Arg Asp Leu Thr Tyr Ser Val Gln Gln Asp Ser Asp
 85 90 95
 Ser Lys His Val Asp Val His Leu Val Gln Leu Lys Asp Ile Cys Glu
 100 105 110
 Asp Ile Ser Asp His Val Glu Gln Ile His Ala Leu Leu Glu Thr Glu
 115 120 125
 Phe Ser Leu Lys Leu Leu Ser Tyr Ser Val Asn Val Ile Val Asp Ile
 130 135 140
 His Ala Val Gln Leu Leu Trp His Gln Leu Arg Val Ser Val Leu Val
 145 150 155 160
 Leu Arg Glu Arg Ile Leu Gln Gly Leu Gln Asp Ala Asn Gly Asn Tyr
 165 170 175
 Thr Arg Gln Thr Asp Ile Leu Gln Ala Phe Ser Glu Glu Thr Lys Glu
 180 185 190
 Gly Arg Leu Asp Ser Leu Thr Glu Val Asp Asp Ser Gly Gln Leu Thr
 195 200 205
 Ile Lys Cys Ser Gln Asn Tyr Leu Ser Leu Asp Cys Gly Ile Thr Ala
 210 215 220
 Phe Glu Leu Ser Asp Tyr Ser Pro Ser Glu Asp Leu Leu Ser Gly Leu
 225 230 235 240
 Gly Asp Met Thr Ser Ser Gln Val Lys Thr Lys Pro Phe Asp Ser Trp
 245 250 255
 Ser Tyr Ser Glu Met Glu Lys Glu Phe Pro Glu Leu Ile Arg Ser Val
 260 265 270
 Gly Leu Leu Thr Val Ala Ala Asp Ser Ile Ser Thr Asn Gly Ser Glu
 275 280 285
 Ala Val Thr Glu Glu Val Ser Gln Val Ser Leu Ser Val Asp Asp Lys
 290 295 300
 Gly Gly Cys Glu Glu Asp Asn Ala Ser Ala Val Glu Glu Gln Pro Gly
 305 310 315 320
 Leu Thr Leu Gly Val Ser Ser Ser Ser Gly Glu Ala Leu Thr Asn Ala
 325 330 335

Ala Gln Pro Ser Ser Glu Thr Val Gln Gln Glu Ser Ser Ser Ser Ser
 340 345 350
 His His Asp Ala Lys Asn Gln Gln Pro Val Pro Cys Glu Asn Ala Thr
 355 360 365
 Pro Lys Arg Thr Ile Arg Asp Cys Phe Asn Tyr Asn Glu Asp Ser Pro
 370 375 380
 Thr Gln Pro Thr Leu Pro Lys Arg Gly Leu Phe Leu Lys Glu Glu Thr
 385 390 395 400
 Phe Lys Asn Asp Leu Lys Gly Asn Gly Gly Lys Arg Gln Met Val Asp
 405 410 415
 Leu Lys Pro Glu Met Ser Arg Ser Thr Pro Ser Leu Val Asp Pro Pro
 420 425 430
 Asp Arg Ser Lys Leu Cys Leu Val Leu Gln Ser Ser Tyr Pro Asn Ser
 435 440 445
 Pro Ser Ala Ala Ser Gln Ser Tyr Glu Cys Leu His Lys Val Gly Asn
 450 455 460
 Gly Asn Leu Glu Asn Thr Val Lys Phe His Ile Lys Glu Ile Ser Ser
 465 470 475 480
 Ser Leu Gly Arg Leu Asn Asp Cys Tyr Lys Glu Lys Ser Arg Leu Lys
 485 490 495
 Lys Pro His Lys Thr Ser Glu Glu Val Pro Pro Cys Arg Thr Pro Lys
 500 505 510
 Arg Gly Thr Gly Ser Gly Lys Gln Ala Lys Asn Thr Lys Ser Ser Ala
 515 520 525
 Val Pro Asn Gly Glu Leu Ser Tyr Thr Ser Lys Ala Ile Glu Gly Pro
 530 535 540
 Gln Thr Asn Ser Ala Ser Thr Ser Ser Leu Glu Pro Cys Asn Gln Arg
 545 550 555 560
 Ser Trp Asn Ala Lys Leu Gln Leu Gln Ser Glu Thr Ser Ser Ser Pro
 565 570 575
 Ala Phe Thr Gln Ser Ser Glu Ser Ser Val Gly Ser Asp Asn Ile Met
 580 585 590
 Ser Pro Val Pro Leu Leu Ser Lys His Lys Ser Lys Lys Gly Gln Ala
 595 600 605
 Ser Ser Pro Ser His Val Thr Arg Asn Gly Glu Val Val Glu Ala Trp
 610 615 620
 Tyr Gly Ser Asp Glu Tyr Leu Ala Leu Pro Ser His Leu Lys Gln Thr
 625 630 635 640
 Glu Val Leu Ala Leu Lys Leu Glu Asn Leu Thr Lys Leu Leu Pro Gln
 645 650 655

Lys Pro Arg Gly Glu Thr Ile Gln Asn Ile Asp Asp Trp Glu Leu Ser
 660 665 670
 Glu Met Asn Ser Asp Ser Glu Ile Tyr Pro Thr Tyr His Val Lys Lys
 675 680 685
 Lys His Thr Arg Leu Gly Arg Val Ser Pro Ser Ser Ser Asp Ile
 690 695 700
 Ala Ser Ser Leu Gly Glu Ser Ile Glu Ser Gly Pro Leu Ser Asp Ile
 705 710 715 720
 Leu Ser Asp Glu Glu Ser Ser Met Pro Leu Ala Gly Met Lys Lys Tyr
 725 730 735
 Ala Asp Glu Lys Ser Glu Arg Ala Ser Ser Ser Glu Lys Asn Glu Ser
 740 745 750
 His Ser Ala Thr Lys Ser Ala Leu Ile Gln Lys Leu Met Gln Asp Ile
 755 760 765
 Gln His Gln Asp Asn Tyr Glu Ala Ile Trp Glu Lys Ile Glu Gly Phe
 770 775 780
 Val Asn Lys Leu Asp Glu Phe Ile Gln Trp Leu Asn Glu Ala Met Glu
 785 790 795 800
 Thr Thr Glu Asn Trp Thr Pro Pro Lys Ala Glu Met Asp Asp Leu Lys
 805 810 815
 Leu Tyr Leu Glu Thr His Leu Ser Phe Lys Leu Asn Val Asp Ser His
 820 825 830
 Cys Ala Leu Lys Glu Ala Val Glu Glu Glu Gly His Gln Leu Leu Glu
 835 840 845
 Leu Ile Ala Ser His Lys Ala Gly Leu Lys Asp Met Leu Arg Met Ile
 850 855 860
 Ala Ser Gln Trp Lys Glu Leu Gln Arg Gln Ile Lys Arg Gln His Ser
 865 870 875 880
 Trp Ile Leu Arg Ala Leu Asp Thr Ile Lys Ala Glu Ile Leu Ala Thr
 885 890 895
 Asp Val Ser Val Glu Asp Glu Glu Gly Thr Gly Ser Pro Lys Ala Glu
 900 905 910
 Val Gln Leu Cys Tyr Leu Glu Ala Gln Arg Asp Ala Val Glu Gln Met
 915 920 925
 Ser Leu Lys Leu Tyr Ser Glu Gln Tyr Thr Ser Ser Ser Lys Arg Lys
 930 935 940
 Glu Glu Phe Ala Asp Met Ser Lys Val His Ser Val Gly Ser Asn Gly
 945 950 955 960
 Leu Leu Asp Phe Asp Ser Glu Tyr Gln Glu Leu Trp Asp Trp Leu Ile
 965 970 975

Asp Met Glu Ser Leu Val Met Asp Ser His Asp Leu Met Met Ser Glu
 980 985 990

Glu Gln Gln Gln His Leu Tyr Lys Arg Tyr Ser Val Glu Met Ser Ile
 995 1000 1005

Arg His Leu Lys Lys Thr Glu Leu Leu Ser Lys Val Glu Ala Leu Lys
 1010 1015 1020

Lys Gly Gly Val Leu Leu Pro Asn Asp Leu Leu Glu Lys Val Asp Ser
 1025 1030 1035 1040

Ile Asn Glu Lys Trp Glu Leu Leu Gly Val Phe Ala Phe Leu Leu Leu
 1045 1050 1055

Phe Val Gly Tyr Val Tyr Ile Phe Cys Val Val Lys Tyr Ser Val Arg
 1060 1065 1070

Phe Leu Ile
 1075

<210> 198

<211> 3113

<212> DNA

<213> Homo sapiens

<400> 198

```

gcaaacacat tgaagtacag gtagcccagg aaactagaaa tgtatctact ggctctgctg 60
aaaatgaaga aaagtcagaa gttcaagcaa tcatcgaatc tactcctgag ctggatatgg 120
acaaagatct cagtggatat aaaggttcaa gcactccac caaaggcata gagaacaaag 180
cttttgatcg caatacagaa tctctctttg aagaactgtc ttcagctggc tcaggcctaa 240
taggagatgt ggatgaagga gcagatttac taggaatggg tcgggaagtt gagaatctta 300
tattagaaaa tacacaactg ttggaaacca aaaatgcttt gaacatagtg aagaatgatt 360
tgatagcaaa agtggatgaa ctgacctgtg agaaagatgt gctgcaaggg gaattggagg 420
ctgtgaagca agccaaactg aaactagagg aaaagaacag agaattggag gaagagctta 480
ggaaagctcg ggcagaagct gaagatgcag ggcaaaaagc aaaagatgac gatgatagtg 540
atattccac agcccagagg aaacgggtta ctagagtaga aatggcccggt gttctcatgg 600
agcgaaacca gtataaagag agattgatgg agcttcagga agctgttcga tggacagaga 660
tgattcgggc atcacgagaa aatccagcca tgcaggaaaa aaaaagggtca agcatttggtc 720
agtttttcag ccgacttttc agctcctcaa gtaacacgac taagaagcct gaaccacctg 780
ttaatctgaa gtacaatgca cccacgtctc atgttactcc gtccgtcaag aaaagaagca 840
gcaccttate tcagctcctt ggggataagt ccaaagcctt tgatttcctt agtgaagaaa 900
ctgaagctag tttagcctca cgcagagaac aaaagagaga gcagtatcgt caggtaaaag 960
cacatgttca gaaggaagac ggtagagtgc aggccttttg ctggagtctg cctcagaagt 1020
acaaacaggt aaccaatggt caagggtgaaa ataagatgaa aaatttacct gtgcctgtct 1080
atctcagacc tctggatgaa aaagatacat caatgaagct gtggtgtgct gttggagtca 1140
atctatctgg tgggaagacc agagatggtg gttctgttgt tggagcaagt gtattttaca 1200
aggatgttgc tggtttgat acagaaggca gtaaacagcg aagtgcctct cagagtagtt 1260
tagataagtt agatcaggaa cttaaggaac agcagaagga gttaaaaaat caagaagaat 1320
tatccagtct agtttggtac tgtaccagca ctcatcggc tacaaaagtt cttattattg 1380
atgctgttca acctggcaac atcctagaca gtttctactgt ttgcaactct catgttctgt 1440
gcattgcaag tgtgccaggt gcacgagaaa cagactaccc tgcaggagaa gatctttcag 1500
aatctggtca ggtagacaaa gcatctttat gtggaagtat gacaagcaac agctcagcag 1560
agacagacag cctgttagga ggcatacag tggttggttg ttctgcagaa ggtgtgacgg 1620
gagctgccac tccccctagt acaaatggtg cttctccagt gatggataaa ccaccagaaa 1680
tggaagcaga aaatagttag gttgatgaa atgttccaac agcagaagaa gcaactgaag 1740
ctacagaagg gaatgcgggg tcagctgaag acacagtgga catctcccaa actggcgtct 1800
acacagagca tgtctttaca gatccttttg gagttcagat cccagaagac ctctccccag 1860
tgtatcagtc gagcaatgac tcagatgcat ataaagatca aatatcagta ctgccaaatg 1920

```

```

aacaagactt ggtgagagaa gaagcccaga aaatgagtag tcttttacca actatgtggc 1980
ttggagctca aaatggctgt ttgtatgtcc attcatctgt agcccagtgaggaggaaatgtc 2040
tccattccat taaacttaaa gattcgattc tcagtattgt acacgtgaag ggaatcgtgt 2100
tagtagccct ggctgacggc acccttgcaa tctttcacag aggagtggat gggcagtgagg 2160
atttgtcaaa ctatcacctc ttagaccttg gacggcctca tcattccatc cgttgcatga 2220
ctgtggtaca tgacaaagtc tgggtgtggc ataggaacaa aatctatgtg gtgcagccaa 2280
aggccatgaa aatagagaaa tcttttgatg cacatcccag gaaggagagc caagtgcgac 2340
agcttgctgt ggtgggggat ggcgtgtggg tctccattcg cttggattct acgctccgtc 2400
tctatcatgc acacacttat caacatctac aggatgtgga cattgagcct tatgtaagca 2460
aaatgttagg tactggaaaa ctgggcttct cttttgtgag aattacagct cttatggtgt 2520
cttgtaatcg tttgtgggtg gggacaggaa atgggtgtcat tatctccatc ccattgacag 2580
aaagtaagta tatttttaga taactgccat ggaacaaata ggagaattat aggaaatagt 2640
tatgtctgaa attcaaactc gtgttagctc aagaaaatca gtgatggcaa agatctagct 2700
atagttaact tcaactcaat gaaacttata aattctagga aaataagttt tcatgtatca 2760
agaccaatac tcataattaa aagtttttcg ttgtcaaaac attttcacag ttcaggaatc 2820
acagtcctat ttcattctttt gaaataaaaag ttaaagtcca tttttcttaa gccttattat 2880
accattatcc aaaaacacta cctagcattc atcttagttt ttcatatctc cttagcagat 2940
agtttagtat attccatttg tcttatttga ggtttaaaaa aagttgtgga agaagttctt 3000
caggagttca gcaagccttt ccatctatct tctattttta aagaatgtga tttattgttt 3060
ttatgaataa aatatacctc gtgtgtttct caaaaaaaa aaaaaaaaaa aaa 3113

```

<210> 199

<211> 828

<212> PRT

<213> Homo sapiens

<400> 199

```

Met Asp Lys Asp Leu Ser Gly Tyr Lys Gly Ser Ser Thr Pro Thr Lys
 1             5             10             15

Gly Ile Glu Asn Lys Ala Phe Asp Arg Asn Thr Glu Ser Leu Phe Glu
      20             25             30

Glu Leu Ser Ser Ala Gly Ser Gly Leu Ile Gly Asp Val Asp Glu Gly
      35             40             45

Ala Asp Leu Leu Gly Met Gly Arg Glu Val Glu Asn Leu Ile Leu Glu
      50             55             60

Asn Thr Gln Leu Leu Glu Thr Lys Asn Ala Leu Asn Ile Val Lys Asn
      65             70             75             80

Asp Leu Ile Ala Lys Val Asp Glu Leu Thr Cys Glu Lys Asp Val Leu
      85             90             95

Gln Gly Glu Leu Glu Ala Val Lys Gln Ala Lys Leu Lys Leu Glu Glu
      100             105             110

Lys Asn Arg Glu Leu Glu Glu Glu Leu Arg Lys Ala Arg Ala Glu Ala
      115             120             125

Glu Asp Ala Gly Gln Lys Ala Lys Asp Asp Asp Asp Ser Asp Ile Pro
      130             135             140

Thr Ala Gln Arg Lys Arg Phe Thr Arg Val Glu Met Ala Arg Val Leu
      145             150             155             160

Met Glu Arg Asn Gln Tyr Lys Glu Arg Leu Met Glu Leu Gln Glu Ala
      165             170             175

```

Val Arg Trp Thr Glu Met Ile Arg Ala Ser Arg Glu Asn Pro Ala Met
 180 185 190
 Gln Glu Lys Lys Arg Ser Ser Ile Trp Gln Phe Phe Ser Arg Leu Phe
 195 200 205
 Ser Ser Ser Ser Asn Thr Thr Lys Lys Pro Glu Pro Pro Val Asn Leu
 210 215 220
 Lys Tyr Asn Ala Pro Thr Ser His Val Thr Pro Ser Val Lys Lys Arg
 225 230 235 240
 Ser Ser Thr Leu Ser Gln Leu Pro Gly Asp Lys Ser Lys Ala Phe Asp
 245 250 255
 Phe Leu Ser Glu Glu Thr Glu Ala Ser Leu Ala Ser Arg Arg Glu Gln
 260 265 270
 Lys Arg Glu Gln Tyr Arg Gln Val Lys Ala His Val Gln Lys Glu Asp
 275 280 285
 Gly Arg Val Gln Ala Phe Gly Trp Ser Leu Pro Gln Lys Tyr Lys Gln
 290 295 300
 Val Thr Asn Gly Gln Gly Glu Asn Lys Met Lys Asn Leu Pro Val Pro
 305 310 315 320
 Val Tyr Leu Arg Pro Leu Asp Glu Lys Asp Thr Ser Met Lys Leu Trp
 325 330 335
 Cys Ala Val Gly Val Asn Leu Ser Gly Gly Lys Thr Arg Asp Gly Gly
 340 345 350
 Ser Val Val Gly Ala Ser Val Phe Tyr Lys Asp Val Ala Gly Leu Asp
 355 360 365
 Thr Glu Gly Ser Lys Gln Arg Ser Ala Ser Gln Ser Ser Leu Asp Lys
 370 375 380
 Leu Asp Gln Glu Leu Lys Glu Gln Gln Lys Glu Leu Lys Asn Gln Glu
 385 390 395 400
 Glu Leu Ser Ser Leu Val Trp Ile Cys Thr Ser Thr His Ser Ala Thr
 405 410 415
 Lys Val Leu Ile Ile Asp Ala Val Gln Pro Gly Asn Ile Leu Asp Ser
 420 425 430
 Phe Thr Val Cys Asn Ser His Val Leu Cys Ile Ala Ser Val Pro Gly
 435 440 445
 Ala Arg Glu Thr Asp Tyr Pro Ala Gly Glu Asp Leu Ser Glu Ser Gly
 450 455 460
 Gln Val Asp Lys Ala Ser Leu Cys Gly Ser Met Thr Ser Asn Ser Ser
 465 470 475 480
 Ala Glu Thr Asp Ser Leu Leu Gly Gly Ile Thr Val Val Gly Cys Ser
 485 490 495

Ala Glu Gly Val Thr Gly Ala Ala Thr Ser Pro Ser Thr Asn Gly Ala
 500 505 510
 Ser Pro Val Met Asp Lys Pro Pro Glu Met Glu Ala Glu Asn Ser Glu
 515 520 525
 Val Asp Glu Asn Val Pro Thr Ala Glu Glu Ala Thr Glu Ala Thr Glu
 530 535 540
 Gly Asn Ala Gly Ser Ala Glu Asp Thr Val Asp Ile Ser Gln Thr Gly
 545 550 555 560
 Val Tyr Thr Glu His Val Phe Thr Asp Pro Leu Gly Val Gln Ile Pro
 565 570 575
 Glu Asp Leu Ser Pro Val Tyr Gln Ser Ser Asn Asp Ser Asp Ala Tyr
 580 585 590
 Lys Asp Gln Ile Ser Val Leu Pro Asn Glu Gln Asp Leu Val Arg Glu
 595 600 605
 Glu Ala Gln Lys Met Ser Ser Leu Leu Pro Thr Met Trp Leu Gly Ala
 610 615 620
 Gln Asn Gly Cys Leu Tyr Val His Ser Ser Val Ala Gln Trp Arg Lys
 625 630 635 640
 Cys Leu His Ser Ile Lys Leu Lys Asp Ser Ile Leu Ser Ile Val His
 645 650 655
 Val Lys Gly Ile Val Leu Val Ala Leu Ala Asp Gly Thr Leu Ala Ile
 660 665 670
 Phe His Arg Gly Val Asp Gly Gln Trp Asp Leu Ser Asn Tyr His Leu
 675 680 685
 Leu Asp Leu Gly Arg Pro His His Ser Ile Arg Cys Met Thr Val Val
 690 695 700
 His Asp Lys Val Trp Cys Gly Tyr Arg Asn Lys Ile Tyr Val Val Gln
 705 710 715 720
 Pro Lys Ala Met Lys Ile Glu Lys Ser Phe Asp Ala His Pro Arg Lys
 725 730 735
 Glu Ser Gln Val Arg Gln Leu Ala Trp Val Gly Asp Gly Val Trp Val
 740 745 750
 Ser Ile Arg Leu Asp Ser Thr Leu Arg Leu Tyr His Ala His Thr Tyr
 755 760 765
 Gln His Leu Gln Asp Val Asp Ile Glu Pro Tyr Val Ser Lys Met Leu
 770 775 780
 Gly Thr Gly Lys Leu Gly Phe Ser Phe Val Arg Ile Thr Ala Leu Met
 785 790 795 800
 Val Ser Cys Asn Arg Leu Trp Val Gly Thr Gly Asn Gly Val Ile Ile
 805 810 815

Ser Ile Pro Leu Thr Glu Ser Lys Tyr Ile Phe Arg
820 825

<210> 200
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 200
tnaggtttgc acttcttctt gcaaattcc

29

<210> 201
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 201
cnaatatctg agtctgtcct gcgggactc

29

<210> 202
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 202
cnggctctgt gatggctgaa tggaaagaa

29

<210> 203
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 203
angagtccaa ttaaagaacg aaaagcggg 29

<210> 204
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 204
cntcagcttg ggcaagagta aagagggca 29

<210> 205
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 205
tnatttaaga tgctgtgtaa gcctctcgc 29

<210> 206
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 206
tntctgtgtg cacagagctt tggagtggc 29

<210> 207
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_f ature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 207
gnttggattc tctggcagag tacacctgc

29

<210> 208
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 208
gnaggcatat cttttacagg ttcagctcc

29

<210> 209
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 209
cncagtgaga caggtagtag gagccagat

29

<210> 210
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 210
angtaaattc cagccaggat gatggccgc

29

<210> 211
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 211
tngagtgtgg aattgcgctt cttacctat

29

<210> 212
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 212
gngtgaagtc ttcctgggaa ccataatct

29

<210> 213
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 213
tnttcctga agagctggag aggtgctaa

29

<210> 214
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 214
gntctaccat gtgaagaagg aacgcaaaa 29

<210> 215
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 215
tnggcaaagc tgtgctgcag gatagagtg 29

<210> 216
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 216
angtgaagga ctgtaagccc acacaagct 29

<210> 217
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 217
tnatgacagc ccaggctgtg ttatctgca 29

<210> 218
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 218
cngggccttc gttttcacta ccttcagaa

29

<210> 219
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 219
tnaagacggt gactgagagg cagacaagg

29

<210> 220
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 220
tncctagtcc ctttaggtag ctctgcaga

29

<210> 221
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 221
gngcacgaga aagaaggcga ggatggcta

29

<210> 222
<211> 29
<212> DNA
<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc_featur

<222> (2)

<223> biotinylated phosphoramidite residue

<400> 222

tnggacactg tggattctga gtcttggtgg

29

<210> 223

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc_feature

<222> (2)

<223> biotinylated phosphoramidite residue

<400> 223

ancaggaggc agtgggttct atagagtcc

29

<210> 224

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc_feature

<222> (2)

<223> biotinylated phosphoramidite residue

<400> 224

cncttggtgtg cctgtttctc aattgcaga

29

<210> 225

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc_feature

<222> (2)

<223> biotinylated phosphoramidite residue

<400> 225

cnctagctgt tcggctttac caaggagtt

29

<210> 226
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 226
ancacgctct gacgaatgag caacctctc

29

<210> 227
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 227
cnaacacaga ctggaagcct agagtcgct

29

<210> 228
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 228
gnaaaccagg aaatgtacac tgacacaat

29

<210> 229
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 229
tnatcaatac tgggtgacagt ctgctccaa 29

<210> 230
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 230
gncataaccc ttgcacgaa gctgatctt 29

<210> 231
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 231
anatttaagc atttaacgtg aaggatagg 29

<210> 232
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 232
tnagagactg ggaaaccaac agccactgc 29

<210> 233
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 233
anggagcaag ttcttgagag tatcctgtt

29

<210> 234
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 234
anggagcaag ttcttgagag tatcctgtt

29

<210> 235
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 235
gnatggaggg agagagaaca caaattaac

29

<210> 236
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 236
gngacagtgt tgtgctgaag caggattcc

29

<210> 237
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 237
cntctccaac ttccacaatt tgctcacta

29

<210> 238
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 238
tnggaggaag agtggcagag gagcttata

29

<210> 239
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 239
cngtggtttg ttcttaggaa ggtagaagc

29

<210> 240
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 240
cngccagcca gcagcaaagc aaattaaga

29

<210> 241
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 241
tngaggaaag aaggggtggag gtctgcaca

29

<210> 242
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 242
cggtgggatt tatttaacat gatcttggc

29

<210> 243
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 243
ccaatgggta tgatgatggt tcttcct

27

<210> 244
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 244
anggatgcca tccagatgag gccacagct

29

<210> 245
<211> 29
<212> DNA
<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc_feature

<222> (2)

<223> biotinylated phosphoramidite residue

<400> 245

ancttcttct gcagctcatt caactcctg

29

<210> 246

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc_feature

<222> (2)

<223> biotinylated phosphoramidite residue

<400> 246

gntcctccta gaccacaaag tagaaagca

29

<210> 247

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc_feature

<222> (2)

<223> biotinylated phosphoramidite residue

<400> 247

gnctgacttt ctctccagtt tgtgaaatc

29

<210> 248

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc_feature

<222> (2)

<223> biotinylated phosphoramidite residue

<400> 248

gngtggggtg aaaagggaat gattaggga

29

<210> 249

<211> 29

<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 249
tnattcatgg gcagctcatt ggcgggctc

29

<210> 250
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 250
cngctgagac tcacacactg aatttcctt

29

<210> 251
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 251
cntcttggtc cggatgatgt ttttatcac

29

<210> 252
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 252

tntctcggtta tatggaggac gaatagact 29

<210> 253
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 253
ctctttatga gcatgatatg gcttcag 27

<210> 254
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 254
cntgctgccc gacttaaact gagaaccaa 29

<210> 255
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 255
gnngacaact cccatagttg aggtttgtc 29

<210> 256
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 256
tnggaagagt gacccagggg cccaaagca 29

<210> 257
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 257
cncgtgcaagc gagtggtttt cagggctgt 29

<210> 258
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 258
tngagccaag gagagagcag acaggctga 29

<210> 259
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 259
ancccccaga agtacaagga catgccaag 29

<210> 260
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)

<223> biotinylated phosphoramidite residue

<400> 260

cnatagcatc agcatcaaca tggtgacaa

29

<210> 261

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 261

ctccattctc cttgactatc ttctccc

27

<210> 262

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc_feature

<222> (2)

<223> biotinylated phosphoramidite residue

<400> 262

tncctggtgc catcatgatt gtatgaggc

29

<210> 263

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc_feature

<222> (2)

<223> biotinylated phosphoramidite residue

<400> 263

anaggctcct ccattcctac agccatctt

29

<210> 264

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<220>

<221> misc_feature

<222> (2)

<223> biotinylated phosphoramidite residue

<400> 264
cngtccaact gcttgtaggt tatagcaga 29

<210> 265
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 265
tnctctactt cacccttttc ggtgcatcg 29

<210> 266
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 266
tncataaaat gacccacac ctctactg 29

<210> 267
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 267
gngaggtagc caggcatctc tgtgcattt 29

<210> 268
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 268
ancacagcag gaggtgagga ggaggagat

29

<210> 269
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 269
cnttgatctg agagcttttc accgtcaag

29

<210> 270
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 270
anctgccaag aagaggagag tggtaaatt

29

<210> 271
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 271
angaaaaaga agtgtcatga tccagtaca

29

<210> 272
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 272
tnatacttgg acaggataga gcgaggttt 29

<210> 273
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 273
cncgactgcc ttaaaatgta aacctggat 29

<210> 274
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 274
tngcactggg aaagtgattg tgaggagta 29

<210> 275
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 275
tngtgctgcc aaagaacagg agcctcaaa 29

<210> 276
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 276
ctgctgctca tttgttcaat aatgtcaac

29

<210> 277
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 277
tngcactggt gtcacgacgg cttggtctc

29

<210> 278
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 278
anaacagagc agtccagagg aagaacatc

29

<210> 279
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 279
anatgaccag atcctctcag aagatttcc

29

<210> 280

<211> 29
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> oligonucleotide

<220>
 <221> misc_feature
 <222> (2)
 <223> biotinylated phosphoramidite residue

<400> 280
 tnccagtgc tgggcatgca tgaaggcta 29

<210> 281
 <211> 29
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> oligonucleotide

<220>
 <221> misc_feature
 <222> (2)
 <223> biotinylated phosphoramidite residue

<400> 281
 ancagcaaac tcttcctttc gcttgctgc 29

<210> 282
 <211> 29
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> oligonucleotide

<220>
 <221> misc_feature
 <222> (2)
 <223> biotinylated phosphoramidite residue

<400> 282
 tntttctcac aggtcagttc atccacttt 29

<210> 283
 <211> 57
 <212> PRT
 <213> Homo sapiens

<400> 283
 Met Cys Arg Pro Phe Leu Ser Leu Leu Leu Cys Ser Thr Lys Cys Phe
 1 5 10 15

Leu Leu Cys Gly Leu Gly Gly Thr His Val Thr Phe Val Ser Cys Ser
 20 25 30

Lys Ala Gly Ala Thr Pro Ser Ser Leu Phe Ser Thr Gln His Gln Ala

35

40

45


Leu Ser Arg His Pro Ile Asn His Cys
50 55

Applicant's or agent's file reference 1290.1001010	International application No. PCT/US 00/25135
---	---

**INDICATIONS RELATING TO DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on pages <u>333</u> , line <u>35</u> to <u>35</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution AMERICAN TYPE CULTURE COLLECTION	
Address of depositary institution (including postal code and country) American Type Culture Collection (ATCC) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit see Attachment A	Accession Number see Attachment A
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input checked="" type="checkbox"/>	
In respect of those designations for which a European patent is sought, the Applicant(s) hereby informs the International Bureau that the Applicant wishes that, until the publication of the mention of the grant of a European patent or for 20 years from the date of filing if the application is refused or withdrawn or deemed to be withdrawn, the biological material deposited with the American Type Culture Collection under Accession No. <u>see Attachment A</u>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application
Authorized officer 

<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on:
Authorized officer

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(Additional Sheet)

C. ADDITIONAL INDICATIONS (Continued)

shall be made available as provided in ~~Rule 28(3) EPC only~~ by the issue of a sample to an expert nominated by the requester (Rule 28(4) EPC).

In respect of the designation of Australia in the subject PCT application, and in accordance with Regulation 3.25(3) of the Australian Patents Regulations, the Applicant hereby gives notice that the furnishing of a sample of the biological material deposited with the American Type Culture Collection under Accession No. ~~Attachment A~~ shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention and who is nominated in a request for the furnishing of a sample.

In respect of the designation of Canada in the subject PCT application, the Applicant hereby informs the International Bureau that the Applicant wishes that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the biological material deposited with the American Type Culture Collection under Accession No. ~~Attachment A~~ and referred to in the application to an independent expert nominated by the Commissioner.

Attachment A

-1-

Deposit of Clones

Clones AX65_22, BD335_14, BG241_1, BL187_4, BL249_18, BO71_1, BO365_2, BV51_1, BV140_3, BV141_2, CC194_4, and DA136_11 were deposited on October 3, 1996 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98196, from which each clone comprising a particular polynucleotide is obtainable.

Clones AR415_4, AS63_29, BG160_1, BO432_4, BO538_2, BR595_4, CI490_2, CI522_1, CN238_1, CO390_1, and AY304_1 (an additional isolate of clone AY304_14) were deposited on October 25, 1996 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98232, from which each clone comprising a particular polynucleotide is obtainable. Clone AY304_14 was deposited on October 23, 1997 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and was given the accession number 98561.

Clones AJ20_2, AR440_1, AS164_1, AX8_1, BD176_3, BD339_1, BD427_1, BL229_22, BV123_16, and CH377_1 were deposited on November 15, 1996 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98261, from which each clone comprising a particular polynucleotide is obtainable.

Clones BD441_1, BD441_2, BG102_3, BK158_1, BP163_1, BZ16_3, CC182_1, CG109_1 and CJ397_1 were deposited on November 20, 1996 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98264, from which each clone comprising a particular polynucleotide is obtainable.

Clones AM795_4, AT340_1, BG132_1, BG219_2, BG366_2, BV172_2, CC247_10, CI480_9, CO722_1, and CT748_2 were deposited on December 5, 1996 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98271, from which each clone comprising a particular polynucleotide is obtainable.

Clones AJ1_1, AQ73_3, BG142_1, BV66_1, BV291_3, CK201_1, CQ331_2, CT550_1, CT585_1 and CT797_3 were deposited on December 13, 1996 with the ATCC

Attachment A

-2-

(American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98278, from which each clone comprising a particular polynucleotide is obtainable.

Clones CB107_1, CG300_3, CJ145_1, CJ160_11, CO20_1, CO223_1, CO310_2, CP258_3, CW1155_3 and CZ247_2 were deposited on December 17, 1996 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98279, from which each clone comprising a particular polynucleotide is obtainable. Clone CO223_3 was deposited on January 9, 1997 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and was given the accession number 98291.

Clones AM666_1, BN387_3, BQ135_2, CR678_1, CW420_2, CW795_2, CW823_3, DF989_3, DL162_2, DL162_1, and EC172_1 were deposited on January 10, 1997 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98292, from which each clone comprising a particular polynucleotide is obtainable.

INTERNATIONAL SEARCH REPORT

International Application No

US 00/25135

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/47 C12N1/21 C12N5/10 C12Q1/68
A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, STRAND

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,L	WO 98 17687 A (GENETICS INST) 30 April 1998 (1998-04-30) the document throws doubt on the priority of the application abstract; claims 20-22 see SEQ ID NO: 8 and 9 (pp.73-77) page 18, line 30 -page 20, line 2 page 23, line 12 -page 24, line 14 page 31, line 12 -page 64, line 16 -----	1-11

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

14 December 2000

Date of mailing of the international search report

30.01.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Oderwald, H

INTERNATIONAL SEARCH REPORT

national application No.
PCT/US 00/25135

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-11

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-11

An isolated polynucleotide comprising SEQ ID NO: 41 which encodes a protein of SEQ ID NO: 42 (BG160_1). A host cell, a process for producing said protein, a protein produced by said process, a composition comprising said protein.

2. Claims: 12, 13

An isolated polynucleotide comprising SEQ ID NO: 129. A protein encoded by said polynucleotide having amino acid sequence SEQ ID NO: 130 (C0722_1).

Information on patent family members

F . US 00/25135

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9817687 A	30-04-1998	AU 5004097 A EP 0960199 A	15-05-1998 01-12-1999